



(Please scan this QR Code
to view the DRHP)

**DRAFT RED HERRING
PROSPECTUS**

Dated: September 30, 2025
Please read Section 26 and 32 of the
Companies Act, 2013
(This Draft Red Herring Prospectus will be
updated upon filing with the RoC)
100% Book Built Issue



REDNEX PHARMACEUTICALS LIMITED
CIN: U24304GJ2020PLC119176

Registered Office	Contact Person	Email and Telephone	Website
Survey No. 586 and 231, Near SKF Bearing, Bavla Bagodara N.H 8A, Kerala, Taluka: Bavla, Ahmedabad, Gujarat, India, 382220	Rima Amitbhai Dalal Company Secretary & Compliance Officer	Email: info@rednexpharma.com Tel. No.: +91- 83201-31437	Website: https://rednexpharma.com/

Promoters of the Company	Chetan Rugnathbhai Matholiya, Jayeshkumar Amarshibhai Sabava and Akashbhai Mansukhbhai Gangadiya

DETAILS OF THE ISSUE				
Type	Fresh Issue Size	Offer for Sale Size	Total Offer Size (in ₹ lakhs)	Eligibility
Fresh Issue	Upto 27,36,000 Equity Shares aggregating up to ₹ [●] Lakhs	Nil	₹ [●] Lakhs	This Issue is being made in terms of regulation 229(2) and 253(1) of chapter IX of the SEBI (ICDR) Regulations, 2018 as amended.
DETAILS OF OFFER FOR SALE, SELLING SHAREHOLDERS AND THEIR AVERAGE COST OF ACQUISITION- NOT APPLICABLE AS THE ENTIRE ISSUE CONSTITUTES FRESH ISSUE OF EQUITY SHARES				
RISK IN RELATION TO THE FIRST ISSUE				
The face value of the Equity Shares is ₹10. The Floor Price, Cap Price and Issue Price determined by our Company, in consultation with the Book Running Lead Manager, on the basis of the assessment of market demand for the Equity Shares by way of the Book Building Process, as stated under “Basis for Issue Price” on page 90 should not be considered to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after listing.				
GENERAL RISKS				
Investments in Equity and Equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of the investors is invited to the section “Risk Factors” beginning on page 27 of this Draft Red Herring Prospectus.				
ISSUER ABSOLUTE RESPONSIBILITY				
Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Draft Red Herring Prospectus contains all information with regard to the Company and the Issue, which is material in the context of the Issue, that the information contained in this Draft Red Herring Prospectus is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which makes this Draft Red Herring Prospectus as a whole or any of such information or the expression of any such opinions or intentions, misleading in any material respect.				
LISTING				
The Equity Shares Issued through Red Herring Prospectus are proposed to be listed on the SME Platform of BSE Limited (“BSE SME”). In terms of the Chapter IX of the SEBI (ICDR) Regulations, 2018 as amended from time to time. For the purpose of this Issue, the Designated Stock Exchange will be the BSE Limited (“BSE”).				
BOOK RUNNING LEAD MANAGER TO THE ISSUE				
Name and Logo		Contact Person	Email & Telephone	
 HEM SECURITIES LIMITED		Roshni Lahoti	Email: ib@hemsecurities.com Tel. No.: +91- 022- 49060000	
REGISTRAR TO THE ISSUE				
Name and Logo		Contact Person	Email & Telephone	
 BIGSHARE SERVICES PVT. LTD.		Babu Rapheal	Email: ipo@bigshareonline.com Tel No.: +91- 022- 6263 8200	
BID/ISSUE PERIOD				
ANCHOR PORTION ISSUE OPENS/CLOSES ON: [●]*		BID/ISSUE OPENS ON: [●]**	BID/ISSUE CLOSES ON: [●]**	

**Our Company may, in consultation with the Book Running Lead Manager, may consider participation by Anchor Investors in accordance with the SEBI (ICDR) Regulations. The Anchor Investor Bid/Issue Period shall be one Working Day prior to the Bid/Issue Opening Date.*
***Our Company may, in consultation with the BRLM, may consider closing the Bid/Issue Period for QIBs one Working Day prior to the Bid/Issue Closing Date in accordance with the SEBI (ICDR) Regulations.*
#The UPI mandate end time and date shall be at 5:00 p.m. on Bid/Issue Closing Day.



REDNEX PHARMACEUTICALS LIMITED
CIN: U24304GJ2020PLC119176

Our Company was originally incorporated as a Private Limited Company under the name “Rednex Pharmaceuticals Private Limited” on December 29, 2020 under the provisions of the Companies Act, 2013 with the Registrar of Companies, Ahmedabad bearing CIN: U24304GJ2020PTC119176. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extraordinary General Meeting, held on December 30, 2024 and consequently, the name of our Company was changed from “Rednex Pharmaceuticals Private Limited” to “Rednex Pharmaceuticals Limited” vide a fresh certificate of incorporation dated January 21, 2025 issued by the Registrar of Companies, Central Processing Centre bearing CIN: U24304GJ2020PLC119176. For further details of Incorporation, change of registered office of our Company, please refer to chapter titled **“History and Corporate Structure”** beginning on page 146 of this Draft Red Herring Prospectus.

Registered Office: Survey No. 586 and 231, Near SKF Bearing, Bavla Bagodara N.H 8A, Kerala, Taluka: Bavla, Ahmedabad, Gujarat, India, 382220

Contact Person: Rima Amitbhai Dalal, Company Secretary & Compliance Officer **Tel No:** +91- 83201-31437

E-mail: info@rednexpharma.com ; **Website:** <https://rednexpharma.com/> ;

Promoter of our Company: Chetan Rugnathbhai Matholiya, Jayeshkumar Amarshibhai Sabava and Akashbhai Mansukhbhai Gangadiya

DETAILS OF THE ISSUE		
INITIAL PUBLIC OFFER OF UPTO 27,36,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE "EQUITY SHARES") OF REDNEX PHARMACEUTICALS LIMITED ("OUR COMPANY" OR "RPL" OR "THE ISSUER") AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹[●] LAKHS ("PUBLIC ISSUE") OUT OF WHICH [●] EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING ₹ [●] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF [●] EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹[●] PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹[●] LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.34% AND [●] % RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BRLM AND WILL BE ADVERTISED IN ALL EDITION OF [●] (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER) AND ALL EDITION OF [●] (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER, AND GUJARATI EDITION OF [●], REGIONAL NEWSPAPER (GUJARATI BEING THE REGIONAL LANGUAGE OF AHMEDABAD WHERE OUR REGISTERED OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO THE SME PLATFORM OF BSE LIMITED ("BSE LIMITED") FOR THE PURPOSES OF UPLOADING ON THEIR WEBSITE. In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding ten Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company, for reasons to be recorded in writing extend the Bid/Issue Period for a minimum of one Working Day, subject to the Bid/Issue Period not exceeding ten Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a press release and also by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank. The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders (of which one third of the Non-Institutional Portion shall be reserved for Bidders with an application size of more than two lots and up to such lots equivalent to not more than ₹10 lakhs and two-thirds of the Non-Institutional Portion shall be reserved for Bidders with an application size exceeding ₹ 10 lakhs) and under-subscription in either of these sub-categories of Non-Institutional Portion may be allocated to Bidders in the other subcategory of Non-Institutional Portion, subject to valid Bids being received at or above the Issue Price and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of Individual Bidders using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 273 of this Draft Red Herring Prospectus		
RISK IN RELATION TO THE FIRST ISSUE		
This being the first issue of the issuer, there has been no formal market for the securities of the issuer. The face value of the Equity Shares is ₹10. The Issue Price/ Floor Price/ Price Band determined by our Company, in consultation with the Book Running Lead Managers, on the basis of the assessment of market demand for the Equity Shares by way of the Book Building Process, as stated under "Basis for Issue Price" on page 90 should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after listing.		
GENERAL RISKS		
Investments in Equity and Equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of the investors is invited to the section "Risk Factors" beginning on page 27 of this Draft Red Herring Prospectus.		
ISSUER ABSOLUTE RESPONSIBILITY		
The Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Draft Red Herring Prospectus contains all information with regard to the Company and the Issue, which is material in the context of the Issue, that the information contained in this Draft Red Herring Prospectus is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which makes this Draft Red Herring Prospectus as a whole or any of such information or the expression of any such opinions or intentions, misleading in any material respect.		
LISTING		
The Equity Shares Issued through this Draft Red Herring Prospectus are proposed to be listed on the SME Platform of BSE Limited ("BSE SME"). In terms of the Chapter IX of the SEBI (ICDR) Regulations, 2018 as amended from time to time, our Company has received "in-principle" approval letter dated [●] from Bombay Stock Exchange Limited ("BSE") for using its name in the Issue Document for listing of our shares on the SME Platform of BSE ("BSE SME"). For the purpose of this Issue, the Designated Stock Exchange will be the Bombay Stock Exchange Limited ("BSE").		
BOOK RUNNING LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	
 Hem Securities		
HEM SECURITIES LIMITED 904, A Wing, Naman Midtown, Senapati Bapat Marg, Elphinstone Road, Lower Parel, Mumbai-400013, India Tel. No.: +91- 022- 49060000; Fax No.: +91- 022- 22625991 Email: ib@hemsecurities.com Investor Grievance Email: redressal@hemsecurities.com Website: www.hemsecurities.com Contact Person: Roshni Lahoti SEBI Regn. No. INM000010981	BIGSHARE SERVICES PVT. LTD. Address: Office No. S6-2, 6th Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri East, Mumbai – 400 093, Maharashtra, India Tel. No.: 022- 6263 8200 Email: ipo@bigshareonline.com Website: www.bigshareonline.com Contact Person: Mr. Babu Rapheal SEBI Registration No.: INR000001385	
ISSUE PROGRAMME		
ANCHOR PORTION ISSUE OPENS/CLOSES ON: [●]*	BID/ISSUE OPENS ON: [●]**	BID/ISSUE CLOSES ON: [●]**

*The Company may, in consultation with the Book Running Lead Manager, consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/Issue Period shall be one Working Day prior to the Bid/Issue Opening Date.

**Our Company may, in consultation with the BRLM, consider closing the Bid/Issue Period for QIBs one Working Day prior to the Bid/Issue Closing Date in accordance with the SEBI ICDR Regulations.

#The UPI mandate end time and date shall be at 5:00 p.m. on Bid/Issue Closing Day.

TABLE OF CONTENTS

SECTION	CONTENTS	PAGE NO.
I.	GENERAL	
	DEFINITIONS AND ABBREVIATIONS	1
	CERTAIN CONVENTIONS, USE OF FINANCIAL INFORMATION AND MARKET DATA AND CURRENCY OF FINANCIAL PRESENTATION	18
	FORWARD LOOKING STATEMENTS	20
II.	SUMMARY OF DRAFT RED HERRING PROSPECTUS	21
III.	RISK FACTORS	27
IV.	INTRODUCTION	
	THE ISSUE	53
	SUMMARY OF OUR FINANCIAL STATEMENTS	55
	GENERAL INFORMATION	58
	CAPITAL STRUCTURE	68
	OBJECTS OF THE ISSUE	80
	BASIS FOR ISSUE PRICE	90
	STATEMENT OF SPECIAL TAX BENEFITS	98
V.	ABOUT THE COMPANY	
	INDUSTRY OVERVIEW	102
	OUR BUSINESS	118
	KEY INDUSTRY REGULATIONS AND POLICIES	137
	HISTORY AND CORPORATE STRUCTURE	146
	OUR MANAGEMENT	150
	OUR PROMOTERS & PROMOTER GROUP	165
	DIVIDEND POLICY	171
VI.	FINANCIAL INFORMATION OF THE COMPANY	
	RESTATED FINANCIAL STATEMENTS	172
	OTHER FINANCIAL INFORMATION	218
	STATEMENT OF FINANCIAL INDEBTEDNESS	219
	MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS	223
	CAPITALISATION STATEMENT	232
VII.	LEGAL AND OTHER INFORMATION	
	OUTSTANDING LITIGATION AND MATERIAL DEVELOPMENTS	233
	GOVERNMENT AND OTHER APPROVALS	237
	OUR GROUP COMPANIES	243
	OTHER REGULATORY AND STATUTORY DISCLOSURES	245
VIII.	ISSUE RELATED INFORMATION	
	TERMS OF THE ISSUE	260
	ISSUE STRUCTURE	269
	ISSUE PROCEDURE	273
	RESTRICTIONS ON FOREIGN OWNERSHIP OF INDIAN SECURITIES	303
IX.	MAIN PROVISIONS OF ARTICLES OF ASSOCIATION OF OUR COMPANY	305
X.	OTHER INFORMATION	
	MATERIAL CONTRACTS AND DOCUMENTS FOR INSPECTION	317
	DECLARATION	318

SECTION I – GENERAL

DEFINITIONS AND ABBREVIATIONS

This Draft Red Herring Prospectus uses certain definitions and abbreviations which, unless the context otherwise indicates or implies, shall have the meaning as provided below. References to any legislation, act, regulation, rule, guideline or policy shall be to such legislation, act, regulation, rule, guideline or policy, as amended, supplemented or re-enacted from time to time, and any reference to a statutory provision shall include any subordinate legislation made from time to time under that provision.

The words and expressions used in this Draft Red Herring Prospectus but not defined herein, shall have, to the extent applicable, the meaning ascribed to such terms under the Companies Act, 2013, the SEBI (ICDR) Regulations, 2018, the Securities Contracts Regulation Act, 1956 ("SCRA"), the Depositories Act or the rules and regulations made there under.

*Notwithstanding the foregoing, terms used in the sections **"Statement of Special Tax Benefits"**, **"Financial Information of the Company"** and **"Main Provisions of the Articles of Association"** on page 98, 172 and 305 respectively, shall have the meaning ascribed to such terms in such sections.*

General Terms

Terms	Description
"Rednex", "The Company", "our Company", "the Issuer", "Rednex Pharmaceuticals Limited", "we", "us" and "our"	Rednex Pharmaceuticals Limited, a Company incorporated in India under the Companies Act, 2013 having its Registered office at Survey No. 586 and 231, Near SKF Bearing, Bavla Bagodara N.H 8A, Kerala, Taluka: Bavla, Ahmedabad, Gujarat, India, 382220.
"you", "your" or "yours"	Prospective investors in this Issue.

Company related terms

Term	Description
AOA / Articles / Articles of Association	Articles of Association of our Company, as amended, from time to time.
Audit Committee	The Audit Committee of our Board of Directors constituted in accordance with Section 177 of the Companies Act, 2013 as described in the chapter titled " Our Management " beginning on page 150 of this Draft Red Herring Prospectus.
Auditors/ Statutory Auditors	The Statutory Auditors of our Company being M/s. Krupal Bhuvu & Co.
Banker to our Company	State Bank of India
Board of Directors / the Board / our Board	The Board of Directors of our Company, including all duly constituted Committees thereof. For further details of our Directors, please refer to section titled " Our Management " beginning on page 150 of this Draft Red Herring Prospectus.
Chartered Engineer	Rohitkumar Rakholiya, Chartered Engineer, appointed in relation to certification of information relating to the installed capacity, available capacity, actual production and capacity utilisation of our products included in this Draft Red Herring Prospectus.
Chief Financial Officer/ CFO	The Chief Financial Officer of our Company being Akashbhai Mansukhbhai Gangadiya.
Company Secretary and Compliance Officer	The Company Secretary & Compliance Officer of our Company being Rima Amitbhai Dalal.
Depositories	A depository registered with SEBI under the Securities and Exchange Board of India (Depositories and Participants) Regulations, 1996 as amended from time to time, being, National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL).
Depositories Act	The Depositories Act, 1996, as amended from time to time
DIN	Directors Identification Number
Director(s) / Our Directors	The Director(s) of our Company, unless otherwise specified. For details of our directors, see " Our Management " on page 150 of this Draft Red Herring Prospectus
DP/ Depository Participant	A depository participant as defined under the Depositories Act, 1996.
DP ID	Depository's Participant's Identity Number.

Equity Shareholders/Shareholders	Persons/ Entities holding Equity Shares of our Company.
Equity Shares	Equity Shares of our Company of face value of Rs. 10/- each unless otherwise specified in the context thereof.
Fugitive economic offender	Shall mean an individual who is declared a fugitive economic offender under section 12 of the Fugitive Economic Offenders Act, 2018.
GIR Number	General Index Registry Number
Group Company	Our group company as disclosed in the section “ Our Group Company ” on page 243 of the Draft Red Herring Prospectus.
HNI	High Net worth Individual.
HUF	Hindu Undivided Family
IBC	The Insolvency and Bankruptcy Code, 2016
Independent Director	An Independent Director as defined under Section 2(47) of the Companies Act, 2013 and as defined under the Listing Regulations. For details of our Independent Directors, see “ Our Management ” on page 150 of this Draft Red Herring Prospectus.
Ind AS or Indian Accounting Standards	Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015, as amended.
ISIN	International Securities Identification Number. In this case being INE16E601016.
IT Act	The Income Tax Act, 1961 as amended till date.
JV/ Joint Venture	A commercial enterprise undertaken jointly by two or more parties which otherwise retain their distinct identities.
Key Management Personnel/ KMP	Key Management Personnel of our Company in terms of Regulation 2(1) (bb) of the SEBI Regulations and the Companies Act, 2013. For details, see section titled “ Our Management ” on page 150 of this Draft Red Herring Prospectus.
Memorandum /Memorandum of Association/ MOA	Memorandum of Association of Rednex Pharmaceuticals Limited as amended from time to time.
Materiality Policy	The policy adopted by our Board on September 26, 2025 for identification of Group Company, material outstanding litigation and material outstanding dues to creditors, pursuant to the disclosure requirements under the SEBI (ICDR) Regulations, 2018 as amended from time to time.
Nomination and Remuneration Committee	The Nomination and Remuneration Committee of our Board constituted in accordance with Section 178 of the Companies Act, 2013 as described in the chapter titled “ Our Management ” beginning on page 150 of this Draft Red Herring Prospectus.
Non-Executive Director	The non-executive directors (other than the Independent Directors) of our Company in terms of the Companies Act, and the rules thereunder. For details, see section titled “ Our Management ” on page 150 of this Draft Red Herring Prospectus.
NRIs/ Non-Resident Indians	Person of Indian origin as defined under Consolidated foreign direct investment policy 2017.
Person or Persons	Any Individual, Sole Proprietorship, Unincorporated Association, Unincorporated Organization, Body Corporate, Corporation, Company, Partnership, Limited Liability Company, Joint Venture, or Trust or any other entity or organization validly constituted and/or incorporated in the jurisdiction in which it exists and operates, as the context requires.
Promoter Group	Includes such Persons and companies constituting our promoter group covered under Regulation 2(1) (pp) of the SEBI (ICDR) Regulations, 2018 as enlisted in the section “ Our Promoters & Promoter Group ” beginning on page 165 of this Draft Red Herring Prospectus.
Promoter(s)	Shall mean promoters of our Company i.e. Chetan Rugnathbhai Matholiya, Jayeshkumar Amarshibhai Sabava, and Akashbhai Mansukhbhai Gangadiya. For further details, please refer to section titled “ Our Promoters & Promoter Group ” beginning on page 165 of this Draft Red Herring Prospectus.
RBI Act	The Reserve Bank of India Act, 1934 as amended from time to time.
Registered Office and Factory	The Registered Office and Factory of our Company situated at Survey No. 586 and 231, Near SKF Bearing, Bavla Bagodara N.H 8A, Kerala, Taluka: Bavla, Ahmedabad, Gujarat, India, 382220.

Restated Financial Statement	The restated financial information of the Company comprises of Restated Financial Statements of Assets and Liabilities as at March 31, 2025 and the Restated Statements of Profit and Loss and Restated Cash Flows for the fiscal year ended March 31, 2025, March 31, 2024 and March 31, 2023 together with the summary of significant accounting policies, explanatory notes, and notes to the restated financial statements of our Company prepared in accordance with Indian GAAP and the Companies Act and restated in accordance with the SEBI (ICDR) Regulations, 2018 and the Revised Guidance Note on Reports in Company Prospectuses (Revised 2019) issued by the ICAI, together with the schedules, notes and annexure thereto.
RoC / Registrar of Companies	Registrar of Companies, Ahmedabad
Senior Management / Senior Management Personnel	Senior Management or Senior Management Personnel means the officers and personnel of the issuer as defined in Regulation 2(1)(bbbb) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. For details, please refer section titled <i>“Our Management”</i> on page 150 of this Draft Red Herring Prospectus
Stakeholders’ Relationship Committee	Stakeholders’ Relationship Committee of our Company constituted in accordance with Section 178 of the Companies Act, 2013 and as described in the chapter titled <i>“Our Management”</i> beginning on page 150 of this Draft Red Herring Prospectus
Stock Exchange	Unless the context requires otherwise, refers to, BSE SME.
Shareholders	Shareholders of our Company from time to time.
Sub- Account	Sub- accounts registered with SEBI under the Securities and Exchange Board of India (Foreign Institutional Investor) Regulations, 1995, other than sub-accounts which are foreign corporate or foreign individuals.
Subscriber to MOA	Initial Subscribers to MOA being Chetan Rugnathbhai Matholiya, Jayeshkumar Amarshibhai Sabava, and Akashbhai Mansukhbhai Gangadiya

Issue Related Terms

Terms	Description
Abridged Prospectus	Abridged prospectus means a memorandum containing such salient features of a prospectus as may be specified by SEBI in this behalf
Acknowledgement Slip	The slip or document issued by the Designated Intermediary to a bidder as proof of registration of the Application.
Allocation/ Allocation of Equity Shares	The Allocation of Equity Shares of our Company pursuant to Fresh Issue of Equity Shares to the successful Bidders.
Allotment Advice	A note or advice or intimation of Allotment sent to the Bidders who have been allotted Equity Shares after the Basis of Allotment has been approved by the Designated Stock Exchange
Allotment/Allot/Allotted	Unless the context otherwise requires, means the allotment of Equity Shares, pursuant to the Fresh Issue to successful Bidders
Allottee (s)	A successful bidder to whom the Equity Shares are allotted.
Anchor Investor	A Qualified Institutional Buyer, applying under the Anchor Investor Portion in accordance with the requirements specified in the SEBI ICDR Regulations and the Red Herring Prospectus and who has Bid for an amount of at least Rs. 200 lakhs.
Anchor Escrow Account /Escrow Account(s)	Account opened with Anchor Escrow Bank for the Issue and in whose favour the Anchor Investors will transfer money through direct credit or NEFT or RTGS in respect of the Bid Amount when submitting a Bid.
Anchor Investor Allocation	The price at which Equity Shares will be allocated to the Anchor Investors in terms of the Red Herring Prospectus.
Anchor Investor Allocation Price	The price at which Equity Shares will be allocated to the Anchor Investors in terms of the Red Herring Prospectus and the Prospectus, which will be decided by our Company in consultation with the Book Running Lead Managers during the Anchor Investor Bid/ Issue Period
Anchor Investor Application Form	The application form used by an Anchor Investor to make a Bid in the Anchor Investor Portion and which will be considered as an application for Allotment in terms of the Red Herring Prospectus and Prospectus

Anchor Investor Bid/Issue Period	One working day prior to the Bid/ Issue Opening Date, on which Bids by Anchor Investors shall be submitted and allocation to the Anchor Investors shall be completed.
Anchor Investor Issue Price	The final price at which the Equity Shares will be Allotted to the Anchor Investors in terms of the Red Herring Prospectus and the Prospectus, which price will be equal to or higher than the Issue Price but not higher than the Cap Price. The Anchor Investor Issue Price will be decided by our Company, in consultation with the Book Running Lead Manager.
Anchor Investor Portion	Up to 60% of the QIB Portion which may be allocated by our Company, in consultation with the Book Running Lead Manager, to the Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations. One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price, in accordance with the SEBI ICDR Regulations.
Anchor Investor Pay-in Date	With respect to Anchor Investor(s), it shall be the Anchor Investor Bidding Date, and in the event the Anchor Investor Allocation Price is lower than the Issue Price, not later than two Working Days after the Bid/ Issue Closing Date.
Application Amount	The amount at which the Applicant makes an application for the Equity Shares of our Company in terms of Draft Red Herring Prospectus.
Application Supported by Block Amount (ASBA)	An application, whether physical or electronic, used by ASBA Bidders to make a Bid and authorize an SCSB to block the Bid Amount in the ASBA Account and will include applications made by UPI Bidders using the UPI Mechanism where the Bid Amount will be blocked upon acceptance of UPI Mandate Request by the bidders using the UPI Mechanism.
ASBA Account	A bank account maintained by ASBA Bidders with an SCSB and specified in the ASBA Form submitted by such ASBA Bidder in which funds will be blocked by such SCSB to the Bid Amount extent of the specified in the ASBA Form submitted by such ASBA Bidder and includes a bank account maintained by an Individual Investor/ non-institutional investors linked to a UPI ID, which will be blocked in relation to a Bid by an Individual Investor/ non-institutional investors Bidding through the UPI Mechanism.
ASBA Application Location(s)	Locations at which ASBA Applications can be uploaded by the SCSBs.
ASBA Bid	A Bid made by an ASBA Bidder.
ASBA Bidder	Any prospective investor(s) / Bidder (s) in this Issue who apply(ies) through the ASBA process except Anchor Investor
ASBA Form/Bid cum Application	An application form (with or without UPI ID, as applicable), whether physical or electronic, used by Bidders which will be considered as the application for Allotment in terms of the Red Herring Prospectus.
Bankers to the Issue/ Public Issue Bank/ Sponsor Bank	Collectively, Escrow Collection Bank(s), Public Issue Account Bank(s), Sponsor Bank and Refund Bank(s), as the case may be
Banker to the Issue Agreement	Agreement dated [●] entered into amongst the Company, Book Running Lead Manager, the Registrar to the Issue and the Sponsor Bank/Banker to the Issue.
Basis of Allotment	The basis on which the Equity Shares will be Allotted to successful bidders under the Issue and which is described in the chapter titled “ Issue Procedure ” beginning on page 273 of this Draft Red Herring Prospectus.
Bid	An indication to make an offer during the Bid/ Issue Period by a Bidder (other than an Anchor Investor) pursuant to submission of the ASBA Form, or during the Anchor Investor Bid/ Issue Period by an Anchor Investor, pursuant to submission of the Anchor Investor Application Form, to subscribe to or purchase the Equity Shares at a price within the Price Band, including all revisions and modifications thereto as permitted under the SEBI ICDR Regulations and in terms of the Red Herring Prospectus and the Bid cum Application Form. The term “Bidding” shall be construed accordingly.
Bid Amount	The highest value of optional Bids indicated in the Bid cum Application Form and payable by the Individual Investor or blocked in the ASBA Account upon submission of the Bid in the Issue.

Bid cum Application Form	The form in terms of which the Bidder has made a Bid, including ASBA Form, and which has been considered as the application for the Allotment pursuant to the terms of the Red Herring Prospectus and this Prospectus
Bid Lot	[●] Equity Shares and in multiples of [●] Equity Shares thereafter
Bid / Issue Closing Date	Except in relation to any Bids received from the Anchor Investors, the date after which the Syndicate, the Designated Branches and the Registered Brokers shall not accept the Bids, which shall be notified in all editions of the English national newspaper [●], all editions of Hindi national newspaper [●] and Gujarati Edition of Regional newspaper [●] where the registered office of the company is situated, each with wide circulation, and in case of any revision, the extended Bid/ Issue closing Date also to be notified on the website and terminals of the Syndicate, SCSB's and Sponsor Bank, as required under the SEBI ICDR Regulations.
Bid / Issue Opening Date	Except in relation to any Bids received from the Anchor Investors, the date on which the Syndicate, the Designated Branches and the Registered Brokers shall start accepting Bids, which shall be notified in all editions of the English national newspaper [●], all editions of Hindi national newspaper [●] and Gujarati Edition of Regional newspaper [●] where the registered office of the company is situated, each with wide circulation, and in case of any revision, the extended Bid/ Issue Opening Date also to be notified on the website and terminals of the Syndicate and SCSBs, as required under the SEBI ICDR Regulations.
Bid / Issue Period	Except in relation to any Bids received from the Anchor Investors, the period between the Bid / Issue Opening Date and the Bid / Issue Closing Date, inclusive of both days, during which Bidders can submit their Bids, including any revisions thereof. Provided however that the Bid/ Issue Period shall be kept open for a minimum of three Working Days for all categories of Bidders, other than Anchor Investors.
Bidder/Investor/Applicant	Any prospective investor who makes a bid pursuant to the terms of the Red Herring Prospectus and the Bid-Cum-Application Form and unless otherwise stated or implied, which includes an ASBA Bidder and an Anchor Investor.
Bidding	The process of making a Bid.
Bidding/ Collection Centres	Centres at which the designated intermediaries shall accept the ASBA Forms, i.e. Designated SCSB Branches for SCSBs, specified locations for syndicates, broker centres for registered brokers, designated RTA Locations for RTAs and designated CDP locations for CDPs.
Book Building Process / Book Building Method	Book building process, as provided in Part A of Schedule XIII of the SEBI ICDR Regulations, in terms of which the Offer is being made.
BRLM / Book Running Lead Manager	The Book Running Lead Manager to the Issue in this case being Hem Securities Limited, SEBI Registered Category I Merchant Banker.
Broker Centres	Broker Centres notified by the Stock Exchanges, where the bidders can submit the Application Forms to a Registered Broker. The details of such Broker Centres, along with the names and contact details of the Registered Brokers are available on the websites of the Stock Exchanges.
Business Day	Monday to Friday (except public holidays).
CAN/Confirmation of Allocation Note	The Note or advice or intimation sent to each successful Applicant indicating the Equity which will be allotted, after approval of Basis of Allotment by the designated Stock Exchange.
Cap Price	The higher end of the price band above which the Issue Price will not be finalized and above which no Bids (or a revision thereof) will be accepted.
Client Id	Client Identification Number maintained with one of the Depositories in relation to Demat account.
Collecting Depository Participants or CDPs	A depository participant as defined under the Depositories Act, 1996, registered with SEBI and who is eligible to procure Applications at the Designated CDP Locations in terms of circular no. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 issued by SEBI.
Collecting Registrar and Share Transfer Agent	Registrar to the Issue and share transfer agents registered with SEBI and eligible to procure Bids at the Designated RTA Locations in terms of circular no. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 issued by SEBI and of the SEBI UPI Circulars.

Controlling Branches of the SCSBs	Such branches of the SCSBs which coordinate with the BRLM, the Registrar to the Issue and the Stock Exchange.
Demographic Details	The demographic details of the applicants such as their Address, PAN, name of the applicant's father/husband, investor status, Occupation and Bank Account details and UPI ID, wherever applicable.
Depositories Act	The Depositories Act, 1996, as amended from time to time.
Depository / Depositories	A depository registered with SEBI under the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 as amended from time to time, being NSDL and CDSL.
Depository Participant/ DP	A Depository Participant as defined under the Depositories Act.
Designated CDP Locations	Such locations of the CDPs where Applicant can submit the Bid-Cum-Application Forms to Collecting Depository Participants. The details of such Designated CDP Locations, along with names and contact details of the Collecting Depository Participants eligible to accept Bid-Cum-Application Forms are available on the website of the Stock Exchange i.e. www.bseindia.com
Designated Date	The date on which the funds from the Anchor Escrow Accounts are transferred to the Public Issue Account or the Refund Account(s), as appropriate, and the relevant amounts blocked by the SCSBs are transferred from the ASBA Accounts, to the Public Issue Account and/or are unblocked, as applicable, in terms of the Red Herring Prospectus and the Prospectus after finalization of basis of allotment with the Designated Stock Exchange following which Equity Shares may be Allotted to successful Bidders in the Issue.
Designated Intermediaries, Collecting Agent	An SCSB's with whom the bank account to be blocked, is maintained, a syndicate member (or sub-syndicate member), a Stock Broker registered with recognized Stock Exchange, a Depository Participant, a registrar to an issue and share transfer agent (RTA) (whose names is mentioned on website of the stock exchange as eligible for this activity).
Designated Market Maker	[•]
Designated RTA Locations	Such locations of the RTAs where Bidder can submit the Bid-Cum-Application Forms to RTAs. The details of such Designated RTA Locations, along with names and contact details of the RTAs eligible to accept Bid-Cum-Application Forms are available on the websites of the Stock Exchange i.e. www.bseindia.com
Designated SCSB Branches	Such branches of the SCSBs which shall collect the ASBA Application Form from the Applicant and a list of which is available on the website of SEBI at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes . Recognized-Intermediaries or at such other website as may be prescribed by SEBI from time to time.
Designated Stock Exchange	BSE Ltd. ("SME Exchange") ("BSE SME")
DP ID	Depository Participant's identity number.
DP/ Depository Participant	A depository participant as defined under the Depositories Act, 1996.
Draft Red Herring Prospectus/ DRHP	Draft Red Herring Prospectus dated September 30, 2025 filed with BSE SME.
Electronic Transfer of Funds	Refunds through NACH, NEFT, Direct Credit or RTGS as applicable.
Eligible FPI(s)	FPIs that are eligible to participate in this Issue in terms of applicable laws, other than individuals, corporate bodies and family offices.
Eligible NRI(s)	A Non-Resident Indian in a jurisdiction outside India where it is not unlawful to make an offer or invitation under the offer and in relation to whom this Draft Red Herring Prospectus will constitute an invitation to subscribe for the Equity Shares.
Eligible QFIs	QFIs from such jurisdictions outside India where it is not unlawful to make an Offer or invitation under the Offer and in relation to whom the Prospectus constitutes an invitation to purchase the Equity shares Offered thereby and who have opened Demat accounts with SEBI registered qualified depository participants.
Escrow Account(s)	The account(s) to be opened with the Escrow Collection Bank and in whose favour the Anchor Investors will transfer money through NACH/direct credit/NEFT/RTGS in respect of the Bid Amount when submitting a Bid.

Escrow Collection Bank(s)	The bank(s) which are clearing members and registered with SEBI as bankers to an Issue under the SEBI BTI Regulations and with whom the Escrow Account(s) will be opened, in this case being [●]
FII/ Foreign Institutional Investors	Foreign Institutional Investor as defined under SEBI (Foreign Institutional Investors) Regulations, 1995, as amended) registered with SEBI under applicable laws in India.
First Bidder/Applicant/Bidders	Bidder(s) whose name shall be mentioned in the Bid cum Application Form or the Revision Form and in case of joint bids, whose name shall also appear as the first holder of the beneficiary account held in joint names
Floor Price	The lower end of the Price Band, subject to any revision thereto, at or above which the Issue Price and the Anchor Investor Issue Price will be finalised and below which no Bids will be accepted and which shall not be less than the face value of the Equity Shares
Fresh Issue	The Issue of up to 27,36,000 Equity Shares aggregating up to Rs. [●] lakhs by our Company for subscription pursuant to the terms of the Draft Red Herring Prospectus.
Foreign Venture Capital Investors	Foreign Venture Capital Investors registered with SEBI under the SEBI (Foreign Venture Capital Investor) Regulations, 2000.
FPI / Foreign Portfolio Investor	A Foreign Portfolio Investor who has been registered pursuant to the Securities and Exchange Board of India (Foreign Portfolio Investors) Regulations, 2014, provided that any FII or QFI who holds a valid certificate of registration shall be deemed to be a foreign portfolio investor till the expiry of the block of three years for which fees have been paid as per the SEBI (Foreign Institutional Investors) Regulations, 1995, as amended.
Fraudulent Borrower	Fraudulent borrower as defined under Regulation 2(1) (III) of the SEBI ICDR Regulations.
Fugitive Economic Offender	An individual who is declared a fugitive economic offender under section 12 of the Fugitive Economic Offenders Act, 2018
General Corporate Purposes	Include such identified purposes for which no specific amount is allocated or any amount so specified towards general corporate purpose or any such purpose by whatever name called, in the offer document. Provided that any Offer related expenses shall not be considered as a part of general corporate purpose merely because no specific amount has been allocated for such expenses in the offer document.
General Information Document (GID)	The General Information Document for investing in public offers, prepared and issued in accordance with the circular (SEBI/HO/CFD/DIL1/CIR/P/2020/37) dated March 17, 2020 issued by SEBI, suitably modified and updated pursuant to the circular (SEBI/HO/CFD/DIL2/CIR/P/2020/50) dated March 30, 2020 and the UPI Circulars and any subsequent circulars or notifications issued by SEBI from time to time. The General Information Document shall be available on the websites of the Stock Exchanges and the BRLM.
Gross Proceeds	The gross proceeds of the Fresh Issue that will be available to our Company
Individual Bidders/ Individual Investors	Individual Bidders, submitting Bids, who applies for minimum application size of two lots per application. Provided that the minimum application size shall be above ₹2 lakhs (including HUFs applying through their Karta and Eligible NRIs and does not include NRIs other than Eligible NRIs).
Individual Investor Portion	The portion of the Issue being not less than 35% of the Net Issue, consisting of [●] Equity Shares of face value of ₹10/ each, available for allocation to Individual Bidders.
Issue Agreement	The Issue Agreement dated September 29, 2025 between our Company and Book Running Lead Manager pursuant to which certain arrangements have been agreed to in relation to the Issue.
Issue Price	The final price at which Equity Shares will be Allotted to successful Bidders, other than Anchor Investors. Equity Shares will be Allotted to Anchor Investors at the Anchor Investor Issue Price in terms of the Red Herring Prospectus. The Issue Price will be decided by our Company, in consultation with the BRLM on the Pricing Date, in accordance with the Book Building Process and in terms of the Red Herring Prospectus.

Issue Proceeds	Proceeds to be raised by our Company through this Issue, for further details please refer chapter titled “ Objects of the Issue ” beginning on page 80 of this Draft Red Herring Prospectus
Issue/Public size/Initial Public Offering/IPO	The Initial Public Offer of upto 27,36,000 Equity shares of Rs. 10/- each at Issue price of Rs. [●]/- per Equity share, including a premium of Rs. [●]/- per equity share aggregating to Rs. [●] lakhs.
Listing Agreement	The Equity Listing Agreement to be signed between our Company and the Stock Exchange.
Market Making Agreement	The Market Making Agreement dated [●] between our Company, Book Running Lead Manager and the Market Maker.
Market Maker	The Market Maker to the Issue, in this case being [●].
Market Maker Reservation Portion	The reserved portion of [●] Equity Shares of ₹ 10/- each at an Issue price of ₹ [●] each aggregating to ₹ [●] Lakhs to be subscribed by Market Maker in this Issue.
Mandate Request	Mandate Request means a request initiated on the Individual Investor by sponsor bank to authorize blocking of funds equivalent to the application amount and subsequent debit to funds in case of allotment.
Mobile App(s)	The mobile applications listed on the website of SEBI at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=43 or such other website as may be updated from time to time, which may be used by UPI Bidders to submit Bids using the UPI Mechanism
Mutual Funds	A mutual fund registered with SEBI under the SEBI (Mutual Funds) Regulations, 1996, as amended from time to time.
Mutual Fund Portion	5% of the Net QIB Portion, or [●] Equity Shares, which shall be available for allocation to Mutual Funds only on a proportionate basis, subject to valid Bids being received at or above the Issue Price
Net Proceeds	Proceeds received from the Issue excluding Issue related expenses. For further information on the use of Issue Proceeds and Issue expenses, please refer to the section titled “ Objects of the Issue ” beginning on page 80 of this Draft Red Herring Prospectus.
Net QIB Portion	The portion of the QIB Portion less the number of Equity Shares Allocated to the Anchor Investors.
Non – Resident	A person resident outside India, as defined under FEMA and includes NRIs, FPIs and FVCIs
Non-Institutional Investors/Non-Institutional Bidders	All Bidders that are not QIBs, Individual Investors and who have Bid for Equity Shares, for application size of more than two lots (but not including NRIs other than Eligible NRIs).
Non-Institutional Portion/ Non-Institutional Category	The portion of the Issue being not less than 15% of the Issue, consisting of [●] Equity Shares of face value of ₹10/ each of which (a) One-third of the portion available to NIBs shall be reserved for applicants with an application size of more than two lots and up to such lots equivalent to not more than ₹10,00,000/- and (b) Two-third of the portion available to NIBs shall be reserved for applicants with an application size of more than ₹ 10,00,000/- subject to valid Bids being received at or above the Issue Price. Provided that the unsubscribed portion in either of the sub-categories specified in clauses (a) or (b), may be allocated to applicants in the other sub-category of non-institutional investors.
Other Investor	Investors other than Individual Investors. These include individual applicants other than individual investors and other investors including corporate bodies or institutions irrespective of the number of specified securities applied for.
Overseas Corporate Body/OCB	Overseas Corporate Body means and includes an entity defined in clause (xi) of Regulation 2 of the Foreign Exchange Management (Withdrawal of General Permission to Overseas Corporate Bodies (OCB's) Regulations 2003 and which was in existence on the date of the commencement of these Regulations and immediately prior to such commencement was eligible to undertake transactions pursuant to the general permission granted under the Regulations. OCBs are not allowed to invest in this Offer.
Pay-in-Period	The period commencing on the Bid/Offer Opening date and extended till the closure of the Anchor Investor Pay-in-Date.
Payment through electronic transfer of funds	Payment through NECS, NEFT or Direct Credit, as applicable.

Person / Persons	Any individual, sole proprietorship, unincorporated association, unincorporated organization, body corporate, corporation, company, partnership, limited liability company, joint venture, or trust or any other entity or organization validly constituted and / or incorporated in the jurisdiction in which it exists and operates, as the context requires
Price Band	Price Band of a minimum price (Floor Price) of Rs. [●] and the maximum price (Cap Price) of Rs. [●] and includes revisions thereof. The Price Band and the minimum Bid Lot will be decided by our Company in consultation with the BRLM and advertised in two national daily newspapers (one each in English and in Hindi) with wide circulation and one daily regional newspaper with wide circulation at least two working days prior to the Bid / Issue Opening Date.
Pricing Date	The date on which our Company in consultation with the BRLM, will finalize the Issue Price.
Prospectus	The Prospectus dated [●], to be filed with the Registrar of Companies in accordance with the provisions of Section 26 & 32 of the Companies Act, 2013, containing, inter alia, the Issue Price, size of the Issue and certain other information.
Public Issue Account	Account to be opened with the Bankers to the Offer to receive monies from the SCSBs from the bank account of the Applicant, on the Designated Date.
Public Issue Account Bank	The bank with whom the Public Issue Account is opened for collection of Bid Amounts from Escrow Account and ASBA Account on the Designated Date, in this case being [●].
QIB Portion / QIB Category	The portion of the Net Issue (including the Anchor Investor Portion) being not more than 50% of the Net Issue comprising [●] * Equity Shares which shall be allocated to QIBs (including Anchor Investors), on a proportionate basis, including the Anchor Investor Portion (in which allocation shall be on a discretionary basis, as determined by our Company in consultation with the BRLMs), subject to valid Bids being received at or above the Issue Price or Anchor Investor Issue Price (for Anchor Investors). *Subject to finalization of Basis of Allotment
Qualified Institutional Buyers/ QIBs	Qualified institutional buyers as defined under Regulation 2(1) (ss) of the SEBI ICDR Regulations.
Red Herring Prospectus / RHP	The Red Herring Prospectus to be issued in accordance with Section 32 of the Companies Act, 2013 and the provisions of the SEBI ICDR Regulations, which will not have complete particulars of the price at which the Equity Shares will be Issued and the size of the Issue, including any addenda or corrigendum thereto. The Red Herring Prospectus will be filed with the RoC at least three Working Days before the Bid/Issue Opening Date and will become the Prospectus upon filing with the RoC after the Pricing Date.
Refund Account	The 'no-lien' and 'non-interest bearing' account opened with the Refund Bank, from which refunds, if any, of the whole or part, of the Bid Amount to the Anchor Investors shall be made.
Refund Bank / Refund Banker	Bank which is / are clearing member(s) and registered with the SEBI as Bankers to the Issue at which the Refund Account will be opened, in this case being [●]
Refund through electronic transfer of funds	Refunds through NECS, direct credit, RTGS or NEFT, as applicable
Registered Broker	The stockbrokers registered with the stock exchanges having nationwide terminals, other than the members of the Syndicate and eligible to procure Bids.
Registrar Agreement	The agreement dated September 26, 2025 entered into between our Company and the Registrar to the Issue in relation to the responsibilities and obligations of the Registrar to the Issue pertaining to the Issue.
Registrar and Share Transfer Agents or RTAs	Registrar and share transfer agents registered with SEBI and eligible to procure Applications at the Designated RTA Locations in terms of circular no. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 issued by SEBI.
Registrar/ Registrar to the Issue/ RTI	Registrar to the Issue, in this case being Bigshare Services Private Limited.
Regulation S	Regulation S under the U.S. Securities Act of 1933, as amended from time to time

Reservation Portion	The portion of the Offer reserved for category of eligible Applicants as provided under the SEBI (ICDR) Regulations, 2018.
Revision Form	The form used by the Bidders to modify the quantity of Equity Shares or the Bid Amount in any of their Bid Cum Application Forms or any previous Revision Form(s), as applicable. QIBs and Non – Institutional Investors are not allowed to withdraw or lower their Bids (in terms of quantity of Equity Shares or the Bid Amount) at any stage.
Securities laws	Means the Act, the Securities Contracts (Regulation) Act, 1956, the Depositories Act, 1996 and the rules and regulations made thereunder and the general or special orders, guidelines or circulars made or issued by the Board thereunder and the provisions of the Companies Act, 2013 or any previous company law and any subordinate legislation framed thereunder, which are administered by the Board.
Self-Certified Syndicate Bank(s) / SCSB(s)	Shall mean a Banker to an Offer registered under Securities and Exchange Board of India (Bankers to an Issue) Regulations, 1994, as amended from time to time, and which offer the service of making Application/s Supported by Blocked Amount including blocking of bank account and a list of which is available on https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes or at such other website as may be prescribed by SEBI from time to time.
Specified Locations	Collection centres where the SCSBs shall accept application form, a list of which is available on the website of SEBI (https://www.sebi.gov.in/) and updated from time to time
Specified Securities	Equity shares issued through this Draft Red Herring Prospectus.
Sponsor Bank	Sponsor Bank means a Banker to the Issue registered with SEBI, which is appointed by the Issuer to act as a conduit between the Stock Exchanges and NPCI (National Payments Corporation of India) in order to push the mandate, collect requests and / or payment instructions of the Individual Investors into the UPI.
Sub Syndicate Member	A SEBI Registered member of BSE appointed by the BRLM and / or syndicate member to act as a Sub Syndicate Member in the Issue.
Syndicate	Includes the BRLM, Syndicate Members and Sub Syndicate Members.
Syndicate Agreement	Agreement to be entered into amongst our Company, the BRLM and the Syndicate Members, in relation to the collection of Bid cum Application Forms by the Syndicate Members.
Syndicate ASBA Bidding Locations	Bidding Centres where an ASBA Bidder can submit their Bid in terms of SEBI Circular no. CIR/CFD/DIL/1/2011 dated April 29, 2011.
Syndicate Members / Members of the Syndicate	Intermediaries registered with SEBI eligible to act as a syndicate member and who is permitted to carry on the activity as an underwriter, in this case being [●].
Syndicate or members of the Syndicate	Collectively, the BRLM and the Syndicate Members.
Systemically Important Non – Banking Financial Company	Systemically important non-banking financial company as defined under Regulation 2(1) (iii) of the SEBI ICDR Regulations.
Transaction Registration Slip/ TRS	The slip or document issued by the member of the Syndicate or SCSB (only on demand) as the case may be, to the Bidder as proof of registration of the Application.
U.S. Securities Act	U.S. Securities Act of 1933, as amended
Underwriter	The BRLM and the Underwriter, who have underwritten this Issue pursuant to the provisions of the SEBI (ICDR) Regulations, 2018 and the Securities and Exchange Board of India (Underwriters) Regulations, 1993, as amended from time to time.
Underwriting Agreement	The Agreement dated [●] entered between the Underwriter(s) and our Company.
UPI	Unified payments interface which is an instant payment mechanism, developed by the National Payment Corporation of India.
UPI Circulars	Circular number CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 issued by SEBI, as amended by its Circular number SEBI/HO/CED/DIL/CIR/2016/26 dated January 21, 2016 and Circular number SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 1, 2018 issued by SEBI as amended or modified by SEBI from time to time, including Circular number SEBI/HO/CFD/DIL2/CIR/P/2019/50 dated April 3, 2019, Circular number SEBI/HO/CFD/DIL2/CIR/P/2019/76 dated June 28, 2019, Circular number SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019, Circular number SEBI/HO/CFD/DCR2/CIR/P/2019/133 dated November 8, 2019, Circular number

	SEBI/HO/CFD/DIL2/CIR/P/2020/50 dated March 30, 2020, SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021, SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021, SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/P/2022/45 dated April 5, 2022 as amended pursuant to SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022 and any other circulars issued by SEBI or any other governmental authority in relation thereto from time to time.
UPI ID	ID created on UPI for single window mobile payment system developed by the National Payment Corporation of India.
UPI Mandate Request/ Mandate Request	A request (intimating the UPI Bidders, by way of a notification on the UPI application and by way of a SMS directing the UPI Bidders to such UPI application) to the UPI Bidders initiated by the Sponsor Bank to authorise blocking of funds equivalent to the Bid Amount in the relevant ASBA Account through the UPI, and the subsequent debit of funds in case of Allotment.
UPI Mechanism	The mechanism that was used by an RBI to make a Bid in the Offer in accordance with the UPI Circulars on Streamlining of Public Issues.
UPI PIN	Password to authenticate UPI transaction
Venture Capital Fund/VCF	Foreign Venture Capital Funds (as defined under the Securities and Exchange Board of India (Venture Capital Funds) Regulations, 1996) registered with SEBI under applicable laws in India.
WACA	Weighted average cost of acquisition.
Wilful Defaulter(s)	Wilful defaulter as defined under Regulation 2(1) (III) of the SEBI (ICDR) Regulations, 2018.
Working Day	In accordance with Regulation 2(1) (mmm) of SEBI (ICDR) Regulations, 2018, working days means, all days on which commercial banks in Mumbai are open for business. However, in respect of– (a) announcement of Price Band; and (b) Bid/ Issue period, working days shall mean all days, excluding Saturdays, Sundays and public holidays, on which commercial banks in Mumbai are open for business; (c) In respect to the time period between the Bid/ Issue Closing Date and the listing of the Equity Shares on the Stock Exchange, working day shall mean all trading days of the Stock Exchange, excluding Sundays and bank holidays, as per circulars issued by SEBI.

Technical and Industry Related Terms

Term	Description
ABDM	Ayushman Bharat Digital Mission
ABHA	Ayushman Bharat Health Account
AHU	Air Handling Unit
ALU ALU	Aluminium- Aluminium
API	Active Pharmaceutical Ingredients
B2B	Business-to-Business
BMR	Batch Manufacturing Record
BOD	Biological Oxygen Demand
CAGR	Compound Annual Growth Rate
CMOs	Contract Manufacturing Organizations
CPI	Consumer Price Index
CRAMS	Contract research and manufacturing services
CROs	Contract Research Organizations
DGCA	Directorate General of Civil Aviation
DIs	Drug Intermediates
DPCO	Drugs (Prices Control) Order, 2013
DII	Domestic Institutional Investors
DPIIT	Department for Promotion of Industry and Internal Trade
DRHP	Draft Red Herring Prospectus
DRUGS BILL, 2022	Drugs, Medical Devices and Cosmetics Bill, 2022
EBITDA	Earnings Before Interest, Taxes, Depreciation, and Amortization

EBITDA Margin	EBITDA divided by Revenue from Operations
ECA	Essential Commodities Act, 1955
EDQM	European Directorate of Quality Medicines
EOI	Expression of Interest
EMDEs	Emerging Market and Developing Economies
ETP and STP	Effluent Treatment Plant and Sewage treatment plant
FBD	Fluid Bed Dryer
FDCA	Food & Drugs Control Administration
FY	Fiscal Year
GDP	Gross Domestic Product
GMP	Good Manufacturing Practices
GVA	Gross Value Added
HS Code	Harmonized System Code (for exports/imports)
IBR	Indian Boilers Regulations
IPQA	In Process Quality Assurance
IIP	Index of Industrial Production
IPO	Initial Public Offering
IPQC	In-Process Quality Control
ISO 9001:2015	International Quality Management System Standard
KSMs	Key Starting Materials
LAF	Laminar Air Flow
MEIS	Merchandise Exports from India Scheme
MNA	Middle East and North Africa
MSME	Micro, Small and Medium Enterprises
NCH	National Commission for Homoeopathy
NIPER	National Institutes of Pharmaceutical Education and Research
NLEM	National List of Essential Medicines – 2022
PRIP	Promotion of Research and Innovation in Pharma
OTC	Over the Counter
PAT	Profit After Tax
PMI	Purchasing managers' index
PLI	Production-Linked Incentive
PMEGP	Prime Minister's Employment Generation Programme
PPDS	Pharmaceutical Promotion and Development Scheme
PTUAS	Pharmaceutical Technology Upgradation Assistance Scheme
QA	Quality Assurance
QC	Quality Control
QEHS	Quality, Environment, Health and Safety
RBI	Reserve Bank of India
Repo Rate	Rate at which RBI lends to commercial banks
RLAF	Reverse Laminar Air Flow
RMG	Rapid Mixer Granulator
RoCE	Return on Capital Employed
RoE	Return on Equity
SBIRI	Small Business Innovation Research Initiative
SPI	Strengthening of Pharmaceutical Industry
WHO	World Health Organization

Key Performance Indicators

KPI	Explanations
Revenue from Operations	Revenue from Operations is used by our management to track the revenue profile of the business and in turn helps to assess the overall financial performance of our Company and volume of our business
EBITDA	EBITDA provides information regarding the operational efficiency of the business
EBITDA Margin (%)	EBITDA Margin (%) is an indicator of the operational profitability and financial performance of our business

PAT	Profit after tax provides information regarding the overall profitability of the business.
PAT Margin (%)	PAT Margin (%) is an indicator of the overall profitability and financial performance of our business.
Net Worth	Net worth is used by the management to ascertain the total value created by the entity and provides a snapshot of current financial position of the entity.
Return on Net Worth (%)	Return on Net worth provides how efficiently our Company generates profits from shareholders' funds.
RoCE (%)	RoCE provides how efficiently our Company generates earnings from the capital employed in the business.

Conventional terms and Abbreviations

Abbreviation	Full Form
Rs. / Rupees/ INR / Rs.	Indian Rupees
AS / Accounting Standard	Accounting Standards as issued by the Institute of Chartered Accountants of India
A/c	Account
ACS	Associate Company Secretary
AGM	Annual General Meeting
ASBA	Applications Supported by Blocked Amount
AMT	Amount
AIF	Alternative Investment Funds registered under the Securities and Exchange Board of India (Alternative Investment Funds) Regulations, 2012, as amended.
AY	Assessment Year
AOA	Articles of Association
Approx.	Approximately
Bn	Billion
BG/LC	Bank Guarantee / Letter of Credit
BRLM	Book Running Lead Manager
BSE	Bombay Stock Exchange Limited
CDSL	Central Depository Services (India) Limited
CAGR	Compounded Annual Growth Rate
CAN	Confirmation of Allocation Note
Companies Act, 2013	Companies Act, 2013 to the extent in force pursuant to the notification of sections of the Companies Act, 2013 along with the relevant rules made thereunder as amended.
Companies Act, 1956	Companies Act, 1956 (without reference to the provisions that have ceased upon notification of the Companies Act, 2013) along with the relevant rules made thereunder
Consolidated FDI Policy	The extant consolidated FDI Policy, effective from October 15, 2020, issued by the DPIIT, and any modifications thereto or substitutions thereof, issued from time to time.
CA	Chartered Accountant
CAIIB	Certified Associate of Indian Institute of Bankers
CB	Controlling Branch
CC	Cash Credit
CIN	Corporate Identification Number
CIT	Commissioner of Income Tax
CS	Company Secretary
CS & CO	Company Secretary & Compliance Officer
CFO	Chief Financial Officer
CSR	Corporate Social Responsibility
C.P.C.	Code of Civil Procedure, 1908
Cr.P.C.	Code of Criminal Procedure, 1973
CENVAT	Central Value Added Tax
CST	Central Sales Tax
CWA/ICWA	Cost and Works Accountant/Institute of Cost and Works Accountant
WTD	Whole-Time Director

MD	Managing Director
DIN	Director Identification Number
DIPPT	Department for Promotion of Industry and Internal Trade, Ministry of Commerce and Industry (<i>formerly Department of Industrial Policy and Promotion</i>), GoI.
DP	Depository Participant
DP ID	Depository Participant's Identification Number
EBITDA	Earnings Before Interest, Taxes, Depreciation & Amortization
ECS	Electronic Clearing System
ESIC	Employee's State Insurance Corporation
EPFA	Employee's Provident Funds and Miscellaneous Provisions Act, 1952
EMI	Equated Monthly Instalment
EPS	Earnings Per Share
EGM /EOGM	Extraordinary General Meeting
ESOP	Employee Stock Option Plan
EXIM/ EXIM Policy	Export – Import Policy
FCNR Account	Foreign Currency Non-Resident Account
FIPB	Foreign Investment Promotion Board
FY / Fiscal/Financial Year	Period of twelve months ended March 31 of that particular year, unless otherwise stated
FEMA	Foreign Exchange Management Act, 1999 as amended from time to time, and the regulations framed there under.
FCNR Account	Foreign Currency Non-Resident Account
FBT	Fringe Benefit Tax
FDI	Foreign Direct Investment
Fis	Financial Institutions
FPIs	“Foreign Portfolio Investor” means a person who satisfies the eligibility criteria prescribed under regulation 4 and has been registered under Chapter II of Securities and Exchange Board of India (Foreign Portfolio Investors) Regulations, 2014, which shall be deemed to be an intermediary in terms of the provisions of the SEBI Act, 1992.
FTA	Foreign Trade Agreement
FVCI	Foreign Venture Capital Investors registered with SEBI under the Securities and Exchange Board of India (Foreign Venture Capital Investors) Regulations, 2000.
FEMA	Foreign Exchange Management Act, 1999, including the rules and regulations thereunder
FEMA Rules	Foreign Exchange Management (Non-debt Instruments) Rules, 2019
Finance Act	Finance Act, 1994
FV	Face Value
GoI/Government	Government of India
GDP	Gross Domestic Product
GST	Goods and Services Tax
GVA	Gross Value Added
HUF	Hindu Undivided Family
HNI	High Net Worth Individual
HSL	Hem Securities Limited
IBC	The Insolvency and Bankruptcy Code, 2016
ICAI	The Institute of Chartered Accountants of India
ISIN	International Securities Identification Number
IST	Indian Standard Time
ICWAI	The Institute of Cost Accountants of India
IMF	International Monetary Fund
IIP	Index of Industrial Production
IPO	Initial Public Offer
ICSI	The Institute of Company Secretaries of India
IT	Information Technology
IT Act	Information Technology Act, 2000
IFRS	International Financial Reporting Standards
INR / Rs. / Rupees	Indian Rupees, the legal currency of the Republic of India

I.T. Act	Income Tax Act, 1961, as amended from time to time
IT Authorities	Income Tax Authorities
IT Rules	Income Tax Rules, 1962, as amended, except as stated otherwise
Indian GAAP	Generally Accepted Accounting Principles in India
Ind AS	Indian Accounting Standards as referred to in and notified by the Ind AS Rules
Ind AS Rules	The Companies (Indian Accounting Standard) Rules, 2015
IRDA	Insurance Regulatory and Development Authority
KMP	Key Managerial Personnel
LLB	Bachelor of Law
Ltd.	Limited
LLP	Limited Liability Partnership
MAT	Minimum Alternate Tax
MoF	Ministry of Finance, Government of India
MoU	Memorandum of Understanding
M. A	Master of Arts
MCA	Ministry of Corporate Affairs, Government of India
M. B. A	Master of Business Administration
MAT	Minimum Alternate Tax
M. Com	Master of Commerce
Mn	Million
M. E	Master of Engineering
M. Tech	Masters of Technology
Merchant Banker	Merchant Banker as defined under the Securities and Exchange Board of India (Merchant Bankers) Regulations, 1992
MSME	Micro, Small and Medium Enterprises
MAPIN	Market Participants and Investors Database
NA	Not Applicable
NCLT	National Company Law Tribunal
Net worth	The aggregate of paid-up Share Capital and Share Premium account and Reserves and Surplus (excluding revaluation reserves) as reduced by aggregate of Miscellaneous Expenditure (to the extent not written off) and debit balance of Profit & Loss Account
NACH	National Automated Clearing House
NEFT	National Electronic Funds Transfer
NECS	National Electronic Clearing System
NAV	Net Asset Value
NCT	National Capital Territory
NPV	Net Present Value
NRIs	Non-Resident Indians
NRE Account	Non-Resident External Account
NRO Account	Non-Resident Ordinary Account
NSE	National Stock Exchange of India Limited
NOC	No Objection Certificate
NSDL	National Securities Depository Limited
P.A.	Per Annum
PF	Provident Fund
PG	Post Graduate
PGDBA	Post Graduate Diploma in Business Administration
PLR	Prime Lending Rate
PAC	Persons Acting in Concert
P/E Ratio	Price/Earnings Ratio
PAN	Permanent Account Number
PAT	Profit After Tax
P.O.	Purchase Order
PBT	Profit Before Tax
PLI	Postal Life Insurance
POA	Power of Attorney
PSU	Public Sector Undertaking(s)

Pvt.	Private
Q.C.	Quality Control
RoC	Registrar of Companies
RBI	The Reserve Bank of India
Regulation S	Regulation S under the U.S. Securities Act
Registration Act	Registration Act, 1908
ROE	Return on Equity
R&D	Research & Development
Rs. or Rs.	Rupees, the official currency of the Republic of India
RONW	Return on Net Worth
RTGS	Real Time Gross Settlement
SBO Rules	Significant Beneficial Owners, Rules, 2018
SCRA	Securities Contracts (Regulation) Act, 1956, as amended from time to time
SCRR	Securities Contracts (Regulation) Rules, 1957, as amended from time to time
SME	Small and Medium Enterprises
SMP	Senior Managerial Personnel / Senior Management Personnel
SCSB	Self-Certified syndicate Banks
SEBI Act	Securities and Exchange Board of India Act, 1992, as amended
SEBI AIF Regulations	Securities and Exchange Board of India (Alternate Investments Funds) Regulations, 2012, as amended.
SEBI FPI Regulations	Securities and Exchange Board of India (Foreign Portfolio Investors) Regulations, 2014, as amended from time to time.
SEBI FVCI Regulations	Securities and Exchange Board of India (Foreign Venture Capital Investor) Regulations, 2000, as amended from time to time.
SEBI Insider Trading Regulations	Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended
SEBI LODR/SEBI (Listing Obligations and Disclosure Requirement) Regulations/Listing Regulations	Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement), Regulations 2015, as amended from time to time.
SEBI (PFUTP) Regulations / PFUTP Regulations	Securities and Exchange Board of India (Prohibition of Fraudulent and Unfair Trade Practices relating to Securities Markets) Regulations, 2003
SEBI Regulations/ SEBI ICDR Regulations	Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended.
SEBI SBEB Regulations	Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014.
SEBI Takeover Regulations / Takeover Regulations / Takeover Code	Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended.
SEBI VCF Regulations	Securities and Exchange Board of India (Venture Capital Funds) Regulations, 1996 as amended from time to time.
SEBI	Securities and Exchange Board of India
STT	Securities Transaction Tax
Sub-Account	Sub-accounts registered with SEBI under the SEBI (Foreign Institutional Investor) Regulations, 1995, other than sub-accounts which are foreign corporate or foreign individuals.
Sec.	Section
SPV	Special Purpose Vehicle
TAN	Tax Deduction Account Number
TRS	Transaction Registration Slip
Trade Marks Act	Trade Marks Act, 1999
TIN	Taxpayers Identification Number
UIN	Unique identification number
U.N.	United Nations
US/United States	United States of America
USD/ US\$/ \$	United States Dollar, the official currency of the United States of America
U.S. GAAP	Generally Accepted Accounting Principles in the United States of America
VAT	Value Added Tax

VCF / Venture Capital Fund	Venture Capital Funds (as defined under the Securities and Exchange Board of India (Venture Capital Funds) Regulations, 1996) registered with SEBI under applicable laws in India.
WDV	Written Down Value
WTD	Whole Time Director
w.e.f.	With effect from
-, (Rs.)	Represent Outflow

The words and expressions used but not defined in this Draft Red Herring Prospectus will have the same meaning as assigned to such terms under the Companies Act, 2013, the Securities and Exchange Board of India Act, 1992 (the “SEBI Act”), the SCRA, SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 the Depositories Act and the rules and regulations made thereunder.

CERTAIN CONVENTIONS, PRESENTATION OF FINANCIAL, INDUSTRY AND MARKET DATA AND CURRENCY OF PRESENTATION

In this Draft Red Herring Prospectus, the terms “we”, “us”, “our”, the “Company”, “our Company”, unless the context otherwise indicates or implies, refers to Rednex Pharmaceuticals Limited. All references in the Draft Red Herring Prospectus to “India” are to the Republic of India. All references in the Draft Red Herring Prospectus to the “U.S.”, “USA” or “United States” are to the United States of America.

In this Draft Red Herring Prospectus, unless the context otherwise requires, all references to one gender also refers to another gender and the word “Lac/ Lakh” means “one hundred thousand”, the word “million (mn)” means “Ten Lac/ Lakh”, the word “Crore” means “ten million” and the word “billion (bn)” means “one hundred crore”. In this Draft Red Herring Prospectus, any discrepancies in any table between total and the sum of the amounts listed are due to rounding-off.

Use of Financial Data

Unless stated otherwise, throughout this Draft Red Herring Prospectus, all figures have been expressed in Rupees and Lakh. Unless stated otherwise, the financial data in the Draft Red Herring Prospectus is derived from our restated financial information prepared for the year ended March 31, 2025, March 31, 2024, and March 31, 2023 in accordance with Indian GAAP, the Companies Act and SEBI (ICDR) Regulations, 2018 included under Section titled “*Financial Information of the Company*” beginning on page 172 of this Draft Red Herring Prospectus.

There are significant differences between Indian GAAP, the International Financial Reporting Standards (“IFRS”) and the Generally Accepted Accounting Principles in the United States of America (“U.S. GAAP”). Accordingly, the degree to which the Indian GAAP financial statements included in this Draft Red Herring Prospectus will provide meaningful information is entirely dependent on the reader’s level of familiarity with Indian accounting practice and Indian GAAP. Any reliance by persons not familiar with Indian accounting practices on the financial disclosures presented in this Draft Red Herring Prospectus should accordingly be limited. We have not attempted to explain those differences or quantify their impact on the financial data included herein, and we urge you to consult your own advisors regarding such differences and their impact on our financial data.

Any percentage amounts, as set forth in “*Risk Factors*”, “*Our Business*”, “*Management’s Discussion and Analysis of Financial Condition and Results of Operations*” and elsewhere in the Draft Red Herring Prospectus unless otherwise indicated, have been calculated on the basis of the Company’s restated financial statements prepared in accordance with the applicable provisions of the Companies Act, Indian GAAP and restated in accordance with SEBI (ICDR) Regulations, 2018, as stated in the report of our Peer Review Auditor, set out in section titled “*Financial Information of the Company*” beginning on page 172 of this Draft Red Herring Prospectus. As on date of the Draft Red Herring Prospectus we don’t have any subsidiaries. Our fiscal year commences on April 1 of every year and ends on March 31 of every next year.

For additional definitions used in this Draft Red Herring Prospectus, see the section “*Definitions and Abbreviations*” on page 1 of this Draft Red Herring Prospectus. In the section titled “*Main Provisions of the Articles of Association*”, on page 305 of the Draft Red Herring Prospectus defined terms have the meaning given to such terms in the Articles of Association of our Company.

Use of Industry & Market Data

Unless stated otherwise, industry and market data and forecast used throughout the Draft Red Herring Prospectus was obtained from internal Company reports, data, websites, Industry publications report as well as Government Publications. Industry publication data and website data generally state that the information contained therein has been obtained from sources believed to be reliable, but that their accuracy and completeness and underlying assumptions are not guaranteed and their reliability cannot be assured.

Although, we believe industry and market data used in the Draft Red Herring Prospectus is reliable, it has not been independently verified by us or the BRLM or any of their affiliates or advisors. Similarly, internal Company reports and data, while believed by us to be reliable, have not been verified by any independent source. There are no standard data gathering methodologies in the industry in which we conduct our business and methodologies and assumptions may vary widely among different market and industry sources.

In accordance with the SEBI (ICDR) Regulations, 2018 the section titled “*Basis for Issue Price*” on page 90 of this Draft Red Herring Prospectus includes information relating to our peer group companies. Such information has been derived from publicly available sources, and neither we, nor the BRLM, have independently verified such information.

Currency of Financial Presentation

All references to “Rupees” or “INR” or “Rs.” or “₹” are to Indian Rupees, the official currency of the Republic of India. Except where specified, including in the section titled “*Industry Overview*” throughout the Draft Red Herring Prospectus all figures have been expressed in Lakhs.

Any percentage amounts, as set forth in “*Risk Factors*”, “*Our Business*”, “*Management's Discussion and Analysis of Financial Conditions and Results of Operations*” on page 27, 118 and 223 respectively of this Draft Red Herring Prospectus, unless otherwise indicated, have been calculated based on our restated financial statements prepared in accordance with Indian GAAP.

The Draft Red Herring Prospectus contains conversion of certain US Dollar and other currency amounts into Indian Rupees that have been presented solely to comply with the requirements of the SEBI (ICDR) Regulations, 2018. These conversions should not be construed as a representation that those US Dollar or other currency amounts could have been, or can be converted into Indian Rupees, at any particular rate.

FORWARD LOOKING STATEMENTS

This Draft Red Herring Prospectus includes certain “forward-looking statements”. We have included statements in the Draft Prospectus which contain words or phrases such as “will”, “aim”, “is likely to result”, “believe”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “project”, “should”, “will pursue” and similar expressions or variations of such expressions, that are “forward-looking statements”. Also, statements which describe our strategies, objectives, plans or goals are also forward-looking statements.

All forward-looking statements are subject to risks, uncertainties and assumptions about us that could cause actual results to differ materially from those contemplated by the relevant forward-looking statement. Forward-looking statements reflect our current views with respect to future events and are not a guarantee of future performance. These statements are based on our management’s beliefs and assumptions, which in turn are based on currently available information. Although we believe the assumptions upon which these forward-looking statements are based are reasonable, any of these assumptions could prove to be inaccurate, and the forward-looking statements based on these assumptions could be incorrect. Important factors that could cause actual results to differ materially from our expectations include but are not limited to:

1. The loss of one or more marketing partners, the deterioration of their financial condition or prospects, or a reduction in their demand for our products or our inability to maintain and increase the number of our arrangements for the marketing and distribution of our products
2. Decrease in market growth for our product or failure to respond to change in market conditions
3. Failure to comply with the quality standards and technical specifications prescribed by our customers
4. Cancellation of existing and future orders which may expose us to warranty claims;
5. The pharmaceutical market is subject to regulation and failures to comply with the existing and future regulatory requirements in any pharmaceutical market
6. Instances where our drugs fail to meet standards prescribed under applicable law and action by regulatory authorities.
7. Any change in government policies resulting in increases in taxes payable by us;
8. Failure of our suppliers in meeting their obligations with respect to supply of raw materials and components;
9. The occurrence of natural disasters or calamities;
10. General economic, political and other risks that are out of our control;
11. Inflation, deflation, unanticipated turbulence in interest rates, equity prices or other rates or prices;
12. Company’s ability to successfully implement its growth strategy and expansion plans;
13. Failure to comply with regulations prescribed by authorities of the jurisdictions in which we operate;
14. Inability to successfully obtain registrations in a timely manner or at all;
15. Occurrence of Environmental Problems & Uninsured Losses;
16. Concentration of ownership among our Promoters.

For further discussion of factors that could cause our actual results to differ, see the Section titled “***Risk Factors***”, “***Our Business***” and “***Management’s Discussion and Analysis of Financial Condition and Results of Operations***” beginning on page 27, 118 and 223 respectively of the Draft Red Herring Prospectus. By their nature, certain market risk disclosures are only estimates and could be materially different from what actually occurs in the future. As a result, actual future gains or losses could materially differ from those that have been estimated.

There can be no assurance to investors that the expectations reflected in these forward-looking statements will prove to be correct. Given these uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and not to regard such statements to be a guarantee of our future performance.

Neither our Company or our Directors or our Officers or Book Running Lead Manager or Underwriter nor any of their respective affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after the date hereof or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition. In accordance with SEBI requirements, our Company and the BRLM will ensure that investors in India are informed of material developments until such time as the grant of listing and trading permission by the Stock Exchange for the Equity Shares allotted pursuant to this Issue.

SECTION II – SUMMARY OF DRAFT RED HERRING PROSPECTUS

A. OVERVIEW OF BUSINESS

We are engaged in manufacturing of a wide range of pharmaceutical products finding application across various therapeutic areas. We also manufacture pharmaceutical products under loan license or contract manufacturing for our clients. We have developed our product portfolio in various dosage forms that includes Tablets, Capsules, External Preparation (Cream/Gel/Ointment/Lotion), Oral Liquid and Dry Syrup. Our products cater to the major therapeutic areas, including Antibacterial, Antitussive, Analgesic, Anticold, Antacid, Antimalarial, Antifungal, Antidiarrheal, Anti-Allergy, etc

For further details, please refer to the chapter titled “Our Business” beginning on page 118 of this Draft Red Herring Prospectus.

OVERVIEW OF THE INDUSTRY

The Indian Pharmaceutical Industry has witnessed a robust growth over the past few years moving on from a turnover of approx. US \$ 1 billion in 1990 to over US \$30 billion in 2015 of which the export turnover is approximately US \$ 15 billion. The country now ranks 3rd world wide by volume of production and 14th by value, thereby accounting for around 10% of world’s production by volume and 1.5% by value. Globally, it ranks 4th in terms of generic production and 17th in terms of export value of bulk actives and dosage forms. Indian exports are destined to more than 200 countries around the globe including highly regulated markets of US, West Europe, Japan and Australia.

For further details, please refer to the chapter titled “Industry Overview” beginning on page 102 of this Draft Red Herring Prospectus.

B. PROMOTERS

Chetan Rugnathbhai Matholiya, Jayeshkumar Amarshibhai Sabava and Akashbhai Mansukhbhai Gangadiya are the Promoters of our Company. For further details, see “Our Promoters & Promoter Group” beginning on page 165 of this Draft Red Herring Prospectus.

C. DETAILS OF THE ISSUE

This is an Initial Public Issue of upto 27,36,000 Equity Shares of face value of ₹10 each of our Company for cash at a price of ₹[●] per Equity Share (including a share premium of ₹[●] per Equity Share) aggregating to ₹[●] lakhs (“The Issue”), out of which [●] Equity Shares of face value of ₹10 each for cash at a price of ₹[●] per Equity Share aggregating up to ₹[●] lakhs will be reserved for subscription by the market maker to the issue (the “Market Maker Reservation Portion”). The Issue less Market Maker Reservation Portion i.e., Issue of [●] Equity Shares of face value of ₹10 each, at an issue price of ₹ [●] per Equity Share for cash, aggregating to ₹ [●] lakhs is hereinafter referred to as the “Net Issue”. The Public Issue and Net Issue will constitute 26.34% and [●] % respectively of the post- issue paid-up Equity Share capital of our Company.

D. OBJECTS OF THE ISSUE

Our Company intends to utilize the proceeds of the Issue to meet the following objects:

		(₹ in Lakhs)
Sr. No	Particulars	Amount
1	Repayment in full or in part, of certain of our outstanding borrowings	900.00
2	Funding capital expenditure towards purchase of new machinery	608.40
3	Funding to meet Working Capital requirements	1500.00
4	General Corporate Purpose	[●]
	Total	[●]

For further details please refer to the chapter titled “Object of the Issue” beginning on page 80 of this Draft Red Herring Prospectus.

E. PRE-ISSUE SHAREHOLDING OF PROMOTERS AND PROMOTER GROUP

Our Promoters & Promoter Group collectively hold 76,50,000 Equity shares of face value of ₹10/- each of our Company aggregating to 100.00% of the pre-issue paid-up Share Capital of our Company. Following are the details of the shareholding of the Promoters and Promoter Group, as on date of this Draft Red Herring Prospectus: -

Sr. No.	Names	Pre-IPO		Post-IPO	
		Shares Held	%	Shares Held	%
	Promoters				
1	Chetan Rugnathbhai Matholiya	25,49,736	33.33%	25,49,736	[●]
2	Jayeshkumar Amarshibhai Sabava	25,50,492	33.34%	25,50,492	[●]
3	Akashbhai Mansukhbhai Gangadiya	25,49,736	33.33%	25,49,736	[●]
	Sub Total (A)	76,49,964	100.00%	76,49,964	[●]
	Promoter Group				
4	Kartikkumar Mansukhbhai Gangadiya	9	Negligible	9	[●]
5	Mitalben Chetanbhai Matholiya	9	Negligible	9	[●]
6	Mitbhai Natubhai Sabava	9	Negligible	9	[●]
7	Shaileshbhai Rugnathbhai Matholiya	9	Negligible	9	[●]
	Sub Total (B)	36	Negligible	36	[●]
	Grand Total (A+B)	76,50,000	100.00	76,50,000	[●]

EA. SHAREHOLDING OF PROMOTERS / PROMOTER GROUP AND ADDITIONAL TOP 10 SHAREHOLDERS OF THE COMPANY AS AT ALLOTMENT:

Sr. No.	Pre-Issue shareholding as at the date of Advertisement			Post-Issue shareholding as at Allotment ⁽³⁾			
	Shareholders	Number of Equity Shares ⁽²⁾	Share Holding (in %) ⁽²⁾	At the lower end of the price band (₹[●])		At the upper end of the price band (₹[●])	
				Number of Equity Shares ⁽²⁾	Share holding (in %) ⁽²⁾	Number of Equity Shares ⁽²⁾	Share holding (in %) ⁽²⁾
Promoters							
1.	Chetan Rugnathbhai Matholiya	25,49,736	33.33%	[●]	[●]%	[●]	[●]%
2.	Jayeshkumar Amarshibhai Sabava	25,50,492	33.34%	[●]	[●]%	[●]	[●]%
3.	Akashbhai Mansukhbhai Gangadiya	25,49,736	33.33%				
	Sub Total (A)	76,49,964	100.00%	[●]	[●]%	[●]	[●]%
Promoter Group ⁽¹⁾							
1.	Kartikkumar Mansukhbhai Gangadiya	9	Negligible	[●]	[●]%	[●]	[●]%
2.	Mitalben Chetanbhai Matholiya	9	Negligible	[●]	[●]%	[●]	[●]%
3.	Mitbhai Natubhai Sabava	9	Negligible	[●]	[●]%	[●]	[●]%
4.	Shaileshbhai Rugnathbhai Matholiya	9	Negligible	[●]	[●]%	[●]	[●]%
	Sub Total (B)	36	Negligible	[●]	[●]%	[●]	[●]%

**Our Company have only seven shareholders consisting promoter and promoter group. For further details, please refer to the chapter titled “Capital Structure” beginning on page 68 of this Draft Red Herring Prospectus.*

Notes:

- 1) The Promoter Group shareholders are Kartikkumar Mansukhbhai Gangadiya, Mitalben Chetanbhai Matholiya, Mitbhai Natubhai Sabava, and Shaileshbhai Rugnathbhai Matholiya.
- 2) Includes all options that have been exercised until date of prospectus and any transfers of equity shares by existing shareholders after the date of the pre-issue and price band advertisement until date of prospectus.
- 3) Based on the Issue price of ₹[●] and subject to finalization of the basis of allotment.

F. SUMMARY OF FINANCIAL INFORMATION

Following are the details as per the restated financial statements for the financial years ended on March 31, 2025, March 31, 2024, and March 31, 2023:

<i>(₹ in Lakhs)</i>			
Particulars	March 31, 2025	March 31, 2024	March 31, 2023
Equity Share Capital	425.00	425.00	425.00
Net worth	947.07	520.67	327.24
Total Income	4,612.09	2,448.24	172.09
Profit after tax	426.40	193.43	(92.55)
Earnings per Share	5.57	2.53	(1.54)
Net Asset Value per Share (Based on Weighted Average Number of Shares)	12.38	6.81	5.44
Total Borrowings (including current maturities of long-term borrowings)	1,914.05	1,921.65	1,035.39

For further details, please refer to the section titled “**Financial Information**” beginning on page 172 of this Draft Red Herring Prospectus.

G. AUDITOR QUALIFICATIONS

There are no audit qualifications which have not been given effect in the restated financial statements.

H. SUMMARY OF OUTSTANDING LITIGATIONS

A summary of outstanding litigations proceedings involving our Company, Promoters and Directors as on the date of this Draft Red Herring Prospectus are as below: -

Litigations/ Matters against our Company:

Nature of Litigation	Number of Cases Outstanding	Amount in dispute (Amount in lakhs)
Other Pending Litigation	1	10.00

Litigations/ Matters against our Promoters and Directors:

Nature of Litigation	Number of Cases Outstanding	Amount in dispute (Amount in lakhs)
Criminal Proceedings	1	Unascertainable

Amount mentioned to the extent quantifiable. The amount may be subject to additional interest/other charges being levied by the concerned authorities which are unascertainable as on date of this Draft Red Herring Prospectus

For further details, see “**Outstanding Litigation and Material Developments**” beginning on page 233 of this Draft Red Herring Prospectus. Any adverse decisions in the aforesaid proceedings may have a material effect on our business, future financial performance and results of operations.

I. RISK FACTORS

For details on the risks involved in our business, please see the Chapter titled “**Risk Factors**” beginning on page 27 of this Draft Red Herring Prospectus.

J. SUMMARY OF CONTINGENT LIABILITIES

Nil

K. SUMMARY OF RELATED PARTY TRANSACTIONS

Following is the summary of the related party transactions based on Restated Financial Statements entered by the Company for the financial years ended on March 31, 2025, March 31, 2024, and March 31, 2023:

RELATED PARTY DISCLOSURES

A. List of Related Parties as per AS – 18

Particulars	Names of Related Parties	Nature of Relationship
Key Management Personnel (KMP)	Chetan Rugnathbhai Matholiya	Chairman and Whole-Time Director
	Akashbhai Mansukhbhai Gangadiya	Whole Time Director & CFO
	Jayeshkumar Amarshibhai Sabava	Managing Director
	Rima Amitbhai Dalal	Company Secretary & Compliance Officer w.e.f 14th Aug, 2025
Relatives of KMP	Dakshaben Jayeshbhai Sabava	Wife of Managing Director
	Kartikkumar Mansukhbhai Gangadiya	Brother of Whole Time Director & CFO
	Natubhai Amarshibhai Sabava	Brother of Managing Director
	Shaileshbhai Rugnathbhai Matholiya	Brother of Chairman and Whole-Time Director
	Mitalben Chetanbhai Matholiya	Wife of Chairman and Whole-Time Director
Enterprises over which any person, who is a key management personnel or has direct and indirect interest in voting power, can exercise significant influence	Bhagat Enterprise	KMP/ Relative of KMP having significant influence/ interest
	Rednex Pharmaceuticals	KMP/ Relative of KMP having significant influence/ interest
	Narayan Pharma House LLP	KMP/ Relative of KMP having significant influence/ interest
	Lalko Minerals	KMP/ Relative of KMP having significant influence/ interest
	Lalko Exim Pvt Ltd	KMP/ Relative of KMP having significant influence/ interest
	Greenwood Enterprise	KMP/ Relative of KMP having significant influence/ interest
	Gopinath Enterprise	KMP/ Relative of KMP having significant influence/ interest
	Xender Pharmaceuticals	KMP/ Relative of KMP having significant influence/ interest

B. Related party transactions

(Amount in Rs. Lakhs)

Sr. No.	Name of Party	Nature of Transactions	31.03.2025	31.03.2024	31.03.2023
1	Chetan Rugnathbhai Matholiya	Directors Remuneration	3.47	0.97	0.50
		Loan Taken	30.30	12.25	200.03
		Loan Returned	74.73	3.75	239.24
2	Akashbhai Mansukhbhai Gangadiya	Directors Remuneration	1.00	0.97	0.50
		Loan Taken	14.25	39.50	116.64
		Loan Returned	6.45	3.00	174.31
3	Jayeshkumar Amarshibhai Sabava	Directors Remuneration	3.47	0.97	0.50
		Loan Taken	5.00	14.46	167.24
		Loan Returned	16.47	4.00	215.89
4	Shaileshbhai Rugnathbhai Matholiya	Salary	5.00	2.98	2.15
		Loan Taken	5.00	1.00	14.41
		Loan Returned	15.27	9.00	0.25
5	Dakshaben Jayeshbhai Sabava	Salary	2.95	0.00	0.00
6	Kartikkumar Mansukhbhai Gangadiya	Salary	5.60	0.00	0.00
		Loan Taken	9.00	0.00	8.00
		Loan Returned	25.11	4.00	0.00
7	Natubhai Amarshibhai Sabava	Salary	3.00	2.99	2.40
8	Mitalben Chetanbhai Matholiya	Salary	2.95	0.00	0.00
		Loan Taken	0.00	0.00	7.39
9	Bhagat Enterprise	Purchase of Goods	22.18	2.53	
10	Rednex Pharmaceuticals	Purchase of Goods	70.14	7.83	2.69
		Sales of Goods	0.00	0.64	0.00
		Advance Taken	0.00	0.00	1.05
		Advance Given (Repaid)	23.84	49.45	0.00

		Rent	0.07	0.00	0.00
11	Narayan Pharma House LLP	Purchase of Goods	61.00	5.04	1.16
12	Lalko Minerals	Purchase of Goods	0.36	0.03	
13	Lalko Exim Pvt Ltd	Purchase of Goods	10.01	0.00	0.00
14	Greenwood Enterprise	Purchase of Goods	3.73	0.87	0.00
15	Gopinath Enterprise	Purchase of Goods	50.87	0.84	0.17
16	Xender Pharmaceuticals	Sales of Goods	18.08	2.67	3.47
		Advance Given (Repaid)	0.00	8.93	0.00

C. Outstanding Balances

(Amount in Rs. Lakhs)

Sr. No.	Name of Party	Nature of Transactions	31.03.2025	31.03.2024	31.03.2023
1	Chetan Rugnathbhai Matholiya	Remuneration payable	1.00	1.47	0.50
		Loans and Advances	107.70	152.13	143.63
2	Akashbhai Mansukhbhai Gangadiya	Remuneration payable	1.00	1.47	0.50
		Loans and Advances	82.72	89.17	52.67
3	Jayeshkumar Amarshibhai Sabava	Remuneration payable	1.00	1.47	0.50
		Loans and Advances	108.06	119.52	109.06
4	Shaileshbhai Rugnathbhai Matholiya	Loans and Advances	7.35	17.63	25.63
		Salary	0.45		
5	Dakshaben Jayeshbhai Sabava	Loans and Advances	1.75	1.75	1.75
		Salary	0.50		
6	Kartikkumar Mansukhbhai Gangadiya	Loans and Advances	15.60	31.71	35.71
		Salary	0.10		
7	Mitalben Chetanbhai Matholiya	Loans and Advances	7.39	7.39	7.39
		Salary	0.50	0.00	0.00
8	Bhagat Enterprise	Trade Payable	(4.21)	(11.57)	0.00
9	Rednex Pharmaceuticals	Rent Payable	0.07	0.00	0.00
		Advance Taken (Returned)	0.00	0.00	14.46
		Advance Given (Repaid)	58.83	34.98	0.00
10	Narayan Pharma House LLP	Trade Payable	10.88	12.40	0.69
11	Lalko Minerals	Trade Payable	0.00	0.03	0.00
12	Lalko Exim Pvt Ltd	Trade Payable	0.01		
13	Greenwood Enterprise	Trade Payable	1.08	0.00	0.00
14	Gopinath Enterprise	Trade Payable	4.31	(14.94)	2.12
15	Xender Pharmaceuticals	Trade Recievable	9.24	0.00	2.39
		Advance Given (Repaid)	8.93	8.93	0.00

For further details, please refer to the **Note-29 Related Party Disclosures** of chapter titled “**Financial Information of the Company**” on page 211 of this Draft Red Herring Prospectus.

L. DETAILS OF FINANCING ARRANGEMENTS

There are no financing arrangements whereby the promoters, members of the promoter group, the directors of the issuer and their relatives have financed the purchase of securities of the issuer other than in the normal course of the business of the financing entity during the period of six months immediately preceding the date of this Draft Red Herring Prospectus.

M. WEIGHTED AVERAGE PRICE OF THE SHARES ACQUIRED BY PROMOTERS IN LAST ONE YEAR

Sr. No.	Name of Promoters	No. of Equity Shares Acquired	Weighted Average Price (in ₹)
1.	Chetan Rugnathbhai Matholiya	11,33,216	Nil*
2.	Jayeshkumar Amarshibhai Sabava	11,33,552	
3.	Akashbhai Mansukhbhai Gangadiya	11,33,216	

*Pursuant to allotment of Bonus Issue in the ratio of 4:5 vide Board Resolution dated September 09, 2025.

N. AVERAGE COST OF ACQUISITION OF SHARES

The average cost of acquisition of Equity Shares by our Promoters is set forth in the table below:

Sr. No.	Name of the Promoters	No. of Shares held	Average cost of Acquisition (in ₹)
1.	Chetan Rugnathbhai Matholiya	25,49,736	5.56
2.	Jayeshkumar Amarshibhai Sabava	25,50,492	5.56
3.	Akashbhai Mansukhbhai Gangadiya	25,49,736	5.56

O. PRE-IPO PLACEMENT

Our Company is not considering any pre-IPO placement of equity shares of the Company.

P. EQUITY SHARES ISSUED FOR CONSIDERATION OTHER THAN CASH

Except as set out below we have not issued Equity Shares for consideration other than cash in the last one year:

Date of Allotment	Number of Equity Shares	Face value (₹)	Issue Price (₹)	Reason for Allotment	Benefits Accrued to our Company	Name of Allottees	No. of Shares Allotted (Face value of ₹ 10 each)
September 09, 2025	34,00,000	10	-	Bonus in the ratio of 4:5 i.e. 4 (four) equity shares for every 5 (five) equity share held	Capitalization of Reserves & Surplus*	Akashbhai Mansukhbhai Gangadiya	11,33,216
						Chetan Rugnathbhai Matholiya	11,33,216
						Jayeshkumar Amarshibhai Sabava	11,33,552
						Shaileshbhai Rugnathbhai Matholiya	4
						Kartikkumar Mansukhbhai Gangadiya	4
						Mitalben Chetanbhai Matholiya	4
						Mitbhai Natubhai Sabava	4

*Above allotment of shares has been made out of Reserve & Surplus available for distribution to shareholders and no part of revaluation reserve has been utilized for the purpose.

Q. SPLIT/ CONSOLIDATION OF EQUITY SHARES

Our Company has not undertaken split or consolidation of the Equity Shares in the one (1) year preceding the date of this Draft Red Herring Prospectus.

R. EXEMPTION FROM COMPLYING WITH ANY PROVISIONS OF SECURITIES LAWS, IF ANY, GRANTED BY SEBI

As on date of the Draft Red Herring Prospectus, our Company has not availed any exemption from complying with any provisions of securities laws granted by SEBI.

RISK FACTORS

An investment in our Equity Shares involves a high degree of financial risk. Prospective investors should carefully consider all the information in the Draft Red Herring Prospectus, particularly the “**Financial Information of the Company**” and the related notes, “**Our Business**” and “**Management’s Discussion and Analysis of Financial Condition and Results of Operations**” on page 172, 118, and 223 respectively of this Draft Red Herring Prospectus and the risks and uncertainties described below, before making a decision to invest in our Equity Shares.

The risk factors set forth below are not exhaustive and do not purport to be complete or comprehensive in terms of all the risk factors that may arise in connection with our business or any decision to purchase, own or dispose of the Equity Shares. This section addresses general risks associated with the industry in which we operate and specific risks associated with our Company. Any of the following risks, individually or together, could adversely affect our business, financial condition, results of operations or prospects, which could result in a decline in the value of our Equity Shares and the loss of all or part of your investment in our Equity Shares. While we have described the risks and uncertainties that our management believes are material, these risks and uncertainties may not be the only risks and uncertainties we face. Additional risks and uncertainties, including those we currently are not aware of or deem immaterial, may also have an adverse effect on our business, results of operations, financial condition and prospects.

This Draft Red Herring Prospectus contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the considerations described below and elsewhere in this Draft Red Herring Prospectus. The financial and other related implications of risks concerned, wherever quantifiable, have been disclosed in the risk factors below. However, there are risk factors the potential effects of which are not quantifiable and therefore no quantification has been provided with respect to such risk factors. In making an investment decision, prospective investors must rely on their own examination of our Company and the terms of the Offer, including the merits and the risks involved. You should not invest in this Issue unless you are prepared to accept the risk of losing all or part of your investment, and you should consult your tax, financial and legal advisors about the particular consequences to you of an investment in our Equity Shares.

Materiality

The Risk factors have been determined on the basis of their materiality. The following factors have been considered for determining the materiality.

- 1. Some events may not be material individually but may be found material collectively.*
- 2. Some events may have material impact qualitatively instead of quantitatively.*
- 3. Some events may not be material at present but may be having material impact in future.*

Note:

The risk factors as envisaged by the management along with the proposals to address the risk if any. Unless specified or quantified in the relevant risk factors below, we are not in a position to quantify the financial implication of any of the risks described in this section.

*In this Draft Red Herring Prospectus, any discrepancies in any table between total and the sums of the amount listed are due to rounding off. Any percentage amounts, as set forth in “**Risk Factors**” on page 27 and “**Management Discussion and Analysis of Financial Condition and Results of Operations**” on page 223 of this Draft Red Herring Prospectus unless otherwise indicated, has been calculated on the basis of the amount disclosed in the “**Restated Financial Statements**” on page 172 of this Draft Red Herring Prospectus.*

- 1. **Our business is dependent on the sale of our products through third party marketing partners and distributors. The loss of one or more marketing partners or distributors, the deterioration of their financial condition or a reduction in their demand for our products or our inability to maintain and increase the number of our arrangements for the marketing and distribution of our products could adversely affect our business, results of operations, financial conditions and cash flows.***

We focus on introducing our products in the emerging markets. We sell and market our products through third-party distributors and participants in the pharmaceutical market. We largely operate on a principal to principal model with different marketers. Moreover, we also undertake contract manufacturing of pharmaceutical products on a loan license basis, who possess the necessary marketing authorizations and market our products under their own brand names.

Our revenue from operations from contract manufacturing and principal to principal model in the last three financial year is as under:

Particulars	FY 24-25	% of Revenue	FY 23-24	% of Revenue	FY 22-23	% of Revenue
Contract Manufacturing under Loan License	1030.32	22.50%	18.46	0.76%	0.00	0.00%
Principal to Principal Model	3549.79	77.50%	2422.09	99.24%	170.25	100.00%
Total	4580.12	100.00%	2440.54	100.00%	170.25	100.00%

There is no assurance that our business from arrangements with marketing partners will not decline in the future as a result of increased competition, pricing pressures or fluctuation in the demand or supply of our products. Similarly, in the event of any breakthroughs in the development or invention of alternative products, we may be exposed to the risk of our products being substituted to a greater or lesser extent by these alternatives, and we may fail to introduce new products that would cater to the demand by our marketing partners.

Further, some of our marketing partners may start manufacturing their own products or switch production to our competitors and may discontinue their arrangement with us. Although we manufacture our products for few customers under loan license, with options for renewal, our dependence on such parties subjects us to a number of other risks, including (i) not being able to control the amount and timing of resources that our partners may devote to the marketing, selling and distribution of our products, (ii) financial difficulties, (iii) a reduction in the amount of business we obtain from our customers, which could be due to circumstances specific to them, such as pricing pressures, or adverse market conditions affecting our supply chain or the pharmaceutical industry, (iv) a reduction in the amount of business we obtain from our customers, or the loss of one or more of our key customers could have an adverse effect on our business, results of operations, financial condition and cash flows.

Further, we may not be able to find suitable marketing partners and distributors or successfully enter into arrangements on commercially reasonable terms or at all. If our competitors provide greater incentives to our partners, our partners may choose to partner with our competitors. As a result of these arrangements, many of the variables that may affect our business, are not exclusively within our control. We cannot assure that termination of arrangements for any reason, or if our marketing partners or distributors fail to fulfil their obligations or otherwise do not effectively market, sell or distribute our products, or if our relationships with any of such marketing partners are disrupted in the future, our business, financial condition, results of operations and cash flows will not be adversely affected.

2. We are subject to strict technical specifications, quality requirements, regular inspections and audits by our customers. Our failure to comply with the quality standards and technical specifications prescribed by such customers may lead to loss of business from such customers and could negatively impact our business.

Our products and manufacturing processes are subject to stringent quality standards and specifications. Adherence to quality standards is a critical factor in our production process as any deviations from the required specifications by our Company or failure to comply with the technical specifications of our customers regarding the composition of drugs, may lead to a recall of products or cancellation of the orders placed by our customers. Further, for any change in the product specifications, manufacturing process, manufacturing method or raw material used, we are required to inform or obtain prior consent from some of our customers. While we believe we undertake the necessary measures to ensure that our facilities comply with the applicable standards as imposed by our customers, any failure on our part to maintain the applicable standards and manufacture products according to prescribed specifications, may lead to cancellation of the order, loss of customers, loss of reputation and goodwill of our Company. Additionally, it could expose us to monetary liability and/or litigation. Our customers are typically provided the right to audit our manufacturing facilities, processes or systems, after providing a certain period of notice. Further to these audits, our customers have issued certain major observations, minor observations and recommendations. There can be no assurance that such audits would not result in any adverse observations in the future or that our customers will necessarily engage us for their outsourcing operations. The audit may involve inspection of, *inter alia*, our manufacturing facility and equipment, quality control procedures, review of the manufacturing processes and raw materials and packaging.

In addition, we are required to ensure that our products are sold, distributed and consumed within their prescribed shelf-life. Any lapse in monitoring expiry dates, storage, distribution, or recall of expired products may result in regulatory action, penalties, and reputational damage. The presence of expired products in the market can also lead to loss of customer trust, cancellation of orders and adverse impact on our financial performance.

In some circumstances, we are also required to furnish testing certificates to the customers certifying that the quality of the products is as per the agreed specifications. Our customers may reject the products in case of, *inter alia*, manufacturing defects, and discrepancy with respect to prescribed specifications, and we are responsible to replace such products free of any additional cost within a stipulated timeframe. However, if we are required to pay any indemnity in the future, it may have an adverse impact on our revenue from operations and financial condition. In addition, for any changes in the product specifications, analytical methods, batch manufacturing reports or raw material used, some agreements require us to obtain prior consent from our customers. We are also responsible for the procurement of raw materials, including APIs and packaging materials in accordance with the specifications provided by the customer and in certain cases, the third-party vendor should be approved by the customer. In cases of recall of the product manufactured by our Company, we are required to bear all the expenses and costs of such recall either upfront or by way of deduction from our bills, and the customers may also opt to terminate their business on account of such recall. In the past, we have had instances of products being recalled from markets. We cannot assure you that such events will not occur in future and any happening of any such events in future may have a material adverse effect on our business operations and financial performance.

3. *We derive a significant part of our revenue from few customers. If one or more of such customers choose not to source their requirements from us, our business, cash flows, financial condition and results of operations may be adversely affected*

The table below sets out the revenue contribution as a percentage of our total revenue from operations from our largest customer, our top five customers and our top ten customers, for Fiscal 2025, Fiscal 2024 and Fiscal 2023.

Particulars	Fiscals 2025		Fiscals 2024		Fiscals 2023	
	Amount	As a % of revenue from operations	Amount	As a % of revenue from operations	Amount	As a % of revenue from operations
Largest Customer	801.17	17.49%	1219.46	49.97%	56.46	33.16%
Top 5 Customers	2636.17	57.56%	1828.30	74.91%	115.67	67.94%
Top 10 Customers	3337.96	72.88%	2135.12	87.49%	141.02	82.83%

Reliance on a limited number of customers for our business may generally involve several risks. While we have developed relationships with certain of our customers, there can be no assurance that our significant customers in the past will continue to place orders or maintain the current level of business with us in the future. In order to retain some of our existing customers, we may also be required to offer terms to such customers which may place restraints on our resources. The loss of one or more of these significant customers or a significant decrease in business from any such key customer, whether due to circumstances specific to such customer or adverse market conditions affecting the pharmaceutical industry or the economic environment generally, may materially and adversely affect our business, results of operations and financial condition. Further, our reliance on a select group of customers may also constrain our ability to negotiate favourable arrangements, which may have an impact on our profit margins and financial performance. The deterioration of the financial condition or business prospects of these customers could reduce their requirement of our products and result in a significant decrease in the revenues we derive from these customers. We cannot assure you that we will be able to maintain historic levels of business from our significant customers, or that we will be able to significantly reduce customer concentration in the future.

Additionally, our customers have high and stringent standards for product quality and quantity as well as delivery schedules. Our customers conduct regular inspections and audits at our manufacturing facility and any failure to meet our customers' expectations could result in the cancellation of our purchase orders. There are also a number of factors, other than our performance that could cause the loss of a customer, which include those customers who may demand price reductions, set-off any payment obligations, require indemnification for themselves or their affiliates, or replace their existing products with alternative products, any of which may have an adverse effect on our business, financial condition, results of operations and prospects.

4. *The pharmaceutical market is subject to extensive regulation and failures to comply with the existing and future regulatory requirements in any pharmaceutical market could expose us to litigation or other liabilities, which could adversely affect our reputation, business, financial condition and results of operations*

We operate in a highly regulated industry and our operations are subject to extensive regulation governing the pharmaceutical market. The manufacturing, testing, marketing and sale of pharmaceutical products are subject to extensive regulation in India and other countries. We are required to comply with the regulatory requirements of various local, state, provincial and national regulatory authorities, such as Deputy Director Industrial Safety and Health, , Commissioner Food

& Drugs Control Administration Gujarat State, Inspector of Legal Metrology, Gujarat Pollution Control Board and international regulatory authorities Ministry of Health Kingdom of Cambodia, and the Food & Drugs Authority, Ghana etc. We are subject to international and national guidelines and regulations concerning development, testing, manufacturing processes, equipment and facilities. Further, as we expand our operations and geographical scope, we may be exposed to more complex and newer regulatory and administrative requirements and legal risks, any of which may require expertise in which we have limited experience as well as impose significant compliance costs on us.

Regulatory agencies may, for instance, delay, limit or deny approval for many reasons, including:

- changes to the regulatory approval process, including new data requirements for product candidates in those jurisdictions in which we or our customers may be seeking approval;
- drug manufacturers constantly have to monitor the efficacy and safety of their products throughout the drug life cycle which involves significant regulatory challenges. Any drug during its life cycle can be recalled for safety reasons by the drug regulators;
- resource constraints at the agency resulting in delayed review of submitted information; and
- the manufacturing processes, facilities, systems or personnel may not meet the applicable GMP guidelines.

Inspections by regulatory authorities that identify any deficiencies could result in remedial actions, production slowdown or facility closure, which would disrupt the manufacturing process and supply of products to our customers. In addition, such failure to comply could expose us to contractual liability claims, including claims by customers or recall or other corrective actions, the cost of which could be significant.

For instance, our company had received a communication from the government authorities in the past declaring certain of our formulations as 'Not of Standard Quality', pursuant to which we initiated a product recall from the market. Any such events in future, where government authorities declare our products of as "Not of Standard Quality", may require us to initiate product recalls which can materially affect our reputation and financial position.

In addition, we believe applicable regulations have become increasingly stringent and if new legislation or regulations are enacted or existing legislation or regulations are amended or are interpreted or enforced differently, we may be required to obtain additional approvals or operate according to different manufacturing or operating standards. This may require a change in our development and manufacturing techniques or additional capital investments in our facilities. Any related costs may be significant. If we fail to comply with applicable regulatory requirements in the future, then we may be subject to warning letters and/or civil or criminal penalties and fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, restrictions on the import and export of our products, debarment, exclusion, disgorgement of profits, operating restrictions and criminal prosecution and the loss of contracts and resulting revenue losses.

5. Under-utilization of our manufacturing capacities and an inability to effectively utilize our expanded manufacturing capacities could have an adverse effect on our business, future prospects and future financial performance.

The table below sets out our total annual installed capacity and capacity utilization of our facility for the periods indicated below:

(Unit in Number-lakhs)

Category	As at and for the year ended March 31, 2025			As at and for the year ended March 31, 2024			As at and for the year ended March 31, 2023		
	Annual Installed Capacity	Capacity utilized	Capacity utilization (%)	Annual Installed Capacity	Capacity utilized	Capacity utilization (%)	Annual Installed Capacity	Capacity utilized	Capacity utilization (%)
Tablets	3240	1,081.23	33.00%	1080	181.88	17.00%	1080	36.60	3.39%
Capsules	3216	356.39	11.00%	864	507.06	59.00%	864	4.34	0.50%
Dry Syrups	36	13.06	36.00%	36	14.48	40.00%	36	1.68	4.67%
Oral Liquids	144	85.12	59.00%	144	1.26	1.00%	-	-	-
External Preparation	86.4	32.50	38.00%	86.4	0.11	-	-	-	-

These figures are not indicative of future capacity utilization rates, which is dependent on various factors, including availability of raw materials, demand for our products, customer preferences, our ability to manage our inventory and implement our growth strategies. In the event of non-materialization of our estimates and expected orders, due to factors including adverse economic scenario and change in demand, our capacities may not be fully utilized thereby adversely impacting our financial performance. Under-utilization of our existing and proposed manufacturing capacities over

extended periods, or significant under-utilization in the short term, or an inability to fully realize the benefits of our recently implemented capacity expansion, could materially and adversely impact our business, growth prospects and future financial performance. As a result, we may see a delay in ramping up production and a lag in utilization rates after periods of capacity expansion. If we are unable to ramp up production and the existing level of capacity utilization rate at our manufacturing facility, our margins and profitability may be adversely affected.

6. *We have a limited operating history which may make it difficult for investors to assess our future growth prospects and business.*

Our Company was incorporated in 2020 and we started our commercial production in FY 22-23. As a result, our operating history is limited, which may impact the ability to fully assess our business performance, future prospects, and overall viability. Certain of our competitors may have a longer operating history and more experience to us in the businesses in which we operate. Although, our promoters Chetan Rugnathbhai Matholiya and Jayeshkumar Amarshibhai Sabava have the experience of around 11 years each in the pharmaceutical industry along with our promoter Akashbhai Mansukhbhai Gangadiya who has an experience of 8 years in pharmaceutical industry and an overall experience of 16 years, there can be no assurance that we will be able to successfully pursue our growth strategies. We may be unable to understand the nuances of the industry given our short operating history, particularly demand and supply trends and customer trends. In the event we fail to understand the market operations and risks in connection with such operations, it may have an adverse impact on our business, prospects, financial condition and results of operations. Further, due to our limited operating history, investors may not be able to evaluate our business, future prospects and viability.

7. *If we are unable to introduce new products in a timely manner or if the products we commercialize do not perform as expected, our business, results of operations, financial condition and cash flows may be adversely affected.*

Our success depends significantly on our ability to develop and commercialize new formulations. Commercialization requires us to successfully develop, test, manufacture and obtain the required regulatory approvals for our products, while complying with applicable regulatory and safety standards. The development and commercialization process is time-consuming and costly, with uncertain outcomes. Due to the prolonged period of time for developing a new product, delays associated with regulatory approval process as well as competitive factors, we may invest resources in developing products that may not be successful commercially, which could have an adverse effect on our business, results of operations and financial condition. Our ongoing investments in new product could result in higher costs without a proportionate increase in revenues. Our newly-developed products may not perform as projected in our business plans, and necessary regulatory approvals may not be obtained in a timely manner, if at all. We cannot assure you that our product development activities will yield business for our company, or that the costs of our ongoing investments in new product launches will result in corresponding increases in revenues. If we are not able to successfully develop and commercialize our products in a timely manner, or at all, our business, results of operations and financial condition could be adversely affected.

8. *Our business is dependent and will continue to depend on our manufacturing facility, and we are subject to certain risks in our manufacturing process. Any slowdown or shutdown in our manufacturing operations or strikes, work stoppages or increased wage demands by our employees that could interfere with our operations could have an adverse effect on our business, financial condition and results of operations.*

We conduct our operations through our manufacturing facility situated at Bavla, Ahmedabad which is spread across approximately 9,212.63 sq. mtrs. The core of our business relies on efficient management of the manufacturing facility, however our operations face a spectrum of operational risks, some of which are beyond our control, such as the breakdown, failure of equipment or industrial accidents, severe weather conditions and natural disasters. Any significant malfunction or breakdown of our machinery, our equipment, our process systems, our IT systems may entail significant repair and maintenance costs and cause delays in our operations. If we are unable to repair our assets and systems in a timely manner or at all, our operations may need to be suspended until we procure the appropriate assets to replace them. Success of our operations depend on availability of labour and good relationships with our labour force. As of the date of this Draft Red Herring Prospectus, our employees are not members of any organised labour unions. Strikes and lockouts as a result of disputes with our labour force may adversely affect our operations. While we have not had instance of strikes, lockouts or labour disputes in the past, we cannot assure you that we shall not experience any strikes or lockouts on account of labour disputes in the future. Such events could disrupt our operations and may have a material adverse effect on our business, financial condition and results of operations. Further, we may be subject to manufacturing disruptions due to contraventions by us of any of the conditions of our regulatory approvals, which may require our manufacturing facilities to cease, or limit, production until the disputes concerning such approvals are resolved.

In the event of occurrence of any accidents, our business operations may be interrupted. We may also be required to incur costs to remedy the damage caused by such incidents, pay fines which could have an adverse effect on our business,

financial condition and results of operations. Further, although we have not experienced any significant disruptions at our manufacturing facility in the past, we cannot assure you that we will not experience any disruptions in our operations in the future. Moreover, certain environmental laws impose strict liability for accidents and damages resulting from hazardous substances and any failure to comply with such laws may lead to closure, penalties, fines and imprisonment. Our manufacturing processes are subject to risks from industrial accidents at our manufacturing facilities. Our manufacturing activities can be dangerous and any accident, could cause serious injury to people or property and in certain circumstances, even death, and this may adversely affect our production schedules, costs, sales and ability to meet customer demand. We cannot assure you that we will not experience them in the future and our business, financial condition and results of operations may be adversely impacted.

Our inability to effectively respond to such events and rectify any disruption, in a timely manner and at an acceptable cost, could lead to the slowdown or shutdown of our operations or the under-utilization of our manufacturing facilities, which in turn may have an adverse effect on our business, financial condition and results of operations.

9. *We do not have long-term agreements with suppliers for our raw materials and an increase in the cost of, or a shortfall in the availability or quality of such raw materials could have an adverse effect on our business, financial condition and results of operations*

During the Fiscal 2025, 2024 and 2023, our cost of goods sold (cost of materials consumed, Purchase of stock and changes in inventories of finished goods) was ₹ 3,635.20 lakhs, ₹ 1,789.75 lakhs and ₹ 178.08 lakhs respectively, which represented 79.37%, 73.33% and 104.60% of our revenue from operations. The raw materials we use in our manufacturing process are primarily sourced from third party suppliers in India. In addition, we usually do not enter into long-term supply contracts/agreements with any of our raw material suppliers and typically source raw materials from the open market. The absence of long-term contracts/agreements at fixed prices exposes us to volatility in the prices of raw materials that we require and we may be unable to pass these costs onto our customers, which may reduce our profit margins. For the Fiscal 2025, 2024 and 2023, our purchases from our largest supplier, top 5 and top 10 vendors/suppliers are as below:

(₹ in lakhs)

Particulars	Fiscals 2025		Fiscals 2024		Fiscals 2023	
	Amount	As a % of revenue from operations	Amount	As a % of revenue from operations	Amount	As a % of revenue from operations
Largest Supplier	260.37	6.39 %	258.19	11.49 %	45.21	13.51 %
Top 5 Supplier	955.93	23.45 %	1029.50	45.83 %	157.08	46.93 %
Top 10 Supplier	1555.17	38.15 %	1452.29	64.66 %	236.64	70.70 %

We face a risk that one or more of our existing suppliers may discontinue their supplies to us, and any inability on our part to procure raw materials from alternate suppliers in a timely manner, or on commercially acceptable terms, may adversely affect our business, financial condition and results of operations. In addition, under certain loan license arrangements, our Company is obligated to procure raw materials from vendors specified by the customer. Any increase in raw material prices may result in corresponding increase in our product costs depending on the contractual terms and in the instance where we are unable to pass on the price of such increased cost of raw materials our profitability and results of operations may be adversely affected

The quality of our products is primarily derived from the quality of our raw materials, and any deterioration in the quality of raw materials supplied to us will have an adverse effect on the quality of our products, market reputation and sales volumes. There can be no guarantee that we will be able to maintain our current line-up of suppliers or adequate supply of such raw materials at all times. Further our Company has outstanding dues of trade payables during the Fiscals 2025, 2024 and 2023 of ₹ 1,927.43 lakhs, ₹ 714.34 lakhs and ₹ 235.03 lakhs respectively. Any delay in payment to our creditors may impact our long-standing relations with our suppliers and may result in stoppage of timely or at all delivery of raw material. Any such disruption would impact the production and overall financial position of our Company.

10. *If any of our products cause, or are perceived to cause, side effects, our business, results of operations and financial condition could be adversely affected*

Our business, results of operations and financial condition could be adversely affected if any of our products cause or are perceived to cause side effects. These side effects may result from various factors, some of which are beyond our control. Our products may also be perceived to cause side effects when misused or when conclusive determinations regarding the causes of side effects are unattainable. Additionally, determinations by one or more regulators that products with similar pharmaceutical ingredients could lead to side effects could affect our business, results of operations and financial condition.

While we have not faced any such instance till the date of the Draft Red Herring Prospectus, we may be subject to a number of consequences, including

- serious injury or fatality, arising from the use of our products;
- a fall in the demand for, and sales of our products;
- the recall or withdrawal of specific products;
- withdrawal or cancellation of regulatory approvals for the manufacturing unit;
- damage to our reputation; and
- exposure to lawsuits and regulatory investigation relating to the specific product and additional liabilities, fines or sanctions.

In the event that we experience any of these consequences, our business, results of operations and financial condition could be adversely affected.

11. Our Company has incurred losses in Fiscal 2023, and may do so in the future, which could have a material adverse effect on our business and growth prospects.

Our Company incurred losses of Rs 92.55 Lakhs in the Fiscal 2023. In order to continue our operations, our company may require continual financial support either as debt or as equity. We may not have the ability to provide such support on a continual basis. Our Company commenced its commercial operations in Fiscal 2023. As Fiscal 2023 marked the first year of our manufacturing operations, our Company incurred losses during this period. In the event our Company continue to incur losses, our cash flows and financial condition would continue to be adversely affected. However our company generated profit after tax of Rs 193.43 lakhs and Rs 426.40 lakhs in Fiscal 2024 and 2025 respectively, any failure to increase our revenues sufficiently to keep pace with our expenses could prevent us from achieving profitability or positive cash flow on a consistent basis and which in turn could adversely affect our ability to, among others, fund our operations, pay debts in a timely manner or finance proposed business expansions or investments. Any of the foregoing could adversely affect our business, cash flows and financial condition

12. Our Company may not be successful in penetrating new markets. If we are unable to do so and implement our business objectives effectively, our business, financial condition and results of operations may be adversely affected.

We are looking to continue our expansion into new markets like: Cambodia, Ghana, Iraq and Dubai and this subjects us to various challenges, including our lack of familiarity with the culture and economic conditions of these new regions, language barriers, difficulties in staffing and managing such operations, and the lack of brand recognition and reputation in such regions. In addition, the risks involved in entering new geographic markets and expanding operations, may be higher than expected, and we may face significant competition in such markets. By expanding into new geographical regions, we could be subject to additional risks associated with establishing and conducting operations, including compliance with a wide range of laws, regulations and practices; increase in our dependency on external agencies such as the third-party suppliers for supply of raw materials, distributors and marketing partners, exposure to expropriation or other government actions; and political, economic and social instability. If we are unable to penetrate new markets and implement our business objectives effectively in such regions, our business, results of operations and financial condition may be adversely affected.

Further in order to expand into new geographies and directly export our products to certain countries or regions, it is mandatory that our manufacturing facility be registered with the concerned regulatory authorities of such jurisdictions. Failure to obtain such registrations or renewals within the prescribed timelines may restrict our ability to export to those markets, which in turn could adversely affect our sales, revenues and growth prospects. The process of securing plant registrations is often complex, time-consuming, and subject to varying requirements depending on the jurisdiction. In some cases, regulatory authorities may require detailed inspections of our facilities and production processes, and there is no assurance that we will continue to meet such evolving standards at all times. Any delay, suspension, or rejection of plant registration applications could disrupt our business plans for those territories.

Additionally, in certain regions, it is also necessary to obtain product-specific registrations or approvals before commencing sales. These registrations may involve extensive documentation, product testing, quality validation, or compliance with local standards. Any failure or delay in securing product registrations may limit our ability to access those markets, delay product launches, or result in additional compliance costs. Consequently, our inability to obtain or renew plant and/or product registrations in a timely manner, or at all, could materially and adversely impact our export opportunities, business operations, financial condition, and results of operations.

13. Our inability to successfully implement some or all our business strategies in a timely manner or at all could have an adverse effect on our business

As part of our strategy aimed towards business growth and improvement of market position, we intend to implement several business strategies, which include:

- Launch of new products in the emerging markets;
- Expanding into new Regulated and Emerging Markets;
- Strategic alliance for CDMO;
- acquiring new customers;
- identifying customer requirements and preferences in such markets;
- obtaining approvals and certifications for our products in such jurisdictions;
- making accurate assessments of the resources we will require;
- developing and improving our internal administrative infrastructure, particularly our financial, operational, communications, internal control and other internal systems;
- recruiting, training and retaining sufficient skilled management, technical and marketing personnel;
- maintaining high levels of customer satisfaction; and
- adhering to expected performance and quality standards.

The aforesaid strategies are subject to certain risks and uncertainties. Our strategies may not succeed due to various factors, many of which are beyond our control, including our inability to reduce our debt and our operating costs, our failure to develop new products with growth potential as per the changing market preferences and trends, our failure to execute agreements with our partners, our failure to effectively market our new products or foresee challenges with respect to our business initiatives, our failure to sufficiently upgrade our infrastructure, machines, automation, equipment and technology as required to cater to the requirement of changing demand and market preferences, our failure to maintain quality and consistency in our operations or to ensure scaling of our operations to correspond with our strategies and customer demand, changes in GoI policy or regulation, our inability to respond to regular competition, and other operational and management difficulties. Any failure on our part to implement our strategy due to many reasons as attributed aforesaid could be detrimental to our long-term business outlook and our growth prospects and may materially adversely affect our business, results of operations and financial condition. Further, for any reason, in the event the benefits we realize are less than our estimates or the implementation of these strategies and operating plans adversely affect our operations.

14. We may not be able to adequately protect or continue to use our intellectual property.

We have registered our logo as trademark under class 05 with the Registrar of Trademarks in India, under the Trade Marks Act, 1999. The said trademark is registered in the name of M/s Rednex Pharmaceuticals where our promoters are partners and our company has made the applications for trademark assignment from the respective trademark owner in the name of the company. If these assignments are not properly registered or challenged by third parties, our rights to use these trademarks may be adversely affected, which could materially impact our business, reputation, and financial performance. For details of our intellectual property rights, see “***Government and Other Approvals***” on page 237 of this Draft Red Herring Prospectus.

In particular, the use of similar trade names by third parties may result in confusion among our customers, and we are exposed to the risk that entities in India and elsewhere could pass off their products as our products, including imitation products, which may adversely affect sale of our products, resulting in a decrease in market share due to a decrease in demand for our products. Such imitation products may not only result in loss of sales but also adversely affect our reputation and consequently our future sales and results of operations. In the event of such unauthorized use, we may be compelled to pursue legal action for the protection of our brand and intellectual property, which may divert our attention and resources thereby affecting our business operations. Any litigation, whether or not it is resolved in our favour, could result in significant expense to us and divert the efforts of our technical and management personnel, which may adversely affect our business operations or financial results. For any of these reasons, despite our efforts, we may be unable to prevent third parties from infringing upon or misappropriating our intellectual property.

15. We derive a portion of our revenues from merchant exports and are subject to risk of international trade.

We have historically derived a significant portion of our revenues from operations from sales of our product to domestic merchant exporter who exports the products to different countries like Angola, Cameroon, Congo, Fiji, Iraq, Liberia, Myanmar, Guyana, Nigeria, Qatar, Papua new guinea, Sierra Leone, Solomon, Somalia, South Sudan, UAE, Zambia etc. Currently our export sales are dependent on these countries and if in future, we are unable to diversify our export sales to other countries or if we are not able to sell our products to these countries at all, our revenue from operations will be impacted. During the Fiscal 2025, 2024 and 2023, our revenues from our exports amounted to ₹ 2,616.23 lakhs, ₹ 1,910.72 lakhs and ₹ 5.10 lakhs respectively, which constituted 57.12 %, 78.29 % and 3.00 % respectively, of our total revenues from operations. Therefore, any developments in the global pharmaceutical industry in which we operate could have an

impact on our sales from exports. We are exposed to risks associated with geopolitical instability, regulatory uncertainty, and compliance challenges, which may adversely affect our business, financial condition and results of operations. Further from time to time, tariffs, quotas and other tariff and non-tariff trade barriers may be imposed on our products in jurisdictions in which we operate or seek to sell our products. There can be no assurance that the countries where we export, among others, will not impose trade restrictions on us in future. We may also be prohibited from exporting to certain restricted countries that may be added to the sanctions list maintained by the Government of India or other foreign governments. Any such imposition of trade barriers may have an adverse effect on our results of operations and financial condition.

Our operations are subject to risks that are specific to each country where our products are exported, including:

- Social, economic, political, geopolitical conditions and adverse weather conditions, such as natural disasters, civil disturbance, terrorist attacks, war or other military action, which may adversely affect our business and operations;
- Changes in foreign laws, regulations and policies, including restrictions on trade, import and export license requirements, and tariffs and taxes, intellectual property enforcement issues and changes in foreign trade and investment policies and

In addition, our export to these markets may decline as a result of increased competition, regulatory action, pricing pressures including as a result of anti-dumping measures, fluctuations in the demand for or supply of our products. Our failure to effectively react to these situations or to successfully introduce new products in these markets could adversely affect our business, prospects, results of operations and financial position.

16. Our business is working capital intensive. If we are unable to borrow to meet our working capital requirements, it may materially and adversely affect our business and results of operations

Our business requires a significant amount of working capital. As a result, we are required to maintain sufficient stock at all times in order to meet manufacturing requirements, thus increasing our storage and working capital requirements. Consequently, there could be situations where the total funds available may not be sufficient to fulfil our commitments, and hence we may need to incur additional indebtedness in the future, or utilize internal accruals to satisfy our working capital needs. Further, we require a substantial amount of capital and will continue to incur significant expenditure in maintaining and growing our existing infrastructure. As of March 31, 2025, our utilized working capital facilities amounted to ₹1229.54 lakhs. The actual amount of our future capital requirements may differ from estimates as a result of, among other factors, unforeseen delays or cost overruns, unanticipated expenses, regulatory changes, economic conditions, technological changes and additional market developments. Further, our ability to arrange financing and the costs of capital of such financing are dependent on numerous factors, including general economic and capital market conditions, credit availability from banks, investor confidence, the continued success of our operations and other laws that are conducive to our raising capital in this manner. We have not faced any instances of material losses or adverse impact on our business or results of operations due to the failure of obtaining additional financing in the past three Fiscal years. However, we cannot assure you that we will be able to renew existing funding arrangements or obtain additional financing on acceptable terms, in a timely manner or at all, to meet our working capital needs. Our inability to do so may adversely affect our expansion plans, business, financial condition and results of operations. While a portion of our Net Proceeds are proposed to be utilized towards funding of working capital requirements of our Company, we may, in view of our working capital requirements, still require additional alternate working capital funding. We cannot assure you that we will be able to efficiently deploy the Net Proceeds for working capital purposes in a timely and efficient manner. For details in relation to our working capital requirements, please see **“Objects of the Issue - Funding the working capital requirements of our Company”** on page 80. If we decide to raise additional funds through the incurrence of debt, our interest and debt repayment obligations will increase, and could have a significant effect on our profitability and cash flows and we may be subject to additional covenants, which could limit our ability to access cash flows from operations. Any issuance of equity, on the other hand, could result in a dilution of your shareholding. Accordingly, continued increase in our working capital requirements may have an adverse effect on our financial condition, cash flows and results of operations.

17. Our Company had negative cash flow from operating, investing and financing activity in recent fiscals, details of which are given below. Sustained negative cash flow could adversely impact our business and financial condition

The detailed break up of our cash flows is summarized in below mentioned table and our Company has reported negative net cash flow from operating & investing activities in the Fiscals 2025, 2024 and 2023. Sustained negative cash flow could adversely impact our business, financial condition and results of operations.

(₹ in lakhs)

Particulars	F.Y. 2024-25	F.Y. 2023-24	F.Y. 2022-23
Net Cash flow from Operating Activities	252.71	89.11	(343.83)
Net Cash flow from Financing Activities	(219.27)	(742.01)	(593.10)

Net Cash flow from Investing Activities	(133.65)	772.61	937.77

Cash flow of a company is a key indicator to show the extent of cash generated from operations. If we are not able to generate sufficient cash flows in future, it may adversely affect our business and financial operations. For further details of the cash flows of the company, kindly refer section titled **“Financial Information of the Company- Cash Flow Statements”** beginning on Page 179 of this Draft Red Herring Prospectus.

18. Our international business exposes us to complex management, legal, tax and economic risks, which could adversely affect our business, results of operations and financial condition

We generate a portion of our revenues from sale of our products through local merchant exporters to international markets. Alongside, we have obtained registration for our manufacturing facility at Ghana and Cambodia and have applied for registration of our beta lactum and general pharma plant at Iraq, Dubai and North Sudan. These regulatory registrations will facilitate us to market our products in these geographies, among others. As part of our growth strategy, we aim to expand our global presence, enter new markets and further diversify our operations. For details, see **“Our Business – Our Strategies”** on page 123. Set forth below are the details of our revenue from sale of our products through local merchant exporters to international markets for the Financial Years 2025, 2024 and 2023:

(₹ in lakhs)

Particulars	Fiscals 2025		Fiscals 2024		Fiscals 2023	
	Amount	As a % of revenue from operations	Amount	As a % of revenue from operations	Amount	As a % of revenue from operations
Merchant Export	2616.23	57.12%	1910.72	78.29%	5.10	3.00%

Owing to the nature of our operations, we are subject to risks in connection with compliance with the laws of countries where we operate or export our products to, restrictions on the import and export of certain formulations, drugs by the local agencies, multiple tax and cost structures, cultural and language factors, among others. Furthermore, the accounting standards, tax laws and other regulations in the jurisdictions we operate in are subject to differing interpretations. Regulatory requirements are still evolving in many markets and are subject to change and as a result may, at times, be unclear or inconsistent. Consequently, we may inadvertently fail to comply with such regulations, which could lead to enforced shutdowns and other sanctions imposed by the relevant authorities, as well as the withholding or delay in receipt of regulatory approvals for our formulations, which may increase our costs for complying with applicable laws, rules and other requirements. Any such instance could adversely affect our business, financial condition, cash flows, and results of operations. Our direct international operations in the countries where we seek registrations may also subject us to exchange rate fluctuations, which are influenced by factors such as global uncertainty, financial market volatility, trade disruptions, commerce, pricing stability, and supply chain continuity. In addition, escalating costs, including rising tariffs, have the potential to diminish the profitability of international trade and negatively affect our international operations. These factors can have the potential to adversely affect our business, financial condition, cash flows, and results of operations.

19. Inventories and trade receivables form a major part of our current assets. Failure to manage our inventory and trade receivables could have an adverse effect on our sales, profitability, cash flow and liquidity.

Inventories and trade receivables form a major part of our current assets. The results of operations of our business are dependent on our ability to effectively manage our inventory and trade receivables. To effectively manage our inventory, we must be able to accurately estimate customer demand / potential orders and supply requirements and purchase new inventory accordingly. However, if we misjudge expected customer demand / potential orders, it could cause either a shortage of products or an accumulation of excess inventory. During the Fiscals 2025, 2024 and 2023 our inventories were ₹ 1,621.58 lakhs, ₹ 673.92 lakhs and ₹ 191.84 lakhs.

To effectively manage our trade receivables, we must be able to accurately evaluate the credit worthiness of our customers and ensure that suitable terms and conditions are given to them in order to ensure our continued relationship with them. However, if we fail to accurately evaluate the credit worthiness of our customers, it may lead to bad debts, delays in recoveries and / or write-offs which could lead to a liquidity crunch, thereby adversely affecting our business and results of operations. During the Fiscals 2025, 2024 and 2023 our trade receivables were ₹ 1,452.29 lakhs, ₹ 570.93 lakhs and ₹ 139.70 lakhs. We may be subject to working capital risks due to delays or defaults in payment by clients, which may restrict our ability to procure raw materials and make payments when due. In addition, any delay or failure on our part to supply the required quantity or quality of products, within the stipulated time period, to our customers may in turn cause delay in payment or refusal of payment by the customer. Such defaults/delays by our customers in meeting their payment obligations

to us may have a material effect on our business, financial condition and results of operations. Such situation may require an additional and, consequently, higher finance cost which will adversely impact our profitability.

20. *Geographical concentration of our manufacturing facility may adversely affect our operations, business and financial condition*

We manufacture and supply our products to customers in different geographies from our manufacturing facility located in Bavla, Ahmedabad, Gujarat. Any disruption to our manufacturing facility may result in production shutdowns. Further, any communal agitations in any parts of Gujarat causing significant loss to infrastructure, shutdown of business and industry or damage to property may affect our operations. Additionally, if our manufacturing facility is harmed or rendered inoperable by natural or man-made disasters, including earthquakes, fire, floods, acts of terrorism and power outages, it may render it difficult or impossible for us to efficiently operate our business for some period of time which may adversely affect our business, financial condition, result of operations and cash flows. Our manufacturing operations require significant labour and are also reliant on government policies in terms of taxes, duties and incentives made applicable by the state government. As a result, any unfavourable policies of the state government or state or local governments in this region, could adversely affect our business, financial condition and results of operations.

While we derive revenue from sales in various states of India like: Gujarat, Haryana, Karnataka, Madhya Pradesh, Maharashtra, Rajasthan and from export through merchant exporters, our majority sales is derived from the state of Gujarat. During the last three financial years, we derived 40.25%, 20.40% and 94.01% of our revenue from the state of Gujarat. Due to the geographic concentration of our operations in Gujarat, our operations are susceptible to local and regional factors, such as economic and weather conditions, natural disasters, demographic changes, and other unforeseen events and circumstances. Consequently, any significant social, political or economic disruption, or natural calamities or civil disruptions in this region, or changes in policies of the state or local governments or the government of India or adverse developments related to competition in this region, may adversely affect our business, results of operations, financial condition and cash flows. While we have not experienced any of the above adverse situations that had an adverse impact on our business operations and financial conditions in the past, we cannot assure you that these adverse situations will not arise in the future.

21. *We are subject to increasingly stringent environmental, health and safety laws, regulations and standards. Non-compliance with and adverse changes in health, safety, labour, and environmental laws and other similar regulations to our manufacturing operations may adversely affect our business, results of operations and financial condition.*

We are subject to a wide range of laws and government regulations, including in relation to safety, health, labour, and environmental protection. These safety, health, labour, and environmental protection laws and regulations impose controls on air and water release or discharge, noise levels, storage handling, treatment, processing, disposal of hazardous materials, including the management of certain hazardous waste, and exposure to hazardous substances with respect to our employees, along with other aspects of our manufacturing operations. For instance, there is a limit on the amount of pollutant discharge that our manufacturing facility may release into the air and water. Environmental laws and regulations in India have become and continue to be more stringent, and the scope and extent of new environmental regulations, including their effect on our operations, cannot be predicted with any certainty. In case of any change in environmental or pollution regulations, we may be required to invest in, among other things, environmental monitoring, pollution control equipment, and emissions management and other expenditure to comply with environmental standards. Any failure on our part to comply with any existing or future regulations applicable to us may result in legal proceedings, including public interest litigation being commenced against us, third party claims or the levy of regulatory fines. Further, any violation of the environmental laws and regulations may result in fines, criminal sanctions, revocation of operating permits, or shutdown of our manufacturing facility. The occurrence of any of these events could have an adverse effect on our business, results of operations and financial condition.

As a consequence of unanticipated regulatory or other developments, future environmental and regulatory related expenditures may vary substantially from those currently anticipated. We cannot assure you that our costs of complying with current and future environmental laws and other regulations will not adversely affect our business, results of operations or financial condition. In addition, we could incur substantial costs, our products could be restricted from entering certain markets, and we could face other sanctions, if we were to violate or become liable under environmental laws or if our products become non-compliant with applicable regulations. Our potential exposure includes fines and civil or criminal sanctions, third-party property damage or personal injury claims and clean-up costs. The amount and timing of costs under environmental laws are difficult to predict. We cannot assure you that we will not be involved in future litigation or other proceedings, or be held liable in any litigation or proceedings including in relation to safety, health and environmental matters, the costs of which may be significant.

22. *We may be subject to pricing pressure from our customers, which could have an adverse effect on our business, cash flows, results of operations and financial condition.*

We face continued competitive pressure. As such, we, may experience a decline in the prices at which our products can be sold. In such instances, in order to continue to supply these products at competitive prices, we must reduce our production costs. We may not be able to improve our production efficiencies to a degree sufficient for maintaining the required margins. Moreover, we may not be able to cease production of such products, either due to our ongoing contractual obligations or the risk of losing our existing customer relationships, and as a result may be required to bear a loss on such products. Further competition may lead to price erosion, lower revenue growth rates and lower margins in the future. Should reductions in our production costs fail to keep pace with reductions in market prices for the products we sell, there could be an adverse effect on our business, financial condition and results of operations. While we have not faced any such instances that materially impacted our operations in the last three Fiscal years, we cannot assure you that such instances will not occur in the future.

23. *Our historical performance is not indicative of our future growth or financial results and we may not be able to sustain our historical growth rates.*

We have experienced significant revenue growth in recent years, revenue from operations increasing from Rs. 170.25 lakhs in FY 2022-23 to Rs. 4580.12 lakhs in FY 2024-25, representing a CAGR of approximately 418.67%. While our recent performance demonstrates our ability to capitalize on market opportunities, we cannot guarantee the sustained maintenance of these high growth rates. The pharmaceutical industry is highly competitive, with both organized and unorganized players operating across India. Our competitors may possess advantages in pricing, durability, product quality, user experience, operational efficiency, timely delivery, or reliability. Staying abreast of technological advancements is essential for maintaining a competitive edge. Our ability to adapt to the evolving industry landscape will significantly impact our competitive standing. Several of our strategic initiatives are in their early stages. The inherent uncertainties of strategic endeavours require a cautious approach, and we cannot rule out potential challenges or adjustments. We remain committed to navigating the evolving market landscape and optimizing our strategies for long-term success.

24. *Failure to maintain confidential information of our customers could adversely affect our business, results of operations, cash flows and financial condition or damage our reputation.*

We are required to keep confidential certain details of our customers pursuant to the respective agreements or purchase orders with such customers. In the event of any breach or alleged breach of our confidentiality arrangements with our customers, these customers may initiate litigation against us for breach of confidentiality obligations. Moreover, if our customers' confidential information is misappropriated by us or our employees, our customers may seek damages and compensation from us. Assertions of misappropriation of confidential information or the intellectual property of our customers against us, if successful, could have an adverse effect on our business, results of operations, cash flows and financial condition. Even if such assertions against us are unsuccessful, they may cause us to incur reputational harm and substantial cost.

25. *In the past, there have been delays in filings with the Registrar of Companies (RoC) and other non-compliance under the companies act, which may result in penalties.*

Our Company has not complied with certain statutory provisions under the Companies Act 2013 which inter-alia includes non-filing of form CHG-1 for creation of charge on a vehicle loan taken in the past, which is non-compliance of section 77 of the Companies Act, 2013 read with rules made thereunder and attracts penalty under section 86 and/or other relevant provision(s) of Companies Act, 2013, as may be applicable. However, no such loans are outstanding as on date of this Draft Red Herring Prospectus. Further, there has been some instances of clerical errors in the forms filed with the RoC such as such as wrong due date of AGM in MGT-7A, variances between the amounts disclosed as deposits or other specified sums in the Company's audited financial statements and those reported in Form DPT-3. Although, no show cause notice in respect of the above has been received by the Company till date, any penalty imposed for such inadvertent errors in future by any regulatory authority could affect our financial conditions to that extent.

In the past, there have been certain instances of delays in filing of certain statutory forms, which have been subsequently filed by payment of an additional fee as specified by Registrar of Companies. No show cause notice in respect to the above has been received by our Company till date and no penalty or fine has been imposed by any regulatory authority in respect to the same. It cannot be assured, that there will not be such instances in the future or our Company will not commit any further delays in relation to its reporting requirements, or any penalty or fine will not be imposed by any regulatory authority in respect to the same. The happening of such event may cause a material effect on our results of operations and financial position

26. *We operate in a market that is highly competitive to provide outsourced pharmaceutical manufacturing services,*

As a pharmaceutical manufacturing company, we compete to provide a comprehensive range of pharmaceutical products to our clients. For our contract manufacturing business, our primary competitors are CDMO companies, contract manufacturers focusing on a limited number of dosage forms, contract manufacturers providing multiple dosage forms, and large pharmaceutical companies offering third-party manufacturing services to fill their excess capacity. We also compete with other pharmaceutical companies involved in marketing pharmaceutical formulations. See also “***Our Business – Competition***” on page 135. Some of our competitors may possess substantially greater manufacturing, financial, marketing, technical, or other resources than us. This provides them with a potential advantage, enabling more agile responses to changes in market demand through the introduction of new, alternative, or emerging technologies. Further, our competitors may succeed in developing products that are more effective, more popular or cheaper than any products we may develop, which may render our products obsolete or uncompetitive, and we may be unable to achieve the desired growth. Should our competitors gain significant market share at our expense, particularly within our focused therapeutic areas, it could have an adverse effect on our business, results of operations, and financial condition

27. *Adverse publicity regarding our products could negatively impact us.*

There are potential risks related to adverse publicity within the pharmaceutical industry for the products manufactured by us. Negative publicity, whether directly targeting our products or arising from concerns about similar products offered by competitors, poses a significant threat to our company's reputation and financial stability. Specifically, any negative feedback received from the consumers or any kind of dissemination of studies, reports, or media coverage that questions the efficacy or safety of our products, or raises related concerns, can erode consumer trust and diminish product perception. This erosion of trust can directly translate into reduced demand, as prospective and existing consumers may become hesitant to use such or similar products.

The consequences of decreased product demand are multifaceted. Primarily, a decline in sales will result in lower revenue generation. This reduction in revenue will subsequently impact our cash flow, potentially creating challenges in meeting operational cash flow requirements. Furthermore, adverse publicity can hinder our ability to attract new clientele, limiting market expansion and future growth opportunities.

28. *Orders in our order book may be delayed or cancelled or withdrawn or may not translate to revenue, which may have a material adverse effect on our business, results of operations and financial condition.*

As on August 15, 2025 we have an outstanding order book of Rs 1848.69 lakhs. In addition, when the product delivery proceeds as scheduled, it is possible that our clients may default and fail to pay amounts due. We cannot guarantee that the income anticipated in our order book will be realized on time, or at all. Any cancellations or withdrawals of such orders, may occur from time to time and could reduce the amount of our order book and the income and profits expected from such orders. Any delay, cancellation or payment default could have a material adverse effect on our business, results of operations and financial condition. Thus the order book information included in this Draft Red Herring Prospectus is does not necessarily indicate our future earnings. Our order book should not be considered in isolation or as a substitute for performance measures. In addition, our product delivery schedule may vary due to various factors that may be beyond our control, including, among others, the availability of raw materials, timely delivery and execution of the order.

29. *Our Company operates under several statutory and regulatory approvals in respect of our operations. Failure to obtain or maintain licenses, registrations, permits and approvals may affect our business and results of operations.*

We require various statutory and regulatory licenses, registrations and approvals to operate our business. Many of these approvals are granted for fixed periods of time and need renewal from time to time. Non-renewal of the said permits and licenses would adversely affect our Company's operations, thereby having a material adverse effect on our business, results of operations and financial condition. There can be no assurance that the relevant authorities will issue any of such approvals or licenses in a timely manner, or at all. Such non-compliance may expose us to penalties, including monetary fines and potential prosecution of our directors or officers. In certain circumstances, authorities may also direct us to absorb contract workers as regular employees, which could have a material adverse impact on our costs, operations, and financial condition. Further, any adverse publicity or scrutiny arising from such non-compliance may harm our reputation and stakeholder confidence. Further any default by our Company in complying with the same may result in the cancellation of such licenses, approvals or registrations which may result in the interruption of our operations and adversely affect our business. For further details, please refer to section titled “***Government and Other Approvals***” beginning on page 237 of the Draft Red Herring Prospectus.

30. *Our manufacturing facility is situated on leased premises.*

Our manufacturing facility is situated at survey No. 231, Near SKF Bearing, Kerala, Bagodra, Bavla, Ahmedabad, Gujarat, which is taken on lease from M/s. Rednex Pharmaceuticals (a partnership firm of our promoters Chetan Rugnathbhai Matholiya Jayeshkumar Amarshibhai Sabava and Akashbhai Mansukhbhai Gangadiya). Any adverse impact on the title /ownership rights/ development rights of our landlords may adversely affect our operations. Further in the event of non-renewal of these lease agreements, our operations and profitability may be adversely affected. We cannot assure you that we will be able to continue the above arrangement on commercially favorable terms in future. If we are required to vacate the current premises, we would be required to make alternative arrangements for our infrastructure, and we cannot assure that the new arrangements will be on commercially acceptable/favorable terms. If we do not comply with certain conditions of the lease agreement, it may lead to termination of the same which would have an adverse effect on our operations and there can be no assurance that renewal of lease agreement will be entered into. In the event of non-renewal, we may be required to shift to a new location and there can be no assurance that the arrangement our Company entered into in respect of new premises would be on such terms and conditions as the present one. For details on properties taken on rent by us please refer to the section titled ***“Our Business”*** beginning on page 118 of this Draft Red Herring Prospectus.

31. *Reforms in the healthcare industry and the uncertainty associated with pharmaceutical pricing and related matters could adversely affect the marketing, pricing and demand for our products.*

Our success will depend in part on the extent to which government and health administration authorities, private health insurers and other third-party payers will pay for our products. In many countries, including India, pharmaceutical prices are subject to regulation. Price controls operate differently in different countries and can cause wide variations in prices between markets. Currency fluctuations can aggravate these differences. The existence of price controls can limit the revenues we earn from our products. For example, in India, prices of certain pharmaceutical products are determined by the Drug Prices Control Order, 2013 (“DPCO”), promulgated by the Government of India and administered by the National Pharmaceutical Pricing Authority (“NPPA”). If a given pharmaceutical product falls within the DPCO, the product’s price could be significantly lower than what its market price would be without such price restriction. Any changes to these prices stipulated by the DPCO, NPPA or other similar authorities, or the inclusion of other of our pharmaceutical products not currently within the DPCO, could have an adverse effect on our profitability. Any unforeseen changes in the regulatory environment in relation to prices of our products, or our inability to comply with the applicable regulatory requirements could adversely affect our business, results of operations and cash flows.

32. *The cost of implementing new technologies for our operations could be significant and could adversely affect our business, financial condition and results of operations.*

Our future success may depend in part on our ability to respond to technological advances and emerging standards and practices on a cost effective and timely basis. We cannot assure you that we will be able to successfully make timely and cost-effective enhancements and additions to the technology, keep up with technological improvements in order to meet our customers’ needs or that the technology developed by others will not render our products less competitive or attractive. In addition, rapid and frequent technology and market demand changes can often render existing technologies and equipment obsolete, requiring substantial new capital expenditures or write-down of assets. Our failure to successfully adopt such technologies in a cost effective and a timely manner could increase our costs (in comparison to our competitors who are able to successfully implement such technologies) and lead to us being less competitive in terms of our prices or quality of services we provide. Further, implementation of new or upgraded technology may not be cost effective, which may adversely affect our profitability. Any of the above events may adversely affect our business, financial condition, results of operations and prospects.

33. *Our insurance coverage may not be adequate to protect us against all potential losses to which we may be subject and this may have a material effect on our business and financial condition.*

While we maintain insurance coverage namely include vehicle insurance, Standard Fire & Special Perils for our building, plant and machinery, furniture, fixture and fittings and stocks, and Employees Compensation Insurance Policy in amounts which we believe are commercially appropriate. We believe that we have adequate insurance coverage for known risks. However, for unforeseen circumstances, we may not have sufficient insurance coverage to cover all possible economic losses, including when the loss suffered is not easily quantifiable. Even if we have made a claim under an existing insurance policy, we may not be able to successfully assert our claim for any liability or loss under such insurance policy. Additionally, there may be various other risks and losses for which we are not insured either because such risks are uninsurable or not insurable on commercially acceptable terms. The occurrence of an event for which we are not adequately or sufficiently insured could have an adverse effect on our business, results of operations, financial condition and cash flows. For further

details of our Insurance Policies, please refer section titled ***“Our Business”*** beginning on page 118 of this Draft Red Herring Prospectus.

34. *Failures in internal control systems could cause operational errors which may have an adverse impact on our profitability.*

We are responsible for establishing and maintaining adequate internal control measures commensurate with the size and complexity of operations. Internal control systems comprising policies and procedures are designed to ensure sound management of our operations, safekeeping of our assets, optimal utilization of resources, reliability of our financial information and compliance. The systems and procedures are periodically reviewed and routinely tested and cover all functions and business areas

While we believe that we have adequate controls, we are exposed to operational risks arising from the potential inadequacy or failure of internal processes or systems, and our actions may not be sufficient to guarantee effective internal controls in all circumstances. Given the size of our operations, it is possible that errors may repeat or compound before they are discovered and rectified. Our management information systems and internal control procedures that are designed to monitor our operations and overall compliance may not identify every instance of non-compliance or every suspicious transaction. These factors may have an adverse effect on our reputation, business, results of operations, cash flows and financial condition. There can be no assurance that deficiencies in our internal controls will not arise in the future, or that we will be able to implement, and continue to maintain, adequate measures to rectify or mitigate any such deficiencies in our internal controls. Any inability on our part to adequately detect, rectify or mitigate any such deficiencies in our internal controls may adversely impact our ability to accurately report, or successfully manage, our financial risks, and to avoid fraud.

35. *Our Company and promoters are involved in certain legal proceedings and potential litigations. Any adverse decision in such proceedings may render us/ them liable to liabilities/ penalties/ prosecutions and may adversely affect our business and results of operations.*

Our Company and promoters are currently involved in certain legal proceedings. A summary of outstanding litigations proceedings involving our Company, Promoters and Directors as on the date of this Draft Red Herring Prospectus are as below: -

Litigations/ Matters against our Company:

Nature of Litigation	Number of Cases Outstanding	Amount in dispute (Amount in lakhs)
Other Pending Litigation	1	10.00

Litigations/ Matters against our Promoters and Directors:

Nature of Litigation	Number of Cases Outstanding	Amount in dispute (Amount in lakhs)
Criminal Proceedings	1	Unascertainable

Amount mentioned to the extent quantifiable. The amount may be subject to additional interest/other charges being levied by the concerned authorities which are unascertainable as on date of this Draft Red Herring Prospectus

For further details, see ***“Outstanding Litigation and Material Developments”*** beginning on page 233 of this Draft Red Herring Prospectus. Any adverse decisions in the aforesaid proceedings may have a material effect on our business, future financial performance and results of operations.

36. *We are dependent on third party transportation providers for the delivery of our raw material and final products. Accordingly, continuing increases in transportation costs or unavailability of transportation services may have an adverse effect on our business, financial condition, results of operations and prospects*

We use third party transportation providers for the delivery of our raw material and final products. Transportation strikes if happen could have an adverse effect on overall industry and accordingly may affect our receipt of raw materials and our ability to deliver our final products to our customers. In addition, transportation costs in India have been steadily increasing over the past several years. Continuing increases in transportation costs or unavailability of transportation services for our products may have an additional cost escalation which may have an adverse effect on our business, financial condition, results of operations and prospects. In addition, problems with its road networks, electricity grid, communication systems or any other public facility could disrupt our normal business activity, including our supply of raw materials and the delivery of our products to customers by third-party transportation providers. These problems could interrupt our business operations, which could have a material adverse effect on our results of operations and financial condition.

Transportation & Handling Charges represented 0.63 %, 0.09 % and 0.10 % respectively, of our total revenue from operations during Fiscals 2025, 2024 and 2023. We are subject to the risk of increases in freight costs. If we cannot fully offset any increases in freight costs, through increases in the prices for our products, we would experience lower margins.

- 37. *We intend to utilize a portion of the Net Proceeds for funding our capital expenditure requirements. If the costs of this development and the risk of unanticipated delays in implementation and cost overruns related to the said development are higher than expected, it could have a material adverse effect on our financial condition, results of operations and growth prospects***

We intend to utilize a portion of the Net Proceeds for repayment in full or in part, of certain of our outstanding borrowings, Funding capital expenditure towards purchase of new machinery, funding to meet working capital requirements and general corporate purpose. For further details of the proposed Objects of the Issue, see '**Objects of the Issue**' on page 80. We have relied on certain quotations received from third parties for estimation of the costs for our capital expenditure requirements and these have not been independently appraised by any bank or financial institution. We cannot assure you that we will be able to place orders for our capital expenditure in a timely manner or at all. While we have obtained the quotations from various vendors in relation to our capital expenditure requirements, most of these quotations are valid for a certain period of time and may be subject to revisions, and other commercial and technical factors. The fund requirements, the deployment of funds and the intended use of the Net Proceeds are based on our management estimates, current and valid quotations from suppliers or vendors, and other commercial and technical factors. There could be delays in the said development as a result of, among other things unforeseen litigations, disputes with external agencies, increase in input costs, taxes and duties, interest and finance charges, cost escalation and, or force majeure event, any of which could give rise to cost overruns and delay in our implementation schedules. Further, if the costs in relation to our civil construction work and capital expenditures are higher than expected, it could have material adverse effect on our financial condition, results of operations and growth prospects.

- 38. *Our operations involve activities and materials which are hazardous in nature and could result in a suspension of operations, injury to our personnel, emission of pollutants and/or the imposition of civil or criminal liabilities which could adversely affect our business, results of operations, cash flow and financial condition***

Certain operations at our manufacturing facility can cause accidents during the manufacturing process resulting in serious injuries or death of employees or other persons, if improperly handled, and cause damage to our properties or equipment and the properties of others or to the environment. Despite ensuring that employee safety manuals covering employee safety and environmental procedures are in place and that hazard identification and risk assessments with respect to our operations are periodically carried out, our operations are subject to significant hazards, including explosions, fires, mechanical failures and other operational problems, inclement weather and natural disasters, discharges or releases of hazardous substances and other environmental risks.

We use flammable and hazardous materials, such as isopropyl alcohol, acetone, methylene dichloride solvents in our manufacturing processes. The improper handling or storage of these materials could result in fire, industrial accidents, injuries to our personnel, property and damage to the environment. While we have not experienced any such instances in the past three Fiscals, we cannot assure you that such instances will not occur in the future. In case of any such occurrences, we may be required to temporarily reduce our manufacturing capacity or suspend our operations. Such occurrences may adversely affect our business operations, financial condition and results of operations. In addition, we may be required to incur costs to remedy the damage caused by such incidents. While we have not faced any such instances in the past, we cannot assure you that such instances will not arise in the future. Such incidents could subject us to litigation resulting from occupational exposure to hazards at our facility and adversely affect our reputation. If these claims and lawsuits, individually or in the aggregate, are resolved against us, our business, results of operations, cash flows and financial condition could be adversely affected. If any of the foregoing were to occur, our business operations, financial condition and results of operations could be adversely affected.

Further, our customers may require us to invest in additional safety protocols which can impose incremental expenses and may impact our ability to operate at optimum efficiencies. Any such action by any of our customers may adversely impact our business, results of operations, cash flows and financial condition.

- 39. *We have in the past entered into related party transactions and may continue to do so in the future. There can be no assurance that such transactions, individually or in the aggregate, will not have an adverse effect on our Company's financial condition and results of operations.***

Our Company has entered into various transactions with our directors, relatives of directors, group company and promoter group. These transactions, inter-alia includes purchase, sales, remuneration, rent, loans and advances etc. For details, please

refer to ***“Note - 29 - Related Party Transactions”*** under Section titled ***“Financial Information of the Company”*** and Chapter titled ***“Capital Structure”*** beginning on page 211 and 68 respectively of this Draft Red Herring Prospectus. Our Company has entered into such transactions due to easy proximity and quick execution in accordance with Companies Act 2013 and other applicable laws. Although all related-party transactions that we may enter into in the future are subject to approval by our Audit Committee, Board or shareholders, as required under the Companies Act, we cannot assure you that such future transactions or any other future transactions, individually or in aggregate, will not have an adverse effect on our financial condition and results of operations or that we could not have achieved more favourable terms if such transactions are not entered into with related parties. Furthermore, it is likely that we may enter into related party transactions in the future. Any future transactions with our related parties could potentially involve conflicts of interest. Accordingly, there can be no assurance that such transactions, individually or in the aggregate, will not have a material adverse effect on our business, financial condition, cash flows, results of operations and prospects.

40. *We are dependent on our promoter and other key personnel, and the loss of, or our inability to attract or retain, such persons could affect our business, results of operations, financial condition and cash flows.*

Our performance depends largely on the efforts and abilities of our Promoters and other key personnel. Our promoters Chetan Rugnathbhai Matholiya and Jayeshkumar Amarshibhai Sabava have the experience of around 11 years each in the pharmaceutical industry along with our promoter Akashbhai Mansukhbhai Gangadiya who has an experience of 8 years in pharmaceutical industry and an overall experience of 16 years. They have over the years-built relations with suppliers, customers, regulators and other persons who are connected with us and have been actively involved in the day-to-day operations and management. Further we believe that the inputs and experience of our senior management, in particular, and other key personnel are valuable for product development activities, procurement of raw materials, successful delivery of products and our overall business operations of our Company. For details in relation to the experience of our key management personnel, see ***“Our Management”*** on page 150 of this Draft Red Herring Prospectus. We cannot assure you that these individuals or any other member of our senior management team will not leave us or join a competitor or that we will be able to retain such personnel or find adequate replacements in a timely manner, or at all. We may require a long period of time to hire and train replacement personnel when qualified personnel terminate their employment with our Company. We may also be required to increase our levels of employee compensation more rapidly than in the past to remain competitive in attracting employees that our business requires. The loss of the services of such persons may have an effect on our business, results of operations, financial condition and cash flows.

41. *Our Company has taken unsecured loans that may be recalled by the lenders at any time.*

Our Company have availed unsecured loans which may be called by their lenders at any time. As on March 31, 2025, the unsecured loan amounting to ₹330.56 lakhs were due to promoters and their relatives. In the event that promoter seeks a repayment of any such loan, our Company would need to find alternative sources of financing to the extent of outstanding balance. Also, there is no formal agreement with promoters and their relative for such financing arrangements. As a result, any such demand may affect our business, cash flows, financial condition and results of operations. For further details on financing arrangements entered into by our Company, please refer chapter titled ***“Statement of Financial Indebtedness”*** beginning on page 219 of this Draft Red Herring Prospectus.

42. *Our lenders have charge over our immovable and movable properties in respect of finance availed by us.*

We have secured our lenders by creating a charge over our movable and immovable properties in respect of Cash Credit, Term loans and bank guarantees availed by us from State Bank of India Limited. We have been extended such loan against hypothecation of our Company’s property and current assets along with hypothecation of property of promoter group. For further information on the financing and loan agreements along with the total amounts outstanding and the details of the repayment schedule, please refer to chapter ***“Statement of Financial Indebtedness”*** beginning on page 219 of this Draft Red Herring Prospectus.

43. *The Objects of the Issue for which funds are being raised, are based on our management estimates and have not been appraised by any bank or financial institution or any independent agency.*

The deployment of funds will be entirely at our discretion, based on the parameters as mentioned in the chapter titled ***“Objects of the Issue”***. The fund requirement and deployment, as mentioned in the ***“Objects of the Issue”*** on page 80 of this Draft Red Herring Prospectus is based on the estimates of our management and has not been appraised by any bank or financial institution or any other independent agency. These fund requirements are based on our current business plan. We cannot assure that the current business plan will be implemented in its entirety or at all. In view of the highly competitive and dynamic nature of our business, we may have to revise our business plan from time to time and consequently these fund requirements. The deployment of the funds as stated under chapter ***“Objects of the Issue”*** is at the discretion of our

Board of Directors and is not subject to monitoring by any external independent agency. Further, we cannot assure that the actual costs or schedule of implementation as stated under chapter ***“Objects of the Issue”*** will not vary from the estimated costs or schedule of implementation. Any such variance may be on account of one or more factors, some of which may be beyond our control. Occurrence of any such event may delay our business plans and/or may have an adverse bearing on our expected revenues and earnings.

44. Any variation in the utilization of the Net Proceeds as disclosed in this Draft Red Herring Prospectus shall be subject to certain compliance requirements, including prior approval of the shareholders of our Company.

We propose to utilize the Net Proceeds towards repayment in full or in part, of certain of our outstanding borrowings, Funding capital expenditure towards purchase of new machinery, funding to meet working capital requirements and general corporate purpose. For further details of the proposed Objects of the Issue, see ***“Objects of the Issue”*** beginning on page 80. However, these Objects of the Issue have not been appraised by any bank, financial institution or other independent agency. Further, we cannot determine with any certainty if we would require the Net Proceeds to meet any other expenditure or fund any exigencies arising out of the competitive environment, business conditions, economic conditions or other factors beyond our control. In accordance with the Companies Act, 2013 and the SEBI ICDR Regulations, we cannot undertake any variation in the utilization of the Net Proceeds as disclosed in this Draft Red Herring Prospectus without obtaining the approval of shareholders of our Company through a special resolution. In the event of any such circumstances that require us to vary the disclosed utilization of the Net Proceeds, we may not be able to obtain the approval of the shareholders of our Company in a timely manner, or at all. Any delay or inability in obtaining such approval of the shareholders of our Company may adversely affect our business or operations. Further, our Promoters would be required to provide an exit opportunity to the shareholders of our Company who do not agree with our proposal to modify the Objects of the Issue, at a price and manner as prescribed by SEBI. Additionally, the requirement to provide an exit opportunity to such dissenting shareholders of our Company may deter our Promoters from agreeing to the variation of the proposed utilization of the Net Proceeds, even if such variation is in the interest of our Company. Further, we cannot assure you that the Promoter will have adequate resources at their disposal at all times to enable them to provide an exit opportunity. In light of these factors, we may not be able to vary the Objects of the Issue to use any unutilized proceeds of the Issue, if any, even if such variation is in the interest of our Company. This may restrict our Company's ability to respond to any change in our business or financial condition, if any, which may adversely affect our business and results of operations.

45. Industry information included in this Draft Red Herring Prospectus has been derived from industry sources. There can be no assurance that such third-party statistical, financial and other industry information is complete, reliable or accurate.

This Draft Red Herring Prospectus includes information on Industry in which we operate from various sources. For further details, please see ***“Industry Overview”*** beginning on page 102. The data has been furnished by independent agency on their websites and has no relationship with our Company, its Promoters, Directors, or the Book Running Lead Manager as on the date of this Draft Red Herring Prospectus. The data used in these sources may have been reclassified by us for the purposes of presentation and may also not be comparable. Industry sources and publications generally state that the information contained therein has been obtained from sources generally believed to be reliable, but that their accuracy, completeness and underlying assumptions are not guaranteed and their reliability cannot be assured. Industry sources and publications are also prepared based on information as of specific dates and may no longer be current or reflect current trends. Industry sources and publications may also base their information on estimates, projections, forecasts and assumptions that may prove to be incorrect. Accordingly, investors must rely on their independent examination of, and should not place undue reliance on, or base their investment decision solely on this information. The recipient should not construe any of the contents in this report as advice relating to business, financial, legal, taxation or investment matters and are advised to consult their own business, financial, legal, taxation, and other advisors concerning the transaction.

46. Our employees and clients may engage in misconduct or other improper or illegal activities, including misrepresentation, noncompliance with regulatory requirements and breach of contractual obligations

Our business is exposed to the risk of misconduct by both employees and clients, including but not limited to misconduct, noncompliance with regulatory requirements and breach of contractual obligations. Any potential failure to comply with applicable laws and regulations, comply with contractual obligations, adhere to established manufacturing and quality-control standards, or engage in misconduct could adversely affect our operations. Furthermore, laws and regulations may impose restrictions or prohibitions on various business practices, such as pricing, discounting, marketing, promotions, sales commissions, and client incentive programs. Additionally, our clients may engage in misconduct, including the relabelling or repackaging of products manufactured by us. Such client misconduct could subject us to criminal penalties, fines, and the potential revocation of licenses. We cannot assure you that we will not face any such instances of misconduct by our

employees or clients in the future. In the event that misconduct by our employees, suppliers, and clients materializes, we may be subject to criminal penalties fines, regulatory approval revocation, and damage to our reputation. Further, any cessation or reduction of our business with us by any of our key clients as a result of any misconduct by our employees could have an adverse effect on our business, results of operations, and financial condition.

47. *We have not identified any alternate source of funding and hence any failure or delay on our part to mobilize the required resources or any shortfall in the Issue proceeds may delay the implementation schedule.*

The proposed fund requirement as detailed in the section titled “*Objects of the Issue*” is to be funded from the proceeds of this Issue. We have not identified any alternate source of funding and hence any failure or delay on our part to mobilize the required resources or any shortfall in the Issue proceeds may delay the implementation schedule. We therefore, cannot assure that we would be able to execute our future plans/strategy within the given timeframe. For details, please refer to the Chapter titled “*Objects of the Issue*” beginning on page 80 of this Draft Red Herring Prospectus.

48. *Delay/ default in payment of statutory dues may attract penalties and in turn have an adverse impact on our financial condition.*

We are required to make certain payments to various statutory authorities from time to time, including but not limited to payments pertaining to employee provident fund, employee state insurance, income tax and GST. The table below sets forth the details of delay in payment of the statutory dues paid by our Company in relation to our employees for the periods indicated below:

GST No.: 24AAKCR6961N1ZO							
Int. on Late payment of GST							
Sr. No.	Return	Month	Due date	Date of Filing	Delay in days	Total Late Fee (in ₹)	Total Int. Paid (in ₹)
1	GSTR-3B	Feb-24	20-Mar-24	21-Mar-24	1.00	50.00	4.00
2	GSTR-3B	Mar-25	20-Apr-25	21-Apr-25	1.00	50.00	17.00

(₹ in Lakhs)

Particulars	Financial Year 2025		Financial Year 2024		Financial Year 2023	
	Number of Instances	Amount delayed	Number of Instances	Amount delayed	Number of Instances	Amount delayed
The Employees Provident Fund and Miscellaneous Provisions Act, 1952	2	0.04	2	0.74	2	0.54
Labour Welfare Fund	2	0.03	2	0.01	-	-

We cannot assure you to that we will be able to pay our statutory dues timely, or at all, in the future. While there have been minor delays in payment of statutory dues in the past, our Company has corrected such non-compliances by repaying the amounts with applicable interest. Any failure or delay in payment of such statutory dues may expose us to statutory and regulatory action, as well as significant penalties, and may adversely impact our business, results of operations, cash flows and financial condition.

49. *Our ability to pay any dividends will depend upon future earnings, financial condition, cash flows and working capital requirements.*

We may retain all our future earnings, if any, for use in the operations and expansion of our business. As a result, we may not declare dividends in the foreseeable future. Any future determination as to the declaration and payment of dividends will be at the discretion of our Board of Directors and will depend on factors that our Board of Directors deem relevant, including among others, our results of operations, financial condition, cash requirements, business prospects and any other financing arrangements. Accordingly, realization of a gain on shareholders investments may largely depend upon the appreciation of the price of our Equity Shares. There can be no assurance that our Equity Shares will appreciate in value. For details of our Dividend history refer to the Section “*Dividend Policy*” on page 171 of the Draft Red Herring Prospectus.

50. *Fraud, theft, employee negligence or similar incidents may adversely affect our results of operations and financial condition.*

Our operations may be subject to incidents of theft or damage to inventory and other operational components. The business may also encounter some inventory loss on account of employee theft, supplier fraud and general administrative error.

While we have not experienced any such instance in the past, there can be no assurance that we will not experience any fraud, theft, employee negligence, security lapse or similar incidents in the future, which could adversely affect our results of operations and financial condition.

51. *None of our Directors have prior experience of holding a directorship in a listed company*

None of our directors have prior experience holding directorships in a listed company. For further details, please see, “***Our Management – Brief profiles of our directors***” starting on page 150 of this Draft Red Herring Prospectus. Following listing of the Equity Shares, our Company will be subject to applicable corporate governance requirements under the SEBI Listing Regulations, including additional compliance and disclosure requirements. Any non-compliance with the regulatory framework, arising as a result of lack of experience of our directors, may subject us to adverse regulatory actions, and may adversely impact our reputation, financial condition and Equity Share price.

52. *The Objects of the Issue for which funds are being raised, are based on our management estimates and have not been appraised by any bank or financial institution or any independent agency. Any variation between the estimation and actual expenditure as estimated by the management could result in execution delays or influence our profitability.*

The deployment of funds will be entirely at our discretion, based on the parameters as mentioned in the chapter titled “***Objects of the Issue***”. The fund requirement and deployment, as mentioned in the “***Objects of the Issue***” on page 80 of this Draft Red Herring Prospectus is based on the estimates of our management and has not been appraised by any bank or financial institution or any other independent agency. These fund requirements are based on our current business plan. We cannot assure that the current business plan will be implemented in its entirety or at all. In view of the dynamic nature of our business, we may have to revise our business plan from time to time and consequently these fund requirements. The deployment of the funds as stated under chapter “***Objects of the Issue***” is at the discretion of our Board of Directors. Further, we cannot assure that the actual costs or schedule of implementation as stated under chapter “***Objects of the Issue***” will not vary from the estimated costs or schedule of implementation. Any such variance may be on account of one or more factors, some of which may be beyond our control. Occurrence of any such event may delay our business plans and/or may have an adverse bearing on our expected revenues and earnings.

53. *We are subject to the risk of failure of, or a material weakness in, our internal control systems inclusive of information and reporting systems. If the company is unable to establish and maintain an effective system of internal controls and compliance, our business and reputation could be adversely affected.*

We are exposed to risks arising from the inadequacy or failure of internal systems inclusive of information and reporting system or processes, and any actions we may take to mitigate these risks may not be sufficient to ensure an effective internal control environment. Given our volume of transactions, errors may be repeated or compounded before they are discovered and rectified. Our management information systems and internal control procedures may not be able to identify non-compliance or suspicious transactions in a timely manner, or at all. Moreover, our internal systems may not be fully capable of tracking certain operational and key business metrics, which are crucial for efficient decision-making and business performance. Where internal control weaknesses are identified, our actions may not be sufficient to fully correct such weaknesses. As a result, we may incur expenses or suffer monetary losses, which may not be covered by our insurance policies and may result in a material effect on our business, financial condition and results of operations.

54. *Certain key performance indicators for certain listed industry peers included in this Draft Red Herring Prospectus have been sourced from public sources and there is no assurance that such financial and other industry information is complete.*

Pursuant to the requirements of the SEBI ICDR Regulations, we have included certain key performance indicators, comprising financial and operational information, for certain listed industry peers, in the “***Basis for Issue Price***” beginning on page 90 of the Draft Red Herring Prospectus. Although this information is sourced from and relied upon on the consolidated/ standalone audited financial statements of the relevant listed industry peers as available on the websites of the Stock Exchanges, including the annual reports of the respective companies submitted to Stock Exchanges, there is no assurance that this information with respect to industry peers is either complete. There may be different methodologies and formulas used to compute the various ratios.

55. *There is no monitoring agency appointed by Our Company to monitor the utilization of the Issue proceeds.*

As per SEBI (ICDR) Regulations, 2018, as amended, appointment of monitoring agency is required only for Issue size above ₹5,000.00 lakhs. Hence, we have not appointed any monitoring agency to monitor the utilization of Issue proceeds.

However, the audit committee of our Board will monitor the utilization of Issue proceeds in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Further, our Company shall inform about material deviations in the utilization of Issue proceeds to the stock exchange and shall also simultaneously make the material deviations / adverse comments of the audit committee public.

56. *Technology failures or Cyber-attacks or other security breaches could have a material adverse effect on our business, results of operation or financial condition*

IT systems are critical to our ability to manage our operations. Our IT systems enable us to coordinate our operations, from planning, production scheduling, raw material ordering, invoicing, delivery, customer relationship, management and decision support. If we do not allocate and effectively manage the resources necessary to build and sustain the proper IT infrastructure, we could be subject to transaction errors, processing inefficiencies, customer service disruptions and, in some instances, loss of customers.

We face cyber threats, threats to the physical security of our facilities and employees, the potential for business disruptions associated with IT failures, natural disasters, or public health crises. If we are unable to protect sensitive information, our customers could question the adequacy of our threat mitigation and detection processes and procedures. Due to the evolving nature of these security threats, the impact of any future incident cannot be predicted.

57. *Our Promoters have extended personal guarantee in the loan facilities obtained by our Company, and any failure or default by our Company to repay such loans in accordance with the terms and conditions of the financing documents could trigger repayment obligations on them, which may impact their ability to effectively service their obligations and thereby, impact our business and operations.*

Our Promoters, Chetan Rugnathbhai Matholiya, Jayeshkumar Amarshibhai Sabava and Akashbhai Mansukhbhai Gangadiya and promoter group Prabhaben Rugnathbhai Matholiya and M/s Rednex Pharmaceuticals, have extended personal guarantees in the loan facilities taken by our Company from State Bank of India Limited and may continue to provide such personal guarantee post listing. Any default or failure by us to repay the loans in a timely manner, or at all could trigger repayment obligations of our guarantors in respect of such loans, which in turn, could have an impact on their ability to effectively service their obligations, thereby having an effect on our business, results of operation and financial condition. Furthermore, in the event that these individuals withdraw these guarantees, our lenders for such facilities may ask for alternate guarantees, repayment of amounts outstanding under such facilities, or even terminate such facilities. We may not be successful in procuring guarantees satisfactory to the lenders, and as a result may need to repay outstanding amounts under such facilities or seek additional sources of capital, which could affect our financial condition and cash flows. For further details, please refer to chapter titled “*Statement of Financial Indebtedness*” beginning on page 219 of this Draft Red Herring Prospectus.

58. *Excessive dependence State Bank of India Limited in respect of Loan facilities obtained by our Company.*

Our company has been sanctioned bank guarantees/ cash credit facilities and term loans by State Bank of India Limited. The Company is dependent on such facilities and any default under such arrangement with such lender may create problem for operation of the Company, which may affect the financial stability of the Company. At the same time this may result into difficulty in arranging for funds for re-payment and may also adversely affect the financial position of the Company.

59. *We are subject to certain restrictive covenants in debt facilities provided to us by our lenders.*

We have entered into agreements for availing debt facilities from lenders. Our financing arrangements contain restrictive covenants whereby we are required to obtain approval from our lenders, regarding, among other things such as major changes in share capital, management, changes in fixed assets, creation of any other charge, undertake any guarantee obligation etc. Certain covenants in these agreements require us to obtain approval/permission from our lenders in certain conditions. There can be no assurance that such consents will be granted or that we will be able to comply with the financial covenants under our financing arrangements. In the event of default or the breach of certain covenants, our lender has the option to make the entire outstanding amount payable immediately. There can be no assurance that we will be able to comply with these financial or other covenants or that we will be able to obtain consents necessary to take the actions that we believe are required to operate and grow our business. For further details in this regard, please refer to chapter titled “*Statement of Financial Indebtedness*” beginning on page 219 of this Draft Red Herring Prospectus.

60. *The average cost of acquisition of Equity Shares by our Promoters is lower than the face value of Equity Share.*

The average cost of acquisition of Equity Shares of our Promoters is lower than the face value of Equity Shares i.e., ₹10/-

For further details regarding the average cost of acquisition of Equity Shares by our Promoters in our Company and build-up of Equity Shares of our Promoters in our Company, please see section titled “*Capital Structure*” beginning on page 68 of this Draft Red Herring Prospectus.

61. *Significant differences exist between Accounting Standards and other accounting principles, such as Indian GAAP, US GAAP and International Financial Reporting Standards (“IFRS”), which investors may be more familiar with and consider material to their assessment of our financial condition.*

Our Restated Financial Information have been prepared in accordance with the Accounting Standards, and have been restated in accordance with the SEBI ICDR Regulations, the SEBI Circular and the Prospectus Guidance Note. We have not attempted to quantify the impact of Indian GAAP, US GAAP, IFRS or any other system of accounting principles on the financial data included in this Draft Red Herring Prospectus, nor do we provide a reconciliation of our financial statements to those of Indian GAAP, US GAAP, IFRS or any other accounting principles. US GAAP and IFRS differ in significant respects from Accounting Standards. Accordingly, the degree to which the Restated Financial Information included in this Draft Red Herring Prospectus will provide meaningful information is entirely dependent on the reader’s level of familiarity with Accounting Standards and the SEBI ICDR Regulations. Any reliance by persons not familiar with the accounting practices on the financial disclosures presented in this Draft Red Herring Prospectus should accordingly be limited.

62. *Our Promoters and the Promoter Group will jointly continue to retain majority shareholding in our Company after the issue, which will allow them to determine the outcome of the matters requiring the approval of shareholders.*

Our promoters along with the promoter group will continue to hold collectively [●] % of the post issue paid up share capital of the company. As a result of the same, they will be able to exercise significant influence over the control of the outcome of the matter that requires approval of the majority shareholder’s vote. Such a concentration of the ownership may also have the effect of delaying, preventing or deterring any change in the control of our company. In addition to the above, Our Promoters & Promoter Group will continue to have the ability to take actions that are not in, or may conflict with our interest or the interest of some or all of our minority shareholders and there is no assurance that such action will not have any adverse effect on our future financials or results of operations.

63. *We may be subject to surveillance measures, such as the Additional Surveillance Measures (ASM) and the Graded Surveillance Measures (GSM) by the Stock Exchanges which may adversely affect trading price of our Equity Shares.*

SEBI and Stock Exchanges in order to enhance market integrity and safeguard interest of investors, have been introducing various enhanced pre-emptive surveillance measures. The main objective of these measures is to alert and advice investors to be extra cautious while dealing in these securities and advice market participants to carry out necessary due diligence while dealing in these securities. Accordingly, SEBI and Stock Exchanges have provided for (a) GSM on securities where such trading price of such securities does not commensurate with financial health and fundamentals such as earnings, book value, fixed assets, net-worth, price per equity multiple and market capitalization; and (b) ASM on securities with surveillance concerns based on objective parameters such as price and volume variation and volatility.

On listing, we may be subject to general market conditions which may include significant price and volume fluctuations. The price of our Equity Shares may also fluctuate after the issue due to several factors such as volatility in the Indian and global securities market, our profitability and performance, performance of our competitors, changes in the estimates of our performance or any other political or economic factor. The occurrence of any of the abovementioned factors may trigger the parameters identified by SEBI and the Stock Exchanges for placing securities under the GSM or ASM framework such as net worth and net fixed assets of securities, high low variation in securities, client concentration and close to close price variation. In the event our Equity Shares are subject to such pre-emptive surveillance measures implemented by any of the Stock Exchanges, we may be subject to certain additional restrictions in connection with trading of our Equity Shares such as limiting trading frequency (for example, trading either allowed once in a week or a month) or freezing of price on upper side of trading which may have an adverse effect on the market price of our Equity Shares or may in general cause disruptions in the development of an active trading market for our Equity Shares.

64. *We may require further equity issuance, which will lead to dilution of equity and may affect the market price of our Equity Shares or additional funds through incurring debt to satisfy our capital needs, which we may not be able to procure and any future equity offerings by us.*

Our growth is dependent on having a strong balance sheet to support our activities. In addition to the IPO Proceeds and our internally generated cash flow, we may need other sources of financing to meet our capital needs which may include entering into new debt facilities with lending institutions or raising additional equity in the capital markets. We may need to raise additional capital from time to time, dependent on business conditions. The factors that would require us to raise additional capital could be business growth beyond what the current balance sheet can sustain; additional capital requirements imposed due to changes in regulatory regime or significant depletion in our existing capital base due to unusual operating losses. Any fresh issue of shares or convertible securities would dilute existing holders, and such issuance may not be done at terms and conditions, which are favorable to the then existing shareholders of our Company. If our Company decides to raise additional funds through the incurrence of debt, our interest obligations will increase, and we may be subject to additional covenants, which could further limit our ability to access cash flows from our operations. Such financings could cause our debt - equity ratio to increase or require us to create charges or liens on our assets in favor of lenders. We cannot assure you that we will be able to secure adequate financing in the future on acceptable terms, in time, or at all. Our failure to obtain sufficient financing could result in the delay or abandonment of our expansion plans. Our business and future results of operations may be affected if we are unable to implement our expansion strategy.

Any future issuance of Equity Shares by our Company may dilute shareholding of investors in our Company; and hence affect the trading price of our Company's Equity Shares and its ability to raise capital through an issue of its securities. In addition, any perception by investors that such issuances or sales might occur could also affect the trading price of our Company's Equity Shares. Additionally, the disposal, pledge or encumbrance of Equity Shares by any of our Company's major shareholders, or the perception that such transactions may occur may affect the trading price of the Equity Shares. No assurance may be given that our Company will not issue Equity Shares or that such shareholders will not dispose of, pledge or encumber their Equity Shares in the future.

65. *The Issue price of our Equity Shares may not be indicative of the market price of our Equity Shares after the Issue and the market price of our Equity Shares may decline below the issue price and you may not be able to sell your Equity Shares at or above the Issue Price.*

Prior to the Issue, there has been no public market for the Equity Shares, and an active trading market on the Stock Exchanges may not develop or be sustained after the Issue. Listing and quotation do not guarantee that a market for the Equity Shares will develop, or if developed, the liquidity of such market for the Equity Shares. The Issue Price of the Equity Shares will be determined by our Company in consultation with the BRLMs through the Book Building Process. This price will be based on numerous factors, as described under "**Basis for the Issue Price**" on page 90 and may not be indicative of the market price of the Equity Shares at the time of commencement of trading of the Equity Shares or at any time thereafter. The market price of the Equity Shares may be subject to significant fluctuations in response to, among other factors, variations in our operating results of our Company, market conditions. Consequently, the price of our Equity Shares may be volatile, and you may be unable to resell your Equity Shares at or above the Issue Price, or at all. There has been significant volatility in the Indian stock markets in the recent past, and our Equity Share price could fluctuate significantly because of market volatility. A decrease in the market price of our Equity Shares could cause investors to lose some or all of their investment.

66. *Certain data mentioned in this Draft Red Herring Prospectus has not been independently verified.*

We have not independently verified data from industry publications contained herein and although we believe these sources to be reliable, we cannot assure that they are complete or reliable. Such data may also be produced on a different basis from comparable information compiled with regard to other countries. Therefore, discussions of matters relating to India and its economy are subject to the limitation that the statistical and other data upon which such discussions are based have not been verified by us and may be incomplete or unreliable.

67. *Any of the Bidders are not permitted to withdraw or lower their Bids (in terms of quantity of Equity Shares or the Bid Amount) at any stage after submitting a Bid.*

Pursuant to the SEBI ICDR Regulations, Any of the Bidders are not permitted to withdraw or lower their Bids (in terms of quantity of Equity Shares or the Bid Amount) at any stage after submitting a Bid. While we are required to complete Allotment, listing and commencement of trading pursuant to the Offer within three (3) Working Days from the Bid/ Offer Closing Date, events affecting the Bidders' decision to invest in our Equity Shares, including adverse changes in international or national monetary policy, financial, political or economic conditions, our business, results of operations, cash flows and financial condition may arise between the date of submission of the Bid and Allotment, listing and commencement of trading. We may complete the Allotment, listing and commencement of trading of our Equity Shares even if such events occur and such events may limit the Bidders' ability to sell our Equity Shares Allotted pursuant to the Offer or may cause the trading price of our Equity Shares to decline on listing.

EXTERNAL RISK FACTORS

68. Political, economic or other factors that are beyond our control may have an adverse effect on our business and results of operations.

We are dependent on domestic, regional and global economic market conditions. Our performance, growth and market price of our Equity Shares are and will be dependent to a large extent on the health of the economy in which we operate. There have been periods of slowdown in the economic growth of India. Demand for our goods may be adversely affected by an economic downturn in domestic, regional and global economies. Further, global economic and political factors that are beyond our control, influence forecasts directly affect performance. These factors include interest rates, rates of economic growth, fiscal and monetary policies of governments, inflation, deflation, foreign exchange fluctuations, consumer credit availability, fluctuations in commodities markets, consumer debt levels, unemployment trends and other matters that influence consumer confidence, spending and tourism. The Government of India has traditionally exercised and continues to exercise influence over many aspects of the economy. Our business and the market price and liquidity of our Equity Shares may be affected by these factors, social and civil unrest and other political, economic or other developments in or affecting India. The rate of economic liberalization could change, and specific laws and policies affecting the industry, foreign investment and other matters affecting investment in our securities could change as well. Any significant change in such liberalization and deregulation policies could adversely affect business and economic conditions in India, generally, and our business, prospects, financial condition and results of operations, in particular.

69. The extent and reliability of Indian infrastructure could adversely affect our Company's results of operations and financial condition.

India's physical infrastructure is in developing phase compared to that of many developed nations. Any congestion or disruption in its port, rail and road networks, electricity grid, communication systems or any other public facility could disrupt our Company's normal business activity. Any deterioration of India's physical infrastructure would harm the national economy, disrupt the transportation of goods and supplies, and add costs to doing business in India. These problems could interrupt our Company's business operations, which could have an adverse effect on its results of operations and financial condition.

70. Instability in financial markets could materially and adversely affect our results of operations and financial condition.

The Indian economy and financial markets are significantly influenced by worldwide economic, financial and market conditions. Any financial turmoil, especially in the United States of America or Europe, may have a negative impact on the Indian economy. Although economic conditions differ in each country, investors' reactions to any significant developments in one country can have adverse effects on the financial and market conditions in other countries. A loss in investor confidence in the financial systems, particularly in other emerging markets, may cause increased volatility in Indian financial markets. For example, any global financial turmoil originating from the United States of America may lead to a loss of investor confidence in worldwide financial markets. Indian financial markets have also experienced the contagion effect of the global financial turmoil, evident from the sharp decline in SENSEX, BSE's benchmark index in the past. Any prolonged financial crisis may have an adverse impact on the Indian economy and us, thereby resulting in a material and adverse effect on our business, operations, financial condition, profitability and price of our Equity Shares.

71. Any natural calamities or outbreak of any infectious or virulent diseases, if uncontrolled, may have an adverse effect on our operations.

India has experienced natural calamities such as earthquakes, tsunamis, floods etc. In recent years, the extent and severity of these natural disasters determine their impact on the Indian economy. Prolonged spells of abnormal rainfall or other natural calamities could have a negative impact on the Indian economy, which could adversely affect our business, prospects, financial condition and results of operations as well as the price of the Equity Shares. Further, an outbreak of any infectious or virulent diseases, such as severe acute respiratory syndrome, the COVID-19 virus, the H1N1 virus, avian influenza (bird flu), the Zika virus or the Ebola virus, if uncontrolled, may have a material adverse effect on the economies of certain countries and our operations. If any of our employees or the employees of our suppliers and/or customers are infected with such diseases or if a significant portion of our workforce refuses to work for fear of contracting an infectious disease, our Company, our suppliers and/or our customers may be required to shut down operations for a period of time, and this could adversely affect our business, results of operations and financial condition.

72. Terrorist attacks or war or conflicts involving India or other countries could adversely affect consumer and business

sentiment and the financial markets and adversely affect our business.

Terrorist attacks and other acts of violence or war may adversely affect global equity markets and economic growth as well as the Indian economy and stock markets. Such acts negatively impact business and economic sentiment, which could adversely affect our business and profitability. Also, India has from time to time experienced, and may continue to experience, social and civil unrest and hostilities with neighbouring countries. Armed conflicts could disrupt communications and adversely affect the Indian economy. Such events could also create a perception that investments in Indian companies involve a high degree of risk. This, in turn, could have a material adverse effect on the market for securities of Indian companies, including our Equity Shares. The consequences of any armed conflicts are unpredictable and we therefore may not be able to foresee events that could have an adverse effect on our business.

73. Changing regulations in India could lead to new compliance requirements that are uncertain.

The regulatory environment in which we operate is evolving and is subject to change. The Government of India may implement new laws or other regulations that could affect the pharmaceutical industry or sector that we primarily serve, which could lead to new compliance requirements. New compliance requirements could increase our costs or otherwise adversely affect our business, financial condition and results of operations. Further, the manner in which new requirements will be enforced or interpreted can lead to uncertainty in our operations and could adversely affect our operations. Our business and financial performance could be adversely affected by any unexpected or onerous requirements or regulations resulting from any changes in laws or interpretation of existing laws, or the promulgation of new laws, rules and regulations. Any such changes and the related uncertainties with respect to the implementation or change in the legal framework may have a material adverse effect on our business, financial condition and results of operations.

74. Investor may be subject to Indian taxes arising out of capital gains on the sale of the Equity Shares.

Under current Indian tax laws, capital gains arising from the sale of equity shares within 12 months in an Indian company are classified as short-term capital gains and generally taxable. Any gain realized on the sale of listed equity shares on a stock exchange that are held for more than 12 months is considered as long-term capital gains and is taxable. Any long-term gain realized on the sale of equity shares, which are sold other than on a recognized stock exchange and on which no STT has been paid, is also subject to tax in India. Capital gains arising from the sale of equity shares are exempt from taxation in India where an exemption from taxation in India is provided under a treaty between India and the country of which the seller is resident. Generally, Indian tax treaties do not limit India's ability to impose tax on capital gains. As a result, residents of other countries may be liable to pay tax in India as well as in their own jurisdiction on a gain on the sale of equity shares.

75. Any downgrading of India's sovereign rating by an independent agency or restrictions on ability of Indian companies to raise foreign capital may harm our ability to raise financing.

Any adverse revisions to India's credit ratings for domestic and international debt by international rating agencies may adversely impact our ability to raise additional financing, and the interest rates and other commercial terms at which such additional financing may be available. This could have an adverse effect on our business and future financial performance, our ability to obtain financing for capital expenditures and the trading price of our Equity Shares. Further, we are subject to exchange controls that regulate borrowing in foreign currencies, including those specified under the Foreign Exchange Management Act (the "FEMA") and the rules thereunder. Such regulatory restrictions limit our financing sources for our projects under development and hence could constrain our ability to obtain financing on competitive terms and refinance existing indebtedness. In addition, we cannot assure you that the required approvals for the same will be granted to us without onerous conditions, or at all. Limitations on foreign debt may adversely affect our business growth, results of operations and financial condition.

76. Risks relating to international trade policies, tariffs, sanctions, and export/import restrictions

Our business operations are dependent on international trade, as we export pharmaceutical products to various countries. Any adverse changes in international trade policies, including the imposition of new tariffs, duties, quotas, or other trade barriers by governments, may increase our costs of procurement or reduce the competitiveness of our products in export markets. For instance, higher tariffs on key raw materials could adversely impact our cost structure, while tariffs on pharmaceutical exports could reduce our margins or make our products less attractive to overseas buyers. Further, our ability to conduct business in certain geographies is subject to the prevailing foreign trade regulations and sanctions regimes. International sanctions or restrictions imposed by multilateral organizations (such as the United Nations), trade blocs (such as the European Union), or individual countries (such as the United States) may limit or prohibit our ability to sell products, engage with suppliers, or operate in certain jurisdictions. Any expansion of such sanctions to include

countries where we source raw materials or sell our products could disrupt our supply chain and adversely affect our revenues.

In addition, sudden changes in bilateral or multilateral trade agreements, revocation of preferential tariff status, or tightening of import/export regulations for pharmaceutical products may adversely impact our business. Compliance with evolving trade regulations and sanctions also entails additional administrative, legal, and monitoring costs. Any inability to effectively manage risks arising from tariffs, sanctions, or other trade restrictions may materially and adversely affect our supply chain, international sales, financial condition, and results of operations.

77. Foreign investors are subject to foreign investment restrictions under Indian law that limit our ability to attract foreign investors, which may adversely affect the trading price of the Equity Shares.

Under the foreign exchange regulations currently in force in India, transfers of shares between non-residents and residents are freely permitted (subject to certain restrictions) if they comply with the pricing guidelines and reporting requirements specified by the RBI. If the transfer of shares, which are sought to be transferred, is not in compliance with such pricing guidelines or reporting requirements or falls under any of the exceptions referred to above, then the prior approval of the RBI will be required. Additionally, shareholders who seek to convert the Indian Rupee proceeds from a sale of shares in India into foreign currency and repatriate that foreign currency from India will require a no objection/tax clearance certificate from the income tax authority. Additionally, the GoI may impose foreign exchange restrictions in certain emergency situations, including situations where there are sudden fluctuations in interest rates or exchange rates, where the GoI experiences extreme difficulty in stabilizing the balance of payments or where there are substantial disturbances in the financial and capital markets in India. These restrictions may require foreign investors to obtain the GoI's approval before acquiring Indian securities or repatriating the interest or dividends from those securities or the proceeds from the sale of those securities. We cannot assure you that any required approval from the RBI or any other GoI agency can be obtained on any particular terms, or at all.

SECTION IV – INTRODUCTION

THE ISSUE

PRESENT ISSUE IN TERMS OF THIS DRAFT RED HERRING PROSPECTUS	
Issue of Equity Shares of face value of ₹ 10/- each ⁽¹⁾⁽²⁾	Issue of up to 27,36,000* Equity Shares of face value of ₹10/- each for cash at a price of ₹[●] (including a Share premium of ₹[●] per Equity Share) per share aggregating to ₹[●] Lakhs.
Out of which:	
Issue Reserved for the Market Makers	Up to [●] Equity Shares of face value of ₹10/- each (including a Share premium of ₹[●] per Equity Share) aggregating to ₹ [●] Lakhs.
Net Issue to the Public	Up to [●] Equity Shares of face value of ₹10/- each (including a Share premium of ₹[●] per Equity Share) aggregating to ₹ [●] Lakhs.
Out of which*	
A. QIB Portion ⁽³⁾⁽⁴⁾⁽⁵⁾	Not more than [●] Equity Shares of face value of ₹10/- each (including a Share premium of ₹[●] per Equity Share) aggregating up to ₹ [●] lakhs.
Of which	
i) Anchor Investor Portion	Up to [●] Equity Shares of face value of ₹10/- each (including a Share premium of ₹[●] per Equity Share) aggregating up to ₹ [●] lakhs.
ii) Net QIB Portion (assuming Anchor Investor Portion is fully subscribed)	Up to [●] Equity Shares of face value of ₹10/- each (including a Share premium of ₹[●] per Equity Share) aggregating up to ₹ [●] lakhs.
Of which	
(a) Available for allocation to Mutual Funds only (5% of the Net QIB Portion)	Up to [●] Equity Shares of face value of ₹10/- each (including a Share premium of ₹[●] per Equity Share) aggregating up to ₹ [●] lakhs
(b) Balance of QIB Portion for all QIBs including Mutual Funds	Up to [●] Equity Shares of face value of ₹10/- each (including a Share premium of ₹[●] per Equity Share) aggregating up to ₹ [●] lakhs
B. Non-Institutional Portion	Not less than [●] Equity Shares of face value of ₹10/- each (including a Share premium of ₹[●] per Equity Share) aggregating up to ₹ [●] lakhs
Of which	
(a) One-third of the portion available to NIBs shall be reserved for applicants with an application size of more than two lots and up to such lots equivalent to not more than ₹10,00,000/-	Up to [●] Equity Shares of face value of ₹10/- each (including a Share premium of ₹[●] per Equity Share) aggregating up to ₹ [●] lakhs
(b) Two-third of the portion available to NIBs shall be reserved for applicants with an application size of more than ₹ 10,00,000/-	Up to [●] Equity Shares of face value of ₹10/-each (including a Share premium of ₹[●] per Equity Share) aggregating up to ₹ [●] lakhs
C. Individual Investor Portion	Not less than [●] Equity Shares of face value of ₹10/-each (including a Share premium of ₹[●] per Equity Share) aggregating up to ₹ [●] lakhs
Pre and Post – Issue Equity Shares	
Equity Shares outstanding prior to the Issue	76,50,000 Equity Shares of face value of ₹10 each
Equity Shares outstanding after the Issue	[●] Equity Shares of face value of ₹10 each
Use of Net Proceeds by our Company	Please see the chapter titled “ <i>Objects of the Issue</i> ” on page 80 of this Draft Red Herring Prospectus.

* Subject to finalization of the Basis of Allotment. Number of shares may need to be adjusted for lot size upon determination of issue price.

Notes:

- 1) The Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, as amended from time to time. This Issue is being made by our company in terms of Regulation of 229 (2) of SEBI ICDR Regulations read with Rule 19(2)(b)(i) of SCRR wherein not less than 25% of the post – issue paid up equity share capital of our company are being offered to the public for subscription.
- 2) The Issue has been authorized by the Board of Directors vide a resolution passed at its meeting held on September 26, 2025 and by the Shareholder of our Company, vide a special resolution passed pursuant to Section 62(1)(c) of the Companies Act, 2013 at the Extra Ordinary General Meeting held on September 26, 2025.
- 3) The SEBI ICDR Regulations permit the issue of securities to the public through the Book Building Process, which states that, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non Institutional Bidders and not less than 35% of the Net Issue shall be available for allocation on a proportionate basis to Individual Bidders and not more than 50% of the Net Issue shall be allotted on a proportionate basis to QIBs, subject to valid Bids being received at or above the Issue Price. Accordingly, we have allocated the Net Issue i.e., not more than 50% of the Net Issue to QIB and not less than 35% of the Net Issue shall be available for allocation to Individual Investors and not less than 15% of the Net Issue shall be available for allocation to non-institutional bidders. Further, (a) One-third of the portion available to NIBs shall be reserved for applicants with application size of more than two lots and up to such lots equivalent to not more than ₹ 10,00,000/-, and (b) Two-third of the portion available to NIBs shall be reserved for applicants with application size of more than ₹ 10,00,000/-. Provided that the unsubscribed portion in either of the sub-categories specified in clauses (a) or (b), could be allocated to applicants in the other sub-category of NIBs .The allocation to each NIB shall not be less than the minimum NIB Application Size, subject to availability of Equity Shares in the Non-Institutional Portion and the remaining available Equity Shares, if any, was available for allocation on a proportionate basis in accordance with the conditions specified in this regard in Schedule XIII of the SEBI ICDR Regulations.
- 4) Subject to valid Bids being received at or above the Issue Price, under subscription, if any, in any category, except in the QIB Portion, would be allowed to be met with spill-over from any other category or combination of categories of Bidders at the discretion of our Company in consultation with the Book Running Lead Managers and the Designated Stock Exchange, subject to applicable laws.

Our Company may, in consultation with the Book Running Lead Manager, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations. One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription in the Anchor Investor Portion, the remaining Equity Shares shall be added to the QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allotment in the Mutual Fund Portion will be added to the Net QIB Portion and allocated proportionately to the QIB Bidders (other than Anchor Investors) in proportion to their Bids. For further details, please refer section titled “**Issue Procedure**” beginning on page 273 of this Draft Red Herring Prospectus

SUMMARY OF OUR FINANCIAL STATEMENTS

RESTATED STATEMENT OF ASSETS AND LIABILITIES

(Amount in Rs. Lakhs)

Sr. No.	Particulars	As at		
		31-03-25	31-03-24	31-03-23
A)	EQUITY AND LIABILITIES			
1.	Shareholders' Funds			
(a)	Share Capital	425.00	425.00	425.00
(b)	Reserves & Surplus	522.07	95.67	-97.76
	Total (1)	947.07	520.67	327.24
2.	Non-Current Liabilities			
(a)	Long Term Borrowings	929.32	955.88	489.91
(b)	Deferred Tax Liabilities (net)	-	11.75	-
(c)	Long Term Provisions	10.05	1.91	0.34
	Total (2)	939.37	969.55	490.25
3.	Current Liabilities			
(a)	Short Term Borrowings	984.73	965.77	545.48
(b)	Trade Payables			
	Due to Micro and Small Enterprises	392.01	41.34	-
	Due to Others excluding Micro and Small Enterprises	1,535.42	673.00	235.03
(c)	Other Current Liabilities	110.27	92.05	112.49
(d)	Short Term Provisions	103.32	12.63	0.00
	Total (3)	3,125.75	1,784.79	893.00
	Total Equity and Liabilities (1+2+3)	5,012.19	3,275.01	1,710.49
B)	ASSETS			
1.	Non-Current Assets			
(a)	Property, Plant and Equipment and Intangible Assets			
	i) Property, Plant and Equipment	1,595.70	1,624.11	425.43
	ii) Intangible Assets	8.64	14.23	5.59
	iii) Capital Work in progress	-	-	611.68
(b)	Non-Current Investment	-	-	-
(c)	Deferred tax assets (net)	0.41	-	17.78
(d)	Other Non-Current Assets	8.36	46.83	15.10
	Total (1)	1,613.11	1,685.17	1,075.58
2.	Current Assets			
(a)	Trade Receivables	1,452.29	570.93	139.70
(b)	Cash and Bank Balances	28.52	121.72	2.01
(c)	Inventories	1,621.58	673.92	191.84
(d)	Short-Term Loans and Advances	208.04	140.44	293.10
(e)	Other Current Assets	88.65	82.83	8.26
	Total (2)	3,399.08	1,589.84	634.91
	Total (1+2)	5,012.19	3,275.01	1,710.49
	Significant Accounting Policies			
	Notes to Restated Financial Statement			

RESTATED STATEMENT OF PROFIT AND LOSS

(Amount in Rs. Lakhs)

Sr. No.	Particulars	For the period ended		
		31-03-25	31-03-24	31-03-23
1	Revenue From Operations	4,580.12	2,440.54	170.25
2	Other Income	31.97	7.71	1.84
3	Total Income (1+2)	4,612.09	2,448.24	172.09
4	Expenses			
(a)	Cost of Material Consumed	3,635.20	1,789.75	178.08
(b)	Purchase of Stock in Trade	86.48	1.04	-
(c)	Change in Inventories of finished goods, wip	-592.97	-26.67	-35.21
(d)	Employee Benefit Expenses	257.47	99.64	25.60
(e)	Finance Costs	158.95	120.25	58.67
(f)	Depreciation and Amortisation Expenses	287.05	116.74	22.48
(g)	Other Expenses	264.23	113.34	32.80
5	Total Expenses 4(a) to 4(g)	4,096.41	2,214.09	282.42
6	Profit Before Exceptional & Extraordinary items & Tax (3-5)	515.68	234.15	-110.33
7	Exceptional item & Extraordinary Items	-	-	-
8	Profit Before Extraordinary items & Tax (6-7)	515.68	234.15	-110.33
9	Prior Period Expenses	-	-	-
10	Profit Before Tax (8-9)	515.68	234.15	-110.33
11	Tax Expense:			
(a)	Net Current Tax	101.44	11.19	-
(b)	Deferred Tax	-12.16	29.53	-17.78
(c)	Income Tax of Previous Year		-	-
12	Total Tax Expenses 11(a) to 11(c)	89.28	40.72	-17.78
13	Profit for the Year (10-12)	426.40	193.43	-92.55
14	Earning per equity share of Rs.10 each			
	Basic and Diluted (Rs.)	5.57	2.53	-1.54

RESTATED CASH FLOW STATEMENT

(Amount in Rs. Lakhs)

Particulars		For the period ended		
		31-03-25	31-03-24	31-03-23
A) Cash Flow from Operating Activities:				
Net Profit before tax as per Statement of Profit & Loss		515.68	234.15	-110.33
Adjustment for:				
Depreciation and amortization Expenses		287.05	116.74	22.48
Interest on Deposit		-2.32	-2.10	-0.35
Subsidy		-24.55	-	-
Finance Cost		150.60	113.65	20.82
Gratuity Provision		8.16	1.57	0.34
Operating profit before working capital changes		934.62	464.01	-67.04
Changes in Working Capital				
(Increase)/Decrease in Trade Receivables		-881.36	-431.23	-139.70
(Increase)/Decrease in Inventory		-947.66	-482.08	-191.84
(Increase)/Decrease in Short Term Loans & Advances		-131.87	149.96	-238.30
(Increase)/Decrease in Other Current Assets		-5.82	-74.57	-6.59
Increase/(Decrease) in Trade Payables		1,213.09	479.31	228.74
Increase/(Decrease) in Other Current Liabilities		18.22	-20.44	70.81
Increase/(Decrease) in Provisions, etc		-10.78	1.45	-
Cash generated from operations		188.44	86.41	-343.92
Less: Income Taxes paid		64.27	2.70	0.09
Net cash flow from operating activities	A	252.71	89.11	-343.83
B) Cash Flow from Investing Activities:				
Purchase of Fixed Assets including of CWIP		-253.05	-712.38	-579.94
Increase in Fixed Deposit		9.66	-10.42	-6.25
Other Non-Current Assets		21.80	-21.31	-7.26
Interest on Deposit		2.32	2.10	0.35
Net cash flow from investing activities	B	-219.27	-742.01	-593.10
C) Cash Flow from Financing Activities:				
Increase/(Decrease) in Short Term Borrowings		18.96	420.29	545.48
Increase/(Decrease) in Long Term Borrowings		-26.56	465.97	-1.89
Finance Cost		-150.60	-113.65	-20.82
Subsidy		24.55	-	-
Fresh issued of share during the year		-	-	415.00
Net cash flow from financing activities	C	-133.65	772.61	937.77
Net Increase/(Decrease) In Cash & Cash Equivalents	(A+B+C)	-100.21	119.71	0.84
Cash equivalents at the beginning of the year		121.72	2.01	1.17
Cash equivalents at the end of the year		21.51	121.72	2.01

Notes:

1.

(Amount in Rs. Lakhs)

Component of Cash and Cash equivalents	As at		
	31-03-25	31-03-24	31-03-23
Cash on hand	10.36	21.02	0.40
Balance With banks			
(i) In Current Accounts	0.54	100.70	1.61
(ii) Fixed Deposit with Maturity between (0-3 months)	10.61	-	-
Total	21.51	121.72	2.01

- Cash flows are reported using the indirect method, whereby profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from regular revenue generating, financing and investing activities of the company are segregated.
- The accompanying Restated significant accounting policies, Restated notes to accounts and notes on adjustments for Restated financial Statement (Note 1 to 32, Annexure IV & V) are an integral part of this statement. As per our annexed report of even date

GENERAL INFORMATION

Brief Summary:

Our Company was originally incorporated as a Private Limited Company under the name “Rednex Pharmaceuticals Private Limited” on December 29, 2020 under the provisions of the Companies Act, 2013 with the Registrar of Companies, Ahmedabad bearing CIN: U24304GJ2020PTC119176. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extraordinary General Meeting, held on December 30, 2024 and consequently, the name of our Company was changed from “Rednex Pharmaceuticals Private Limited” to “Rednex Pharmaceuticals Limited” vide a fresh certificate of incorporation dated January 21, 2025 issued by the Registrar of Companies, Central Processing Centre bearing CIN: U24304GJ2020PLC119176.

For further details please refer to chapter titled “**History and Corporate Structure**” beginning on page 146 of this Draft Red Herring Prospectus.

CIN	U24304GJ2020PLC119176
Registration No.	119176
Date of Incorporation	December 29, 2020
Registered Office	Rednex Pharmaceuticals Limited Survey No. 586 and 231, Near SKF Bearing, Bavla Bagodara N.H 8A, Kerala, Taluka: Bavla, Ahmedabad, Gujarat, India, 382220 Tel. No.: +91- 81600-35021 Email: info@rednexpharma.com Website: https://rednexpharma.com/
Designated Stock Exchange	SME Platform of BSE “BSE SME”
Address of the Registrar of Companies	Registrar of Companies, Ahmedabad RoC Bhavan, Opp Rupal Park Society Behind Ankur Bus Stop, Naranpura, Ahmedabad-380013 Gujarat India. Tel No: 079-27438531 Email id: roc.ahmedabad@mca.gov.in Website: www.mca.gov.in

Board of Directors:

The Board of Directors of our Company as on the date of filing of this Draft Red Herring Prospectus consists of:

Name of Directors	Designation	Address	DIN
Chetan Rugnathbhai Matholiya	Chairman & Whole-Time Director	L-201, Aarohi Elegance, Gala Gymkhana Road, Near Aarohi Crest, South Bopal, Bopal, Ahmedabad- 380058, Gujarat	09013701
Jayeshkumar Amarshibhai Sabava	Managing Director	L-104, Aarohi Elegance, Gala Gymkhana Road, Near Aarohi Crest, South Bopal, Bopal, Ahmedabad-380058 Gujarat	09013702
Akashbhai Mansukhbhai Gangadiya	Whole Time Director and CFO	92, Satsang park, Ratanpura, NR Hariom Bungalows, Vastral, Ahmedabad- 382418 Gujarat	09013700
Narendrabhai Dineshbhai Khambhaliya	Non-executive Director	1612, Smashan Pase, Chotalal na jin pase, Lathidad, Botad- 364710, Gujarat	11259501
Rashmi Krunal Lakhani	Independent Director	39/4, Patel Park Society, Behind Pancham Maill, Nikol Gam Road, Nikol, Ahmedabad- 382350, Gujarat	08206547
Kashyap Naranbhai Thummar	Independent Director	Flat No. 22, GTU Staff Quarter, GTU Campus, Visat Gandhinagar Highway, Gujarat Technological University, Ahmedabad, Gujarat- 382424	11297561

For further details in relation to our directors, please refer to chapter titled **“Our Management”** on page 150 of this Draft Red Herring Prospectus.

Chief Financial Officer	Company Secretary & Compliance Officer
Akashbhai Mansukhbhai Gangadiya Rednex Pharmaceuticals Limited Survey No. 586 and 231, Near SKF Bearing, Bavla Bagodara N.H 8A, Kerala, Taluka: Bavla, Ahmedabad, Gujarat, India, 382220 Tel. No.: +91- 81600-35021 Email: cfo@rednexpharma.com Website: https://rednexpharma.com/	Rima Amitbhai Dalal Rednex Pharmaceuticals Limited Survey No. 586 and 231, Near SKF Bearing, Bavla Bagodara N.H 8A, Kerala, Taluka: Bavla, Ahmedabad, Gujarat, India, 382220 Tel. No.: +91- 83201-31437 Email: cs@rednexpharma.com Website: https://rednexpharma.com/

Investor Grievances:

Investors may contact our Company Secretary and Compliance Officer and/or the Registrar to the Issue and/or the Lead Manager, in case of any pre-issue or post-issue related problems, such as non-receipt of letters of allotment, credit of allotted Equity Shares in the respective beneficiary account or refund orders, etc.

All grievances in relation to the application through ASBA process may be addressed to the Registrar to the Issue, with a copy to the relevant Designated Intermediary with whom the ASBA Form was submitted, giving details such as the full name of the sole or First Applicant, ASBA Form number, Applicants DP ID, Client ID, PAN, number of Equity Shares applied for, date of submission of ASBA Form, address of Bidder, the name and address of the relevant Designated Intermediary, where the ASBA Form was submitted by the Bidder, ASBA Account number in which the amount equivalent to the Bid Amount was blocked and UPI ID used by the Individual Investors. Further, the Bidder shall enclose the Acknowledgment Slip from the Designated Intermediaries in addition to the documents or information mentioned hereinabove.

For all Issue related queries and for redressal of complaints, Applicants may also write to the Book Running Lead Manager. All complaints, queries or comments received by Stock Exchange/SEBI shall be forwarded to the Book Running Lead Manager, who shall respond to the same.

All grievances relating to the Anchor Investors may be addressed to the Registrar to the Issue, giving full details such as name of the sole or first Applicant, Bid cum Application Form number, Applicants DP ID, Client ID, PAN, date of the Anchor Investor Application Form, address of the Applicant, number of Equity Shares applied for, Bid Amount paid on submission of the Anchor Investor Application Form and the name and address of the relevant BRLM where the Anchor Investor Application Form was submitted by the Anchor Investor. For all Issue related queries and for redressal of complaints, investors may also write to the BRLM.

Details of Key Intermediaries pertaining to this Issue and our Company:

Book Running Lead Manager to the Issue	Legal Advisor to the Issue
Hem Securities Limited Address: 904, A Wing, Naman Midtown, Senapati Bapat Marg, Elphinstone Road, Lower Parel, Mumbai-400013, Maharashtra, India Tel No.: +91-22-4906 0000 Email: ib@hemsecurities.com Investor Grievance Email: redressal@hemsecurities.com Website: www.hemsecurities.com Contact Person: Roshni Lahoti SEBI Reg. No.: INM000010981	Zenith India Lawyers Address: D-49, Sushant Lok-III, Sector-57, Gurugram, Haryana- 122003 Tel: 0124-4240681 Email: team@zilawyers.com Website: https://zilawyers.com Contact Person: Raj Rani Bhalla Designation: Managing Partner
Registrar to the Issue	Statutory Auditor
Bigshare Services Private Limited Address: S6-2, 6th Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East) Mumbai – 400093, India. Telephone: +91 22 6263 8200 Facsimile: +91 22 6263 8299 Email: ipo@bigshareonline.com	M/s. Krupal Bhuva & Co., Chartered Accountants Address: 407-408, Golden Plaza, Amar Jawan Circle, Nikol, Ahmedabad, Gujarat – 382350 Tel No.: +91- 9687302245 Email: Krupalbhuva@yahoo.com Firm Registration No.: 0146585W

Investor Grievance Email: investor@bigshareonline.com Website: www.bigshareonline.com Contact Person: Mr. Ganesh Shinde SEBI Registration Number: INR000001385 CIN: U99999MH1994PTC076534	Membership No: 182312 Peer Review Certificate Number: 020962 Contact Person: Krupal Bipinbhai Bhuva
Banker to our Company	Syndicate Member*
State Bank of India Address: Neptune Tower Complex, Off Ashram Road, Opp Gandhigram Metro Station, Ahmedabad, Gujarat- 380009 Telephone: 7600036152, 7779063671 E-mail ID: sbi.03993@sbi.co.in Contact Person: Madhav Kumar & Anuj Jalan	[•]
Bankers to the Issue/ Refund Banker/ Sponsor Bank*	
[•]	

**The Banker to the Issue (Sponsor Bank) and Syndicate Member shall be appointed prior to filing of the Red Herring Prospectus with the RoC.*

Designated Intermediaries:

Self-Certified Syndicate Banks (SCSB's)

The list of SCSBs, as updated till date, is available on website of Securities and Exchange Board of India at below link.
<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=34>;
<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=35>
Investors are requested to refer the SEBI website for updated list of SCSBs and their designated branches.

Self-Certified Syndicate Banks eligible as Sponsor Banks for UPI

The list of Self Certified Syndicate Banks that have been notified by SEBI to act as Investors Bank or Issuer Bank for UPI mechanism are provide on the website of SEBI on
<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=41>

Syndicate SCSB Branches

In accordance with SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2019/76 dated June 28, 2019 and SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019, Individual Investors Applying using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appears on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=40>) and updated from time to time. A list of SCSBs and mobile applications, which are live for applying in public issues using UPI mechanism, is provided as 'Annexure A' for the SEBI circular number SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019, as amended.

Registered Brokers

The list of the Registered Brokers including details such as postal address, telephone number and email address, is provided on the website of the SEBI at (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes>), respectively, as updated from time to time.

Registrar and Share Transfer Agents

The list of the Registrar to Issue and Share Transfer Agents (RTAs) eligible to accept Applications forms at the Designated RTA Locations, including details such as address, telephone number and e-mail address, are provided at <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=10>, as updated from time to time.

Collecting Depository Participants (CDP's)

The list of the Collecting Depository Participants (CDPs) eligible to accept Application Forms at the Designated CDP Locations, including details such as name and contact details, are provided at <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=19> for NSDL CDPs and at <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=18> for CDSL CDPs, as updated from time to time. The list of branches of the SCSBs named by the respective SCSBs to receive deposits of the Bid cum

Application Forms from the Designated Intermediaries will be available on the website of the SEBI (www.sebi.gov.in) at and as updated from time to time.

Brokers to the Issue

All members of the recognized stock exchanges would be eligible to act as Brokers to the Issue.

Expert Opinion

Except as stated below, our Company has not obtained any expert opinions:

Our Company has received written consent dated September 23, 2025 from M/s. Krupal Bhuvra & Co, Chartered Accountants, to include their name as required under section 26(1) of the Companies Act, 2013 read with SEBI ICDR Regulations, in this Draft Red Herring Prospectus, and as an “expert” as defined under section 2(38) of the Companies Act, 2013 to the extent and in their capacity as our Statutory Auditors and such consent has not been withdrawn as of the date of this Draft Red Herring Prospectus.

In addition, our Company has received written consent dated September 24, 2025 from Mr. Rohitkumar Rakholiya Independent Chartered Engineer to include his name as required under Section 26(5) of the Companies Act, 2013 read with SEBI ICDR Regulations, in this Draft Red Herring Prospectus, and as an “expert” as defined under Section 2(38) of the Companies Act, 2013 to the extent and his capacity as independent chartered engineer in respect of details regarding capacity utilization of our Company and such consent has not been withdrawn as on the date of this Draft Red Herring Prospectus

However, the term “expert” shall not be construed to mean an “expert” as defined under the U.S. Securities Act, 1933.

Inter-se Allocation of Responsibilities

Since, Hem Securities Limited is the sole Book Running Lead Manager to this Issue, a statement of inter se allocation of responsibilities among Book Running Lead Manager is not applicable.

Monitoring Agency

As per regulation 262(1) of SEBI ICDR Regulations, the requirement of monitoring agency is not mandatory if the Issue size is up to ₹5,000 Lakh. Since the Issue size is below ₹5,000 Lakh, our Company has not appointed any monitoring agency for this Issue. However, as per section 177 of the Companies Act, the Audit Committee of our Company, would be monitoring the utilization of the proceeds of the Issue.

Green Shoe Option

No Green Shoe Option is applicable for this Issue.

Credit Rating

As this is an issue of Equity Shares, there is no credit rating for the Issue.

IPO Grading

Since the issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018 there is no requirement of appointing an IPO Grading agency.

Debenture Trustees

As this is an issue of Equity Shares, the appointment of Debenture trustees is not required.

Filing of Draft Red Herring Prospectus/ Red Herring Prospectus/Prospectus with the SEBI/ ROC

The Draft Red Herring Prospectus is being filed with BSE Ltd., Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001 Maharashtra, India.

The Draft Red Herring Prospectus will not be filed with SEBI, nor will SEBI issue any observation on the Offer Document in terms of Regulation 246(2) of SEBI (ICDR) Regulations, 2018. Pursuant to Regulation 246(5) of SEBI (ICDR) Regulations, 2018 and SEBI Circular Number SEBI/HO/CFD/DIL1/CIR/P/2018/011 dated January 19, 2018, a copy of Red Herring Prospectus/ Prospectus will be filed online through SEBI Intermediary Portal at <https://siportal.sebi.gov.in>.

A copy of the Red Herring Prospectus along with the material contracts and documents required to be filed under Section 32 of the Companies Act, 2013 would be filed with the RoC at its office through the electronic portal at <http://www.mca.gov.in> and a copy of the Prospectus to be filed under Section 26 of the Companies Act, 2013 would be filed with the RoC at its office and through the electronic portal at <http://www.mca.gov.in>.

Book Building Process

Book Building, with reference to the Issue, refers to the process of collection of Bids on the basis of the Red Herring Prospectus within the Price Band. The Price Band shall be determined by our Company in consultation with the Book Running Lead Manager in accordance with the Book Building Process, and advertised in all editions of the English national newspaper [●], all editions of Hindi national newspaper [●] and Gujarati Edition of Regional newspaper [●] where our registered office is situated at least two working days prior to the Bid/ Issue Opening date. The Issue Price shall be determined by our Company, in consultation with the Book Running Lead Manager in accordance with the Book Building Process after the Bid/ Issue Closing Date. Principal parties involved in the Book Building Process are:

- Our Company;
- The Book Running Lead Manager in this case being Hem Securities Limited,
- The Syndicate Member(s) who are intermediaries registered with SEBI/ registered as brokers with BSE Ltd. and eligible to act as Underwriters. The Syndicate Member(s) will be appointed by the Book Running Lead Manager;
- The Registrar to the Issue and;
- The Designated Intermediaries and Sponsor bank

The SEBI ICDR Regulations have permitted the Issue of securities to the public through the Book Building Process, wherein allocation to the public shall be made as per Regulation 253 of the SEBI ICDR Regulations.

The Issue is being made through the Book Building Process wherein not more than 50% of the Net Issue shall be available for allocation on a proportionate basis to QIBs, provided that our Company may in consultation with the Book Running Lead Manager allocate upto 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI (ICDR) Regulations (the “**Anchor Investor Portion**”), out of which one third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Issue Price. 5% of the QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders in the following manner: (a) 1/3rd of the portion available to NIBs shall be reserved for applicants with an application size of more than 2 lots and upto such lots equivalent to not more than ₹ 10,00,000, (b) 2/3rd of the portion available to NIBs shall be reserved for applicants with an application size of more than ₹ 10,00,000 and the unsubscribed portion in either of the sub-categories specified in clauses (a) or (b), could be allocated to applicants in the other sub-category of NIBs and the remaining shares, if any, shall be allotted on a proportionate basis in accordance with the conditions specified in this regards in Schedule XIII of SEBI ICDR Regulations and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders, who applies for minimum application size, in accordance with the SEBI Regulations, subject to valid Bids being received at or above the Issue Price.

All potential Bidders except the Anchor Investors, may participate in the Issue through an ASBA process by providing details of their respective bank account which will be blocked by the SCSBs or, in case of UPI Bidders, by alternatively using the UPI Mechanism. Anchor Investors are not permitted to participate in the Issue through the ASBA process. Under-subscription if any, in any category, except in the QIB Category, would be allowed to be met with spill over from any other category or a combination of categories at the discretion of our Company in consultation with the Book Running Lead Manager and the Designated Stock Exchange.

In accordance with the SEBI ICDR Regulations any category of Bidders are not allowed to withdraw or lower the size of their Bids (in terms of the quantity of the Equity Shares or the Bid Amount) at any stage. Allocation to the Anchor Investors will be on a discretionary basis.

Allotment to Individual Bidders shall not be less than the minimum application value, subject to availability of Equity Shares in Individual Investor Portion, and the remaining available Equity Shares, if any, shall be allotted on a proportionate

basis. Under – subscription, if any, in any category, would be allowed to be met with spill – over from any other category or a combination of categories at the discretion of our Company in consultation with the Book Running Lead Manager and the Stock Exchange. However, under-subscription, if any, in the QIB Portion will not be allowed to be met with spill over from other categories or a combination of categories.

Each Bidder by submitting a Bid in the Issue, will be deemed to have acknowledged the above restrictions and the terms of the Issue. Bidders should note that the Issue is also subject to obtaining the final listing and trading approvals of the Stock Exchanges, which our Company shall apply for after Allotment; and filing of the Prospectus with the RoC.

In terms of SEBI Circular No. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, all the investors (except Anchor Investors) applying in a public issue shall use only Application Supported by Blocked Amount (ASBA) process for application providing details of the bank account which will be blocked by the Self Certified Syndicate Banks (SCSBs) for the same. Further, pursuant to SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 01, 2018, Individual Investors applying in public issue may use either Application Supported by Blocked Amount (ASBA) facility for making application or also can use UPI as a payment mechanism with Application Supported by Blocked Amount for making application. For details in this regards, specific attention are invited to the chapter titled **“Issue Procedure”** beginning on page 273 of the Draft Red Herring Prospectus.

The process of Book Building under the SEBI ICDR Regulations is subject to change from time to time and the investors are advised to make their own judgment about investment through this process prior to making a Bid or application in the Issue.

For further details on the method and procedure for Bidding, please see section entitled **“Issue Procedure”** on page 273 of this Draft Red Herring Prospectus.

Illustration of the Book Building and Price Discovery Process:

For an illustration of the Book Building Process and the price discovery process, please refer to the chapter titled **“Issue Procedure”** on page 273 of this Draft Red Herring Prospectus.

Bid/ Issue Program:

Event	Indicative Dates
Bid/ Issue Opening Date	[●] ¹
Bid/ Issue Closing Date	[●] ²
Finalization of Basis of Allotment with the Designated Stock Exchange (T+1)	[●]
Initiation of Allotment / Refunds / Unblocking of Funds from ASBA Account or UPI ID linked bank account (T+2)	[●]
Credit of Equity Shares to Demat accounts of Allottees (T+2)	[●]
Commencement of trading of the Equity Shares on the Stock Exchange (T+3)	[●]

⁽¹⁾ Our Company in consultation with the Book Running Lead Manager may consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/Issue Period shall be one Working Day prior to the Bid/Issue Opening Date in accordance with the SEBI ICDR Regulations.

⁽²⁾ Our Company in consultation with the BRLM, consider closing the Bid/ Issue Period for QIBs one Working Day prior to the Bid/Issue Closing Date in accordance with the SEBI ICDR Regulations.

The above timetable is indicative and does not constitute any obligation on our Company or the Book Running Lead Manager. Whilst our Company shall ensure that all steps for the completion of the necessary formalities for the listing and the commencement of trading of the Equity Shares on the Stock Exchange are taken within 3 Working Days of the Bid/ Issue Closing Date, the timetable may change due to various factors, such as extension of the Bid/Issue Period by our Company, revision of the Price Band or any delays in receiving the final listing and trading approval from the Stock Exchange. The Commencement of trading of the Equity Shares will be entirely at the discretion of the Stock Exchange and in accordance with the applicable laws.

Bid Cum Application Forms and upward revisions to the same will be accepted only between 10.00 A.M. to 05.00 P.M. (IST) during the Issue Period (except for the Bid/ Issue Closing Date). On the Bid/ Issue Closing Date, the Bid Cum Application Forms will be accepted only between 10.00 A.M. to 3.00 P.M. (IST) for all bidders.

Due to the limitation of time available for uploading the Bid Cum Application Forms on the Bid/Issue Closing Date, Bidders are advised to submit their applications one (1) day prior to the Bid/ Issue Closing Date and, in any case, not later than 3.00 P.M. (IST) on the Bid/ Issue Closing Date. Any time mentioned in this Draft Red Herring Prospectus is IST. Bidders are cautioned that, in the event a large number of Bid Cum Application Forms are received on the Bid/Issue Closing Date, as is typically experienced in public Issue, some Bid Cum Application Forms may not get uploaded due to the lack of sufficient time. Such Bid Cum Application Forms that cannot be uploaded will not be considered for allocation under this Issue. Applications will be accepted only on Working Days, i.e., Monday to Friday (excluding any public holidays). Neither our Company nor the BRLM is liable for any failure in uploading the Bid Cum Application Forms due to faults in any software/hardware system or otherwise.

In accordance with SEBI ICDR Regulations, Bidders/Applicants are not allowed to withdraw or lower the size of their application (in terms of the quantity of the Equity Shares or the Application amount) at any stage.

In case of discrepancy in the data entered in the electronic book vis-à-vis the data contained in the physical Bid Cum Application Form, for a particular Applicant, the details as per the file received from Stock Exchange may be taken as the final data for the purpose of Allotment. In case of discrepancy in the data entered in the electronic book vis-à-vis the data contained in the physical or electronic Bid Cum Application Form, for a particular ASBA Applicant, the Registrar to the Issue shall ask the relevant SCSBs/ RTAs / DPs / stock brokers, as the case may be, for the rectified data.

Underwriting

The Company and the Book Running Lead Manager to the Issue hereby confirm that the Issue will be 100% Underwritten by the Underwriter, [●], in the capacity of Underwriter to the Issue.

Pursuant to the terms of the Underwriting Agreement dated [●] entered into by Company, Underwriter, the obligations of the Underwriter are subject to certain conditions specified therein. The Details of the Underwriting commitments are as under:

Details of the Underwriter	No. of shares underwritten	Amount Underwritten (₹ in Lakhs)	% of Total Issue Size Underwritten
[●]	[●]	[●]	[●]

**Includes upto [●] Equity Shares of the Market Maker Reservation Portion which are to be subscribed by the Market Maker, [●] in its own account in order to claim compliance with the requirements of Regulation 261 of the SEBI (ICDR) Regulations, 2018, as amended.*

In the opinion of the Board of Directors of our Company, the resources of the above-mentioned Underwriter are sufficient to enable them to discharge their respective obligations in full.

Change in Statutory Auditors during the last three (3) years

There is no change in the statutory auditor during the last three years.

Withdrawal of the Issue

Our Company in consultation with the BRLM, reserve the right to not to proceed with the Issue at any time before the Bid/ Issue Opening Date without assigning any reason thereof.

If our Company withdraws the Issue any time after the Bid/ Issue Opening Date but before the allotment of Equity Shares, a public notice within 2 (two) working days of the Bid/ Issue Closing Date, providing reasons for not proceeding with the Issue shall be issued by our Company. The notice of withdrawal will be issued in the same newspapers where the pre- Issue and price band advertisements have appeared and the Stock Exchange will also be informed promptly. The BRLM, through the Registrar to the Issue, will instruct the SCSBs to unblock the ASBA Accounts within 1 (one) working Day from the day of receipt of such instruction.

If our Company withdraws the Issue after the Bid/ Issue Closing Date and subsequently decides to proceed with an Issue of the Equity Shares, our Company will have to file a fresh Draft Red Herring Prospectus with the stock exchange where the Equity Shares may be proposed to be listed.

Notwithstanding the foregoing, the Issue is subject to obtaining (i) the final listing and trading approvals of the Stock Exchange with respect to the Equity Shares issued through the Red Herring Prospectus, which our Company will apply for only after Allotment; and (ii) the Filing of Red Herring Prospectus/ Prospectus with RoC.

Details of the Market Making arrangement for this Issue

Our Company and the BRLM has entered into Market Making Agreement dated [●] with the following Market Maker, to fulfil the obligations of Market Making for this issue:

Name	[●]
Correspondence Address	
Tel No.	
E-mail	
Website	
Contact Person	
SEBI Registration No.	
Market Maker Registration No.	

In accordance with Regulation 261 of the SEBI ICDR Regulations, we have entered into an agreement with the Book Running Lead Manager and the Market Maker (duly registered with BSE to fulfil the obligations of Market Making) dated [●] to ensure compulsory Market Making for a minimum period of three years from the date of listing of equity shares offered in this Issue.

[●], registered with SME Platform of BSE (BSE SME) will act as the Market Maker and has agreed to receive or deliver of the specified securities in the market making process for a period of three years from the date of listing of our Equity Shares or for a period as may be notified by any amendment to SEBI ICDR Regulations.

The Market Maker shall fulfil the applicable obligations and conditions as specified in the SEBI (ICDR) Regulations, and its amendments from time to time and the circulars issued by the BSE and SEBI regarding this matter from time to time.

Following is a summary of the key details pertaining to the Market making arrangement:

- The Market Maker(s) (individually or jointly) shall be required to provide a 2-way quote for 75% of the time in a day. The same shall be monitored by the stock exchange. Further, the Market Maker(s) shall inform the exchange in advance for each and every black out period when the quotes are not being offered by the Market Maker(s).
- The prices quoted by Market Maker shall be in compliance with the Market Maker Spread Requirements and other particulars as specified or as per the requirements of the SME platform of BSE (BSE SME) and SEBI from time to time.
- The minimum depth of the quote shall be Rs.1,00,000/-. However, the investors with holdings of value less than ₹1,00,000/- shall be allowed to offer their holding to the Market Maker(s) (individually or jointly) in that scrip provided that he sells his entire holding in that scrip in one lot along with a declaration to the effect to the selling broker.
- The Market Maker shall not sell in lots less than the minimum contract size allowed for trading on the SME platform of BSE (in this case currently the minimum trading lot size is [●] equity shares of face value of ₹10/ each; however, the same may be changed by the SME platform of BSE from time to time).
- After a period of three (3) months from the market making period, the Market Maker would be exempted to provide quote if the Shares of Market Maker in our company reaches to 25% of Issue Size. Any Equity Shares allotted to Market Maker under this Issue over and above 25% of Issue Size would not be taken in to consideration of computing the threshold of 25% of Issue Size. As soon as the Shares of Market Maker in our Company reduces to 24% of Issue Size, the Market Maker will resume providing 2-way quotes.
- There shall be no exemption/ threshold on downside. However, in the event the Market Maker exhausts his inventory through market making process, BSE may intimate the same to SEBI after due verification.
- Execution of the order at the quoted price and quantity must be guaranteed by the Market Maker(s), for the quotes given by him.

- There would not be more than five Market Makers for a script at any point of time and the Market Makers may compete with other Market Makers for better quotes to the investors.
- On the first day of the listing, there will be pre-opening session (call auction) and there after the trading will happen as per the equity market hours. The circuits will apply from the first day of the listing on the discovered price during the pre-open call auction.
- The Market maker may also be present in the opening call auction, but there is no obligation on him to do so.
- There will be special circumstances under which the Market Maker may be allowed to withdraw temporarily/fully from the market – for instance due to system problems, any other problems. All controllable reasons require prior approval from the Exchange, while *force-majeure* will be applicable for non-controllable reasons. The decision of the Exchange for deciding controllable and non-controllable reasons would be final.
- The Market Maker(s) shall have the right to terminate said arrangement by giving a 3 (three) months' notice or on mutually acceptable terms to the Merchant Banker, who shall then be responsible to appoint a replacement Market Maker(s) and execute a fresh arrangement. In case of termination of the above mentioned Market Making agreement prior to the completion of the compulsory Market Making period, it shall be the responsibility of the BRLM to arrange for another Market Maker in replacement during the term of the notice period being served by the Market Maker but prior to the date of releasing the existing Market Maker from its duties in order to ensure compliance with the requirements of regulation 261(1) of the SEBI (ICDR) Regulations, 2018, as amended. Further our Company and the BRLM reserve the right to appoint other Market Makers either as a replacement of the current Market Maker or as an additional Market Maker subject to the total number of Designated Market Makers does not exceed five or as specified by the relevant laws and regulations applicable at that particulars point of time. The Market Making Agreement is available for inspection at our office from 10.00 A.M. to 5.00 P.M. on working days.
- **Risk containment measures and monitoring for Market Makers:** SME portal of BSE will have all margins, which are applicable on BSE main board viz., Mark-to-Market, Value-At-Risk (VAR) Margin, Extreme Loss Margin, Special Margins and Base Minimum Capital etc. BSE can impose any other margins as deemed necessary from time-to-time.
- **Punitive Action in case of default by Market Makers:** The Exchange will monitor the obligations on a real time basis and punitive action will be initiated for any exceptions and/or non-compliances. Penalties/ fines may be imposed by the Exchange on the Market Maker, in case he is not able to provide the desired liquidity in a particular security as per the specified guidelines. These penalties/ fines will be set by the Exchange from time to time. The Exchange will impose a penalty on the Market Maker in case he is not present in the market (offering two-way quotes) for at least 75% of the time. The nature of the penalty will be monetary as well as suspension in market making activities/ trading membership. The Department of Surveillance and Supervision of the Exchange would decide and publish the penalties/ fines/ suspension for any type of misconduct/ manipulation/ other irregularities by the Market Maker from time to time.
- **Price Band and Spreads:** The price band shall be 20% and the market maker spread (difference between the sell and the buy quote) shall be within 10% or as intimated by Exchange from time to time.
- Pursuant to SEBI Circular number CIR/MRD/DSA/31/2012 dated November 27, 2012, limits on the upper side for market makers during market making process has been made applicable, based on the Issue size and as follows:

Issue Size	Buy quote exemption threshold (including mandatory initial inventory of 5% of the Issue Size)	Re-Entry threshold for buy quote (including mandatory initial inventory of 5% of the Issue Size)
Up to ₹20 Crore	25%	24%
₹20 to ₹50 Crore	20%	19%
₹50 to ₹80 Crore	15%	14%
Above ₹80 Crore	12%	11%

The SEBI Circular bearing reference no: CIR/MRD/DP/ 02/2012 dated January 20, 2012, has laid down that for issue size up to ₹ 250 crores, the applicable price bands for the first day shall be:

- i. In case equilibrium price is discovered in the Call Auction, the price band in the normal trading session shall be 5% of the equilibrium price.
- ii. In case equilibrium price is not discovered in the Call Auction, the price band in the normal trading session shall be 5% of the issue price.

CAPITAL STRUCTURE

Set forth below are the details of the Equity Share Capital of our Company as on the date of this Draft Red Herring Prospectus.

(₹ in Lakhs, except share data)

Sr. No.	Particulars	Aggregate Value at Face value	Aggregate Value at Issue Price*
A	Authorized Share Capital 1,10,00,000 Equity Shares of face value of ₹ 10/- each,	1100.00	-
B	Issued, Subscribed & Paid-up Share Capital prior to the Issue 76,50,000 Equity Shares of face value of ₹10/- each	765.00	-
C	Present Issue in terms of this Draft Red Herring Prospectus* Upto 27,36,000 Equity Shares of face value of ₹ 10/-each at a Premium of ₹ [●] per share ⁽¹⁾ <i>Which comprises of:</i>	[●]	[●]
D	Reservation for Market Maker Portion [●] Equity Shares of face value of ₹10/- each at a price of ₹[●] per Equity Share reserved as Market Maker Portion	[●]	[●]
E	Net Issue to Public Net Issue to Public of [●] Equity Shares of face value of ₹10/- each at a price of ₹[●] per Equity Share to the Public	[●]	[●]
F	Issued, Subscribed and Paid-up Equity Share Capital after the Issue [●] Equity Shares of face value of ₹10/- each		[●]
G	Securities Premium Account Before the Issue (as on date of this Draft Red Herring Prospectus)		Nil
	After the Issue		[●]

*To be updated upon finalization of the Issue Price.

1. The Present Issue of upto 27,36,000 Equity Shares of face value of ₹10/- each in terms of this Draft Red Herring Prospectus has been authorized pursuant to a resolution of our Board of Directors dated September 26, 2025 and by special resolution passed under Section 62(1)(c) of the Companies Act, 2013 at an Extra-Ordinary General Meeting of the members held on September 26, 2025.

Classes of Shares: -

Our Company has only one class of share capital i.e. Equity Shares of face value of ₹ 10/- each only. All the issued Equity Shares are fully paid-up. Our Company has no outstanding convertible instruments as on the date of this Draft Red Herring Prospectus.

NOTES TO THE CAPITAL STRUCTURE:

1. Changes in Authorised Equity Share Capital of our Company:

Sr. No.	Particulars of increase	Cumulative No. of Equity Shares	Face value of Equity Share	Cumulative Authorized Share Capital (₹ in lakhs)	Date of Meeting	Whether AGM/EGM
1.	On incorporation	1,00,000	10	10,00,000	-	N.A.
2.	Increase in authorised Share Capital of the Company from Rs. 10,00,000 to Rs. 4,25,00,000	42,50,000	10	4,25,00,000	August 04, 2022	EGM
3.	Increase in authorised Share Capital of the Company from Rs. 4,25,00,000 to Rs. 11,00,00,000	1,10,00,000	10	11,00,00,000	September 05, 2025	AGM

2. Equity Share Capital History of our Company:

a) The following table sets forth details of the history of the Paid-up Equity Share capital of our Company:

Date of Allotment of Equity Shares	No. of Equity Shares allotted	Face value (₹)	Issue Price (₹) (including Premium)	Consideration Cash/ Other than Cash	Nature of Allotment	Cumulative No. of Equity Shares	Cumulative Securities Premium (₹)	Cumulative Paid-Up Capital (₹)
On incorporation	1,00,000	10	10	Cash	Subscription to MOA ⁽ⁱ⁾	1,00,000	Nil	10,00,000
August 23, 2022	41,50,000	10	10	Cash	Rights Issue ⁽ⁱⁱ⁾	42,50,000	Nil	4,25,00,000
September 09, 2025	34,00,000	10	0	Other than Cash	Bonus Issue ⁽ⁱⁱⁱ⁾	76,50,000	Nil	7,65,00,000

All the above-mentioned shares are fully paid up since the date of allotment.

i. *Initial Subscribers to the Memorandum of Association subscribed 1,00,000 Equity Shares of face value of ₹ 10/- each, details of which are given below:*

S. No.	Name of Subscribers	Number of Equity Shares Subscribed (Face value of ₹ 10 each)
1.	Akashbhai Mansukhbhai Gangadiya	33,333
2.	Chetan Rugnathbhai Matholiya	33,333
3.	Jayeshkumar Amarshibhai Sabava	33,334
	Total	1,00,000

ii. *Rights issue of 41,50,000 Equity Shares of face value of ₹10/- each fully paid up, details of which are given below:*

S. No.	Name of Allottees	Number of Shares Allotted (Face value of ₹ 10 each)
1.	Akashbhai Mansukhbhai Gangadiya	13,83,195
2.	Chetan Rugnathbhai Matholiya	13,83,195
3.	Jayeshkumar Amarshibhai Sabava	13,83,610
	Total	41,50,000

iii. *Bonus Issue of 34,00,000 Equity Shares of face value of ₹ 10/- each fully paid up in the ratio of 4:5 i.e. 4 (four) Equity Shares for every 5 (five) Equity Shares as per the details mentioned below:*

S. No.	Name of Allottees	Number of Shares Allotted (Face value of ₹ 10 each)
1.	Akashbhai Mansukhbhai Gangadiya	11,33,216
2.	Chetan Rugnathbhai Matholiya	11,33,216
3.	Jayeshkumar Amarshibhai Sabava	11,33,552
4.	Shaileshbhai Rugnathbhai Matholiya	4
5.	Kartikkumar Mansukhbhai Gangadiya	4
6.	Mitalben Chetanbhai Matholiya	4
7.	Mitbhai Natubhai Sabava	4
	Total	34,00,000

b) Preference Share Capital

As on the date of this Draft Red Herring Prospectus, our Company does not have any Preference Share Capital.

3. Issue of Equity Shares for consideration other than cash

Except as set out below we have not issued Equity Shares for consideration other than cash:

Date of Allotment	Number of Equity Shares	Face value (₹)	Issue Price (₹)	Reason for Allotment	Benefits Accrued to our Company	Name of Allottees	No. of Shares Allotted (Face value of ₹ 10 each)
September 09, 2025	34,00,000	10	-	Bonus in the ratio of 4:5 i.e. 4 (four) equity shares for every 5 (five) equity share held	Capitalization of Reserves & Surplus*	Akashbhai Mansukhbhai Gangadiya	11,33,216
						Chetan Rugnathbhai Matholiya	11,33,216
						Jayeshkumar Amarshibhai Sabava	11,33,552
						Shaileshbhai Rugnathbhai Matholiya	4
						Kartikkumar Mansukhbhai Gangadiya	4
						Mitalben Chetanbhai Matholiya	4
						Mitbhai Natubhai Sabava	4

**Above allotment of shares has been made out of Reserve & Surplus available for distribution to shareholders and no part of revaluation reserve has been utilized for the purpose.*

4. Details of Allotment made in the last two years preceding the date of Draft Red Herring Prospectus:

Except as mentioned in point 2 (a) (iii) above, we have not issued any Equity Share in the last two years preceding the date of Draft Red Herring Prospectus.

- No Equity Shares have been allotted pursuant to any scheme approved under sections 230-234 of the Companies Act, 2013.
- Our Company has not issued any shares pursuant to an Employee Stock Option Scheme.
- Except for the Bonus Issue made on September 09, 2025 for 34,00,000 Equity Shares of face value of ₹10/- each as mentioned in point no. 2 (a) (iii) above, no Equity shares have been issued at price below the Issue price within last one year from the date of the Draft Red Herring Prospectus.
- We have not revalued our assets since inception and have not issued any Equity Shares (including bonus shares) by capitalizing any revaluation reserves.
- The issuer company is in compliance with the provisions of the Companies Act, 2013 with respect to issuance of securities since inception till the date of filing of this Draft Red Herring Prospectus.

10. Shareholding Pattern of the Company

The table below represents the shareholding pattern of our Company in accordance with Regulation 31 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as on the date of this Draft Red Herring Prospectus:

I - Our Shareholding Pattern:

C a t e g o r y	Category of shareholder	Nos . of sha re hol der s	No. of fully paid- up equity shares held	No. of Par tly pai d- up equ ity sha res hel d	No. of shar es und erlyi ng Dep osito ry Rec eipts	Total nos. shares held	Sharehold ing as a % of total no. of shares (calculated as per SCRR, 1957) As a % of (A+B+C2)	Number of Voting Rights held in each class of securities*				No. of Shar es Und erlyi ng Out s tandi ng conv ertib le	Sharehold ing, as a % assuming full conversion of convertible securities (as a percentage of diluted share capital) As a % of (A+B+C2)	Number of Locked in shares		Number of Shares pledged or otherwise encumber ed		Number of equity shares held in dematerial ized form
								No of Voting Rights			Total as a % of (A+B + C)			N o. (a Shares (b)	As a % of total Shares held (b)	N o. (a Shares (b)	As a % of total Share s held (b)	
								Class Equity Shares of ₹10/- each^	Cl as s eg : y	Total								
I	II	III	IV	V	VI	VII = IV+V+VI	VIII	IX				X	XI=VII+X	XII		XIII		XIV
(A)	Promoters & Promoter Group	7	76,50,000	-	-	76,50,000	100	76,50,000	-	76,50,000	100	-	100	-	-	-	76,50,000	
(B)	Public	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
(C)	Non- promoter- Non Public	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
(C1)	Shares underlying DRs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
(C2)	Shares held by Emp. Trusts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Total	7	76,50,000	-	-	76,50,000	100	76,50,000	-	76,50,000	100	-	100	-	-	-	76,50,000	

Notes-

- As on date of this Draft Red Herring Prospectus 1 Equity share holds 1 vote. We have only one class of Equity Shares of face value of ₹ 10/- each. We have entered into tripartite agreement with CDSL & NSDL.
- Our Company will file the shareholding pattern in the form prescribed under Regulation 31 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, one day prior to the listing of the Equity shares. The shareholding pattern will be uploaded on the Website of the Stock Exchange before commencement of trading of such Equity Shares.

11. List of Shareholders of the Company holding 1% or more of the paid- up Share Capital of the Company: -

a) As on the date of filing of this Draft Red Herring Prospectus: -

Sr. No.	Names of Shareholder	Shares Held (Face value of ₹ 10 each)	% Pre-Issue paid up Share Capital *
1.	Akashbhai Mansukhbhai Gangadiya	25,49,736	33.33
2.	Chetan Rugnathbhai Matholiya	25,49,736	33.33
3.	Jayeshkumar Amarshibhai Sabava	25,50,492	33.34
	Total	76,49,964	100.00

** the % has been calculated based on existing (pre-issue) Paid up Capital of the Company*

b) Ten days prior to the date of filing of this Draft Red Herring Prospectus: -

Sr. No.	Names of Shareholder	Shares Held (Face value of ₹ 10 each)	% Pre-Issue paid up Share Capital *
1.	Akashbhai Mansukhbhai Gangadiya	25,49,736	33.33
2.	Chetan Rugnathbhai Matholiya	25,49,736	33.33
3.	Jayeshkumar Amarshibhai Sabava	25,50,492	33.34
	Total	76,49,964	100.00

** the % has been calculated based on existing (pre-issue) Paid up Capital of the Company*

c) One Year prior to the date of filling of this Draft Red Herring Prospectus: -

Sr. No.	Names of Shareholders	Shares Held (Face value of ₹ 10 each)	% Pre-Issue paid up Share Capital *
1.	Akashbhai Mansukhbhai Gangadiya	14,16,526	33.33
2.	Chetan Rugnathbhai Matholiya	14,16,526	33.33
3.	Jayeshkumar Amarshibhai Sabava	14,16,944	33.34
	Total	42,49,996	100.00

**Details of shares held on September 29, 2024 and percentage held has been calculated based on the paid-up capital of our Company as on September 29, 2024.*

d) Two Year prior to the date of filling of this Draft Red Herring Prospectus:

Sr. No.	Names of Shareholders	Shares Held (Face value of ₹ 10 each)	% Pre-Issue paid up Share Capital *
1.	Akashbhai Mansukhbhai Gangadiya	14,16,528	33.33
2.	Chetan Rugnathbhai Matholiya	14,16,528	33.33
3.	Jayeshkumar Amarshibhai Sabava	14,16,944	33.34
	Total	42,50,000	100.00

**Details of shares held on September 29, 2023 and percentage held has been calculated based on the paid-up capital of our Company as on September 29, 2023.*

12. Our Company has not made any Initial Public Offer of specified securities in the preceding two years from the date of filing of this Draft Red Herring Prospectus.

13. There will be no further issue of capital, whether by way of issue of bonus shares, preferential allotment, Right issue or in any other manner during the period commencing from the date of the Draft Red Herring Prospectus until the Equity Shares of our Company have been listed or application money unblocked on account of failure of Issue. Further, except for the allotment of equity shares pursuant to the issue, our Company does not intend to alter its capital structure within six months from the date of opening of the Issue, by way of split/ consolidation of the denomination of Equity Shares. However, our Company may further issue Equity Shares (including issue of securities convertible into Equity Shares) whether preferential or otherwise after the date of the listing of equity shares to finance an acquisition, merger or joint venture or for regulatory compliance or such other scheme of arrangement or any other purpose as the Board of Directors may deem fit, if an opportunity of such nature is determined by the Board of Directors to be in the interest of our Company.

14. Capital Buildup in respect of Shareholding of our Promoters

As on the date of this Draft Red Herring Prospectus, Our Promoters, Chetan Rugnathbhai Matholiya, Jayeshkumar Amarshibhai Sabava and Akashbhai Mansukhbhai Gangadiya, collectively holds 76,49,964 Equity Shares of face value of ₹10/- each of our Company. None of the Equity Shares held by our Promoters are subject to any pledge.

Set forth below is the build-up of the shareholding of our Promoters in our Company since incorporation.

Date of Allotment and made fully paid up/ Transfer	No. of Equity Shares	Face value Per Share (₹)	Issue/ Acquisition /Transfer Price (₹)	Consideration	Nature of Issue	Pre-Issue Shareholding %	Post-Issue Shareholding %
(A) Chetan Rugnathbhai Matholiya							
Upon Incorporation	33,333	10	10	Cash	Upon Incorporation	0.44	[●]
August 23, 2022	13,83,195	10	10	Cash	Rights Issue	18.08	[●]
September 25, 2024	-2	10	Nil	Nil	Transfer of shares by way of gift ⁽ⁱ⁾	Negligible	[●]
September 03, 2025	-6	10	Nil	Nil	Transfer of shares by way of gift ⁽ⁱⁱ⁾	Negligible	[●]
September 09, 2025	11,33,216	10	Nil	Other than cash	Bonus in the ratio of 4:5	14.81	[●]
Total (A)	25,49,736					33.33	[●]
(B) Jayeshkumar Amarshibhai Sabava							
Upon Incorporation	33,334	10	10	Cash	Upon Incorporation	0.44	[●]
August 23, 2022	13,83,610	10	10	Cash	Rights Issue	18.09	[●]
September 03, 2025	-4	10	Nil	Nil	Transfer of shares by way of gift ⁽ⁱⁱⁱ⁾	Negligible	[●]
September 09, 2025	11,33,552	10	Nil	Other than cash	Bonus in the ratio of 4:5	14.82	[●]
Total (B)	25,50,492					33.34	
(C) Akashbhai Mansukhbhai Gangadiya							
Upon Incorporation	33,333	10	10	Cash	Upon Incorporation	0.44	[●]
August 23, 2022	13,83,195	10	10	Cash	Rights Issue	18.08	[●]
September 25, 2024	-2	10	Nil	Nil	Transfer of shares by way of gift ^(iv)	Negligible	[●]
September 03, 2025	-6	10	Nil	Nil	Transfer of shares by way of gift ^(v)	Negligible	[●]
September 09, 2025	11,33,216	10	Nil	Other than cash	Bonus in the ratio of 4:5	14.81	[●]
Total (C)	25,49,736					33.33	[●]
Total (A+B+C)	76,49,964						[●]

Note: None of the Shares has been pledged by our Promoters.

(i) Details of transfer of shares by Chetan Rugnathbhai Matholiya by way of gift of 2 Equity Shares of face value of ₹10/- each dated September 25, 2024.

Sr. No.	Date of Transfer	Name of Transferor	No. of Shares	Name of Transferee
1.	September 25, 2024	Chetan Rugnathbhai Matholiya	1	Mitalben Chetanbhai Matholiya
			1	Mitbhai Natubhai Sabava
Total			2	

(ii) Details of transfer of shares by Chetan Rugnathbhai Matholiya by way of gift of 6 Equity Shares of face value of ₹10/- each dated September 03, 2025.

Sr. No.	Date of Transfer	Name of Transferor	No. of Shares	Name of Transferee
1.	September 03, 2025	Chetan Rugnathbhai Matholiya	6	Mitalben Chetanbhai Matholiya
Total			6	

(iii) Details of transfer of shares by Jayeshkumar Amarshibhai Sabava by way of gift of 4 Equity Shares of face value of ₹10/- each dated September 03, 2025.

Sr. No.	Date of Transfer	Name of Transferor	No. of Shares	Name of Transferee
1.	September 03, 2025	Jayeshkumar Amarshibhai Sabava	4	Mitbhai Natubhai Sabava
Total			4	

(iv) Details of transfer of shares by Akashbhai Mansukhbhai Gangadiya by way of gift of 2 Equity Shares of face value of ₹10/- each dated September 25, 2024.

Sr. No.	Date of Transfer	Name of Transferor	No. of Shares	Name of Transferee
1.	September 25, 2024	Akashbhai Mansukhbhai Gangadiya	1	Shaileshbhai Rugnathbhai Matholiya
			1	Kartikkumar Mansukhbhai Gangadiya
Total			2	

(v) Details of transfer of shares by Akashbhai Mansukhbhai Gangadiya by way of gift of 6 Equity Shares of face value of ₹10/- each dated September 04, 2025.

Sr. No.	Date of Transfer	Name of Transferor	No. of Shares	Name of Transferee
1.	September 04, 2025	Akashbhai Mansukhbhai Gangadiya	4	Kartikkumar Mansukhbhai Gangadiya
			2	Mitalben Chetanbhai Matholiya
Total			6	

15. The average cost of acquisition of or subscription of shares by our Promoters is set forth in the table below:

Sr. No.	Name of the Promoters	No. of Shares held	Average cost of Acquisition (in ₹)
1	Akashbhai Mansukhbhai Gangadiya	25,49,736	5.56
2	Chetan Rugnathbhai Matholiya	25,49,736	5.56
3	Jayeshkumar Amarshibhai Sabava	25,50,492	5.56

16. Shareholding of Promoters & Promoter Group

Following are the details of pre and post Issue shareholding of persons belonging to the category “Promoters and Promoter Group”:

Sr. No	Names	Pre IPO		Post IPO	
		Shares Held (Face value of ₹ 10 each)	%	Shares Held (Face value of ₹ 10 each)	%
	Promoters				
1.	Chetan Rugnathbhai Matholiya	25,49,736	33.33%	25,49,736	[●]
2.	Jayeshkumar Amarshibhai Sabava	25,50,492	33.34%	25,50,492	[●]
3.	Akashbhai Mansukhbhai Gangadiya	25,49,736	33.33%	25,49,736	
	Sub Total (A)	76,49,964	100.00%	76,49,964	[●]
	Promoter Group				
4.	Shailesh Rugnathbhai Matholiya	9	Negligible	9	[●]
5.	Kartikkumar Mansukhbhai Gangadiya	9	Negligible	9	[●]

6.	Mitalben Chetanbhai Matholiya	9	Negligible	9	[●]
7.	Mitbhai Natubhai Sabava	9	Negligible	9	[●]
	Sub Total (B)	36	Negligible	36	[●]
	Grand Total (A+B)	76,50,000	100.00%	76,50,000	[●]

17. Except as provided below, no Equity Shares were acquired/ purchased/ sold by the Promoters and Promoter Group, Directors and their immediate relatives within six months immediately preceding the date of filing of this Draft Red Herring Prospectus.

Date of Allotment/ Transfer	Name of Shareholders	No. of Equity Share (Face value of ₹ 10 each)	% of Pre issue Capital	Subscribed/ Acquire/ Transfer	Category of Allottees (Promoters/ Promoter Group/ Director)
September 09, 2025	Akashbhai Mansukhbhai Gangadiya	25,49,736	33.33%	Allotment of Bonus Shares in the ratio of 4:5	Director and Promoter
	Chetan Rugnathbhai Matholiya	25,50,492	33.34%		Director and Promoter
	Jayeshkumar Amarshibhai Sabava	25,49,736	33.33%		Director and Promoter
	Shaileshbhai Rugnathbhai Matholiya	9	Negligible		Promoter Group
	Kartikkumar Mansukhbhai Gangadiya	9	Negligible		Promoter Group
	Mitalben Chetanbhai Matholiya	9	Negligible		Promoter Group
	Mitbhai Natubhai Sabava	9	Negligible		Promoter Group
Total		76,50,000	100.00%		

18. None of our Promoters, Promoter Group, our Directors and their relatives has entered into any financing arrangement or financed the purchase of the Equity Shares of our Company by any other person during the period of six months immediately preceding the date of filing of the Draft Red Herring Prospectus.

19. Details of Promoter's Contribution Locked-in for Three Years

Pursuant to Regulation 236 and 238 of SEBI (ICDR) Regulations, 2018, an aggregate of 20% of the post issue capital held by our Promoters shall be considered as Promoter's Contribution ("Promoter's Contribution") and shall be locked-in for a period of three years from the date of allotment of Equity shares issued pursuant to this Issue. The lock in of Promoter's Contribution would be created as per applicable law and procedure and details of the same shall also be provided to the Stock Exchange before listing of the Equity Shares.

As on the date of this Draft Red Herring Prospectus, our Promoters collectively hold 76,49,964 Equity Shares of face value of ₹10/- each constituting [●] % of the Post-Issued, subscribed and paid-up Equity Share Capital of our Company, which are eligible for the Promoter's contribution.

Our Promoters have given written consent to include 21,40,000 Equity Shares of face value of ₹10/- each held by them and subscribed and held by them as part of Promoter's Contribution constituting [●] % of the post issue Equity Shares of our Company. Further, they have agreed not to sell or transfer or pledge or otherwise dispose of in any manner, the Promoter's contribution, for a period of three years from the date of allotment in the Issue.

Date of Allotment/ transfer and made fully paid up	No. of Equity Shares locked-in*	Face value Per Share (₹)	Issue/ Acquisition/ Transfer Price (₹)	Nature of transaction	Post-Issue Shareholding %	Lock in Period
Chetan Rugnathbhai Matholiya						
September 09, 2025	7,13,000	10.00	-	Bonus in the ratio of 4:5	[●]	3 years
Total	7,13,000					
Jayeshkumar Amarshibhai Sabava						
September 09, 2025	7,14,000	10.00	-	Bonus in the ratio of 4:5	[●]	3 years

Total	7,14,000					
Akashbhai Mansukhbhai Gangadiya						
September 09, 2025	7,13,000	10.00	-	Bonus in the ratio of 4:5	[●]	3 years
Total	7,13,000					
Total	21,40,000				[●]	

*Assuming full subscription to the Issue.

The minimum Promoter's contribution has been brought in to the extent of not less than the specified minimum lot and from persons defined as **"Promoter"** under the SEBI (ICDR) Regulations. All Equity Shares, which are being locked in are not ineligible for computation of Minimum Promoter's Contribution as per Regulation 237 of the SEBI (ICDR) Regulations, 2018 and are being locked in for 3 years as per Regulation 238(a) of the SEBI (ICDR) Regulations, 2018 i.e. for a period of three years from the date of allotment of Equity Shares in this issue.

No Equity Shares proposed to be locked-in as Minimum Promoter's Contribution have been issued out of revaluation reserve or for consideration other than cash and revaluation of assets or capitalization of intangible assets, involved in such transactions.

Eligibility of Share for "Minimum Promoter's Contribution in terms of clauses of Regulation 237(1) of SEBI (ICDR) Regulations, 2018

Reg. No.	Promoter's Minimum Contribution Conditions	Eligibility Status of Equity Shares forming part of Promoter's Contribution
237(1) (a) (i)	Specified securities acquired during the preceding three years, if they are acquired for consideration other than cash and revaluation of assets or capitalization of intangible assets is involved in such transaction	The Minimum Promoter's contribution does not consist of such Equity Shares which have been acquired for consideration other than cash and revaluation of assets or capitalization of intangible assets. <u>Hence Eligible</u>
237 (1) (a) (ii)	Specified securities acquired during the preceding three years, resulting from a bonus issue by utilization of revaluation reserves or unrealized profits of the issuer or from bonus issue against Equity Shares which are ineligible for minimum promoter's contribution	The minimum Promoter's contribution does not consist of such Equity Shares. <u>Hence Eligible</u>
237 (1) (b)	Specified securities acquired by promoters during the preceding one year at a price lower than the price at which specified securities are being offered to public in the initial public offer	The minimum Promoter's contribution does not consist of such Equity Shares. <u>Hence Eligible.</u>
237(1) (c)	Specified securities allotted to promoter during the preceding one year at a price less than the issue price, against funds brought in by them during that period, in case of an issuer formed by conversion of one or more partnership firms, where the partners of the erstwhile partnership firms are the promoters of the issuer and there is no change in the management: Provided that specified securities, allotted to promoters against capital existing in such firms for a period of more than one year on a continuous basis, shall be eligible	The minimum Promoter's contribution does not consist of such Equity Shares. <u>Hence Eligible.</u>
237 (1) (d)	Specified securities pledged with any creditor.	Our Promoters have not Pledged any shares with any creditors. Accordingly, the minimum Promoter's contribution does not consist of such Equity Shares. <u>Hence, Eligible.</u>

Details of Promoter's Contribution Locked-in for One Year and Two Years

In terms of Regulation 238(b) of the SEBI (ICDR) Regulations, 2018, in addition to the Minimum Promoter's contribution which is locked in for three years held by the promoters, as specified above, the 50% of pre-issue Equity Share capital constituting 27,54,982.00 Equity Shares of face value of ₹10/- each shall be locked in for a period of one year and remaining

50% of pre-issue Equity Shares constituting 27,54,982.00 Equity Shares of face value of ₹10/- each shall be locked-in for a period of two years from the date of allotment of Equity Shares in this Issue.

Details of pre-issue equity shares held by persons other than the promoters locked-in for One Year

In terms of Regulation 239 of the SEBI (ICDR) Regulations, 2018, in addition to the Minimum Promoters contribution as per regulation 238(a) and 238(b) of the SEBI (ICDR) Regulations, 2018, the entire pre-issue capital held by persons other than the promoters' holding constituting 36 Equity Shares of face value of ₹10/- each shall be locked in for a period of one year from the date of allotment of Equity Shares in this Issue.

Inscription or recording of non-transferability

In terms of Regulation 241 of the SEBI (ICDR) Regulations, 2018, the Equity Shares which are subject to lock-in shall carry inscription '**non-transferable**' along with the Ratio of specified non-transferable period mentioned in the face of the security certificate. The shares which are in dematerialized form, if any, shall be locked-in by the respective depositories. The details of lock-in of the Equity Shares shall also be provided to the Designated Stock Exchange before the listing of the Equity Shares.

Other requirements in respect of lock-in:

- a) In terms of Regulation 242 of the SEBI (ICDR) Regulations, the locked in Equity Shares held by the Promoters as specified above, can be pledged with any scheduled commercial bank or public financial institution or a systemically important non-banking finance company or a housing finance company as collateral security for loan granted by such bank or institution provided that the pledge of Equity Shares is one of the terms of the sanction of the loan. Provided that securities locked in as minimum promoter's contribution may be pledged only if, in addition to fulfilling the above requirements, the loan has been granted by such bank or institution, for the purpose of financing one or more of the objects of the Issue.
 - b) There shall be a lock-in of 90 days on 50% of the Equity Shares allotted to the Anchor Investors from the date of Allotment, and a lock-in of 30 days on the remaining 50% of the Equity Shares allotted to the Anchor Investors from the date of Allotment.
 - c) In terms of Regulation 243 of the SEBI (ICDR) Regulations, the Equity Shares held by persons other than the Promoters prior to the Issue may be transferred to any other person holding the Equity Shares which are locked in as per Regulation 239 of the SEBI (ICDR) Regulations, subject to continuation of the lock-in in the hands of the transferees for the remaining period and compliance with the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as applicable.
 - d) Further in terms of Regulation 243 of the SEBI (ICDR) Regulations, the specified securities held by the promoters and locked-in as per regulation 238 may be transferred to another promoters or any person of the promoter group or a new promoters or a person in control of the issuer subject to continuation of the lock-in in the hands of the transferees for the remaining period and compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as applicable.
20. Neither, we nor our Promoters, Directors and the BRLM to this Issue have entered into any buyback and/ or standby arrangements and/ or similar arrangements for the purchase of our Equity Shares from any person.
 21. As on the date of this Draft Red Herring Prospectus, the entire Issued, Subscribed and Paid-up Share Capital of our Company is fully paid up. Since the entire issue price in respect of the issue is payable on application, all the successful applicants will be allotted fully paid- up Equity shares.
 22. The BRLM i.e. Hem Securities Limited and their associates do not hold any Equity Shares in our Company as on the date of filing of this Draft Red Herring Prospectus.
 23. As on the date of this Draft Red Herring Prospectus, we do not have any Employees Stock Option Scheme / Employees Stock Purchase Scheme and we do not intend to allot any shares to our employees under Employee Stock Option Scheme/ Employee Stock Purchase Plan from the proposed issue. As and when, options are granted to our employees under the Employee Stock Option Scheme, our Company shall comply with the SEBI (Share Based Employee Benefits) Regulations, 2014.

24. We have 7 (seven) shareholders as on the date of filing of this Draft Red Herring Prospectus.
25. As on the date of filing of this Draft Red Herring Prospectus, there are no outstanding warrants, options or rights to convert debentures, loans or other instruments which would entitle Promoters or any shareholders or any other person any option to acquire our Equity Shares after this Initial Public Offer.
26. Our Company has not raised any bridge loan against the proceeds of the Issue.
27. As on the date of this Draft Red Herring Prospectus, none of the shares held by our Promoters/ Promoter Group are subject to any pledge.
28. We hereby confirm that there will be no further issue of capital whether by way of issue of bonus shares, preferential allotment, rights issue or in any other manner during the period commencing from the date of the Draft Red Herring Prospectus until the Equity Shares offered have been listed or application money unblocked on account of failure of Issue.
29. None of our Equity Shares has been issued out of revaluation reserve created out of revaluation of assets.
30. An over-subscription to the extent of 10.00% of the Issue, subject to the maximum post issue paid up capital of ₹ 25 Crore, can be retained for the purpose of rounding off to the nearest integer during finalizing the allotment, subject to minimum allotment, which is the minimum application size in this Issue. Consequently, the actual allotment may go up by a maximum of 10.00% of the Issue, as a result of which, the post-issue paid up capital after the Issue would also increase by the excess amount of allotment so made. In such an event, the Equity Shares held by the Promoters and subject to 3-year lock- in shall be suitably increased; so as to ensure that 20% of the post Issue paid-up capital is locked in.
31. Allocation to all categories shall be made on a proportionate basis subject to valid applications received at or above the Issue Price. Under subscription, if any, in any of the categories, would be allowed to be met with spill-over from any of the other categories or a combination of categories at the discretion of our Company in consultation with the BRLM and Designated Stock Exchange i.e. BSE. Such inter-se spill over, if any, would be affected in accordance with applicable laws, rules, regulations and guidelines.
32. In case of over-subscription in all categories the allocation in the issue shall be as per the requirements of Regulation 253 of SEBI (ICDR) Regulations, 2018 and its amendments from time to time.
33. At any given point of time there shall be only one denomination of the Equity Shares, unless otherwise permitted by law.
34. Our Company shall comply with such disclosure and accounting norms as may be specified by BSE, SEBI and other regulatory authorities from time to time.
35. There are no Equity Shares against which depository receipts have been issued.
36. Other than the Equity Shares, there is no other class of securities issued by our Company.
37. There are no safety net arrangements for this public issue.
38. As per RBI regulations, OCBs are not allowed to participate in this issue.
39. Our Promoters & Promoter Group will not participate in this Issue.
40. This Issue is being made through Book Building Method.
41. Our Company has not made any public issue or rights issue of any kind or class of securities since its incorporation.
42. In terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended, (the SCRR) the Issue is being made for at least 25% of the post-issue paid-up Equity Share capital of our Company. Further, this Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, as amended from time to time.

43. No person connected with the Issue shall offer any incentive, whether direct or indirect, in the nature of discount, commission, and allowance, or otherwise, whether in cash, kind, services or otherwise, to any Applicant.
44. We shall ensure that transactions in Equity Shares by the Promoters and members of the Promoter Group, if any, between the date of filing the Red Herring Prospectus with the RoC and the Issue Closing Date are reported to the Stock Exchanges within 24 hours of such transactions being completed.

OBJECTS OF THE ISSUE

The Issue includes a fresh Issue of upto 27,36,000 Equity Shares of our Company at an Issue Price of Rs. [●] per Equity Share.

We intend to utilize the proceeds of the Issue to meet the following objects:

1. Repayment in full or in part, of certain of our outstanding borrowings
2. Funding capital expenditure towards purchase of new machinery
3. Funding to meet working capital requirements
4. General Corporate Purpose

(Collectively referred as the “**Objects**”)

We believe that listing will enhance our corporate image and visibility of brand name of our Company. We also believe that our Company will receive the benefits from listing of Equity Shares on the SME Platform of BSE (BSE SME). It will also provide liquidity to the existing shareholders and will also create a public trading market for the Equity Shares of our Company. The main object clause of our Memorandum of Association and the objects incidental and ancillary to the main objects enables us to undertake the activities for which funds are being raised in the Issue. The existing activities of our Company are within the objects clause of our Memorandum of Association.

Net Proceeds

The details of the Net Proceeds are set forth below:

Particulars	Amount (₹ in Lacs)
Gross Proceeds of the Issue	[●]
Less: Issue related expenses in relation to Issue	[●]
Net Proceeds	[●]

Requirement of Funds and Utilization of Net Proceeds

The Net Proceeds are proposed to be used in accordance with the details as set forth below:

(Rs. in lakhs)

Sr No	Particulars	Amount
1	Repayment in full or in part, of certain of our outstanding borrowings	900.00
2	Funding capital expenditure towards purchase of new machinery	608.40
3	Funding to meet Working Capital requirements	1,500.00
4	General Corporate Purpose	[●]
	Total	[●]

Our fund requirements and deployment thereof are based on internal management estimates of our current business plans and have not been appraised by any bank or financial institution. These are based on current conditions and are subject to change in light of changes in external circumstances or costs or in other financial conditions, business strategy, as discussed further below.

Means of Finance

We intend to finance our Objects of Issue through Net Issue Proceeds which is as follows:

Particulars	Amount (Rs. in Lakhs)
Net Issue Proceeds	[●]
Total	[●]

Since, the entire fund requirement are to be funded from the proceeds of the Issue, there is no requirement to make firm arrangements of finance under Regulation 230(1)(e) of the SEBI ICDR Regulations through verifiable means towards at least 75% of the stated means of finance, excluding the amounts to be raised through the proposed Issue.

In case of any increase in the actual utilization of funds earmarked for the Objects, such additional funds for a particular activity will be met by way of means available to our Company, including from internal accruals. If the actual utilization towards any of the Objects is lower than the proposed deployment such balance will be used for future growth opportunities

including funding existing objects, if required. In case of delays in raising funds from the Issue, our Company may deploy certain amounts towards any of the abovementioned Objects through a combination of Internal Accruals or Unsecured Loans (Bridge Financing) and in such case the Funds raised shall be utilized towards repayment of such unsecured Loans or recouping of Internal Accruals. However, we confirm that no bridge financing has been availed as on date, which is subject to being repaid from the Issue Proceeds.

As we operate in competitive environment, our Company may have to revise its business plan from time to time and consequently our fund requirements may also change. Our Company's historical expenditure may not be reflective of our future expenditure plans. Our Company may have to revise its estimated costs, fund allocation and fund requirements owing to various factors such as economic and business conditions, increased competition and other external factors which may not be within the control of our management. This may entail rescheduling or revising the planned expenditure and funding requirements, including the expenditure for a particular purpose at the discretion of the Company's management.

For further details on the risks involved in our business plans and executing our business strategies, please see the section titled **"Risk Factors"** beginning on page 27 of the Draft Red Herring Prospectus.

Details of Utilization of Net Proceeds

The details of utilization of the Net Proceeds are set forth herein below:

1. Repayment in full or in part, of certain of our outstanding borrowings

Our Company has entered into various borrowing arrangements with banks including borrowings in the form of cash credit, and term loan. For details of our outstanding financial indebtedness, see **'Statement of Financial Indebtedness'** on page 219. As at July 31, 2025, we had outstanding cash credit facility and term loan from SBI bank Limited of Rs 1,571.72 lakhs

We propose to utilize an estimated amount of ₹900.00 lakh from the Net Proceeds to repay in full or in part of certain of our outstanding borrowings, listed below and availed from the lender by our Company. Pursuant to the terms of the financing arrangements, prepayment of certain borrowings may attract prepayment charges as prescribed by the respective lender. Such prepayment charges, as applicable, will be funded from the internal accruals of our Company. We believe that such repayment will help reduce our outstanding indebtedness and debt servicing costs and enable utilization of our internal accruals for further investment in our business growth and expansion. The details of the borrowings availed by our Company, which are proposed to be fully or partially repaid from the Net Proceeds are mentioned below:

(Rs in lakhs)

Name of Lender	Purpose	Sanctioned Amount	Rate of interest	Primary & Collateral Security	Re-Payment Schedule	Moratorium	Outstanding amount as on July 31, 2025
SBI Bank Limited	Cash Credit facility	700.00	8.85%	Note-1*	On demand	-	660.68
	Term Loan facility	988.00	8.85%	Note-1*	84 monthly instalments	13 months	911.04
Total							1571.72

*Note-1 Primary & collateral security for cash credit facility and term loan facility:

Primary security-

- Hypothecation of all plant and machinery in the name of the Company.
- Hypothecation of all stock and receivables.

Collateral security-

- Immovable property 1: Plot/House No. 23, Survey No. 663, Botad, Ahmedabad
- Immovable property 2: Block no. 231, Kerala, Bavla, Ahmedabad
- Immovable property 3: Block no. 586, Kerala, Bavla, Ahmedabad
- Also personal guarantee of Chetan Rugnathbhai Matholiya, Jayeshkumar Amarshibhai Sabava and Akashbhai Mansukhbhai Gangadiya (directors of the Company); Prabhaben Matholiya (Relative of director of the Company) and corporate guarantee of M/s Rednex Pharmaceuticals.

- Note: In accordance with Clause 9(A)(2)(b) of Part A of Schedule VI of the SEBI ICDR Regulations which requires a certificate from the auditor certifying the utilization of loan for the purposed availed, our Company has obtained the*

requisite certificate from our Statutory Auditor by way of their certificate dated September 26, 2025. **Funding capital expenditure towards purchase of new machinery:**

Our Company intends to make capital expenditure towards installation of additional plant & machinery. Our Company proposes to use part of net proceeds to the extent to ₹608.40 Lakhs for installation of additional plant & machinery like: Granulation line, packaging line, Tablets Compression, Air Handling Unit, Lab instrument, Tube filling machine in the existing factory premises at Bavla, Ahmedabad, as per the Quotations received from vendors. The company intends to expand its manufacturing capacity with these new machineries. The detailed break-down of these estimated costs is as below:

Sr. No.	Description	Amount (₹in lakhs)
(A)	Granulation line	226.16
(B)	Packaging line	157.71
(C)	Tablets Compression	117.60
(D)	Air Handling Unit	41.97
(E)	Lab instrument	35.46
(F)	Tube filling machine	29.50
	Total	608.40

(A) Granulation line:

(Rs. in lakhs)

Sr. No.	Machine name	Vendor Name	Validity Period	Unit	Unit Price	Total Value
1.	High Speed Sifter	SSPM Systems & Engineers Private Limited	Quotation dated August 27, 2025 is valid for 18 months	1	5.85	5.85
2.	Paste Kettle 200 Ltr (Dual Pillar) Basic "Sigma Paste Kettle" 200 ltr			1	6.14	6.14
3.	RMG 800 Ltr Basic "SigmaGran" 800ltr with PLC and Color Touch Screen 7			1	46.14	46.14
4.	FBD 300 Kg Basic "Sigmaform" FBD 300kg with PLC and Color Touch Screen 7			1	40.72	40.72
5.	Co Mill "Sigma Mill" Co mill with 1.5mm Conical Sieve (Vaccum Rated Design)			1	3.24	3.24
6.	Octagonal Blender 4000 Ltr Basic "Sigma Blend" 4000 ltr			1	24.52	24.52
7.	Common PCS For Blender and RMG Loading Common Vaccum Transfer System for blender loading and RMG loading system			1	6.45	6.45
8.	E -Tablet Coating Basic "Sigma Coat" 60" with PLC and Color Touch Screen 7"			1	49.27	49.27
	Total					182.31
	Packaging charges					9.35
	Total value					191.66
	GST (18%)					34.50
	Total value (inclusive of GST and Packaging charges)					226.16

(B) Packaging Line:

Sr. No.	Machine name	Vendor Name	Validity Period	Unit	Unit Price	Total Value
1.	HC TR MAX 300	Helios Concrew Private Limited	Quotation dated August 25, 2025 is valid for 18 months	2	40.97	81.94
	Blister packaging (Fully automatic)					
	Foil charges					0.10
	Packing charges					0.30
	Insurance charges					0.33
	Total					41.70
	GST (18%)					7.51
	Total Value inclusive GST [B1]					97.55
2.	Galaxy 130 cartoning machine with one set of change parts	Accupack Engineering Private Limited	Quotation dated August 25, 2025 is valid for 18 months	1	50	50.00
	Packing					0.99
	Total					50.99
	GST					9.18
	Value (inclusive of GST) [B2]					60.16
	Total [B1] + [B2]					157.71

(C) Tablets Compression:

Sr. No.	Machine name	Vendor Name	Validity Period	Unit	Unit Price	Total Value
1.	Basic Machine Model (Eco -V)	Parle Elizabeth Tools Private Limited	Quotation dated September 01, 2025 is valid for 18 months	1	42.54	42.54
2.	Compression Machine (Eco-VII)			1	49.82	49.82
3.	Accura Double Rotary Model B-4 27STN "D" Tooling Tablet Press Machine with cGMP Standard. (Suitable for small scale and mid-scale production/single layer and double layer product)	Fluidpack	Quotation dated August 26, 2025 is valid for 90 days	1	7.30	7.30
	Total					99.66
	GST (18%)					17.94
	Value inclusive GST					117.60

(D) Air Handling Unit:

Sr. No.	Machine name	Vendor Name	Validity Period	Unit	Unit Price	Total Value
1.	Low Side	CAEPL Clean Air Engineers Private Limited	Quotation dated August 26, 2025 is valid for 18 months	1	18.32	18.32
2.	Air Handling Unit			1	12.57	12.57
3.	Ducting			1	4.68	4.68
	Total					35.57
	GST (18.00%)					6.40
	Value inclusive GST					41.97

(E) Lab instrument:

Sr. No.	Machine name	Vendor Name	Validity Period	Unit	Unit Price	Total Value

1.	Shimadzu Prominence-i LC-2030	Anachrom Sales & Services	Quotation dated September 07, 2025 is valid for 18 months	2	15.00	30.00
	Shipping and packing charges					0.05
	Total					30.05
	GST (18%)					5.41
	Value inclusive GST					35.46

(F) Tube Filling Machine:

Sr. No.	Machine name	Vendor Name	Validity Period	Unit	Unit Price	Total Value
1.	Automatic Double Head Linear Tube Filling Sealing & Coding Machine Bew-150 GMP Model	Bhavani Engineering Works	Quotation dated August 26, 2025 is valid for 18 months	1	25.00	25.00
	GST (18%)					4.50
	Value inclusive GST					29.50

Notes:

- We have considered the above quotations for the budgetary estimate purpose and have not placed orders for them. The actual cost of procurement and actual supplier/dealer may vary.
- Quotation received from the vendor mentioned above is valid as on the date of this Draft Red Herring Prospectus. However, we have not entered into any definitive agreements with any of the vendor and there can be no assurance that the same vendor would be engaged to eventually supply the machineries or at the same costs.
- The machinery models and quantity to be purchased are based on the present estimates of our management. The Management shall have the flexibility to revise such estimates (including but not limited to change of vendor or any modification/addition/deletion of machineries) at the time of actual placement of the order. In such case, the Management can utilize the surplus of proceeds, if any, arising at the time of actual placement of the order, to meet the cost of such other machinery or utilities, as required. Furthermore, if any surplus from the proceeds remains after meeting the total cost of machineries and utilities for the aforesaid purpose, the same will be used for our general corporate purposes, subject to limit of 15% of the amount raised by our Company through this offer or Rs 10 crores whichever is lower.
- We are not acquiring any second-hand machinery.
- The quotations relied upon by us in arriving at the above cost are valid for a specific period of time and may lapse after the expiry of the said period. Consequent upon which, there could be a possible escalation in the cost of machineries proposed to be acquired by us at the actual time of purchase, resulting in increase in the estimated cost. Further, cost will be escalated on account of freight expenses, installation charges, packaging & forwarding, custom duty etc. Such cost escalation would be met out of our internal accruals.

3. Funding to meet working capital requirements

With the expansion of manufacturing capacity, the operations of the company is expected to grow which will lead to additional working capital requirements. We fund a majority of our working capital requirements in the ordinary course of business from banks facilities and internal accruals. Our Company requires additional working capital for funding its incremental working capital requirements and releasing the internal accruals deployed in working capital.

Our Company proposes to utilize ₹900 lakhs of the Net Proceeds in Fiscal 2026 and ₹600 lakhs of the Net Proceeds in Fiscal 2027 and towards our Company's working capital requirements. The incremental and proposed working capital requirements and key assumptions with respect to the determination of the same are mentioned below:

Details of Estimation of Working Capital requirement are as follows:

(₹ in Lakhs)

S. No.	Particulars	Actual (Restated)			Estimated	Projected
		Fiscal 2023	Fiscal 2024	Fiscal 2025	Fiscal 2026	Fiscal 2027
I	Current Assets					
	Inventories	191.84	673.92	1,621.58	2,068.19	2,925.18
	Trade receivables	139.70	570.93	1,452.29	2,235.48	2,849.41
	Short term loans and Advances	293.10	140.44	208.04	603.52	915.30
	Other Current Assets	8.26	82.83	88.65	177.30	239.36
	Total (A)	632.90	1,468.12	3,370.56	5,084.49	6,929.24
II	Current Liabilities					
	Trade payables	235.03	714.34	1,927.43	1,561.78	1,162.13
	Other Current Liabilities	112.49	92.05	110.27	170.35	200.65
	Short Term Provisions	0.00	12.63	103.32	340.54	505.39
	Total (B)	347.52	819.02	2,141.02	2,072.68	1,868.16
III	Total Working Capital Gap (A-B)	285.38	649.10	1,229.54	3,011.81	5,061.08
IV	Funding Pattern					
	Short Term borrowings & Internal accrual	285.38	649.10	1,229.54	2,111.81	4,461.08
	IPO Proceeds		N/A			900.00
					600.00	

Assumptions for working capital requirements

The following table sets forth the details of the holding period (with days rounded to the nearest whole number) considered for financial years ended March 31, 2025, March 31, 2024 and March 31, 2023, as well as projections for financial year ended March 31, 2026 and March 31, 2027.

Particulars	Unit	Fiscal 2023	Fiscal 2024	Fiscal 2025	Fiscal 2026	Fiscal 2027
		Audited	Audited	Audited	Estimated	Projected
Trade Receivables	Days	150	53	81	90	95
Trade Payables	Days	132	77	118	90	50
Inventories	Days	206	65	91	97	93

Justification:

Sr No	Particulars	Justification
1	Trade Receivables	The historical holding days of trade receivables has been ranging from 81 days to 150 days during Fiscal 2023 to Fiscal 2025. As per the current credit terms and prevalent trend of the industry & in order to expand company's operations, the holding level for debtors is estimated at 90 days during Fiscal 26 and projected at 95 days during Fiscal 27 of total revenue from operations. The projected increase in trade receivables days is a strategic decision aimed at fostering higher sales growth. We intend to provide our customers with extended credit periods, allowing them more time to settle their invoices. By offering this flexibility, we expect to stimulate increased sales volume and foster stronger customer relationships. Furthermore, we are intending to increase our installed capacity by capital expenditure towards installation of additional plant and machinery at existing factory premises which will foster increased revenue from operations.
2	Trade Payables	Past trend of trade payable holding days has been in the range of 77 days to 132 days approximately during Fiscal 2023 to Fiscal 2025. However, with additional working capital funding, our Company intends to reduce trade payable to 90 days during Fiscal 26 and eventually to 50 days during Fiscal 27 to avail competitive purchase price to increase overall profitability of our Company. By reducing the time it takes to settle our payables, we aim to negotiate more favorable terms and conditions with our suppliers, enabling us to access competitive pricing for the raw materials we procure. Timely settlements not only solidify our long-term relationships with suppliers but also ensure the continuity of our supply chain.
3	Inventories	Inventories include raw materials and finished goods. The historical holding days of inventories has been in range of 91 days to 206 days during Fiscal 2023 to Fiscal 2025. As we are intending expansion in our existing factory premises, it will additionally require higher levels of inventory to achieve operational efficiency. With the perspective to increase

		business operations, the Company estimates inventories holding days to be around 97 days in Fiscal 25 and 93 days in Fiscal 26. Further in order to avoid any supply chain disruption the company expects to maintain such inventory levels, ensuring that there is a sufficient buffer to meet operational and customer requirements.

4. General Corporate Purpose

Our management, in accordance with the policies of our Board, will have flexibility in utilizing the proceeds earmarked for general corporate purposes. We intend to deploy the balance Fresh Issue proceeds aggregating Rs. [●] towards the general corporate purposes to drive our business growth. In accordance with the policies set up by our Board, we have flexibility in applying the remaining Net Proceeds, for general corporate purpose including but not restricted to, meeting operating expenses, initial development costs for projects other than the identified projects, and the strengthening of our business development and marketing capabilities, meeting exigencies, which the Company in the ordinary course of business may not foresee or any other purposes as approved by our Board of Directors, subject to compliance with the necessary provisions of the Companies Act, 2013.

We confirm that any issue related expenses shall not be considered as a part of General Corporate Purpose. Further in case, our actual Issue expenses turn to be lesser than the estimated Issue expenses of ₹ [●] lakhs, such surplus amount shall be utilized for General Corporate Purpose in such a manner that the amount for general corporate purposes, as mentioned in the Draft Red Herring Prospectus, shall not exceed 15% of the amount raised by our Company through this Issue or Rs. 10 crores whichever is lower.

Issue Related Expenses

The total estimated Issue Expenses are ₹ [●], which is [●] % of the total Issue Size. The details of the Issue Expenses are tabulated below:

Activity	Estimated expenses ⁽¹⁾ (Rs. in Lakh)	As a % of Estimated Issue Expenses	As a % of total Issue Size
Book Running Lead Manger Fees	[●]	[●]	[●]
Fees Payable to Registrar to the Issue	[●]	[●]	[●]
Fees Payable for Advertising and Publishing Expenses	[●]	[●]	[●]
Fees Payable to Regulators including Stock Exchanges	[●]	[●]	[●]
Payment for Printing & Stationery, Postage, etc.	[●]	[●]	[●]
Fees Payable to Auditor, Legal Advisors and other Professionals	[●]	[●]	[●]
Others (Fees payable for Marketing & distribution expenses, Selling Commission, Brokerage, Processing Fees*, Underwriting fees and Miscellaneous Expenses)	[●]	[●]	[●]
Total	[●]	[●]	[●]

(1) Amounts will be finalized and incorporated in the Prospectus on determination of Issue Price. Issue expenses include applicable taxes, where applicable. Issue expenses are estimates and are subject to change.

(2) Selling commission payable to the SCSBs on the portion for Individual Bidders, Non-Institutional Bidders, which are directly procured by the SCSBs, would be as follows:

Portion for Individual Bidders*	[●] % of the Amount Allotted* (plus applicable taxes)
Portion for Non-Institutional Bidders*	[●] % of the Amount Allotted* (plus applicable taxes)

*Amount allotted is the product of the number of Equity Shares Allotted and the Issue Price. The selling commission payable to the SCSBs will be determined on the basis of the bidding terminal ID as captured in the Bid Book of BSE or NSE

(3) No uploading/ processing fees shall be payable by our Company to the SCSBs on the applications directly procured by them. Processing fees payable to the SCSBs on the portion for Individual Bidders and Non-Institutional Bidders which are procured by the members of the Syndicate/ sub-Syndicate/ Registered Broker/ CRTAs/ CDPs and submitted to SCSB for blocking, would be as follows:

Portion for Individual Bidders	[●] per valid Bid cum Application Form (plus applicable taxes)
Portion for Non-Institutional Bidders	[●] per valid Bid cum Application Form (plus applicable taxes)

Notwithstanding anything contained above the total processing fee payable under this clause will not exceed [●] (plus applicable taxes) and in case if the total processing fees exceeds [●] (plus applicable taxes) then processing fees will be paid on pro-rata basis.

(4) The processing fees for applications made by UPI Bidders using the UPI Mechanism would be as follows:

Members of the Syndicate/ RTAs/ CDPs (uploading charges)	[●] per valid application (plus applicable taxes)
Sponsor Bank - [●]	[●] per valid Bid cum Application Form* (plus applicable taxes) The Sponsor Bank shall be responsible for making payments to the third parties such as remitter bank, NPCI and such other parties as required in connection with the performance of its duties under the SEBI circulars, the Syndicate Agreement and other applicable laws.

*For each valid application by respective Sponsor Bank

Notwithstanding anything contained above in this clause the total Uploading charges/ Processing fees payable to Members of the Syndicate/ RTAs/ CDPs for applications made by Individual Bidders (up to two lots), Non-Institutional Bidders (for an application size of more than two lots and up to ₹500,000) using the UPI Mechanism and in case if the total uploading charges/ processing fees exceeds [●] (plus applicable taxes) then uploading charges/ processing fees using UPI Mechanism will be paid on pro-rata basis.

(5) Selling commission on the portion for Individual Bidders and Non-Institutional Bidders which are procured by members of the Syndicate (including their sub-Syndicate Members), Registered Brokers, CRTAs and CDPs or for using 3-in-1 type accounts- linked online trading, demat & bank account provided by some of the Registered Brokers which are Members of the Syndicate (including their Sub-Syndicate Members) would be as follows:

Portion for Individual Bidders	[●] % of the Amount Allotted* (plus applicable taxes)
Portion for Non-Institutional Bidders	[●] % of the Amount Allotted* (plus applicable taxes)

*Amount Allotted is the product of the number of Equity Shares Allotted and the Issue Price

Uploading charges payable to Members of the Syndicate (including their sub-Syndicate Members), CRTAs and CDPs on the applications made by RIBs using 3-in-1 accounts and Non-Institutional Bidders which are procured by them and submitted to SCSB for blocking or using 3-in- 1 accounts, would be as follows: [●] plus applicable taxes, per valid application bid by the Syndicate (including their sub-Syndicate Members), CRTAs and CDPs.

Bidding charges payable to the Registered Brokers, CRTAs/ CDPs on the portion for Individual Bidders and Non-Institutional Bidders which are directly procured by the Registered Brokers or CRTAs or CDPs and submitted to SCSB for processing, would be as follows:

Portion for Individual Bidders*	[●] per valid application (plus applicable taxes)
Portion for Non-Institutional Bidders*	[●] per valid application (plus applicable taxes)

* Based on valid applications

Notwithstanding anything contained above the total uploading/ bidding charges payable under this clause will not exceed [●] (plus applicable taxes) and in case if the total uploading/ bidding charges exceeds [●] (plus applicable taxes) then uploading charges will be paid on pro-rata basis.

The Selling Commission payable to the Syndicate/ Sub-Syndicate Members will be determined on the basis of the application form number/ series, provided that the application is also bid by the respective Syndicate/ Sub-Syndicate Member. For clarification, if a Syndicate ASBA application on the application form number/ series of a Syndicate/ Sub-Syndicate Member, is bid by an SCSB, the Selling Commission will be payable to the SCSB and not the Syndicate/ Sub-Syndicate Member. Bidding Charges payable to members of the Syndicate (including their sub-Syndicate Members), CRTAs and CDPs on the portion for RIBs and Non-Institutional Bidders which are procured by them and submitted to SCSB for blocking, would be as follows: [●] plus applicable taxes, per valid application bid by the Syndicate (including their sub-Syndicate Members), CRTAs and CDPs.

The selling commission and bidding charges payable to Registered Brokers the CRTAs and CDPs will be determined on the basis of the bidding terminal ID as captured in the Bid Book of BSE or NSE

All such commissions and processing fees set out above shall be paid as per the timelines in terms of the Syndicate Agreement and Escrow and Sponsor Bank Agreement. Further, the processing fees for applications made by UPI Bidders

using the UPI Mechanism may be released to the remitter banks (SCSBs) only after such banks provide a written confirmation on compliance with SEBI Circular No: SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021 read with SEBI Circular No: SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021.

Proposed Schedule of Implementation:

The proposed year wise break up of deployment of funds and Schedule of Implementation of Net Issue Proceeds is as under:

(₹ in Lakhs)

Sr. No	Particulars	Amount to be deployed and utilized in	
		F.Y. 2025-26*	F.Y. 2026-27*
1.	Repayment in full or in part, of certain of our outstanding borrowings	900.00	Nil
2.	Funding capital expenditure towards purchase of new machinery	608.40	Nil
3.	Funding to meet Working Capital requirements	900.00	600.00
4.	General Corporate Purpose	[●]	[●]
	Total	[●]	[●]

* The above timelines with respect to the implementation are as planned and indicative.

Means of finance of the project

Since, the entire fund requirement is to be funded from the proceeds of the Fresh Issue and existing identifiable internal accruals, there is no requirement to make firm arrangements of finance under Regulation 230(1)(e) of the SEBI ICDR Regulations through verifiable means towards at least 75% of the stated means of finance. In case of a shortfall in the Proceeds from the Fresh Issue or any increase in the actual utilisation of funds earmarked for the Objects, our Company may explore a range of options including utilizing our internal accruals and/or seeking additional debt from existing and/or other lenders. For further details on the risks involved in our business plans and executing our business strategies, please see the section titled **“Risk Factors”** beginning on page 27 of the Draft Red Herring Prospectus.

Appraisal

None of the Objects have been appraised by any bank or financial institution or any other independent third-party organization. The funding requirements of our Company and the deployment of the proceeds of the Issue are currently based on available quotations and management estimates. The funding requirements of our Company are dependent on a number of factors which may not be in the control of our management, including but not limited to variations in interest rate structures, changes in our financial condition and current commercial conditions of our Business and are subject to change in light of changes in external circumstances or in our financial condition, business or strategy.

Shortfall of Funds

Any shortfall in meeting the fund requirements will be met by way of internal accruals and or unsecured Loans.

Bridge Financing Facilities

Our Company has not raised any bridge loans from any bank or financial institution as on the date of this Draft Red Herring Prospectus, which are proposed to be repaid from the Net Proceeds. However, depending upon business requirements, our Company may consider raising bridge financing facilities, including through secured or unsecured loans. If any bridge financing is availed to fund any of the objects mentioned above, then the same would be repaid out of the IPO proceeds and such utilization (towards repayment of Bridge Loan) shall be construed to be done for the specific object itself.

Monitoring Utilization of Funds

As the size of the offer will not exceed Rs. 5,000 Lakhs, the appointment of Monitoring Agency would not be required as per Regulation 262(1) of the SEBI ICDR Regulations. Our Board and the management will monitor the utilization of the Net Offer Proceeds through our audit committee. Pursuant to Regulation 32 of the SEBI Listing Regulations, our Company shall on half-yearly basis disclose to the Audit Committee the Application of the proceeds of the Offer. On an annual basis, our Company shall prepare a statement of funds utilized for purposes other than stated in the Red Herring Prospectus and place it before the Audit Committee. Such disclosures shall be made only until such time that all the proceeds of the offer have been utilized in full.

Interim Use of Proceeds

Pending utilization of the Issue proceeds of the Issue for the purposes described above, our Company will deposit the Net Proceeds with scheduled commercial banks included in schedule II of the RBI Act.

Our Company confirms that it shall not use the Net Proceeds for buying, trading or otherwise dealing in shares of any listed company or for any investment in the equity markets or investing in any real estate product or real estate linked products.

Variation in Objects

In accordance with Section 27 of the Companies Act, 2013, our Company shall not vary the objects of the Issue without our Company being authorized to do so by the Shareholders by way of a special resolution. In addition, the notice issued to the Shareholders in relation to the passing of such special resolution shall specify the prescribed details as required under the Companies Act and shall be published in accordance with the Companies Act and the rules there under. As per the current provisions of the Companies Act, our Promoters or controlling Shareholders would be required to provide an exit opportunity to such shareholders who do not agree to the proposal to vary the objects, at such price, and in such manner, as may be prescribed by SEBI, in this regard.

Other confirmations

There are no material existing or anticipated transactions with our Promoters, our Directors, our Company's key Managerial personnel, in relation to the utilization of the Net Proceeds. No part of the Net Proceeds will be paid by us as consideration to our Promoters, our directors or key managerial personnel except in the normal course of business and in compliance with the applicable laws.

BASIS FOR ISSUE PRICE

Investors should read the following summary with the section titled “**Risk Factors**”, the details about our Company under the section titled “**Our Business**” and its financial statements under the section titled “**Financial Information of the Company**” beginning on page 27, 118 and 172 respectively of the Draft Red Herring Prospectus. The trading price of the Equity Shares of Our Company could decline due to these risks and the investor may lose all or part of his investment.

Price Band/ Issue Price shall be determined by our Company in consultation with the Book Running Lead Manager on the basis of the assessment of market demand for the Equity Shares through the Book Building Process and on the basis of the qualitative and quantitative factors as described in this section. The face value of the Equity Shares is ₹ 10/- each and the Issue Price is [●] times of the face value at the lower end of the Price Band and [●] times of the face value at the upper end of the Price Band.

For the purpose of making an informed investment decision, the investors should also refer “**Risk Factors**”, “**Our Business**” and “**Financial Statement as restated**” beginning on page 27, 118 and 172 respectively of this Draft Red Herring Prospectus.

QUALITATIVE FACTORS

We believe the following business strengths allow us to successfully compete in the industry:

- a) Wide product portfolio
- b) Well-equipped and regulatory compliant Manufacturing Facility
- c) In-house testing, quality control and quality assurance.
- d) Loan license and marketing arrangement with pharmaceutical companies
- e) Experienced Promoters with domain knowledge

For a detailed discussion on the qualitative factors which form the basis for computing the price, please refer to sections titled “**Our Business**” beginning on page 118 of this Draft Red Herring Prospectus.

QUANTITATIVE FACTORS

The information presented below relating to our Company is based on the Restated Financial Statements. For details, please refer section titled “**Financial Information of the Company**” on page 172 of this Draft Red Herring Prospectus.

Some of the quantitative factors which may form the basis for calculating the Issue Price are as follows:

1. Basic & Diluted Earnings per share (EPS) (Face value of ₹ 10 each):

As per the Restated Financial Statements:

Sr. No	Period	Basic & Diluted (₹)	Weights
1.	Financial Year 2022-2023	(1.54)	1
2.	Financial Year 2023-2024	2.53	2
3.	Financial Year 2024-2025	5.57	3
	Weighted Average	3.37	6

Notes:

- i. The figures disclosed above are based on the Restated Financial Statements of the Company.
- ii. The face value of each Equity Share is ₹10.00.
- iii. Earnings per Share has been calculated in accordance with **Accounting Standard 20 – “Earnings per Share”** issued by the Institute of Chartered Accountants of India.
- iv. The above statement should be read with Significant Accounting Policies and the Notes to the Restated Financial Statements as appearing in Annexure IV.
- v. Basic Earnings per Share = Net Profit/(Loss) after tax, as restated attributable to equity shareholders/ Weighted average number of equity shares outstanding during the year/ period.
- vi. Diluted Earnings per Share = Net Profit/(Loss) after tax, as restated attributable to equity shareholders/ Weighted average number of diluted potential equity shares outstanding during the year/ period.

2. Price Earning (P/E) Ratio in relation to the Price Band of ₹ [●] to ₹ [●] per Equity Share of Face Value of ₹ 10/- each fully paid up

Particulars	(P/E) Ratio at the Floor Price	(P/E) Ratio at the Cap Price
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2024-2025	[●]	[●]
P/E ratio based on the Weighted Average EPS, as restated.	[●]	[●]

Industry P/E Ratio*	(P/E) Ratio
Highest (Sakar Healthcare Limited)	46.13
Lowest (Medico Remedies Limited)	40.03
Industry Average	43.08

* For the purpose of industry, we have considered those companies which are engaged in the similar line of business segment as of our Company, however, they may not be exactly comparable in terms of product portfolio or the size of our Company. The peers have been included for the purpose of broad comparison.

3. Average Return on Return on Net worth (RoNW)*

Sr. No	Period	RoNW (%)	Weights
1	Financial Year 2022-2023	(28.28) %	1
2	Financial Year 2023-2024	37.15%	2
3	Financial Year 2024-2025	45.02%	3
	Weighted Average	30.18%	6

Note:

- The RoNW has been computed by dividing net profit after tax (excluding exceptional items) with restated Net worth as at the end of the year/ period
- Weighted average = Aggregate of year-wise weighted RoNW divided by the aggregate of weights i.e. (RoNW x Weight) for each year/ Total of weights.

4. Net Asset Value (NAV) per Equity Share:

(₹ in lakhs)

Sr. No.	NAV per Equity Share	Outstanding at the end of the year
1.	As at March 31, 2023	5.44
2.	As at March 31, 2024	6.81
3.	As at March 31, 2025	12.38
4.	NAV per Equity Share after the Issue	
	I. Floor Price	[●]
	II. Cap Price	[●]
5.	Issue Price	[●]

Notes: -

- NAV per share = Restated Net worth at the end of the year/period divided by Weighted average number of equity shares outstanding at the end of the year/ period.
- Net worth is computed as the sum of the aggregate of paid-up equity share capital, all reserves created out of the profits, securities premium account received in respect of equity shares.
- Issue Price per Equity Share will be determined by our Company in consultation with the Book Running Lead Manager.

5. Comparison of Accounting Ratios with Industry Peers:

Name of Company	Current Market Price (₹)	Face Value	EPS		PE	RoNW (%)	Book Value (₹)	Total Income (₹ in Cr)
			Basic	Diluted				
Rednex Pharmaceuticals Limited	[●]	10	5.57	5.57	[●]	45.02%	22.28	46.12
Peer Group								
Medico Remedies Limited	48.84	2	1.22	1.22	40.03	16.16%	7.53	153.63
Sakar Healthcare Limited	366.70	10	7.97	7.95	46.13	6.19%	128.75	178.90

Notes:

- Source-All the financial information for listed industry peers are sourced from their audited financial results for the year ended March 31, 2025 as available on the stock exchange.

- ii) Market Price for the listed peer mentioned above is sourced from stock exchange data dated September 25, 2025 to compute the corresponding financial ratios. For our Company, we have taken Current Market Price as the issue price of equity share.
- iii) Further, P/E Ratio is based on the current market price of the respective scrips.
- iv) The EPS, NAV, RoNW and Total Income of our Company are taken as per Restated Financial Statement for the Financial Year 2024-25 as adjusted with the effect of Bonus Issue.
- v) NAV per share is computed as the closing net worth divided by the closing outstanding number of paid-up equity shares as adjusted with the effect of Bonus Issue.
- vi) P/E Ratio of the peer company is sourced from their audited financial results for the year ended March 31, 2025 and stock exchange data dated September 25, 2025
- vii) RoNW has been computed as net profit after tax divided by closing net worth.
- viii) Net worth has been computed in the manner as specifies in Regulation 2(1) (hh) of SEBI (ICDR) Regulations, 2018.
- ix) The face value of Equity Shares of our Company is ₹ 10/- per Equity Share and the Issue price is [●] times the face value of equity share.

6. Key Performance Indicators

The KPIs disclosed below have been used historically by our Company to understand and analyze the business performance, which in result, help us in analysing the growth of our company.

The KPIs disclosed below have been approved by a resolution of our Audit Committee dated September 26, 2025 and the members of the Audit Committee have verified the details of all KPIs pertaining to our Company. Further, the members of the Audit Committee have confirmed that there are no KPIs pertaining to our Company that have been disclosed to any investors at any point of time during the three years period prior to the date of filing of this Draft Red Herring Prospectus. Further, the KPIs herein have been certified by M/s Krupal Bhuva & Co., Chartered Accountants, by their certificate dated September 26, 2025.

The KPIs of our Company have been disclosed in the sections titled **“Our Business”** and **“Management’s Discussion and Analysis of Financial Condition and Results of Operations – Key Performance Indicators”** on pages 118 and 223 respectively. We have described and defined the KPIs, as applicable, in **“Definitions and Abbreviations”** on page 1.

Our Company confirms that it shall continue to disclose all the KPIs included in this section on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or till the complete utilization of the proceeds of the Fresh Issue as per the disclosure made in the Objects of the Issue Section, whichever is later or for such other duration as may be required under the SEBI ICDR Regulations. Further, the ongoing KPIs will continue to be certified by a member of an expert body as required under the SEBI ICDR Regulations.

Key Performance Indicators of our Company

(Rs. In Lakhs except percentages and ratios)

Key Financial Performance	FY 2024-25	FY 2023-24	FY 2022-23
Revenue from operations ⁽¹⁾	4,580.12	2,440.54	170.25
EBITDA ⁽²⁾	921.36	456.84	(68.87)
EBITDA Margin ⁽³⁾	20.12%	18.72%	(40.45) %
PAT	426.40	193.43	(92.55)
PAT Margin ⁽⁴⁾	9.31%	7.93%	(54.36) %
Net Worth ⁽⁵⁾	947.07	520.67	327.24
Return on Net Worth ⁽⁶⁾	45.02%	37.15%	(28.28) %
RoCE (%) ⁽⁷⁾	23.29%	14.24%	(6.57) %

Notes:

⁽¹⁾ Revenue from Operations means the Revenue from Operations as appearing in the Restated Financial Statements

⁽²⁾ EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses – Other Income

⁽³⁾ ‘EBITDA Margin’ is calculated as EBITDA divided by Revenue from Operations

⁽⁴⁾ ‘PAT’ is calculated as Profit before tax – Tax Expenses.

⁽⁵⁾ ‘PAT Margin’ is calculated as PAT for the period/year divided by revenue from operations.

⁽⁶⁾ Net worth means the aggregate value of the paid-up share capital and reserves and surplus of the company.

⁽⁷⁾ Return on Net Worth is ratio of Profit after Tax and Net Worth.

⁽⁸⁾ Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders’ equity plus total borrowings {current & non-current}.

Explanation for KPI metrics

KPI	Explanations
Revenue from Operations	Revenue from Operations is used by our management to track the revenue profile of the business and in turn helps to assess the overall financial performance of our Company and volume of our business
EBITDA	EBITDA provides information regarding the operational efficiency of the business
EBITDA Margin (%)	EBITDA Margin (%) is an indicator of the operational profitability and financial performance of our business
PAT	Profit after tax provides information regarding the overall profitability of the business.
PAT Margin (%)	PAT Margin (%) is an indicator of the overall profitability and financial performance of our business.
Net Worth	Net worth is used by the management to ascertain the total value created by the entity and provides a snapshot of current financial position of the entity.
Return on Net Worth (%)	Return on Net worth provides how efficiently our Company generates profits from shareholders' funds.
RoCE (%)	RoCE provides how efficiently our Company generates earnings from the capital employed in the business.

7. Set forth below are the details of comparison of key performance of indicators with our listed industry peers:

Key Financial Performance	Rednex Pharmaceuticals Limited			Medico Remedies Limited			Sakar Healthcare Limited		
	Fiscal 2025	Fiscal 2024	Fiscal 2023	Fiscal 2025	Fiscal 2024	Fiscal 2023	Fiscal 2025	Fiscal 2024	Fiscal 2023
Revenue from operations	4,580.12	2,440.54	170.25	15,094.06	14,492.07	14,043.74	17,758.47	15,335.17	13,335.90
EBITDA	921.36	456.84	(68.87)	1,500.29	1,290.93	961.99	4,962.98	3,836.35	3,313.71
EBITDA Margin	20.12%	18.72%	(40.45) %	9.94%	8.91%	6.85%	27.95%	25.02%	24.85%
PAT	426.40	193.43	(92.55)	1,009.32	829.09	724.15	1,750.20	1,167.09	1,275.86
PAT Margin	9.31%	7.93%	(54.36) %	6.69%	5.72%	5.16%	9.86%	7.61%	9.57%
Net Worth	947.07	520.67	327.24	6,246.89	5,237.10	4,384.30	28,259.59	25,753.11	17,334.71
Return on Net Worth	45.02%	37.15%	(28.28) %	16.16%	15.83%	16.52%	6.19%	4.53%	7.36%
RoCE (%)	23.29%	14.24%	(6.57) %	19.22%	20.56%	20.88%	8.41%	7.20%	8.02%

Notes:

- i) 'Revenue from Operations' means the Revenue from Operations as appearing in the Restated Financial Statements
- ii) 'EBITDA' is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income
- iii) 'EBITDA Margin' is calculated as EBITDA divided by Revenue from Operations
- iv) 'PAT' is calculated as Profit before tax – Tax Expenses.
- v) 'PAT Margin' is calculated as PAT for the period/year divided by revenue from operations.
- vi) 'Net worth' means the aggregate value of the paid-up share capital and reserves and surplus of the company.
- vii) 'Return on Equity' is ratio of Profit after Tax and Average Shareholder Equity
- viii) 'Return on Capital Employed' is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus total borrowings {current & non-current}.

8. Weighted average cost of acquisition

- a) The price per share of our Company based on the primary/ new issue of shares (equity / convertible securities)

There has been no issuance of Equity Shares, other than Equity Shares issued pursuant to a bonus issue on September 09, 2025 during the 18 months preceding the date of this Draft Red Herring Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-Issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of 30 days ("Primary Issue").

- b) The price per share of our Company based on the secondary sale / acquisition of shares (equity shares)

There have been no secondary sale/ acquisitions of Equity Shares, where the promoters, members of the promoter group, Promoter selling shareholders or shareholder(s) having the right to nominate director(s) in the board of directors of the Company are a party to the transaction (excluding gifts of shares), during the 18 months preceding the date of this certificate, where either acquisition or sale is equal to or more than 5% of the fully diluted paid up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days. ("Secondary Transaction").

- c) Since there are no such transactions to report to under (a) and (b) therefore, information based on last 5 primary or secondary transactions (secondary transactions where Promoter / Promoter Group entities or shareholder(s) having the right to nominate director(s) in the Board of our Company, are a party to the transaction), not older than 3 years prior to the date of this certificate irrespective of the size of transactions, is as below:

Primary Transactions:

Except as disclosed below, there have been no primary transactions in the last three years preceding the date of this Draft Red Herring Prospectus:

Date of Allotment	No. of equity shares allotted	Face value	Issue Price per equity shares (₹)	Nature of Allotment	Nature of consideration	Total Consideration (in ₹ lakhs)
September 09, 2025	34,00,000	10	Nil	Bonus Issue	Other than Cash	Nil

Secondary Transactions:

Except as disclosed below, there have been no secondary transactions by the Promoter, members of the Promoter Group or shareholder(s) having the right to nominate director(s) in the Board of Directors of our Company are a party to the transaction, in the last three years preceding the date of this Draft Red Herring Prospectus:

Date of Transfer	Name of transferor	Name of transferee	No. of equity shares allotted	Face Value	Price per equity shares (₹)	Nature of Transaction	Total Consideration (in ₹ lakhs)
September 04, 2025	Mitalben Chetanbhai Matholiya	Shaileshbhai Rugnathbhai Matholiya	4	10	Nil	Gift	Nil

September 04, 2025	Akashbhai Mansukhbhai Gangadiya	Kartikkumar Mansukhbhai Gangadiya	4	10	Nil	Gift	Nil
		Mitalben Chetanbhai Matholiya	2	10	Nil	Gift	Nil
September 03, 2025	Jayeshkumar Amarshibhai Sabava	Mitbhai Natubhai Sabava	4	10	Nil	Gift	Nil
September 03, 2025	Chetan Rugnathbhai Matholiya	Mitalben Chetanbhai Matholiya	6	10	Nil	Gift	Nil

d) Weighted average cost of acquisition, floor price and cap price

Types of transactions	Weighted average cost of acquisition (₹ per Equity Shares)	Floor price* (i.e. ₹ [●])	Cap price* (i.e. ₹ [●])
Weighted average cost of acquisition of primary / new issue as per paragraph 8(a) above.	NA^	NA^	NA^
Weighted average cost of acquisition for secondary sale / acquisition as per paragraph 8(b) above.	NA^^	NA^^	NA^^
Weighted average cost of acquisition of primary issuances / secondary transactions as per paragraph 8(c) above.	Nil	[●] times	[●] times

^There were no primary/ new issue of shares (equity/ convertible securities) other than Equity Shares issued pursuant to a bonus issue on September 09, 2025 in last 18 months prior to the date of this Draft Red Herring Prospectus.

^^There were no secondary transaction of shares as mentioned in paragraph 8(b) above, in last 18 months from the date of this Draft Red Herring Prospectus.

* To be updated at Prospectus stage.

Detailed explanation for Issue Price/ Cap Price being [●] times of WACA of primary issuances/ secondary transactions of Equity Shares (as disclosed above) along with our Company's KPIs and financial ratios for Fiscals 2025, 2024 and 2023:

[●]*

*To be included upon finalization of the Price Band.

Explanation for the Issue Price/Cap Price, being [●] times of WACA of primary issuances/ secondary transactions of Equity Shares (as disclosed above) in view of the external factors which may have influenced the pricing of the Issue.

[●]*

*To be included upon finalization of the Price Band.

Rednex Pharmaceuticals Limited is a Book Built Issue and the pre-Issue and price band advertisement for the same shall be published 2 working days before opening of the Issue in all editions of the English national newspaper [●], all editions of Hindi national newspaper [●] and Gujarati Edition of Regional newspaper [●] where the registered office of the company is situated each with wide circulation.

The Issue Price of ₹ [●] shall be determined by our Company in consultation with the BRLM and will be justified by us in consultation with the BRLM on the basis of the above information. Investors should read the above mentioned information along with ***“Our Business”, “Risk Factors” and “Restated Financial Statements”*** on pages 118, 27 and 172 respectively, to have a more informed view. The trading price of the Equity Shares of our Company could decline due to the factors mentioned in ***“Risk Factors”*** or any other factors that may arise in the future and you may lose all or part of your investments.

STATEMENT OF SPECIAL TAX BENEFITS

To,
The Board of Directors
Rednex Pharmaceuticals Limited
Survey No. 586 and 231, Near SKF Bearing,
Bavla Bagodara N.H 8A, Kerala, Bavla, Ahmedabad,
Gujarat, India, 382220

Sub: Statement of Tax Benefits ('The Statement') available to Rednex Pharmaceuticals Limited, and its shareholders, prepared in accordance with the requirement in Schedule VI-Clause 9L of Securities and Exchange Board of India (Issue of Capital Disclosure Requirements) Regulations 2018, as amended ("The Regulation")

Dear Sirs,

We hereby report that the enclosed annexure prepared by the management of Rednex Pharmaceuticals Limited states the special tax benefits available to the Company and the shareholders of the Company under the Income-Tax Act, 1961, the Customs Act, 1962, the Central Goods and Services Tax Act, 2017, the Integrated Goods and Services Tax Act, 2017, the Union Territory Goods and Services Tax Act, 2017, respective State Goods and Services Tax Act, 2017 (collectively the "GST Act") presently in force in India. Several of these benefits are dependent on the Company or its shareholders fulfilling the conditions prescribed under the relevant provisions of the Act. Hence, the ability of the Company or its shareholders to derive the tax benefits is dependent upon fulfilling such conditions, which, based on business imperatives that the Company may face in the future, the Company may or may not choose to fulfill.

The benefits discussed in the enclosed Annexure cover only special tax benefits available to the Company do not cover any general tax benefits available to the Company. Further, the preparation of the enclosed statement and the contents stated therein is the responsibility of the Company's management.

We are informed that this Statement is only intended to provide general information to the investors and is neither designed nor intended to be a substitute for professional tax advice. In view of the individual nature of the tax consequences and the changing tax laws, each investor is advised to consult his or her own tax consultant with respect to the specific tax implications arising out of their participation in the proposed initial public offering of Equity shares ("the Issue") by the Company.

We do not express any opinion or provide any assurance as to whether:

- a. The Company or its shareholders will continue to obtain these benefits in the future; or
- b. The conditions prescribed for availing the benefits have been/would be met.

The contents of the enclosed statement are based on information, explanations and representations obtained from the Company and on the basis of our understanding of the business activities and operations of the Company.

Limitations:

Our views are based on facts and assumptions indicated to us and the existing provisions of tax law and its interpretations, which are subject to change or modification from time to time by subsequent legislative, regulatory, administrative, or judicial decisions. Any such changes, which could also be retrospective, could have an effect on the validity of our views stated herein.

We assume no obligation to update this statement on any events subsequent to its issue, which may have a material effect on the discussions herein. This report including enclosed annexure are intended solely for your information and for the inclusion in the Draft offer document/ offer document or any other issue related material in connection with the proposed

initial public offer of the Company and is not to be used, referred to or distributed for any other purpose without our prior written consent.

This statement has been prepared solely in connection with the Proposed Issue by the Company under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended.

For, Krupal Bhuvu & Co.
Chartered Accountants
(FRN: 146585W)

(CA Krupal Bhuvu)
Proprietor
M. No: 182312
UDIN:25182312BMIRTZ2768
Date: September 26, 2025
Place: Ahmedabad

ANNEXURE TO THE STATEMENT OF SPECIAL TAX BENEFITS

The information provided below sets out the special tax benefits available to the Company and the Equity Shareholders under the Income Tax Act, 1961, presently in force in India. It is not exhaustive or comprehensive and is not intended to be a substitute for professional advice. Investors are advised to consult their own tax consultant with respect to the tax implications of an investment in Equity Shares, particularly in view of the fact that certain recently enacted legislation may not have a direct legal precedent or may have a different interpretation on the benefits, that an investor can avail.

A. SPECIAL DIRECT AND INDIRECT TAX BENEFITS TO THE COMPANY:

Pursuant to **Section 115BAB of the Income-tax Act, 1961**, a domestic company set up and registered on or after **1st October 2019** and engaged in the business of manufacture or production of any article or thing, which commences such operations on or before 31st March 2024, may, at its option, **be taxed on its total income at the concessional rate of 15% (plus applicable surcharge and cess)**, subject to the fulfillment of specified conditions.

The option shall be available provided that—

1. The company is not formed by splitting up or reconstruction of an existing business (except as permitted under Section 33B), does not use second-hand plant or machinery beyond the permissible limit of 20%, and does not 80-ID was claimed.
2. The company is **engaged exclusively in the business of manufacture or production of an article or thing**, or in research in relation thereto, or distribution of such products, but not in businesses such as development of software, mining, marble processing, gas bottling, printing of books, cinematograph films, or such other businesses as may be notified.
3. The income is computed—
 - without claiming specified deductions under Chapter VI-A (**other than Section 80JAA and 80M**), Section 10AA, Section 32(1)(iia), Section 32AD, Section 33AB, Section 33ABA, Section 35(1)(ii)/(iia)/(iii), Section 35(2AA), Section 35(2AB), Section 35AD, Section 35CCC, and Section 35CCD;
 - without set-off of brought forward losses or unabsorbed depreciation relating to such deductions; and
 - by claiming depreciation only as per Section 32 (excluding additional depreciation under Section 32(1)(iia)).

Further, where income includes amounts not derived from or incidental to manufacturing, and for which no specific rate is separately provided, such income shall be taxed at normal tax rate.

The Company is eligible for the **lower corporate tax rate of 17.16%** (including surcharge and cess) under section 115BAB of the Income-tax Act, 1961.

B. SPECIAL TAX BENEFITS AVAILABLE TO SHAREHOLDERS

The shareholders of the company are not entitled to any Special Tax benefits under the Income Tax Act, 1961, and the GST Act.

NOTES:

1. The above Annexure of special tax benefits sets out the provisions of Tax Laws in a summary manner only. It is not a complete analysis or listing of all potential tax consequences of the purchase, ownership, and disposal of shares.
2. The Company is availing the benefit of exemption from Basic Custom Duty, IGST and Compensation cess on import of inputs under Advance Authorisation scheme.
3. The above Annexure covers only the special tax benefits under the Act, read with the relevant rules, circulars and notifications and does not cover any benefit under any other law in force in India. This Annexure also does not discuss any tax consequences in countries outside India of an investment in the shares of an Indian company.
4. The above Annexure of special tax benefits is as per the current direct tax laws relevant for the assessment year

2026-27. Several of these benefits are dependent on the Company or its shareholders fulfilling the conditions prescribed under the relevant provisions of the Tax Laws.

5. In respect of non-residents, the tax rates and consequent taxation mentioned above will be further subject to any benefits available under the relevant Double Taxation Avoidance Agreement, if any, entered into between India and the country in which the non-resident has fiscal domicile.
6. This Annexure is intended only to provide general information to the investors and is neither designed nor intended to be a substitute for professional tax advice. In view of the individual nature of tax consequences, each investor is advised to consult his or her tax advisor with respect to specific tax consequences of his/her investment in the shares of the Company.
7. For the purpose of reporting here, we have not considered the general tax benefits available to the company or shareholders.
8. No assurance is given that the revenue authorities/ courts will concur with the views expressed herein. The views are based on the existing provisions of law and its interpretation, which are subject to changes from time to time. We do not assume responsibility to update the views consequent to such changes.

For, Krupal Bhuvu & Co.
Chartered Accountants
(FRN: 146585W)

(CA Krupal Bhuvu)
Proprietor
M.No: 182312
UDIN:25182312BMIRTZ2768
Date: September 26, 2025
Place: Ahmedabad

SECTION V – ABOUT THE COMPANY

INDUSTRY OVERVIEW

The information in this section has been extracted from various websites and publicly available documents from various industry sources. The data may have been re-classified by us for the purpose of presentation. Neither we nor any other person connected with the issue has independently verified the information provided in this section. Industry sources and publications, referred to in this section, generally state that the information contained therein has been obtained from sources generally believed to be reliable but their accuracy, completeness and underlying assumptions are not guaranteed and their reliability cannot be assured, and, accordingly, investment decisions should not be based on such information.

*Investors should note that this is only a summary of the industry in which we operate and does not contain all information that should be considered before investing in the Equity Shares. Before deciding to invest in the Equity Shares, prospective investors should read this Draft Red Herring Prospectus, including the information in “**Our Business**” and “**Financial Information**” beginning on pages 118 and 172 respectively of this Draft Red Herring Prospectus. An investment in the Equity Shares involves a high degree of risk. For a discussion of certain risks in connection with an investment in the Equity Shares, see “**Risk Factors**” beginning on page 27 of this Draft Red Herring Prospectus.*

Global economic prospects


Global growth is stabilizing as inflation returns closer to targets and monetary easing supports activity in both advanced economies and emerging market and developing economies (EMDEs). This should give rise to a broad-based, moderate global expansion over 2025-26, at 2.7 percent per year, as trade and investment firm. However, growth prospects appear insufficient to offset the damage done to the global economy by several years of successive negative shocks, with particularly detrimental outcomes in the most vulnerable countries. From a longer-term perspective, catch-up toward advanced economy income levels has steadily weakened across EMDEs over the first quarter of the twenty-first century. Heightened policy uncertainty and adverse trade policy shifts represent key downside risks to the outlook. Other risks include escalating conflicts and geopolitical tensions, higher inflation, more extreme weather events related to climate change, and weaker growth in major economies. On the upside, faster progress on disinflation and stronger demand in key economies could result in greater-than-expected global activity. The subdued growth outlook and multiple headwinds underscore the need for decisive policy action. Global policy efforts are required to safeguard trade, address debt vulnerabilities, and combat climate change. National policy makers need to resolutely pursue price stability, as well as boost tax revenues and rationalize expenditures in order to achieve fiscal sustainability and finance needed investments. Moreover, to raise longer-term growth and put development goals on track, interventions that mitigate the impact of conflicts, lift human capital, bolster labor force inclusion, and confront food insecurity will be critical.

The global economic context has become modestly more favourable since last June, following several years characterized by overlapping negative shocks. Inflation appears to be moderating without a substantial slowdown in key economies, and monetary policy easing has now become widespread. In the next couple of years, deceleration in the two main engines of the global economy—the United States and China—is expected to be offset by firming growth elsewhere, including in many emerging market and developing economies. In all, the post-pandemic global economic expansion is forecast to remain on a steady path. However, the global economy appears to be settling at a relatively low level of growth—one insufficient to foster sustained economic development and catchup in per capita incomes—with the possibility of further headwinds from heightened policy uncertainty, growing trade fragmentation, slower than-anticipated progress in reducing inflation, and weaker activity in major economies.

Aggregate commodity prices softened by about 3 percent in 2024, primarily reflecting improving supply conditions for energy and food commodities, despite heightened geopolitical tensions. Commodity prices are projected to ease further over the forecast horizon. A small decline in oil prices last year reflected ample potential oil supply amid decelerating global oil consumption. A significant further decrease in oil prices is expected in 2025-26 as production expands while global oil demand growth remains modest. Base metals prices are set to stabilize over the forecast horizon, mirroring steady global growth. Meanwhile, prices for staple food crops, having fallen notably in 2024, are expected to post a small further decline.

Global headline inflation has continued to gradually ease, in part reflecting falling commodity prices and the lagged effects of monetary tightening. Inflation is now close to targets in many advanced economies and EMDEs, with the share of economies with above-target inflation on a downward trend and set to reach in 2025 its lowest level since the peak in 2022. Core inflation

briefly edged up in some EMDEs and advanced economies at about the middle of last year on persistent strength in services inflation. However, it has since generally resumed a gradual decline.



Fiscal policy is estimated to have been broadly neutral for global growth in 2024, with previously expected fiscal consolidation plans delayed in some major economies. Going forward, fiscal policy is generally anticipated to be modestly contractionary. The pace of fiscal consolidation is expected to pick up in EMDEs excluding China, and in some advanced economies—although not in the United States—as governments intensify efforts to realign spending with revenues. This is likely to exert a modest drag on near-term global growth.


Over the longer term, comprehensive and wide ranging reforms will be necessary to foster greater prosperity and address the root causes of insufficient growth prospects in many EMDEs. Tackling the rising incidence of conflict is crucial to reversing declines in living standards in some of the most vulnerable countries. Targeted policies are needed to boost growth-enhancing investment, including in human capital, and advance labour force inclusion, especially in EMDE regions where the working-age population is projected to increase substantially. Bolstering food security is paramount. Acute food insecurity remains elevated, with conflict as a key driver, posing dire implications for both the immediate well-being and the lifetime prospects of those affected.

Global trade


Global trade in goods and services rebounded in 2024, growing by an estimated 2.7 percent after a tepid expansion in the previous year. Growth in goods trade accelerated in the second half of 2024, following a weaker-than-expected recovery in the first half. The pickup was partly driven by precautionary inventory buildup in anticipation of possible trade dislocations, including those resulting from dockworker strikes on the U.S. East Coast and the Gulf of Mexico, as well as announced and potential higher tariffs in the United States. Maritime transit and freight rates increased in the latter half of 2024, reflecting disruptions in maritime transport and higher shipping volumes. However, these costs remain well below the peaks seen during the pandemic and have not had a significant impact on the availability of goods or global delivery times thus far.

The recovery in global goods trade last year was uneven across country groups. Goods trade expanded steadily in EMDEs, while it remained weak in most advanced economies, except for the United States, as a result of sluggish growth. Moreover, leading indicators signal continued weakness in advanced-economy goods trade. Among EMDEs, the expansion in goods trade in 2024 was broad-based across region - except in the Middle East and North Africa (MNA), where trade contracted because of oil production cuts by OPEC+ members.

A. Goods trade growth



B. Global PMI: New export orders




Global services purchasing managers' index (PMI) for new export orders suggest that the recovery in services trade has stabilized, reflecting a slowdown in the growth of travel services. Recent data on tourist arrivals indicate that tourism activity has recovered to pre-pandemic levels in nearly all regions except for EAP, where strict pandemic-control measures remained in place for longer.

Against this backdrop, global trade growth is forecast to pick up to an average of about 3.1 percent in 2025-26, supported by slightly firming trade growth in the euro area which accounts for one-fourth of global trade as well as in Japan and EMDEs excluding China. Nevertheless, global trade growth over the forecast horizon is projected to remain below pre-pandemic averages, in line with heightened trade-restrictive measures and the overall relative softness in output and investment growth. Nearly two-thirds of countries are expected to experience lower trade growth in 2025-26 compared to their 2010-19 averages a period that was also characterized by subdued trade growth. A major downside risk to the trade outlook is the increased likelihood of surging trade restrictions and related uncertainty in light of policy shifts following key elections. Other downside risks include weaker than- expected global demand, escalating geopolitical tensions, and further disruptions in maritime transport.

(Source-<https://openknowledge.worldbank.org/server/api/core/bitstreams/f983c12d-d43c-4e41-997e-252ec6b87dbd/content>)

Indian Economy

India's economy shows robust expansion, with real GDP for FY25 estimated at Rs. 1,87,97,000 crore (US\$ 2.20 trillion), from Rs. 1,76,51,000 crore (US\$ 2.06 trillion) in FY24 with a growth rate of 6.5%. This growth is driven by rising employment and stronger private consumption, supported by improving consumer sentiment, which is expected to keep the momentum going in the near future.



Source: World Bank

Trade remains a critical pillar of India's growth story with exports reaching Rs. 37,31,000 crore (US\$ 436.6 billion) in FY25, led by Engineering Goods (26.88%), Petroleum Products (13.86%) and Electronic Goods (8.89%). These exports helped the economy stay resilient during the pandemic when other sectors slowed. Union Minister of Commerce and Industry, Mr. Piyush Goyal projects exports to reach Rs. 85,44,000 crore (US\$ 1 trillion) by 2030.

India's ability to attract Foreign Direct Investment (FDI) has also strengthened. The country received record FDI inflows amounting to Rs. 4,21,929 crore (US\$ 49.3 billion) in FY25 a 15% increase over FY24, supported by a stable policy environment, a large domestic market and

steady economic growth positioning the country as a key destination for global capital. This capital inflow also complements government plans for increased investment in infrastructure and asset-building projects to further boost economic growth.

India's external economic position is improving. The current account deficit narrowed to Rs. 1,98,726 crore (US\$ 23.30 billion), or 0.6% of GDP, in FY25 from Rs. 2,21,754 crore (US\$ 26.00 billion), or 0.7% of GDP, in FY24. This improvement was due to higher net receipts from services and secondary income, according to the Reserve Bank of India (RBI).

Recent Developments

India is primarily a domestic demand-driven economy, with consumption and investments contributing to 70% of the economic activity. With India's economy showing resilient growth, supported by strong domestic demand, policy reforms, and a healthy investment pipeline, several new projects and developments are underway across key sectors. This positive development across key sectors is evident from following key economic data points.

- According to the Department for Promotion of Industry and Internal Trade (DPIIT), India's cumulative FDI inflow stood at Rs. 91,45,988 crore (US\$ 1.07 trillion) between April 2000-March 2025 with major share coming from Mauritius at Rs. 15,36,849 crore (US\$ 180.19 billion) with a total share of 25%, followed by Singapore at 24% with Rs. 14,91,603 crore (US\$ 174.88 billion), the United States (US) at 10% with Rs. 6,02,574 crore (US\$ 70.65 billion), the Netherlands at 7% with Rs. 4,54,613 crore (US\$ 53.3 billion), and Japan at 6% with Rs. 3,78,653 crore (US\$ 44.39 billion).
- As of July 4, 2025, India's foreign exchange reserves stood at Rs. 59,68,048 crore (US\$ 699.74 billion).
- In May 2025, private equity (PE) and venture capital (VC) investments reached Rs. 20,470 crore (US\$ 2.4 billion) across 97 deals.
- Foreign Institutional Investors (FII) outflows in FY25 were close to Rs. 1,27,000 crore (US\$ 14.89 billion), while Domestic Institutional Investors (DII) bought in Rs. 6,00,000 crore (US\$ 70.34 billion) in the same period.
- The HSBC India Manufacturing Purchasing Managers' Index (PMI) rose to a 14-month high of 58.4 in June 2025 from 57.6 in May, indicating a strong improvement in manufacturing conditions. Robust domestic and international demand drove sharp increases in output and new orders, while employment saw a record rise as firms expanded their workforce to meet rising workloads. New export orders surged, marking the third-fastest growth since the survey began in 2005. Although input cost inflation eased, producer prices increased as companies passed on higher freight and labour costs to customers.
- India saw a robust 10.35% growth in passengers carried by domestic airlines at 431.98 lakh in FY25, from 391.46 lakh in FY24, according to the Directorate General of Civil Aviation (DGCA).
- India secured 39th position out of 133 economies in the Global Innovation Index 2024. India rose from 81st position in 2015 to 39th position in 2024. India ranks third position in the global number of scientific publications.
- In FY25, the Goods and Services Tax (GST) recorded its highest-ever gross collection at Rs. 22,08,000 crore (US\$ 258 billion), registering a YoY growth of 9.4%. The average monthly collection stood at Rs. 1,84,000 crore (US\$ 21.57 billion).
- In May 2025, the overall Index of Industrial Production (IIP) stood at 156.6 (base 2011–12 = 100), reflecting a YoY growth of 1.2%. The mining, manufacturing and electricity sectors stood at 136.6, 154.3 and 216, respectively.
- According to data released by the Ministry of Statistics & Programme Implementation (MoSPI), India's Consumer Price Index (CPI) - Combined inflation was 3.34% in March 2025 against 4.85% in March 2024.
- India's wheat procurement for FY26 has reached 29.7 million tonnes as of May 22, 2025, the highest in four years and up 13.5% YoY. Strong production of 115.43 million tonnes, favourable weather, and bonuses above the Minimum Support Price (MSP) in key states have driven this growth. The Food Corporation of India expects procurement to hit 32.5 million tonnes by season end, raising stocks to 44 million tonnes, well above the 18.4 million tonnes needed for the Public Distribution System.

Government Initiatives

Over the years, the Indian government has introduced many initiatives to strengthen the nation's economy. The Indian government has been effective in developing policies and programmes that are not only beneficial for citizens to improve their financial stability but also for the overall growth of the economy. Over recent decades, India's rapid economic growth has led to a substantial increase in its demand for exports. Besides this, several of the government's flagship programmes, including Make in India, Start-up India, Digital India, the Smart City Mission, and the Atal Mission for Rejuvenation and Urban Transformation, is aimed at creating immense opportunities in India. In this regard, some of the initiatives taken by the government to improve the economic condition of the country are mentioned below:

- On July 5, 2025, the Union Cabinet approved the Rs. 1,00,000 crore (US\$ 11.72 billion) Research, Development and Innovation (RDI) Scheme, launching long term, low or zero interest funding via a special purpose fund under the ANRF to jump start India's R&D ecosystem and support deep tech and startup innovation.
- On March 27, 2025, the Reserve Bank of India proposed doubling the investment cap for individual foreign investors in listed firms from 5% to 10%, with a combined foreign individual limit increasing to 24%, to counter Foreign Portfolio Investment (FPI) outflows.
- According to a report by Wood Mackenzie in January 2025, India, the US, and West Asia are expected to collectively add 100 Gigawatts (GW) of solar capacity by 2025, while China is anticipated to continue its leadership in the solar industry.
- In July 2024, the Ministry of Finance held the Union Budget and announced that for 2024-25, the total receipts other than borrowings and the total expenditure are estimated at Rs. 32,07,000 crore (US\$ 375 billion) and Rs. 48,21,000 crore (US\$ 564 billion), respectively.
- In February 2024, the Finance Ministry announced the total expenditure in Interim 2024-25 estimated at Rs. 47,65,768 crore (US\$ 571.64 billion) of which total capital expenditure is Rs. 11,11,111 crore (US\$ 133.27 billion).
- On January 22, 2024, Prime Minister Mr. Narendra Modi announced the 'Pradhan Mantri Suryodaya Yojana'. Under this scheme, one crore households will receive rooftop solar installations.
- On September 17, 2023, Prime Minister Mr. Narendra Modi launched the Central Sector Scheme PM-VISHWAKARMA in New Delhi. The new scheme aims to provide recognition and comprehensive support to traditional artisans & craftsmen who work with their hands and basic tools. This initiative is designed to enhance the quality, scale, and reach of their products, as well as to integrate them with Micro, Small and Medium Enterprises (MSME) value chains.
- On August 6, 2023, Amrit Bharat Station Scheme was launched to transform and revitalize 1,309 railway stations across the nation. This scheme envisages development of stations on a continuous basis with a long-term vision.
- On June 28, 2023, the Ministry of Environment, Forests, and Climate Change introduced the 'Draft Carbon Credit Trading Scheme, 2023'.
- From April 1, 2023, Foreign Trade Policy 2023 was unveiled to create an enabling ecosystem to support the philosophy of 'Aatmanirbhar Bharat' and 'Local goes Global'.
- To enhance India's manufacturing capabilities by increasing investment and production in the sector, the government of India has introduced the Production Linked Incentive Scheme (PLI) for Pharmaceuticals.
- Prime Minister's Development Initiative for North-East Region (PM-DevINE) was announced in the Union Budget 2022-23 with a financial outlay of Rs. 1,500 crore (US\$ 182.35 million).
- Prime Minister Mr Narendra Modi has inaugurated a new food security scheme for providing free food grains to Antyodaya Ann Yojna (AAY) & Primary Household (PHH) beneficiaries, called Pradhan Mantri Garib Kalyan Ann Yojana (PMGKAY) from January 1, 2023.

Road Ahead

India's economy grew by 6.5% in FY25. With a 7.4% growth rate in Q4 FY25, with RBI projecting a growth rate of 6.5% in FY26 as well. India's comparatively strong position in the external sector reflects the country's positive outlook for economic growth and rising employment rates. In 2024, India rose to 15th place globally in FDI rankings and retained its position as South Asia's top recipient.



In H1 FY25, India's growth-focused approach was underscored by the government's capital expenditure outlay of Rs. 15,02,000 crore (US\$ 176 billion), reinforcing its commitment to infrastructure-led development.

In the Union Budget of FY26, capital expenditure took lead by steeply increasing the capital expenditure outlay by 10% to Rs. 11,21,000 crore (US\$ 131 billion) over Rs. 10,18,000 crore (US\$ 119 billion) in FY25. Stronger revenue generation because of improved tax compliance, increased profitability of the company, and increasing economic activity also contributed to rising capital spending levels.

India's total goods and service exports surged by 76% over the past decade, touching Rs. 70,36,425 crore (US\$ 825 billion) in FY25, driven by strong performance in engineering goods, electronics, and pharmaceuticals. With a reduction in port congestion, supply networks are being restored.

With a proactive set of administrative actions by the government, flexible monetary policy, and a softening of global commodity prices and supply-chain bottlenecks, inflationary pressures in India look to be on the decline overall.

Source: <https://www.ibef.org/economy/indian-economy-overview>

INDUSTRY SCENARIO

PHARMACEUTICALS

The Indian Pharmaceutical Industry has witnessed a robust growth over the past few years moving on from a turnover of approx. US \$ 1 billion in 1990 to over US \$30 billion in 2015 of which the export turnover is approximately US \$ 15 billion. The country now ranks 3rd world wide by volume of production and 14th by value, thereby accounting for around 10% of world's production by volume and 1.5% by value. Globally, it ranks 4th in terms of generic production and 17th in terms of export value of bulk actives and dosage forms. Indian exports are destined to more than 200 countries around the globe including highly regulated markets of US, West Europe, Japan and Australia. It has shown tremendous progress in terms of infrastructure development, technology base creation and a wide range of products. It has established its essence and determination to flourish in the changing environment. The industry now produces bulk drugs belonging to all major therapeutic groups requiring complicated manufacturing technologies. Formulations in various dosage forms are being produced in GMP compliant facilities. Strong scientific and technical manpower and pioneering work done in process development have made this possible.

Recognizing the potential for growth, the Government of India took up the initiative of developing the Indian Pharmaceuticals sector by creating a separate Department in July 2008. The Department is entrusted with the responsibility of policy, planning, development and regulation of Pharmaceutical Industries. An assessment of the Indian Pharmaceutical Industry's strength reveals the following key features:

- Strong export market- India exported drugs worth US\$ 15 billion to more than 200 countries including highly regulated markets in the US, Europe, Japan and Australia. Large Indian pharma companies have emerged as among the most competitive in the evolving generic space in North America and have created an unmatched platform in this space. Indian companies are also making their presence felt in the emerging markets around the world, particularly with a strong portfolio in anti-infective and antiretroviral.
- Large domestic pharma companies have continued to grow, assuming leadership position in many therapies and segments in the Indian market as well as creating a strong international exports back-bone.
- Competitive market with the emergence of a number of second-tier Indian companies with new and innovative business modules.
- Indian players have also developed expertise in significant biologics capabilities.
- Biologic portfolios while still nascent in India are being built with an eye on the future.
- Multinational companies have continued to invest significantly in India and are making their presence felt across most segments of the Indian pharma market. Companies have also begun to invest in increasing their presence in tier II cities and rural areas and making medical care more accessible to a large section of the Indian population.
- Low cost of production.
- Low R&D costs.
- Innovative Scientific manpower.
- Excellent and world-class national laboratories specializing in process development and development of cost-effective technologies.
- Increasing balance of trade in Pharma sector.
- An efficient and cost effective source for procuring generic drugs, especially the drugs going off patent in the next few years.
- An excellent center for clinical trials in view of the diversity in population.

Experience & Expertise

India is the only country with largest number of US-FDA compliant plants (more than 262 including APIs) outside of USA. We have nearly 1400 WHO-GMP approved Pharma Plants, 253 European Directorate of Quality Medicines (EDQM) approved plants with modern state of the art Technology. No other country can boast of such an infrastructure.

Thus Indian pharma companies have a wide variety of experience in manufacturing as per global standards. Through intensive competition in the Indian market, Indian companies are experienced in the manufacturing of a variety of formulations that makes them efficient and competitive in their operations.

The Indian pharma market is mature with decades of experience in generics manufacturing, catering to the needs of the general population. These companies have the experience and know-how to produce quality drugs in an efficient, high-quality and cost-effective manner without compromising on any aspect. There are many companies manufacturing drugs for oncology, AIDS and other complex therapies.

Low cost of manufacture

India is capable of manufacturing low-cost generic alternatives due to a number of economic factors favoring the industry. Some of these include the competitive land rates, the cheap labor available, low resource costs like water, electricity etc., lower cost of production machinery. Importantly, the various drugs like, Intermediates, APIs and Formulation companies are seamlessly integrated while following international regulations of safety.

Research & Development

The Government has taken several policy initiatives for strengthening Research & Development in Pharmaceuticals sector such as fiscal incentives to R&D units sector and streamlining of procedures concerning development of new drug molecules, clinical research and new drug delivery systems leading to new R&D set-ups with excellent infrastructure in the field of original drug discovery.

India has a large branded generics market which enables most companies to launch their version of a generic drug in the market place. Research and Development is an important aspect for development of generics that match the quality and cost targets.

India is now increasingly recognized as a strategic partner in the drug discovery value chain. Further, there are Indian companies which are investing in their R&D centers and are offering early stage discovery services as well as promising molecules. A large scientific pool in India is dedicated to Research and Development of patent non-infringing methodologies for drugs.

Highly educated, specialized scientists

India's rich human capital is the strongest asset for the Indian Pharmaceuticals Industry which is a knowledge-led industry. Various studies show that the scientific talent pool of Indians is the second largest English-speaking group worldwide, after the US. This enables easier access to qualifications that handle the basic work in a plant or an R&D set-up in India. National Institute of Pharmaceutical Education and Research (NIPER) at Mohali is a premier institute in the field of Pharmaceuticals. The institute is a member of Association of Commonwealth Universities. NIPER Mohali is offering Masters level programs and PhD programs in 15 streams. The laboratories here are fully equipped with modern facilities and the available facilities are of international level and standards. Further, six new National Institutes of Pharmaceutical Education and Research (NIPER) were opened in 2007. Recently, three new NIPERs have been proposed in the states of Maharashtra, Rajasthan and Chattisgarh.

Experience in International Servicing

Many of the Indian pharmaceutical companies are experienced in servicing top multinational companies for their highly regulated markets, meeting their stringent quality expectations. The same experience enables Indian organizations to cater to the needs of the regulatory authorities of most nations across the world. Further, technical consultancy capability of NIPERs is contributing to the growth of the industry.


Indian clinical trials industry has developed a complete gamut of clinical research services capabilities of global standards. From medical writing to site management, data management, regulatory submissions to patient recruitment the expertise meets the highest standards of stringent regulatory conditions internationally.

There is an effective control system to monitor the quality of pharmaceuticals at all the levels in India. There are various agencies/ bodies under Ministry of Health & Family Welfare and Department of Pharmaceuticals. They are responsible for standard of drugs, market authorizations, import licenses, cGMP, monitoring of quality of drugs & cosmetics manufactured, pre & post licensing inspection, and price control etc. The recent initiatives through new legislations and optimized processes are targeted towards regulating the industry better and effectively.


Drugs have to comply with stringent quality provisions under the Drugs and Cosmetic Act of India. Any drug including API conforms to the specifications of the prescribed pharmacopeias or those claimed on the label ensuring that all the products manufactured in India are of highest quality. All the pharmaceutical products are inspected at the customs port of the country by competent authorities before they are shipped out.

(Source: <https://pharma-dept.gov.in/pharma-industry-promotion>)

STRUCTURE OF PHARMACEUTICALS SECTOR IN INDIA



EVOLUTION OF THE SECTOR



IMPORTANT SEGMENTS IN INDIAN PHARMACEUTICAL SECTOR

1. ACTIVE PHARMACEUTICAL INGREDIENTS (APIS)

- Active Pharmaceutical Ingredient (or API) is a crucial segment of the pharma industry, contributing to around 35% of the market. API is the biologically active component of a drug that causes an intended medical effect.

- India is the 3rd largest producer of API accounting for an 8% share of the Global API Industry. About 500+ different APIs are manufactured in India, and it contributes 57% of APIs to prequalified list of the WHO.

2. CONTRACT RESEARCH AND MANUFACTURING SERVICES (CRAMS)

- Contract research and manufacturing services (CRAMS) is one of the fastest growing segments in the pharmaceutical and biotechnology industry. The pharmaceutical market uses outsourcing services from providers in the form of contract research organizations (CROs) and contract manufacturing organizations (CMOs).


3. BIOSIMILARS

- The biosimilars market in India is estimated to grow at a compounded annual growth rate (CAGR) of 22% to become US\$ 12 billion by 2025. This would represent almost 20% of the total pharmaceutical market in India.

4. FORMULATIONS

- Largest exporter of formulations in terms of volume, with 14% market share and 12th in terms of export value.
- Double-digit growth is expected over the next five years.
- According to Allied Market Research, the Indian pharmaceutical packaging market was valued at US\$ 1,434.1 million in 2020 and is expected to reach US\$ 3,027.14 million by 2030, at a CAGR of 7.54%.

INDIAN PHARMACEUTICALS MARKET



- Indian pharmaceutical industry is known for its generic medicines and low-cost vaccines globally. Transformed over the years as a vibrant sector, presently Indian pharma ranks third in pharmaceutical production by volume. The Pharmaceutical industry in India is the third largest in the world in terms of volume and 14th largest in terms of value. The pharma sector currently contributes to around 1.72% of the country's GDP.


- The Indian pharmaceuticals industry is expected to grow 9-11% in the financial year 2024, as per ICRA.

- In FY23, the Indian pharma market saw a year-on-year growth of nearly 5%, reaching US\$ 49.78 billion. During FY18 to FY23, the Indian pharmaceutical industry logged a

compound annual growth rate (CAGR) of 6-8%, primarily driven by an 8% increase in exports and a 6% rise in the domestic market.


- Major Segments of the Pharmaceutical Industry are Generic drugs, OTC Medicines and API/Bulk Drugs, Vaccines, Contract Research & Manufacturing, Biosimilars & Biologics.
- Market size of India pharmaceuticals industry is expected to reach US\$ 65 billion by 2024, ~US\$ 130 billion by 2030 and ~US\$ 450 billion market by 2047.
- India is 3rd largest market for APIs globally, 8% share in the Global API Industry, 500+ different APIs are manufactured in India, and it contributes 57% of APIs to the prequalified list of the WHO.
- Pharmaceutical is one of the top ten attractive sectors for foreign investment in India. The pharmaceutical exports from India reach more than 200 nations around the world, including highly regulated markets of the USA, West Europe, Japan, and Australia.
- The market size of the medical devices sector in India was estimated to be US\$ 11 billion in 2023 and its share in the global medical device market is estimated to be 1.5%. The government has set ambitious target to elevate the medical devices industry in India to US\$ 50 billion by 2030.
- The pharmaceutical sector targets Rs. 11,08,380 crore (US\$ 130 billion) by 2030, while biotechnology aims for Rs. 25,57,800 crore (US\$ 300 billion) by the same year.

PHARMACEUTICALS EXPORT TO CONTINUE WITNESSING POSITIVE GROWTH



- Indian pharmaceutical industry is known for its generic medicines and low-cost vaccines globally. Transformed over the years as a vibrant sector, presently Indian Pharma ranks third in pharmaceutical production by volume. Indian drugs are exported to more than 200 countries in the world, with the US as the key market.
- India's drugs and pharmaceuticals exports stood at Rs. 2,59,658 crore (US\$ 30.38 billion) in FY25 and Rs. 2,43,119 crore (US\$ 27.82 billion) in FY24.
- About 20% of the global exports in generic drugs are met by India.
- India's pharmaceutical industry is projected to experience substantial growth, with exports expected to reach Rs. 30,76,500 crore (US\$ 350 billion) by 2047, a 10-15 times increase from current levels.
- The government has set ambitious target to elevate the medical devices industry in India from its current US\$ 11 billion valuation to US\$ 50 billion by 2030.
- Building on the outstanding performance in FY21, Indian pharmaceutical exports registered a healthy performance in FY22 and FY23. The pharma exports in FY22 sustained a growth despite the global trade disruptions and drop in demand for COVID-related medicines.
- The Indian vaccine industry developed Covid vaccine with indigenous technology in collaboration with India's research institutions like Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV) within the shortest time on par with highly developed countries like America and EU. India has provided 301 million doses of vaccines to more than 100 countries.

R&D SPENDING IN INDIAN PHARMACEUTICALS



- R&D investments: Projected at Rs. 17,000 crore (US\$ 2 billion) by FY28.
- Policy focus on IP, tech commercialization, procurement, education, skill development, and regulatory reforms to attract private R&D investment.
- New initiative to promote pharmaceutical research through centres of excellence and priority fields; plan to set up 157 nursing colleges alongside government medical colleges.
- ICMR labs to open for joint research by public/private medical faculty and private R&D teams.
- Interim Budget 2024-25:
 - US\$ 120 million (Rs. 1,000 crore) for bulk drug parks.

- Total pharma industry development outlay raised to US\$ 156.5 million (Rs. 1,300 crore).
- Medical device parks promotion budget raised to US\$ 18 million (Rs. 150 crore).
- 2023 initiatives: National Policy on R&D and Innovation in Pharma-MedTech, PRIP scheme, and Human Resource Development scheme for MedTech.
- PRIP scheme: Rs. 720.97 crore (US\$ 82.5 million) to fund Centres of Excellence at NIPER and milestone-based private R&D projects.

NOTABLE TRENDS IN THE INDIAN PHARMACEUTICALS SECTOR

Increasing Exports	• About 20% of the global exports in generic drugs are met by India. • India's drugs and pharmaceuticals exports stood at Rs. 2,59,658 crore (US\$ 30.38 billion) in FY25 and Rs. 2,43,119 crore (US\$ 27.82 billion) in FY24.
Product Launch	• Cipla: Received CDSCO approval to market plazomicin for complicated urinary tract infections (cUTI), impacting ~150 million patients annually • Lupin (Nov 2023): Launched world's first fixed-dose triple combination drug for managing COPD • Emcure Pharmaceuticals: First to launch Orofer FCM 750, targeting iron deficiency and anaemia • Glenmark: First in India to launch Akynzeo I.V. to prevent chemotherapy-induced nausea and vomiting, under license from Helsinn
Expansion	• In October 2022, Lupin signed an agreement to acquire two inhalation brands from Sunovion Pharmaceuticals Inc. • Glenmark became the first Indian pharmaceutical company to launch Indacaterol + Mometasone fixed-Dose combination drug for Asthma. • Sanofi announced its plans to invest US\$ 435 million over the next six years to expand its global capability center (GCC) in Hyderabad, India by increasing the headcount and further developing the facility.
Partnerships	• June 2023: MoU signed for recognition of Indian Pharmacopoeia in Suriname. • May 2023: Ministry of Minority Affairs and Ministry of Ayush partnered to promote Unani medicine in India. • Japanese firms invited to invest in Indian pharmaceutical and medical device sector; cooperation aims to strengthen global supply chains for APIs and medical devices. • Q1 2024: Indian pharma industry saw 24 M&A deals worth US\$ 456.3 million.

GROWTH DRIVERS

Supply-side drivers of Indian pharmaceuticals sector:

1. Launch of patented drugs:

- Following the introduction of product patents, several multinational companies are expected to launch patented drugs in India.
- Growth in the number of lifestyle diseases in India could boost the sale of drugs in this segment.
- High Court allowing to export patent drugs, to foreign players in the Indian market

2. Medical infrastructure:

- The presence of a skilled workforce as well as high managerial and technical competence is a source of attraction for private players. Pharma companies have already increased spending in the country to tap rural markets and develop better infrastructure.
- Promotion of Medical Devices Parks: Objective of the scheme is Creation of world class infrastructure facilities in order to make Indian medical device industry a global leader.
- In March 2024, Union Minister for Chemicals & Fertilizers and Health & Family Welfare Dr. Mansukh Mandaviya inaugurated 27 greenfield bulk drug park projects and 13 greenfield manufacturing plants for medical devices.

3. Scope in generics market:

- India has the second-highest number of US FDA approved plants outside the US and is the largest provider of generic drugs globally.
- According to Mr. Bhagwant Khuba, Minister of State (MoS) for Chemicals and Fertilisers, India's pharmaceutical industry is the third largest by volume and the 14th largest by value in the world, generating more than 60,000 generic drugs across 60 therapeutic categories.
- About 20% of the global exports in generic drugs are met by India

4. Over-The-Counter (OTC) drugs:

- The Union government, in 2022, proposed to introduce over-the-counter (OTC) drugs in India through an amendment in the Drugs and Cosmetics Rules and allow their sale in the retail market without doctors' prescription.
- A draft notification issued by the Union health ministry has proposed that the 16 drugs, which include common antipyretic medicine such as paracetamol 500 mg, some laxatives, nasal decongestants and topical antifungal creams be included in the OTC drug category.

5. Patent Expiry:

- About 120 drugs are expected to go off-patent over the next 10 years; with expected worldwide revenue between US\$ 80 to 250 billion.

Demand drivers of Indian pharmaceuticals sector

1. Accessibility:

- New business models expected to penetrate tier-2 and 3 cities.
- Over 160,000 hospital beds expected to be added each year in the next decade.
- India's generic drugs account for 20% of global exports in terms of volume, making the country the largest provider of generic medicines globally.

2. Acceptability:

- Rising levels of education to increase acceptability of pharmaceuticals.
- Patients to show greater propensity to self-medicate, boosting the OTC market.
- Acceptance of biologics and preventive medicines to rise.
- Surge in medical tourism due to increased patient inflow from other countries.

3. Pradhan Mantri Bhartiya Janaushadhi Kendras:

- As of January 2024, the total number of Jan Aushadhi Kendras in the country are 10,607.
- Prime Minister Mr. Narendra Modi during his Independence Day 2023 speech said that the government has plans to increase the number of 'Jan Aushadhi Kendras' from 10,000 to 25,000.
- The Government plans to provide free generic medicines to half the population at an estimated cost of US\$ 5.4 billion.

4. Strategic Opportunity:

- The Trump 2.0 agenda, expected to prioritize the China Plus One approach in pharmaceutical manufacturing and diversify supply chains, presents a growth opportunity for Indian drug makers. Moreover, potential increases in tariffs on Chinese products could create space for Indian pharma companies to bridge supply gaps in the US generic drug market.

FAVOURABLE POLICY MEASURES SUPPORT GROWTH

1. Strengthening of Pharmaceutical Industry (SPI)

The Ministry's scheme "Strengthening of Pharmaceutical Industry (SPI)" with a total financial outlay of US\$ 60.9 million (Rs. 500 crore) extends support required to existing pharma clusters and MSMEs across the country to improve their productivity, quality and sustainability.

2. Scheme for Development of Pharma industry – Umbrella Scheme

The Department of Pharmaceuticals has prepared an Umbrella Scheme namely ‘Scheme for Development of Pharma industry’. Which comprises of the following sub schemes:

- Assistance to Bulk Drug Industry for Common Facilitation Centres
- Assistance to Medical Device Industry for Common Facilitation Centres
- Assistance to Pharmaceutical Industry (CDP-PS)
- Pharmaceutical Promotion and Development Scheme (PPDS)
- Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS)

3. Support for technology upgrades and FDIs

Ayushman Bharat Digital Mission (ABDM): Under the ABDM, citizens will be able to create their ABHA (Ayushman Bharat Health Account) numbers, to which their digital health records can be linked. This will enable creation of longitudinal health records for individuals across various healthcare providers and improve clinical decision making by healthcare providers.

The pilot of ABDM is completed in the six Union Territories of Ladakh, Chandigarh, Dadra & Nagar Haveli and Daman & Diu, Puducherry, Andaman and Nicobar Islands and Lakshadweep with successful demonstration of technology platform developed by the NHA.

During the pilot, digital sandbox was created in which more than 774 partner solutions are undergoing integration. As of September 4, 2023, 450,164,619 Ayushman Bharat Health Accounts have been created and 224,967 doctors and 218,602 health facilities have been registered in ABDM.

4. Promotion of Medical Devices Parks

Objective of the scheme is Creation of world class infrastructure facilities in order to make Indian medical device industry a global leader.

Easy access to standard testing and infrastructure facilities through creation of world class Common Infrastructure Facilities for increased competitiveness will result into significant reduction of the cost of production of medical devices leading to better availability and affordability of medical devices in the domestic market.

5. Production Linked Incentive

In September 2020, the government announced production-linked incentive (PLI) scheme for the pharmaceutical industry worth Rs. 15,000 crore (US\$ 2.04 billion).

The production-linked incentive (PLI) scheme was introduced to encourage Indian manufacturers to produce critical key starting materials (KSMs), drug intermediates (DIs) and active pharmaceutical ingredients (APIs). To support this, the government granted funds worth US\$ 932.66 million.

PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 crore (US\$ 838.16 million) during the tenure of the scheme from 2020-21 to 2029-30.

6. Interim Budget 2024-25

In the Interim Budget 2024-25, the government earmarked US\$ 120 million (Rs 1,000 crore) for the promotion of bulk drug parks for FY25, a significant increase from the previous year.

The total outlay for the development of the pharmaceutical industry for FY25 was increased to US\$ 156.5 million (Rs. 1,300 crore) while the budget for the promotion of medical device parks was raised to US\$ 18 million (Rs. 150 crore) for FY25.

The allocation for assistance to medical device clusters for common facilities (AMD-CF) was pegged at US\$ 4.1 million (Rs. 40 crore) for FY25.

The outlay for the Jan Aushadhi scheme, the initiative to provide affordable generic medicines in the country, was hiked to US\$ 34 million (Rs. 284.5 crore) for FY25, up from US\$ 13 million (Rs. 110 crore) in the revised estimate for FY24.

7. Biotechnology Industry Research Assistance Council

BIRAC has been established to promote research & innovation capabilities in India's biotech industry. The council will provide funding to biotech companies for technology & product development.

BIRAC under Small Business Innovation Research Initiative (SBIRI) scheme supports innovations in biotechnology.

8. Biotechnology Based Programme for Women

Programme on application of biotechnology for women was done to provide employment, skill development, awareness generation, health improvement & socio-economic upliftment of the women population.

9. National Biopharma Mission

The Industry - Academia mission was launched in June 2017 to boost development of biopharmaceuticals in India.

10. National Commission for Homoeopathy (NCH) Bill, 2018

In December 2018, the Government of India approved the National Commission for Homoeopathy, Bill, 2018 in order to have more transparency in the sector.

11. Scheme for Promotion of Research and Innovation in Pharma MedTech Sector (PRIP)

The Department of Pharmaceuticals will soon launch the Scheme for the Promotion of Research and Innovation in Pharma (PRIP) MedTech Sector. The scheme has been approved by the Union Cabinet for a period of five years starting from 2023-24 to 2027-28 with a total outlay of Rs. 5,000 crore (US\$ 604.5 million).

Foreign direct investment (FDI)

Up to 100%, FDI has been allowed through automatic route for Greenfield pharmaceuticals projects. For Brownfield pharmaceuticals projects, FDI allowed is up to 74% through automatic route and beyond that through government approval.

(Source: https://www.ibef.org/download/1754987017_Pharmaceuticals-May-2025.pdf)

PLI SCHEME FOR BULK DRUG MANUFACTURING 2025 – NEW SUBSIDY GUIDELINES

The Government of India has updated the Bulk Drug Production Linked Incentive Scheme 2025, providing revised subsidies and guidelines for the manufacturing of critical Active Pharmaceutical Ingredients (APIs) within the country. This initiative supports the “Atmanirbhar Bharat” mission by reducing import dependency and boosting local pharmaceutical manufacturing. With the 2025 update, the scheme offers more structured incentives, expands the list of eligible APIs, and encourages MSMEs and larger pharmaceutical manufacturers to participate actively. The Bulk Drug Production Linked Incentive Scheme 2025 plays a vital role in ensuring that India remains self-sufficient in the production of essential bulk drugs for both domestic consumption and global supply.

Key Features of the 2025 PLI Scheme for Bulk Drugs

Here are the major highlights of the Bulk Drug Production Linked Incentive Scheme 2025:

- 20+ additional APIs included in the revised list
- Subsidy of up to 20% based on sales performance and plant capacity
- Incentives applicable for greenfield and brownfield projects
- Higher support for fermentation-based drugs, which India heavily imports
- Faster approval timelines for units in dedicated pharma parks

- Encouragement of environmentally compliant manufacturing units

These changes ensure faster execution of projects and higher participation from Indian companies to develop critical healthcare infrastructure.

Newly Covered API Categories in 2025

The updated Bulk Drug Production Linked Incentive Scheme 2025 covers the following major drug components:

API Category	Newly Added Drugs (2025)
Antibiotics	Erythromycin, Azithromycin
Cardiovascular	Atorvastatin, Losartan
Diabetes Care	Metformin, Glimepiride
Pain Management	Diclofenac, Paracetamol
Hormonal APIs	Levothyroxine, Estradiol
Fermentation-Based Drugs	Rifampicin, Streptomycin
Oncology	Methotrexate, Cyclophosphamide

These bulk drugs are crucial for manufacturing widely prescribed medicines and ensuring continuous supply to Indian hospitals and chemists.

Subsidy Structure and Eligibility

Under the Bulk Drug Production Linked Incentive Scheme 2025, eligible manufacturers receive graded incentives based on sales thresholds and type of API produced.

- Fermentation-based APIs: Up to 20% incentive for 6 years
- Chemical synthesis APIs: Up to 10% incentive for 5 years
- Minimum investment required: ₹20 crore to ₹400 crore depending on project scale
- Fast-track clearances through National Single Window System

Eligible manufacturers must commit to production timelines and environmental compliance. Startups, MSMEs, and joint ventures are all encouraged to apply.

Why the 2025 Update Matters for India's Pharma Sector

The revised Bulk Drug Production Linked Incentive Scheme 2025 addresses crucial gaps in the Indian pharmaceutical value chain. Key advantages include-

- Reduction in API imports, especially from China
- Strengthening of domestic R&D and production units
- Improvement in drug security and availability
- Job creation across pharma clusters in India
- Boost to India's role as a global drug supplier

By supporting indigenous manufacturing, this scheme ensures India can respond swiftly to public health needs while reducing foreign dependency.

How to Apply for the PLI Scheme in 2025

Interested companies must submit an Expression of Interest (EOI) and project proposal through the official portal of the Department of Pharmaceuticals. Required documents include:

- Detailed business plan
- Investment breakdown
- Pollution clearance certificates
- Manufacturing site details
- API production timeline

Shortlisted applicants under the Bulk Drug Production Linked Incentive Scheme 2025 will receive approvals within 60 days of submission.

(Source: <https://www.indianpharma.in/pli-scheme-bulk-drugs-2025-update/>)

VISION PHARMA 2047

By the year 2047, the Government aims to accomplish the following goals:

- Make India a global leader in the manufacturing of affordable, innovative & quality pharmaceuticals & medical devices for the goal of Vasudhaiva Kutumbakam
- Vishwaguru in innovation & Research for delivering health care products to future generations in a sustainable manner, introducing natural products
- Ensure accessibility & affordability of patient-centric products for better healthcare outcomes for universal health coverage by building upon partnerships across industry, science and governments
- Contribute to the Health System to attain a union of equity, efficacy, and efficiency towards developing a holistic products profile with a focus on NCDs, AMR, and rare & neglected diseases
- Create equilibrium between social, economic, & governance aspects through facilitative, balanced & progressive policy and regulatory framework
- Reduce India's carbon footprint in Pharma-MedTech to align with Hon'ble PM's vision of Panchamrita
- Identifying critical suppliers, de-risking & decarbonising the supply chain, and promoting local sourcing
- Medical Devices to be an integral part of global supply chains for raw materials, components, spare parts, assemblies/subassemblies, etc.
- Digitisation and technology upgradation in the delivery of services & products under Jan Aushadhi Pariyojana.

(Source: <https://www.investindia.gov.in/blogs/pharmaceutical-sector-spotlight-driving-innovation-india>)

OUR BUSINESS

Some of the information contained in the following discussion, including information with respect to our plans and strategies, contain forward-looking statements that involve risks and uncertainties. You should read the section “Forward-Looking Statements” for a discussion of the risks and uncertainties related to those statements and also the section “Risk Factors” for a discussion of certain factors that may affect our business, financial condition or results of operations. Our actual results may differ materially from those expressed in or implied by these forward-looking statements. Our fiscal year ends on March 31 of each year, so all references to a particular fiscal are to the Twelve-month period ended March 31 of that year. In this section, a reference to the “Rednex”, “Company” or “we”, “us” or “our” means Rednex Pharmaceuticals Limited.

*All financial information included herein is based on our “**Financial information of the Company**” included on page 172 of this Draft Red Herring Prospectus.*

We are engaged in manufacturing of a wide range of pharmaceutical products finding application across various therapeutic areas. We also manufacture pharmaceutical products under loan license or contract manufacturing for our clients. We have developed our product portfolio in various dosage forms that includes Tablets, Capsules, External Preparations (Cream/Gel/Ointment/Lotion), Oral Liquid and Dry Syrup. Our products cater to the major therapeutic areas, including Antibacterial, Antitussive, Analgesic, Anticold, Antacid, Antimalarial, Antifungal, Antidiarrheal, Anti-Allergy, etc

We operate from our WHO-GMP approved manufacturing facility situated at Bavla, Ahmedabad which is spread across 9,212.63 sq. mtrs. Our manufacturing facility comprises of two separate manufacturing blocks (i) General pharma product manufacturing plant and (ii) Beta Lactum plant. The facility is equipped with automated and efficient machines and other equipment along with in-house laboratory and a storage facility to store finished goods and raw materials.

The beta lactum plant produces beta-lactam and cephalosporins antibiotics such as Cefixime, Amoxicillin, Ampicillin, Cefpodoxime, Cefadroxil & lactic Acid, Cefuroxime, Flucloxacillin, Cloxacillin, Cephalexin etc. in the form of Tablets, Capsule and Dry Syrup. Due to the high risk of cross-contamination, beta-lactam production requires specialized containment and isolation from other drug manufacturing areas. Our dedicated beta lactum plant is therefore focused on manufacturing of antibiotics in controlled, standalone facility to prevent cross-contamination, ensure worker safety, and meet strict global regulatory standards. The General Pharma product plant makes everyday formulations such as Erythromycin Tablets and Suspension, Omeprazole Capsules, Pantoprazole with Domperidone Capsules, Diclofenac Gel, Hydrocortisone acetate cream, Dextromethorphan with Phenylephrine and Chlorpheniramine Syrup, Artemether and Lumefantrine Tablets, Ambroxol with Levosalbutamol and Guaiphenesin Syrup, Paracetamol with Ibuprofen Suspension and tablets, Paracetamol Suspension and tablets, Paracetamol with Doclofenac and Caffeine Tablets, Azithromycin Tablets and Suspension, Levocetirizine with Montelukast Syrup and Tablets, Pregabalin Capsules etc.

We manufacture pharmaceutical products in the form of Tablets, Capsules, External Preparation (Creams/Gels/Ointments/Lotions), Oral Liquids and Dry Syrups. Our facility has received FDCA License, WHO Certificate, ISO 9001:2015 quality management system certification and ISO 14001:2015 Environment Management System certification for manufacturing of General Tablets, Capsules, Oral Liquid, External Preparations and Dry Syrup. During the Fiscal 2025, 2024 and 2023 we derived revenue from sales of 250, 67 and 21 number of pharmaceutical products

We also undertake contract manufacturing of pharmaceutical products on a loan license basis, wherein our manufacturing facilities are utilized by third-party companies (loan license holders) who possess the necessary marketing authorizations and market the products under their own brand names. This model enables us to optimize our manufacturing capacities and establish long-term business relationships. In addition to contract manufacturing, we also sell our products to third-party distributors and participants in the pharmaceutical market. Under this arrangement, we sell finished goods on a principal-to-principal model.

We focus on introducing our products in the emerging markets. Our facility received approval from The Food & Drugs Authority, Ghana and Pharmaceutical Manufacturer Registration License from Kingdom of Cambodia. Furthermore, we have applied for approvals/registration of our facility from the regulatory authorities of Dubai, Iraq and North Sudan. Currently, we export our products largely through local merchant exporters in countries like: Angola, Cameroon, Congo, Fiji, Iraq, Liberia, Myanmar, Guyana, Nigeria, Qatar, Papua new guinea, Sierra Leone, Soloman, Somalia, South sudan UAE, Zambia etc.

Our Company is led by our Promoter, Chetan Rugnathbhai Matholiya, Jayeshkumar Amarshibhai Sabava and Akashbhai Mansukhbhai Gangadiya having an experience of around 11 years, 11 years and 8 years in the pharmaceutical industry respectively. Our experience and exposure in the industry allow us to deal with various types of formulation used in various applications.

Key Performance Indicators of our Company

(₹ In Lakhs except percentages and ratios)

Key Financial Performance	FY 2024-25	FY 2023-24	FY 2022-23
Revenue from operations ⁽¹⁾	4,580.12	2,440.54	170.25
EBITDA ⁽²⁾	921.36	456.84	(68.87)
EBITDA Margin ⁽³⁾	20.12%	18.72%	(40.45) %
PAT ⁽⁴⁾	426.40	193.43	(92.55)
PAT Margin ⁽⁵⁾	9.31%	7.93%	(54.36) %
Net Worth ⁽⁶⁾	947.07	520.67	327.24
RoNW(%) ⁽⁷⁾	45.02%	37.15%	(28.28) %
RoCE (%) ⁽⁸⁾	23.29%	14.24%	(6.57)%

Notes:

- (1) 'Revenue from Operations' means the Revenue from Operations as appearing in the Restated Financial Statements
- (2) 'EBITDA' is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income
- (3) 'EBITDA Margin' is calculated as EBITDA divided by Revenue from Operations
- (4) 'PAT' is PAT available for owner of the group.
- (5) 'PAT Margin' is calculated as PAT available for owner of the group for the period/year divided by revenue from operations.
- (6) 'Net worth means Equity share capital + Reserves and surplus (including, Securities Premium, General Reserve and surplus in statement of profit and loss).
- (7) 'Return on Net Worth' is ratio of Profit after Tax and Net Worth.
- (8) 'Return on Capital Employed' is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus total borrowings {current & non-current}.

OUR COMPETITIVE STRENGTHS

Wide product portfolio

We have developed our product portfolio in various dosage forms that includes Tablets, Capsules, External Preparations (Cream/Gel/Ointment/Lotion), Oral Liquid and Dry Syrup which has enabled us to reach a range of target customers in India and abroad. Our products cater to the major therapeutic areas including Antibacterial, Antitussive, Analgesic, Anticold, Antacid, Antimalarial, Antifungal, Antidiarrheal, AntiAllergy, Antihistaminic with Nutritional supplements, Appetite Enhancer, Antiseptic, Antidepressants, Muscle Relaxants, Anti Acne, Anti Ulcer, Antianxiety etc. During the last three financial years we expanded our revenue from sale of 21 pharmaceutical products to sale of 250 pharmaceutical products. However, our company has received product approval for a wide range of pharmaceutical products. As on date of the Draft Red Herring Prospectus, our company has received product approvals for around 664 pharmaceutical products.

Details of product approvals under various therapeutic categories in specific dosage forms is as under:

Therapeutic category	Tablets	Capsules	Dry Syrup	Oral Liquid	External Preparations
Analgesic	16			48	27
Antacid		24		26	
Anthelmintics	3			4	
Anti acne					4
Anti-allergy	7			22	
Antianginal	1				
Antianxiety	1				
Antibacterial	92	36	66	17	9
Anticholinergic				1	
Antidepressant	2				
Antidiarrheal				9	

Antiemetic				3	
Antifungal		3			44
Antihemorrhage	1				
Antihistamine				8	
Antimalarial	7			2	
Antiplatelet	1				
Antipsychotic	1				
Antiseptic					18
Antispasmodic and anti-foaming agent				2	
Antitussive				84	
Antiulcer				5	
Appetite enhancer				19	
Corticosteroids				1	
Diuretics		1			
Haematinics				2	
Hypertension	3				
Laxative				12	
Muscle relaxant	1				
Nutritional supplements				3	
Pde5 inhibitor	4				
Scabicial & pediculicides					3
Steroid					13
Urinary alkalinizers				4	
UTI				4	
Total approvals	140	64	66	276	118

Details of revenue from various therapeutic category during the Fiscal 2025, 2024 and 2023 are as under:

(₹ In Lakhs)

Therapeutic Category	March 31, 2025		March 31, 2024		March 31, 2023	
	Amount	% of Total Revenue from Operations	Amount	% of Total Revenue from Operations	Amount	% of Total Revenue from Operations
Antibacterial	2352.95	51.37%	2352.49	96.19%	168.49	98.97%
Antitussive	606.12	13.23%	4.38	0.18%	0.00	0.00%
Analgesic	329.17	7.19%	1.32	0.05%	0.00	0.00%
Anticold	219.88	4.80%	0.00	0.00%	0.00	0.00%
Antacid	182.45	3.98%	0.00	0.00%	0.00	0.00%
Antimalarial	172.72	3.77%	71.14	2.91%	0.00	0.00%
Antifungal	113.78	2.48%	0.00	0.00%	0.00	0.00%
Antidiarrheal	68.84	1.50%	0.00	0.00%	0.00	0.00%
Anti-Allergy	62.78	1.37%	6.85	0.28%	0.00	0.00%
Antihistaminic with Nutritional supplements	47.83	1.04%	0.00	0.00%	0.00	0.00%
Anticonvulsants	47.68	1.04%	0.00	0.00%	0.00	0.00%
Others*	375.92	8.20%	4.36	0.39%	1.76	1.03%
Total	4580.12	100%	2440.54	100.00%	170.25	100.00%

*Others include Therapeutic Categories like: Laxative, Appetite Enhancer, Anthelmintics, Antiseptic, Antidepressants, Antiemetic, Alkalizer, Anti Anginal, Muscle Relaxants, Anti Acne, Diuretics, Anti-Ulcer, Lipid Lowering Agent, Antianxiety, Vasodilator, Antiplatelet, Scabicial & Pediculicide, Dental Care, Antidiabetic, Antispasmodic, Melasma Steroid, Antihypertensive, Anticholinergic etc.

This reflects business diversity among our key therapies and enables us to reduce concentration risks in our business, while also propelling business across multiple therapeutic areas. The table below reflects our focus on portfolio expansion and product offerings.

Details of revenue from various dosage forms during the Fiscal 2025, 2024 and 2023 are as under:

(₹ In Lakhs)

Dosage Forms	March 31, 2025		March 31, 2024		March 31, 2023	
	Amount	% of Total Revenue from Operations	Amount	% of Total Revenue from Operations	Amount	% of Total Revenue from Operations
Tablets	1547.92	33.80%	628.40	25.75%	122.45	71.92%
Capsules	1104.47	24.11%	1457.50	59.72%	9.04	5.31%
Dry Syrups	331.73	7.24%	332.35	13.62%	35.32	20.74%
Oral Liquids	1113.85	24.32%	12.07	0.49%	0.00	0.00%
External Preparations	363.78	7.94%	2.08	0.09%	0.00	0.00%
Other Items	118.36	2.58%	8.14	0.33%	3.45	2.02%
Total	4580.12	100.00%	2440.54	100.00%	170.25	100.00%

Well-equipped and regulatory compliant Manufacturing Facility

We operate from our WHO-GMP approved manufacturing facility situated at Bavla, Ahmedabad which is spread across 9,212.63 sq. mtrs. Our manufacturing facility comprises of two separate manufacturing blocks (i) General pharma product manufacturing plant and (ii) Beta Lactum plant.

Our facility is equipped with automated and efficient machinery that enable precise control over production parameters, ensuring consistent quality and efficacy. Our machineries include fluid bed dryer, compression machine, granulator, capsule ejector, air handling unit, packaging machine, capsule filling machine, liquid manufacturing tank, water phase vessel, ointment vacuum pump, visual inspection machine etc that facilitate process like: dispensing, granulation, blending, compression, coating, emulsification, mixing and cooling, filtration, drying, sieving etc where adherence to stringent quality and safety standards is paramount. Each of these processes contribute to our ability to deliver quality products that comply with regulatory standards. Additionally, our facility is equipped with in-house laboratory, a storage facility to store finished goods and raw materials. We have installed capacity to manufacture 3240 lakhs tablets / year, 3216 lakhs Capsules / year, 144 lakhs Oral Liquid Bottles/ year and 86.4 lakhs external preparation tubes/ year and 36 lakhs dry syrup bottles/ year. For details of installed capacity of our facility please see ***“Our Business - Capacity Utilization”*** on page 134.

Also, we have installed 527.200 kw (DC) of solar panels on the rooftop and the parking area so as to power our own operations through renewable energy sources. This will further reduce the carbon footprint by adopting clean energy. Our Manufacturing Facility is subject to regular audit by our client or their external consultants and the regulatory authority of respective jurisdiction.

The beta lactum plant produces beta-lactam and cephalosporins antibiotics such as Cefixime, Amoxicillin, Ampicillin, Cefpodoxime, Cefadroxil & lactic Acid, Cefuroxime, Flucloxacillin, Cloxacillin, Cephalexin etc. in the form of Tablets, Capsule and Dry Syrup. Due to the high risk of cross-contamination, beta-lactam production requires specialized containment and isolation from other drug manufacturing areas. Our dedicated beta lactum plant is therefore focused on manufacturing of anti-bodies in controlled, standalone facility to prevent cross-contamination, ensure worker safety, and meet strict global regulatory standards. The General Pharma product plant makes everyday formulations such as Erythromycin Tablets and Suspension, Omeprazole Capsules, Diclofenac Gel, Dextromethorphan with Phenylephrine and Chlorpheniramine Syrup, Artemether and Lumefantrine Tablets, Ambroxol with Levosalbutamol and Guaiphenesin Syrup, Paracetamol with Ibuprofen Suspension and tablets, Paracetamol with Doclofenac and Caffeine Tablets, Azithromycin Tablets and Suspension, Levocetirizine with Montelukast Syrup and Tables etc. We continually invest in expanding our manufacturing infrastructure.

Our revenue from operations from (i) General Pharma product plant and (ii) Beta Lactum plant in the last three financial year is as under:

(₹ In Lakhs)

Particulars	FY 24-25	%	FY 23-24	%	FY 22-23	%
General Pharma product plant	2759.39	60.25%	91.06	3.73%	0.00	0.00%
Beta Lactum plant	1820.73	39.75%	2349.49	96.27%	170.25	100.00%
Total	4580.12	100.00%	2440.54	100.00%	170.25	100.00%

In-house testing, quality control and quality assurance.

Our Company is committed to maintain the quality standards through quality checks, detailed analysis, and the continuous development of process improvements. Our comprehensive in-house testing facility includes a fully equipped quality control laboratory that conducts assessment of active ingredients, uniformity of weight, dissolution/disintegration studies, pH measurement, viscosity testing, microbial limit tests, and stability studies etc, ensuring adherence to industry benchmarks. We are supported by testing laboratory for process optimization and test our products against the specified industry standards or customer specifications. As on June 30, 2025 our team consists of 146 permanent employees, out of which 25 employees are science graduates or postgraduates ensuring that the quality of our products meets customer requirements and established industry standards along with focus on continuous improvements to our manufacturing processes. Our Testing, Quality Control and Quality Assurance team is also responsible for ensuring the quality of our raw material that we use for our manufacturing of our products. Our laboratory is equipped with 3 high performance liquid chromatography, 2 stability chambers and 1 dissolution machines, 4 BOD Incubator, 1 Polarimeter, 1 Digital Halogen Moisture Analyzer Balance, 1 UV cabinet, 1 Gas Chromatography, 1 Digital Tablet Friability Test Apparatus, Muffle Furnace, Disintegration Apparatus, Microscope, Antibiotic Zone Reader, Centrifuge, PH meter, Conductivity Meter, Hot Air oven etc. Our in-house laboratory and testing capabilities have enabled us to expand our product offerings from 21 commercial products in Fiscal 2023 to 250 commercial products in Fiscal 2025.

Loan license and marketing arrangement with pharmaceutical companies

We also undertake contract manufacturing of pharmaceutical products on a loan license basis, wherein our manufacturing facilities are utilized by third-party companies (loan license holders) who possess the necessary marketing authorizations and market the products under their own brand names. This model enables us to optimize our manufacturing capacities and establish long-term business relationships. In addition to contract manufacturing, we also sell our products to third-party distributors and participants in the pharmaceutical market. Under this arrangement, we sell finished goods on a principal-to-principal model. As on August 15, 2025 we have an outstanding order book of Rs 1848.69 lakhs. Our revenue from operations from contract manufacturing and principal to principal model in the last three financial year is as under:

(₹ In Lakhs)

Particulars	FY 2024-25	% of revenue from operations	FY 23-24	% of revenue from operations	FY 22-23	% of revenue from operations
Principal to Principal Model	3549.79	77.50%	2422.09	99.24%	170.25	100.00%
Contract Manufacturing under Loan License	1030.32	22.50%	18.46	0.76%	0.00	0.00%
Total	4580.12	100.00%	2440.54	100.00%	170.25	100.00%

During the last 3 years we have received repeat orders from about 11 number of customers. We believe that our ability to build and strengthen our relationships with our customers stems from various factors, such as our product quality, our manufacturing capabilities, our track record of compliance, the consistency of our supply and our competitive pricing. Our customer engagements are dependent on us delivering quality products consistently. Our potential customers may require considerable amounts of time to approve us as suppliers to ensure that all their quality controls are met and that we meet all their regulatory requirements across a variety of jurisdictions and multiple regulators.

The following table sets forth the contribution to our revenue from operations from our largest, top five and top 10 customers for the periods indicated:

(₹ In Lakhs)

Particulars	Fiscals 2025		Fiscals 2024		Fiscals 2023	
	Amount	As a % of revenue from operations	Amount	As a % of revenue from operations	Amount	As a % of revenue from operations
Largest Customer	801.17	17.49%	1219.46	49.97%	56.46	33.16%
Top 5 Customers	2636.17	57.56%	1828.30	74.91%	115.67	67.94%
Top 10 Customers	3337.96	72.88%	2135.12	87.49%	141.02	82.83%

Experienced Promoters with domain knowledge

Our Promoters and senior management bring domain expertise and over a decade of experience in the pharmaceutical industry, which has been pivotal to the growth and development of our Company. Our Chairman, Whole-Time Director and Promoter, Chetan Rugnathbhai Matholiya and our Managing Director and Promoter, Jayeshkumar Amarshibhai Sabava both hold the degree of Master of Pharmacy (Pharmaceutics) and have an experience of around 11 years each in the industry. They play a key role in product planning and development and sales and marketing activities of our company. Moreover, our Whole Time Director, CFO and Promoter Akashbhai Mansukhbhai Gangadiya is a Bachelor of Commerce and has around 16 years of experience with 8 years of experience in pharmaceutical industry. Our Promoters have been associated with the Company since incorporation and have played a significant role in shaping and developing the operations of our business. Thus, we are well placed to capitalize the knowledge and experience of our management team which has been instrumental in growth of our Company.

As of June 30, 2025 we have a team of 146 permanent employees including a team of 25 employees who are science graduates and post graduates. We therefore believe that our qualified management and employee base have enabled us to extend our operating capabilities, improve the technical quality of our products and facilitate our growth in the industry. Our management team continues to focus on production, marketing and new growth areas. We believe that the knowledge and experience of our Promoters, along with team of skilled personnel, provides us with a significant competitive advantage, as we seek to expand our production capacities and product portfolio, in our existing as well as new markets.

OUR BUSINESS STRATEGIES

Increasing our manufacturing capacity to focus on the growing demand of our core products:

As on the date of this Draft Red Herring Prospectus, we have one manufacturing facility situated at Bavla, Ahmedabad, Gujarat, for the production of our wide range of pharmaceutical products. We intend to expand our manufacturing operations by purchasing new machineries to increase our production capacity. We intend to purchase Granulation machine, Tablets Compression machine, Packaging machine, Tube filling machine & Lab Instrument and Air handling unit at our existing manufacturing facility which will increase our existing capacity. Currently, the production process is impacted by significant downtime during the cleaning and preparation stages required when switching between formulations. This particularly affects the turnaround time between manufacturing different formulations, as the machinery requires extensive cleaning to avoid cross-contamination. The new machines are expected to significantly reduce such downtime, thereby streamlining batch transitions and improving overall throughput. We propose to utilize the additional capacity for manufacturing a range of existing as well as new pharmaceutical products. We intend to utilize net proceeds to the extent of Rs.608.40 lakhs towards such capital expenditure for procurement of these machineries. For details, please refer to the chapter ***“Objects of the Issue”*** on page 80 of this DRHP.

Expand our existing product portfolio

We have consistently sought to diversify our portfolio of products which could cater to customers across various therapeutic categories and geographies. We have expanded our product offerings from 21 commercial products in Fiscal 2023 to 250 commercial products during Fiscal 2025. While we seek to continue to strengthen our existing product portfolio, we intend to further diversify into products with prospects for increased growth and profitability. We are expanding our operations beyond

India in the international markets of Ghana and Cambodia, where we have received plant registration and in the international markets of Iraq, Dubai and North Sudan where we have applied plant registration.

Expand our geographical reach

As per the Annual Report 2023-24 issued by the Department of Pharmaceuticals, the Indian pharmaceutical industry is the world's third largest by volume and the 14th largest by value. The total annual turnover of pharmaceuticals was 4,17,345 crore for financial year (FY) 2023-24 and has grown at an average of 10.08 percent over the last five years. In FY 2023-24, the total value of pharmaceuticals exported was 2,19,439 crores. India is globally the largest supplier of generic drugs, accounting for about 20 percent of the global supply. It manufactures about 60,000 generic brands, across 60 therapeutic categories *Source: <https://pharma-dept.gov.in/annual-report>*

We have developed relationships with various customers that has helped us expand our product offerings, processes and geographic reach. As of March 31, 2025, our product portfolio was sold to 128 Customers. During the Fiscal 2025, Fiscal 2024 and Fiscal 2023, we derived 42.88%, 21.71% and 97.00% of our revenue from operations in India and 57.12%, 78.29% and 3.00% of our revenue from operations through merchant export. Our Company continues to focus on growing sales to the export market.

The Geographical breakup of our revenue from operations during the last 3 financial years is tabulated below:

(₹ In Lakhs)

Particulars	Fiscals 2025		Fiscals 2024		Fiscals 2023	
	Amount	As a % of revenue from operations	Amount	As a % of revenue from operations	Amount	As a % of revenue from operations
India						
Gujarat	1843.71	40.25%	497.83	20.40%	160.06	94.01%
Haryana	1.26	0.03%	0.00	0.00%	0.00	0.00%
Karnataka	3.59	0.08%	0.00	0.00%	0.00	0.00%
Madhya Pradesh	1.41	0.03%	0.00	0.00%	0.00	0.00%
Maharashtra	102.54	2.24%	31.99	1.31%	5.09	2.99%
Rajasthan	5.05	0.11%	0.00	0.00%	0.00	0.00%
Tamil Nadu	0.67	0.01%	0.00	0.00%	0.00	0.00%
Uttar Pradesh	5.19	0.11%	0.00	0.00%	0.00	0.00%
Uttarakhand	0.47	0.01%	0.00	0.00%	0.00	0.00%
Export through Merchant Exporters	2616.23	57.12%	1910.72	78.29%	5.10	3.00%
Total	4580.12	100.00%	2440.54	100.00%	170.25	100.00%

Our facility received approval from The Food & Drugs Authority, Ghana and Pharmaceutical Manufacturer Registration License from Kingdom of Cambodia. Furthermore, we have applied for approvals/registration of our facility from the regulatory authorities of Dubai, Iraq and North Sudan. Besides, our marketing team is constantly reaching out to new and the existing customers across the globe, for adding new products. Further, with the capacity expansion, we believe our Company will have sufficient space to cater the existing and new orders both domestically and globally in time and with a competitive pricing. Further in order to expand our footprint we have also participated in exhibition like: Pharma Live Expo 2023 which was attended by many global pharmaceutical businesses. We plan to strengthen our market domestically to other Indian states and expand our exports and diversify geographically to mitigate risks. By solidifying our domestic presence and exploring international opportunities, we aim to enhance our market reach and customer accessibility.

Improve cost management and operational efficiencies along with focus on rationalizing our indebtedness.

We plan to enhance our profitability by continuing to improve our cost management and operational efficiencies; by further implementing process efficiency whereby we strive to improve the production process to optimize our processes and achieve higher efficiency. We intend to continue enhancing our operational efficiencies, to increase economies of scale, better absorb

our fixed costs, reduce our other operating costs and strengthen our competitive position. We would focus on improving capacity utilization at our production facilities, through increase in our overall production volumes. We will continue to seek to manage our supply chain costs through optimal inventory levels, economic orders and other measures.

We have entered into various financing arrangements from time to time, with various lenders. The financing arrangements availed by our Company include inter alia term loans and cash credit facilities. For further details, see “**Statement of Financial Indebtedness**” on page 219. As of March 31, 2025, our company was sanctioned secured loan of ₹1124.79 lakhs which had an outstanding balance of Rs 1583.49 lakhs. Set out in the table below is our debt equity ratio and Debt service coverage ratio and RoCE as on March 31, 2025, March 31, 2024, and March 31, 2023.

(₹ In Lakhs)

Particulars	As on		
	March 31, 2025	March 31, 2024	March 31, 2023
Debt equity ratio*	2.02	3.69	3.16
Debt service coverage Ratio**	3.04	1.96	(1.77)
RoCE [#]	23.29%	14.24%	(6.57) %

*Debt equity ratio is calculated as Total Borrowings divided by Shareholder Equity.

** Debt service coverage ratio is calculated as Earning available for Debt Service divided by Interest + Installments

[#]RoCE is calculated as Earnings before interest and taxes (EBIT) divided by Capital Employed. EBIT is calculated as Profit before tax plus interest expense.

Our Company proposes to utilize an estimated amount of ₹900.00lakhs from the net proceeds towards full or partial repayment or pre-payment of certain borrowings availed by our Company. We expect that such repayment/pre-payment will help reduce our outstanding indebtedness and debt servicing costs, in turn improving our margins and also enable utilization of our internal accruals for further investment in our business growth and expansion. Additionally, we anticipate that our improved financial leverage will enhance our ability to raise further resources in the future to fund our potential business development opportunities and plans to grow and expand our business. For further details, see ‘**Objects of the Issue**’ on page 80.

Focus on Quality, Environment, Health and Safety (QEHS)

We believe that maintaining a standard of quality for our products is critical to our continued growth. In our Manufacturing Facility, we have put in place quality check systems that cover areas of our manufacturing process and product delivery, to ensure consistent quality, efficiency and safety of products. Our products go through various quality checks at various stages. Many of our customers and regulatory authorities have audited and approved our manufacturing facility in the past, which ensures our customers regarding the continuance of quality of our facility, processes and product.

We are committed towards quality, environment, health and safety in pursuant of which we have quality certifications such as ISO 9001:2015 and ISO 14001:2015 and WHO- GMP, for our Manufacturing Facility. Further, our facility is equipped with an in-house effluent treatment plant for the treatment of water and evaporator to treat wastewater.

Furthermore, we have obtained membership of third-party waste management companies such as E-Coli Waste Management Private Limited and Maurya Enviro Project Private Limited for waste management and treatment, storage and disposal of waste. We adhere to quality standards as prescribed by our customers to meet the desired requirement; hence we get repetitive orders from our customers. We work to ensure a safe and healthy workplace and therefore, we have installed comprehensive safety equipment like Fire extinguishers. We prioritize the health and safety of our employees and undertake initiatives to promote employee health and their overall well-being by facilitating periodical health check-ups.

OUR PRODUCT PORTFOLIO

1. TABLETS

Tablet is a solid dosage form of medication, commonly used for delivering active pharmaceutical ingredients (API) in a convenient and controlled manner. Tablets can vary in shape, such as round, oval, or square, and are designed to be swallowed, chewed, or dissolved in water. The tablet contains the API, which is the active ingredient that produces the desired therapeutic effect, along with excipients. Excipients are inactive substances that help give the tablet its structure, stability, and control the release of the API.



The revenue from sale of top 10 variants of tablets during the last three financial years are as under:

(₹ In Lakhs)

Product Generic Name	Therapeutic Category	Fiscals 2025		Fiscals 2024		Fiscals 2023	
		Amount	As a % of revenue	Amount	As a % of revenue	Amount	As a % of revenue
Erythromycin Stearate BP 250 mg	Antibacterial	308.86	6.74%	0.00	0.00%	0.00	0.00%
Artemether 80 mg + Lumefantrine 480 mg	Antimalarial	142.65	3.11%	71.12	2.91%	0.00	0.00%
Cefixime dispersible IP 200 mg	Antibacterial	140.86	3.08%	132.03	5.41%	45.59	26.78%
Cefpodoxime dispersible 200 mg	Antibacterial	109.93	2.40%	73.25	3.00%	42.64	25.04%
Azithromycin IP 500 mg	Antibacterial	61.01	1.33%	0.00	0.00%	0.00	0.00%
Cefixime USP 400 mg	Antibacterial	52.29	1.14%	27.45	1.12%	0.00	0.00%
Diclofenac Sodium 50 mg, Paracetamol 325 mg, Caffeine 30 mg	Analgesic	50.57	1.10%	0.00	0.00%	0.00	0.00%
Cefixime 200 mg and Ofloxacin 200 mg	Antibacterial	48.83	1.07%	71.20	2.92%	0.00	0.00%
Cefixime USP 200 mg	Antibacterial	48.09	1.05%	0.00	0.00%	0.00	0.00%
Paracetamol BP 500 mg	Analgesic	44.31	0.97%	0.00	0.00%	0.00	0.00%

2. CAPSULES

A capsule is a solid dosage form used to deliver medication, and it typically consists of a gelatin or similar substance shell that encloses the active pharmaceutical ingredient (API) and excipients. When the capsule reaches the digestive system, the shell dissolves, releasing the medication for absorption.



The revenue from sale of top 10 variants of capsules during the last three financial years is as under:

(₹ In Lakhs)

Product Generic Name	Therapeutic Category	Fiscals 2025		Fiscals 2024		Fiscals 2023	
		Amount	As a % of revenue	Amount	As a % of revenue	Amount	As a % of revenue
Cefixime 400 mg	Antibacterial	338.95	7.40%	667.49	27.35%	0.00	0.00%
Amoxicillin BP 500 mg	Antibacterial	236.09	5.15%	530.99	21.76%	0.00	0.00%
Ampicillin 250 mg & Cloxacillin 250 mg	Antibacterial	145.40	3.17%	172.66	7.07%	0.00	0.00%
Amoxicillin BP 250 mg	Antibacterial	46.18	1.01%	0.00	0.00%	0.00	0.00%
Pregabalin 300 mg	Anticonvulsants	43.90	0.96%	0.00	0.00%	0.00	0.00%
Omeprazole BP 40 mg	Antacid	41.76	0.91%	0.00	0.00%	0.00	0.00%
Nitrofurantoin USP 100 mg	Antibacterial	29.15	0.64%	0.00	0.00%	0.00	0.00%
Pantoprazole 40 mg (EC) & Domperidone 30 mg (SR) IP	Antacid	25.53	0.56%	0.00	0.00%	0.00	0.00%
Flucloxacillin BP 500 mg	Antibacterial	17.07	0.37%	0.00	0.00%	0.00	0.00%
Omeprazole BP 20 mg	Antacid	16.71	0.36%	0.00	0.00%	0.00	0.00%

3. EXTERNAL PREPARATIONS

External preparations refer to medications and treatments that are applied directly to the skin, mucous membranes, or other external surfaces of the body. These formulations are designed to act locally, providing targeted relief or treatment for various conditions without affecting the body systemically. They are commonly used for treating skin conditions, reducing pain and inflammation, protecting wounds, and providing moisture.

Types of External Preparations

- **Ointment:** Ointment are semi-solid preparations with an oily base. They are commonly used for moisturizing, protecting the skin, and delivering active ingredients for conditions like eczema, psoriasis, and burns.
- **Cream:** Cream are semi-solid emulsions that contain both water and oil components. They are lighter than ointments and absorb quickly into the skin. Creams are often used for treating skin infections, rashes, and inflammatory conditions like dermatitis.
- **Gel:** Gel are semi-solid, water-based preparations that provide a jelly-like consistency. They are non-greasy, absorb quickly, and are ideal for conditions where rapid absorption is required.
- **Lotion:** Lotion is a topical preparation meant to be applied to the skin.



The revenue from sale of top 10 variants of external preparation during the last three financial years is as under:

(₹ In Lakhs)

Product Generic Name	Therapeutic Category	Type of External preparation	Fiscals 2025		Fiscals 2024		Fiscals 2023	
			Amount	As a % of revenue	Amount	As a % of revenue	Amount	As a % of revenue
Ketoconazole 2%, Neomycin 0.1%, Iodochlorhydroxyquinoline 1%, Tolnaftate 1% & Clobetasol Propionate 0.05% w/w	Antifungal	Cream	188.67	4.12%	0.00	0.00%	0.00	0.00%
Luliconazole IP 1 % w/w	Antifungal	Cream	15.82	0.35%	0.00	0.00%	0.00	0.00%
Mupirocin IP 2% w/w	Antibacterial	Ointment	15.23	0.33%	0.00	0.00%	0.00	0.00%
Hydrocortisone Acetate BP 1 % w/w	Antifungal	Cream	11.84	0.26%	0.00	0.00%	0.00	0.00%
Diclofenac diethylamine 1.16 Methyl salicylate 10, Linseed oil 3 and menthol 0.5 % w/w	Analgesic	Gel	11.64	0.25%	0.00	0.00%	0.00	0.00%
Clobetasole Propionate 0.05%, Miconazole Nitrate 2%, Neomycin 0.5% w/w	Antifungal	Cream	7.60	0.17%	0.00	0.00%	0.00	0.00%
Choline Salicylate 8.7 % and Lignocaine HCl 2% w/w	Anti-Ulcer	Gel	7.56	0.17%	0.00	0.00%	0.00	0.00%
Diclofenac diethylamine 1.16, Methyl salicylate 10, Linseed oil 3 and menthol 5 % w/w	Analgesic	Gel	6.71	0.15%	0.00	0.00%	0.00	0.00%
Clindamycin 1%, Nicotinamide 4 % gel w/w	Anti Acne	Gel	6.30	0.14%	0.00	0.00%	0.00	0.00%
Diclofenac diethylamine 1.16, Methyl salisylate 10, Linseed oil 3 and menthol 5, Capsaicin 0.025% w/w	Analgesic	Gel	6.19	0.14%	0.00	0.00%	0.00	0.00%

4. ORAL LIQUIDS

Oral liquids are a popular and versatile form of medication that are intended to be taken by mouth. These formulations are particularly beneficial for individuals who have difficulty swallowing solid dosage forms like tablets or capsules. This includes populations such as children, the elderly, and those with certain medical conditions. Oral liquids offer flexibility in dosing, often come in flavored versions to improve taste, and generally provide faster absorption than solid forms.



The revenue from sale of top 10 variants of Oral Liquid during the last three financial years is as under:

(₹ In Lakhs)

Product Generic Name	Therapeutic Category	Fiscals 2025		Fiscals 2024		Fiscals 2023	
		Amount	As a % of revenue	Amount	As a % of revenue	Amount	As a % of revenue
Dextromethorphan Hbr 15mg, Phenylephrine HCL 5mg and Chlorpheniramine Maleate 2mg	Antitussive	337.15	7.36%	0.00	0.00%	0	0.00%
Ambroxol Hcl 30mg, Levosalbutamol 1mg and Guaiphenesin 50mg	Antitussive	108.62	2.37%	0.00	0.00%	0	0.00%
Ibuprofen 100mg and paracetamol 125mg	Analgesic	68.77	1.50%	0.00	0.00%	0	0.00%
Bromhexine Hcl 2mg, Terbutaline Sulphate 1.25mg, Guaiphenesin 50mg & Menthol 0.5mg	Antitussive	48.10	1.05%	0.00	0.00%	0	0.00%
Cyproheptadine 2mg, Vitamin B1 2.5mg, Vitamin B2 2.5mg, Vitamin B6 0.75mg, Niacinamide 22.5mg and D-Panthenol 2.5mg	Antihistaminic with Nutritional supplements	44.86	0.98%	0.00	0.00%	0	0.00%
Levocetirizine 2.5mg and Montelukast 4mg	Anti-Allergy	43.35	0.95%	5.38	0.22%	0	0.00%
Cyproheptadine Hcl 2mg and Tricholine Citrate 275mg	Appetite Enhancer	31.51	0.69%	0.98	0.04%	0	0.00%
Liquid Paraffin 1.25ml, Milk of Magnesia 3.75mg and Sodium Picosulphate 3.3mg	Laxative	30.45	0.66%	0.00	0.00%	0	0.00%
Cetirizine HCL 5mg, Dextromethorphan Hbr 10mg,	Antitussive	29.59	0.65%	0.00	0.00%	0	0.00%

Ambroxol HCL 15mg and Menthol 0.5mg							
Paracetamol Bp 125mg	Analgesic	29.01	0.63%	0.00	0.00%	0	0.00%

5. Dry Syrups

Dry syrup, also known as a reconstituted oral suspension, is a formulation in which the active ingredient is present in powdered form and mixed with water just before use. Dry syrups are particularly useful in pediatric medicine because they allow for more flexible dosing, improved stability, and a longer shelf life compared to liquid syrups. Unlike liquid formulations, dry syrups contain minimal water, which makes them more resistant to microbial growth. It is used in children for the treatment of typhoid fever, urinary tract infections, skin and soft tissue infections and lower respiratory infections etc.



The revenue from sale of top 10 variants of Dry Syrup during the last three financial years is as under:

(₹ In Lakhs)

Product Generic Name	Therapeutic Category	Fiscals 2025		Fiscals 2024		Fiscals 2023	
		Amount	As a % of revenue	Amount	As a % of revenue	Amount	As a % of revenue
Amoxicillin BP 125mg	Antibacterial	104.81	2.29%	95.44	3.91%	2.30	1.35%
Cefixime USP 100mg	Antibacterial	80.18	1.75%	45.70	1.87%	0.00	0.00%
Amoxicillin BP 250mg	Antibacterial	31.57	0.69%	0.00	0.00%	3.09	1.81%
Cefpodoxime Proxetil IP 100mg	Antibacterial	20.56	0.45%	19.27	0.79%	11.29	6.63%
Cephalexin BP 250mg	Antibacterial	15.29	0.33%	3.40	0.14%	0.00	0.00%
Cefpodoxime Proxetil IP 50mg	Antibacterial	14.76	0.32%	10.62	0.44%	6.96	4.09%
Cephalexin BP 125mg	Antibacterial	9.67	0.21%	4.53	0.19%	0.00	0.00%
Cefixime IP 100mg	Antibacterial	9.10	0.20%	5.91	0.24%	3.19	1.88%
Cefixime IP 50mg	Antibacterial	7.69	0.17%	6.98	0.29%	2.31	1.36%
Cefixime USP 200mg	Antibacterial	7.57	0.17%	0.00	0.00%	0.00	0.00%

OUR MANUFACTURING FACILITY


OUR FACTORY



MANUFACTURING PLANT



MANUFACTURING PROCESSES



1. Raw Material Handling

Raw and packaging materials are received and checked against purchase orders. Each lot is quarantined until quality control approves it. Once released, materials are labelled with status tags and recorded in the Batch Manufacturing Record (BMR). This ensures only approved materials are used for production.

2. Dispensing/Weighing

Materials are accurately weighed according to the batch formula in a controlled environment, often under reverse laminar air flow units to prevent contamination. The weights are cross-checked with theoretical requirements, and any deviations are documented. This step ensures the right quantity of each ingredient enters the process.

3. Processing

Each dosage form has a specific method of conversion from raw materials to bulk product. The manufacturing process generally involves a series of steps to ensure uniformity, stability, and quality of the final product.

- **Tablets:** It begins with **granulation (if required)**, where the raw materials are processed to improve flow ability and compressibility. This is followed by **mixing**, in which the active pharmaceutical ingredient (API) and excipients are thoroughly combined to achieve a homogeneous blend. The mixture is then subjected to **drying** to remove excess moisture and ensure the desired consistency. After drying, the material undergoes **blending**, where lubricants and other necessary additives are incorporated. The prepared blend is then fed into a tablet press for **compression**, resulting in tablets of uniform size, shape, and weight. Finally, depending on the product requirements, the tablets may undergo **coating**, which serves purposes such as masking taste, improving appearance, controlling drug release, or providing protection from environmental factors.
- **Capsules:** It begins with the preparation of the blend or the use of ready-mix pellets, where the active pharmaceutical ingredient (API) is either mixed with suitable excipients to form a homogeneous blend or pre-formulated pellets are used. This prepared material is then subjected to capsule filling, where the formulation is accurately dosed and filled into empty hard capsules using specialized filling machines. After filling, the capsules undergo inspection to check for defects such as weight variation, improper sealing, or damaged shells, ensuring only quality capsules proceed for packaging and distribution.
- **External Preparations:** It begins with the **preparation of the oil phase**, where the oil-soluble components are measured and melted, if necessary. In parallel, the **aqueous phase** is prepared by dissolving water-soluble ingredients in purified water under controlled conditions. Both phases are then combined through **mixing or emulsification**, depending on whether an emulsion or homogeneous blend is required. Once the mixture is formed, adjustments are made to the **pH and viscosity** to ensure product stability, skin compatibility, and ease of application. The process concludes with obtaining the **final bulk formulation**, which is then transferred for filling, packaging, and quality testing before release.
- **Oral Liquids:** It usually begins with the **preparation of a sugar base (if required)**, where sugar is dissolved in purified water to form a syrup that enhances taste and viscosity. To this base, **water, active pharmaceutical**

ingredients (APIs), preservatives, and flavors are added under controlled mixing conditions to achieve a uniform solution or suspension. The formulation is then subjected to **pH adjustment** to ensure product stability and compatibility with the active ingredients. After this, the liquid is passed through **filtration** to remove any particulate matter and obtain a clear solution. Finally, the batch is brought to the **desired final volume adjustment** using purified water, ensuring accurate strength and consistency before it proceeds to filling and packaging.

- **Dry Syrups:** It begins with **drying and sieving sugar (if required)** to obtain a fine, uniform powder that serves as the base. This is then **blended with the active pharmaceutical ingredients (APIs) and suitable excipients** to achieve a homogeneous mixture, ensuring uniform distribution of the drug in each dose. Once the blend is ready, it is **filled into bottles** under controlled conditions, after which the containers are sealed, labelled, and packed for distribution. The final product is intended to be reconstituted with water by the patient or pharmacist before administration.

4. In-Process Quality Controls (IPQC)

These checks are carried out at different stages of manufacturing to ensure the product meets the required quality standards before final packaging. The **basic checks** include monitoring **weight or volume** to confirm uniformity in dosage, checking the **appearance** to ensure consistency in color, clarity, and texture, and measuring **pH or viscosity** (as applicable) to verify formulation stability. Additionally, **bulk blend uniformity** is assessed to ensure even distribution of active ingredients, and a proper **reconciliation** of raw materials and intermediates is performed to confirm that there are no discrepancies in quantities used or produced. These checks play a crucial role in maintaining product quality, safety, and compliance with regulatory requirements.

5. Cleaning & Line Clearance

It is an essential step in pharmaceutical manufacturing to ensure product safety and compliance with Good Manufacturing Practices (GMP). Before and after the production of each batch, all **equipment and manufacturing areas are thoroughly cleaned** to eliminate any residues and prevent cross-contamination. Following cleaning, the **Quality Assurance (QA) team performs line clearance**, which involves a systematic check to confirm that no remnants of previous products, raw materials, packaging materials, or labels remain in the area. This step is critical for maintaining batch integrity, avoiding mix-ups, and ensuring that only the correct materials are used in subsequent manufacturing processes.

6. Filling & Packing

It involves transferring the **bulk product into suitable primary containers** such as bottles, tubes, alu-blister packs, alu-alu packs, alu-strip packs, or capsules, depending on the dosage form. During this stage, only **approved printed materials** are used, and care is taken to ensure that each unit is properly **labelled with the correct product information**. After labelling, the products undergo **secondary packaging**, which includes placing them into cartons along with inserts or leaflets that provide usage instructions and regulatory details. This process not only safeguards the **stability and integrity** of the product but also ensures **patient safety, accurate identification, and full compliance with regulatory requirements**.

7. In-Process Quality Assurance (IPQA)

It is a continuous monitoring system implemented during manufacturing to ensure that each stage of production consistently meets defined quality standards. Critical parameters are checked in real time, such as weight variation, hardness of tablets, pH or viscosity of liquids and semisolids, blend uniformity, and fill weight. These checks help identify and correct deviations immediately, preventing potential defects from carrying over into the final product. In addition to these, basic checks are performed, including weight/volume, appearance, pH/viscosity (as applicable), blend uniformity, and reconciliation. By ensuring adherence to these parameters, IPQA plays a vital role in maintaining product quality, patient safety, and regulatory compliance.

8. Quality Control Test

Quality Control (QC) tests are performed to ensure that predefined specifications and regulatory standards are met. These tests verify the identity, purity, potency, and safety of the product before it is released for distribution. Typical QC tests include assessment of active ingredients, uniformity of weight, dissolution/disintegration studies, pH measurement, viscosity testing, microbial limit tests, and stability studies, depending on the dosage form. Packaging components and labelling materials are also examined to confirm compliance with approved standards. QC testing ensures that every batch of product is consistent, safe, effective, and in accordance with Good Manufacturing Practices (GMP) requirements.

9. Release & Dispatch

Once all manufacturing and testing steps are completed including Batch Manufacturing Record (BMR), In-Process Quality Control (IPQC) results, Quality Control (QC) laboratory reports, Line clearance and reconciliation records, the Batch Release Authorization is issued.

CAPACITY AND CAPACITY UTILIZATION

Below are the details of the installed and the utilized capacity of our company:

(Unit in Number-lakhs.)

Category	As at and for the year ended March 31, 2025			As at and for the year ended March 31, 2024			As at and for the year ended March 31, 2023		
	Annual Installed Capacity	Capacity utilized	Capacity utilization (%)	Annual Installed Capacity	Capacity utilized	Capacity utilization (%)	Annual Installed Capacity	Capacity utilized	Capacity utilization (%)
Tablets	3240	1,081.23	33.00%	1080	181.88	17.00%	1080	36.60	3.39%
Capsules	3216	356.39	11.00%	864	507.06	59.00%	864	4.34	0.50%
Dry Syrups	36	13.06	36.00%	36	14.48	40.00%	36	1.68	4.67%
Oral Liquid	144	85.12	59.00%	144	1.26	1.00%	0	-	-
External Preparation	86.4	32.50	38.00%	86.4	0.11	0	0	-	-

As per the certificate dated September 24, 2025 received from Rohitkumar Rakholiya., Chartered Engineers.

INFRASTRUCTURE FACILITIES

Availability of Raw Material

The raw materials we use in our manufacturing process are primarily sourced from third party suppliers in India. Our raw materials include Active Pharmaceutical Ingredients (APIs), Excipients, Flavours & Colours, Coating & Film-Forming Agents, Preservatives, Stabilizers & Solvents etc. During the Fiscal 2025, 2024 and 2023, our purchases from our top 10 suppliers amounted to Rs. 1555.17 Lakhs, Rs. 1452.29 Lakhs and Rs. 236.64 Lakhs representing 38.15 %, 64.66 % and 70.70 % of our total purchases.

Power and fuel - The requirement of power in our manufacturing facility is met through Uttar Gujarat Viji Company Ltd. We use diesel generators to meet exigencies to ensure that our facilities are operational during power failures. In our continued efforts toward sustainability and cost-efficiency, we have installed solar panels at our factory premises, which supplement our power requirements through renewable energy.

Water - Our current water consumption at our manufacturing facility is sourced from borewell.

Collaborations/ Tie Ups/ Joint Ventures

Except as disclosed in this Draft Red Herring Prospectus and normal course of business, we do not have any collaborations/ Ties Ups/Joint Ventures as on date.

Plant & Machinery

Some of the major plant and machinery installed at our manufacturing unit includes: Air handling unit, Air Compressor, water chiller, Electric Evaporator, Dehumidifier, IBR Steam Boiler, Cooling Tower, Static Pass Box, Reverse Laminar Air Flow (RLAF), Effluent Treatment Plant and Sewage treatment plant (ETP & STP), Paste Kettle, Sifter 30" single deck, Multi mill, Rapid Mixer Granulator (RMG), Fluid Bed Dryer (FBD), Tray Dryer, Octagonal Blender, Tablets Compression Machine, Dust Extractor, Conventional coating machine, Tablets inspection belt and Pharma metal detector, Semi-automatic Capsule Filling Machine, Polishing And Dust Extractor Machine, Automatic Capsule Filling Machine, Capsule Vacuum Pump, Damage Capsule Sorter, Empty Capsule Ejector, Strip Packing Machine, Aluminum Strip Packing Machine, Alu-Alu Packing Machine, Aluminum blister machine, Automatic Two Head Air Jet Cleaning Machine, Automatic Dry Syrup Powder Filling & Sealing Machine, Automatic Single Head Screw Capping Machine, induction sealing machine Automatic Self Adhesive Vertical Labelling Machine, Liquid manufacturing plant, Sugar charging system, Auto Four Head Gear Filling Machine, Automatic

Single Head Cap Sealing Cum Screw Capping Machine, Visual Inspection Belt , Ointment manufacturing plant, Automatic Tube Filling Machine, Packing Conveyor Belt, Carton Coding Machine, stripping machine, Batch code printing unit,

Our laboratory is equipped with 3 high performance liquid chromatography, 2 stability chambers and 1 dissolution machines, 4 BOD Incubator, 1 Polarimeter, 1 Digital Halogen Moisture Analyzer Balance, 1 UV cabinet, 1 Gas Chromatography, 1 Digital Tablet Friability Test Apparatus, Muffle Furnace, Disintegration Apparatus, Microscope, Antibiotic Zone Reader, Centrifuge, PH meter, Conductivity Meter, Hot Air oven etc

Sales and Marketing

We sell our products through loan license basis and to third-party distributors and participants in the pharmaceutical market. Under this arrangement, we sell finished goods on a principal-to-principal model. Our products primarily cater to the business-to-business segment. We sell directly to majority of our customers which allows us to understand the specifications of our customers. Our team is responsible for the marketing of our products, negotiating prices, procuring repeat orders and ensuring timely dispatch and deliveries. Our sales team has built relationships with a number of our customers. Our revenue from operations from manufacturing and trading activities in the last three financial year is as under:

(₹ In Lakhs)

Particulars	FY 2024-25	% of Total Revenue	FY 23-24	% of Total Revenue	FY 22-23	% of Total Revenue
Manufacturing	4492.07	98.08%	2439.44	99.96%	170.25	100.00%
Trading	88.05	1.92%	1.10	0.04%	0.00	0.00%
Total	4580.12	100.00%	2440.54	100.00%	170.25	100.00%

Competition

The pharmaceutical market is experiencing a notable surge in competition, fueled by its inherent attractiveness driven by its size, growth prospects, and the sector's critical role in healthcare. As a result, large number of companies, ranging from multinational corporates to agile startups, are entering the business and intensifying competition as each strives to capture a share in the market. Our competition varies by market, therapeutic area and product category, and within each category, upon dosage strengths and drug delivery. We also compete to provide manufacturing services to pharmaceutical companies in the contract manufacturing industry. Our competition includes contract manufacturing companies focusing on a limited number of dosage forms, multiple dosage forms; and large pharmaceutical companies offering third-party manufacturing services to utilize their excess capacity. To stay ahead of our competitors, we regularly upgrade our equipment and technology for our manufacturing facilities. We continuously seek new product registrations, marketing authorizations and other approvals from regulatory authorities to increase our product offerings. Some of the listed companies that manufacture products similar to ours include Sakar Healthcare Ltd and Medico Remedies Ltd etc.

Human Resource:

We have in our team qualified, technical, skilled and unskilled personnel who are abreast with our manufacturing activities. They are committed & dedicated to maintain the specified standard, quality & safety of our products. As on June 30, 2025 we have deployed 146 permanent employees.

For the month of June 2025, our Company has deposited amount of ₹1.95 lakhs with the Employee Provident Fund Organization for its 66 Employees covered under Employees' Provident Fund.

Insurance

Operating our business involves many risks, which, if not insured, could adversely affect our business and results of operations. We maintain insurance coverage that we consider customary in the industry against certain of the operating risks. Our insurance policies include vehicle insurance, Saral Bharat Laghu Udhya Suraksha for our building, plant and machinery, furniture, fixture and fittings and stocks, and Employees Compensation Insurance Policy. We believe that our current level of insurance is adequate for our business and consistent with industry practice, and we have not historically experienced a loss in excess of our policy limits. We may not be able to obtain insurance coverage in the future to cover all risks inherent in our business, or insurance, if available, may be at rates that we do not consider to be commercially reasonable. For further details, kindly refer

the section on “**Risk Factors**” beginning on page 27 of this Draft Red Herring Prospectus. Our insurance coverage may not adequately protect us against all material hazards, which may affect our business, results of operations and financial condition.

Immovable Properties

Details of our immovable property are as below:

Sr. No.	Details of the Property	Actual Use	Owned/Leased
1.	Survey No. 586, Near SKF Bearing, Bavla, Kerala, Bagodra, Kerala, Ahmedabad, Gujarat - 382220	Registered Office and Factory	Owned
2.	Survey No. 231, Near SKF Bearing, Kerala, Bagodra, Bavla, Ahmedabad, Gujarat - 382220		Leased

Intellectual Property Related Approvals

Sr. No.	Trademark	Nature of trademark	Owner*	Registration Number and Date	Class	Present Status
1		Pharmaceutical Preparation	M/s. Rednex Pharmaceuticals	Trademark No. 3642953 and dated September 25, 2017	5	Registered

**The said trademarks are registered in the name of M/s. Rednex Pharmaceuticals and the applications for trademark assignment from the respective trademark owner in the name of the Company has been made.*

KEY INDUSTRY REGULATIONS AND POLICIES

The following description is a summary of certain sector-specific statutes, regulations and policies as prescribed by the Government of India and other regulatory bodies that are applicable to us in order to carry out our business and operations in India. The information detailed below has been obtained from various legislations, including rules and regulations promulgated by regulatory bodies that are available in the public domain. The description set out below is only intended to provide general information to the investors and may not be exhaustive and is neither designed nor intended to substitute for professional legal advice. The statements below are based on the current provisions of Indian law, and remain subject to judicial and administrative interpretations thereof, which are subject to change or modification by subsequent legislative, regulatory, administrative, or judicial decisions. The Company may be required to obtain licenses and approvals depending upon the prevailing laws and regulations as applicable. For details of such approvals, please see the section titled “Government and other Approvals” on page 237.

For the purpose of the business undertaken by our Company, it is required to comply with various laws, statutes, rules, regulations, executive orders, etc. that may be applicable from time to time. The details of such approvals have more particularly been described for your reference in the chapter titled “Government and other Approvals” beginning on page number 237 of this Draft Red Herring Prospectus.

APPLICABLE LAWS AND REGULATIONS

BUSINESS/ TRADE RELATED LAWS AND REGULATIONS

The Factories Act, 1948

The Factories Act, 1948, as amended, defines a “factory” to cover any premises which employs 10 or more workers on any day of the preceding 12 months and in which a manufacturing process is carried on with the aid of power or any premises where at least 20 workers are employed, and where a manufacturing process is carried on without the aid of power. Each state government has enacted rules in respect of the prior submission of plans and their approval for the establishment of factories and registration/licensing thereof. The Factories Act provides for imposition of fines and imprisonment of the manager and occupier of the factory in case of any contravention of the provisions of the Factories Act.

The Environment Protection Act, 1986 and The Environment (Protection) Rules, 1986

The Environmental Protection Act, 1986 is an "umbrella" legislation designed to provide a framework for coordination of the activities of various Central and State authorities established under various laws. The potential scope of the Act is broad, with "environment" defined to include water, air and land and the interrelationships which exist among water, air and land, and human beings and other living creatures such as plants, micro-organisms and property. Further, the Ministry of Environment and Forests looks into Environment Impact Assessment. The Ministry receives proposals for expansion, modernization and setting up of projects and the impact which such projects would have on the environment which is assessed by the Ministry in detail before granting clearances for such proposed projects.

National Environmental Policy, 2006

This Policy seeks to extend the coverage, and fill in gaps that still exist, in light of present knowledge and accumulated experience. This policy was prepared through an intensive process of consultation within the Government and inputs from experts. It does not displace, but builds on the earlier policies. It is a statement of India's commitment to making a positive contribution to international efforts. This is a response to our national commitment to a clean environment, mandated in the Constitution in Articles 48 A and 51 A (g), strengthened by judicial interpretation of Article 21. The dominant theme of this policy is that while conservation of environmental resources is necessary to secure livelihoods and well-being of all, the most secure basis for conservation is to ensure that people dependent on particular resources obtain better livelihoods from the fact of conservation, than from degradation of the resource.

The Water (Prevention and Control of pollution) Act, 1974 (the “Water Act”)

The Water Act aims to prevent and control water pollution as well as restore water quality by establishing and empowering the Central Pollution Control Board and the State Pollution Control Boards. Under the Water Act, any person establishing any

industry, operation or process, any treatment or disposal system, use of any new or altered outlet for the discharge of sewage or new discharge of sewage, must obtain the consent of the relevant State Pollution Control Board, who is empowered to establish standards and conditions that are required to be complied with.

The Air (Prevention and Control of Pollution) Act, 1981 (the “Air Act”)

The Air (Prevention and Control of Pollution) Act, 1981 has been enacted to provide for the prevention, control and abatement of air pollution. Pursuant to the provisions of the Air Act, any person, establishing or operating any industrial plant within an air pollution control area, must obtain the consent of the relevant State Pollution Control Board prior to establishing or operating such industrial plant. No person operating any industrial plant in any air pollution control area is permitted to discharge the emission of any air pollutant in excess of the standards laid down by the State Pollution Control Board.

Hazardous Wastes (Management, Handling and Transboundary Movement) Rules, 2008 (“Hazardous Wastes Rules”)

The Hazardous Wastes Rules impose an obligation on every occupier of an establishment generating hazardous waste to recycle or reprocess or reuse such wastes in a registered recycler or to dispose of such hazardous wastes in an authorized disposal facility. Every person engaged, inter alia, in the generation, processing, treatment, package, storage and destruction of hazardous waste is required to obtain an authorization from the relevant state PCB for collecting, recycling, reprocessing, disposing, storing and treating the hazardous waste.

Drugs and Cosmetics Act, 1940 (the “DCA”) and the Drugs and Cosmetics Rules, 1945 (the “DCA Rules”)

The DCA regulates the import, manufacture, distribution and sale of drugs and cosmetics and prohibits the import, manufacture and sale of certain drugs and cosmetics which are, inter alia, misbranded, adulterated, spurious or harmful. The DCA and DCA Rules specify the requirement of a license for the manufacture or sale of any drug or cosmetic including for the purpose of examination, testing or analysis. It further mandates that every person holding a license must keep and maintain such records, registers and other documents as may be prescribed which may be subject to inspection by the relevant authorities. Any violations of the provisions of the DCA, including those pertaining to the manufacturing and import of spurious drugs, non-disclosure of specified information and a failure to keep the required documents are punishable with a fine, or imprisonment or both. The DCA Rules lay down the functions of the central drugs laboratory established under Section 6 of the DCA. Under the DCA Rules, an import license is required for importing drugs. The form and manner of application for import license has also been provided under the DCA Rules.

Drugs (Control) Act, 1950 (“Drugs Act”)

The Drugs Act controls the sale, supply and distribution of certain drugs notified by the Central Government. The Drugs Act lays down, amongst others, limitations on the maximum quantity of any drug which may be possessed by a dealer or producer, the maximum price at which a drug may be sold, and the maximum quantity which may be sold to any person by a dealer or a producer. Further, the Drugs Act empowers the relevant authorities to prohibit the disposal, or direct the sale, of any specified drug. The Drugs Act prescribes penalties, including fine or imprisonment or both, for the contravention of its provisions.

Uniform Code for Pharmaceutical Marketing Practices, 2024 (“UCPMP Code”)

The UCPMP Code is a mandatory code issued by the Department of Pharmaceuticals, Government of India, relating to promotion and marketing practices for Indian pharmaceutical companies and the medical devices industry. The UCPMP Code is applicable to pharmaceutical companies, medical representatives, agents of pharmaceutical companies such as distributors, wholesalers, retailers, and pharmaceutical manufacturer’s associations. The UCPMP Code mandates that the promotion of a drug must be consistent with the terms of its marketing approval and prohibits offering or providing any gifts, pecuniary advantages, or benefits in kind to healthcare professionals or their family members (both immediate and extended) by pharmaceutical companies or their agents and violations of the UCPMP Code can lead to various actions as per the UCPMP Code.

The Essential Commodities Act, 1955 (the “ECA”)

The ECA empowers the Central Government, to control production, supply and distribution, trade and commerce in certain essential commodities for maintaining or increasing supplies or for securing their equitable distribution and availability at fair

prices or for securing any essential commodity for the defence of India or the efficient conduct of military operations. Using the powers under it, various ministries/departments of the Central Government have issued control orders for regulating production, distribution, quality aspects, movement and prices pertaining to the commodities which are essential and administered by them. The State Governments have also issued various control orders to regulate various aspects of trading in essential commodities such as food grains, edible oils, pulses kerosene, sugar and drugs.

Drugs (Prices Control) Order, 2013 (the “DPCO”)

The DPCO has been notified under the ECA. The first schedule to the DPCO consists of a list of essential medicines or formulations. In relation to these scheduled formulations, the DPCO inter alia prescribes the method for calculating the ceiling price and provides that the Government shall fix and notify the ceiling prices. The DPCO also prescribes the method for calculating the retail price of a new drug in the domestic market for existing manufacturers of scheduled formulations. Further, under the DPCO, the Government has been assigned the task to monitor the production and availability of scheduled formulations and the active pharmaceutical ingredients contained in the scheduled formulation.

National Pharmaceuticals Pricing Policy, 2012 (the “2012 Policy”)

The 2012 policy intends to provide the principles for pricing of essential drugs specified in the National List of Essential Medicines – 2011 declared by the Ministry of Health and Family Welfare, Government of India and modified from time to time (the National List of Essential Medicines – 2022(“NLEM”) was notified on September 13, 2022), in order to ensure the availability of such medicines at reasonable price, while providing sufficient opportunity for innovation and competition to support the growth of the industry. The prices are regulated based on the essential nature of the drugs. Further, the 2012 Policy regulates the price of formulations only, through market-based pricing which is different from the earlier principle of cost-based pricing. Accordingly, the formulations will be priced by fixing a ceiling price and the manufacturers of such drugs will be free to fix any price equal to or below the ceiling price.

The New Drugs and Clinical Trial Rules, 2019 (the “NDC Rules”)

The clinical trials in India are controlled by the Directorate General of Health Services under the Ministry of Health and Family Welfare, Government of India and the NDC Rules lay down the process mechanics and guidelines for clinical trials, including procedure for approval for clinical trials. Clinical trials require obtaining free, informed and written consent from each study subject. The NDC Rules also provide for compensation in case of injury or death caused during clinical trials. The Central Drugs Standard Control Organization has issued the guidance for industry for submission of clinical trial application for evaluating safety and efficacy, for the purpose of submission of clinical trial application as required under the NDC Rules. Further, under the NDC Rules, the ethics committee constituted thereunder is required to register itself with the central licensing authority in order to conduct any clinical trial, bioavailability study or bioequivalence study. The NDC Rules further provide for the composition and functions of the ethics committee and its period of validity. The NDC Rules further mandate the maintenance of records for a period of five years after the completion of the clinical trial, bioavailability study or bioequivalence study, as the case may be.

The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 (the “DMRA”)

The DMRA seeks to control advertisements of drugs in certain cases and prohibits advertisement of remedies that claim to possess magic qualities. In terms of the DMRA, advertisements include any notice, circular, label, wrapper or other document or announcement. It also specifies the ailments for which no advertisement is allowed and prohibits advertisements that misrepresent, make false claims or mislead. Further, the Drugs and Magic Remedies (Objectionable Advertisements) Rules, 1955 have been framed for effective implementation of the provisions of the DMRA.

The Poisons Act, 1919 (the “Poisons Act”)

The Poisons Act restricts the use of poisons, and these include aconite, arsenic, morphine, heroin, essential oils of almonds, oxalic acid, poppies, chloroform, zinc chloride etc. The Poisons Act empowers the Central Government to prohibit the importation into India across any customs frontier defined by the Central Government of any specified poison and enables state governments to grant licenses for the possession, sale, wholesale or retail and fixing of the fee, if any, of poisons. The Poisons Act also enables state governments to regulate the classes of persons to whom such license may be granted, the maximum quantity of poison which may be permitted to be sold to any one person.

The Legal Metrology Act, 2009 (“Legal Metrology Act”) and the Legal Metrology (Packaged Commodities) Rules, 2011 (the “LM Rules”)

The Legal Metrology Act, 2009 came into effect on January 14, 2010 and has repealed and replaced the Standard of Weights and Measures Act, 1976 and the Standards of weights and Measures (Enforcement) Act, 1985. The Legal Metrology Act seeks to establish and enforce standards of weights and measures, regulate trade and commerce in weights, measures and other goods which are sold or distributed by weight, measure or number and for matters incidental thereto. The Legal Metrology Act, inter alia, provides for: (a) approval of model of weight or measure; (b) verification of prescribed weight or measure by Government approved Test Centre; (c) exempting regulation of weight or measure or other goods meant for export; (d) nomination of a Director by a company who will be responsible for complying with the provisions of the enactment; (e) empowering the Central Government to make rules for enforcing the provisions of the enactment; and (f) penalty for offences and compounding of offences. The Legal Metrology (Packaged Commodities) Rules, 2011, were introduced under the Legal Metrology Act, and prescribe requirements as to the pre-packing of any commodity for sale, distribution or delivery.

The Indian Boilers Act, 1923 (the “Boilers Act”) and the Indian Boiler Regulations, 1950 (the “Boilers Regulations”)

The Boilers Act inter alia provides that no owner of a boiler shall use the boiler or permit it to be used unless it has been registered in accordance with the provisions of the Boilers Act. Under the Boilers Act, “boiler” means a pressure vessel in which steam is generated for use external to itself by application of heat which is wholly or partly under pressure when steam is shut off. The Boilers Act also provides for penalties for illegal use of boilers, penalty for breach of rules and other penalties. The Boilers Regulations provide for inter alia, standard requirements with respect to material, construction, safety and testing of boilers.

The Public Liability Insurance Act, 1991 (“PLI Act”) and Public Liability Insurance Rules, 1991 (“PLI Rules”)

The primary objective of the PLI Act is to provide public liability insurance for the purpose of providing immediate relief to the persons affected by an accident occurring while handling any hazardous substance and for matters connected therewith or incidental thereto. The PLI Act imposes a duty on the owner to take out insurance policies before manufacturing, processing, treating, storing, packaging or transporting hazardous substances, for any damage arising out of an accident involving such hazardous substances. Hazardous substances have to be taken the meaning as provided under the Environment Protection Act, 1986, and the list has been further enumerated by the government by way of a notification. The penalty for contravention of the provisions of the PLI Act includes imprisonment or fine or both. Further, the PLI Rules mandate that the owner contributes towards the Environmental Relief Fund a sum equal to the premium paid on the insurance policies.

The Bureau of Indian Standards Act, 2016 (the “BIS Act”)

The BIS Act was notified on March 22, 2016 and came into effect from October 12, 2017. The BIS Act establishes the Bureau of Indian Standards (BIS) as the National Standards Body of India. It has broadened BIS’s ambit and allows the Central Government to make it mandatory for certain notified goods, articles, processes etc. to carry standard marks.

The Bureau of Indian Standards Rules, 2018 (the “Bureau of Indian Standards Rules”).

The Bureau of India Standards Rules, 2018, as amended, have been notified, in supersession of the Bureau of Indian Standards Rules, 1987, in so far as they relate to Chapter IV A of the said rules relating to registration of the articles notified by the Central Government, and in supersession of the Bureau of Indian Standards Rules, 2017 except in relation to things done or omitted to be done before such supersession. Under the Bureau of Indian Standards Rules, the bureau is required to establish Indian standards in relation to any goods, article, process, system or service and shall reaffirm, amend, revise or withdraw Indian standards so established as may be necessary

The Micro, Small and Medium Enterprises Development Act, 2006

In order to promote and enhance the competitiveness of Micro, Small and Medium Enterprise (MSME) the Act was enacted. With effect from April 01, 2025 the Manufacturing enterprises and enterprises rendering Services have been re-classified as Micro enterprise, where the investment in plant and machinery does not exceed Rs.2.5 Crore and annual turnover does not exceed Rs. 10 Crore; Small enterprise, where the investment in plant and machinery does not exceed Rs.25 crore and annual

turnover does not exceed Rs. 100 Crore; a Medium enterprise, where the investment in plant and machinery does not exceed Rs. 125 crore and annual turnover does not exceed Rs. 500 Crore.

LAWS RELATING TO SPECIFIC STATE WHERE ESTABLISHMENT IS SITUATED

Stamp Act in various states

The purpose of the Stamp Act was to streamline and simplify transactions of immovable properties and securities by the State Government. The Stamp Act provides for the imposition of stamp duty at the specified rates on instruments listed in Schedule IA of the Stamp Act. Stamp duty is payable on all instruments/ documents evidencing a transfer or creation or extinguishment of any right, title or interest in immovable property. However, under the Constitution of India, the states are also empowered to prescribe or alter the stamp duty payable on such documents executed within the states. Therefore, the State Government of Gujarat, is empowered to prescribe or alter the stamp duty as per their need.

Professions, Trade, Callings and Employments Act in various states

The professional tax slabs in India are applicable to those citizens of India who are either involved in any profession or trade. The State Government of Gujarat, is empowered with the responsibility of structuring as well as formulating the respective professional tax criteria and is also required to collect funds through professional tax. The professional taxes are charged on the income of individuals, profits of business or gains of vocations. The tax payable under the State Acts by any person earning a salary or wage shall be deducted by his employer from the salary or wages payable to such persons before such salary or wages is paid to him, and such employer shall, irrespective of whether such deduction has been made or not when the salary and wage is paid to such persons, be liable to pay tax on behalf of such persons and employer has to obtain the registration from the assessing authority in the prescribed manner.

TAX RELATED LEGISLATIONS

Income Tax Act, 1961

The IT Act is applicable to every Company, whether domestic or foreign whose income is taxable under the provisions of the IT Act or Rules made thereunder depending upon its Residential Status and Type of Income involved. The IT Act provides for the taxation of persons resident in India on global income and persons not resident in India on income received, accruing or arising in India or deemed to have been received, accrued or arising in India. Every Company which is assessed to income tax under the IT Act is required to comply with the provisions thereof, including those relating to Tax Deduction at Source, Advance Tax, Minimum Alternative Tax and like. Every such Company is also required to file its returns by October 31st of each assessment year.

The Goods and Services Tax Act, 2017

The GST Act levies indirect tax throughout India to replace many taxes levied by the Central and State Governments. The GST Act was applicable from July 1, 2017 and combined the Central Excise Duty, Commercial Tax, Value Added Tax (VAT), Food Tax, Central Sales Tax (CST), Introit, Octroi, Entertainment Tax, Entry Tax, Purchase Tax, Luxury Tax, Advertisement Tax, Service Tax, Customs Duty, Surcharges. GST is levied on all transactions such as sale, transfer, purchase, barter, lease, or import of goods and/or services. India has adopted a dual GST model, meaning that taxation is administered by both the Union and State Governments. Transactions made within a single state are levied with Central GST (CGST) by the Central Government and State GST (SGST) by the government of that state. For inter-state transactions and imported goods or services, an Integrated GST (IGST) is levied by the Central Government. GST is a consumption-based tax; therefore, taxes are paid to the state where the goods or services are consumed and not the state in which they were produced.

EMPLOYMENT AND LABOUR LAWS

Employees' Provident Funds and Miscellaneous Provisions Act, 1952 (EPF Act)

The EPF Act is applicable to an establishment employing more than 20 employees and as notified by the government from time to time. All the establishments under the EPF Act are required to be registered with the appropriate Provident Fund Commissioner. Also, in accordance with the provisions of the EPF Act, the employers are required to contribute to the

employees' provident fund the prescribed percentage of the basic wages, dearness allowances and remaining allowance (if any) payable to the employees. The employee shall also be required to make an equal contribution to the fund. The Central Government under Section 5 of the EPF Act (as mentioned above) frames Employees' Provident Scheme, 1952.

Employees Deposit Linked Insurance Scheme, 1976

The scheme shall be administered by the Central Board constituted under section 5A of the EPF Act. The provisions relating to recovery of damages for default in payment of contribution with the percentage of damages are laid down under Section 8A of the act. The employer falling under the scheme shall send to the Commissioner within fifteen days of the close of each month a return in the prescribed form. The register and other records shall be produced by every employer to Commissioner or other officer so authorized shall be produced for inspection from time to time. The amount received as the employer's contribution and also Central Government's contribution to the insurance fund shall be credited to an account called as "Deposit-Linked Insurance Fund Account."

The Employees' Pension Scheme, 1995

Family pension in relation to this act means the regular monthly amount payable to a person belonging to the family of the member of the Family Pension Fund in the event of his death during the period of reckonable service. The scheme shall apply to all the employees who become a member of the EPF or PF of the factories provided that the age of the employee should not be more than 59 years in order to be eligible for membership under this act. Every employee who is member of EPF or PF has an option of the joining scheme. The employer shall prepare a Family Pension Fund contribution card in respect of the entire employee who is member of the fund.

The Employees' Compensation Act, 1923 (EC Act)

The Employees' Compensation Act, 1923 provides for payment of compensation to injured employees or workmen by certain classes of employers for personal injuries caused due to an accident arising out of and during the course of employment. Under the EC Act, the amount of compensation to be paid depends on the nature and severity of the injury. The EC Act also lays down the duties/obligations of an employer and penalties in cases of non-fulfilment of such obligations. There are separate methods of calculation or estimation of compensation for injury sustained by the employee. The employer is required to submit to the Commissioner for Employees' Compensation a report regarding any fatal or serious bodily injury suffered by an employee within 7 days of death/serious bodily injury.

Payment of Gratuity Act, 1972

The Act shall apply to every factory, mine plantation, port and railway company; to every shop or establishment within the meaning of any law for the time being in force in relation to shops and establishments in a State, in which 10 or more persons are employed, or were employed, on any day of the preceding twelve months; such other establishments or class of establishments, in which 10 or more employees are employed, on any day of the preceding twelve months, as the Central Government, may by notification, specify in this behalf. A shop or establishment to which this Act has become applicable shall be continued to be governed by this Act irrespective of the number of persons falling below ten at any day. The gratuity shall be payable to an employee on termination of his employment after he has rendered continuous service of not less than five years on superannuation or his retirement or resignation or death or disablement due to accident or disease. The five-year period shall be relaxed in case of termination of service due to death or disablement.

Maternity Benefit Act, 1961

The Act provides for leave and right to payment of maternity benefits to women employees in case of confinement or miscarriage etc. The Act is applicable to every establishment which is a factory, mine or plantation including any such establishment belonging to government and to every establishment of equestrian, acrobatic and other performances, to every shop or establishment within the meaning of any law for the time being in force in relation to shops and establishments in a state, in which 10 or more persons are employed, or were employed, on any day of the preceding twelve months; provided that the state government may, with the approval of the Central Government, after giving at least two months' notice shall apply any of the provisions of this Act to establishments or class of establishments, industrial, commercial, agricultural or otherwise.

The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 (the "Act")

In order to curb the rise in sexual harassment of women at workplace, this Act was enacted for prevention and redressal of complaints and for matters connected therewith or incidental thereto. The terms 'sexual harassment' and 'workplace' are both defined in the Act. Every employer should constitute an "Internal Complaints Committee" and every officer and member of the Committee shall hold office for a period of not exceeding three years from the date of nomination. Any aggrieved woman can make a complaint in writing to the Internal Committee in relation to sexual harassment of female at workplace. Every employer has a duty to provide a safe working environment at workplace which shall include safety from the persons coming into contact at the workplace, organising awareness programs and workshops, display of rules relating to the sexual harassment at any conspicuous part of the workplace, provide necessary facilities to the internal or local committee for dealing with the complaint, such other procedural requirements to assess the complaints.

Child Labour (Prohibition and Regulation) Act, 1986 (the "CLPR Act")

The CLPR Act seeks to prohibit the engagement of children in certain occupations and to regulate the conditions of work of children in certain other occupations. Part B of the Schedule to the CLPR Act strictly prohibits employment of children in cloth printing, dyeing and weaving processes and cotton ginning and processing and production of hosiery goods.

EMPLOYMENT AND LABOUR LAWS CODIFICATION

The Code on Wages, 2019

The Code received the assent of the President of India on August 8, 2019. The provisions of the Code shall come into effect from the date notified in the Official Gazette by the Central Government. This code will replace the four existing ancient laws namely (i) the Payment of Wages Act, 1936, (ii) the Minimum Wages Act, 1948, (iii) the Payment of Bonus Act, 1965, and (iv) the Equal Remuneration Act, 1976. This code will apply to all employees and allows the Central Government to set a minimum statutory wage.

Occupational Safety, Health and Working Conditions Code, 2019

The Government of India enacted 'The Occupational Safety, Health and Working Conditions Code, 2020 which received the assent of the President of India on September 28, 2020. The provisions of this code will be brought into force on a date to be notified by the Central Government. It proposes to subsume 13 labour legislations, including the Factories Act, 1948, the Contract Labour (Regulation and Abolition) Act, 1970, the Inter-State Migrant Workmen (Regulation of Employment and Conditions of Service) Act, 1979, that concern our business.

Industrial Relations Code, 2020

The Government of India enacted 'The Industrial Relations Code, 2020' which received the assent of the President of India on September 28, 2020. The provisions of this code will be brought into force on a date to be notified by the Central Government. It proposes to subsume three separate legislations, namely, the Industrial Disputes Act, 1947, the Trade Unions Act, 1926 and the Industrial Employment (Standing Orders) Act, 1946.

Code on Social Security, 2020

The Government of India enacted 'The Code on Social Security, 2020 which received the assent of the President of India on September 28, 2020. The provisions of this code will be brought into force on a date to be notified by the Central Government. It proposes to subsume nine separate legislations including the Employee's Compensation Act, 1923, the Employees' State Insurance Act, 1948, the Employees' Provident Funds and Miscellaneous Provisions Act, 1952, the Maternity Benefit Act, 1961 and the Payment of Gratuity Act, 1972.

INTELLECTUAL PROPERTY LEGISLATIONS

Trade Marks Act, 1999 ("TM Act")

The Trademarks Act, 1999 provides for the application and registration of trademarks in India for granting exclusive rights to marks such as a brand, label and heading and obtaining relief in case of infringement for commercial purposes as a trade description. The TM Act prohibits any registration of deceptively similar trademarks or chemical compounds among others. It also provides for penalties for infringement, falsifying and falsely applying for trademarks.

GENERAL LAWS

Apart from the above list of laws, which is inclusive in nature and not exhaustive, general laws like the following are also applicable to our Company:

The Bharatiya Nyaya Sanhita, 2023 ("BNS")

The Bharatiya Nyaya Sanhita, 2023 consolidates and replaces the Indian Penal Code, 1860 and inter alia provides for the substantive criminal law in India. The Act defines offences, prescribes punishments and sets out liability for individuals and entities. Key provisions cover offences against the State, human body, property, documents and cyber-enabled crimes along with penalties for corporate fraud and misconduct. Compliance with this Act is relevant for entities and their management in the context of criminal liability, fraud prevention and corporate governance.

The Bharatiya Nagarik Suraksha Sanhita, 2023 ("BNSS")

The Bharatiya Nagarik Suraksha Sanhita, 2023 replaces the Code of Criminal Procedure, 1973 and lays down the procedural framework for investigation, trial and adjudication of offences. The Act, inter alia, provides for registration of FIRs, powers of investigation, rights of the accused, trial processes and mechanisms for appeal. It also introduces timelines for filing chargesheets and mandates use of technology in investigation and trial. Compliance with this Act is relevant for entities in relation to criminal proceedings against them or their personnel.

The Bharatiya Sakshya Adhiniyam, 2023 ("BSA")

The Bharatiya Sakshya Adhiniyam, 2023 replaces the Indian Evidence Act, 1872 and governs the admissibility and relevancy of evidence in judicial proceedings. The Act, inter alia, provides for documentary, oral, electronic and digital evidence and prescribes rules for burden of proof, examination of witnesses and evidentiary value of records. Compliance with this Act is relevant for entities in connection with legal proceedings involving documentary and electronic records.

The Negotiable Instruments Act, 1881 ("NI Act")

The Negotiable Instruments Act, 1881 as amended regulates promissory notes, bills of exchange and cheques and defines the rights and obligations of parties thereto. The Act, inter alia, provides for the recognition of negotiable instruments, endorsement, transferability and penalties for dishonour of cheques. It prescribes criminal liability for dishonour of cheques due to insufficiency of funds and enables summary trial procedures. Compliance with this Act is relevant for entities issuing or accepting negotiable instruments in the course of business.

The Consumer Protection Act, 2019 ("CPA")

The Consumer Protection Act, 2019 consolidates provisions relating to consumer rights, protection and dispute redressal. The Act, inter alia, provides for establishment of Consumer Commissions, product liability, unfair trade practices, misleading advertisements and e-commerce rules. It empowers consumers to seek compensation against defective goods or deficient services. Compliance with this Act is relevant for entities engaged in sale of goods or provision of services including through digital platforms.

The Transfer of Property Act, 1882 ("TPA")

The Transfer of Property Act, 1882 as amended regulates the transfer of immovable property in India. The Act, inter alia, provides for sale, mortgage, lease, exchange and gift of property and prescribes the rights and obligations of transferors and transferees. It governs conditions, restrictions and formalities relating to such transfers. Compliance with this Act is relevant for entities involved in acquisition, disposal or development of immovable property.

The Arbitration and Conciliation Act, 1996 ("Arbitration Act")

The Arbitration and Conciliation Act, 1996 as amended provides the legal framework for arbitration, conciliation and related alternative dispute resolution mechanisms in India. The Act, inter alia, provides for recognition and enforcement of arbitration agreements, conduct of arbitral proceedings and enforceability of domestic and foreign awards. It incorporates provisions aligned with UNCITRAL Model Law and prescribes timelines for expeditious disposal. Compliance with this Act is relevant for entities entering into contracts containing arbitration clauses or subject to arbitration proceedings.

The Information Technology Act, 2000 ("IT Act")

The Information Technology Act, 2000 as amended provides the framework for electronic governance, cyber security and regulation of digital transactions. The Act, inter alia, provides legal recognition to electronic records and signatures, prescribes liability for cybercrimes and empowers authorities to regulate intermediaries. Rules framed thereunder including the Information Technology (Reasonable Security Practices and Procedures and Sensitive Personal Data or Information) Rules, 2011 and the Information Technology (Intermediary Guidelines and Digital Media Ethics Code) Rules, 2021 impose obligations on entities processing data and operating digital platforms. Compliance with this Act is relevant for entities engaged in electronic transactions, data handling and online services.

The Companies Act, 2013 ("Companies Act")

The Companies Act, 2013 as amended consolidates and regulates the law relating to companies in India. The Act, inter alia, provides for incorporation, management, governance, audit and winding up of companies and prescribes duties and liabilities of directors and officers. It also sets out requirements relating to disclosure, corporate governance, accounts and investor protection. Compliance with this Act is relevant for all corporate entities, their management and shareholders.

The Sale of Goods Act, 1930 ("SOGA")

The Sale of Goods Act, 1930 as amended regulates contracts relating to sale of goods in India. The Act, inter alia, provides for conditions and warranties in contracts of sale, transfer of ownership, rights and duties of buyer and seller and remedies in case of breach. It governs implied conditions such as title, quality and fitness of goods. Compliance with this Act is relevant for entities engaged in sale or purchase of goods in the ordinary course of business.

The Registration Act, 1908 ("Registration Act")

The Registration Act, 1908 as amended provides for registration of documents relating to immovable property and certain other instruments. The Act, inter alia, prescribes documents compulsorily registrable, procedures for presentation, time limits and effects of non-registration. It ensures public notice of transactions and maintains records affecting property rights. Compliance with this Act is relevant for entities executing property-related documents or transactions.

The Indian Contract Act, 1872 ("Contract Act")

The Indian Contract Act, 1872 as amended governs contracts and agreements enforceable by law in India. The Act, inter alia, provides for the essentials of a valid contract, performance and breach of contracts, contracts relating to indemnity, guarantee, bailment, pledge and agency. It defines the rights and obligations of contracting parties and remedies for breach. Compliance with this Act is relevant for entities entering into commercial agreements in the course of business.

HISTORY AND CORPORATE STRUCTURE

Brief History and Background of our Company

Our Company was originally incorporated as a Private Limited Company under the name “Rednex Pharmaceuticals Private Limited” on December 29, 2020 under the provisions of the Companies Act, 2013 with the Registrar of Companies, Ahmedabad bearing CIN: U24304GJ2020PTC119176. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extraordinary General Meeting, held on December 30, 2024 and consequently, the name of our Company was changed from “Rednex Pharmaceuticals Private Limited” to “Rednex Pharmaceuticals Limited” vide a fresh certificate of incorporation dated January 21, 2025 issued by the Registrar of Companies, Central Processing Centre bearing CIN: U24304GJ2020PLC119176.

Chetan Rugnathbhai Matholiya, Jayeshkumar Amarshibhai Sabava and Akashbhai Mansukhbhai Gangadiya were the initial subscribers to the Memorandum of Association of our Company.

Address of the Registered Office and Factory:

Registered Office and Factory	Survey No. 586 and 231, Near SKF Bearing, Bavla Bagodara N.H 8A, Kerala, Taluka: Bavla, Ahmedabad, Gujarat, India, 382220

Changes in the Registered Office of the Company since incorporation:

Except as disclosed below, there has not been any change in our Registered Office since inception of the Company till the date of the Draft Red Herring Prospectus.

Effective Date	From	To	Reason for Change
June 30, 2022	Survey No 221 And 231, NR SKF Bearing Bavla Bagodara N.H. 8A, Kerala, Bavla Ahmedabad Gujarat- 382220	Survey No. 586 and 231, Near SKF Bearing, Bavla Bagodara N.H 8A, Kerala, Taluka: Bavla, Ahmedabad, Gujarat, India, 382220	For Operational Reasons

Main Objects of our Company as per the Memorandum of Association:

The main object of our Company, as set forth in our Memorandum of Association, is as follows:

To manufacture, formulate, process, develop, refine, import, export, wholesale and/or retail trade all kinds of pharmaceuticals, antibiotics, drugs, medicines, biologicals, nutraceuticals, healthcare, ayurvedic and dietary supplement products, medicinal preparations, vaccines, chemicals, chemical products, dry salters, mineral waters, wines, cordials, liquors, soups, broths and other restoratives or foods and also to deal in medicinal goods such as surgical instruments, contraceptives, photographic goods, oils, perfumes, cosmetics, patent medicines, soaps, artificial limbs, hospital requisites, proprietary medicines, veterinary medicines and tinctures extracts and to carry on the business of vialling, bottling, repacking, processing of tablets, capsules, syrups, injections, ointments, etc. and also to carry on the business of chemists, druggists, buyers, sellers, agents, distributors and stockists of all kinds of pharmaceuticals and allied products.

Amendments to the Memorandum of Association

Set out below are the amendments that have been made to our Memorandum of Association, since inception of the Company till the date of the Draft Red Herring Prospectus.

Date of Meeting	Type of Meeting	Nature of Amendments
August 04, 2022	EGM	Clause V of the Memorandum of Association was amended to reflect increase in the authorized share capital of the Company from ₹10.00 Lakh divided into 100,000 Equity Shares of face value of ₹10/- each to ₹425.00 Lakhs divided into 42,50,000 Equity Shares of face value of ₹10/- each.

Date of Meeting	Type of Meeting	Nature of Amendments
December 30, 2024	EGM	Conversion of our Company from Private Limited to Public Limited Company. Consequently, name of the Company has been changed from “Rednex Pharmaceuticals Private Limited to “Rednex Pharmaceuticals Limited” and fresh Certificate of Incorporation consequent upon conversion to Public Limited Company issued dated January 21, 2025 bearing CIN: U24304GJ2020PLC119176 was issued by Registrar of Companies, Central Processing Centre.
September 05, 2025	AGM	Clause V of the Memorandum of Association was amended to reflect increase in the authorized share capital of the Company from 425.00 Lakh divided into 42,50,000 Equity Shares of face value of ₹10/- each to ₹1100.00 Lakhs divided into 1,10,00,000 Equity Shares of face value of ₹10/- each.

Major events and milestones of our Company:

The Table below sets forth some of the major events in the history of our Company:

Year	Key Events/ Milestone/ Achievements
2020	Incorporated in 2020 as Rednex Pharmaceuticals Private Limited
2022	Received approvals from FDCA for Beta Lactum Plant
2023	Accredited with ISO 9001:2015 for Quality Management System
2023	Received World Health Organization- Good Manufacturing Practices certificate for Beta Lactum Plant
2024	Received approvals from FDCA for General Plant
2024	Received FDA GMP Certificate from Republic of Ghana
2024	Received Pharmaceutical Manufacturer Registration License from Kingdom of Cambodia Beta Lactum
2025	Received World Health Organization- Good Manufacturing Practices certificate for General Pharma Plant
2025	Accredited with ISO 14001:2015 for Environment Management System

Other details about our Company:

For details regarding the description of our Company’s activities, products, market, growth, awards & recognitions, capacity, locations, technology, marketing strategy, competition and our customers, managerial competence, standing with reference to prominent competitors, launch of key products, entry in new geographies or exit from existing markets, major distributors and customers, segment, marketing and competition, please refer to the chapters titled **“Our Business”**, **“Management’s Discussion and Analysis of Financial Conditions and Results of Operations”** and **“Basis for Issue Price”** on pages 118, 223 and 90 respectively of this Draft Red Herring Prospectus. For details of our management and managerial competence and for details of shareholding of our Promoters, please refer to sections titled **“Our Management”** and **“Capital Structure”** beginning on page 150 and 68 of this Draft Red Herring Prospectus respectively.

Changes in activities of our Company during the last five (5) Years:

There has not been any change in the activity of our Company during the last five (5) years preceding the date of this Draft Red Herring Prospectus.

Our Holding Company:

As on the date of the Draft Red Herring Prospectus, our Company is not a subsidiary of any company.

Our Subsidiaries:

As on the date of this Draft Red Herring Prospectus, our Company has no Subsidiary Company.

Our Associates and Joint Ventures:

As on the date of this Draft Red Herring Prospectus, our Company does not have any Associate Company and Joint Ventures.

Joint Ventures:

As on date of this Draft Red Herring Prospectus our Company does not have any joint ventures.

Details regarding material acquisitions or divestments of business/ undertakings, mergers, amalgamation, any revaluation of assets, etc.:

Our Company has not made any material acquisitions or divestments of business/ undertakings mergers, amalgamation, any revaluation of assets, etc. in the last 10 years preceding the date of this Draft Red Herring Prospectus.

Injunction or Restraining Order:

Except as disclosed in the section titled “*Outstanding Litigation and Material Developments*” beginning on page 233 of this Draft Red Herring Prospectus, there are no injunctions/restraining orders that have been passed against our Company.

Capacity/ Facility Creation, Location of Plants:

For details pertaining to capacity/ facility creation, location of plant refer section “*Our Business*” on page 118 of this Draft Red Herring Prospectus.

Details of launch of key products, entry in new geographies or exit from existing markets:

For details pertaining to launch of key services, entry in new geographies or exit from existing markets, please refer chapter titled “*Our Business*” on page 118 of this Draft Red Herring Prospectus.

Number of shareholders of our Company:

Our Company has Seven (7) shareholders as on the date of this Draft Red Herring Prospectus. For further details on the shareholding pattern of our Company, please refer to the chapter titled “Capital Structure” beginning on page 68 of the Draft Red Herring Prospectus.

Changes in the Management:

For details of change in Management, please see chapter titled “*Our Management*” on page 150 of the Draft Red Herring Prospectus.

Agreement with key managerial personnel or Directors or Promoters or Senior Management or any other employee of the Company:

There are no agreements entered into by key managerial personnel or Directors or Promoters or any other employee, either by themselves or on behalf of any other person, with any shareholder or any other third party with regard to compensation or profit sharing in connection with dealings in the securities of the Company.

Significant Strategic or Financial Partners:

Except as disclosed in this Draft Red Herring Prospectus, Our Company does not have any strategic or financial partners as on the date of this Draft Red Herring Prospectus.

Time and Cost Overruns in Setting up Projects:

There have been no time or cost overruns due to reasons attributable to our Company in our operations.

Defaults or Rescheduling of Borrowings with Financial Institutions/ Banks:

There have been no defaults or rescheduling of borrowings with any financial institutions/ banks as on the date of the Draft Red Herring Prospectus.

Other Agreements:**(i) Non-Compete Agreement:**

Our Company has not entered into any Joint Venture Agreement as on the date of filing of this Draft Red Herring Prospectus.

(ii) Joint Venture Agreement:

Our Company has not entered into any Joint Venture Agreement as on the date of filing of this Draft Red Herring Prospectus

(iii) Shareholders Agreements:

There are no subsisting shareholder's agreements among our shareholders in relation to our Company, to which our Company is a party or otherwise has notice of the same as on the date of the Draft Red Herring Prospectus.

(iv) Collaboration Agreements:

As on date of this Draft Red Herring Prospectus, Our Company is not a party to any collaboration agreements.

(v) Other Material Agreement:

Our Company has not entered into any other subsisting material agreements other than in the ordinary course of business of our Company, as on the date of this Draft Red Herring Prospectus.

OUR MANAGEMENT

Board of Directors:

As of the date of this Draft Red Herring Prospectus, we have 6 (Six) Directors on our Board, which includes 1 (One) Managing Director, 2 (Two) Whole Time Director, 1 (One) Non-Executive Director, and 2 (Two) Independent Directors, out of which, Board of Directors comprises of 1 (One) woman director. The present composition of our Board and its committees is in accordance with the corporate governance requirements prescribed under the Companies Act and the SEBI Listing Regulations.

The following table sets forth the details regarding the Board of Directors of our Company as on the date of filing of this Draft Red Herring Prospectus:

Name, Designation, DIN, Date of Birth Age, Address, Occupation, Qualification, Current Term, Date of Appointment	Other Directorships
Chetan Rugnathbhai Matholiya Designation: Chairman & Whole-Time Director Age: 34 years Date of Birth: April 13, 1991 Address: L-201, Aarohi Elegance, Gala Gymkhana Road, Near Aarohi Crest, South Bopal, Bopal, Ahmedabad- 380058, Gujarat Experience: 11 years Occupation: Business Qualification: Master of Pharmacy (Pharmaceutics) Current Term: For a period of 3 consecutive years w.e.f August 14, 2025, liable to retire by rotation Period of Directorship: Since December 29, 2020 DIN: 09013701	Nil
Jayeshkumar Amarshibhai Sabava Designation: Managing Director Age: 35 years Date of Birth: February 05, 1990 Address: L-104, Aarohi Elegance, Gala Gymkhana Road, Near Aarohi Crest, South Bopal, Bopal, Ahmedabad-380058 Gujarat Experience: 11 years Occupation: Business Qualification: Master of Pharmacy (Pharmaceutics) Current Term: For a period of 3 consecutive years w.e.f August 14, 2025, not liable to retire by rotation	Nil

Name, Designation, DIN, Date of Birth Age, Address, Occupation, Qualification, Current Term, Date of Appointment	Other Directorships
Period of Directorship: Since December 29, 2020 DIN: 09013702	
Akashbhai Mansukhbhai Gangadiya Designation: Whole Time Director and CFO Age: 36 years Date of Birth: July 25, 1989 Address: 92, Satsang park, Ratanpura, NR Hariom Bungalows, Vastral, Ahmedabad-382418 Gujarat Experience: 16 years Occupation: Business Qualification: B.com Current Term: For a period of 3 consecutive years w.e.f August 14, 2025, liable to retire by rotation Period of Directorship: Since December 29, 2020 DIN: 09013700	Companies: Lalko Minerals Private Limited
Narendrabhai Dineshbhai Khambhaliya Designation: Non-Executive Director Age: 35 years Date of Birth: January 23, 1990 Address: 1612, Smashan Pase, Chotalal na jin pase, Lathidad, Botad- 364710, Gujarat Experience: 07 years Occupation: Service Qualification: Higher Secondary School Graduate Current Term: w.e.f September 01, 2025, liable to retire by rotation DIN: 11259442	Nil
Rashmi Krunal Lakhani Designation: Independent Director Age: 33 years Date of Birth: August 22, 1992	Nil

Name, Designation, DIN, Date of Birth Age, Address, Occupation, Qualification, Current Term, Date of Appointment	Other Directorships
Address: 39/4, Patel Park Society, Behind Pancham Maill, Nikol Gam Road, Nikol, Ahmedabad- 382350, Gujarat Experience: 6 years Occupation: Service Qualification: Company Secretary Current Term: For a period of 5 consecutive years w.e.f September 01, 2025 DIN: 11259501	
Kashyap Naranbhai Thummar Designation: Independent Director Age: 37 years Date of Birth: October 14, 1987 Address: Flat No. 22, GTU Staff Quarter, GTU Campus, Visat Gandhinagar Highway, Gujarat Technological University, Ahmedabad, Gujarat- 382424 Experience: 14 years Occupation: Service Qualification: Doctor of philosophy (Pharmacy) Current Term: For a period of 5 consecutive years w.e.f September 16, 2025 DIN: 11297561	Nil

Brief Profile of Directors:

1. **Chetan Rugnathbhai Matholiya** aged 34 years is the Chairman, Whole- Time Director and Promoter of our Company. He has an overall experience of around 11 years in the pharmaceutical industry. He holds degree of Master of Pharmacy (Pharmaceutics) from Saurashtra University. He also served as a Pharmacist under the National Rural Health Mission (NRHM) in 2014. He currently looks into purchase, marketing and regulatory activities along with overall business development of the company.
2. **Jayeshkumar Amarshibhai Sabava** aged 35 years is the Managing Director and Promoter of our Company. He has an overall experience of around 11 years in the pharmaceutical industry. He holds degree of Master of Pharmacy (Pharmaceutics) from Gujarat Technological University. He also served as a Pharmacist under the National Rural Health Mission (NRHM) in 2014. He has been instrumental in the development of our product portfolio. He has since inception focused on product planning and development and has been actively involved in the product development activities along with a focus on quality assurance.
3. **Akashbhai Mansukhbhai Gangadiya** aged 36 years is the Whole-Time Director and Chief Financial Officer of our Company. He has an overall experience of 16 years with 8 years of experience in the pharmaceutical industry. He has completed B.com from G.B. Shah Commerce College, in the year 2009. He looks in the day-to-day operations in the plant and financial activities of the Company.

4. **Narendrabhai Dineshbhai Khambhaliya** aged 35 years is the Non-Executive Director of the Company. He has an overall work experience of 7 years. He has completed his higher secondary school from Gujarat Secondary and Higher Secondary Education Board, Gandhinagar, in the year 2007. He looks after banking activities of the company.
5. **Rashmi Krunal Lakhani** aged 33 years is the Independent Director of the Company. She is a qualified Company Secretary with an overall work experience of around 6 years. He was appointed on the board of our company since September 01, 2025.
6. **Kashyap Naranbhai Thummar** aged 37 years is the Independent Director of the Company. He holds the degree of Doctor of Philosophy (Pharmacy) from Saurashtra University. He has an overall experience of 14 years in the field of Pharmacy. He is the author of the book Determination of Adulteration of Anti-obesity Drug in Herbal medicinal Products. He is involved in various research and development activities in the pharmaceutical sector. He is currently working as Assistant Professor in Gujarat Technological University.

Confirmations:

As on the date of this Draft Red Herring Prospectus:

- a) None of our Directors are or were a director of any listed company during the last five years preceding the date of this Draft Red Herring Prospectus, whose shares have been or were suspended from being traded on the BSE or the NSE, during the term of their directorship in such company.
- b) None of our Directors are or were a director of any listed company which has been or was delisted from any stock exchange during the tenure of their directorship in such company.
- c) None of our Directors are categorized as a wilful defaulter or a fraudulent borrower, as defined under Regulation 2(1)(III) of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018.
- d) None of our Directors is declared a fugitive economic offender under section 12 of the Fugitive Economic Offenders Act, 2018.

Nature of any family relationship between our Directors

The following Directors of the Company are related to each other within the meaning of Section 2 (77) of the Companies Act, 2013. Details of which are as follows:

Sr. No.	Name of the Director	Relationship with other Directors
1.	Narendrakumar Dineshbhai Khambhaliya	Spouse's Brother of Jayeshkumar Amarshibhai Sabava

Arrangements with major Shareholders, Customers, Suppliers or Others:

We have not entered into any arrangement or understanding with our major shareholders, customers, suppliers or others, pursuant to which any of our Directors were selected as Directors or members of the senior management.

Service Contracts:

The Directors of our Company have not entered into any service contracts with our company which provides for benefits upon termination of their employment.

Details of Borrowing Powers of Directors:

Pursuant to a special resolution passed at an Extraordinary General Meeting of our Company held on August 14, 2025 and pursuant to provisions of Section 180(1)(c) and other applicable provisions, if any, of the Companies Act, 2013 and rules made thereunder, the Board of Directors of the Company have been authorized to borrow monies from time to time, any sum or sums of money on such security and on such terms and conditions as the Board may deem fit, notwithstanding that the money to be borrowed together with the money already borrowed by our Company may exceed in the aggregate, its paid up capital and free

reserves and security premium (apart from temporary loans obtained/ to be obtained from bankers in the ordinary course of business), provided that the outstanding principal amount of such borrowing at any point of time shall not exceed in the aggregate of ₹ 100/- crores (Indian Rupees one-hundred crores Only).

Compensation of our Directors:

The compensation payable to our Managing Director, Whole-time Directors and Non-Executive Director will be governed as per the terms of their appointment and shall be subject to the provisions of Sections 2(54), 188, 196, 197, 198 and 203 and any other applicable provisions, if any of the Companies Act, 2013 read with Schedule V thereto and the rules made there under.

The following compensation has been approved for:

a) Managing Director & Whole-time Director:

Particulars	Chetan Rugnathbhai Matholiya	Jayeshkumar Amarshibhai Sabava	Akashbhai Mansukhbhai Gangadiya
Appointment/ Change in Designation	Appointed as Director w.e.f December 29, 2020 and re-designated as Chairman and Whole-time Director w.e.f August 14, 2025	Appointed as Director w.e.f December 29, 2020 and re-designated as Managing Director w.e.f August 14, 2025	Appointed as Director w.e.f December 29, 2020 and re-designated as Whole-time Director and CFO w.e.f August 14, 2025
Current Designation	Chairman & Whole-Time Director	Managing Director	Whole Time Director and CFO
Terms of Appointment	3 years Liable to Retire by rotation	3 years Not liable to Retire by rotation	3 years Liable to Retire by rotation
Remuneration & Perquisites	Upto ₹60,00,000/- (Rupees sixty- lakhs only) per annum along with other perquisites, benefits, incentives and allowances	Upto ₹60,00,000/- (Rupees sixty- lakhs only) per annum along with other perquisites, benefits, incentives and allowances	Upto ₹60,00,000/- (Rupees sixty- lakhs only) per annum along with other perquisites, benefits, incentives and allowances
Compensation paid in the FY 2024-2025	Rs. 3,46,600/-	Rs. 3,46,600/-	Rs. 1,00,200/-

Bonus or Profit-Sharing Plan for our Directors:

We have no bonus or profit-sharing plan for our Directors.

Sitting Fees:

Pursuant to the provision of section 197(5) of the Companies Act, 2013 read with the rule 4 of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the remuneration payable in terms of sitting fees to the Directors (including Independent Directors) of the Company, such sum as may be decided by the Board of Directors which shall not exceed ₹1,00,000/- (Rupees One Lakh Only) per meeting of the Board or Committee thereof.

Shareholding of our Directors as on the date of this Draft Red Herring Prospectus:

Sr. No.	Name of the Director	No. of Shares Held	Holding in %
1.	Chetan Rugnathbhai Matholiya	25,49,736	33.33%
2.	Jayeshkumar Amarshibhai Sabava	25,50,492	33.34%
3.	Akashbhai Mansukhbhai Gangadiya	25,49,736	33.33%
	Total	76,49,964	100.00%

None of the Independent Directors of the Company holds any Equity Shares of Company as on the date of this Draft Red Herring Prospectus.

As on the date of the filing of this Draft Red Herring Prospectus, we do not have any Subsidiary Company as defined under Section 2(6) of the Companies Act, 2013.

Our Articles of Association do not require our Directors to hold any qualification Equity Shares in the Company.

INTEREST OF DIRECTORS

All the Directors may be deemed to be interested to the extent of remuneration and reimbursement of expenses payable to them under the Articles, and to the extent of remuneration paid to them for services rendered as an officer or employee of the Company. For further details, please refer to Chapter titled ***“Our Management”*** beginning on page 150 of this Draft Red Herring Prospectus.

Our directors may also be regarded as interested to the extent of their shareholding and dividend payable thereon, if any, and to the extent of Equity Shares, if any held by them in our Company or held by their relatives. Further our directors are also interested to the extent of unsecured loans or advances, if any, given by them to our Company or by their relatives or by the companies/ firms in which they are interested as Directors/ Members/ Partners. Further our directors are also interested to the extent of loans or advances, if any, taken by them or their relatives or taken by the companies/ firms in which they are interested as Directors/ Members/ Partners.

Except as stated otherwise in this Draft Red Herring Prospectus, our Company has not entered into any Contract, Agreements or Arrangements during the preceding two years from the date of the Draft Red Herring Prospectus in which the Directors are interested directly or indirectly and no payments have been made to them in respect of the contracts, agreements or arrangements which are proposed to be entered into with them.

Except as stated in this section ***“Our Management”*** or the section titled ***“Financial information of the Company –Note 29 - Related Party Disclosure”*** beginning on page 150 and 211 respectively of this Draft Red Herring Prospectus, and except to the extent of shareholding in our Company, our Directors do not have any other interest in our business.

Interest in the property of Our Company:

The registered office and factory of the Company situated at Survey No. 231, Near SKF Bearing, Kerala, Bagodra, Bavla, Ahmedabad, Gujarat – 382220 is acquired on lease vide Leave and License Agreement dated August 18, 2022 from M/s. Rednex Pharmaceuticals, a Partnership firm, where our Promoters Chetan Rugnathbhai Matholiya, Jayeshkumar Amarshibhai Sabava and Akashbhai Mansukhbhai Gangadiya are interested as partners.

Except as mentioned above and in this Draft Red Herring Prospectus our directors do not have any interest in any property acquired by our Company during the period of two years before filing of this Draft Red Herring Prospectus or proposed to be acquired by us as on date of this Draft Red Herring Prospectus.


Changes in Board of Directors in Last 3 Years:

Sr. No.	Name of Directors	Date of Event	Nature of Event	Reasons for Change
1	Chetan Rugnathbhai Matholiya	August 14, 2025	Re-designated as Chairman and Whole- Time Director	To ensure better Corporate Governance
2	Jayeshkumar Amarshibhai Sabava	August 14, 2025	Re-designated as Managing Director	
3	Akashbhai Mansukhbhai Gangadiya	August 14, 2025	Re-designated as Whole-Time Director and CFO	
4	Narendrabhai Dineshbhai Khambhaliya	September 01, 2025	Appointed as an additional Non-Executive Director	
		September 05, 2025	Regularized as Non-Executive Director	

5	Rashmi Krunal Lakhani	September 01, 2025	Appointed as an Additional Independent Director	
		September 05, 2025	Regularized as Independent Director	
6	Kashyap Naranbhai Thummar	September 16, 2025	Appointed as an Additional Independent Director	
		September 26, 2025	Regularized as Independent Director	

MANAGEMENT ORGANISATION STRUCTURE

The following chart depicts our Management Organization Structure:



COMPLIANCE WITH CORPORATE GOVERNANCE

In addition to the applicable provisions of the Companies Act, 2013, provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and SEBI (ICDR) Regulations, 2018 in respect of corporate governance will be applicable to our Company immediately upon the listing of our Company's Equity Shares on Stock Exchanges. The requirements pertaining to constitution of the committees such as the Audit Committee, Stakeholders Relationship Committee, Nomination and Remuneration Committees and Corporate Social Responsibility Committee have been complied with. Our Board undertakes to take all necessary steps to continue to comply with all the requirements of Listing Regulations and the Companies Act, 2013.

Our Board has been constituted in compliance with the Companies Act, 2013 and in accordance with the best practices in corporate governance. Our Board functions either as a full board or through various committees constituted to oversee specific operational areas. The executive management provides our Board detailed reports on its performance periodically.

Our Board of Directors consist of six (6) Directors of which two (2) are Independent Directors one of whom is a women director on the Board. The constitution of our Board is in compliance with the provisions of section 149 of the Companies Act, 2013.

Our Company has constituted the following committees:

1. Audit Committee

Our Company at its Board Meeting held on September 16, 2025 has approved the constitution of an Audit Committee ("*Audit Committee*") in compliance with the provisions of the Section 177 of the Companies Act, 2013 read with rule 6 of the

companies (Meeting of board and its power) rules, 2014 and Regulation 18 of SEBI Listing Regulations. The Audit Committee comprises following members:

Name of the Director	Status in Committee	Nature of Directorship
Kashyap Naranbhai Thummar	Chairman	Independent Director
Rashmi Krunal Lakhani	Member	Independent Director
Jayeshkumar Amarshibhai Sabava	Member	Managing Director

The Company Secretary of the Company shall act as a Secretary to the Audit Committee. The Chairman of the Audit Committee shall attend the Annual General Meeting of the Company to furnish clarifications to the shareholders on any matter relating to accounts. The scope and function of the Audit Committee and its terms of reference shall include the following:

A. Tenure of the Committee:

The Audit Committee shall continue to be in function as a committee of the Board until otherwise resolved by the Board, to carry out the functions of the Audit Committee as approved by the Board.

B. Meetings of the Committee:

The committee shall meet at least four times in a year and not more than one hundred and twenty days shall elapse between any two meetings. The quorum for the meeting shall be either two members or one third of the members of the committee, whichever is higher but there shall be presence of two Independent Directors at each meeting.

C. Power of the Committee:

The Audit Committee shall have powers, including the following:

- to investigate any activity within its terms of reference;
- to seek information from any employee;
- to obtain outside legal or other professional advice;
- to secure attendance of outsiders with relevant expertise, if it considers necessary as may be prescribed under the Companies Act, 2013 (together with the rules thereunder) and SEBI Listing Regulations; and
- To have full access to information contained in records of Company.

D. Role of the Committee:

The Role of Audit Committee together with its powers as per Part C of Schedule II of SEBI Listing Regulation and Companies Act, 2013 shall be as under:

The role of the Audit Committee shall include the following:

- Overseeing the Company's financial reporting process and disclosure of its financial information to ensure that its financial statements are correct, sufficient and credible;
- Recommending to the Board for the appointment, re-appointment, replacement, remuneration and terms of appointment of the statutory auditors of the Company;
- Reviewing and monitoring the statutory auditor's independence and performance, and effectiveness of audit process;
- Approving payments to the statutory auditors for any other services rendered by the statutory auditors;
- Reviewing, with the management, the annual financial statements and auditor's report thereon before submission to the Board for approval, with particular reference to:
 - Matters required to be included in the Director's Responsibility Statement to be included in the Board's report in terms of clause (c) of sub-section 3 of Section 134 of the Companies Act;
 - Changes, if any, in accounting policies and practices and reasons for the same;
 - Major accounting entries involving estimates based on the exercise of judgment by management;
 - Significant adjustments made in the financial statements arising out of audit findings;
 - Compliance with listing and other legal requirements relating to financial statements;
 - Disclosure of any related party transactions; and
 - Qualifications and modified opinions in the draft audit report.
- Reviewing, with the management, the quarterly, half-yearly and annual financial statements before submission to the Board for approval;

- 7) Reviewing, with the management, the statement of uses/ application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document/ prospectus/ notice and the report submitted by the monitoring agency monitoring the utilization of proceeds of a public or rights issue, and making appropriate recommendations to the Board to take up steps in this matter. This also includes monitoring the use/application of the funds raised through the proposed initial public offer by the Company;
- 8) Approval or any subsequent modifications of transactions of the Company with related parties and omnibus approval for related party transactions proposed to be entered into by the Company subject to such conditions as may be prescribed;
- 9) Scrutiny of inter-corporate loans and investments;
- 10) Valuation of undertakings or assets of the Company, wherever it is necessary;
- 11) Evaluation of internal financial controls and risk management systems;
- 12) Establishing a vigil mechanism for directors and employees to report their genuine concerns or grievances;
- 13) Reviewing, with the management, the performance of statutory and internal auditors, and adequacy of the internal control systems;
- 14) Reviewing the adequacy of internal audit function if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;
- 15) Discussing with internal auditors on any significant findings and follow up thereon;
- 16) Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the Board;
- 17) Discussing with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;
- 18) Looking into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors;
- 19) Reviewing the functioning of the whistle blower mechanism;
- 20) Approving the appointment of the chief financial officer or any other person heading the finance function or discharging that function after assessing the qualifications, experience and background, etc. of the candidate;
- 21) Reviewing the utilization of loans and/ or advances from/investment by the holding company in any subsidiary exceeding ₹1,000 million or 10% of the asset size of the subsidiary, whichever is lower including existing loans / advances / investments;
- 22) Considering and commenting on the rationale, cost-benefits and impact of schemes involving merger, demerger, amalgamation etc., on the Company and its shareholders;
- 23) Such roles as may be delegated by the Board and/or prescribed under the Companies Act, 2013 and SEBI Listing Regulations or other applicable law; and
- 24) Carrying out any other functions as is mentioned in the terms of reference of the audit committee or containing into SEBI (LODR) Regulations 2015.

Further, the Audit Committee shall mandatorily review the following information:

- 1) Management's discussion and analysis of financial condition and results of operations;
- 2) statement of significant related party transactions (as defined by the audit committee), submitted by management;
- 3) management letters / letters of internal control weaknesses issued by the statutory auditors;
- 4) internal audit reports relating to internal control weaknesses;
- 5) the appointment, removal and terms of remuneration of the chief internal auditor shall be subject to review by the audit committee; and
- 6) statement of deviations:
 - a. quarterly statement of deviation(s) including report of monitoring agency, if applicable, submitted to stock exchange(s) in terms of Regulation 32(1) of the SEBI ICDR Regulations;
 - b. Annual statement of funds utilized for purposes other than those stated in the offer document/prospectus/notice in terms of Regulation 32(7) of the SEBI ICDR Regulations.

2. Nomination and Remuneration Committee

Our Company at its Board Meeting held on September 16, 2025 has approved the constitution of Nomination and Remuneration Committee in compliance with the provisions of Section 178, Schedule V and all other applicable provisions of the Companies Act, 2013 read with Rule 6 of the Companies (Meetings of Board and its Power) Rules, 2014 and Regulation 19 SEBI Listing Regulations. The Nomination and Remuneration Committee comprises following members:

Name of the Director	Status in Committee	Nature of Directorship
Kashyap Naranbhai Thummar	Chairman	Independent Director
Rashmi Krunal Lakhani	Member	Independent Director
Narendrabhai Dineshbhai Khambhaliya	Member	Non-executive Director

The Company Secretary of the Company shall act as a Secretary to the Nomination and Remuneration Committee. The Chairman of the Nomination and Remuneration Committee is entitled to attend the general Meeting of the company to furnish clarifications to the shareholders on any matter relating to remuneration. The scope and function of the Committee and its terms of reference shall include the following:

A. Tenure of the Committee:

The Nomination and Remuneration Committee shall continue to be in function as a committee of the Board until otherwise resolved by the Board.

B. Meetings of the Committee:

The committee shall meet as and when the need arises, subject to at least one meeting in a year. The quorum for the meeting shall be one third of the total strength of the committee or two members, whichever is greater, including at least one independent director in attendance.

C. Scope and terms of reference:

The terms of reference of the Nomination and Remuneration Committee as per Regulation 19 and Part D of Schedule II of SEBI Listing Regulations and Companies Act, 2013 shall be as under:

- 1) formulating the criteria for determining qualifications, positive attributes and independence of a director and recommend to the Board a policy relating to the remuneration of the directors, key managerial personnel and other employees;
- 2) For the appointment of an independent director, the committee shall evaluate the balance of skills, knowledge and experience on the Board and on the basis of such evaluation, prepare a description of the role and capabilities required of an independent director. The person recommended to the board of directors of the Company for appointment as an independent director shall have the capabilities identified in such description. For the purpose of identifying suitable candidates, the Committee may:
 - a. use the services of external agencies, if required;
 - b. consider candidates from a wide range of backgrounds, having due regard to diversity; and
 - c. Consider the time commitments of the candidates.
- 3) formulation of criteria for evaluation of the performance of independent directors and the Board;
- 4) devising a policy on diversity of our Board;
- 5) identifying persons, who are qualified to become directors or who may be appointed in senior management in accordance with the criteria laid down, recommending to the Board their appointment and removal and carrying out evaluation of every director's performance;
- 6) determining whether to extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of independent directors;
- 7) recommending remuneration of executive directors and any increase therein from time to time within the limit approved by the members of our Company;
- 8) recommending remuneration to non-executive directors in the form of sitting fees for attending meetings of the Board and its committees, remuneration for other services, commission on profits;
- 9) recommending to the Board, all remuneration, in whatever form, payable to senior management;
- 10) performing such functions as are required to be performed by the compensation committee under the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, as amended;
- 11) engaging the services of any consultant/professional or other agency for the purpose of recommending compensation

- structure/policy;
- 12) analyzing, monitoring and reviewing various human resource and compensation matters;
- 13) reviewing and approving compensation strategy from time to time in the context of the then current Indian market in accordance with applicable laws;
- 14) framing suitable policies and systems to ensure that there is no violation, by an employee of any applicable laws in India or overseas, including:
 - a. The SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended; or
 - b. The SEBI (Prohibition of Fraudulent and Unfair Trade Practices relating to the Securities Market) Regulations, 2003, as amended; and
- 15) Performing such other functions as may be delegated by the Board and/or prescribed under the SEBI Listing Regulations, Companies Act, each as amended or other applicable law.

3. Stakeholders Relationship Committee

Our Company at its Board Meeting held on September 16, 2025 has approved the constitution of the Stakeholders Relationship Committee in compliance with the provisions of the Section 178(5) and all other applicable provisions of the Companies Act, 2013 read with the Rules framed thereunder and Regulation 20 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The constituted Stakeholders Relationship Committee comprises the following:

Name of the Director	Status in Committee	Nature of Directorship
Kashyap Naranbhai Thummar	Chairman	Independent Director
Rashmi Krunal Lakhani	Member	Independent Director
Jayeshkumar Amarshibhai Sabava	Member	Managing Director

The Company Secretary of our Company shall act as a Secretary to the Stakeholder Relationship Committee. The scope and function of the Stakeholder Relationship Committee and its terms of reference shall include the following:

- A. Tenure:** The Stakeholder Relationship Committee shall continue to be in function as a committee of the Board until otherwise resolved by the Board, to carry out the functions of the Stakeholder Relationship Committee as approved by the Board.
- B. Meetings:** The Stakeholder Relationship Committee shall meet at least once in a year, and shall report to the Board on a quarterly basis regarding the status of re-dressal of the complaints received from the shareholders of the Company. The quorum for the meeting shall be one third of the total strength of the committee or two members, whichever is higher.
- C. Scope and terms of reference:** The terms of reference of the Stakeholders Relationship Committee as per Regulation 20 and Part D of Schedule II of SEBI Listing Regulations, 2015 and Companies Act, 2013 shall be as under:
 - 1. Resolving the grievances of the security holders of the listed entity including complaints related to transfer/transmission of shares, non-receipt of annual report, non-receipt of declared dividends, issue of new/duplicate certificates, general meetings etc.;
 - 2. Review of measures taken for effective exercise of voting rights by shareholders;
 - 3. Review of adherence to the service standards adopted by the listed entity in respect of various services being rendered by the Registrar & Share Transfer Agent;
 - 4. Review of the various measures and initiatives taken by the listed entity for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/ annual reports/ statutory notices by the shareholders of the company;
 - 5. Allotment, transfer of shares including transmission, splitting of shares, changing joint holding into single holding and vice versa, issue of duplicate shares in lieu of those torn, destroyed, lost or defaced or where the space at back for recording transfers have been fully utilized;

6. Formulation of procedures in line with the statutory guidelines to ensure speedy disposal of various requests received from shareholders from time to time;
7. To issue duplicate share or other security(ies) certificate(s) in lieu of the original share/security(ies) certificate(s) of the Company.;
8. Non-receipt of share certificate(s), non-receipt of declared dividends, non-receipt of interest/ dividend warrants, non-receipt of annual report and any other grievance/ complaints with Company or any officer of the Company arising out in discharge of his duties;
9. Oversee the performance of the Registrar & Share Transfer Agent and also review and take note of complaints directly received and resolved them;
10. Oversee the implementation and compliance of the Code of Conduct adopted by the Company for prevention of Insider Trading for Listed Companies as specified in the Securities & Exchange Board of India (Prohibition of insider Trading) Regulations, 2015 as amended from time to time;
11. Any other power specifically assigned by the Board of Directors of the Company from time to time by way of resolution passed by it in a duly conducted Meeting; and
12. Such roles as may be delegated by the Board and/ or prescribed under the Companies Act, 2013 and SEBI Listing Regulations or other applicable law.

Policy on Disclosures & Internal procedure for prevention of Insider Trading:

The provisions of Regulation 8 and 9 of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 will be applicable to our Company immediately upon the listing of its Equity Shares on the Stock Exchange. We shall comply with the requirements of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 on listing of our Equity Shares on stock exchange. Further, Board of Directors have approved and adopted in Board meeting held on September 26, 2025 the policy on insider trading in view of the proposed public issue. Our Board is responsible for setting forth policies, procedures, monitoring and adherence to the rules for the preservation of price sensitive information and the implementation of the Code of Conduct for Prevention of Insider Trading conduct under the overall supervision of the Board.

KEY MANAGERIAL PERSONNEL AND SENIOR MANAGERIAL PERSONNEL

Our Company is supported by a team of professionals having exposure to various operational aspects of our business. A brief detail about the Key Managerial Personnel of our Company is provided below:

Name, Designation & Educational Qualification	Age	Year/period of joining	Compensation paid for F.Y. ended 24-25 (₹ in Lakhs)	Overall experience (in years)	Previous employment
Chetan Rugnathbhai Matholiya Designation: Chairman & Whole-Time Director Educational Qualification: Master of Pharmacy (Pharmaceutics) Term of office: 3 Years	34	2020	3.47	11	M/s Rednex Pharmaceuticals
Jayeshkumar Amarshibhai Sabava Designation: Managing Director Educational Qualification: Master of Pharmacy (Pharmaceutics) Term of office: 3 Years	35	2020	3.47	11	M/s Rednex Pharmaceuticals
Akashbhai Mansukhbhai Gangadiya	36	2020	1.00	16	M/s Rednex Pharmaceuticals

Designation: Whole-Time Director and Chief Financial Officer Educational Qualification: B.com Term of office: 3 Years					
Rima Amitbhai Dalal Designation: Company Secretary and Compliance Officer Educational Qualification - Company Secretary	32	2025	Nil	10	Shivansh Finserve Limited
Rajen Kanjibhai Limbani Designation: Plant Head Educational Qualification: Master of Pharmacy (Quality Assurance)	35	2023	8.87	11	Cadila Pharmaceuticals Limited

BRIEF PROFILE OF KEY MANAGERIAL PERSONNEL AND SENIOR MANAGERIAL PERSONNEL

Chetan Rugnathbhai Matholiya - Please refer to section “**Brief Profile of our Directors**” beginning on page 150 of this Draft Red Herring Prospectus for details.

Jayeshkumar Amarshibhai Sabava - Please refer to section “**Brief Profile of our Directors**” beginning on page 150 of this Draft Red Herring Prospectus for details.

Akashbhai Mansukhbhai Gangadiya - Please refer to section “**Brief Profile of our Directors**” beginning on page 150 of this Draft Red Herring Prospectus for details.

Rima Amitbhai Dalal is the Company Secretary and Compliance Officer of our Company. She is a qualified Company Secretary and an associate member of the Institute of Company Secretaries of India from year 2015 with an overall work experience of 10 years. She is currently responsible for the overall Corporate Governance and secretarial Compliance of our Company.

Senior Managerial Personnel

Rajen Kanjibhai Limbani is the Plant Head of our Company. He holds the degree of Master of Pharmacy (Quality Assurance) from Gujarat Technological University. He is associated with our organization since 2023. He has an overall experience of 11 years in the pharmaceuticals industry. His research papers were published in journals such as International Bulletin of Drug Research in the year 2014. He is the Plant Head of the company and looks after overall production and planning activities of the company.

We confirm that:

- All the persons named as our Key Managerial Personnel and Senior Managerial Personnel above are the permanent employees of our Company.
- There is no understanding with major shareholders, customers, suppliers or any others pursuant to which any of the above-mentioned Key Managerial Personnel and Senior Managerial Personnel have been recruited.
- None of our KMPs except Chetan Rugnathbhai Matholiya Jayeshkumar Amarshibhai Sabava and Akashbhai Mansukhbhai Gangadiya, are part of the Board of Directors.
- In respect of all above mentioned Key Managerial Personnel there has been no contingent or deferred compensation accrued for the financial year ended March 31, 2025.
- Except for the terms set forth in the appointment letters, the Key Managerial Personnel and Senior Managerial Personnel have not entered into any other contractual arrangements or service contracts (including retirement and termination benefits) with the issuer.
- Our Company does not have any bonus/ profit sharing plan for any of the Key Managerial Personnel and Senior Managerial Personnel.
- None of the Key Managerial Personnel and Senior Managerial Personnel hold any shares of our Company as on the date of filing of this Draft Red Herring Prospectus except as under:

Sr. No.	Name of the KMP's	No. of Shares held	Holding in %
1.	Chetan Rugnathbhai Matholiya	25,49,736	33.33%
2.	Jayeshkumar Amarshibhai Sabava	25,50,492	33.34%
3.	Akashbhai Mansukhbhai Gangadiya	25,49,736	33.33%
	Total	76,49,964	100.00%

- h. Presently, we do not have Employee Stock Option Plan (ESOP)/ Employee Stock Purchase Scheme (ESPS) for our employees.
- i. The turnover of KMPs and SMPs is not high, compared to the Industry to which our company belongs.

Nature of any family relationship between Key Managerial Personnel (KMP) and Senior Management Personnel (SMP)

None of our KMP's and SMP's are related to each other as on the date of filing of this Draft Red Herring Prospectus.

Payment of benefits to officers of Our Company (*non-salary related*)

Except as disclosed in this Draft Red Herring Prospectus and any statutory payments made by our Company to its officers, our Company has not paid any sum, any non-salary related amount or benefit to any of its officers or to its employees including amounts towards super-annuation, ex-gratia/ rewards.

Except statutory benefits upon termination of employment in our Company or superannuation, no officer of our Company is entitled to any benefit upon termination of such officer's employment in our Company or superannuation.

Changes in the Key Managerial Personnel and Senior Managerial Personnel in last three years:

There have been no changes in the Key Managerial Personnel of our Company during the last 3 (three) year except as stated below:

Sr. No.	Name of KMP's/ SMP's	Designation and period	Appointment/ Cessation/ Re-designation	Reasons
1.	Chetan Rugnathbhai Matholiya	Appointed as Director w.e.f December 29, 2020 and re-designated as Chairman and Whole-time Director w.e.f August 14, 2025	Appointment and Re-designation	To comply with the provisions of the Companies Act, 2013 and to ensure better Corporate Governance
2.	Jayeshkumar Amarshibhai Sabava	Appointed as Director w.e.f December 29, 2020 and re-designated as Managing Director w.e.f August 14, 2025	Appointment and Re-designation	
3.	Akashbhai Mansukhbhai Gangadiya	Appointed as Director w.e.f December 29, 2020 and re-designated as Whole-time Director and CFO w.e.f August 14, 2025	Appointment and Re-designation	
4.	Rima Amitbhai Dalal	Appointed as Company Secretary and Compliance Officer w.e.f. August 14, 2025	Appointment	
5.	Rajen Kanjibhai Limbani	Appointed as Plant Head w.e.f May 11, 2023	Appointment	

Interest of our Key Managerial Personnel and Senior Managerial Personnel

Except for as disclosed in the Draft Red Herring Prospectus and to the extent of remuneration allowed and reimbursement of expenses incurred by them for or on behalf of the Company, none of our Key Managerial Personnel and Senior Management Personnel are interested in our Company. For details, please refer section titled ***"Financial information of the Company – Note 29 - Related Party Disclosures"*** beginning on page 211 of this Draft Red Herring Prospectus.

Interest in the property of our Company

Except as disclosed above in section titled ***“Our Management – Interest of Directors - Interest in the property of Our Company”*** our KMPs and SMPs do not have any interest in any property acquired by our Company in a period of two years before the filing of this Draft Red Herring Prospectus or proposed to be acquired by us as on the date of filing the Draft Red Herring Prospectus with RoC.

Details of the Service Contracts of the Key Managerial Personnel and Senior Management Personnel

Except for the terms set forth in the appointment letters, the Key Managerial Personnel and Senior Management Personnel have not entered into any other contractual arrangements with our Company for provision of benefits or payments of any amount upon termination of employment.

Employee Stock Option Plan ('ESOP')/ employee stock purchase scheme ('ESPS Scheme') to Employees

Presently, we do not have any ESOP/ ESPS Scheme for our employees.

PROMOTERS & PROMOTER GROUP

A. OUR PROMOTERS:

The Promoters of our Company are:

1. Chetan Rugnathbhai Matholiya
2. Jayeshkumar Amarshibhai Sabava
3. Akashbhai Mansukhbhai Gangadiya

As on date of this Draft Red Herring Prospectus, our Promoters, in aggregate, holds 76,49,964 Equity shares of face value ₹10/- each of our Company, representing 100.00% of the pre-issue paid-up Equity Share capital of our Company. For details of the build-up of the Promoters' shareholding in our Company, see "***Capital Structure – History of the Equity Share Capital held by our Promoters***", on pages 68 of this Draft Red Herring Prospectus.

Brief Profile of our Promoters are as under:

	Chetan Rugnathbhai Matholiya – Chairman and Whole-Time Director Chetan Rugnathbhai Matholiya, aged 34 years, is one of our Promoters and is also the Chairman and Whole-Time Director on our Board. For further details, i.e., his date of birth, residential address, educational qualifications, experience in business or employment, business and financial activities, special achievements, positions/posts held in the past and other directorships, see "<i>Our Management – Brief profile of Directors</i>" on page 150. Other ventures of our Promoters - Except as mentioned below and as set out in the chapter titled '<i>Our Management</i>', our Promoters are not involved with any other venture, as a shareholder/ stakeholder, proprietor, partner, promoters or director. Partnership Firm: 1. M/s Rednex Pharmaceuticals 2. M/s Xender Pharmaceuticals LLP: 1. Narayan Pharma House LLP His permanent account number is BHXPM1580N. For details of his shareholding, please see "<i>Capital Structure</i>" on page 68. Jayeshkumar Amarshibhai Sabava- Managing Director

	Jayeshkumar Amarshibhai Sabava, aged 35 years, is one of our Promoters and is also the Managing Director on our Board. For further details, i.e., his date of birth, residential address, educational qualifications, experience in business or employment, business and financial activities, special achievements, positions/posts held in the past and other directorships, see <i>“Our Management –Brief profile of Directors”</i> on page 150. Other ventures of our Promoters - Except as mentioned below and as set out in the chapter titled <i>‘Our Management’</i>, our Promoters are not involved with any other venture, as a shareholder/ stakeholder, proprietor, partner, promoters or director. Partnership Firm: 1. M/s Rednex Pharmaceuticals 2. M/s Xender Pharmaceuticals Limited Liability Partnership: 1. Narayan Pharma House LLP His permanent account number is DTQPS9382R. For details of his shareholding, please see <i>“Capital Structure”</i> on page 68.
	Akashbhai Mansukhbhai Gangadiya – Whole Time Director and CFO Akashbhai Mansukhbhai Gangadiya, aged 36 years, is one of our Promoters and is also the Whole Time Director and CFO on our Board. For further details, i.e., his date of birth, residential address, educational qualifications, experience in business or employment, business and financial activities, special achievements, positions/posts held in the past and other directorships, see <i>“Our Management –Brief profile of Directors”</i> on page 150. Other ventures of our Promoters - Except as mentioned below and as set out in the chapter titled <i>‘Our Management’</i>, our Promoters are not involved with any other venture, as a shareholder/ stakeholder, proprietor, partner, promoters or director. Partnership Firm: 1. M/s Green Wood Enterprise 2. M/s Lalko Minerals 3. M/s Rednex Pharmaceuticals His permanent account number is AMQPG5732P. For details of his shareholding, please see <i>“Capital Structure”</i> on page 68.

Confirmations/ Declarations:

In relation to our Promoters, our Company confirms that the PAN, Bank Account Numbers, Passport Number, Aadhaar Card Number and Driving License number shall be submitted to BSE at the time of filing of this Draft Red Herring Prospectus.

Undertaking/ Confirmations:

None of our Promoters or Promoter Group or Group Company have been:

- Prohibited or debarred from accessing or operating in the capital market or restrained from buying, selling or dealing in securities under any order or direction passed by SEBI or any other authority or
- Refused listing of any of the securities issued by such entity by any stock exchange, in India or abroad.
- No material regulatory or disciplinary action is taken by any stock exchange or regulatory authority in the past one year in respect of our Promoters, Group Company and Companies promoted by the promoters of our company.
- There are no defaults in respect of payment of interest and principal to the debenture/ bond/ fixed deposit holders, banks, FIs by our Company, our Promoters, Group Company and Companies promoted by the promoters during the past three years.
- The litigation record, the nature of litigation, and status of litigation of our Company, Promoters, Group company are disclosed in chapter titled ***“Outstanding Litigations and Material Developments”*** beginning on page 233 of this Draft Red Herring Prospectus.
- None of our Promoters, person in control of our Company are or have ever been a promoter, director or person in control of any other company which is debarred from accessing the capital markets under any order or direction passed by the SEBI or any other authority.

Interest of our Promoters:

i. Interest in promotion and shareholding of Our Company:

Our Promoters are interested in the promotion of our Company and also to the extent of their shareholding and shareholding of their relatives, from time to time, for which they are entitled to receive dividend payable, if any, and other distribution in respect of the Equity Shares held by them and their relatives. As on the date of this Draft Red Herring Prospectus, our Promoters, Chetan Rugnathbhai Matholiya, Jayeshkumar Amarshibhai Sabava and Akashbhai Mansukhbhai Gangadiya collectively holds 76,49,964 Equity Shares of face value ₹ 10/- each in our Company i.e., 100.00% of the pre issue paid up Equity Share Capital of our Company. Our Promoters may also be deemed to be interested to the extent of the remuneration, as per the terms of their appointment and reimbursement of expenses payable to them and unsecured loan advanced to/ taken from them, if any. For details, please refer to ***Note 29 – “Related Party Transactions”*** beginning on page 211 of this Draft Red Herring Prospectus.

For details regarding the shareholding of our Promoters in our Company, please see ***“Capital Structure”*** on page 68 of this Draft Red Herring Prospectus.

ii. Interest in the property of Our Company:

Except for, the registered office and factory of the company situated at Survey No. 231, NR. SKF Bearing, Bavla- Bagodara, N.H.- 8A, Kerala, Ta. Bavla, Ahmedabad - 382220 which is acquired on lease vide Leave and License Agreement. dated August 18, 2022 from M/s. Rednex Pharmaceuticals, a Partnership firm, where our Promoters Chetan Rugnathbhai Matholiya, Jayeshkumar Amarshibhai Sabava and Akashbhai Mansukhbhai Gangadiya are interested as partners, our Promoters do not have any other interest in any property acquired by our Company in a period of two years before filing of this Draft Red Herring Prospectus or proposed to be acquired by us as on date of this Draft Red Herring Prospectus:

iii. In transactions for acquisition of land, construction of building and supply of machinery

Except as stated in the Draft Red Herring Prospectus, our Promoters are not interested in any transaction for the acquisition of land, construction of building or supply of machinery.

iv. Other Interests in our Company

For transactions in respect of loans and other monetary transactions entered in past please refer ***Note - 29*** on ***“Related Party Transactions”*** on page 211 forming part of ***“Financial Information of the Company”*** of this Draft Red Herring Prospectus.

Payment or Benefits to Our Promoters & Promoter Group during the last 2 years:

For details of payments or benefits paid to Our Promoters & Promoter Group, please refer to the paragraph *“Compensation of our Directors”* in the chapter titled *“Our Management”* beginning on page 150 also refer *Note- 29* on *“Related Party Transactions”* on page 211 forming part of *“Financial Information of the Company”* and Paragraph on *“Interest of Promoters”* in chapter titled *“Our Promoters & Promoter Group”* on page 165 of this Draft Red Herring Prospectus.

Companies/ Firms with which our Promoters have disassociated in the last (3) three years:

Our Promoters have not disassociated themselves from any of the Company, Firms or other entities during the last three years preceding the date of this Draft Red Herring Prospectus.

Other ventures of our Promoters:

Save and except as disclosed in this section titled *“Our Promoters & Promoter Group”* beginning on page 165 of this Draft Red Herring Prospectus, there are no ventures promoted by our Promoters in which they have any business interests/ other interests.

Litigation details pertaining to our Promoters:

For details on litigations and disputes pending against the Promoters and defaults made by the Promoters please refer to the section titled *“Outstanding Litigations and Material Developments”* beginning on page 233 of this Draft Red Herring Prospectus.

Material Guarantees:

Except as stated in the *“Statement of financial indebtedness”* and *“Restated financial information”* of the company beginning on page 219 and 172 of this Draft Red Herring Prospectus respectively, our Promoters have not given any material guarantee to any third party with respect to the Equity Shares as on the date of this Draft Red Herring Prospectus.

Experience of Promoters in the line of business:

Our Promoters, Chetan Rugnathbhai Matholiya, Jayeshkumar Amarshibhai Sabava and Akashbhai Mansukhbhai Gangadiya have an overall experience of around 11 years, 11 years and 8 years respectively in pharmaceutical industry. The Company shall also endeavour to ensure that relevant professional help is sought as and when required in the future.

Related Party Transactions:

Except as stated in *“Note – 29 Related Party Transactions”* beginning on page 211 of this Draft Red Herring Prospectus, and as stated therein, our Promoters or any of the Promoter Group Entities do not have any other interest in our business.

B. OUR PROMOTER GROUP

In addition to the Promoters named above, the following natural persons are part of our Promoter Group:

(a) Natural persons i.e., an immediate relative of the promoters

As per Regulation 2(1) (pp) (ii) of the SEBI (ICDR) Regulations, 2018, the Natural persons who are part of the Promoter Group (due to their relationship with the Promoters) are as follows:

Relationship	Name of the Relatives		
	Chetan Rugnathbhai Matholiya	Akashbhai Mansukhbhai Gangadiya	Jayeshkumar Amarshibhai Sabava
Father	Rugnathbhai Govindbhai Matholiya	Mansukhbhai Becharbhai Gangadiya	Amarshibhai Jerambhai Sabva
Mother	Prabhaben Rugnathbhai Matholiya	Hansaben Manshukhbhai Gangadiya	Kanchanben Amarshibhai Sabva
Spouse	Mitalben Chetanbhai Matholiya	Manishaben Akashbhai Gangadiya	Dakshaben Jayeshbhai Sabava
Brother	Shaileshbhai Rugnathbhai Matholiya	Kartikkumar Mansukhbhai Gangadiya	Natubhai Amarshibhai Sabava
Sister	Varsha Bipinkumar Sabva	Trushna Ashwinbhai Koradiya	Naynaben Pareshbhai Motka
			Ramilaben Bipinbhai Bhavnagariya
			Varshaben Kalpeshbhai Zankhaniya
Son	Purv Chetanbhai Matholiya	Umang Akashabhai Gangadiya	Jiyan Jayeshkumar Sabava
		Harshil Akashabhai Gangadiya	
Daughter	Saachi Chetan Matholiya	-	Nitya Jayeshkumar Sabava
Spouse's Father	Jagdishbhai Karshnbhai Matariya	Dhanjibhai Amarshibhai Zulasana	Dineshbhai Dayabhai Khambhaliya
Spouse's Mother	Madhuben Jagdishbhai Matariya	Manjulaben Dhanjibhai Zulasana	Jasuben Dineshbhai Khambhaliya
Spouse's Brother	Aashishbhai Jagdishbhai Matariya	Rajendra Dhanjibhai Zulasana	Narendrakumar Dineshbhai Khambhaliya
	Bhavin Jagdishbhai Patel		
Spouse's Sister	-	Arunaben Jayeshbhai Oganja	-
		Madhuriben Pradipbhai Vegad	
		Naynaben Pankajbhai Matholiya	

(b) Corporate Entities or Firms forming part of the Promoter Group:

As per Regulation 2(1)(pp)(iv) of the SEBI (ICDR) Regulations, 2018, the following entities would form part of our Promoter Group:

S. No.	Nature of Relationship	Name of Entities
A.	Any Body Corporate in which 20% or more of the Equity Share Capital is held by Promoter or an immediate relative of the Promoter or a firm or Hindu Undivided Family	1. Lalko Exim Private Limited 2. Lalko Minerals Private Limited

	(HUF) in which Promoter or any one or more of his immediate relatives are a member.	
B.	Any Body Corporate in which a body corporate as provided in (A) above holds twenty per cent or more, of the equity share capital.	-
C.	Any Hindu Undivided Family or firm in which the aggregate share of the promoter and their relatives is equal to or more than twenty per cent of the total capital.	Partnership Firms: 1. M/s Rednex Pharmaceuticals 2. M/s Green Wood Enterprise 3. M/s Lalko Minerals 4. M/s Xender Pharmaceuticals Limited Liability Partnership: 1. Narayan Pharma House LLP

(c) Other persons included in Promoter Group

None of other persons forms part of Promoter group for the purpose of shareholding of the Promoter Group under Regulation 2(1) (pp)(v) of SEBI (ICDR) Regulations 2018.

DIVIDEND POLICY

Under the Companies Act, 2013 our Company can pay dividends upon a recommendation by our Board of Directors and approval by a majority of the shareholders at the General Meeting and as per provisions of Articles of Association of our Company. The shareholders of the Company have the right to decrease but not to increase the amount of dividend recommended by the Board of Directors. The dividends may be paid out of profits of our Company in the year in which the dividend is declared or out of the undistributed profits or reserves of previous fiscal years or out of both. The Articles of Association of our Company also gives the discretion to our Board of Directors to declare and pay interim dividends. All Dividends upon recommendation by our Board of Directors and approved by the shareholders at the General Meeting will be paid to credit of registered shareholders by way of cheque or warrant or in any electronic mode.

The dividend distribution policy of our Company was approved and adopted by our Board on September 26, 2025 (the "**Dividend Distribution Policy**"). The declaration and payment of dividend will be recommended by our Board of Directors and approved by the shareholders of our Company at their discretion and will depend on a number of factors, including the results of operations, earnings, capital requirements and surplus, general financial conditions, applicable Indian legal restrictions and other factors considered relevant by our Board of Directors.

Our Company has not paid/ declared any dividend in last three years from date of this Draft Red Herring Prospectus. Our Company's corporate actions pertaining to payment of dividends in the past are not to be taken as being indicative of the payment of dividends by our Company in the future.

SECTION VI: FINANCIAL INFORMATION OF THE COMPANY

RESTATED FINANCIAL STATEMENTS

INDEPENDENT AUDITOR'S EXAMINATION REPORT ON RESTATED FINANCIAL INFORMATION

To,
**The Board of Directors of
Rednex Pharmaceuticals Limited,**
Survey No. 586 and 231, Nr.
SKF Bearing, Bavla-Bagodara
N. H. -8A, Kerala, Bavla,
Ahmedabad, Gujarat, India, 382220

Dear Sir,

We have examined the attached Restated Financial Statement of **Rednex Pharmaceuticals Limited** (hereunder referred to “the Company”, “Issuer”) comprising the Restated Statement of Assets and Liabilities as at March 31, 2025, March 31, 2024, and March 31, 2023, the Restated Statement of Profit & Loss and the Restated Cash Flow Statement for the year ended March 31, 2025, March 31, 2024, and March 31, 2023, the statement of Significant Accounting Policies and other explanatory Information (Collectively referred to as “the Restated Financial Statement”) as approved by the Board of Directors in their meeting held on 26th September, 2025 for the purpose of inclusion in the Draft Red Herring Prospectus/Red Herring Prospectus/Prospectus (“Offer Document”) prepared by the Company in connection with its proposed SME Initial Public Offer of equity shares (“SME IPO”) prepared in terms of the requirements of:-

- a) Section 26 of Part I of Chapter III of the Companies Act, 2013 as amended (the “Act”);
- b) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations 2018 as amended (“ICDR Regulations”); and
- c) The Guidance Note on Reports in Company Prospectuses (Revised 2019) issued by the Institute of Chartered Accountants of India as amended from time to time. (“Guidance Note”)

The Company’s Board of Directors is responsible for the preparation of the Restated Financial Statement for the purpose of inclusion in the offer document to be filed with relevant Stock Exchange, Securities and Exchange Board of India, and Registrar of Companies, Ahmedabad in connection with the proposed SME IPO. The Restated Financial Statements have been prepared by the management of the Company for the year ended on March 31, 2025, March 31, 2024, and March 31, 2023 on the basis of Significant Accounting Policies and Notes to Accounts as set out in Annexure IV and V to the Restated Financial Statement. The Board of Directors of the company’s responsibility includes designing, implementing, and maintaining adequate internal control relevant to the preparation and presentation of the Restated Financial Statement. The Board of Directors is also responsible for identifying and ensuring that the Company complies with the Companies Act, (ICDR) Regulations and the Guidance Note

We confirm that there is no express refusal by the peer review board of ICAI to renew the certificate and the process to renew the peer review certificate has been initiated by us.

We have examined such Restated Financial Statement taking into consideration:

- a) The scope of work and other terms of our engagement agreed upon with you in accordance with our engagement letter dated 05th August, 2025 in connection with the proposed IPO of equity shares of the Company;
- c) Concepts of test checks and materiality to obtain reasonable assurance based on verification of evidence supporting the Restated Financial Statements; and

This Restated Financial Statements have been compiled by the management from:

- a) Audited financial statements of the company as at and for the Year ended on March 31, 2025, March 31, 2024, and March 31, 2023 prepared in accordance with the Accounting Standards as prescribed under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014, as amended, and other accounting principles generally accepted in India, Audited Financial statement of the company for the year ended March 31, 2025, which has been approved by the Board of Directors at their meeting held on 5th September, 2025
- b) The Financial Statement for the Year ended on March 31, 2025, March 31, 2024, and March 31, 2023 have been Audited by us vide our report dated 05th September, 2025, 01st September 2024 and 01st September 2023, respectively.

The modification in restated financials was carried out based on the modified reports, if any, issued by us which is giving rise to modifications on the financial statements as at and for the years ended March 31, 2025, March 31, 2024, and March 31, 2023.

- a) The Restated Financial Statement have been made after incorporating adjustments for the changes in accounting policies, material errors and regrouping / reclassifications retrospectively in respective financial years to reflect the same accounting treatment as per the changed accounting policy for all reporting periods, if any;
- b) The Restated Financial Statement have been made after incorporating adjustments for prior period and other material amounts in the respective financial year to which they relate;
- c) Extra-ordinary items that need to be disclosed separately in the accounts has been disclosed wherever required;
- d) Profits and losses have been arrived at after charging all expenses including depreciation and after making such adjustments/restatements and regroupings as in our opinion are appropriate and are to be read in accordance with the Significant Accounting Policies and Notes to Accounts as set out in Annexure IV and V to this report;
- e) Adjustments in Restated Financial Statement have been made in accordance with the correct accounting policies,
- f) There was no change in accounting policies, which needs to be adjusted in the Restated Financial Statement, except accounting of retirement benefits was accounted on as per management estimate basis, however during the restatement Company has accounted such retirement benefits according to AS-15(Revised) and accordingly accounted based on actuarial valuation certificate.
- g) There are no revaluation reserves, which need to be disclosed separately in the Restated Financial Statement
- h) The Company has not paid dividend during FY 2022-23 to FY 2024-25.

In accordance with the requirements of Part I of Chapter III of Act including rules made there under, ICDR Regulations, Guidance Note and Engagement Letter, we report that

- a) The “Restated Statement of Assets and Liabilities” as set out in Annexure I to this report, of the Company as at March 31, 2025, March 31, 2024, and March 31, 2023 is prepared by the Company and approved by the Board of Directors. These Restated Statement of Assets and Liabilities, have been arrived at after making such adjustments and regroupings to the individual financial statements of the Company, as in our opinion were appropriate and more fully described in Significant Accounting Policies and Notes to Accounts as set out in Annexure IV and V to this Report.
- b) The “Restated Statement of Profit and Loss” as set out in Annexure II to this report, of the Company for Financial year ended March 31, 2025, March 31, 2024, and March 31, 2023 is prepared by the Company and approved by the Board of Directors. These Restated Statement of Profit and Loss have been arrived at after making such adjustments and regroupings to the individual financial statements of the Company, as in our opinion were appropriate and more fully described in Significant Accounting Policies and Notes to Accounts as set out in Annexure IV to this Report.
- c) The “Restated Statement of Cash Flow” as set out in Annexure III to this report, of the Company for Financial year ended March 31, 2025, March 31, 2024, and March 31, 2023 is prepared by the Company and approved by the Board of Directors.

These Statement of Cash Flow, as restated have been arrived at after making such adjustments and regroupings to the individual financial statements of the Company, as in our opinion were appropriate and more fully described in Significant Accounting Policies and Notes to Accounts as set out in Annexure IV and V to this Report.

We have also examined the following other financial information relating to the Company prepared by the Management and as approved by the Board of Directors of the Company and annexed to this report relating to the Company for Financial year ended March 31, 2025, March 31, 2024, and March 31, 2023 proposed to be included in the Offer Document for the proposed IPO.

Significant Accounting Policy and Notes to The Restated financial Statements	Annexure IV
Restated Statement of Share Capital, Reserves and Surplus	Note-2
Restated Statement of Long Term Borrowings/ Statement of principle Term of Secured loan and Assets charges as security	Note-3, 3(A)
Restated Statement of Deferred Tax (Assets) / Liabilities	Note-4
Restated Statement of long-term Provisions	Note-5
Restated Statement of Short - Term Borrowings/ Statement of principle Term of Secured loan and Assets charges as security and Statement of term & Condition of unsecured Loans.	Note-6, 6(A), 6(B)
Restated Statement of Trade Payables	Note-7
Restated Statement of Other Current Liabilities and short-term Provisions	Note-8
Restated Statement of Short Term Provisions	Note-9
Restated Statement of Property, Plant and Equipment and Intangible Assets	Note-10
Restated Statement of Other Non-Current Assets	Note-11
Restated Statement of Trade Receivables	Note-12
Restated Statement of Cash and Bank Balances	Note-13
Restated Statement of Inventory	Note-14
Restated Statement of Short-Term Loans and Advances	Note-15
Restated Statement of Other Current Assets	Note-16
Restated Statement of Revenue from operation	Note-17
Restated Statement of Other Income	Note-18
Restated Statement of Cost of Material Consumed	Note-19
Restated Statement of Purchase of Stock-In-Trade	Note-20A
Restated Statement of Changes in Inventories of Finished Goods, WIP	Note-20B
Restated Statement of Employee Benefits Expenses	Note-21
Restated Statement of Finance Cost	Note-22
Restated Statement of Depreciation & Amortization	Note-23
Restated Statement of Other Expenses	Note-24
Restated Statement of Tax Expense	Note-25
Restated Statement of Mandatory Accounting Ratios	Note-26
Restated Statement of Other Financial Ratio	Note-27
Restated Statement of Contingent Liabilities & Capital Commitment	Note-28
Restated Statement of Related Party Transaction	Note-29
Restated Statement of Capitalization	Note-30
Restated Statement of Tax Shelter	Note-31
Additional Regulatory Information and Statement of events occurring after the Balance sheet date	Note-32
Material Adjustment to the Restated Financial	Annexure V

In our opinion, the above Restated Financial Statements along with Note 2 to 32 read with the Significant Accounting Policies and Material Adjustment to the Restated Financial as set out in Annexure IV and V are prepared after making adjustments and regrouping as considered appropriate and have been prepared in accordance with the Companies Act, ICDR Regulations, Our Engagement Letter and Guidance Note issued by ICAI.

We, M/s. Krupal Bhuvu & Co., Chartered Accountants have been subjected to the peer review process of the Institute of Chartered Accountants of India (ICAI) and our peer Review Certificate holds the peer review certificate dated 17th June, 2025 valid till 31st May, 2028.

The preparation and presentation of the Restated Financial Statements referred to above are based on the Audited financial statements of the Company and are in accordance with the provisions of the Act and ICDR Regulations. The Financial Statements and information referred to above is the responsibility of the management of the Company.

The report should not in any way be construed as a re-issuance or re-dating of any of the previous audit reports issued by us and nor should this report be construed as a new opinion on any of the financial statements referred to therein.

We have no responsibility to update our report for events and circumstances occurring after the date of the report.

Our report is intended solely for use of the Board of Directors for inclusion in the Draft Offer Document/ Offer Document to be filed with Securities and Exchange Board of India, relevant stock exchange and Registrar of Companies, Ahmedabad in connection with the proposed IPO. Our report should not be used, referred to, or distributed for any other purpose except with our prior consent in writing.

For Krupal Bhuva & Co.

Chartered Accountants

FRN: - 146585W

CA Krupal B. Bhuva

Proprietor

M. No. 182312

Place: Ahmedabad

Date: 26th September, 2025

UDIN: 25182312BMIRTX9419

ANNEXURE - I
RESTATED STATEMENT OF ASSETS AND LIABILITIES

(Amount in Rs. Lakhs)

Sr. No.	Particulars	Notes	As at		
			31-03-25	31-03-24	31-03-23
A)	EQUITY AND LIABILITIES				
1.	Shareholders' Funds				
(a)	Share Capital	2	425.00	425.00	425.00
(b)	Reserves & Surplus	2	522.07	95.67	-97.76
	Total (1)		947.07	520.67	327.24
2.	Non-Current Liabilities				
(a)	Long Term Borrowings	3	929.32	955.88	489.91
(b)	Deferred Tax Liabilities (net)	4	-	11.75	-
(c)	Long Term Provisions	5	10.05	1.91	0.34
	Total (2)		939.37	969.55	490.25
3.	Current Liabilities				
(a)	Short Term Borrowings	6	984.73	965.77	545.48
(b)	Trade Payables	7			
	Due to Micro and Small Enterprises		392.01	41.34	-
	Due to Others excluding Micro and Small Enterprises		1,535.42	673.00	235.03
(c)	Other Current Liabilities	8	110.27	92.05	112.49
(d)	Short Term Provisions	9	103.32	12.63	0.00
	Total (3)		3,125.75	1,784.79	893.00
	Total Equity and Liabilities (1+2+3)		5,012.19	3,275.01	1,710.49
B)	ASSETS				
1.	Non-Current Assets				
(a)	Property, Plant and Equipment and Intangible Assets	10			
	i) Property, Plant and Equipment		1,595.70	1,624.11	425.43
	ii) Intangible Assets		8.64	14.23	5.59
	iii) Capital Work in progress		-	-	611.68
(b)	Non-Current Investment		-	-	-
(c)	Deferred tax assets (net)	4	0.41	-	17.78
(d)	Other Non-Current Assets	11	8.36	46.83	15.10
	Total (1)		1,613.11	1,685.17	1,075.58
2.	Current Assets				
(a)	Trade Receivables	12	1,452.29	570.93	139.70
(b)	Cash and Bank Balances	13	28.52	121.72	2.01
(c)	Inventories	14	1,621.58	673.92	191.84
(d)	Short-Term Loans and Advances	15	208.04	140.44	293.10
(e)	Other Current Assets	16	88.65	82.83	8.26
	Total (2)		3,399.08	1,589.84	634.91
	Total (1+2)		5,012.19	3,275.01	1,710.49
	Significant Accounting Policies	1			
	Notes to Restated Financial Statement	2-32			

The accompanying Restated significant accounting policies, Restated notes to accounts and notes on adjustments for Restated financial Statement (Note 1 to 32, Annexure IV & V) are an integral part of this statement.
As per our annexed report of even date.

For Krupal Bhuva & Co.
Chartered Accountants
FRN: 146585W

CA Krupal B. Bhuva
Proprietor
M. No.: 182312
UDIN:
25182312BMIRTX9419
Place: Ahmedabad
Date: September 26, 2025

**For and on behalf of the Board of Directors of
Rednex Pharmaceuticals Limited**

Chetan Rugnathbhai Matholiya
Chairman and Whole-Time Director
DIN: 09013701

Jayeshkumar Amarshibhai Sabava
Managing Director
DIN: 09013702

Rima Amitbhai Dalal
Company Secretary and Compliance
Officer
M. No.: A39280
Place: Ahmedabad
Date: September 26, 2025

Akashbhai Mansukhbhai Gangadiya
Whole Time Director & CFO
DIN: 09013700
Place: Ahmedabad
Date: September 26, 2025

ANNEXURE – II
RESTATED STATEMENT OF PROFIT AND LOSS

(Amount in Rs. Lakhs)

Sr. No.	Particulars	Notes	For the period ended		
			31-03-25	31-03-24	31-03-23
1	Revenue From Operations	17	4,580.12	2,440.54	170.25
2	Other Income	18	31.97	7.71	1.84
3	Total Income (1+2)		4,612.09	2,448.24	172.09
4	Expenses				
(a)	Cost of Material Consumed	19	3,635.20	1,789.75	178.08
(b)	Purchase of Stock in Trade	20A	86.48	1.04	-
(c)	Change in Inventories of finished goods, wip	20B	-592.97	-26.67	-35.21
(d)	Employee Benefit Expenses	21	257.47	99.64	25.60
(e)	Finance Costs	22	158.95	120.25	58.67
(f)	Depreciation and Amortisation Expenses	23	287.05	116.74	22.48
(g)	Other Expenses	24	264.23	113.34	32.80
5	Total Expenses 4(a) to 4(g)		4,096.41	2,214.09	282.42
6	Profit Before Exceptional & Extraordinary items & Tax (3-5)		515.68	234.15	-110.33
7	Exceptional item & Extraordinary Items		-	-	-
8	Profit Before Extraordinary items & Tax (6-7)		515.68	234.15	-110.33
9	Prior Period Expenses		-	-	-
10	Profit Before Tax (8-9)		515.68	234.15	-110.33
11	Tax Expense:				
(a)	Net Current Tax	25	101.44	11.19	-
(b)	Deferred Tax		-12.16	29.53	-17.78
(c)	Income Tax of Previous Year			-	-
12	Total Tax Expenses 11(a) to 11(c)		89.28	40.72	-17.78
13	Profit for the Year (10-12)		426.40	193.43	-92.55
14	Earning per equity share of Rs.10 each				
	Basic and Diluted (Rs.) [#]	26	5.57	2.53	-1.54
	Significant Accounting Policies	1			
	Notes to Restated Financial Statement	2-32			

The accompanying significant accounting policies, Restated notes to accounts and notes on adjustments for Restated financial Statement (Note 1 to 32, Annexure IV & V) are an integral part of this statement.

[#] Basic and diluted earnings per share and other detail for the of reporting dates are considered after taking effect of Bonus issue.

The Schedules referred to above form an integral part of the Profit & Loss A/c as per our annexed report of even date.

For Krupal Bhuva & Co.

Chartered Accountants

FRN: 146585W

For and on behalf of the Board of Directors of

Rednex Pharmaceuticals Limited

CA Krupal B. Bhuva

Proprietor

M. No.: 182312

UDIN:

25182312BMIRTX9419

Place: Ahmedabad

Date: September 26, 2025

Chetan Rugnathbhai Matholiya

Chairman and Whole-Time Director

DIN: 09013701

Jayeshkumar Amarshibhai Sabava

Managing Director

DIN: 09013702

Rima Amitbhai Dalal

Company Secretary and Compliance

Officer

M. No.: A39280

Place: Ahmedabad

Date: September 26, 2025

Akashbhai Mansukhbhai Gangadiya

Whole Time Director & CFO

DIN: 09013700

Place: Ahmedabad

Date: September 26, 2025

ANNEXURE – III
RESTATED CASH FLOW STATEMENT

(Amount in Rs. Lakhs)

Particulars		For the period ended		
		31-03-25	31-03-24	31-03-23
A) Cash Flow from Operating Activities:				
Net Profit before tax as per Statement of Profit & Loss		515.68	234.15	-110.33
Adjustment for:				
Depreciation and amortization Expenses		287.05	116.74	22.48
Interest on Deposit		-2.32	-2.10	-0.35
Subsidy		-24.55	-	-
Finance Cost		150.60	113.65	20.82
Gratuity Provision		8.16	1.57	0.34
Operating profit before working capital changes		934.62	464.01	-67.04
Changes in Working Capital				
(Increase)/Decrease in Trade Receivables		-881.36	-431.23	-139.70
(Increase)/Decrease in Inventory		-947.66	-482.08	-191.84
(Increase)/Decrease in Short Term Loans & Advances		-131.87	149.96	-238.30
(Increase)/Decrease in Other Current Assets		-5.82	-74.57	-6.59
Increase/(Decrease) in Trade Payables		1,213.09	479.31	228.74
Increase/(Decrease) in Other Current Liabilities		18.22	-20.44	70.81
Increase/(Decrease) in Provisions, etc		-10.78	1.45	-
Cash generated from operations		188.44	86.41	-343.92
Less: Income Taxes paid		64.27	2.70	0.09
Net cash flow from operating activities	A	252.71	89.11	-343.83
B) Cash Flow from Investing Activities:				
Purchase of Fixed Assets including of CWIP		-253.05	-712.38	-579.94
Increase in Fixed Deposit		9.66	-10.42	-6.25
Other Non-Current Assets		21.80	-21.31	-7.26
Interest on Deposit		2.32	2.10	0.35
Net cash flow from investing activities	B	-219.27	-742.01	-593.10
C) Cash Flow from Financing Activities:				
Increase/(Decrease) in Short Term Borrowings		18.96	420.29	545.48
Increase/(Decrease) in Long Term Borrowings		-26.56	465.97	-1.89
Finance Cost		-150.60	-113.65	-20.82
Subsidy		24.55	-	-
Fresh issued of share during the year		-	-	415.00
Net cash flow from financing activities	C	-133.65	772.61	937.77
Net Increase/(Decrease) In Cash & Cash Equivalents	(A+B+C)	-100.21	119.71	0.84
Cash equivalents at the beginning of the year		121.72	2.01	1.17
Cash equivalents at the end of the year		21.51	121.72	2.01

Notes:

1.

(Amount in Rs. Lakhs)

Component of Cash and Cash equivalents	As at		
	31-03-25	31-03-24	31-03-23
Cash on hand	10.36	21.02	0.40
Balance With banks			
(i) In Current Accounts	0.54	100.70	1.61
(ii) Fixed Deposit with Maturity between (0-3 months)	10.61	-	-
Total	21.51	121.72	2.01

2. Cash flows are reported using the indirect method, whereby profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from regular revenue generating, financing and investing activities of the company are segregated.

3. The accompanying Restated significant accounting policies, Restated notes to accounts and notes on adjustments for Restated financial Statement (Note 1 to 32, Annexure IV & V) are an integral part of this statement. As per our annexed report of even date.

For Krupal Bhuva & Co.

Chartered Accountants

FRN: 146585W

CA Krupal B. Bhuva

Proprietor

M. No.: 182312

UDIN:

25182312BMIRTX9419

Place: Ahmedabad

Date: September 26, 2025

For and on behalf of the Board of Directors of

Rednex Pharmaceuticals Limited

Chetan Rugnathbhai Matholiya

Chairman and Whole-Time Director

DIN: 09013701

Jayeshkumar Amarshibhai Sabava

Managing Director

DIN: 09013702

Rima Amitbhai Dalal

Company Secretary and Compliance

Officer

M. No.: A39280

Place: Ahmedabad

Date: September 26, 2025

Akashbhai Mansukhbhai Gangadiya

Whole Time Director & CFO

DIN: 09013700

Place: Ahmedabad

Date: September 26, 2025

ANNEXURE-IV & ANNEXURE V

TO RESTATED FINANCIAL STATEMENTS OF COMPANY LIMITED

ANNEXURE-IV

SIGNIFICANT ACCOUNTING POLICY AND NOTES TO THE RESTATED FINANCIAL STATEMENTS

A. BACKGROUND

Our Company was originally incorporated as a Private Limited Company under the name "Rednex Pharmaceuticals Private Limited" on December 29, 2020 under the provisions of the Companies Act, 2013 with the Registrar of Companies, Ahmedabad. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extraordinary General Meeting, held on December 30, 2024 and consequently, the name of our Company was changed from "Rednex Pharmaceuticals Private Limited" to "Rednex Pharmaceuticals Limited" vide a fresh certificate of incorporation dated January 21, 2025 issued by the Registrar of Companies, Central Processing Centre bearing CIN: U24304GJ2020PLC119176. Company is currently engaged in manufacturing Tablets, Capsules, Dry Syrups, Oral Liquids and External Preparations viz. Cream, Ointment, Gel & Lotions for treatment of various diseases.

B. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

1. BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The Restated Statement of Assets and Liabilities of the Company as at March 31, 2025, March 31, 2024, and March 31, 2023 and the Restated Statement of Profit and Loss and Restated Statements of Cash Flows for the year ended on March 31, 2025, March 31, 2024, and March 31, 2023 and the annexure thereto (collectively, the “**Restated Financial Statements**”) have been extracted by the management from the Audited Financial Statements of the Company.

The financial statements of the company have been prepared and presented in accordance with the These Restated financial statements are prepared in accordance with Indian Generally Accepted Accounting Principles (GAAP) under the historical cost convention on the accrual basis except for certain financial instruments which are measured at fair values. GAAP comprises the Accounting Standards notified u/s 133 of the Companies Act, 2013 read with Companies (Accounts) Rules, 2014 and Companies (Accounting Standards) Rules, 2021. The accounting policies have been framed, keeping in view the fundamental accounting assumptions of Going Concern, Consistency and Accrual, as also basic considerations of Prudence, Substance over form, and Materiality. These have been applied consistently, except where a newly issued accounting standard is initially adopted or a revision in the existing accounting standards require a revision in the accounting policy so far in use. The need for such a revision is evaluated on an ongoing basis.

The Financial Statements have been prepared on a going concern basis, in as much as the management neither intends to liquidate the company nor to cease operations. And accordingly, assets, liabilities, income and expenses are recorded. Based on the nature of products and services, and the time between the acquisition of assets and realization in cash or cash equivalents, the company has ascertained its operating cycle as 12 months for the purposes of current and non-current classification of assets and liabilities.

The Restated financial information has been prepared for inclusion in the Draft Red Herring Prospectus (DRHP), Red Herring Prospectus (RHP) and Prospectus (Offer Document) to be filed by the Company with the SME platform of BSE in connection with proposed Initial Public Offer of its equity shares of face value of Rs 10 each of the Company comprising a fresh offer of equity shares, in accordance with the requirements of:

- a) Section 26 of part I of Chapter III of the Act;
- b) relevant provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements Regulations, 2018, issued by the Securities and Exchange Board of India ('SEBI') as amended in pursuance of the Securities and Exchange Board of India Act, 1992; and
- c) Guidance Note on Reports in Company Prospectuses (Revised 2019) issued by the Institute of Chartered Accountants of India (“ICAI”).

2. USE OF ESTIMATES

The preparation of financial statements required the management to make estimates and assumptions that affect the reported balance of assets and liabilities, revenues and expenses and disclosures relating to contingent liabilities. The Management believes that the estimates used in the preparation of financial statements are prudent and reasonable. Future results could differ from these estimates. Any revision of accounting estimates is recognized prospectively in the current and future periods. Significant estimates used by the management in the preparation of these financial statements include estimates of the economic useful life of plant and equipment, provision for expenses, etc.

3. PROPERTY, PLANT AND EQUIPMENT

Property, Plant & Equipment are stated at historical cost less accumulated depreciation and amortization. Cost includes purchase price and all other attributable cost to bring the assets to its working condition for the intended use. Property, Plant & Equipment have been recorded in the books of the Company at WDV as per Companies Act, 2013.

Subsequent expenditures related to Property; Plant & Equipment are added to its book value only if they increase the future benefits from the existing asset beyond its previously assessed standard of performance.

Assets are capitalized as capital work-in-progress till it is not ready for the intended use. At the point when an asset is operating at management's intended use, the cost of asset is transferred to the appropriate category of property, plant and equipment and depreciation/amortization commences.

4. INTANGIBLE ASSETS

Intangible assets that are acquired by the Company are measured initially at cost. After initial recognition, an intangible asset is carried at its cost less accumulated amortization and any accumulated impairment loss.

Subsequent expenditure, if any, is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates.

The estimated useful lives of intangibles are as follows:

Class of Asset	Useful life
Computer software	6 Years

The residual values, useful lives and method of amortization of intangible assets are reviewed at each financial year end and adjusted if appropriate.

An intangible asset is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal of an intangible asset is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognized in statement of profit and loss.

5. DEPRECIATION AND AMORTIZATION

Depreciation is provided on a Written Down Value Method ('WDV') over the estimated useful lives of the property, plant and equipment as estimated by the Management and is recognised in the statement of profit and loss.

Depreciation on additions (disposals) is provided on a pro-rata basis i.e. from (upto) the date on which asset is ready for use (disposed of). Amortization on Intangible assets is provided as prescribed in AS-26, "Intangible Assets" as set out in section 133 of the Act read with relevant rules as set out in schedule II to the Act.

The Management has estimated the useful lives for property, plant and equipment which is similar to the life specified in Schedule II of Companies Act, 2013

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively if appropriate. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

6. BORROWING COSTS

Borrowing cost includes interest and amortization of ancillary costs incurred in connection with the arrangement of borrowings. Borrowing costs directly attributable to the acquisition, construction or production of a qualifying asset that necessarily takes

a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the respective asset. All other borrowing costs are expensed in the period they occur.

7. IMPAIRMENT OF ASSETS

An asset is treated as impaired when the carrying cost of asset exceeds its recoverable value. An impairment loss is charged to the Statement of Profit and Loss in the year in which an asset is identified as impaired. The impairment loss recognized in prior accounting period is reversed if there has been a change in the estimate of amount.

8. INVESTMENTS

Investments, which are readily realizable and intended to be held for not more than one year from the date on which such investments are made, are classified as current investments. All other investments are classified as long-term investments.

On initial recognition, all investments are measured at cost. The cost comprises purchase price and directly attributable acquisition charges such as brokerage, fees and duties.

Current investments are carried in the financial statements at lower of cost and fair value determined on an individual investment basis.

Long-term investments are carried at cost. However, provision for diminution in value is made to recognize a decline other than temporary nature in value of investment.

On disposal of an investment, the difference between its carrying amount and net disposal proceeds is charged or credited to the statement of profit and loss.

8. INVENTORIES

Inventories are valued at lower of cost and net realisable value in case of Finished Goods & at Cost in case of Raw Material. Cost of inventories comprises material cost on FIFO basis, labour and other costs incurred in bringing them to their respective present location and condition.

9. REVENUE RECOGNITION

Revenue from sale of goods is recognized when significant risk and rewards of ownership of the goods have been passed to the buyer and it is reasonable to expect ultimate collection. Sale of goods is recognized net of GST and other taxes as the same is recovered from customers and passed on to the government.

Interest income is accounted on a time proportion basis taking into account the amount outstanding and the rate applicable except interest on income tax.

Other items of income and expenses are recognized on accrual basis.

10. EMPLOYEE BENEFITS

- i) Company's contribution to Provident Fund and other Funds for the year is accounted on accrual basis and charged to the Statement of Profit & Loss for the year. Further ESIC is not applicable on the company due to location benefits.
- ii) Retirement benefits in the form of Gratuity are considered as defined benefit obligations and are provided on the basis of the actuarial valuation
- iii) The company does not allow carry forward of earned leave and the same needs to be encashed within the financial year.

11. SEGMENT ACCOUNTING

In accordance with the Accounting Standard 17 "segment reporting" as prescribed under Companies (Accounting Standard) Rules, 2006 (as amended), as the company is covered under categories of SMC companies, the said accounting standard is not applicable to it.

12. ACCOUNTING FOR TAXES ON INCOME

Tax expense comprises of current and deferred tax. Current income tax is measured at the amount expected to be paid to the tax authorities in accordance with the Income-tax Act, 1961 enacted in India. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date.

(i) Deferred income taxes reflect the impact of timing differences between taxable income and accounting income originating during the current year and reversal of timing differences for the earlier years. Deferred tax is measured using the tax rates and the tax laws enacted or substantively enacted at the reporting date.

(ii) Deferred tax liabilities are recognized for all taxable timing differences. Deferred tax assets are recognized for deductible timing differences only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. In situations where the Company has unabsorbed depreciation or carry forward tax losses, all deferred tax assets are recognized only if there is virtual certainty supported by convincing evidence that they can be realized against future taxable profits.

The carrying amount of deferred tax assets are reviewed at each reporting date. The company writes-down the carrying amount of a deferred tax asset to the extent that it is no longer reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which deferred tax asset can be realized. Any such write-down is reversed to the extent that it becomes reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available.

13. CONTINGENT LIABILITIES AND PROVISIONS

Provisions are recognized only when there is a present obligation as a result of past events and when a reliable estimate of the amount of obligation can be made.

Contingent Liability is disclosed for

- a) Possible obligation which will be confirmed only by future events not wholly within the control of the Company or
- b) Present obligations arising from the past events where it is not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount of the obligation cannot be made.
- c) A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. Where there is a possible obligation or a present obligation that the likelihood of outflow of resources is remote, no provision or disclosure is made.

Contingent Assets are not recognized in the financial statements since this may result in the recognition of income that may never be realized.

14. EARNINGS PER SHARE:

The basic earnings per share is computed by dividing the net profit attributable to owners of the Company for the reporting years by the weighted average number of equity shares outstanding during the reporting years.

The number of shares used in computing diluted earnings per share comprises the weighted average shares considered for deriving basic earnings per share and all dilutive potential equity shares.

There are no potential dilutive instruments issued by the Company, therefore Weighted average number of Equity shares for Basic and Dilutive remain same during the reporting years.

EPS has been calculated to show the Impact of Extra ordinary items during the reporting years.

Adjustment of Bonus issue is given retrospectively as if it happened in the beginning of the reporting period.

15. CASH FLOW:

Cash flows are reported using the indirect method, whereby profit before tax is adjusted for the effects of transactions of non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses

associated with investing or financing cash flows. Cash flows from operating, investing and financing activities of the Company are segregated, accordingly.

16. RELATED PARTY TRANSACTIONS:

Related party transactions are already reported as per AS-18 of Companies (Accounting Standards) Rules, 2021, as amended, in the Note 29 of the enclosed restated financial statements.

17. The previous year figures have been reworked, regrouped, rearranged and reclassified wherever necessary. Accordingly amounts and other disclosure for the preceding years are included as an integral part of the current year financial statement and are to be read in relation to the amounts and other disclosure relating to the current year.

18. All the Figures are rounded off to nearest Lakhs, except otherwise stated.

19. Absolute amounts less than Rs. 500 are appearing in the financial statements as "0" due to presentation in lakhs.

C. CHANGES IN ACCOUNTING POLICIES IN THE YEARS COVERED IN THE RESTATED FINANCIALS

There is no change in significant accounting policies adopted by the Company.

D. NOTES ON RESTATEMENTS MADE IN THE RESTATED FINANCIALS

1. The financial statements including other financial information have been prepared after making such regroupings and adjustments, considered appropriate to comply with the same. As result of these regroupings and adjustments, the amount reported in the financial statements/information may not necessarily be same as those appearing in the respective audited financial statements for the relevant years.
2. Amount due to entities covered under Micro, Small and Medium Enterprises as defined in the Micro, Small, Medium Enterprises Development Act, 2006, have been reported basis of the parties identified by the management and relied upon by the Auditor

3. Realizations:

The Company evaluated the carrying amounts of property, plant and equipment, investments, inventories, loans and advances, receivables and other current assets. In developing the assumptions relating to the possible future uncertainties, the Company, as at the date of approval of these Restated financials has used internal and external sources on the expected future performance of the Company and management expects the carrying amount of these assets will be recovered and sufficient liquidity is available to fund the business operations for at least another 12 months. Due to any unforeseen circumstances the final impact on the Company's assets in future may differ from that estimate as at the date of approval of these Restated Financials.

4. Contractual liabilities

All other contractual liabilities connected with business operations of the Company have been appropriately provided for in the Restated financial statements.

5. Amounts in the financial statements

Amounts in the financial statements are reported in Indian Rupees in lakhs and rounded off to second digit of decimal. Figures in brackets indicate negative values.

6. Auditors Qualifications –

Details of Auditors qualifications and their impact on restated financial statement is given below.

a) Qualification which required adjustment in restated financial statements

Financial Year	Audit Qualifications	Remark
FY 2022-23	NIL	Not Applicable
FY 2023-24	NIL	
FY 2024-25	NIL	

b) Qualification which does not require adjustment in restated financial statements

Financial Year	Audit Qualifications	Remark
FY 2022-23	NIL	Not Applicable
FY 2023-24	NIL	
FY 2024-25	NIL	

ANNEXURE-V

MATERIAL ADJUSTMENTS [AS PER THE ICDR] REGULATION]

Appropriate adjustments have been made in the restated financial statements, whenever required, by reclassification of the corresponding items of assets, liabilities and cash flow statement, in order to ensure consistency and compliance with requirement of Company Act 2013, and Accounting Standards.

The Summary of results of restatements made in the audited financial statements of the Company for the respective years and their impact on the profit /(losses) of the Company is as under.

Statement of adjustments in the Financial Statements

Statement of Reserves & Surplus

(Amount in Lakhs Rs.)

Particulars	31-Mar-25	31-Mar-24	31-Mar-23
Reserve & Surplus as per audited accounts but before adjustments for restated accounts: (a)	522.07	17.48	-89.76
Add: Cumulative Adjustment made in Statement of Profit and Loss Account	-	78.19	-8.00
Net Adjustment in Reserves and Surplus (b)	-	78.19	-8.00
Total Reserve & Surplus as per Restated Accounts: (a+b)	522.07	95.67	-97.76

Statement of Profit and Loss after Tax

The reconciliation of Profit/(loss) after tax as per audited results and the Profit/(loss) after tax as per Restated accounts is presented below in Table-1. This summarizes the results of restatements made in the audited accounts for the respective years and its impact on the respective year profit & losses of the company.

(Amount in Lakhs Rs.)

Particulars	For the Year/Period Ended:		
	31-Mar-25	31-Mar-24	31-Mar-23
Net Profit/(loss) after Tax as per audited accounts but before adjustments for restated accounts:	504.60	107.24	-84.55
Adjustments to Net Profit/(Loss) as per Audited Financial Statements (b)	-78.20	86.19	-8.00
Add: Reversal of Deferred Expenses	39.09	9.77	13.46
Add/(Less): Provision for Gratuity as per AS -15 (Revised)	1.91	-1.57	-0.34
Add (Less): Subsidy misclassification	-1.49	-	1.49
Add (Less): Revenue Expenses Reclassified from Fixed Assets	1.95	-1.47	-0.53
Add (Less): Recognition of expense on accrual basis	11.61	-5.13	-67.37
Add (Less): Interest on Income Tax	1.25	-1.25	-

Add (Less): Interest on MSME	0.20	-0.20	-
Add (Less): Misclassification between Asset & Expense	-	-	-1.77
Add (Less): Prior Period Adjustment	-1.12	-0.84	2.33
Add (less): Capex wrongly charged to P&L	-30.95	23.97	6.98
Add (Less): Change in Depreciation	-115.64	96.23	19.41
Short/(Excess) Provision for Deferred Tax	17.86	-36.20	18.34
Short/(Excess) Provision for Current Tax	-2.87	2.87	-
Net Profit/(Loss) After Tax arrived at After Restatement adjustments (C = A - B)	426.40	193.43	-92.55
Net Profit/(Loss) After Tax as per Restated Accounts	426.40	193.43	-92.55

a) Adjustment of Gratuity Expenses

Company had accounted gratuity on cash basis, however during the restatement, Company has complied with the requirement of AS – 15 (Revised) “Employee Benefits” and accordingly booked Gratuity expenses basis of actuarial valuation report.

b) Adjustment on account of Provision of Deferred Tax Assets:

Due to Provision for Gratuity (Employee benefits), Difference of Depreciation of Fixed Assets as per Companies Act, 2013 and Income Tax Act, 1961 etc. during the period of restatement, The Company has recalculated deferred tax liability and deferred tax assets at the end of respective year ended. For more details refer table of Reconciliation of Statement of Profit and loss as above.

c) Provision of Income Tax (Current/Prior Period):

During the restatement, the Income tax provision was recalculated on restated Profit/(Loss) of respective year, accordingly the effect of revised income tax provision has been made in the Restated Statement of Profit and Loss account. Short/(Excess) provision has adjusted in respective year/period. For More details, refer Note-31 enclosed with the Restated Financial Statement.

d) Adjustment relating to Deferred Expenses

In the audited financial statements for FY 2022-23, certain expenditure was presented under the head “Deferred Expenses” within Current Assets. During preparation of the restated financial statements, such expenditure has been reclassified and recognized in the Statement of Profit and Loss in the respective years, in accordance with the requirements of the Companies Act, 2013 and the applicable Accounting Standards, which do not permit capitalization of deferred expenses under assets.

Further, in the audited financial statements for FY 2024-25, the balance carried forward under “Deferred Expenses” has been fully charged to the Statement of Profit and Loss as a prior period item.

e) Accounting of Certain Expenses on Accrual Basis

During the restatement, certain expenses have been identified which had been accounted for on cash basis instead of accrual basis and therefore, necessary adjustments have been made in Restated Statement of Profit & Loss and Prepaid Expenses in Statement of Assets & Liabilities. For more details refer table of Reconciliation of Statement of Profit and loss as above.

f) Accounting of PPE, Capitalisation, Decapitalisation of Certain Exp

During the restatement, it was noted that certain revenue expenditures had been incorrectly capitalized as fixed assets and, conversely, certain capital expenditures had been wrongly charged to the Statement of Profit and Loss. These errors have been rectified in the restated financial statements by appropriately reclassifying the items. Consequently, the date of capitalization and related depreciation have been recomputed in the Restated Statement of Profit and Loss. For further details, please refer to the table on Reconciliation of Statement of Profit and Loss above.

As per our separate report of even date

For Krupal Bhuvu & Co.

Chartered Accountants

FRN:- 146585W

**For and on behalf of the Board of Directors of
Rednex Pharmaceuticals Limited**

CA Krupal B. Bhuvu

Proprietor

M. No.:- 182312

UDIN: 25182312BMIRTX9419

Place: Ahmedabad

Date: - 26/09/2025

Chetan Rugnathbhai Matholiya

Chairman and Whole-Time
Director

DIN: 09013701

Jayeshkumar Amarshibhai Sabava

Managing Director

DIN: 09013702

Rima Amitbhai Dalal

Company Secretary & Compliance
Office

M. No.: A39280

Place: Ahmedabad

Date: - 26/09/2025

Akashbhai Mansukhbhai Gangadiya

Whole Time Director & CFO

DIN: 09013700

Place: Ahmedabad

Date: - 26/09/2025

NOTE - 2
RESTATED STATEMENT OF SHARE CAPITAL, RESERVES AND SURPLUS

Particulars	As At		
	31-03-2025	31-03-2024	31-03-2023
Share Capital			
Authorized Share Capital			
Equity shares of Rs.10 each	4,250,000	4,250,000	4,250,000
Equity Share Capital (Amount in Lacs)	425.00	425.00	425.00
Issued, Subscribed and Paid-up Share Capital			
Equity Shares of Rs. 10 each fully paid up	4,250,000	4,250,000	4,250,000
Share Capital (Amount in Lacs)	425.00	425.00	425.00
Total (Amount in Lacs)	425.00	425.00	425.00

1. Terms/rights attached to equity shares:

- i. The Company has only one class of shares referred to as equity shares having a par value of Rs.10/-. Each holder of equity shares is entitled to one vote per share.
- ii. In the event of liquidation of the Company, the holders of equity shares shall be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. The amount distributed will be in proportion to the number of equity shares held by the shareholders.
- iii. During the immediately preceding five years, the company has issued right issue of equity shares on 23rd August, 2022 Amounting to Rs. 415 Lacs.
- iv. As the Company is not a subsidiary of any other company, its shares are not held by any holding or ultimate holding company.
- v. There are no shares reserved for issue under options and contracts or commitments for the sale of shares or disinvestment.
- vi. During the period of last five years there are no shares reserved for issue under options and contracts or commitments for the sale of shares or disinvestment.
- vii. During the period of last five years the Company has not bought back any shares
- viii. There are no securities which are convertible into equity/preference shares.
- ix. After current reporting date, there is an increase in authorized capital and issue of bonus shares as detailed in Note – 32

2. The figures disclosed above are based on the restated summary statement of assets and liabilities of the Company.
3. Company does not have any Revaluation Reserve.
4. During the immediately preceding five years, the company has not issued any bonus equity shares.
5. There are no calls unpaid by the Directors or officers of the Company.
6. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.

7. The reconciliation of the number of Equity shares outstanding as at: -

Particulars	As at		
	31-03-25	31-03-24	31-03-23
Number of shares at the beginning	4,250,000	4,250,000	100,000
Add: Bonus Share Issued	-	-	-
Add: Right Issue of shares	-	-	4,150,000
Number of shares at the end	4,250,000	4,250,000	4,250,000

8. The detail of shareholders holding more than 5% of Shares: -

Name of Shareholders	As at (No. of Shares)		
	31-03-25	31-03-24	31-03-23
Akashbhai Mansukhbhai Gangadiya	1,416,526	1,416,528	1,416,528
% of total Shares	33.33%	33.33%	33.33%
% Change	0.00%	0.00%-	0.00%

Chetan Rugnathbhai Matholiya	1,416,526	1,416,528	1,416,528
% of total Shares	33.33%	33.33%	33.33%
% Change	0.00%	0.00%	0.00%
Jayeshkumar Amarshibhai Sabava	1,416,944	1,416,944	1,416,944
% of total Shares	33.34%	33.34%	33.34%
% Change	0.00%	0.00%	0.00%
Total	4,249,996	4,250,000	4,250,000

9. Promoters' Shareholding

Shares held at the end of the year 31.03.2025			
Name	No. of Shares	% of total Shares	% Change during the year
Akashbhai Mansukhbhai Gangadiya	1,416,526.00	33.33%	0.00%
Chetan Rugnathbhai Matholiya	1,416,526.00	33.33%	0.00%
Jayeshkumar Amarshibhai Sabava	1,416,944.00	33.34%	0.00%
Total	4,249,996.00	100.00%	

Shares held at the end of the year 31.03.2024			
Name	No. of Shares	% of total Shares	% Change during the year
Akashbhai Mansukhbhai Gangadiya	1,416,528.00	33.33%	0.00%
Chetan Rugnathbhai Matholiya	1,416,528.00	33.33%	0.00%
Jayeshkumar Amarshibhai Sabava	1,416,944.00	33.34%	0.00%
Total	4,250,000.00	100.00%	

Shares held at the end of the year 31.03.2023			
Name	No. of Shares	% of total Shares	% Change during the year
Akashbhai Mansukhbhai Gangadiya	1,416,528.00	33.33%	0.00%
Chetan Rugnathbhai Matholiya	1,416,528.00	33.33%	0.00%
Jayeshkumar Amarshibhai Sabava	1,416,944.00	33.34%	0.00%
Total	4,250,000.00	100.00%	

Reserves and Surplus

(Amount in Rs. Lakhs)

Particulars	As at		
	31-03-2025	31-03-2024	31-03-2023
Securities Premium Reserve			
Opening Balance	-	-	-
Received on shares issued during the year	-	-	-
Less: Share Issue Expense	-		
Closing Balance	-	-	-
General Reserve			
Opening Balance	-	-	-
Transferred from Statement of Profit and Loss	-	-	-
Closing Balance	-	-	-
Statement of Profit and Loss			
Opening Balance	95.67	-97.76	-5.21
Profit for the Year	426.40	193.43	-92.55
Transferred to General Reserve	-	-	-
Closing Balance	522.07	95.67	-97.76
Balance as at the end of Financial Year	522.07	95.67	-97.76

NOTE – 3
RESTATED STATEMENT OF LONG-TERM BORROWINGS

(Amount in Rs. Lakhs)

Particulars	As At		
	31-03-25	31-03-24	31-03-23
(A) Secured Loan			
(i) Term loans			
From Banks	1,081.92	1,075.88	507.91
Sub-total	1,081.92	1,075.88	507.91
Less: Current Maturities	152.60	120.00	18.00
Total	929.32	955.88	489.91

Notes:

1. The terms and conditions and other information in respect of Secured Loans are given in NOTE-3 (A)
2. The Company does not have any continuing default in repayment of loans and interest as on the reporting date.
3. The Company has not taken any loan from financial institution or banks for any specified purpose for which it is not utilized.
4. The company has not been declared as "wilful defaulter" by any bank or financial Institution or other lender.
5. There is no pending registration or modification or satisfaction of Charge at the end of reporting periods, which required to filed with Registrar of Companies except the following:

(Amount in Rs. Lakhs)

Lender Name	Loan Type/Purpose	Sanction Amount	Date of Sanction	Security
ICICI Bank Limited	Car Loan	6.79	23-09-24	Motor Car

**The above car loan in repaid as on date of the Draft Red Herring Prospectus.*

6. List of persons/entities classified as 'Promoters' and 'Promoter Group' has been determined by the Management and relied upon by the Auditors. The Auditors have not performed any procedure to determine whether the list is accurate and complete.
7. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.
8. The figures disclosed above are based on the restated summary statement of assets and liabilities of the Company.

NOTE 3 (A)
RESTATED STATEMENT OF PRINCIPAL TERMS OF SECURED LOANS AND ASSET CHARGED AS SECURITY

(Amount in Rs. Lakhs)

Sr. No.	Name of Lender	Name	Purpose	Sanction amount	Rate of interest	Primary & Collateral Security	Re-Payment Schedule	Outstanding amount as on		
								31.03.2025	31.03.2024	31.03.2023
1	State Bank of India	Term Loan	For acquisition and installation of plant & machinery	988.00	9.15%	Note 1	Principal is repayable over 84 months commencing from October 2023, after a moratorium up to September 2023, with instalments increasing progressively from Rs. 3 Lakhs to Rs. 22 Lakhs until final maturity in September 2030.	955.98	1,075.88	507.91
2	State Bank of India	Term Loan (Solar)	Installation of solar power plant	123.00	9.15%	Note 1	Loan to be repaid in 84 EMIs of Rs. 2.03 Lakhs/ month.	119.57	-	-
3	ICICI Bank	Vehicle Loan	Vehicle loan availed for purchase of vehicles	6.79	9.65%	Hypothecation of the vehicle	Principal repayable in 60 monthly installments of Rs 0.14 Lakh each and last installment of Rs 0.14 Lakh	6.37	-	-
Total								1,081.92	1,075.88	507.91

Sr No.	Note
Note 1	The borrowings are secured by hypothecation of all plant and machinery, inventories, and trade receivables of the Company. The collateral security comprises equitable mortgage of immovable properties of the Company, relative of Directors and M/s. Rednex Pharmaceuticals. The borrowings are further secured by personal guarantees of the Directors, relatives of Directors, and a corporate guarantee provided by M/s. Rednex Pharmaceuticals.

NOTE- 4
RESTATED STATEMENT OF DEFERRED TAX (ASSETS) / LIABILITIES

(Amount in Rs. Lakhs)

Particulars	As At		
	31-03-25	31-03-24	31-03-23
Opening Balance (A)	Rs.	Rs.	Rs.
Opening Balance of Deferred Tax Asset / (Liability)	(11.75)	17.78	-
DTA / (DTL) on Timing Difference in Depreciation as per Companies Act and Income Tax Act.	10.76	(8.19)	(3.89)
DTA / (DTL) on account of Gratuity provision	1.40	0.27	0.06
DTA / (DTL) on account of Business loss	-	(21.61)	21.61
Total timing difference (B)	12.16	(29.53)	17.78
Closing Balance of Deferred Tax Asset / (Liability) (B)+(A)	0.41	(11.75)	17.78

1. The figures disclosed above are based on the restated summary statement of assets and liabilities of the Company.
2. The Company has created/reversed DTA/DTL as per AS-22 issued by ICAI.
3. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.

NOTE – 5
RESTATED STATEMENT OF LONG-TERM PROVISIONS

(Amount in Rs. Lakhs)

Particulars	As At		
	31-03-25	31-03-24	31-03-23
Provision for Employee Benefit Expense:			
Provision for Gratuity (Refer Note 5A)	10.05	1.91	0.34
Total	10.05	1.91	0.34

(a) As per Accounting Standard 15 - "Employee Benefits", the disclosure of Employee Benefits as defined in the accounting standard are given below:

Defined Benefit Plan: Present value of gratuity is determined based on actuarial valuation using the projected unit credit method.

(b) The figures disclosed above are based on the restated summary statement of assets and liabilities of the Company.

(c) The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.

NOTE – 5A
RESTATED STATEMENT OF EMPLOYEE BENEFIT DISCLOSURE (GRATUITY)

The disclosures required under AS 15 “Employee Benefits” notified in the Companies (Accounting Standards) Rules, 2021 are as given below:

(Amount in Rs. Lakhs)

Particulars	As at		
	31-03-25	31-03-24	31-03-23
1.The amounts recognized in the Balance Sheet are as follows:			
Present value of unfunded obligations Recognized	10.07	1.91	0.34
Net Liability	10.07	1.91	0.34
2.The amounts recognized in the Profit & Loss A/c are as follows:			
Current Service Cost	4.80	1.32	0.34
Interest on Defined Benefit Obligation	0.14	0.02	-
Expected Return on Plan Assets	-	-	-
Net actuarial losses (gains) recognised in the year	3.22	0.22	-
Total, Included in “Salaries, Allowances & Welfare”	8.16	1.57	0.34

3.Changes in the present value of defined benefit obligation:			
Defined benefit obligation as at the beginning of the year/period Net of Fair Value of Opening Plan Assets	1.91	0.34	-
Service cost	4.80	1.32	0.34
Interest cost	0.14	0.02	-
Expected Return on Plan Assets	-	-	-
Net actuarial losses (gains) recognised in the year	3.22	0.22	-
Benefit paid by the Company	-	-	-
Defined benefit obligation as at the end of the year/period	10.07	1.91	0.34
Current	0.02	0.00	0.00
Non Current	10.05	1.91	0.34
Total	10.07	1.91	0.34
Benefit Description (Gratuity Valuation as per Act 1972)			
Retirement Age:	58 years	58 years	58 years
Vesting Period:	5 years	5 years	5 years
The principal actuarial assumptions for the above are:			
Future Salary Rise:	10.00%P.A	10.00%P.A	10.00%P.A
Expected return on plan assets	N.A.	N.A.	N.A.
Discount rate per annum:	6.60%P.A	7.15%P.A	7.30%P.A
Withdrawal Rate:	20.00%P.A	20.00%P.A	20.00%P.A
Mortality Rate:	IALM 2012-14	IALM 2012-14	IALM 2012-14
Valuation Method	Projected Unit Credit (PUC)		
Reconciliation of defined benefit obligation:			
Opening Defined Benefit Obligation	1.91	0.34	-
Transfer in/(out) obligation	-	-	-
Current service cost	4.80	1.32	0.34
Interest cost	0.14	0.02	-
Actuarial loss (gain)	3.22	0.22	-
Closing Defined Benefit Obligation	10.07	1.91	0.34
Change in Plan Assets:			
Plan assets at period beginnig at fair value	-	-	-
Expected return on plan assets	-	-	-
Actuarial loss (gain)	-	-	-
Contributions	-	-	-
Benefits	-	-	-
Plan assets at period end at fair value	-	-	-

Company has disclosed the defined contribution plan in Annexure-IV under Contribution to Provident funds and other funds. As the company makes contribution for all employees as a whole, it has been excluded from above disclosure for KMP.

The remuneration to Key Managerial Personnel (KMP), Director and other related employees excludes the provisions made for gratuity as these are determined on an actuarial basis for the Company as a whole.

NOTE – 6
RESTATED STATEMENT OF SHORT TERM BORROWINGS

(Amount in Rs. Lakhs)

Particulars	As At		
	31-03-2025	31-03-2024	31-03-2023
Loans Repayable on Demand			
A) Secured Loan			
From Bank	501.57	426.46	151.63
(B) Unsecured Loan			
Related Parties			
From Directors	298.47	360.83	305.37

From Relatives of Directors	32.09	58.48	70.48
C) Current Maturity of Long-Term Borrowings	152.60	120.00	18.00
Total	984.73	965.77	545.48

Note:

1. The terms and conditions and other information in respect of Loans are given in NOTE-6 (A) & 6(B)
2. The Company does not have any continuing default in repayment of loans and interest as on the reporting date.
3. The company is not declared as "wilful defaulter" by any bank or financial Institution or other lender as on the reporting date.
4. There is no such borrowing from banks and financial institutions taken by company for specific purpose but not used for same purpose.
5. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.
6. The figures disclosed above are based on the restated summary statement of assets and liabilities of the Company.

NOTE 6 (A)
RESTATED STATEMENT OF PRINCIPAL TERMS OF SHORT-TERM BORROWINGS:

(Amount in Rs. Lakhs)

Sr. No.	Name of Lender	Purpose	Sanction amount	Rate of interest	Primary & Collateral Security	Re-Payment Schedule	Outstanding amount as on 31.03.2025	Outstanding amount as on 31.03.2024	Outstanding amount as on 31.03.2023
A	Secured - From Banks								
1	State Bank of India	Cash Credit	700.00	9.85%	Refer Note 1	Payable on Demand	501.57	426.46	151.63
	TOTAL						501.57	426.46	151.63

Note:

1. The borrowings are secured by hypothecation of all plant and machinery, inventories, and trade receivables of the Company. The collateral security comprises equitable mortgage of immovable properties of the Company, relatives of Directors, M/s. Rednex Pharmaceuticals. The borrowings are further secured by personal guarantees of the Directors and their relatives, and a corporate guarantee provided by M/s. Rednex Pharmaceuticals.
2. The figures disclosed above are based on the restated summary statement of assets and liabilities of the Company.
3. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.

NOTE 6 (B)
RESTATED STATEMENT TERMS & CONDITIONS OF SHORT-TERM UNSECURED LOANS

(Amount in Rs. Lakhs)

Name of Lender	Relation with Lender	Purpose	Rate of Interest	Re-Payment Schedule	31-03-2025	31-03-2024	31-03-2023
A. Related Parties							
From Directors							
Jayeshkumar Amarshibhai Sabava	Managing Director	Business Purpose	0.00%	On-Demand	108.05	119.53	109.07
Chetan Rugnathbhai Matholiya	Chairman and WTD	Business Purpose	0.00%	On-Demand	107.70	152.13	143.63
Akashbhai Mansukhbhai Gangadiya	WTD and CFO	Business Purpose	0.00%	On-Demand	82.72	89.17	52.67
Total (A)					298.47	360.83	305.37

From Relatives of Directors							
Dakshaben Jayeshbhai Sabava	Wife of Director	Business Purpose	0.00%	On-Demand	1.75	1.75	1.75
Kartikkumar Mansukhbhai Gangadiya	Brother of Director	Business Purpose	0.00%	On-Demand	15.60	31.71	35.71
Mitalben Chetanbhai Matholiya	Wife of Director	Business Purpose	0.00%	On-Demand	7.39	7.39	7.39
Shaileshbhai Rugnathbhai Matholiya	Brother of Director	Business Purpose	0.00%	On-Demand	7.35	17.63	25.63
Total (B)					32.09	58.48	70.48
TOTAL (A+B)					330.56	419.31	375.85

- 1) The figures disclosed above are based on the restated summary statement of assets and liabilities of the Company.
2) The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.

NOTE – 7
RESTATED STATEMENT OF TRADE PAYABLES

(Amount in Rs. Lakhs)

Particulars	As at		
	31-03-2025	31-03-2024	31-03-2023
Trade Payables			
Micro and Small Enterprises	392.01	41.34	-
Other than Micro, Small Enterprises	1,535.42	673.00	235.03
Disputed dues- MSME	-	-	-
Total	1,927.43	714.34	235.03

The disclosure of information under the MSMED Act, 2006 has been made to the extent that such parties have been identified based on the information available with the company. The details of the outstanding amounts and interest due to Micro & Small Enterprises are provided below. However, these amounts are disclosed only for reporting purposes and are not provided for in the books of accounts.

(Amount in Rs. Lakhs)

Particulars	As at		
	31-03-2025	31-03-2024	31-03-2023
a) (i) The principal amount remaining unpaid to any supplier at the end of accounting year included in trade payables	392.01	41.34	-
(ii) The interest due on above	3.52	0.20	-
The total of (i) & (ii)	395.53	41.54	-
b) The amount of interest paid by the buyer in terms of section 16 of the Act	-	-	-
c) the amount of interest due and payable for the period (where the principal has been paid but interest under the MSMED Act, 2006 not paid)	-	-	-
d) the amount of interest due and payable relating to earlier years	0.20	-	-
e) The amounts of interest accrued and remaining unpaid at the end of financial year	3.72	0.20	-

The above information has been determined to the extent such parties have been identified on the basis of information available with the company and the same has been relied upon by the auditors.

Trade Payable Ageing as at 31.03.2025
(Amount in Rs. Lakhs)

Outstanding from the due date of payment	MSME*	Others	Disputed dues- MSME	Disputed dues- Others	Total
Unbilled	-	-	-	-	-
Not Due			-	-	-
Less than 1 year	392.01	1,510.79	-	-	1,902.80
1-2 years		24.63	-	-	24.63
2-3 years	-	-	-	-	-
More than 3 years	-	-	-	-	-
Total	392.01	1,535.42			1,927.43

Trade Payable Ageing as at 31.03.2024
(Amount in Rs. Lakhs)

Outstanding from the due date of payment	MSME*	Others	Disputed dues- MSME	Disputed dues- Others	Total
Unbilled	-	-	-	-	-
Not Due			-	-	-
Less than 1 year	41.34	673.00	-	-	714.34
1-2 years	-	-	-	-	-
2-3 years	-	-	-	-	-
More than 3 years	-	-	-	-	-
Total	41.34	673.00	-	-	714.34

Trade Payable Ageing as at 31.03.2023
(Amount in Rs. Lakhs)

Outstanding from the due date of payment	MSME*	Others	Disputed dues- MSME	Disputed dues- Others	Total
Unbilled	-	-	-	-	-
Not Due	-	-	-	-	-
Less than 1 year	-	235.03			235.03
1-2 years	-	-	-	-	-
2-3 years	-	-	-	-	-
More than 3 years	-	-	-	-	-
Total	-	235.03	-	-	235.03

* MSME includes balances due to Micro, Small and Medium Enterprises.

Notes:

1. The figures disclosed above are based on the restated summary statement of assets and liabilities of the Company.
2. Amount due to entities covered under Micro, Small and Medium Enterprises as defined in the Micro, Small, Medium Enterprises Development Act, 2006, have been identified on the basis of information available with the Company.
3. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.
4. Ageing of the Supplier, along with any amount involved in disputes as required by Schedule III of Companies Act, 2013 is disclosed below after it becomes due for payment. In case of no credit terms defined the break-up of age wise supplier balance is given below after considering from the date of transactions.

NOTE – 8
RESTATED STATEMENT OF OTHER CURRENT LIABILITIES

(Amount in Rs. Lakhs)

Particulars	As At		
	31-03-25	31-03-24	31-03-23
Other Current Liabilities			
Statutory Dues Payables	4.72	1.71	-
Advance from customers	16.93	5.60	54.24
Creditors for Expenses	17.84	11.82	7.64
Creditor for Capital Goods	45.06	59.08	45.29
Director Remuneration payable	3.00	4.40	1.50
Salary Payable	22.72	9.44	3.82
Total	110.27	92.05	112.49

Notes:

- 1.The figures disclosed above are based on the restated summary statement of assets and liabilities of the Company.
- 2.The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.

NOTE – 9
RESTATED STATEMENT OF SHORT-TERM PROVISIONS

(Amount in Rs. Lakhs)

Particulars	As At		
	31-03-2025	31-03-2024	31-03-2023
Provision for employee benefits			
Provision for Gratuity	0.02	0.00	0.00
Provision for Income Tax			
Provisions for Tax	99.58	11.19	-
Provision for Interest	-	1.25	-
Others			
Other Provisions	-	-	-
Interest Payable on MSME	3.72	0.20	-
Total	103.32	12.63	0.00

Notes:

1. The figures disclosed above are based on the restated summary statement of assets and liabilities of the Company.
- 2.The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.

NOTE – 10
RESTATED STATEMENT OF PROPERTY, PLANT AND EQUIPMENT AND INTANGIBLE ASSETS

(Amount in Rs. Lakhs)

FY 2022-23

Particulars	Gross Block				Depreciation and amortization				Net Block	
	As at 01.04.2022	Additions during the year	Deletions during the year	As at 31.03.2023	Upto 01.04.2022	During the year	Deletion during the year	Total upto 31.03.2023	As at 31.03.2023	As at 31.03.2022
(i) Property Plant & Equipment										
Freehold Land	127.47	-	-	127.47	-	-	-	-	127.47	127.47
Building	-	120.63	-	120.63	-	4.77		4.77	115.86	-
Plant & Machinery	-	135.09	-	135.09	-	10.17		10.17	124.92	-
Electrical Installation	-	30.12	-	30.12	-	3.25		3.25	26.87	-
Furniture & Fittings	-	28.31	-	28.31	-	3.05		3.05	25.26	-
Computer and Computer Accessories	-	5.24	-	5.24	-	0.19		0.19	5.05	-
Sub-total	127.47	319.39	-	446.86	-	21.43	-	21.43	425.43	127.47
(ii) Intangible										
Computer Software	-	6.64		6.64	-	1.05		1.05	5.59	-
Sub-total	-	6.64	-	6.64	-	1.05	-	1.05	5.59	-
(iii) CWIP										
Building	233.46	82.83	120.63	195.66					195.66	233.46
Electrical Installation	0.42	72.38	25.76	47.04					47.04	0.42
Furniture & Fittings	12.65	89.03	28.31	73.37					73.37	12.65
Plant & Machinery	108.30	309.73	122.42	295.61					295.61	108.30
Computer Software	2.94	3.30	6.24	-					-	2.94
Sub-total	357.77	557.27	303.36	611.68	-	-	-	-	611.68	357.77
Total	485.24	883.30	303.36	1,065.18	-	22.48	-	22.48	1,042.70	485.24
Previous Year	-	-	-	-	-	-		-	-	-

FY 2023-24

Particulars	Gross Block				Depreciation and amortization				Net Block	
	As at 01.04.2023	Additions during the year	Deletions during the year	As at 31.03.202 4	Upto 01.04.2023	During the Period	Deletion during the period	Total upto 31.03.202 4	As at 31.03.2024	As at 31.03.2023

(i) Property Plant & Equipment										
Freehold Land	127.47	-	-	127.47	-	-	-	-	127.47	127.47
Building	120.63	241.20	-	361.83	4.77	16.98	-	21.75	340.08	115.86
Plant & Machinery	135.09	749.55	-	884.64	10.17	58.27	-	68.44	816.20	124.92
Electrical Installation	30.12	110.61	-	140.73	3.25	14.52	-	17.77	122.96	26.87
Furniture & Fittings	28.31	211.20	-	239.51	3.05	21.03	-	24.08	215.43	25.26
Computer and Computer Accessories	5.24	0.18	-	5.42	0.19	3.26	-	3.45	1.97	5.05
Sub-total	446.86	1,312.74	-	1,759.60	21.43	114.06	-	135.49	1,624.11	425.43
(ii) Intangible										
Computer Software	6.64	11.32	-	17.96	1.05	2.68	-	3.73	14.23	5.59
Sub-total	6.64	11.32	-	17.96	1.05	2.68	-	3.73	14.23	5.59
(iii) CWIP										
Building	195.66	45.54	241.20	-	-	-	-	-	-	195.66
Electrical Installation	47.04	57.93	104.97	-						47.04
Furniture & Fittings	73.37	136.97	210.34	-						73.37
Plant & Machinery	295.61	438.56	734.17	-	-	-	-	-	-	295.61
Computer Software	-									
Sub-total	611.68	679.00	1,290.68	-	-	-	-	-	-	611.68
Total	1,065.18	2,003.06	1,290.68	1,777.56	22.48	116.74	-	139.22	1,638.34	1,042.70
Previous Year	485.24	883.30	303.36	1,065.18	-	22.48	-	22.48	1,042.70	485.24

FY 2024-25

Particulars	Gross Block				Depreciation and amortization				Net Block	
	As at 01.04.2024	Additions during the year	Deletions during the year	As at 31.03.2025	Upto 01.04.2024	During the Period	Deletion during the period	Total upto 31.03.2025	As at 31.03.2025	As at 31.03.2024
(i) Property Plant & Equipment										
Freehold Land	127.47	-	-	127.47	-	-	-	-	127.47	127.47
Building	361.83	4.57	-	366.40	21.75	32.37	-	54.12	312.28	340.08
Plant & Machinery	884.64	75.32	-	959.96	68.44	154.01	-	222.45	737.51	816.20
Electrical Installation	140.73	0.29	-	141.02	17.77	31.88	-	49.65	91.37	122.96
Furniture & Fittings	239.51	13.30	-	252.81	24.08	57.55	-	81.63	171.18	215.43
Computer and Computer Accessories	5.42	8.94	-	14.36	3.45	2.68	-	6.13	8.23	1.97
Vehicles	-	7.14	-	7.14	-	1.15	-	1.15	5.99	-

Solar Plant	-	143.49	-	143.49	-	1.82	-	1.82	141.67	-
Sub-total	1,759.60	253.05	-	2,012.65	135.49	281.46	-	416.95	1,595.70	1,624.11
(ii) Intangible										
Computer Software	17.96	-	-	17.96	3.73	5.59	-	9.32	8.64	14.23
Sub-total	17.96	-	-	17.96	3.73	5.59	-	9.32	8.64	14.23
Total	1,777.56	253.05	-	2,030.61	139.22	287.05	-	426.27	1,604.34	1,638.34
Previous Year	1,065.18	2,003.06	1,290.68	1,777.56	22.48	116.74	-	139.22	1,638.34	1,042.70

Notes:

1.1 The figures disclosed above are based on the restated summary statement of assets and liabilities of the Company.

1.2 The Company has not revalued any Property or Plant and Equipment.

2. Title deeds of all the immovable property

The title deeds of all the immovable property are held in the name of the company.

3. Details of Ageing Schedule of Capital Work-in Progress

Capital Work-In-Progress Ageing

Balance as at 31.03.2023

Particulars	Amount in Capital work in progress for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Project in Progress	54.46	557.22	-	-	611.68

Note 1: There has been no Capital Work in Progress which has exceeded its cost compared to its original plan

Note 2: Company does not have any project which is temporary suspended, therefore, disclosure requirement thereof is not applicable.

Balance as at 31.03.2024

Particulars	Amount in Capital work in progress for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Project in Progress	-	-	-	-	-

Balance as at 31.03.2025

Particulars	Amount in Capital work in progress for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Project in Progress	-	-	-	-	-

4. No proceedings have been initiated or pending against the company for holding any benami property under the Prohibition of Benami Property Transaction Act, 1988 and the Rules made thereunder and as amended from time to time.

5. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.

NOTE – 11
RESTATED STATEMENT OF OTHER NON-CURRENT ASSETS

(Amount in Rs. Lakhs)

Particulars	As at		
	31-03-2025	31-03-2024	31-03-2023
Security Deposit	8.36	30.16	8.85
FD with maturity more than 12 months (Held as margin money or security against borrowings, guarantees and other commitments)	-	16.67	6.25
Total	8.36	46.83	15.10

1. The figures disclosed above are based on the restated summary statement of assets and liabilities of the Company.
2. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.

NOTE – 12
RESTATED STATEMENT OF TRADE RECEIVABLES

(Amount in Rs. Lakhs)

Particulars	As at		
	31-03-2025	31-03-2024	31-03-2023
Trade Receivables			
Unsecured and Considered Good	1,452.29	570.93	139.70
Secured & Considered Good	-	-	-
Doubtful	-	-	-
Total	1,452.29	570.93	139.70

Trade Receivables ageing schedule as at 31 March, 2025

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months- 1 years	1-2 years	2-3 years	More than 3 years	
Undisputed Trade receivables- considered good	1,432.17	-	20.12	-	-	1,452.29
Undisputed Trade Receivables- considered doubtful	-	-	-	-	-	-
Disputed Trade Receivables considered good	-	-	-	-	-	-
Disputed Trade Receivables considered doubtful	-	-	-	-	-	-
Total	1,432.17	-	20.12	-	-	1,452.29

Trade Receivables ageing schedule as at 31 March 2024

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months- 1 years	1-2 years	2-3 years	More than 3 years	
Undisputed Trade receivables- considered good	570.93	-	-	-	-	570.93
Undisputed Trade Receivables- considered doubtful	-	-	-	-	-	-
Disputed Trade Receivables considered good	-	-	-	-	-	-
Disputed Trade Receivables considered doubtful	-	-	-	-	-	-
Total	570.93	-	-	-	-	570.93

Trade Receivables ageing schedule as at 31 March 2023

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months-1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade receivables- considered good	139.70	-	-	-	-	139.70
Undisputed Trade Receivables- considered doubtful	-	-	-	-	-	-
Disputed Trade Receivables considered good	-	-	-	-	-	-
Disputed Trade Receivables considered doubtful	-	-	-	-	-	-
Total	139.70	-	-	-	-	139.70

1. The figures disclosed above are based on the restated summary statement of assets and liabilities of the Company.
2. There are no unbilled trade receivables. The Company does not have any trade receivables which are “Not Due” as on the reporting date. Accordingly, no separate disclosure has been made in this regard.
3. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.
4. Ageing of debtors is based on the date of transaction in case there is no credit period agreed at the time of Supply.
5. For lien/charge against trade receivables refer Note No. 3(A) & 6(A)
6. No trade receivables are due from directors or other officers of the Group either severally or jointly with any other person and no trade receivables are due from firms or private companies respectively in which any director is a partner, a director or a member except as reported in Annexure-29

NOTE – 13
RESTATED STATEMENT OF CASH & BANK BALANCES

(Amount in Rs. Lakhs)

Particulars	As at		
	31-03-2025	31-03-2024	31-03-2023
(a) Cash & Cash Equivalents			
Balances with Banks in Current Accounts	0.54	100.70	1.61
Cash on Hand	10.36	21.02	0.40
Fixed deposits with maturity less than 3 months **	10.61	-	-
(b) Others Bank Balance			
Fixed deposits with maturity between 3- 12 months **	7.01	-	-
Total	28.52	121.72	2.01

** Fixed deposits are lien against Bank guarantee.

1. The figures disclosed above are based on the restated summary statement of assets and liabilities of the Company.
2. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.

NOTE – 14
RESTATED STATEMENT OF INVENTORIES

(Amount in Rs. Lakhs)

Particulars	31-03-2025	31-03-2024	31-03-2023
Raw Materials	966.73	612.04	156.63
Finished Goods	228.89	61.88	35.21
WIP	425.96	-	-
Total	1,621.58	673.92	191.84

1. Refer Significant Accounting Policy Note No. IV
2. The figures disclosed above are based on the restated summary statement of assets and liabilities of the Company.
3. Inventory has been physically verified by the management of the Company at the end of respective period/year.
4. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.

5. Entire inventory of the Company has been hypothecated as security against certain bank borrowings of the Company as at reporting dates. For more details of lien/charge against inventories refer Note No 3(A) & 6(A).
6. Quantitative stock statements submitted to bank are not subject to verification/ reconciliation with books.
7. Quarterly statements of current assets filed by the Company with the banks are in agreement with the books of accounts.

As at March 31, 2025

(Amount in Lakhs)

Quarter	Name of Bank	Particulars of Securities Provided	Amount As per Books of Account	Amount As Reported in Quarterly Return	Amount of Difference	Reason
Q1	State Bank of India	Refer Note 1	612.04	612.04	0.00	
Q2	State Bank of India		741.20	741.20	0.00	
Q3	State Bank of India		785.70	785.70	0.00	
Q4	State Bank of India		1621.58	1465.02	156.56	See Note-2

As at March 31, 2024

(Amount in Lakhs)

Quarter	Name of Bank	Particulars of Securities Provided	Amount As per Books of Account	Amount As Reported in Quarterly Return	Amount of Difference	Reason
Q1	State Bank of India	Refer Note 1	612.04	612.04	0.00	
Q2	State Bank of India		303.43	303.43	0.00	
Q3	State Bank of India		603.81	603.81	0.00	
Q4	State Bank of India		673.92	566.68	1.07	See Note-2

As at March 31, 2023

(Amount in Lakhs)

Quarter	Name of Bank	Particulars of Securities Provided	Amount As per Books of Account	Amount As Reported in Quarterly Return	Amount of Difference	Reason
Q1	State Bank of India	Refer Note 1	0.00	0.00	0.00	
Q2	State Bank of India		0.00	0.00	0.00	
Q3	State Bank of India		64.23	64.23	0.00	
Q4	State Bank of India		191.84	191.84	0.00	See Note-2

Note:

1. The borrowings are secured by hypothecation of all plant and machinery, inventories, and trade receivables of the Company. The collateral security comprises equitable mortgage of immovable properties of the Company, relatives of Directors, M/s. Rednex Pharmaceuticals. The borrowings are further secured by personal guarantees of the Directors and their relatives, and a corporate guarantee provided by M/s. Rednex Pharmaceuticals.
2. The discrepancy is on account of the details being submitted on the basis of provisional books. Adjustments pertaining to cut offs, goods in transit, overhead allocation Raw material and finished goods, etc. are done only on finalisation of books of accounts/financial statements.
3. The Company submits the quarterly stock statement by excluding slow-moving stock has led to variances in the reported figures.
4. The variance in debtors is attributable to the netting off of accounts, non-reporting of PPA debtors, and differential treatment of debtors exceeding 90 days, whereas the discrepancy in creditors arises from the exclusion of creditors with balances below Rs. 60,000, inclusion of creditors related to goods and services, and non-consideration of creditors pertaining to capital goods.

NOTE – 15

RESTATED STATEMENT OF SHORT-TERM LOANS AND ADVANCES

(Amount in Lakhs)

Particulars	31-03-2025	31-03-2024	31-03-2023
A) Capital Advances			
Advance for Capital Goods	-	4.97	143.39
B) Other Loans & Advances			
Balance with Government Authorities:	53.93	2.70	0.09
GST Receivables	154.11	132.77	149.62
Total	208.04	140.44	293.10

Notes:

1. The figures disclosed above are based on the restated summary statement of assets and liabilities of the Company.
2. The Company has not granted any loans or advances in the nature of Loan to promoters, directors, KMPs and the related parties (as defined under Companies Act, 2013) either severally or jointly with any other person, that are repayable on demand or without specifying any terms or period of repayment.
3. List of persons/entities classified as 'Promoters' and 'Group Company' has been determined by the Management and relied upon by the Auditors. The Auditors have not performed any procedure to determine whether the list is accurate and complete.
4. Loans and advances given to employees are in nature of advances against salaries and not in nature of loans, therefore are not interest bearing.
5. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.

NOTE – 16
RESTATED STATEMENT OF OTHER CURRENT ASSETS

(Rs. in Lakhs)

Particulars	As at		
	31-03-2025	31-03-2024	31-03-2023
Advance to Supplier	88.65	82.83	8.26
Total	88.65	82.83	8.26

Notes:

1. The figures disclosed above are based on the restated summary statement of assets and liabilities of the Company.
2. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.

NOTE – 17
RESTATED STATEMENT OF REVENUE FROM OPERATIONS

(Rs. in Lakhs)

Particulars	For the Period ended		
	31-03-25	31-03-24	31-03-23
Manufacturing Sales	4,492.07	2,439.44	170.25
Trading Sales	88.05	1.10	-
Total	4,580.12	2,440.54	170.25

Manufacturing Sales bifurcation

(Rs. in Lakhs)

Particulars	For the Period ended		
	31-03-25	31-03-24	31-03-23
Tablets	1,547.92	628.40	122.45
Capsules	1,104.47	1,457.50	9.04
Dry Syrup	331.73	332.35	35.32
Oral Liquid	1,113.85	12.07	-
External Preparation	363.78	2.08	-
Other items	30.32	7.04	3.44
Total	4,492.07	2,439.44	170.25

Notes:

1. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.
2. The figures disclosed above are based on the restated summary statement of profit and loss of the Company.

NOTE – 18
RESTATED STATEMENT OF OTHER INCOME

(Rs. in Lakhs)

Particulars	For the Period ended		
	31-03-25	31-03-24	31-03-23
Interest on Deposit	2.32	2.10	0.35
Subsidy Received	28.75	-	1.49

Sale of Scrap	0.67	5.05	
Discount Received	0.23	0.56	-
Total	31.97	7.71	1.84

Notes:

- 1.The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.
- 2.The figures disclosed above are based on the restated summary statement of profit and loss of the Company.

NOTE – 19
RESTATED STATEMENT OF COST OF MATERIAL CONSUMED

(Rs. in Lakhs)

Particulars	For the Period ended		
	31-03-25	31-03-24	31-03-23
Raw material consumption			
Opening Stock	612.04	156.63	-
Add: Purchase	3,989.89	2,245.16	334.71
	4,601.93	2,401.79	334.71
Less: Closing Stock	966.73	612.04	156.63
Total Raw Material Consumed	3,635.20	1,789.75	178.08

Notes:

- 1.The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.
- 2.The figures disclosed above are based on the restated summary statement of profit and loss of the Company.
3. As per Schedule III requirements, purchases are to be disclosed under broad heads. In our case, the purchases consist of various miscellaneous items, which cannot be grouped meaningfully under broad categories. Hence, purchases have been disclosed in aggregate without further classification.

NOTE – 20A
RESTATED STATEMENT OF PURCHASE OF STOCK IN TRADE

(Rs. in Lakhs)

Particulars	For the Period ended		
	31-03-25	31-03-24	31-03-23
Stock in Trade			
Opening Stock	-	-	-
Purchase of Stock-In- Trade	86.48	1.04	-
	86.48	1.04	-
Less: Closing Stock	-	-	-
Total Purchase of Stock in Trade	86.48	1.04	-

Notes:

1. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.
- 2.The figures disclosed above are based on the restated summary statement of profit and loss of the Company.
3. As per Schedule III requirements, purchases are to be disclosed under broad heads. In our case, the purchases consist of various miscellaneous items, which cannot be grouped meaningfully under broad categories. Hence, purchases have been disclosed in aggregate without further classification.

NOTE – 20B
RESTATED STATEMENT OF CHANGE IN INVENTORIES OF FINISHED GOODS AND WIP

(Rs. in Lakhs)

Particulars	For the Period ended		
	31-03-25	31-03-24	31-03-23
Opening Balance (A)	61.88	35.21	-
Finished Goods	61.88	35.21	-
WIP	-	-	-
Closing Balance(B)	654.85	61.88	35.21
Finished Goods	228.89	61.88	35.21
WIP	425.96	-	-

Increase/(Decrease) in Stock (A-B)	-592.97	-26.67	-35.21

Finished Goods bifurcation

(Rs. in Lakhs)

Particulars	For the Period ended		
	31-03-25	31-03-24	31-03-23
Capsule	98.08	11.20	19.60
External	6.09	-	
Tablet	79.98	38.19	4.47
Oral Liquid	42.71	8.38	
Dry Syrup	2.03	4.11	11.14
Total	228.89	61.88	35.21

Notes:

1. The Inventory has been physically verified on periodic basis by the management.
2. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.
3. The figures disclosed above are based on the restated summary statement of profit and loss of the Company.

NOTE – 21 RESTATED STATEMENT OF EMPLOYEE BENEFITS EXPENSES

(Rs. in Lakhs)

Particulars	For the Period ended		
	31-03-25	31-03-24	31-03-23
Salaries and wages			
Directors' Remuneration	7.93	2.90	1.50
Salary & Wages Expenses	231.87	89.34	23.22
Contribution to provident and other funds:			
-Provident fund	9.27	5.30	0.54
-LWF	0.03	0.02	-
-Gratuity fund	8.16	1.57	0.34
Staff welfare expenses	0.21	0.51	-
Total	257.47	99.64	25.60

Notes:

1. Refer Note 5A for details and disclosure related to Gratuity and other retirement benefits, if any.
2. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.
3. The figures disclosed above are based on the restated summary statement of profit and loss of the Company.

NOTE – 22 RESTATED STATEMENT OF FINANCE COST

(Rs. in Lakhs)

Particulars	For the Period ended		
	31-03-25	31-03-24	31-03-23
Interest expense	150.60	113.65	20.82
Other borrowing costs	8.35	6.60	37.85
Total	158.95	120.25	58.67

Notes:

1. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.
2. The figures disclosed above are based on the restated summary statement of profit and loss of the Company.

NOTE – 23 RESTATED STATEMENT OF DEPRECIATION & AMORTISATION

(Rs. in Lakhs)

Particulars	For the Period ended		
	31-03-25	31-03-24	31-03-23

Depreciation on Tangible Assets	281.46	114.06	21.43
Amortisation of Intangible Assets	5.59	2.68	1.05
Total	287.05	116.74	22.48

Notes:

- 1.The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.
- 2.The figures disclosed above are based on the restated summary statement of profit and loss of the Company.

NOTE – 24
RESTATED STATEMENT OF OTHER EXPENSES

(Rs. in Lakhs)

Particulars	For the Period ended		
	31-03-25	31-03-24	31-03-23
OTHER EXPENSES			
Other Direct Expense			
Electricity Charges	65.91	42.88	9.36
Job Work Charges	83.08	33.94	-
Transportation & Handling Charges	28.83	2.18	0.17
Testing Expense	30.76	9.73	4.15
Factory Expense	10.53	4.20	1.04
Repairs & Maintenance			
Repairs to Machinery	6.09	8.01	0.95
Rates & Taxes	0.18	0.07	7.14
Advertising Expenses	1.18	-	1.83
Other Expenses			
Audit Fees	3.27	2.00	0.50
Insurance	2.49	0.94	1.15
Office Expense	3.09	1.21	0.03
Legal & Professional Fees	1.72	4.11	4.40
License Expense	13.69	-	0.16
Miscellaneous Expenses	5.14	1.85	1.48
Communication Expenses	0.92	0.45	0.11
Printing & Stationery	5.20	1.64	0.31
Travelling & Conveyance Expenses	2.15	0.13	0.02
Total	264.23	113.34	32.80

1. Payment to Auditors

(Rs. in Lakhs)

Particulars	For the Period ended		
	31-03-25	31-03-24	31-03-23
For Statutory Audit	1.80	1.30	0.40
For Company Law Matters	0.45	0.30	0.10
For Taxation matters	1.02	0.40	-
Total	3.27	2.00	0.50

2. CSR Expenditure

The provisions of Section 135 of the Companies Act, 2013 relating to Corporate Social Responsibility are not applicable to the Company, as the prescribed thresholds in respect of net worth, turnover and net profit are not met. Accordingly, no amount has been required to be spent towards CSR activities during the years presented in the restated financial statements.

Notes:

- 1.The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.
- 2.The figures disclosed above are based on the restated summary statement of profit and loss of the Company.

NOTE – 25
RESTATED STATEMENT OF TAX EXPENSE

(Rs. in Lakhs)

Particulars	For the Period ended		
	31-03-25	31-03-24	31-03-23
Current Tax	101.44	11.19	-
Total	101.44	11.19	-

Notes:

1. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.
2. The figures disclosed above are based on the restated summary statement of profit and loss of the Company.

NOTE – 26
RESTATED STATEMENT OF MANDATORY ACCOUNTING RATIOS

(Rs. in Lakhs)

Particulars	As At		
	31-03-25	31-03-24	31-03-23
Net Worth (A)	947.07	520.67	327.24
Profit after Tax (B)	426.40	193.43	-92.55
Number of Equity Share outstanding as on the End of Year (C)	4,250,000	4,250,000	4,250,000
Weighted average no. of Equity shares (D)	7,650,000	7,650,000	6,012,740
Face Value per Share (Rs.)	10.00	10.00	10.00
Restated Basic and Diluted Earning Per Share (Rs.) (B/E)	5.57	2.53	(1.54)
Return on Net worth (%) (B/A)	45.02%	37.15%	(28.28) %
Net asset value per share (A/C) (Face Value of Rs. 10 Each) (Based on Actual Number of Shares)	22.28	12.25	7.70
Net asset value per share (A/C) (Face Value of Rs. 10 Each) (Based on Weighted Average Number of Shares)	12.38	6.81	5.44
EBITDA	921.36	456.84	(68.87)

Notes:

- 1) The ratios have been computed as below:
 - a) Basic and Diluted earnings per share (Rs.): Net profit after tax as restated for calculating diluted EPS / Weighted average number of equity shares outstanding at the end of the period or year for diluted EPS.
 - b) Return on net worth (%): Net profit after tax (as restated) / Net worth at the end of the period or year.
 - c) Net assets value per share: Net Worth at the end of the period or year / Total number of equity shares outstanding at the end of the period or year."
- 2) Weighted average number of equity shares is the number of equity shares outstanding at the beginning of the period/year adjusted by the number of equity shares issued during period/year multiplied by the time weighting factor. The time weighting factor is the number of days for which the specific shares are outstanding as a proportion of total number of days during the period/year.
- 3) Subsequent to the reporting date, the Company has issued bonus shares in the ratio of 4:5. In accordance with the requirements of Accounting Standard (AS) 20 - Earnings Per Share, the number of equity shares outstanding for all periods presented has been adjusted retrospectively, as if the bonus issue had occurred at the beginning of the earliest period reported. Consequently, the basic and diluted earnings per share for all comparative periods have been restated to reflect the impact of the bonus issue, ensuring consistency and comparability across reporting periods.
- 4) Net worth for ratios mentioned in note 1(c) and 1(d) is = Equity share capital + Reserves and surplus (including Securities Premium, if any, General Reserve, if any and surplus in statement of profit and loss).
- 5) EBITDA has been calculated as Profit before tax + Depreciation + Interest Expenses - Other Income
- 6) The figures disclosed above are based on the standalone restated summary statements of financial information of the Company.
- 7) The above statement should be read with the significant accounting policies and notes to restated summary statements of assets and liabilities, profits and losses and cash flows appearing in Annexures IV, I, II and III.

NOTE – 27
RESTATED STATEMENT OF OTHER ACCOUNTING RATIOS

Analytical Ratios for Financial Year 2024-25 and 2023-24

Particulars	Numerator/Denominator	31-03-2025	31-03-2024	Variance	Reasons for change more than 25%
(a) Current Ratio	Current Assets	1.09	0.89	22.1%	Not Applicable
	Current Liabilities				
(b) Debt-Equity Ratio	Total Debts	2.02	3.69	(45.2) %	Due to increase in an Equity due to increase in profit
	Equity				
(c) Debt Service Coverage Ratio	Earning available for Debt Service	3.04	1.96	55.4%	Due to increae in an operating profit
	Interest + Installments				
(d) Return on Equity (%)	Profit after Tax	58.10%	45.63%	27.3%	Increase in a profit available for shareholders
	Average Shareholder's Equity				
(e) Inventory turnover ratio	Total Turnover	3.99	5.64	(29.2) %	Due to increased sales volume and streamlined inventory management processes.
	Average Inventories				
(f) Trade receivables turnover ratio	Total Turnover	4.53	6.87	(34.1) %	Increase in a debtor
	Average Account Receivable				
(g) Trade payables turnover ratio	Total Purchases	3.09	4.73	(34.8) %	Increase in a creditor
	Average Account Payable				
(h) Net capital turnover ratio	Total Turnover	116.87	(10.77)	(1184.7) %	Increase in working capital
	Average Working Capital				
(i) Net profit ratio	Net Profit	9.31%	7.93%	17.5%	Not Applicable
	Total Turnover				
(j) Return on Capital employed	EBIT	23.29%	14.24%	63.5%	Increaese in operating profit
	Capital Employed				
(k) Return on investment	Profit on Investment	NA	NA	NA	Not Applicable
	Weighted Average Investment				

Note 1: RoI for the company is Not Applicable (NA) as during the reporting period, company does not hold any investment.

Analytical Ratios for Financial Year 2023-24 and 2022-23

Particulars	Numerator/Denominator	31-03-2024	31-03-2023	Variance	Reasons
(a) Current Ratio	Current Assets	0.89	0.71	25.3%	Increase in Current Assets
	Current Liabilities				
(b) Debt-Equity Ratio	Total Debts	3.69	3.16	16.6%	Not Applicable
	Equity				
(c) Debt Service Coverage Ratio	Earning available for Debt Service	1.96	(1.77)	(210.2) %	Increase in earning
	Interest + Installments				
(d) Return on Equity (%)	Profit after Tax	45.63%	(55.75) %	(181.8) %	Due to increased PAT in comparison to that of previous year.
	Average Shareholder's Equity				
(e) Inventory turnover ratio	Total Turnover	5.64	1.77	217.6%	Due to increased total turnover in comparison to that of the previous year.
	Average Inventories				

(f) Trade receivables turnover ratio	Total Turnover	6.87	2.44	181.8%	Due to increased total turnover in comparison to that of the previous year.
	Average Account Receivable				
(g) Trade payables turnover ratio	Total Purchases	4.73	2.77	70.6%	Due to increased total purchases in comparison to that of the previous year.
	Average Account Payable				
(h) Net capital turnover ratio	Total Turnover	(10.77)	(1.37)	685.8%	Due to increased total turnover in comparison to that of the previous year.
	Average Working Capital				
(i) Net profit ratio	Net Profit	7.93%	(54.36) %	(114.6) %	Due to increase in net profit
	Total Turnover				
(j) Return on Capital employed	EBIT	14.24%	(6.57) %	(316.8) %	Due to more increase in EBIT of the company than that of the capital employed the ratio has increased.
	Capital Employed				
(k) Return on investment	Profit on Investment	NA	NA	NA	Not Applicable
	Weighted Average Investment				

Note 1: RoI for the company is Not Applicable (NA) as during the reporting period, company does not hold any investment.

NOTE – 28
RESTATED SUMMARY STATEMENT OF CONTINGENT LIABILITIES

(Rs. in Lakhs)

1. Contingent Liabilities

Particulars	As At		
	31-03-25	31-03-24	31-03-23
NIL			
Total			

2. Other Commitments

(Rs. in Lakhs)

Company has issued following Financial Bank Guarantees:

Bank Name	As At		
	31-03-25	31-03-24	31-03-23
NIL			
Total			

Notes:

- 1.The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.
- 2.The figures disclosed above are based on the restated summary statement of profit and loss of the Company.

NOTE – 29
RESTATED STATEMENT OF RELATED PARTY TRANSACTIONS

A. List of Related Parties as per AS – 18

Particulars	Names of Related Parties	Nature of Relationship
Key Management Personnel (KMP)	Chetan Rugnathbhai Matholiya	Chairman and Whole-Time Director
	Akashbhai Mansukhbhai Gangadiya	Whole Time Director & CFO
	Jayeshkumar Amarshibhai Sabava	Managing Director
	Rima Amitbhai Dalal	Company Secretary & Compliance Officer w.e.f 14th Aug, 2025
Relatives of KMP	Dakshaben Jayeshbhai Sabava	Wife of Managing Director
	Kartikkumar Mansukhbhai Gangadiya	Brother of Whole Time Director & CFO
	Natubhai Amarshibhai Sabava	Brother of Managing Director
	Shaileshbhai Rugnathbhai Matholiya	Brother of Chairman and Whole-Time Director

	Mitalben Chetanbhai Matholiya	Wife of Chairman and Whole-Time Director
Enterprises over which any person, who is a key management personnel or has direct and indirect interest in voting power, can exercise significant influence	Bhagat Enterprise	KMP/ Relative of KMP having significant influence/ interest
	Rednex Pharmaceuticals	KMP/ Relative of KMP having significant influence/ interest
	Narayan Pharma House LLP	KMP/ Relative of KMP having significant influence/ interest
	Lalko Minerals	KMP/ Relative of KMP having significant influence/ interest
	Lalko Exim Pvt Ltd	KMP/ Relative of KMP having significant influence/ interest
	Greenwood Enterprise	KMP/ Relative of KMP having significant influence/ interest
	Gopinath Enterprise	KMP/ Relative of KMP having significant influence/ interest
	Xender Pharmaceuticals	KMP/ Relative of KMP having significant influence/ interest

B. Related party transactions

(Rs. in Lakhs)

Sr. No.	Name of Party	Nature of Transactions	31.03.2025	31.03.2024	31.03.2023
1	Chetan Rugnathbhai Matholiya	Directors Remuneration	3.47	0.97	0.50
		Loan Taken	30.30	12.25	200.03
		Loan Returned	74.73	3.75	239.24
2	Akashbhai Mansukhbhai Gangadiya	Directors Remuneration	1.00	0.97	0.50
		Loan Taken	14.25	39.50	116.64
		Loan Returned	6.45	3.00	174.31
3	Jayeshkumar Amarshibhai Sabava	Directors Remuneration	3.47	0.97	0.50
		Loan Taken	5.00	14.46	167.24
		Loan Returned	16.47	4.00	215.89
4	Shaileshbhai Rugnathbhai Matholiya	Salary	5.00	2.98	2.15
		Loan Taken	5.00	1.00	14.41
		Loan Returned	15.27	9.00	0.25
5	Dakshaben Jayeshbhai Sabava	Salary	2.95	0.00	0.00
6	Kartikkumar Mansukhbhai Gangadiya	Salary	5.60	0.00	0.00
		Loan Taken	9.00	0.00	8.00
		Loan Returned	25.11	4.00	0.00
7	Natubhai Amarshibhai Sabava	Salary	3.00	2.99	2.40
8	Mitalben Chetanbhai Matholiya	Salary	2.95	0.00	0.00
		Loan Taken	0.00	0.00	7.39
9	Bhagat Enterprise	Purchase of Goods	22.18	2.53	
10	Rednex Pharmaceuticals	Purchase of Goods	70.14	7.83	2.69
		Sales of Goods	0.00	0.64	0.00
		Advance Taken	0.00	0.00	1.05
		Advance Given (Repaid)	23.84	49.45	0.00
		Rent	0.07	0.00	0.00
11	Narayan Pharma House LLP	Purchase of Goods	61.00	5.04	1.16
12	Lalko Minerals	Purchase of Goods	0.36	0.03	
13	Lalko Exim Pvt Ltd	Purchase of Goods	10.01	0.00	0.00
14	Greenwood Enterprise	Purchase of Goods	3.73	0.87	0.00
15	Gopinath Enterprise	Purchase of Goods	50.87	0.84	0.17
16	Xender Pharmaceuticals	Sales of Goods	18.08	2.67	3.47
		Advance Given (Repaid)	0.00	8.93	0.00

C. Outstanding Balances

(Rs. in Lakhs)

Sr. No.	Name of Party	Nature of Transactions	31.03.2025	31.03.2024	31.03.2023
1	Chetan Matholiya Rugnathbhai	Remuneration payable	1.00	1.47	0.50
		Loans and Advances	107.70	152.13	143.63
2	Akashbhai Gangadiya Mansukhbhai	Remuneration payable	1.00	1.47	0.50
		Loans and Advances	82.72	89.17	52.67
3	Jayeshkumar Sabava Amarshibhai	Remuneration payable	1.00	1.47	0.50
		Loans and Advances	108.06	119.52	109.06
4	Shaileshbhai Matholiya Rugnathbhai	Loans and Advances	7.35	17.63	25.63
		Salary	0.45		
5	Dakshaben Sabava Jayeshbhai	Loans and Advances	1.75	1.75	1.75
		Salary	0.50		
6	Kartikkumar Gangadiya Mansukhbhai	Loans and Advances	15.60	31.71	35.71
		Salary	0.10		
7	Mitalben Matholiya Chetanbhai	Loans and Advances	7.39	7.39	7.39
		Salary	0.50	0.00	0.00
8	Bhagat Enterprise	Trade Payable	(4.21)	(11.57)	0.00
9	Rednex Pharmaceuticals	Rent Payable	0.07	0.00	0.00
		Advance Taken (Returned)	0.00	0.00	14.46
		Advance Given (Repaid)	58.83	34.98	0.00
10	Narayan Pharma House LLP	Trade Payable	10.88	12.40	0.69
11	Lalko Minerals	Trade Payable	0.00	0.03	0.00
12	Lalko Exim Pvt Ltd	Trade Payable	0.01		
13	Greenwood Enterprise	Trade Payable	1.08	0.00	0.00
14	Gopinath Enterprise	Trade Payable	4.31	(14.94)	2.12
15	Xender Pharmaceuticals	Trade Recievable	9.24	0.00	2.39
		Advance Given (Repaid)	8.93	8.93	0.00

Terms & Conditions:

Sales:

The sales to related parties are made on terms equivalent to those that prevail in arm's length transactions and in the ordinary course of business. Sales transactions are based on prevailing price lists. For the financial years under reporting, the Group has not recorded any impairment of receivables relating to amounts owed by related parties.

Purchases:

The purchases of Goods / Services from related parties are made on terms equivalent to those that prevail in arm's length transactions and in the ordinary course of business. Purchase transactions are based on made on normal commercial terms and conditions and market rates.

Loans from related parties:

The Company had taken loans from related parties for business requirement. These loans are unsecured in nature and is payable on demand as described in Note- 6(B)

The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.

The figures disclosed above are based on the restated summary statement of profit and loss of the Company.

List of persons/entities classified as 'Promoters' and 'Promoter Group' has been determined by the Management and relied upon by the Auditors. The Auditors have not performed any procedure to determine whether the list is accurate and complete.

Company has disclosed the defined contribution plan in Annexure-IV under Contribution to Provident funds and other funds. As the company makes contribution for all employees as a whole, it has been excluded from above disclosure for KMP.

#The remuneration to Key Managerial Personnel (KMP), Director and other related employees excludes the provisions made for gratuity as these are determined on an actuarial basis for the Company as a whole.

NOTE – 30
CAPITALISATION STATEMENT

(Rs. in Lakhs)

Particulars	Pre Issue	Post Issue
Borrowings		
Short term debt (A)	832.13	*
Long Term Debt (including current maturities of long term borrowing) (B)	1,081.92	*
Total debts (C)	1,914.05	
Shareholders' funds		
Equity share capital	425.00	*
Reserve and surplus - as restated	522.07	*
Total shareholders' funds	947.07	
Long term debt / shareholder's funds	1.14	*
Total debt / shareholder's funds	2.02	*

(*) The corresponding post issue figures are not determinable at this stage pending the completion of public issue and hence have not been furnished.

Notes:

1. Short term Debts represent which are expected to be paid/payable within 12 months and excludes instalment of term loans repayable within 12 months.
2. Long term Debts represent debts other than Short Term Debts as defined above but includes installment of term loans repayable within 12 months grouped under short term borrowing.
3. The figures disclosed above are based on restated statement of Assets and Liabilities of the Company as at 31-03-2025
4. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.

NOTE – 31
RESTATED STATEMENT OF TAX SHELTER

(Rs. in Lakhs)

Particulars	As at		
	March 31, 2025	March 31, 2024	March 31, 2023
Tax Rate Provision	115BAB	115BAB	Normal
Income Tax Rate (Note-4)	15%	15%	25%
Restated Profit before tax as per books (A)	515.68	234.15	(110.33)
Adjustments:			
Less: Income Consider Separately (Special Rate@ 25.168%)	(2.32)	(2.10)	(0.35)
Disallowed (B)	298.77	120.49	29.91
a. Gratuity	8.16	1.57	0.34
b. Late pay. of Employee's Cont.to PF	0.04	0.74	0.54
c. Stamp Duty paid to increase authorized capital	-	-	6.55
e. Interest on MSME Provision	3.52	0.20	-
d. Depreciations as per Companies Act,2013	287.05	116.74	22.48
e. Interest under Income Tax Act	-	1.25	-
Allowed (C)	224.36	290.39	45.15
a. Depreciation as per IT Act,1961	224.36	164.47	45.15
b. Unabsorbed Business Loss		125.92	
Net Total Income (D=A-C+B)	587.77	62.15	(125.92)
Deduction under chapter VI (F)	-	-	-
80G	-	-	-
Taxable Income/(Loss)	587.77	62.15	(125.92)
Income Tax on Above	88.16	9.32	-
Surcharge	8.82	0.93	-
Health & ED cess 4%	3.88	0.41	-
Income Tax (Special Rate@ 25.168%)	0.58	0.53	-
Tax Payable (Income Tax)	101.44	11.19	-

1. The company has opted for Section 115BAB of the Income Tax Act, 1961 for F.Y. 2023-24 and F.Y. 2024-25.
2. The aforesaid statement of tax shelters has been prepared as per the restated Summary statement of profits and losses of the Company.
3. Statutory tax rate excludes applicable surcharge, education cess and higher education cess of the year concerned.
4. The aforesaid statement of tax shelters has been prepared as per the restated Summary statement of profits and losses of the Company. The permanent/timing differences have been computed considering the acknowledged copies of the income-tax returns/Provisional computation of total income of respective years as stated above.
5. The above statement is in accordance with Accounting Standard - 22, "Accounting for Taxes on Income" prescribed under Section 133 of the Act, read with Rule 7 of Companies (Accounts) Rules, 2021 (as amended).
6. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, I, II and III.

NOTE – 32

ADDITIONAL REGULATORY INFORMATION AND STATEMENT OF EVENTS OCCURRING AFTER THE BALANCE SHEET DATE

1. Normal Operating Cycle and Classification of Assets and Liabilities into Current and Non- Current

- i) In accordance with the requirement of Schedule III, Normal Operating Cycle of the Company's business is determined and duly approved by the Board of Directors.
- ii) Assets and Liabilities of the above business have been classified into Current and Non-Current using the above Normal Operating Cycle and applying other criteria prescribed in Schedule III.

2. Undisclosed Income

- a) During the period of restatement, the Company has no such transactions which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in tax assessments under Income Tax Act, 1961.

3. Transaction with Struck Off Companies

The Company does not have any relationship/ transaction with Struck-off Companies and has not entered into any transactions with struck off companies in the current and previous reporting period.

4. Other Information

- i) The Company has not traded or invested in Crypto currency or Virtual Currency during the restatement period.
- ii) The Company have not advanced or loaned or invested fund to any other person or entity, including foreign entities (intermediaries) with the understanding that the intermediaries shall;
 - a) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries)
 - b) Provide any guarantee, security or the like to or on behalf of Ultimate Beneficiaries"
- iii) The Company have not received any fund from any person or entity, including foreign entities (Funding Parties) with the understanding (whether recorded in writing or otherwise) that The Company shall;
 - (a) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries)
 - (b) Provide any guarantee, security or the like to or on behalf of Ultimate Beneficiaries"
- iv) The Company does not use derivative financial instruments such as forward exchange contracts or options to hedge its risks associated with foreign currency fluctuations or for trading/speculation purpose.
- v) The Company evaluates events and transactions that occur subsequent to the balance sheet date but prior to the approval of financial statements to determine the necessity for recognition and/or reporting of subsequent events and transactions in the financial statements.
- vi) Compliance with number of layers of companies -
The Company is in compliance with the number of layers of companies in accordance with clause 87 of Section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017 for the year ended March 31, 2025, 2024 & 2023."
- vii) Compliance with approved Scheme(s) of Arrangements
The Company has not entered into any Scheme of Arrangements and which has been approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013"

viii) Utilisation of Borrowed funds and share premium:

a) The Company has not utilised the borrowings received from banks and financial institutions for the purpose other than for which it was taken during the period of restatement."

b) During the year ended March 31, 2025, 2024 & 2023, the Company has not advanced or Loans or invested funds (either borrowed funds or share premium or kind of funds) to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding (whether recorded in writing or otherwise) that the Intermediary shall:

i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or

ii) provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries."

c) During the year ended March 31, 2025, 2024 & 2023, the Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

ii) provide any guarantee, security, or the like on behalf of the ultimate beneficiaries."

ix) Non adjustment item:

There is no audit qualifications for the respective periods which require any corrective adjustment in these Restated Financial Statements of the Company."

x) Material Regroupings:

Appropriate adjustments have been made in the restated summary statements of Assets and Liabilities Profits and Losses and Cash flows wherever required by reclassification of the corresponding items of income expenses assets and liabilities in order to bring them in line with the requirements of the SEBI Regulations and Schedule III of Companies Act, 2013"

xi) Trade Receivables, Trade Payables, Borrowings, Loans & Advances and Deposits

Balances of Trade Receivables, Trade Payables, Borrowings and Loans & Advances and Deposits are subject to confirmation and resultant adjustment(s) thereof."

xii) Director Personal Expenses

There are no direct personal expenses debited to the profit and loss account. However, personal expenditure if included in expenses like telephone, vehicle expenses etc. are not identifiable or separable."

xiii) Extra Ordinary Items:

During the year ended on March 31, 2025, 2024 & 2023, company has no extra ordinary Items to be disclosed in accordance with the requirements of AS - 5 ""Net Profit or Loss for the Period, Prior Period Items and Changes in Accounting Policies

xiv) No dividend were declared and paid by the company during the restated period.

xv) Figures have been rounded off to the multiple of lakhs. Previous year's figures have been regrouped, recast and rearranged wherever necessary to make them comparable with the current Period/year figures.

xvi) Details of Benami Property held

The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property under Benami Transactions (Prohibition) Act, 1988. "

xvii) Registration of charges or satisfaction with Registrar of Companies

All the charges against Bank Finance are registered with Registrar of Companies except Vehicle taken during the year."

(xviii) The Company has not revalued its Property, Plant and Equipment and ROU Assets during the year, hence, regulatory information disclosure is not applicable for the Company.

(xix) The Company has not revalued its Intangible Assets during the year, hence, regulatory information disclosure is not applicable for the Company.

(xx) Additional Regulatory Information pursuant to amendment in Schedule III of the Companies Act, 2013 dated 24.03.2021 has been given to the extent applicable to the Company.

(xxi) The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/interpretation have not yet been issued. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.

(xxii) In accordance with the provisions of the Accounting Standard on Impairment of Assets, AS –28, the management has made assessment of assets in use in respect of each cash-generating unit and considering the business prospects related thereto, no provision is considered necessary on account of impairment of assets.

5. STATEMENT OF EVENTS OCCURRING AFTER THE BALANCE SHEET DATE

The Company evaluates events and transactions that occur subsequent to the balance sheet date but prior to approval of the financial statements to determine the necessity for recognition and/or reporting of any of these events and transactions in the financial statements.

Non-Adjusting Events:

a) **Issue of Bonus:** Subsequent to the balance sheet date, the Company has issued bonus equity shares in the ratio of 4:5 in terms of ordinary resolution passed by shareholders of the company in their Annual General Meeting dated 05th September, 2025.

In accordance with AS 4, this constitutes a non-adjusting event, and accordingly, no adjustments have been made in the financial statements for the period ended March 31, 2025.

However, as per the requirements of AS 20 – Earnings Per Share, the EPS for all periods presented has been restated to reflect the bonus issue, as if it had occurred at the beginning of the earliest period reported.

b) **Increase in Authorised Share Capital:** Subsequent to the balance sheet date, the Company has increased its authorised share capital from ₹425.00 lakhs comprising 42,50,000 equity shares of ₹10 each to ₹ 1,100 lakhs comprising 1,10,00,000 equity shares of ₹10 each, pursuant to a resolution passed by the shareholders at the Annual General Meeting held on 5th September, 2025.

The increase in authorised share capital was undertaken to enable greater flexibility for future capital raising initiatives, with the objective of enhancing shareholder base and encouraging wider retail participation.

This event does not affect the financial position as at the balance sheet date and has accordingly been disclosed as a non-adjusting event.

OTHER FINANCIAL INFORMATION

The audited financial statements of our Company as at and for the year ended March 31, 2025, March 31, 2024 and March 31, 2023 and their respective Audit reports thereon (Audited Financial Statements) are available at <https://www.rednexpharmaceuticals.com//>

Our Company is providing a link to this website solely to comply with the requirements specified in the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirement) Regulations, 2018. The Audited Financial Statements do not constitute, (i) a part of the Draft Red Herring Prospectus; (ii) Red Herring Prospectus or (ii) Prospectus, a statement in lieu of a prospectus, an advertisement, an issue or a solicitation of any issue or an offer document to purchase or sell any securities under the Companies Act, 2013, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirement) Regulations, 2018, or any other applicable law in India or elsewhere in the world. The Audited Financial Statements should not be considered as part of information that any investor should consider subscribing for or purchase any securities of our Company and should not be relied upon or used as a basis for any investment decision. Neither our Company, nor BRLM, nor any of their respective employees, directors, affiliates, agents or representatives accept any liability whatsoever for any loss, direct or indirect, arising from any information presented or contained in the Audited Financial Statements, or the opinions expressed therein.

The accounting ratios required under Clause 11 of Part A of Schedule VI of the SEBI (ICDR) Regulations are given below:

Particulars	March 31, 2025	March 31, 2024	March 31, 2023
Profit After Tax (Rs. In Lakhs)	426.40	193.43	(92.55)
Basic & Diluted Earnings per Share	5.57	2.53	(1.54)
Return on Net Worth (%)	45.02%	37.15%	(28.28) %
NAV (Based on no. of share outstanding at the end of year)	22.28	12.25	7.70
NAV per Equity Shares (Based on Weighted Average Number of Shares)	12.38	6.81	5.44
Earnings before interest, tax, depreciation and amortization (EBITDA)	921.36	456.84	(68.87)

STATEMENT OF FINANCIAL INDEBTEDNESS

To,
The Board of Directors
Rednex Pharmaceuticals Limited
Survey No. 586 and 231, Near SKF Bearing,
Bavla Bagodara N.H 8A, Kerala, Bavla, Ahmedabad,
Gujarat, India, 382220.

Proposed initial public offering of equity shares of face value of Rs. 10 each (“Equity Shares” and such initial public offer, an “IPO” or “Issue”) of Rednex Pharmaceuticals Limited.

Dear Sir/Madam,

We, **Krupal Bhuvu & Co., Chartered Accountants**, as the statutory auditors of the Company, have received a request from the Company to certify the Statement of Financial Indebtedness.

Based on our independent examination of the Books of Accounts, Audited Financial Statements, and other documents of **Rednex Pharmaceuticals Limited**, and based on further explanations and information provided by the management of the Company, which we believe to be true and correct to the best of our knowledge and belief, the sanctioned amount of financial indebtedness, principal terms of security for loans, and other related details as on **March 31, 2025**, are mentioned below.

A. SECURED LOANS

STATEMENT OF PRINCIPAL TERMS OF SECURED LOANS AND ASSETS CHARGED AS SECURITY AS ON 31/03/2025:

i) **Fund Based:**

(Amount in Lakhs)

Name of Lender	Type of Credit Facility	Purpose of Credit Facility	Sanctioned Amount	Rate of interest	Primary & Collateral Security	Re- Payment Schedule	Balance as on 31/03/2025
State Bank of India	Cash Credit	Working Capital	7.00	9.60%	Note 1	Repayable on demand, renewable yearly	501.57
State Bank of India	Term Loan	Business Term Loan	988.00	9.60%	Note 1	Principal is repayable over 84 months commencing from October 2023, after a moratorium up to September 2023, with instalments increasing progressively from Rs. 3 Lakhs to Rs. 22 Lakhs until final maturity in September 2030.	955.98
State Bank of India	Term Loan	Solar module plant setup	123.00	9.05%	Note 1	A Moratorium of 02 months (interest to be paid during moratorium), loan to be repaid in 84 EMIs of about Rs.2.03 lakhs/month.	119.57
ICICI Bank	Car Loan ³⁵	Vehicle Purchase	6.79	9.65%	Note 2	Principal repayment in 60 monthly installments of Rs 14,350/- each	6.37
Total (Fund Based)				1583.49			

ii) **Non-Fund-Based**

(Amount In Lakhs)

Name of Lender	Types of Credit Facility	Purpose of Credit Facility	Sanctioned Amount (Lakhs Rs.)	Primary & Collateral Security	Re-Payment Schedule	Moratorium	Outstanding Amount as on 31/03/2025 (₹ Lakhs)
State Bank of India	Bank Guarantee	BG given for business	35.00	Fixed Deposits of ₹6.25 lakh and ₹10.00 lakh.	NA	NA	35.00
Total (Non-Fund Based)							35.00

NOTES

Sr. No.	Particulars
Note 1	(a) Primary Security- by way of Hypothecation of all stock and Receivables of the Company, including stocks of raw material, stock-in-process, finished goods, consumables, and receivables. (present and future). by way of Hypothecation of all Plant and Machinery in the name of the Company. (b) Collateral Security- Equitable Mortgage of the following properties with SBI Bank. 1. By way of Equitable Mortgage All that piece or parcel of immovable property bearing Plot/House No.23 having Plot area admeasuring 97.65 Sq.Mtrs. i.e. 116.80 Sq.Yards N.A.land bearing Survey No.663 admeasuring 24787 Sq.Mtrs. Situate and Lying and being at Botad, Ahmedabad in the name of Prabhben Rugnathbhai Matholiya 2. By way of Equitable Mortgage All that piece or parcel of immovable property bearing Industrial N.A. Land of Block No.231 admeasuring 5477 sq. mtrs., as per Re-Survey/ Promulgation (allotted in lieu of old Block/Survey No.4 paiki 14) paiki towards Western side admeasuring 5000 Sq.Yards i.e. 4180.63 Sq.Mtrs., together with factory type standing construction thereon situate lying & being at Kerela, Bavla, Ahmedabad in the name of M/s. Rednex Pharmaceuticals a Partnership Firm 3. By way of Equitable Mortgage All that piece or parcel of immovable property bearing Industrial N.A. Land of Block No.586 admeasuring 6018Sg.Yards i.e. 5032 Sq.Mtrs., as per ReSurvey/Promulgation (allotted in lieu of old Block/Survey No.4 Paiki 15) together with factory type standing construction thereon situate lying & being at Kerela, Bavla, Ahmedabad in the name of Rednex Pharmaceuticals Pvt.Ltd (c) Personal Guarantee of: - Chetan Matholiya - Jayeshkumar Sabava - Aakashbhai Gangadiya - Prabhben Matholiya (d) Corporate Guarantee of: Rednex Pharmaceuticals (Partnership Firm). Borrower has to comply with the Mandatory Covenants stipulated by the Lenders, which include but are not limited to: - In case of default in repayment of the loan/advances or in the payment of the interest thereon or any of the agreed instalments of the loan on due date(s) by the borrower, the Bank and/or the RBI will have an unqualified right to disclose or publish the borrower's name or the name of the borrower/unit and its directors/partners/proprietors as defaulters/willful defaulters in such manner and through such medium as the Bank or RBI in their absolute discretion may think fit.

	2. In case of default in repayment of the loan/advances or in the payment of the interest thereon or any of the agreed instalments of the loan on due date(s) by the borrower, the Bank and/or the RBI will have an unqualified right to disclose or publish the borrower's name or the name of the borrower/unit and its directors/partners/proprietors as defaulters/willful defaulters in such manner and through such medium as the Bank or RBI in their absolute discretion may think fit. 3. In case of default not corrected within 90 days or restructuring of debt, the regulatory guidelines provide for conversion of debt to equity. The Bank shall have the right to convert loan to equity or other capital in accordance with the regulatory guidelines. Further, in such a scenario, the borrower agrees to facilitate the process of conversion of loan to equity or other capital. In case of listed company approval of shareholders to be obtained. 4. The borrower will utilise the funds for the purpose they have been lent. Any deviation will be dealt with as per RBI guidelines and terms of sanction. 5. Promoter's shares in the borrowing entity should not be pledged to any Bank/NBFC/Institution without our prior consent.
Note 2	The Maruti Eeco car financed under this loan is under hypothecation with ICICI Bank . All rights of the vehicle are with the bank until the loan is fully repaid.

B.) UNSECURED LOANS

STATEMENT OF UNSECURED LOANS TAKEN FROM RELATIVES

(Amount In Lakhs)

Name of Lender	Relation with Lender	Purpose	Rate of Interest	Re-Payment Schedule	31-03-2025
A. Related Parties					
From Directors					
Jayeshkumar Amarshibhai Sabava	Managing Director	Business Purpose	0.00%	On-Demand	108.05
Chetan Matholiya Rugnathbhai	Chairman and Whole-Time Director	Business Purpose	0.00%	On-Demand	107.70
Akashbhai Mansukhbhai Gangadiya	Whole Time Director & CFO	Business Purpose	0.00%	On-Demand	82.72
Total (A)					298.47
From Relatives of Directors					
Dakshaben Jayeshbhai Sabava	Wife of Managing Director	Business Purpose	0.00%	On-Demand	1.75
Kartikkumar Mansukhbhai Gangadiya	Brother of Whole Time Director & CFO	Business Purpose	0.00%	On-Demand	15.60
Mitalben Chetanbhai Matholiya	Wife of Chairman and Whole-Time Director	Business Purpose	0.00%	On-Demand	7.39
Shaileshbhai Rugnathbhai Matholiya	Brother of Chairman and Whole-Time Director	Business Purpose	0.00%	On-Demand	7.35
Total (B)					32.09
Total (A)+(B)					330.56

Note on Unsecured Loans:

1. **No interest has been charged** on any of these loans.
2. The balances mentioned above are as per the **books of accounts of the company** as on 31/03/2025.

For, Krupal Bhuvu & Co.
Chartered Accountants
(FRN: 146585W)

(CA Krupal Bhuvu)
Proprietor
M. No: 182312
UDIN :25182312BMIRTY5400
Place: Ahmedabad
Date: September 26, 2025

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion in conjunction with our restated financial statements attached in the chapter titled “Financial Information of the Company” beginning on page 172. You should also read the section titled “Risk Factors” on page 27 and the section titled “Forward Looking Statements” on page 20 of this Draft Red Herring Prospectus, which discusses a number of factors and contingencies that could affect our financial condition and results of operations. The following discussion relates to us, and, unless otherwise stated or the context requires otherwise, is based on our Restated financial Statements. Our financial statements have been prepared in accordance with Indian GAAP, the Companies Act and the SEBI (ICDR) Regulations and restated as described in the report of our auditor dated September 26, 2025 which is included in this Red Herring Prospectus under “Financial Statements”. The Restated Financial Information has been prepared on a basis that differs in certain material respects from generally accepted accounting principles in other jurisdictions, including US GAAP and IFRS. Our financial year ends on March 31 of each year, and all references to a particular financial year are to the twelve-month period ended March 31 of that year.

BUSINESS OVERVIEW

We are engaged in manufacturing of a wide range of pharmaceutical products finding application across various therapeutic areas. We also manufacture pharmaceutical products under loan license or contract manufacturing for our clients. We have developed our product portfolio in various dosage forms that includes Tablets, Capsules, External Preparation (Cream/Gel/Ointment/Lotion), Oral Liquid and Dry Syrup. Our products cater to the major therapeutic areas, including Antibacterial, Antitussive, Analgesic, Anticold, Antacid, Antimalarial, Antifungal, Antidiarrheal, Anti-Allergy, etc

We operate from our WHO-GMP approved manufacturing facility situated at Bavla, Ahmedabad which is spread across 9,212.63 sq. mtrs. Our manufacturing facility comprises of two separate manufacturing blocks (i) General pharma product manufacturing plant and (ii) Beta Lactum plant. The facility is equipped with automated and efficient machines and other equipment along with in-house laboratory and a storage facility to store finished goods and raw materials.

The beta lactum plant produces beta-lactam and cephalosporins antibiotics such as such as Cefixime, Amoxicillin, Ampicillin, Cefpodoxime, Cefadroxil & lactic Acid, Cefuroxime, Flucloxacillin, Cloxacillin, Cephalexin etc. in the form of Tablets, Capsules and Dry Syrups. Due to the high risk of cross-contamination, beta-lactam production requires specialized containment and isolation from other drug manufacturing areas. Our dedicated beta lactum plant is therefore focused on manufacturing of antibiotics in controlled, standalone facility to prevent cross-contamination, ensure worker safety, and meet strict global regulatory standards. The General Pharma product plant makes everyday formulations such as Erythromycin Tablets and Suspension, Omeprazole Capsules, Pantoprazole with Domperidone Capsules, Diclofenac Gel, Hydrocortisone acetate cream, Dextromethorphan with Phenylephrine and Chlorpheniramine Syrup, Artemether and Lumefantrine Tablets, Ambroxol with Levosalbutamol and Guaiphenesin Syrup, Paracetamol with Ibuprofen Suspension and tablets, Paracetamol Suspension and tablets, Paracetamol with Doclofenac and Caffeine Tablets, Azithromycin Tablets and Suspension, Levocetirizine with Montelukast Syrup and Tables, Pregabalin Capsules etc.

We manufacture pharmaceutical products in the form of Tablets, Capsules, External Preparation (Cream/Gel/Ointment/Lotion), Oral Liquid and Dry Syrup. Our facility has received FDCA License, WHO, ISO 9001:2015 quality management system certification and ISO 14001:2015 Environment Management System for manufacturing of General Tablets, Capsules, Oral Liquids, External Preparations and Dry Syrups. During the Fiscal 2025, 2024 and 2023 we derived revenue from sales of 250, 67 and 21 number of pharmaceutical products

We also undertake contract manufacturing of pharmaceutical products on a loan license basis, wherein our manufacturing facilities are utilized by third-party companies (loan license holders) who possess the necessary marketing authorizations and market the products under their own brand names. This model enables us to optimize our manufacturing capacities and establish long-term business relationships. In addition to contract manufacturing, we also sell our products to third-party distributors and participants in the pharmaceutical market. Under this arrangement, we sell finished goods on a principal-to-principal model.

We focus on introducing our products in the emerging markets. Our facility received approval from The Food & Drugs Authority, Ghana and Pharmaceutical Manufacturer Registration License from Kingdom of Cambodia. Furthermore, we have applied for approvals/registration of our facility from the regulatory authorities of Dubai, Iraq and North Sudan. Currently, we export our products largely through local merchant exporters in countries like: Angola, Cameroon, Congo, Fiji, Iraq, Liberia, Myanmar, Guyana, Nigeria, Qatar, Papua new guinea, Sierra Leone, Soloman, Somalia, South sudan UAE, Zambia etc.

Our Company is led by our Promoter, Chetan Rugnathbhai Matholiya, Jayeshkumar Amarshibhai Sabava and Akashbhai Mansukhbhai Gangadiya having an experience of around 11 years, 11 years and 8 years in the pharmaceutical industry respectively. Our experience and exposure in the industry allow us to deal with various types of formulation used in various applications.

Key Performance Indicators of our Company

(₹ in Lakhs except percentages and ratios)

Key Financial Performance	FY 2024-25	FY 2023-24	FY 2022-23
Revenue from operations ⁽¹⁾	4,580.12	2,440.54	170.25
EBITDA ⁽²⁾	921.36	456.84	(68.87)
EBITDA Margin ⁽³⁾	20.12%	18.72%	(40.45) %
PAT ⁽⁴⁾	426.40	193.43	(92.55)
PAT Margin ⁽⁵⁾	9.31%	7.93%	(54.36%)
Net Worth ⁽⁶⁾	947.07	520.67	327.24
RoNW(%) ⁽⁷⁾	45.02%	37.15%	(28.28%)
RoCE (%) ⁽⁸⁾	23.29%	14.24%	(6.57%)

Notes:

- (1) 'Revenue from Operations' means the Revenue from Operations as appearing in the Restated Financial Statements
- (2) 'EBITDA' is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income
- (3) 'EBITDA Margin' is calculated as EBITDA divided by Revenue from Operations
- (4) 'PAT' is calculated as Profit before tax – Tax Expenses.
- (5) 'PAT Margin' is as PAT for the year divided by revenue from operations.
- (6) 'Net worth means Equity share capital + Reserves and surplus (including, Securities Premium, General Reserve and surplus in statement of profit and loss).
- (7) 'Return on Net Worth' is ratio of Profit after Tax and Net Worth.
- (8) 'Return on Capital Employed' is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus total borrowings {current & non-current}

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

For details in respect of “*Statement of Significant Accounting Policies*”, please refer to *Annexure IV & Annexure V of Restated Financial Statements* beginning on page 181 of this Draft Red Herring Prospectus.

Factors Affecting our Results of Operations

1. The loss of one or more marketing partners, the deterioration of their financial condition or prospects, or a reduction in their demand for our products or our inability to maintain and increase the number of our arrangements for the marketing and distribution of our products
2. Decrease in market growth for our product or failure to respond to change in market conditions
3. Failure to comply with the quality standards and technical specifications prescribed by our customers
4. Cancellation of existing and future orders which may expose us to warranty claims;
5. The pharmaceutical market is subject to regulation and failures to comply with the existing and future regulatory requirements in any pharmaceutical market
6. Instances where our drugs fail to meet standards prescribed under applicable law and action by regulatory authorities.
7. Any change in government policies resulting in increases in taxes payable by us;
8. Failure of our suppliers in meeting their obligations with respect to supply of raw materials and components;
9. The occurrence of natural disasters or calamities;
10. General economic, political and other risks that are out of our control;
11. Inflation, deflation, unanticipated turbulence in interest rates, equity prices or other rates or prices;
12. Company's ability to successfully implement its growth strategy and expansion plans;
13. Failure to comply with regulations prescribed by authorities of the jurisdictions in which we operate;
14. Inability to successfully obtain registrations in a timely manner or at all;
15. Occurrence of Environmental Problems & Uninsured Losses;
16. Concentration of ownership among our Promoters.

Discussion on Result of Operations

The following discussion on results of operations should be read in conjunction with the Restated Financial Statements for the financial years ended on March 31, 2025, March 31, 2024 and March 31, 2023.

(Rs. in Lakhs)

Particulars	March 31, 2025	% of Total Income	March 31, 2024	% of Total Income	March 31, 2023	% of Total Income
Revenue from Operations	4580.12	99.31%	2440.54	99.69%	170.25	98.93%
Other Incomes	31.97	0.69%	7.71	0.31%	1.84	1.07%
Total Income	4612.09	100.00%	2448.24	100.00%	172.09	100.00%
Expenses:						
(a) Cost of Material Consumed	3,635.20	78.82%	1789.75	73.10%	178.08	103.48%
(b) Purchase of Stock-in-Trade	86.48	1.88%	1.04	0.04%	0.00	0.00%
(c) Changes in inventories of finished goods work-in-progress	(592.97)	(12.86) %	(26.67)	(1.09) %	(35.21)	(20.46) %
(d) Employee Benefits Expenses	257.47	5.58%	99.64	4.07%	25.60	14.88%
(e) Finance Costs	158.95	3.45%	120.25	4.91%	58.67	34.09%
(f) Depreciation and Amortization Expense	287.05	6.22%	116.74	4.77%	22.48	13.06%
(g) Other Expenses	264.23	5.73%	113.34	4.63%	32.80	19.06%
Total Expenses (a to g)	4096.41	88.82%	2214.09	90.44%	282.42	164.11%
Profit before Exceptional/ Extraordinary items and tax	515.68	11.18%	234.15	9.56%	(110.33)	(64.11) %
Exceptional item & Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Profit before Extraordinary Items and tax	515.68	11.18%	234.15	9.56%	(110.33)	(64.11) %
Prior Period Expenses	0.00	0.00%	0.00	0.00%	0.00	0.00%
Profit before tax	515.68	11.18%	234.15	9.56%	(110.33)	(64.11) %
Tax Expense						
a) Net Current Tax	101.44	2.20%	11.19	0.46%	0.00	0.00%
b) Deferred Tax	(12.16)	(0.26) %	29.53	1.21%	(17.78)	(10.33) %
Restated Profit for the Period	426.40	9.25%	193.43	7.90%	(92.55)	(53.78) %

Revenue from operations:

Revenue from operations mainly consists of revenue from sale of pharmaceutical products.

Other Incomes

Other income comprises of Interest on Deposit, Subsidy Received, Sale of Scrap and Discount Received.

Total Expenses:

Total expenses consist of Cost of Material Consumed, Purchases of Stock in Trade, Change in inventories of Finished Goods and WIP, Employee benefits expense, Finance costs, Depreciation and amortization expenses and other expenses.

Cost of Material Consumed

Cost of Material consumed expenses primarily comprises of Purchase of Raw Material such as APIs and Packing material.

Purchase of stock in trade

Purchase of stock in trade primarily comprises of Purchases of goods.

Change in inventories of Finished Goods and Work in progress

Change in inventories of stock in trade comprises of increase/ (decrease) in inventory of finished goods and work in progress and Finished goods mainly consists of Capsules, Tablets, Oral Liquids, Dry Syrups and External products.

Employee benefits expense:

Employee benefits expense primarily comprises of Salary and Wages and Contribution to Provident Fund and Other Fund and Staff welfare expenses. Salary and Wages which comprises of Director Remuneration, Salary & Wages Expenses. Contribution to Provident Fund and Other Fund which comprises of Provident Fund, Labour Welfare Fund, Profession Tax and Gratuity.

Finance Costs:

Our Finance cost includes Interest expense and Other Borrowing cost.

Depreciation and Amortization Expenses:

Depreciation and Amortization Expenses include Depreciation on Tangible Assets and Amortization on Intangible Assets which further comprises of depreciation on Building, Plant and Machinery, Electrical Installation, Furniture & Fittings, Computer and Computer Accessories, Vehicles and Solar Plant and Amortization on Computer Software.

Other Expenses:

Other Expenses comprises of Other Direct Expense, Repairs & Maintenance, Rates & Taxes, Advertising Expenses and Other Expenses which further comprises of Electricity Charges, Job Work Charges, Transportation & Handling Charges, Testing Expense, Factory Expense, Repairs to Machinery, Audit Fees, Insurance, Office Expense, Legal & Professional Fees, License Expense, Miscellaneous Expenses, Communication Expenses, Printing & Stationery and Travelling & Conveyance Expenses.

FINANCIAL YEAR 2025 COMPARED TO FINANCIAL YEAR 2024**Total Income:**

The Total Income increased from FY 24 to FY 25, driven by an improvement in Revenue from Operations and Other Income. Total income grew by 88.38%, rising from Rs. 2448.24 Lakhs in FY24 to Rs. 4612.09 Lakhs in FY 25, which was due to growth

in Revenue from Operations by 87.67% in FY 25 and Other Income which grew by 314.93% in FY 25. This overall growth reflects the company's operational performance during the year.

Revenue from Operations

During the financial year 2024-25, the revenue from operations of the Company reported a sales growth of 87.67%, primarily driven by an 84.14% increase in sale of manufactured goods. The growth in manufactured sales was primarily due to increase in sale of External preparation, Oral Liquid and Tablets which grew by 17389.42%, 9128.28% and 146.33% respectively.

Other Income:

During the financial year 2024-25, the other income of the Company increased by 314.93%, from ₹7.71 lakhs in FY 2023-24 to ₹31.97 lakhs in FY 2024-25. This increase was due to a rise in Interest on deposit which increased by 10.48% from ₹2.10 lakhs in FY 2023-24 to ₹2.32 lakhs in FY 2024-25 and majorly from Subsidy Received for ₹28.75 lakhs in FY 2024-25.

Total Expenses

The total expense for the financial year 2024-25 increases to ₹4096.41 Lakhs from ₹2214.09 lakhs in the Financial Year 2023-24 representing an increase of 85.02%. Such increase was due to increases in the volume of business operations of the Company.

Cost of Material Consumed

The Cost of Material Consumed comprises of Material Procured During the Year, Inventory at the Commencement and end of the Year. The Cost of Material Consumed for the financial year 2024-25 increases to ₹3635.20 Lakhs from Rs. 1789.75 lakhs in the Financial Year 2023-24 representing an increase of 103.11%. This increase was due to a rise in opening stock of raw material which increased by 290.76% from ₹156.63 lakhs in FY 2023-24 to ₹612.04 lakhs in FY 2024-25, material procured during the year increased by 77.71% from ₹2245.16 lakhs in FY 2023-24 to ₹3989.89 lakhs in FY 2024-25 and closing stock of raw material increased by 57.95% from ₹612.04 lakhs in FY 2023-24 to ₹966.73 lakhs in FY 2024-25.

Purchases of Stock in Trade

The Purchase of stock in trade for the financial year 2024-25 increased to ₹86.48 lakhs from ₹1.04 lakhs in the Financial Year 2023-24 representing an increase of 8215.38%. Such increase was due to increase in the volume of stock in trade.

Change in inventories of Finished Goods and Work in progress

The Change in inventories of Finished Goods and Work in progress comprises of increase/(decrease) in inventory of Finished Goods and Work in progress in business operation. The Change in inventories of Finished Goods and Work in progress for the financial year 2024-25 is ₹ (592.97) Lakhs from ₹ (26.67) lakhs in the Financial Year 2023-24. This increase was due to a rise in the closing inventories of Finished Goods which increased to Rs. 228.89 Lakhs in Financial Year 2024-25 as against Rs. 61.88 Lakhs in Financial Year 2023-24 representing as increase of 269.89% and work in progress amounting to ₹425.96 lakhs in the Financial Year 2024-25.

Employee benefits expense:

During the financial year 2024-25, the total Employee Benefits Expenses of the Company increased by 158.40%, from ₹99.64 lakhs in FY 2023-24 to ₹257.47 lakhs in FY 2024-25. This increase was due to increase in Salaries and Wages which increased by 159.54% from ₹89.34 lakhs in FY 2023-24 to ₹231.87 lakhs in FY 2024-25, Directors' Remuneration increased by 173.45%, increasing from ₹2.90 lakhs in FY 2023-24 to ₹7.93 lakhs in FY 2024-25, Contribution to Provident and Other Funds increased by 153.37%, increasing from ₹6.89 lakhs in FY 2023-24 to ₹17.46 lakhs in FY 2024-25.

Finance Costs:

During the financial year 2024-25, the Finance cost of the Company increased by 32.18%, from ₹120.25 lakhs in FY 2023-24 to ₹158.95 lakhs in FY 2024-25. This increase was due to increase in Interest expenses by 32.51% from ₹113.65 lakhs in FY

2023-24 to ₹150.60 lakhs in FY 2024-25 and Other Borrowing Costs increased by 26.52% from ₹6.60 lakhs in FY 2023-24 to ₹8.35 lakhs in FY 2024-25.

Depreciation and Amortization Expenses:

Depreciation and Amortization for the financial year 2024-25 stood at ₹287.05 Lakhs as against ₹116.74 Lakhs during the financial year 2023-24. The increase in depreciation and amortization was around 145.89 % which was majorly due to addition in Property, Plant and equipment during the year.

Other Expenses:

During the financial year 2024-25, the Other Expenses of the Company increased by 133.13%, from ₹113.34 lakhs in FY 2023-24 to ₹264.23 lakhs in FY 2024-25. This increase was due to increase Electricity Charges by 53.71% from ₹42.88 lakhs in FY 2023-24 to ₹65.91 lakhs in FY 2024-25, Job Work Charges by 144.78 % from ₹33.94 lakhs in FY 2023-24 to ₹83.08 lakhs in FY 2024-25, Transportation & Handling Charges by 1222.48 % from ₹2.18 lakhs in FY 2023-24 to ₹28.83 lakhs in FY 2024-25, Testing Expense by 216.14 % from ₹9.73 lakhs in FY 2023-24 to ₹30.76 lakhs in FY 2024-25, Factory Expense by 150.71% from ₹4.20 lakhs in FY 2023-24 to ₹10.53 lakhs in FY 2024-25, Printing & Stationery by 217.07% from ₹1.64 lakhs in FY 2023-24 to ₹5.20 lakhs in FY 2024-25, Miscellaneous Expenses by 177.84 % from ₹1.85 lakhs in FY 2023-24 to ₹5.14 lakhs in FY 2024-25 etc.

Restated Profit before tax:

Profit before tax for the financial year 2024-25 increased to ₹515.68 Lakhs as compared to profit of ₹243.15 Lakhs in the financial year 2023-24. The increase of 120.24% was majorly due to factors as mentioned above.

Restated profit after tax:

Profit after tax for the financial year 2024-25 increased to ₹426.40 Lakhs as compared to profit of ₹193.43 Lakhs in the financial year 2023-24. The increase of 120.44 % was due to factors increase in PAT margin. The PAT margin for the financial year 2023-24 was 7.93% and the same has increased to 9.31% in the financial year 2024-25.

FINANCIAL YEAR 2024 COMPARED TO FINANCIAL YEAR 2023

Total Income:

The Total Income increased from FY 2022-23 to FY 2023-24, driven by an improvement in Revenue from Operations and Other Income. Total income grew by 1322.65%, rising from Rs. 172.09 Lakhs in FY2022-23 to Rs. 2448.24 Lakhs in FY 2023-24, which was due to growth in Revenue from Operations by 1333.50 % in FY 24 and Other Income which grew by 318.75 % in FY 2023-24. This overall growth reflects the company's operational performance during the year.

Revenue from Operations

During the financial year 2023-24, the revenue from operations of the Company reported a sales growth of 1333.50 % from ₹170.25 lakhs in FY 2022-23 to ₹ 2440.54 Lakhs in FY 2023-24, primarily driven by an 1332.86% increase in sale of manufactured goods. The growth in manufactured sales was primarily due to addition of General Pharma product plant which increased our production. In FY2022-23 our entire revenue was from Beta Lactum plant but in FY 2023-24 our percentage revenue from Beta Lactum plant was 96.27% while from General Pharma product plant it was 3.73%.

Other Income:

During the financial year 2023-24, the other income of the Company increased by 318.75%, from ₹1.84 lakhs in FY 2022-23 to ₹7.71 lakhs in FY 2023-24. This increase was due to a rise in Interest on deposit which increased by 500.00% from ₹0.35 lakhs in FY 2022-23 to ₹2.10 lakhs in FY 2023-24, Sale of Scrap of ₹5.05 lakhs in FY 2023-24 and Discount received of ₹0.56 lakhs in FY 2023-24.

Total Expenses

The total expense for the financial year 2023-24 increases to ₹2214.09 Lakhs from ₹282.42 lakhs in the Financial Year 2022-23 representing an increase of 683.97 %. Such increase was due to increases in the volume of business operations of the Company.

Cost of Material Consumed

The Cost of Material Consumed comprises of Material Procured During the Year, Inventory at the Commencement and end of the Year. The Cost of Material Consumed for the financial year 2023-24 increases to ₹1789.75 Lakhs from Rs. 178.08 lakhs in the Financial Year 2022-23 representing an increase of 905.03%. This increase was due to opening stock of raw material which was ₹156.63 Lakhs in FY 2023-24, material procured during the year increased by 570.78 % from ₹334.71 lakhs in FY 2022-23 to ₹2245.16 lakhs in FY 2023-24 and closing stock of raw material increased by 290.76% from ₹156.63 lakhs in FY 2022-23 to ₹612.04 lakhs in FY 2023-24.

Purchases of Stock in Trade

The Purchase of stock in trade for the financial year 2023-24 is ₹1.04 lakhs as the trading activity started in FY2023-24.

Change in inventories of Finished Goods and Work in progress

The Change in inventories of Finished Goods and Work in progress comprises of increase/(decrease) in inventory of Finished Goods and Work in progress in business operation. The Change in inventories of Finished Goods and Work in progress for the financial year 2023-24 is ₹ (26.67) Lakhs from ₹ (35.21) lakhs in the Financial Year 2022-23. This increase was due to a rise in the closing inventories of Finished Goods which increased to Rs. 61.88 Lakhs in Financial Year 2023-24 as against Rs. 35.21 Lakhs in Financial Year 2022-23 representing as increase of 75.75%.

Employee benefits expense:

During the financial year 2023-24, the total Employee Benefits Expenses of the Company increased by 289.22%, from ₹25.60 lakhs in FY 2022-23 to ₹99.64 lakhs in FY 2023-24. This increase was due to increase in Salaries and Wages which increased by 284.75% from ₹23.22 lakhs in FY 2022-23 to ₹89.34 lakhs in FY 2023-24, Directors' Remuneration increased by 93.33%, increasing from ₹1.50 lakhs in FY 2022-23 to ₹2.90 lakhs in FY 2023-24, Contribution to Provident and Other Funds increased by 683.13%, increasing from ₹0.88 lakhs in FY 2022-23 to ₹6.89 lakhs in FY 2023-24.

Finance Costs:

During the financial year 2023-24, the Finance cost of the Company increased by 104.96%, from ₹58.67 lakhs in FY 2022-23 to ₹120.25 lakhs in FY 2023-24. This increase was due to increase in Interest expenses by 445.87% from ₹ 20.82 lakhs in FY 2022-23 to ₹113.65 lakhs in FY 2023-24.

Depreciation and Amortization Expenses:

Depreciation and Amortization for the financial year 2023-24 stood at ₹116.74 Lakhs as against ₹22.48 Lakhs during the financial year 2022-23. The increase in depreciation and amortization was around 419.31 % which was majorly due to addition in Property, Plant and equipment during the year.

Other Expenses:

During the financial year 2023-24, the Other Expenses of the Company increased by 245.55%, from ₹32.80 lakhs in FY 2022-23 to ₹113.34 lakhs in FY 2023-24. This increase was due to increase Electricity Charges by 358.12 % from ₹9.36 lakhs in FY 2022-23 to ₹42.88 lakhs in FY 2023-24, Job Work Charges stood at ₹33.94 lakhs in FY 2023-24, Repairs to Machinery by 743.16 % from ₹0.95 lakhs in FY 2022-23 to ₹8.01 lakhs in FY 2023-24, Testing Expense by 134.46 % from ₹4.15 lakhs in FY 2022-23 to ₹9.73 lakhs in FY 2023-24, Factory Expense by 303.85% from ₹1.04 lakhs in FY 2022-23 to ₹4.20 lakhs in FY 2023-24 etc.

Restated Profit before tax:

Profit before tax for the financial year 2023-24 increased to ₹234.15 Lakhs as compared to Loss of ₹ (110.33) Lakhs in the financial year 2022-23. The increase of 312.23% was majorly due to factors as mentioned above.

Restated profit after tax:

Profit after tax for the financial year 2023-24 increased to ₹193.43 Lakhs as compared to Loss of ₹ (92.55) Lakhs in the financial year 2022-23. The increase of 308.99 % was due to factors increase in PAT margin. The PAT margin for the financial year 2022-23 was (54.36) % and the same has increased to 7.93% in the financial year 2023-24.

Information required as per Item (II)(C)(iv) of Part A of Schedule VI to the SEBI Regulations:

An analysis of reasons for the changes in significant items of income and expenditure is given hereunder:

1. Unusual or infrequent events or transactions

There has not been any unusual trend on account of our business activity. Except as disclosed in this Red Herring Prospectus, there are no unusual or infrequent events or transactions in our Company.

2. Significant economic changes that materially affected or are likely to affect income from continuing operations.

There are no significant economic changes that may materially affect or likely to affect income from continuing operations.

3. Known trends or uncertainties that have had or are expected to have a material adverse impact on sales, revenue or income from continuing operations.

Apart from the risks as disclosed under Section “**Risk Factors**” beginning on page 27 of the Red Herring Prospectus, in our opinion there are no other known trends or uncertainties that have had or are expected to have a material adverse impact on revenue or income from continuing operations.

4. Future changes in relationship between costs and revenues

Other than as described in the sections “**Risk Factors**”, “**Our Business**” and “**Management’s Discussion and Analysis of Financial Condition and Results of Operations**” on pages 27, 118 and 223 respectively, to our knowledge, no future relationship between expenditure and income is expected to have a material adverse impact on our operations and finances.

5. Segment Reporting

Our business activity primarily falls within a single business segment and therefore we do not follow any other segment reporting

6. Status of any publicly announced New Products or Business Segment

Except as disclosed in the Chapter “**Our Business**”, our Company has not announced any new product or service.

7. Seasonality of business

Our business is not subject to seasonality. For further information, see “**Industry Overview**” and “**Our Business**” on pages 102 and 118 respectively.

8. Dependence on single or few customers

During the Fiscal 2025, Fiscal 2024 and Fiscal 2023, our top 10 customers contributed approximately 72.88%, 87.49% and 82.83% of our revenue from operations respectively. Moreover, our revenue from our top customer constituted 17.49%, 49.97%

and 33.16% of our revenue from operations for the financial year ended at March 31, 2025, March 31, 2024 and March 31, 2023 respectively.

9. *Competitive conditions*

Competitive conditions are as described under the Chapters “**Industry Overview**” and “**Our Business**” beginning on pages 102 and 118 respectively of this Red Herring Prospectus.

10. *Details of material developments after the date of last balance sheet i.e., March 31, 2025*

After the date of last Balance sheet i.e. March 31, 2025, the following material events have occurred:

- (i) Increase in the Authorized Share Capital of the Company from ₹ 425.00 Lakhs divided into 42,50,000 Equity Shares of ₹ 10/- each to ₹1100.00 Lakhs divided into 1,10,00,000 Equity Shares of Rs. ₹ 10/- each vide Extra Ordinary General Meeting held on September 05, 2025;
- (ii) The Board of Directors in their meeting held on September 09, 2025 allotted 34,00,000 Bonus shares in the ratio of 4:5 i.e. Four (4) Equity shares for every Five (5) Equity share held by each shareholder.

CAPITALISATION STATEMENT

(Amount in Rs. Lakhs)

Particulars	Pre Issue	Post Issue
Borrowings		
Short term debt (A)	832.13	*
Long Term Debt (including current maturities of long term borrowing) (B)	1,081.92	*
Total debts (C)	1,914.05	
Shareholders' funds		
Equity share capital	425.00	*
Reserve and surplus - as restated	522.07	*
Total shareholders' funds	947.07	
Long term debt / shareholder's funds	1.14	*
Total debt / shareholder's funds	2.02	*

(*) The corresponding post issue figures are not determinable at this stage pending the completion of public issue and hence have not been furnished.

Notes:

1. Short term Debts represent which are expected to be paid/payable within 12 months and excludes instalment of term loans repayable within 12 months.
2. Long term Debts represent debts other than Short Term Debts as defined above but includes installment of term loans repayable within 12 months grouped under short term borrowing.
3. The figures disclosed above are based on restated statement of Assets and Liabilities of the Company as at 31-03-2025.

SECTION VII – LEGAL AND OTHER INFORMATION

OUTSTANDING LITIGATION AND MATERIAL DEVELOPMENTS

Except as stated in this section, there are no: (i) criminal proceedings; (ii) actions by statutory or regulatory authorities; (iii) outstanding claims relating to direct and indirect taxes; (iv) disciplinary actions including penalties imposed by SEBI or stock exchanges against the Promoter in the last five financial years, including outstanding action; or (v) Material Litigation (as defined below); involving our Company, its Directors and Promoters, Key Managerial Personnel, Senior Management and Subsidiary Company; or (vi) litigation involving our Group Company, which has a material impact on our Company.

For the purpose of (v) above, our Board, in its meeting held on September 26, 2025 determined that outstanding legal proceedings involving the Company, its Directors, Promoters will be considered as material litigation (“Material Litigation”) based on lower of the threshold criteria mentioned below:

(i) As per the policy of materiality defined by the board of directors of the issuer where the aggregate amount involved in such individual litigation exceeds 5% of profit after tax of the Company, as per the latest annual restated financial statements of the Company or such litigations outcome could have a material impact on the business, operations, prospects or reputations of the Company.

or

(ii) Litigation where the value or expected impact in terms of value, exceeds the lower of the following:

- (a) two percent of turnover, as per the latest annual restated financial statements of the issuer being ₹91.60 lakhs; or*
- (b) two percent of net worth, as per the latest annual restated financial statements of the issuer being ₹18.94 lakhs; or*
- (c) five percent of the average of absolute value of profit or loss after tax, as per the last three annual restated financial statements of the issuer being ₹8.79 lakhs.*

The Company has a policy for identification of Material Outstanding Dues to Creditors in terms of the SEBI (ICDR) Regulations, 2018 as amended for creditors where outstanding due to any one of them exceeds 5% of the Company's trade payables as per the last restated financial statements.

A. LITIGATION INVOLVING THE COMPANY

(a) Criminal proceedings against the Company

As on the date of this Draft Red Herring Prospectus, there are no outstanding criminal proceedings against the Company.

(b) Criminal proceedings filed by the Company

As on the date of this Draft Red Herring Prospectus, there are no outstanding criminal proceedings initiated by the Company.

(c) Other pending material litigations against the Company

1. Sun Pharmaceutical Industries Limited (“Plaintiff”) has filed a commercial suit against Maxtouch Life Science LLP (Maxtouch) and our Issuer Company, Rednex Pharmaceuticals Limited (“Defendants”) before the Bombay High Court (“Court”) being Commercial Intellectual Property Suit No. COMIP/132/2023 (“Case No.”) filed on January 25, 2023 (“Filing Date”) for infringement of trademark, copyright, and passing off (“Type”) concerning the Plaintiff’s VOLINI brand as against VOLINAC manufactured by our Company and marketed by Maxtouch. Sun Pharma has sought reliefs including injunction, delivery-up of infringing goods, damages to the tune of Rs. 10,00,000, and rendition of accounts.

The plaint is supported by trademark registrations, copyright claims, sales invoices, and photographs of the impugned cartons, and the Defendants have been directed to file their replies. In relation to this dispute, the Plaintiff has filed Interim Application IA/1712/2023 (lodged as IA (L) No. 3225 of 2023) seeking interim orders, and Lodging Petition LPETNL/3228/2023, which are presently at the pre-admission stage. The main suit remains pending before the Court.

(d) Other pending material litigations filed by the Company

As on the date of this Draft Red Herring Prospectus, there are no outstanding material litigation filed by the Company.

(e) Actions by statutory and regulatory authorities against the Company

As on the date of this Draft Red Herring Prospectus, there are no outstanding actions by statutory or regulatory authorities initiated against the Company.

B. LITIGATIONS INVOLVING THE PROMOTERS & DIRECTORS OF THE COMPANY

(a) Criminal proceedings against the Promoters & Directors of the company

Our Directors, Akashbhai Mansukhbhai Gangadiya, Chetan Rugnathbhai Matholiya and Jayeshkumar Amarshibhai Sabava are party to a criminal proceeding initiated by the Union of India in Case No. CC 3567 of 2024, filed through the Drugs Inspector, CDSCO Ahmedabad, before the Court of the Chief Judicial Magistrate, Sanand, against their Partnership Firm M/s Rednex Pharmaceuticals on October 07, 2024. The matter pertains to the manufacturing of Clotrimazole with Beclomethasone Dipropionate Cream (Fungdid-B Cream), Batch No. 19285 (Mfg. 10/2019, Exp. 09/2021), which was declared 'Not of Standard Quality' by the Central Drugs Laboratory, Kolkata, as the sample did not conform to the prescribed assay/content. Subsequent joint inspection by CDSCO and FDCA observed violations of Schedule M of the Drugs and Cosmetics Rules, including absence of process validation, stability studies, and Master Formula Records. Prosecution sanction was obtained from the Drugs Controller General of India, and a criminal complaint has been instituted for offences under Sections 17(A)(a) & (f), 18(a)(i), and 18(c) read with Section 34 of the Drugs and Cosmetics Act, punishable under Section 27(a) & (d) of the Act, which are still pending.

(b) Criminal proceedings filed by the Promoters & Directors of the company

As on the date of this Draft Red Herring Prospectus, there are no outstanding criminal proceedings filed by the Promoters & Directors of the Company.

(c) Other pending material litigations against the Promoters & Directors of the company

As on the date of this Draft Red Herring Prospectus, there are no outstanding material litigation initiated against the Promoters & Directors of the Company.

(d) Other pending material litigations filed by the Promoters & Directors of the company

As on the date of this Draft Red Herring Prospectus, there are no other pending litigations initiated by the Promoters & Directors.

(e) Actions by statutory and regulatory authorities against the Promoters & Directors of the company

As on the date of this Draft Red Herring Prospectus, there are no outstanding actions initiated by the statutory and regulatory authorities against the Promoters & Directors.

(f) Disciplinary actions including penalties imposed by SEBI or stock exchanges against the Promoters in the last five financial years, including outstanding action

As on the date of this Draft Red Herring Prospectus, there are no outstanding actions by SEBI or stock exchanges against the Promoters, nor any penalties have been imposed in the last five years.

C. LITIGATION INVOLVING KEY MANAGERIAL PERSONNEL AND SENIOR MANAGERIAL PERSONNEL OF THE COMPANY

a) Criminal proceedings against the Key Managerial Personnel and Senior Managerial Personnel of the Company

As on the date of this Draft Red Herring Prospectus, there are no criminal proceedings against Key Managerial Personnel and Senior Managerial Personnel of the Company.

b) Criminal proceedings filed by the Key Managerial Personnel and Senior Managerial Personnel of the Company

As on the date of this Draft Red Herring Prospectus, there are no criminal proceedings filed by Key Managerial Personnel and Senior Managerial Personnel of the Company.

c) Actions by statutory and regulatory authorities against the Key Managerial Personnel and Senior Managerial Personnel of the Company

As on the date of this Draft Red Herring Prospectus, there are no outstanding actions by statutory or regulatory authorities initiated against Key Managerial Personnel and Senior Managerial Personnel of the Company.

D. LITIGATIONS INVOLVING THE GROUP COMPANY OF THE COMPANY WHICH CAN HAVE A MATERIAL IMPACT ON OUR COMPANY

(a) Criminal proceedings against the group company of the company

As on the date of this Draft Red Herring Prospectus, there are no outstanding criminal proceedings initiated against the group company of the company.

(b) Criminal proceedings filed by the group company of the company

As on the date of this Draft Red Herring Prospectus, there are no outstanding criminal proceedings filed by the group company of the company.

(c) Other pending material litigations against the group company of the company

As on the date of this Draft Red Herring Prospectus, there are no outstanding litigations initiated against the group company, which have been considered material by the Company in accordance with the Materiality Policy.

(d) Other pending material litigations by the group company of the company

As on the date of this Draft Red Herring Prospectus, there are no outstanding litigations initiated by the group company, which have been considered material by the Company in accordance with the Materiality Policy.

(e) Actions by statutory and regulatory authorities against the group company of the company

As on the date of this Draft Red Herring Prospectus, there are no outstanding actions by statutory or regulatory authorities initiated against the group company.

E. TAX PROCEEDINGS

Nature of Proceedings	Number of cases	Amount involved (Rs. in lakhs)	Particulars
Of the Company			
Direct Tax	Nil	Nil	Nil
Indirect Tax	Nil	Nil	Nil
Of the Promoters and Directors			
Direct Tax	Nil	Nil	Nil

Indirect Tax	Nil	Nil	Nil

F. AMOUNTS OWED TO SMALL SCALE UNDERTAKINGS AND OTHER CREDITORS:

The Board of Directors of our Company considers dues exceeding 5% of the Company's trade payables as per the last restated financial statements, to small scale undertakings and other creditors as material dues for our Company.

The trade payables for the year ended on March 31, 2025 were Rs. 1,927.43 lakhs. Accordingly, a creditor has been considered 'material' if the amount due to such creditor exceeds Rs. 96.37 lakhs. This materiality threshold has been approved by our Board of Directors pursuant to the resolution passed on September 26, 2025. Based on these criteria, details of outstanding dues owed as on March 31, 2025 by our Company on are set out below:

(₹ in lakhs)		
Types of creditors	Number of creditors	Amount involved
A. Micro, small and medium enterprises	46	392.01
B. Other Creditors	75	1103.25
Total (A+B)	123	1927.43
C. Material Creditors	2	432.17

The details pertaining to net outstanding dues towards our material creditors as on March 31, 2025 (along with the names and amounts involved for each such material creditor) are available on the website of our Company at <https://www.rednexpharmaceuticals.com/>. It is clarified that such details available on our website do not form a part of this Draft Red Herring Prospectus.

MATERIAL DEVELOPMENTS OCCURRING AFTER LAST BALANCE SHEET DATE:

Except as disclosed in Chapter titled *“Management's Discussion & Analysis of Financial Conditions & Results of Operations”* beginning on page 223 of this Draft Red Herring Prospectus

GOVERNMENT AND OTHER APPROVALS

Our Company has received the necessary licenses, permissions and approvals from the Central and State Governments and other government agencies/ regulatory authorities/certification bodies required to undertake the issue or continue our business activities and except as mentioned below, no further approvals are required for carrying on our present or proposed business activities.

In view of the approvals listed below, we can undertake this issue and our current business activities and no further major approvals from any governmental or regulatory authority or any other entity are required to be undertaken in respect of the issue or to continue our business activities. It must be distinctly understood that, in granting these approvals, the Government of India does not take any responsibility for our financial soundness or for the correctness of any of the statements made or opinions expressed in this behalf. Unless otherwise stated, these approvals are all valid as of the date of this Draft Red Herring Prospectus.

The main objects clause of the Memorandum of Association of our Company and the objects incidental, enable our Company to carry out its activities.

The Company has got following licenses/ registrations/ approvals/ consents/ permissions from the Government and various other Government agencies required for its present business.

I. Approvals for the Issue:

The following approvals have been obtained or will be obtained in connection with the Issue:

Corporate Approvals:

- a. Our Board, pursuant to its resolution dated September 26, 2025 authorized the Issue subject to approval of the shareholders of our Company under Section 62(1)(c) of the Companies Act, 2013 and such other authorities as may be necessary;
- b. The shareholders of our Company have, pursuant to their resolution passed at the Extraordinary General Meeting of our Company held on September 26, 2025 under Section 62(1)(c) of the Companies Act, 2013, authorized the Issue;
- c. Our Board approved this Draft Red Herring Prospectus pursuant to its resolution dated September 30, 2025.

Approval from the Stock Exchange:

- d. In-principle approval dated [●] from the SME Platform of BSE ("BSE SME") for using the name of the Exchange in the Offer documents for listing of the Equity Shares issued by our Company pursuant to the Issue.

Agreements with NSDL and CDSL:

- e. Agreement dated September 24, 2025 between CDSL, the Company and the Registrar to the Issue;
- f. Agreement dated September 24, 2025 between NSDL, the Company and the Registrar to the Issue;
- g. The Company's International Securities Identification Number ("ISIN") is INE16E601016.

II. Incorporation related Approvals obtained by our Company:

Sr. No	Nature of Registration/ License	Registration Number/ CIN	Applicable Laws	Issuing Authority	Date of issue	Date of Expiry
1.	Certificate of Incorporation as Rednex Pharmaceuticals Private Limited	U24304GJ2020PTC119176	Companies Act, 2013	Registrar of Companies, Central Registration Centre	December 29, 2020	Valid until cancelled

Sr. No	Nature of Registration/ License	Registration Number/ CIN	Applicable Laws	Issuing Authority	Date of issue	Date of Expiry
2.	Fresh Certificate of Incorporation consequent upon conversion of Company from Rednex Pharmaceuticals Private Limited to Rednex Pharmaceuticals Limited	U24304GJ2020PLC119176	Companies Act, 2013	Registrar of Companies, Central Processing Centre	January 21, 2025	Valid until Cancelled

III. Corporate and Tax Related Approvals Obtained by Company:

Sr. No.	Nature of Registration/ License	Registration/ License No.	Applicable Laws	Issuing Authority	Date of Issue/ Renewal	Date of Expiry
1.	Permanent Account Number (PAN)	AAKCR6961N	Income Tax Act, 1961	Income Tax Department, Government of India	December 29, 2020	Valid until cancelled
2.	Tax Deduction Account Number (TAN)	AHMR14578E	Income Tax Act, 1961	Income Tax Department, Government of India	June 27, 2025	Valid until cancelled
3.	Certification of registration of Goods and Service tax – Gujarat	24AAKCR6961N1ZO	Goods and Services Tax Act, 2017	Department of Gujarat State Tax	March 02, 2021	Valid until cancelled
4.	Certificate of Enrolment of Profession Tax (Gujarat)	EC0703026162	Gujarat State Tax on Professions, Trades, Calling and Employment Act, 1976	Deputy Profession Tax Commissioner and Taluka Development Officer Bavla	July 30, 2024	Valid Until Cancelled
5.	Certificate of Registration of Profession Tax (Gujarat)	RC0703026163	Gujarat State Tax on Professions, Trades, Calling and Employment Act, 1976	Deputy Profession Tax Commissioner and Taluka Development Officer Bavla	July 30, 2024	Valid Until Cancelled

IV. Approvals Obtained in Relation to Business Operations of our Company:

Our Company requires various approvals and/or licenses to carry on our business. Some of these may expire in the ordinary course of business and applications for renewal of these approvals are submitted in accordance with applicable procedures and requirements.

Sr. No.	Nature of Registration/ License	Registration/ License No.	Applicable Laws	Issuing Authority	Date of Issue/Renewal	Date of Expiry
1.	Legal Entity Identifier (LEI) Certificate	98450003F79D7ED77115	Payments and Settlements Systems Act, 2007	Legal Entity Identifier India Private Limited	April 30, 2025	April 30, 2026

Sr. No.	Nature of Registration/ License	Registration/ License No.	Applicable Laws	Issuing Authority	Date of Issue/Renewal	Date of Expiry
2.	Certificate of Importer- Exporter Code (IEC)	AAKCR6961N	The Foreign Trade (Development and Regulation) Act, 1992	Directorate General of Foreign Trade	February 03, 2022	Valid until cancelled
3.	Udyam Registration Certificate	UDYAM-GJ-01-0042686	The Micro, Small and Medium Enterprises Development Act, 2006	Ministry of Micro, Small and Medium Enterprises, Government of India	January 29, 2021	Valid until cancelled
4.	Certificate for use of a Boiler	GT-13198	The Boilers Act, No. V (Amended 2007) of 1923	Director of Boilers Gujarat State, Ahmedabad	April 08, 2025	April 02, 2026
5.	Factory License	11461/24231/2024	Factories Act, 1948	Deputy Director Industrial Safety and Health Ahmedabad	February 08, 2024	December 31, 2026
6.	Consolidated Consent and Authorization (CC&A)	AWH-74149	Section 25 of the Water (prevention and control of pollution) Act, 1974, Section 21 of the Air (Prevention and control of Pollution) Act, 1981, under Rule 6(2) of the Hazardous and other Wastes (Management & Trans-boundary movement) Rules, 2016	Gujarat Pollution Control Board	July 08, 2024	March 31, 2029
7.	Form 25- Licence to manufacture for sale (or for distribution) of drugs other than those specified in Schedules C, C (1) and X	G/25/2688	Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Commissioner Food & Drugs Control Administration Gujarat State	February 03, 2025	February 02, 2030
8.	Form 28- Licence to manufacture for sale (or for distribution of) drugs specified in Schedules C, C (1) [excluding those specified in schedule X]	G/28/1888	Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Commissioner Food & Drugs Control Administration Gujarat State	February 03, 2025	February 02, 2030
9.	License to Sell, Stock or Exhibit or Offer for Sale or Distribute by Wholesale, Drugs other than those specified in Schedule	GJ-ADR237203	Drugs & Cosmetics Act, 1940; Drugs & Cosmetics Rules, 1945	Assistant Commissioner Food and Drugs Control Administration, Gujarat	May 23, 2024	May 22, 2029

Sr. No.	Nature of Registration/ License	Registration/ License No.	Applicable Laws	Issuing Authority	Date of Issue/Renewal	Date of Expiry
	C, C(1) and X.					
10.	License to Sell, Stock or Exhibit or Offer for Sale or Distribute by Wholesale, Drugs specified in Schedule C, C(1) (Excluding those specified in Schedule X).	GJ-ADR237204	Drugs & Cosmetics Act, 1940; Drugs & Cosmetics Rules, 1945	Assistant Commissioner Food and Drugs Control Administration, Gujarat	May 23, 2024	May 22, 2029
11.	World Health Organization- Good Manufacturing Practices- Beta Lactum	23074410	Food & Drugs Control Administration	Commissioner	July 15, 2023	July 14, 2026
12.	World Health Organization- Good Manufacturing Practices- General	25015490	Food & Drugs Control Administration	Commissioner	January 03, 2025	January 02, 2028
13.	GMP Certificate, Republic of Ghana	FDA/GMP/016/04/25	The Food & Drugs Authority, Ghana	Chief Executive Officer	-	November 30, 2027
14.	Central State Purchase Organisation Registration	DIC/Ahemdabad/2025-26/CSPO/00001	MSME Development Act, 2006	General Manager, District Industries Centre, Ahmedabad	May 08, 2025	May 06, 2028
15.	Pharmaceutical Manufacturer Registration License, Kingdom of Cambodia	CAM N0553PM-24	Law on the Management of Pharmaceuticals of the Kingdom of Cambodia	Ministry of Health, Kingdom of Cambodia	September 09, 2024	September 09, 2029
16.	Issue of Neutral Label Code Number for Export Purpose	GUJ/DRUGS/G/25/2688 GUJ/DRUGS/G/28/1888	Drugs & Cosmetics Act, 1940; Drugs & Cosmetics Rules, 1945	Food and Drugs Control Administration, Gujarat	February 10, 2025	Valid Until Cancelled
17.	Membership of Common Biomedical Waste Treatment Facility	ABD-03-07635	Biomedical waste Rules-2016 & it's amendments & Guidelines of Central Pollution Control Board	E-Coli Waste Management Pvt Ltd	May 01, 2025	April 30, 2028
18.	Common Hazardous Waste Management Facility	MEPPL-775	Hazardous and Other Wastes (Management and Transboundary Movement) Rules 2016, notified under the Environment Protection Act, 1986	Maurya Enviro Project Private Limited	May 16, 2024	May 15, 2027

Sr. No.	Nature of Registration/ License	Registration/ License No.	Applicable Laws	Issuing Authority	Date of Issue/Renewal	Date of Expiry
19.	Registration cum Membership Certificate of Pharmaceuticals Export Promotion Council of India as Manufacturer Exporter	RCMC/PHARMEX CIL/00204/2022-2023	Foreign Trade (Development and Regulation) Act, 1992	Pharmaceuticals Export Promotion Council of India	March 24, 2025	March 31, 2027
20.	Legal Metrology Certificate	GOI/GJ/2025/6931	Legal Metrology (Packaged Commodities), Rules 2011	Director (Legal Metrology)	September 23, 2025	Valid until Cancelled

V. Labour related Approvals obtained by our Company:

Sr. No.	Nature of Registration/ License	Registration/License No.	Applicable Laws	Issuing Authority	Date of Issue	Date of Expiry
1.	Registration under Employees' Provident Funds	GJAHD2269318000	Employees (Provident Fund and Miscellaneous Provisions) Act, 1952	RoC- CRC	December 29, 2020	Valid until Cancelled
2.	Gujarat Labour Welfare Board	HO/0020151		Gujarat Labour Welfare Board	*	Valid until cancelled

**copy of certificate is not traceable*

VI. Intellectual property related approvals:

Sr. No.	Name applied	Nature	Application date/ Renewal date	Allocated till	Application number	Class	Present status
1.		Pharmaceutical Preparation	September 25, 2017	September 24, 2027	3642953	5	Registered

The said trademarks are registered in the name of M/s. Rednex Pharmaceuticals and the applications for trademark assignment from the respective trademark owner in the name of the Company has been made.

VII. Quality Certifications Approvals obtained by our Company:

Manufacturing facility: Survey No. 586 and 231, Near SKF Bearing, Bavla Bagodara N.H 8A, Kerala, Taluka: Bavla, Ahmedabad, Gujarat, India, 382220

Sr. No.	Description	Registration/ License No	Nature of Registration	Authority	Date of Issue	Date of expiry
1.	ISO 9001:2015	305025032050Q	Quality Management System for following scope of activities	QRO Certification LLP	March 20, 2025	March 19, 2028

			Manufacturing of General Tablet, Capsule, Oral Liquid and External Preparation			
			Manufacturing of Beta Lactam Tablet, Capsule and Dry Syrup			
2.	ISO 14001:2015	305025032051E	Environment Management System for following scope of activities Manufacturing of General Tablet, Capsule, Oral Liquid and External Preparation Manufacturing of Beta Lactam Tablet, Capsule and Dry Syrup	QRO Certification LLP	March 20, 2025	March 19, 2028

VIII. Approvals or licenses applied but not received: Nil

OUR GROUP COMPANY

As per the SEBI (ICDR) Regulations, 2018, for the purpose of identification of Group Companies, our Company has considered those companies as our Group Companies with which there were related party transactions as per the Restated Financial Statements of our Company in any of the last three financial years and stub period (if any) and others as considered material by our Board. Further, pursuant to a resolution of our Board dated September 26, 2025 for the purpose of disclosure in relation to Group Companies in connection with the Issue, a company shall be considered material and disclosed as Group Company if such company fulfils the below mentioned conditions: -

- a. the companies with which there were related party transactions (in accordance with AS-18), as disclosed in the Restated Financial Statements (“Restated Financial Statements”); or
- b. if such company fulfils both the below mentioned conditions: -
 - i. Such company that forms part of the Promoter Group of our Company in terms of Regulation 2(1)(pp) of the SEBI (ICDR) Regulations; and
 - ii. Our Company has entered into one or more transactions with such company in preceding fiscal or audit period as the case may be exceeding 10% of total revenue of the company as per Restated Financial Statements.

Except as stated below, there are no companies/entities falling under definition of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 which are to be identified as group company/entity.

1. Lalko Exim Private Limited

Details of our Group Company:

1. Lalko Exim Private Limited (“LEPL”)

CIN	U51909GJ2022PTC133243
Registered Office	Shed No-066, Raghav Ind. Park, S.P. Ring Road, Baroda Xpress Way, Ramol, Ahmedabad, Gujarat-382449

Lalko Exim Private Limited was incorporated on June 24, 2022 under the Companies Act, 2013 pursuant to a certificate of incorporation issued by the Assistant Registrar of Companies, Central Registration Centre.

Its business is trading, marketing, importing, exporting, distributing, storing, stocking, purchasing, selling and otherwise dealing in all kinds and varieties of chemicals like pharma raw materials and industrial chemicals.

Financial Information

In accordance with the SEBI ICDR Regulations, details of reserves (excluding revaluation reserves), sales, profit after tax, earnings per share, basis/diluted earnings per share and Net Asset Value, derived from the latest audited financial statements for Fiscals 2025, 2024, and 2023 for our Group company are available on the website of our company at <https://www.rednexpharmaceuticals.com/>

It is clarified that such details available on our Group Companies’ websites do not form a part of this Draft Red Herring Prospectus. Anyone placing reliance on any other source of information, including our Group Companies’ website, as mentioned above, would be doing so at their own risk.

Other Confirmations:

- a) None of our Group Company have its equity shares listed on any stock exchange.
- b) Further, our Group Company have not made any public or rights issue (as defined under the SEBI ICDR Regulations) of securities in the three years preceding the date of this Draft Red Herring Prospectus.

Common pursuits

There are no common pursuits among our Group Company and our Company.

Nature and extent of interest of our Group Company

a) Interest in the promotion of our Company

Our Group Company does not have any interest in the promotion of our Company.

b) Interest in the property acquired or proposed to be acquired by the Company

Our Group Company is not interested, directly or indirectly, in the properties acquired by our Company in the preceding three years or proposed to be acquired by our Company.

c) Interest in transactions for acquisition of land, construction of building, or supply of machinery

Our Group Company is not interested, directly or indirectly, in any transactions for acquisition of land, construction of building, supply of machinery, with our Company.

Related business transactions and their significance on the financial performance of our Company

Other than the transactions disclosed in the section “*Financial Information –Related Party Transactions*” on page 211 there are no related business transactions between the Group Company and our Company.

Business interest of our Group Company in our Company

Except in the ordinary course of business and as disclosed in the section “*Financial Information –Related Party Transactions*” on page 211, our Group Company has no business interest in our Company.

Litigations

Except as disclosed in the section “*Outstanding litigations and material developments*” on page 233 of this Draft Red Herring Prospectus, there are no outstanding litigations by or against our group company.

Undertaking / Confirmations by our Group Company

None of our Promoters or Promoter Group or Group Company or person in control of our Company has been

- i. Prohibited from accessing or operating in the capital market or restrained from buying, selling or dealing in securities under any order or direction passed by SEBI or any other authority; or
- ii. Refused listing of any of the securities issued by such entity by any stock exchange, in India or abroad.

None of our Promoters, person in control of our Company have ever been a Promoter, Director or person in control of any other Company which is debarred from accessing the capital markets under any order or direction passed by the SEBI or any other authority.

Further, neither our Promoters, the relatives of our individual Promoters (as defined under the Companies Act) nor our Group company have been declared as a wilful defaulter or economic offender by the RBI or any other government authority and there are no violations of securities laws committed by them or any entities they are connected with in the past and no proceedings for violation of securities laws are pending against them.

OTHER REGULATORY AND STATUTORY APPROVALS

Authority for the Issue:

Corporate Approvals:

The Board of Directors has, pursuant to a resolution passed at its meeting held on September 26, 2025 authorized the Issue, subject to the approval of the shareholders of the Company under Section 62(1)(c) and all other applicable provisions of the Companies Act, 2013. The shareholders of the Company have, pursuant to a special resolution passed in Extra Ordinary General Meeting held on September 26, 2025, authorized the Issue under Section 62(1)(c) and all other applicable provisions of the Companies Act, 2013.

In-principal listing Approval

Our Company has obtained an in-principle approval from SME Platform of BSE (BSE SME) for using its name in the Red Herring Prospectus/ Prospectus pursuant to an approval letter dated [●] for listing our shares. BSE is the Designated Stock Exchange.

Prohibition by the Securities and Exchange Board of India (“SEBI”) or other Governmental Authorities:

We confirm that there is no prohibition on our Company, our Promoters, our Promoter Group, our Directors, or the person(s) in control of our Company from accessing or operating in the Capital Markets or debarred from buying, selling or dealing in securities under any order or direction passed by the Board (SEBI) or any securities market regulator in any other jurisdiction or any other authority/ court.

The listing of any securities of our Company has never been refused by any of the Stock Exchanges in India.

Neither our Company, nor our Promoters, Promoter Group, Directors or the person(s) in control of our Company, has ever been associated as Promoters, Promoter Group, Directors or the person(s) in control of any other Company which is debarred from accessing the capital market under any order or directions made by the SEBI or any other regulatory or governmental authority.

There has been no violation of any securities law committed by any of them in the past and no such proceedings are pending against any of them except as details provided in the chapter “*Outstanding Litigations and Material Development*” beginning on page 233 of this Draft Red Herring Prospectus.

Prohibition by the Reserve Bank of India (“RBI”)

Neither our Company, nor Promoters, nor Promoter Group, nor any of our Directors or the person(s) in control of our Company have been identified as a wilful defaulter or fraudulent borrowers by the RBI or other governmental authority and there has been no violation of any securities law committed by any of them in the past and no such proceedings are pending against any of them except as details provided under chapter titled “*Outstanding Litigations and Material Developments*” beginning on page 233 of this Draft Red Herring Prospectus.

Neither our Company, nor our Promoters, nor the relatives (as defined under the Companies Act) of our Promoters, nor Group Companies/Entities have been identified as wilful defaulters or Fraudulent Borrowers by the RBI or any other governmental authority.

PROHIBITION BY SECURITIES MARKET REGULATIONS

Our Company, our Promoters, our Directors and our Promoter’s Group, person(s) in control of the promoters or issuer, have not been prohibited from accessing the capital market or debarred from buying, selling, or dealing in securities under any order or direction passed by the Board or any securities market regulators in any other jurisdiction or any other authority/court.

PROHIBITION WITH RESPECT TO WILFUL DEFAULTER OR A FRAUDULENT BORROWER

Neither our Company, our Promoters, our Directors, Group Company, relatives (as per Companies Act, 2013) of Promoter or the person(s) in control of our Company have been identified as willful defaulter or a fraudulent borrower as defined by the SEBI (ICDR) Regulations, 2018.

COMPLIANCE WITH THE COMPANIES (SIGNIFICANT BENEFICIAL OWNERSHIP) RULES, 2018

Our Company, Promoters and Promoter Group are in compliance with the Companies (Significant Beneficial Ownership) Rules, 2018 to the extent applicable to each of them as on the date of the Draft Red Herring Prospectus.

Confirmations

Our Company confirms that it is not ineligible to make the Issue in terms of Regulation 228 of the SEBI ICDR Regulations. The details of our compliance with Regulation 228 of the SEBI ICDR Regulations are as follows:

- i. Neither our company, nor any of its promoters, promoter group or directors are debarred from accessing the capital market by the Board.
- ii. Neither our promoters, nor any directors of our company are a promoter or director of any other company which is debarred from accessing the capital market by the Board.
- iii. Neither our Company, nor our Promoters or our directors, is a Willful Defaulter or a fraudulent borrower.
- iv. Neither our Promoters nor any of our directors is declared as Fugitive Economic Offender.
- v. There are no outstanding convertible securities or any other right which would entitle any person with any option to receive equity shares of the issuer.

ELIGIBILITY FOR THE ISSUE

Our Company has complied with the conditions of Regulation 230 of SEBI (ICDR) Regulations, 2018 for this Issue.

Our Company is an “Unlisted Issuer” in terms of the SEBI (ICDR) Regulations; and this Offer is an “Initial Public Offer” in terms of the SEBI (ICDR) Regulations.

Our Company is eligible for the Issue in accordance with Regulation 229(2) and other provisions of Chapter IX of the SEBI (ICDR) Regulations, we are an Issuer whose post Offer paid up capital is more than 10 crores but less or equal to 25 crore rupees and we may hence Issue Equity Shares to the public and propose to list the same on the Small and Medium Enterprise Exchange {in this case being the “SME Platform of BSE (BSE SME)”}.

In terms of Regulation 229(3) of the SEBI ICDR Regulations, we confirm that we have fulfilled the eligibility criteria for SME Platform of BSE Limited, which are as follows:

- (a) Our Company was originally incorporated as a Private Limited Company under the name “Rednex Pharmaceuticals Private Limited” on December 29, 2020 under the provisions of the Companies Act, 2013 with the Registrar of Companies, Ahmedabad. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extraordinary General Meeting, held on December 30, 2024 and consequently, the name of our Company was changed from “Rednex Pharmaceuticals Private Limited” to “Rednex Pharmaceuticals Limited” vide a fresh certificate of incorporation dated January 21, 2025 issued by the Registrar of Companies, Central Processing Centre bearing CIN: U24304GJ2020PLC119176.
- (b) As on the date of this Draft Red Herring Prospectus, the Company has a Paid-up Capital of ₹765.00 Lakhs comprising 76,50,000 Equity shares and the Post Issue Paid up Capital (face value) of the company will be ₹[●] Lakh comprising [●] Equity Shares, which is less than ₹25 Crores.

- (c) The Company has a track record of at least 3 years as on the date of filling Draft offer Document/offer document.
- (d) the Company has net tangible assets of ₹ 938.02 Lakhs as on March 31, 2025 respectively which is more than ₹ 300 lakhs (Rs. 3 Crore).
- (e) The Company confirms that it has operating profits (earnings before interest, depreciation and tax) from operations for at least 2 financial years out of preceding three financial years and its net worth as on, March 31, 2025, March 31, 2024 and March 31, 2023 is positive.

<i>(Amount in ₹ Lakhs)</i>			
Particulars	March 31, 2025	March 31, 2024	March 31, 2023
EBITDA	921.36	456.84	(68.87)
Net worth	947.07	520.67	327.24

- (f) **Leverage Ratio**
Leverage ratio of not more than 3:1. Relaxation may be granted to finance companies.
Total Debt / Shareholders Fund as at March 31, 2025 was 2.02 times.
- (g) In the last one year, there has been no change in the name of the company in the preceding full financial year.
- (h) There has been no regulatory action of suspension of trading against the promoter(s) or companies promoted by the promoters by any stock Exchange having nationwide trading terminals. None of our Promoter(s) or directors have been promoter(s) or directors (other than independent directors) of compulsory delisted companies by the Exchange. Accordingly, there is no applicability of compulsory delisting is attracted and none of our Promoter(s) or directors have been promoter(s) or directors (other than independent directors) of companies that are suspended from trading on account of non-compliance. Further, none of our directors are disqualified/ debarred by any of the Regulatory Authority.
- (i) There are no pending defaults in respect of payment of interest and/or principal to the debenture/ bond/ fixed deposit holders by our Company, promoters/ promoting company(ies), Subsidiary Companies.
- (j) The Company confirms that there is no material regulatory or disciplinary action by a stock exchange or regulatory authority in the past one year in respect of promoters, Group Company, companies promoted by the promoters of the Company;
- (k) The net worth computation is computed as per the definition given in SEBI ICDR Regulations.
- (l) The Company has not been referred to the Board for Industrial and Financial Reconstruction (BIFR) or no proceedings have been admitted under Insolvency and Bankruptcy Code against the issuer and Promoting companies;
- (m) Our Company has not been referred to the National Company Law Tribunal (NCLT) under Insolvency and Bankruptcy Code, 2016.
- (n) None of the Directors of our Company have been categorized as a Wilful Defaulter or fraudulent borrowers.
- (o) There is no winding up petition against the Company that has been admitted by the Court or a liquidator has not been appointed of competent Jurisdiction against the Company.
- (p) No material regulatory or disciplinary action by a stock exchange or regulatory authority in the past three years against the company.
- (q) The directors of the issuer are not associated with the securities market in any manner, and there is no outstanding action against them initiated by the Board in the past five years.
- (r) There has been no change in the promoter(s) having significant change in control over the affairs of the Company in the one year preceding the date of filing application to SME Platform of BSE ("BSE SME").

- (s) The composition of the board is in compliance with the requirements of Companies Act, 2013 at the time of in-principle approval.
- (t) There are no litigations record against the applicant, promoters/promoting company(ies), group company, companies & promoted by the promoters/promoting company(ies) except as stated in the section titled “**Outstanding Litigation and Material Developments**” of the Draft Red Herring Prospectus.
- (u) There are no criminal cases/investigation/offences filed against the director of the company except as stated in the section titled “**Outstanding Litigation and Material Developments**” of the Draft Red Herring Prospectus.
- (v) None of the Issues managed by BRLM are returned by BSE in last six months from the date of this Draft Red Herring Prospectus.
- (w) 100% of the Promoter’s shareholding in the Company is in Dematerialised form.

Company has facilitated trading in demat securities and has entered into an agreement with both the depositories.

- (x) Our Company has a website i.e. <https://rednexpharma.com/>

We further confirm that we comply with all the above requirements/ conditions so as to be eligible to be listed on the SME Platform of BSE.

In terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, we confirm that:

1. In accordance with regulation 260 of the SEBI ICDR Regulations, this Issue is 100% underwritten by the BRLM in compliance of Regulations 260(1) and 260(2) of the SEBI (ICDR) Regulations, 2018. For details pertaining to underwriting by BRLM, please refer to Section titled “**General Information**” beginning on page 58 of this Draft Red Herring Prospectus.
2. In accordance with Regulation 261(1) of the SEBI (ICDR) Regulations, we hereby confirm that we will enter into an agreement with the Book Running Lead Manager and with Market Maker to ensure compulsory Market Making for a minimum period of three (3) years from the date of listing of Equity Shares on the SME Platform of BSE (“**BSE SME**”). For further details of the arrangement of market making please refer to section titled “**General Information-Details of the Market Making Arrangements for this Issue**” beginning on page 65 of this Draft Red Herring Prospectus.
3. In accordance with Regulation 268(1) of the SEBI (ICDR) Regulations, 2018, we shall ensure that the total number of proposed allottees in the Offer is greater than or equal to two-hundred (200), otherwise, the entire application money will be refunded forthwith. If such money is not repaid within four days from the date our company becomes liable to repay it, then our company and every officer in default shall, on and from expiry of four days, be liable to repay such application money, with interest at rate of fifteen per cent per annum and within such time as disclosed in the Offer document and BRLM shall ensure the same.
4. Further, in terms of Regulation 246 (4) of the SEBI (ICDR) Regulations, 2018 the prospectus will be displayed from the date of filing in terms of sub-regulation (1) on the website of the SEBI, the Book Running Lead Manager and the BSE SME.
5. In terms of Regulation 246(5) of the SEBI (ICDR) Regulations, we shall ensure that our Book Running Lead Manager submits a copy of the Prospectus along with a Due Diligence Certificate including additional confirmations as required to SEBI at the time of filing the Prospectus with Stock Exchange and the Registrar of Companies. However, as per Regulation 246 (2) of the SEBI (ICDR) Regulations, 2018, the SEBI shall not issue any observation on the offer document.
6. In accordance with Regulation 228(a) of the SEBI (ICDR) Regulations, our Company, its promoters, promoter group or directors are not debarred from accessing the capital markets by the Board;

7. In accordance with Regulation 228(b) of the SEBI (ICDR) Regulations, the companies with which our promoters or directors are associated as a promoter or director are not debarred from accessing the capital markets by the Board;
8. In accordance with Regulation 228(c) of the SEBI (ICDR) Regulations, Neither the issuer nor any of its promoter or directors is a wilful defaulter or a fraudulent borrower.
9. In accordance with Regulation 228(d) of the SEBI (ICDR) Regulations, None of the Issuer's promoter or directors is a fugitive economic offender.
10. In accordance with Regulation 228(e) of the SEBI (ICDR) Regulations there are no any outstanding convertible securities or any other right which would entitle any person with any option to receive equity shares of the issuer.
11. In accordance with Regulation 230(1)(a) of the SEBI (ICDR) Regulations, Application is being made to SME Platform of BSE ("BSE SME") is the Designated Stock Exchange.
12. In accordance with Regulation 230(1)(b) of the SEBI (ICDR) Regulations, our Company has entered into agreement with depositories for dematerialisation of specified securities already issued and proposed to be issued.
13. In accordance with Regulation 230(1)(c) of the SEBI (ICDR) Regulations, all the present Equity share Capital is fully Paid-up.
14. In accordance with Regulation 230(1)(d) of the SEBI (ICDR) Regulations, all the specified securities held by the promoters is already in dematerialised form.

We confirm that there is no material clause of Article of Association that has been left out from disclosure having bearing on the IPO.

We further confirm that we shall be complying with all the other requirements as laid down for such an Offer under Chapter IX of SEBI (ICDR) Regulations, 2018 as amended from time to time and Subsequent circulars and guidelines issued by SEBI and the Stock Exchange.

1. Our Company has facilitated trading in demat securities and has entered into an agreement with both the depositories. Our Company has entered into an agreement with Central Depository Services Limited (CDSL) dated September 24, 2025 and National Securities Depository Limited (NSDL) dated September 24, 2025 for dematerialization of its Equity Shares already issued and proposed to be issued.
2. Our Company has a website i.e <https://rednexpharma.com/>
3. The Equity Shares of our Company held by our Promoter are in dematerialised form; and
4. All the Equity Shares are fully paid-up and there are no partly paid-up Equity Shares as on the date of filing of this Draft Red Herring Prospectus.
5. There has been no change in the promoter(s) having significant change in control over the affairs of the Company in the one year preceding the date of filing application to SME Platform of BSE ("BSE SME").

DISCLAIMER CLAUSE OF SEBI

IT IS TO BE DISTINCTLY UNDERSTOOD THAT SUBMISSION OF DRAFT OFFER DOCUMENT/ OFFER DOCUMENT TO THE SECURITIES AND EXCHANGE BOARD OF INDIA (SEBI) SHOULD NOT IN ANY WAY BE DEEMED OR CONSTRUED THAT THE SAME HAS BEEN CLEARED OR APPROVED BY SEBI. SEBI DOES NOT TAKE ANY RESPONSIBILITY EITHER FOR THE FINANCIAL SOUNDNESS OF ANY SCHEME OR THE PROJECT FOR WHICH THE ISSUE IS PROPOSED TO BE MADE OR FOR THE CORRECTNESS OF THE STATEMENTS MADE OR OPINIONS EXPRESSED IN THE DRAFT OFFER DOCUMENT/ OFFER DOCUMENT. THE BOOK RUNNING LEAD MANAGER, HEM SECURITIES LIMITED HAS CERTIFIED THAT THE DISCLOSURES MADE IN THE DRAFT OFFER DOCUMENT/ OFFER DOCUMENT ARE GENERALLY

ADEQUATE AND ARE IN CONFORMITY WITH THE SEBI (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018 IN FORCE FOR THE TIME BEING. THIS REQUIREMENT IS TO FACILITATE INVESTORS TO TAKE AN INFORMED DECISION FOR MAKING INVESTMENT IN THE PROPOSED ISSUE.

IT SHOULD ALSO BE CLEARLY UNDERSTOOD THAT WHILE THE ISSUER IS PRIMARILY RESPONSIBLE FOR THE CORRECTNESS, ADEQUACY AND DISCLOSURE OF ALL RELEVANT INFORMATION IN THE DRAFT OFFER DOCUMENT/ OFFER DOCUMENT, THE BOOK RUNNING LEAD MANAGER, HEM SECURITIES LIMITED IS EXPECTED TO EXERCISE DUE DILIGENCE TO ENSURE THAT THE ISSUER DISCHARGES ITS RESPONSIBILITY ADEQUATELY IN THIS BEHALF AND TOWARDS THIS PURPOSE, THE BOOK RUNNING LEAD MANAGER, HEM SECURITIES LIMITED, HAS FURNISHED TO SEBI A DUE DILIGENCE CERTIFICATE DATED SEPTEMBER 30, 2025. IN THE FORMAT PRESCRIBED UNDER SCHEDULE V(A) OF THE SEBI (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018.

THE FILING OF THIS DRAFT RED HERRING PROSPECTUS DOES NOT, HOWEVER, ABSOLVE OUR COMPANY FROM ANY LIABILITIES UNDER THE COMPANIES ACT, 2013 OR FROM THE REQUIREMENT OF OBTAINING SUCH STATUTORY AND/ OR OTHER CLEARANCES AS MAY BE REQUIRED FOR THE PURPOSE OF THE PROPOSED ISSUE. SEBI FURTHER RESERVES THE RIGHT TO TAKE UP AT ANY POINT OF TIME, WITH THE BOOK RUNNING LEAD MANAGER ANY IRREGULARITIES OR LAPSES IN THE DRAFT OFFER DOCUMENT/ OFFER DOCUMENT.

All legal requirements pertaining to the Issue will be complied with at the time of filing of the Red Herring Prospectus/ Prospectus with the Registrar of Companies, Ahmedabad in terms of sections 26, 30, 32 and 33 of the Companies Act, 2013.

Statement on Price Information of Past Issues handled by Hem Securities Limited:

Sr. No.	Issue name	Issue size (₹ in Cr.)	Issue Price (₹)	Listing date	Opening Price on listing date	+/- % change in closing price, [+/- % change in closing benchmark]- 30 th calendar days from listing	+/- % change in closing price, [+/- % change in closing benchmark]- 90 th calendar days from listing	+/- % change in closing price, [+/- % change in closing benchmark]- 180 th calendar days from listing
SME IPO's								
1.	Readymix Construction Machinery Limited	37.66	123.00	February 13, 2025	123.00	-33.25% [-2.75%]	-34.88% [6.72%]	-8.94% [6.75%]
2.	Tankup Engineers Limited	19.53	140.00	April 30, 2025	175.00	75.25% [2.05%]	144.96% [1.42%]	N.A.
3.	Unified Data- Tech Solutions Limited	144.47	273.00	May 29, 2025	285.00	16.25% [2.97%]	19.07% [-1.04%]	N.A.
4.	Monolithisch India Limited	82.02	143.00	June 19, 2025	231.55	195.94% [0.71%]	218.53% [1.80%]	N.A.
5.	Safe Enterprises Retail Fixtures Limited	169.74	138.00	June 27, 2025	151.00	62.50% [-3.12%]	48.19% [-2.27%]	N.A.
6.	Shri Hare-Krishna Sponge Iron Limited	29.91	59.00	July 01, 2025	64.80	8.74% [-2.69%]	6.27% [-3.47%]	N.A.
7.	PRO FX Tech Limited	40.30	87.00	July 03, 2025	95.00	26.44% [-3.31%]	-3.45% [-3.13%]	N.A.
8.	Meta Infotech Limited	80.13	161.00	July 11, 2025	225.00	-0.12% [-3.20%]	N.A.	N.A.
9.	Takyon Networks Limited	20.47	54.00	August 06, 2025	55.85	-2.67% [0.22%]	N.A.	N.A.

Sr. No.	Issue name	Issue size (₹ in Cr.)	Issue Price (₹)	Listing date	Opening Price on listing date	+/- % change in closing price, +/- % change in benchmark]- 30 th calendar days from listing	+/- % change in closing price, +/- % change in benchmark]- 90 th calendar days from listing	+/- % change in closing price, +/- % change in benchmark]- 180 th calendar days from listing
10.	Ecoline Exim Limited	76.42	141.00	September 30, 2025	140.85	N.A.	N.A.	N.A.

Source: Price Information www.bseindia.com & www.nseindia.com, Issue Information from respective Prospectus.

- 1) The scrip of Tankup Engineers Limited, Unified Data- Tech Solutions Limited, Monolithisch India Limited, Safe Enterprises Retail Fixtures Limited, Shri Hare-Krishna Sponge Iron Limited, PRO FX Tech Limited have not completed its 180th day from the date of listing; Meta Infotech Limited, Takyon Networks Limited have not completed its 90th day from the date of listing and Ecoline Exim Limited has not completed its 30th day from the date of listing.

Summary statement of Disclosure:

Financial Year	Total no. of IPOs	Total amount of funds raised (₹ Cr.)	No. of IPOs trading at discount- 30 th calendar days from listing			No. of IPOs trading at Premium- 30 th calendar days from listing			No. of IPOs trading at discount- 180 th calendar days from listing			No. of IPOs trading at Premium- 180 th calendar days from listing		
			Over 50%	Between 25-50%	Less than 25%	Over 50%	Between 25-50%	Less than 25%	Over 50%	Between 25-50%	Less than 25%	Over 50%	Between 25-50%	Less than 25%
2023-24	21 ⁽¹⁾	680.45	-	-	1	12	5	3	-	-	2	12	5	2
2024-25	26 ⁽²⁾	2,152.13	-	1	5	11	2	7	-	5	2	11	2	6
2025-26	9 ⁽³⁾	662.99	-	-	2	3	1	2	-	-	-	-	-	-

- 1) The scrip of Vasa Denticity Limited was listed on June 02, 2023; Hemant Surgical Industries Limited was listed on June 05, 2023; Greenchef Appliances Limited was listed on July 06, 2023; Kaka Industries Limited was listed on July 19, 2023; Asarfi Hospital Limited was listed on July 26, 2023; Kahan Packaging Limited was listed on September 15, 2023; Madhusudan Masala Limited was listed on September 26, 2023; Saakshi Medtech And Panels Limited was listed on October 03, 2023; Arabian Petroleum Limited was listed on October 09, 2023, E Factor Experiences Limited was listed on October 09, 2023, Paragon Fine and Speciality Chemical Limited was listed on November 03, 2023, Deepak Chemtex Limited was listed on December 06, 2023, S J Logistics (India) Limited was listed on December 19, 2023, Siyaram Recycling Industries Limited was listed on December 21, 2023, Shanti Spintex Limited was listed on December 27, 2023, Shri Balaji Valve Components Limited was listed on January 03, 2024, New Swan Multitech Limited was listed on January 18, 2024, Harshdeep Hortico Limited was listed on February 05, 2024, Megatherm Induction Limited was listed on February 05, 2024, Sona Machinery Limited was listed on March 13, 2024 and Enfuse Solutions Limited was listed on March 22, 2024.
- 2) The scrip of Aspire & Innovative Advertising Limited was listed on April 03, 2024, Blue Pebble Limited was listed on April 03, 2024, Amkay Products Limited was listed on May 08, 2024, TGIF Agribusiness Limited was listed on May 15, 2024, Energy-Mission Machineries (India) Limited was listed on May 16, 2024, Aztec Fluids & Machinery Limited was listed on May 17, 2024, Premier Roadlines Limited was listed on May 17, 2024, Vilas Transcore Limited was listed on June 03, 2024, Aimtron Electronics Limited was listed on June 06, 2024; Ganesh Green Bharat Limited was listed on July 12, 2024; Chetana Education Limited was listed on July 31, 2024, Aprameya Engineering Limited was listed on August 01, 2024, Sunlite Recycling Industries Limited was listed on August 20, 2024, Aeron Composite Limited was listed on September 04, 2024, Namo eWaste Management Limited was listed on September 11, 2024, My Mudra Fincorp Limited was listed on September 12, 2024, Vision Infra Equipment Solutions Limited was listed on September 13, 2024, Shubhshree Biofuels Energy Limited was listed on September 16, 2024, Wol 3D India Limited was listed on September 30, 2024, Manba Finance Limited was listed on September 30, 2024, Unilex Colours and Chemicals Limited was listed on October 03, 2024, Sahasra

Electronic Solutions Limited was listed on October 04, 2024, Forge Auto International Limited was listed on October 04, 2024, Danish Power Limited was listed on October 29, 2024, Enviro Infra Engineers Limited was listed on November 29, 2024 and Readymix Construction Machinery Limited was listed on February 13, 2025.

- 3) *The scrip of Tankup Engineers Limited was listed on April 30, 2025, Unified Data- Tech Solutions Limited was listed on May 29, 2025, Monolithisch India Limited was listed on June 19, 2025, Safe Enterprises Retail Fixtures Limited was listed on June 27, 2025, Shri Hare-Krishna Sponge Iron Limited was listed on July 01, 2025, PRO FX Tech Limited was listed on July 03, 2025, Meta Infotech Limited was listed on July 11, 2025, Takyon Networks Limited was listed on August 06, 2025 Ecoline Exim Limited was listed on September 30, 2025.*

Note:

- a) Based on date of listing.
- b) CNX NIFTY and BSE SENSEX have been considered as the benchmark index.
- c) Price on NSE or BSE is considered for all of the above calculations as per the designated stock exchange disclosed by the respective issuer at the time of the issue, as applicable.
- d) In case the 30th /90th /180th calendar day is a holiday or scrips are not traded, then data from previous trading day has been considered.
- e) N.A. – Period not completed.
- f) As per SEBI Circular No. CIR/CFD/DIL/7/2015 dated October 30, 2015, the above table should reflect max. 10 issues (initial public offerings) managed by the Book Running Lead Manager. Hence, disclosures is restricted to last 10 equity issues handled by Book Running Lead Manager.

Track Record of past issues handled by Hem Securities Limited:

For details regarding track record of Book Running Lead Manager to the Issue as specified in the Circular reference no. CIR/MIRSD/1/2012 dated January 10, 2012 issued by the SEBI, please refer the website of the Book Running Lead Manager at www.hemsecurities.com.

DISCLAIMER FROM OUR COMPANY, OUR DIRECTORS AND THE BOOK RUNNING LEAD MANAGER

Our Company, the Directors and the Book Running Lead Manager accept no responsibility for statements made otherwise than those contained in this Draft Red Herring Prospectus or, in case of the Company, in the advertisements or any other material issued by or at the instance of the Company and anyone placing reliance on any other source of information would be doing so at their own risk.

The Book Running Lead Manager accept no responsibility, save to the limited extent as provided in the Agreement entered between the Book Running Lead Manager, and our Company on September 29, 2025 and the Underwriting Agreement dated [●] entered into between the Underwriter, and our Company and the Market Making Agreement dated [●] entered into among the Market Maker and our Company. All information shall be made available by our Company, and the Book Running Lead Manager to the public and investors at large and no selective or additional information would be available for a section of the investors in any manner whatsoever including at road show presentations, in research or sales reports, at collection centres or elsewhere.

The Book Running Lead Manager and their respective associates and affiliates may engage in transactions with, and perform services for, our Company, our Promoter Group, Group Company, or our affiliates or associates in the ordinary course of business and have engaged, or may in future engage, in commercial banking and investment banking transactions with our Company, our Promoter Group, Group Company, and our affiliates or associates for which they have received and may in future receive compensation.

Note:

Investors who apply in the Issue will be required to confirm and will be deemed to have represented to our Company, and the Underwriter and their respective directors, officers, agents, affiliates and representatives that they are eligible under all applicable laws, rules, regulations, guidelines and approvals to acquire Equity Shares of our Company and will not offer, sell, pledge or transfer the Equity Shares of our Company to any person who is not eligible under applicable laws, rules, regulations, guidelines and approvals to acquire Equity Shares of our Company. Our Company, the Underwriter and their respective

Directors, officers, agents, affiliates and representatives accept no responsibility or liability for advising any investor on whether such investor is eligible to acquire the Equity Shares in the issue.

DISCLAIMER IN RESPECT OF JURISDICTION

This Issue is being made in India to persons resident in India (including Indian nationals resident in India who are majors, HUFs, companies, corporate bodies and societies registered under applicable laws in India and authorized to invest in shares, Indian mutual funds registered with SEBI, Indian financial institutions, commercial banks, regional rural banks, cooperative banks (subject to RBI permission), or trusts under applicable trust law and who are authorized under their constitution to hold and invest in shares, public financial institutions as specified in Section 2(72) of the Companies Act, 2013, VCFs, state industrial development corporations, insurance companies registered with the Insurance Regulatory and Development Authority, provident funds (subject to applicable law) with a minimum corpus of ₹ 2,500.00 Lakhs and pension funds with a minimum corpus of ₹ 2,500.00 Lakhs, and permitted non-residents including FIIs, Eligible NRIs, multilateral and bilateral development financial institutions, FVCIs and eligible foreign investors, insurance funds set up and managed by army, navy or air force of the Union of India and insurance funds set up and managed by the Department of Posts, India provided that they are eligible under all applicable laws and regulations to hold Equity Shares of our Company. This Draft Red Herring Prospectus does not, however, constitute an offer to sell or an invitation to subscribe for Equity Shares offered hereby in any jurisdiction other than India to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. Any person into whose possession this Draft Red Herring Prospectus comes is required to inform himself or herself about, and to observe, any such restrictions. Any dispute arising out of this Issue will be subject to jurisdiction of the competent court(s) in Ahmedabad only.

No action has been, or will be, taken to permit a public offering in any jurisdiction where action would be required for that purpose. Accordingly, the Equity Shares represented hereby may not be offered or sold, directly or indirectly, and this Draft Red Herring Prospectus may not be distributed in any jurisdiction, except in accordance with the legal requirements applicable in such jurisdiction. Neither the delivery of this Draft Red Herring Prospectus nor any sale hereunder shall, under any circumstances, create any implication that there has been no change in the affairs of our Company from the date hereof or that the information contained herein is correct as of any time subsequent to this date.

DISCLAIMER CLAUSE OF THE SME PLATFORM OF BSE

As required, a copy of this Offer Document has been submitted to BSE Limited (hereinafter referred to as “BSE”).

BSE has given vide its letter [●] permission to the Issuer to use the Exchange’s name in this Offer Document as one of the stock exchanges on which this Issuer’s securities are proposed to be listed. The Exchange has scrutinized draft offer document for its limited internal purpose of deciding on the matter of granting the aforesaid permission to this Issuer. It is to be distinctly understood that the aforesaid permission given by BSE should not in any way be deemed or construed that the offer document has been cleared or approved by BSE; nor does it in any manner:

- i. warrant, certify or endorse the correctness or completeness of any of the contents of this offer document; or
- ii. warrant that this Issuer’s securities will be listed or will continue to be listed on the Exchange; or
- iii. take any responsibility for the financial or other soundness of this Issuer, its Promoter, its management or any scheme or project of this Issuer.
- iv. Warrant, certify or endorse the validity, correctness or reasonableness of the price at which the equity shares are offered by the Company and investors are informed to take the decision to invest in the equity shares of the Company only after making their own independent enquiries, investigation and analysis. The price at which the equity shares are offered by the Company is determined by the Company in consultation with the Merchant Banker (s) to the issue and the Exchange has no role to play in the same and it should not for any reason be deemed or construed that the contents of this offer document have been cleared or approved by BSE. Every person who desires to apply for or otherwise acquire any securities of this Company may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against BSE whatsoever by reason of any loss which may be suffered by such person consequent to or in connection with such subscription/acquisition whether by reason of anything stated or omitted to be stated herein or for any other reason whatsoever.
- v. BSE does not in any manner be liable for any direct, indirect, consequential or other losses or damages including loss of profits incurred by any investor or any third party that may arise from any reliance on this offer document or for the reliability, accuracy, completeness, truthfulness or timeliness thereof.

- vi. The Company has chosen the SME platform on its own initiative and at its own risk, and is responsible for complying with all local laws, rules, regulations, and other statutory or regulatory requirements stipulated by BSE/other regulatory authority. Any use of the SME platform and the related services are subject to Indian laws and Courts exclusively situated in Ahmedabad.

DISCLAIMER CLAUSE UNDER RULE 144A OF THE U.S. SECURITIES ACT

The Equity Shares have not been, and will not be, registered under the U.S. Securities Act 1933, as amended (the “Securities Act”) or any state securities laws in the United States and may not be offered or sold within the United States or to, or for the account or benefit of, “U.S. persons” (as defined in Regulations under the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.

Accordingly, the Equity Shares will be offered and sold (i) in the United States only to “qualified institutional buyers”, as defined in Rule 144A of the Securities Act, and (ii) outside the United States in offshore transactions in reliance on Regulation S under the Securities Act and in compliance with the applicable laws of the jurisdiction where those offers and sales occur.

The Equity Shares have not been, and will not be, registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and applications may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction. Further, each applicant, wherever requires, agrees that such applicant will not sell or transfer any Equity Share or create any economic interest therein, including any offshore derivative instruments, such as participatory notes, issued against the Equity Shares or any similar security, other than pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with applicable laws and legislations in each jurisdiction, including India.

FILING OF OFFER DOCUMENT WITH THE DESIGNATED STOCK EXCHANGE/ SEBI/ ROC

The Draft Red Herring Prospectus is being filed with BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400001, Maharashtra, India.

The Draft Red Herring Prospectus will not be filed with SEBI, nor will SEBI issue any observation on the Offer Document in terms of Regulation 246(2) of SEBI (ICDR) Regulations, 2018. Pursuant to Regulation 246(5) of SEBI (ICDR) Regulations, 2018 and SEBI Circular Number SEBI/HO/CFD/DIL1/CIR/P/2018/011 dated January 19, 2018, a copy of Red Herring Prospectus/ Prospectus will be filed online through SEBI Intermediary Portal at <https://siportal.sebi.gov.in>.

A copy of the Red Herring Prospectus, along with the material contracts and documents required to be filed under Section 26 & 32 of the Companies Act, 2013 was filed to the RoC and a copy of the Prospectus to be filed under Section 26 of the Companies Act, 2013 will be filed to the RoC through the electronic portal at <http://www.mca.gov.in>.

LISTING

The Equity Shares of our Company are proposed to be listed on BSE SME platform. Our Company has obtained in-principle approval from BSE by way of its letter dated [●] for listing of equity shares on BSE SME (BSE SME platform). .

BSE will be the Designated Stock Exchange, with which the Basis of Allotment will be finalized for the offer. If the permission to deal in and for an official quotation of the Equity Shares on the SME Platform is not granted by BSE, our Company shall forthwith repay, all moneys received from the applicants in pursuance of the Draft Red Herring Prospectus. If such money is not repaid within the prescribed time, then our Company becomes liable to repay it, then our Company and every officer in default shall, shall be liable to repay such application money, with interest, as prescribed under the applicable law.

Our Company shall ensure that all steps for the completion of the necessary formalities for listing and commencement of trading at the BSE SME mentioned above are taken within Three (3) Working Days of the Issue Closing Date. If Equity Shares are not Allotted pursuant to the Issue within Three (3) Working Days from the Issue Closing Date or within such timeline as prescribed by the SEBI, our Company shall repay with interest all monies received from applicants, failing which interest shall be due to be paid to the applicants at the rate of 15% per annum for the delayed period Subject to applicable law.

IMPERSONATION

Attention of the Applicants is specifically drawn to the provisions of sub-section (1) of Section 38 of the Companies Act, 2013 which is reproduced below:

Any person who-

- i. Makes or abets making of an application in a fictitious name to a company for acquiring, or subscribing for, its securities; or
- ii. Makes or abets making of multiple applications to a company in different names or in different combinations of his name or surname for acquiring or subscribing for its securities; or
- iii. Otherwise induces directly or indirectly a company to allot, or register any transfer of, securities to him, or to any other person in a fictitious name,

Shall be liable to action under section 447 of the Companies, Act 2013

CONSENTS

Consents in writing of Our Directors, Our Promoters, Our Company Secretary & Compliance Officer, Chief Financial Officer, Our Statutory Auditor, Our Banker to the Company, Book Running Lead Manager, Registrar to the Issue, Legal Advisor to the Issue, Banker to the Issue/ Sponsor Bank*, Syndicate Members*, Underwriter to the Issue* and Market Maker to the Issue* to act in their respective capacities have been obtained as required under section 26 and 32 of the Companies Act, 2013 and shall be filed along with a copy of the Red Herring Prospectus/ Prospectus with the RoC, as required under Sections 32 of the Companies Act, 2013 and such consents will not be withdrawn up to the time of delivery of the Red Herring Prospectus/ Prospectus for filing with the RoC.

**The aforesaid will be appointed prior to filing of Red Herring Prospectus with RoC and their consents as above would be obtained prior to the filing of the Red Herring Prospectus/ Prospectus with RoC.*

In accordance with the Companies Act and the SEBI (ICDR) Regulations, M/s. Krupal Bhuvra & Company, Chartered Accountants (FRN: 0146585W), Statutory Auditor of the Company has agreed to provide their written consent to the inclusion of their respective reports on Statement of Possible Tax Benefits relating to the possible tax benefits and Restated Financial Statements as included in this Draft Red Herring Prospectus/ Red Herring Prospectus/ Prospectus in the form and context in which they appear therein and such consent and reports will not be withdrawn up to the time of delivery of the Red Herring Prospectus/ Prospectus for filing with the RoC.

EXPERTS OPINION

Except as stated below, our Company has not obtained any expert opinions:

For the reports in the section **“Financial Information of the Company”**, **“Statement of Financial Indebtedness**, and **“Statement of Special Tax Benefits”** on page 172, 219, and 98 respectively of this Draft Red Herring Prospectus from the Statutory Auditor, our Company has received written consent from the Statutory Auditors for inclusion of their name.

In addition, our Company has received written consent dated September 24, 2025 from Rohitkumar Rakholiya, Independent Chartered Engineer to include his name as required under Section 26(5) of the Companies Act, 2013 read with SEBI ICDR Regulations, in this Draft Red Herring Prospectus, and as an “expert” as defined under Section 2(38) of the Companies Act, 2013 to the extent and his capacity as independent chartered engineer in respect of details regarding capacity utilization of our Company and such consent has not been withdrawn as on the date of this Draft Red Herring Prospectus

However, the term “expert” shall not be construed to mean an “expert” as defined under the U.S. Securities Act, 1933.

FEES, BROKERAGE AND SELLING COMMISSION PAYABLE

The total fees payable to the Book Running Lead Manager will be as per the (i) Issue Agreement dated September 29, 2025 with the Book Running Lead Manager, (ii) the Underwriting Agreement dated [●] with the Underwriter and (iii) the Market Making Agreement [●] with the Market Maker, a copy of which is available for inspection at our Corporate Office from 10.00 AM to 5.00 PM on Working Days from the date of the Draft Red Herring Prospectus until the Bid/ Issue Closing Date.

FEES PAYABLE TO THE REGISTRAR TO THE ISSUE

The fees payable to the Registrar to the Issue for processing of applications, data entry, printing of CAN, tape and printing of bulk mailing register will be as per the agreement between our Company, and the Registrar to the Issue dated September 26, 2025, a copy of which is available for inspection at our Company's Registered Office.

The Registrar to the Issue will be reimbursed for all out-of-pocket expenses including cost of stationery, postage, stamp duty, and communication expenses. Adequate funds will be provided to the Registrar to the Issue to enable it to send allotment advice by registered post/speed post.

PARTICULARS REGARDING PUBLIC OR RIGHTS ISSUES DURING THE LAST FIVE (5) YEARS

Our Company has not made any previous public or rights issue in India or Abroad the five (5) years preceding the date of this Draft Red Herring Prospectus.

PREVIOUS ISSUES OF EQUITY SHARES OTHERWISE THAN FOR CASH

For detailed description please refer to the section titled "*Capital Structure*" beginning on page 68 of this Draft Red Herring Prospectus.

UNDERWRITING COMMISSION, BROKERAGE AND SELLING COMMISSION ON PREVIOUS ISSUES

Since this is the initial public offering of our Company's Equity Shares, no sum has been paid or has been payable as commission or brokerage for subscribing for or procuring or agreeing to procure subscription for any of the Equity Shares in last five (5) years.

PARTICULARS IN REGARD TO OUR COMPANY AND OTHER LISTED SUBSIDIARIES/ ASSOCIATES UNDER THE SAME MANAGEMENT WITHIN THE MEANING OF SECTION 186 OF THE COMPANIES ACT, 2013 WHICH MADE ANY CAPITAL ISSUE DURING THE LAST THREE YEARS

Neither our Company nor any other companies under the same management within the meaning of Section 186 of the Companies Act, 2013, had made any public issue or rights issue during the last three years

PERFORMANCE VIS-À-VIS OBJECTS- PUBLIC/ RIGHT ISSUE OF OUR COMPANY

Except as stated in the chapter titled "*Capital Structure*" beginning on page 68 our Company has not undertaken any previous public or rights issue.

OPTION TO SUBSCRIBE

- a. Investors will get the allotment of specified securities in dematerialization form only.
- b. The equity shares, on allotment, shall be traded on stock exchange in Demat segment only.

OUTSTANDING DEBENTURES OR BOND ISSUES OR REDEEMABLE PREFERENCE SHARES

As on the date of this Draft Red Herring Prospectus, our Company has no outstanding debentures, bonds or redeemable preference shares.

PARTLY PAID-UP SHARES

As on the date of this Draft Red Herring Prospectus, there are no partly paid-up Equity Shares of our Company.

OUTSTANDING CONVERTIBLE INSTRUMENTS

Our Company does not have any outstanding convertible instruments as on the date of filing this Draft Red Herring Prospectus.

STOCK MARKET DATA FOR OUR EQUITY SHARES

Our Company is an “Unlisted Issuer” in terms of the SEBI (ICDR) Regulations, and this Issue is an “Initial Public Offering” in terms of the SEBI (ICDR) Regulations. Thus, there is no stock market data available for the Equity Shares of our Company.

MECHANISM FOR REDRESSAL OF INVESTOR GRIEVANCES

The agreement between the Registrar to the Issue and our Company provides for retention of records with the Registrar to the Issue for a period of at least three (3) years from the last date of dispatch of the letters of allotment and demat credit to enable the investors to approach the Registrar to the Issue for redressal of their grievances.

We hereby confirm that there are no investor complaints received during the three years preceding the filing of this Draft Red Herring Prospectus. Since there is no investor complaints received, none are pending as on the date of filing of this Draft Red Herring Prospectus.

Investors may contact the BRLM for any complaint pertaining to the Issue. All grievances, may be addressed to the Registrar to the Issue, with a copy to the relevant Designated Intermediary, where the Application Form was submitted, quoting the full name of the sole or first Applicant, Application Form number, Applicants' DP ID, Client ID, PAN, address of the Applicant, number of Equity Shares applied for, date of Application Form, name and address of the relevant Designated Intermediary, where the Bid was submitted and ASBA Account number in which the amount equivalent to the Bid Amount was blocked. Further, the Applicant shall enclose the Acknowledgement Slip or provide the acknowledgement number received from the Designated Intermediaries in addition to the documents/information mentioned hereinabove. Our Company, BRLM and the Registrar accept no responsibility for errors, omissions, commission of any acts of the Designated Intermediaries, including any defaults in complying with its obligations under the SEBI ICDR Regulations.

DISPOSAL OF INVESTOR GRIEVANCES BY OUR COMPANY

Our Company estimates that the average time required by our Company or the Registrar to the Issue for the redressal of routine investor grievances shall be fifteen (15) Working Days from the date of receipt of the complaint. In case of complaints that are not routine or where external agencies are involved, our Company will seek to redress these complaints as expeditiously as possible.

Our Company has appointed Rima Amitbhai Dalal as a Company Secretary and the Compliance Officer to redress complaints, if any, of the investors participating in the Issue. Contact details for our Company Secretary and Compliance Officer are as follows:

Rima Amitbhai Dalal

Company Secretary & Compliance Officer

Rednex Pharmaceuticals Limited

Survey No. 586 and 231, Near SKF Bearing, Bavla Bagodara N.H 8A,
Kerala, Taluka: Bavla, Ahmedabad, Gujarat, India, 382220

Tel. No.: +91- 83201-31437

Email: cs@rednexpharma.com

Website: <https://rednexpharma.com/>

Investors can contact the Compliance Officer or the Registrar in case of any pre-Issue or post-Issue related problems such as non-receipt of letters of allocation, credit of allotted Equity Shares in the respective beneficiary account etc.

Pursuant to the press release no. PR. No. 85/2011 dated June 8, 2011, SEBI has launched a centralized web-based complaints redress system "SCORES". This would enable investors to lodge and follow up their complaints and track the status of redressal of such complaints from anywhere. For more details, investors are requested to visit the website www.scores.gov.in

Our Board by a resolution on September 16, 2025 constituted a Stakeholders Relationship Committee. For further details, please refer to section titled "***Our Management***" beginning on page 150 of this Draft Red Herring Prospectus.

Till date of this Draft Red Herring Prospectus, our Company has not received any investor complaint and no complaints is pending for resolution.

STATUS OF INVESTOR COMPLAINTS

We confirm that we have not received any investor complaint during the three years preceding the date of this Draft Red Herring Prospectus and hence there are no pending investor complaints as on the date of this Draft Red Herring Prospectus.

DISPOSAL OF INVESTOR GRIEVANCES BY LISTED COMPANIES UNDER THE SAME MANAGEMENT AS OUR COMPANY

We do not have any listed company under the same management.

TAX IMPLICATIONS

Investors who are allotted Equity Shares in the Issue will be subject to capital gains tax on any resale of the Equity Shares at applicable rates, depending on the duration for which the investors have held the Equity Shares prior to such resale and whether the Equity Shares are sold on the Stock Exchanges. For details, please refer the section titled "***Statement of Special Tax Benefits***" beginning on page 98 of this Draft Red Herring Prospectus.

PURCHASE OF PROPERTY

Other than as disclosed in Section "***Our Business***" beginning on page 118 of this Draft Red Herring Prospectus there is no property which has been purchased or acquired or is proposed to be purchased or acquired which is to be paid for wholly or partly from the proceeds of the present Issue or the purchase or acquisition of which has not been completed on the date of this Draft Red Herring Prospectus.

Except as stated elsewhere in this Draft Red Herring Prospectus, our Company has not purchased any property in which the Promoter and/or Directors have any direct or indirect interest in any payment made there under.

CAPITALIZATION OF RESERVES OR PROFITS

Save and except as stated in "***Capital Structure***" on page 68 of this Draft Red Herring Prospectus, our Company has not capitalized its reserves or profits at any time since inception.

REVALUATION OF ASSETS

There has not been any revaluation of assets since incorporation of the Company.

SERVICING BEHAVIOR

There has been no default in payment of statutory dues or of interest or principal in respect of our borrowings or deposits.

PAYMENT OR BENEFIT TO OFFICERS OF OUR COMPANY

Except statutory benefits upon termination of their employment in our Company or superannuation, no officer of our Company is entitled to any benefit upon termination of his employment in our Company or superannuation.

Except as disclosed under chapter titled ***“Our Management”*** beginning on page 150 and chapter ***“Financial Information”*** beginning on page 172 of this Draft Red Herring Prospectus none of the beneficiaries of loans and advances and sundry debtors are related to the Directors of our Company.

EXEMPTION FROM COMPLYING WITH ANY PROVISIONS OF SECURITIES LAWS, IF ANY

As on date of the Draft Red Herring Prospectus, our Company has not availed any exemption from complying with any provisions of securities laws granted by SEBI.

SECTION VIII: ISSUE RELATED INFORMATION

TERMS OF THE ISSUE

The Equity Shares being Issued are subject to the provisions of the Companies Act, SCRA, SCRR, SEBI (ICDR) Regulations, the SEBI Listing Regulations, our Memorandum and Articles of Association, the terms of this Draft Red Herring Prospectus, Red Herring Prospectus, Prospectus, Application Form, any Confirmation of Allocation Note ("CAN"), the Revision Form, Allotment advices, and other terms and conditions as may be incorporated in the Allotment advices and other documents/certificates that may be executed in respect of the Issue. The Equity Shares shall also be subject to all applicable laws, guidelines, rules, notifications and regulations relating to the issue of capital and listing and trading of securities issued from time to time by SEBI, the GoI, the Stock Exchange, the RoC, the RBI and/or other authorities, as in force on the date of the Issue and to the extent applicable or such other conditions as may be prescribed by SEBI, RBI, the GoI, the Stock Exchange, the RoC and/or any other authorities while granting its approval for the Issue.

Please note that in terms of SEBI Circular No. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, all the investors (except Anchor Investor) applying in a public Issue shall use only Application Supported by Blocked Amount (ASBA) process for application providing details of the bank account which will be blocked by the Self Certified Syndicate Banks (SCSBs) for the same. Further, pursuant to SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 01, 2018 read with its circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/50 dated April 3, 2019 and circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/76 dated June 28, 2019 has introduced an alternate payment mechanism using Unified Payments Interface (UPI) and consequent reduction in timelines for listing in a phased manner. From December 1, 2023, the UPI Mechanism for Individual Investors applying through Designated Intermediaries was made effective along-with the existing process existing timeline of T+3 days

Further vide the said circular Registrar to the Issue and Depository Participants have been also authorized to collect the Bid-cum-Application forms. Investor may visit the official website of the concerned for any information on operational utilization of this facility of form collection by the Registrar to the Issue and Depository Participants as and when the same is made available.

Authority for the Issue

The present Public Offer of upto 27,36,000 Equity Shares has been authorized by a resolution of the Board of Directors of our Company at their meeting held on September 26, 2025 and was approved by the Shareholders of the Company by passing Special Resolution at the Extra Ordinary General Meeting held on September 26, 2025 in accordance with the provisions of Section 62(1)(c) of the Companies Act, 2013.

Ranking of Equity Shares

The Equity Shares being issued pursuant to Bid/Issue shall be subject to the provisions of the Companies Act, 2013 and our MOA and AOA and shall rank pari-passu in all respects with the existing Equity Shares of our Company including rights in respect of the voting rights and rights to receive dividends and other corporate benefits, if any, declared by us after the date of Allotment. The Allottees, upon Allotment of Equity Shares under this Issue, will be entitled to receive dividends and other corporate benefits, if any, declared by our Company after the date of Allotment. For further details, please refer to section titled, **"Main Provisions of Article of Association"**, beginning on page 305 of this Draft Red Herring Prospectus.

Mode of Payment of Dividend

The declaration and payment of dividend will be as per the provisions of Companies Act, the Articles of Association, the provision of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and any other rules, regulations or guidelines as may be issued by the Government of India in connection thereto and as per the recommendation by the Board of Directors and the Shareholders at their discretion and will depend on a number of factors, including but not limited to earnings, capital requirements and overall financial condition of our Company. We shall pay dividends in cash and as per provisions of the Companies Act and our Articles of Association. Further Interim Dividend (if any declared) will be approved by the Board of Directors. For further details, please refer to section titled **"Dividend Policy"** and **"Main Provisions of Article of Association"** beginning on page 171 and 305 respectively of this Draft Red Herring Prospectus.

Face Value, Issue Price, Floor Price and Price Band

The face value of each Equity Share is ₹10.00 and the Issue Price at the lower end of the Price Band is ₹ [●] per Equity Share (“Floor Price”) and at the higher end of the Price Band is ₹ [●] per Equity Share (“Cap Price”). The Anchor Investor Issue Price is ₹ [●] per Equity Share.

The Price Band and the minimum Bid Lot size will be decided by our Company in consultation with the Book Running Lead Manager, and will be advertised, at least two Working Days prior to the Bid/ Issue Opening Date, in all editions of [●], an English national daily newspaper, all editions of [●], a Hindi national daily newspaper and Gujarati editions of [●] a regional daily newspaper where our registered office is situated each with wide circulation and shall be made available to the Stock Exchange for the purpose of uploading on its website. The Price Band, along with the relevant financial ratios calculated at the Floor Price and at the Cap Price, shall be pre filled in the Bid cum Application Forms available on the website of the Stock Exchange. The Issue Price shall be determined by our Company and in consultation with the Book Running Lead Manager, after the Bid/ Issue Closing Date, on the basis of assessment of market demand for the Equity Shares offered by way of Book Building Process. At any given point of time there shall be only one denomination of the Equity Shares of our Company, subject to applicable laws.

Compliance with SEBI (ICDR) Regulations, 2018

Our Company shall comply with all requirements of the SEBI (ICDR) Regulations. Our Company shall comply with all disclosure and accounting norms as specified by SEBI from time to time.

Compliance with Disclosure and Accounting Norms

Our Company shall comply with all disclosure and accounting norms as specified by SEBI from time to time.

Rights of the Equity Shareholders

Subject to applicable laws, rules, regulations and guidelines and the Articles of Association, the equity shareholders shall have the following rights:

- a) Right to receive dividend, if declared;
- b) Right to receive Annual Reports and notices to members;
- c) Right to attend general meetings and exercise voting rights, unless prohibited by law;
- d) Right to vote on a poll either in person or by proxy;
- e) Right to receive offer for rights shares and be allotted bonus shares, if announced;
- f) Right to receive surplus on liquidation; subject to any statutory or preferential claims being satisfied;
- g) Right of free transferability of the Equity Shares; and
- h) Such other rights, as may be available to a shareholder of a listed Public Limited Company under the Companies Act, terms of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Memorandum and Articles of Association of our Company.

For a detailed description of the main provision of the Articles of Association of our Company relating to voting rights, dividend, forfeiture and lien, transfer, transmission and/ or consolidation/ splitting, etc., please refer to section titled ***“Main Provisions of the Articles of Association”*** beginning on page 305 of this Draft Red Herring Prospectus.

Allotment of securities only in Dematerialized Form

As per regulations made under and Section 29(1) of the Companies Act, 2013 the Equity Shares to be allotted must be in Dematerialized form i.e., not in the form of physical certificates but be fungible and be represented by the statement issued through electronic mode. Hence, the Equity Shares being issued can be applied for in the dematerialized form only. In this context, two agreements have been signed among our Company, the respective Depositories and Registrar to the Issue.

- Tripartite Agreement dated September 24, 2025 between NSDL, Our Company and Registrar to the Issue; and
- Tripartite Agreement dated September 24, 2025 between CDSL, Our Company and Registrar to the Issue;

The trading of the Equity Shares will happen in the minimum contract size of [●] Equity Shares and the same may be modified

by the SME platform of BSE (BSE SME) from time to time by giving prior notice to investors at large.

Allocation and allotment of Equity Shares through this Issue will be done in multiples of [●] Equity Shares of face value of ₹10/- each and is subject to a minimum allotment of [●] Equity Shares of face value of ₹10/- each to the successful applicants in terms of the SEBI circular No. CIR/MRD/DSA/06/2012 dated February 21, 2012.

Minimum Application Value, Market Lot and Trading Lot

In accordance with Regulation 267(2) of the SEBI ICDR (Amendment) Regulations, 2025, our Company shall ensure that the minimum application size shall be two lots per application:

“Provided that the minimum application size shall be above ₹2 lakhs.”

The trading of our Equity Shares on the Stock Exchanges shall only be in dematerialised form. Allotment of Equity Shares will be only in electronic form in multiples of [●] Equity Shares, subject to a minimum Allotment of [●] Equity Shares. For the method of Basis of Allotment, see “*Issue Procedure*” on page 273 of this Draft Red Herring Prospectus.

Further, in accordance with SEBI ICDR (Amendment) Regulations, 2025, the minimum application size in terms of number of specified securities shall not be less than ₹2.00 Lakh

Minimum Number of Allottees

In accordance with Regulation 268 of SEBI (ICDR) Regulations, 2018 the minimum number of allottees in the Issue shall be 200 shareholders. In case the minimum number of prospective allottees is less than 200, no allotment will be made pursuant to this Issue and the monies collected shall be unblocked forthwith.

Jurisdiction

Exclusive jurisdiction for the purpose of this Issue is with the competent courts/ authorities in Ahmedabad, Gujarat.

The Equity Shares have not been and will not be registered under the U.S. Securities Act, 1933, as amended (the “Securities Act”) or any state securities laws in the United States, and may not be offered or sold within the United States, or to, or for the account or benefit of, “U.S. persons” (as defined in Regulation S under the Securities Act), except pursuant to an exemption from or in a transaction not subject to, registration requirements of the Securities Act. Accordingly, the Equity Shares are only being offered or sold outside the United States in compliance with Regulation S under the Securities Act and the applicable laws of the jurisdictions where those offers and sales occur.

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and applications may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

Joint Holders

Where 2 (two) or more persons are registered as the holders of any Equity Shares, they will be deemed to hold such Equity Shares as joint-holders with benefits of survivorship.

Nomination Facility to Investor

In accordance with Section 72 of the Companies Act, 2013 the sole or first applicant, along with other joint applicant, may nominate any one person in whom, in the event of the death of sole applicant or in case of joint applicant, death of all the applicants, as the case may be, the Equity Shares allotted, if any, shall vest. A person, being a nominee, entitled to the Equity Shares by reason of the death of the original holder(s), shall in accordance with Section 72 of the Companies Act, 2013 be entitled to the same advantages to which he or she would be entitled if he or she were the registered holder of the Equity Share(s). Where the nominee is a minor, the holder(s) may make a nomination to appoint, in the prescribed manner, any person to become entitled to Equity Share(s) in the event of his or her death during the minority. A nomination shall stand rescinded upon a sale of equity share(s) by the person nominating. A buyer will be entitled to make a fresh nomination in the manner prescribed. Fresh nomination can be made only on the prescribed form available on request at the Registered Office of our

Company or to the Registrar and Transfer Agents of our Company.

In accordance with Section 72 of the Companies Act, 2013 any Person who becomes a nominee by virtue of Section 72 of the Companies Act, 2013 shall upon the production of such evidence as may be required by the Board, elect either:

- a) to register himself or herself as the holder of the Equity Shares; or
- b) to make such transfer of the Equity Shares, as the deceased holder could have made.

Further, the Board may at any time give notice requiring any nominee to choose either to be registered himself or herself or to transfer the Equity Shares, and if the notice is not complied with within a period of 90 (ninety) days, the Board may thereafter withhold payment of all dividends, bonuses or other moneys payable in respect of the Equity Shares, until the requirements of the notice have been complied with.

Since the allotment of Equity Shares in the Issue is in dematerialized form, there is no need to make a separate nomination with us. Nominations registered with the respective depository participant of the applicant would prevail. If the investors require changing the nomination, they are requested to inform their respective depository participant.

Issue Program

Event	Indicative Date
Bid/ Issue Opening Date	[●] ¹
Bid/ Issue Closing Date	[●] ^{2,3}
Finalization of Basis of Allotment with the Designated Stock Exchange (T+1)	On or about [●]
Initiation of Allotment/ Refunds/ Unblocking of Funds from ASBA Account or UPI Id Linked Bank Account* (T+2)	On or about [●]
Credit of Equity Shares to Demat Accounts of Allottees (T+2)	On or about [●]
Commencement of Trading of The Equity Shares on the Stock Exchange (T+3)	On or about [●]

Note ¹Our Company, in consultation with the Book Running Lead Manager, may consider participation by Anchor Investors in accordance with the SEBI (ICDR) Regulations. The Anchor Investor Bid/Issue Period shall be one Working Day prior to the Bid/Issue Opening Date in accordance with the SEBI (ICDR) Regulations.

²Our Company, in consultation with the Book Running Lead Manager, consider closing the Bid/Issue Period for QIBs one Working Day prior to the Bid/Issue Closing Date in accordance with the SEBI (ICDR) Regulations.

³UPI mandate end time and date shall be at 5.00 p.m. on Bid/Issue Closing Date

*In case of any delay in unblocking of amounts in the ASBA Accounts (including amounts blocked through the UPI Mechanism) exceeding two Working Days from the Bid/ Issue Closing Date, the Bidder shall be compensated at a uniform rate of ₹100 per day or 15% per annum of the Bid Amount, whichever is higher from the date on which the request for cancellation/ deletion is placed in the Stock Exchanges bidding platform until the date on which the amounts are unblocked for the entire duration of delay exceeding two Working Days from the Bid/ Issue Closing Date by the intermediary responsible for causing such delay in unblocking. The Book Running Lead Manager shall, in their sole discretion, identify and fix the liability on such intermediary or entity responsible for such delay in unblocking. For the avoidance of doubt, the provisions of the SEBI circular dated March 16, 2021, as amended pursuant to SEBI circular dated June 2, 2021 shall be deemed to be incorporated in the agreements to be entered into by and between the Company and the relevant intermediaries, to the extent applicable.

The above time table is indicative and does not constitute any obligation on our Company. Whilst our Company shall ensure that all steps for the completion of the necessary formalities for the listing and the commencement of trading of the Equity Shares on BSE is taken within Three Working Days from the Issue Closing Date, the timetable may change due to various factors, such as extension of the Issue Period by our Company or any delays in receiving the final listing and trading approval from the Stock Exchange. The Commencement of trading of the Equity Shares will be entirely at the discretion of the Stock Exchange and in accordance with the applicable laws.

Any circulars or notifications from the SEBI after the date of this Draft Red Herring Prospectus may result in changes to the above-mentioned timelines. Further, the issue procedure is subject to change to any revised circulars issued by the SEBI to this effect.

In terms of the UPI Circulars, in relation to the Issue, the BRLMs will be required to submit reports of compliance with listing timelines and activities prescribed by the SEBI, identifying non-adherence to timelines and processes and an analysis of entities responsible for the delay and the reasons associated with it.

Submission of Bids (Other than Bids from Anchor Investors)

The above timetable is indicative and does not constitute any obligation on our Company or the Book Running Lead Manager. Whilst our Company shall ensure that all steps for the completion of the necessary formalities for the listing and the commencement of trading of the Equity Shares on the Stock Exchange are taken within three Working Days of the Bid/Issue Closing Date, the timetable may change due to various factors, such as extension of the Bid/Issue Period by our Company, revision of the Price Band or any delays in receiving the final listing and trading approval from the Stock Exchange. The Commencement of trading of the Equity Shares will be entirely at the discretion of the Stock Exchange and in accordance with the applicable laws.

Bid-Cum Application Forms and any upward revisions to the same will be accepted only between 10.00 A.M. to 5.00 P.M. (IST) during the Issue Period (except for the Bid/ Issue Closing Date). On the Bid/ Issue Closing Date, the Application Forms should be submitted only between 10.00 a.m. to 3.00 p.m. (IST) for all Bidders. The time for applying for Individual Applicants on Bid/ Issue Closing Date maybe extended in consultation with the Book Running Lead Manager, RTA and BSE taking into account the total number of applications received up to the closure of timings.

On the Bid/ Issue Closing Date, extension of time will be granted by the Stock Exchange only for uploading Bids received from Individual Bidders after taking into account the total number of Bids received and as reported by the Book Running Lead Manager to the Stock Exchange.

It is clarified that Bids not uploaded on the electronic bidding system or in respect of which the full Bid Amount is not blocked by SCSBs or not blocked under the UPI Mechanism in the relevant ASBA Account, as the case may be, would be rejected.

Due to the limitation of time available for uploading the Bid-Cum-Application Forms on the Bid/ Issue Closing Date, Bidders are advised to submit their applications one (1) day prior to the Bid/ Issue Closing Date and, in any case, not later than 3.00 P.M. (IST) on the Bid/ Issue Closing Date. Any time mentioned in this Draft Red Herring Prospectus is IST. Bidders are cautioned that, in the event a large number of Bid-Cum- Application Forms are received on the Bid/ Issue Closing Date, as is typically experienced in public Issue, some Bid-Cum- Application Forms may not get uploaded due to the lack of sufficient time. Such Bid-Cum- Application Forms that cannot be uploaded will not be considered for allocation under this Issue. Applications will be accepted only on Working Days, i.e., Monday to Friday (excluding any public holidays). Neither our Company nor the Book Running Lead Manager is liable for any failure in uploading the Bid-Cum- Application Forms due to faults in any software/hardware system or otherwise.

In accordance with SEBI (ICDR) Regulations, Any of the investor are not allowed to withdraw or lower the size of their Application (in terms of the quantity of the Equity Shares or the Application amount) at any stage. In case of discrepancy in the data entered in the electronic book vis-à-vis the data contained in the physical Bid-Cum- Application Form, for a particular Bidder, the details as per the file received from Stock Exchange may be taken as the final data for the purpose of Allotment. In case of discrepancy in the data entered in the electronic book vis-à-vis the data contained in the physical or electronic Bid-Cum- Application Form, for a particular ASBA Bidder, the Registrar to the Issue shall ask the relevant SCSBs / RTAs / DPs / stock brokers, as the case may be, for the rectified data.

Our Company in consultation with the Book Running Lead Manager, reserves the right to revise the Price Band during the Bid/ Issue Period. The revision in the Price Band shall not exceed 20% on either side, i.e. the Floor Price can move up or down to the extent of 20% of the Floor Price and the Cap Price will be revised accordingly. The Floor Price shall not be less than the face value of the Equity Shares.

In case of any revision to the Price Band, the Bid/ Issue Period will be extended by at least three additional Working Days following such revision of the Price Band, subject to the Bid/ Issue Period not exceeding a total of 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company in consultation with the Book Running Lead Manager, for reasons to be recorded in writing, extend the Bid/ Issue Period for a minimum of one Working Days, subject to the Bid/

Issue Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/ Issue Period, if applicable, will be widely disseminated by notification to the Stock Exchange, by issuing a public notice, and also by indicating the change on the respective websites of the Book Running Lead Manager and the terminals of the Syndicate Members, if any and by intimation to SCSBs, other Designated Intermediaries and the Sponsor Bank, as applicable. In case of revision of Price Band, the Bid Lot shall remain the same.

Minimum Subscription and Underwriting

Minimum subscription in the issue is 90% and the issue is 100% underwritten. As per Section 39 of the Companies Act, 2013, if the stated minimum amount is not subscribed and the sum payable on application is not received within a period of 30 days from the date of the Prospectus, or such other period as may be specified by the SEBI, the application money has to be returned within such period as may be prescribed. If the stated minimum amount has not been subscribed and the sum payable on application is not received within the period specified therein, then the application money shall be repaid within a period of fifteen days from the closure of the issue and if any such money is not so repaid within such period, the directors of the company who are officers in default shall jointly and severally be liable to repay that money with interest at the rate of fifteen percent per annum.

In terms of Regulation 272(2) of SEBI (ICDR) Regulations, in case the Company fails to obtain listing or trading permission from the stock exchanges where the specified securities are proposed to be listed, it shall refund through verifiable means the entire monies received within four days of receipt of intimation from stock exchange(s) rejecting the application for listing of specified securities, and if any such money is not repaid within four days after the issuer becomes liable to repay it, the issuer and every director of the company who is an officer in default shall, on and from the expiry of the fourth day, be jointly and severally liable to repay that money with interest at the rate of fifteen per cent per annum.

Further, in accordance with Regulation 268(1) of the SEBI (ICDR) Regulations, our Company shall ensure that the number of prospective allottees to whom the Equity Shares will allotted will not be less than 200 (Two Hundred). In terms of Regulation 260 of the SEBI (ICDR) Regulations, 2018, the Issue is 100% underwritten. For details of underwriting arrangement, kindly refer the chapter titled “**General Information - Underwriting**” on page 64 of this Draft Red Herring Prospectus. Further, in accordance with Regulation 267 of the SEBI (ICDR) Regulations, 2018, the minimum application size in terms of number of specified securities shall not be less than two lots. Provided that minimum application size shall be above ₹2 lakhs.

Migration to Main Board

As per the provisions of the Chapter IX of the SEBI (ICDR) Regulation, 2018, our Company may migrate to the main board of BSE from the BSE SME on a later date subject to the following:

As per Regulation 280(2) of the SEBI ICDR Regulation, 2018 read along with SEBI ICDR (Amendment) Regulations, 2025, Where the post-issue paid up capital of the Company listed on a BSE SME is likely to increase beyond twenty-five crore rupees by virtue of any further issue of capital by the Company by way of rights issue, preferential issue, bonus issue, etc. the Company shall migrate its equity shares listed on BSE SME to the Main Board and seek listing of the equity shares proposed to be issued on the Main Board subject to the fulfilment of the eligibility criteria for listing of equity shares laid down by the Main Board:

Provided that no further issue of capital shall be made unless –

- a) the shareholders have approved the migration by passing a special resolution through postal ballot wherein the votes cast by shareholders other than promoters in favour of the proposal amount to at least two times the number of votes cast by shareholders other than promoter shareholders against the proposal;
- b) the Company has obtained an in-principle approval from the Main Board for listing of its entire specified securities on it.

Provided further that where the post-issue paid-up capital pursuant to further issue of capital including by way of rights issue, preferential issue, bonus issue, is likely to increase beyond ₹25 crores, the Company may undertake further issuance of capital without migration from SME exchange to the main board, subject to the undertaking to comply with the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as applicable to companies listed on the main board of the stock exchange(s).”

If the Paid-up Capital of the company is more than ₹10 crores but below ₹25 crores, we may still apply for migration to the main board if the same has been approved by a special resolution through postal ballot wherein the votes cast by the shareholders other than the promoters in favour of the proposal amount to at least two times the number of votes cast by shareholders other than promoter shareholders against the proposal.

Any company voluntarily desiring to migrate to the Main board from the SME Platform, amongst others, has to fulfill following conditions:

Parameter	Migration policy from BSE SME Platform to BSE Main Board
Paid up Capital & Market Capitalisation	Paid-up capital of more than 10 Crores and Market Capitalisation should be minimum Rs. 25 Crores <i>(Market Capitalisation will be the product of the price (average of the weekly high and low of the closing price of the related shares quoted on the stock exchange during 3 (Three) months prior to the date of the application) and the post issue number of equity shares.)</i>
Promoter Holding	Promoter(s) shall be holding at least 20% of equity share capital of the company at the time of making application.
Financial Parameters	The applicant company should have positive operating profit (earnings before interest, depreciation and tax) from operations for at least any 2 out of 3 financial years and has positive Profit after tax (PAT) in the immediate preceding Financial Year of making the migration application to Exchange. The applicant company should have a Net worth of at least Rs. 15 crores for 2 preceding full financial years.
Track record of the company in terms of listing/ regulatory actions, etc	The applicant company is listed on SME Exchange/ Platform having nationwide terminals for atleast 3 years.
Regulatory action	No material regulatory action in the past 3 years like suspension of trading against the applicant company, promoters/promoter group by any stock Exchange having nationwide trading terminals. No Debarment of company, promoters/promoter group, subsidiary company by SEBI. No Disqualification/Debarment of directors of the company by any regulatory authority. <u>The applicant company has not received any winding up petition admitted by a NCLT.</u>
Public Shareholder	The applicant company shall have a minimum of 250 public shareholders as per the latest shareholding pattern.
Other parameters like No. of shareholders, utilization of funds	No proceedings have been admitted under the Insolvency and Bankruptcy Code against the applicant company and Promoting companies. No pending Defaults in respect of payment of interest and/or principal to the debenture/bond/fixed deposit holders by the applicant, promoters/promoter group /promoting company(ies), Subsidiary Companies. The applicant company shall obtain a certificate from a credit rating agency registered with SEBI with respect to utilization of funds as per the stated objective pursuant to IPO and/or further funds raised by the company, if any post listing on SME platform. The applicant company has no pending investor complaints. Cooling off period of 2 months from the date the security has come out of trade-to-trade category or any other surveillance action.

Notes:

1. Net worth definition to be considered as per definition in SEBI ICDR.
2. Company is required to submit Information Memorandum to the Exchange as prescribed in SEBI (ICDR) Regulations.
3. The application submitted to the Exchange for listing and mere fulfilling the eligibility criteria does not amount to grant of approval for listing.
4. If the documents and clarification received from the applicant company are not to the satisfaction of BSE, BSE has the right to close the application at any point of time without giving any reason thereof. Thereafter, the company can make

- fresh application as per the extant norms.
5. The Exchange may reject application at any stage if the information submitted to the Exchange is found to be incomplete / incorrect / misleading / false or for any contravention of Rules, Bye-laws and Regulations of the Exchange, Guidelines / Regulations issued by statutory authorities or for any reason in the interest of Investors and market integrity. The Exchange may also reject the application if the company is found not fulfilling internal BSE standards.
 6. Companies that have approached for listing on any stock exchange and has been denied listing for any reason whatsoever or has chosen to withdraw its application from the Exchange, they may reapply for listing after a minimum period of 6 months (6 months after date of rejection/ withdrawal). If rejected for a second time, the company would not be eligible to apply again.
 7. BSE decision w.r.t admission of securities for listing and trading is final.
 8. BSE has the right to change / modify / delete any or all the above norms without giving any prior intimation to the company.
 9. The companies are required to submit documents and comply with the extant norms.
 10. The company shall use BSE's reference regarding listing only after the Exchange grants its in-principle listing approval to the company.

Market Making

The shares offered through this Issue are proposed to be listed on the SME platform of BSE (BSE SME), wherein the Book Running Lead Manager to this Issue shall ensure compulsory Market Making through the registered Market Makers of the SME Exchange for a minimum period of 3 (three) years from the date of listing on the BSE SME.

For further details of the agreement entered into between the Company, the Book Running Lead Manager and the Market Maker please refer to section titled ***“General Information - Details of the Market Making Arrangements for this Issue”*** on page 65 of this Draft Red Herring Prospectus.

Arrangements for disposal of odd lots

The trading of the Equity Shares will happen in the minimum contract size of [●] shares of face value of ₹10/- each in terms of the SEBI circular No. CIR/MRD/DSA/06/2012 dated February 21, 2012. However, the Market Maker shall buy the entire shareholding of a shareholder in one lot, where value of such shareholding is less than the minimum contract size allowed for trading on the SME platform of BSE (“BSE SME”).

As per the extant Guideline of the Government of India, OCBs cannot participate in this Issue

The current provisions of the Foreign Exchange Management (Transfer or Issue of Security by a Person Resident outside India) Regulations, 2000, provides a general permission for the NRIs, FPIs and foreign venture capital investors registered with SEBI to invest in shares of Indian companies by way of subscription in an IPO. However, such investments would be subject to other investment restrictions under the Foreign Exchange Management (Transfer or Issue of Security by a Person Resident outside India) Regulations, 2000, RBI and/or SEBI regulations as may be applicable to such investors.

The Allotment of the Equity Shares to Non-Residents shall be subject to the conditions, if any, as may be prescribed by the Government of India/RBI while granting such approvals.

Allotment of Equity Shares in Dematerialized Form

Pursuant to Section 29 of the Companies Act, 2013, the Equity Shares in the Issue shall be allotted only in dematerialized form. Further, as per the SEBI (ICDR) Regulations, the trading of the Equity Shares shall only be in dematerialized form on the Stock Exchange.

New Financial Instruments

There are no new financial instruments such as deep discounted bonds, debenture, warrants, secured premium notes, etc. issued by our Company through this Issue.

Application by Eligible NRI's, FPI's, VCF's, AIF's registered with SEBI

It is to be understood that there is no reservation for Eligible NRIs, FPIs or VCF registered with SEBI. Such Eligible NRIs, FPIs or VCF registered with SEBI will be treated on the same basis with other categories for the purpose of Allocation.

Restrictions on transfer and transmission of shares or debentures and on their consolidation or splitting

Except for lock-in of the Pre- Issue Equity Shares, Promoter minimum contribution in the Issue and Anchor Investor lock-in as detailed under section titled ***“Capital Structure”*** beginning on page 68 of this Draft Red Herring Prospectus, and except as provided in the Articles of Association of our Company, there are no restrictions on transfers and transmission of Equity Shares and on their consolidation/ splitting. Further, there are no restrictions on transmission of shares/ debentures and on their consolidation/ splitting except as provided in the Articles of Association. For further details, please refer to section titled ***“Main Provisions of the Articles of Association”*** beginning on page 305 of this Draft Red Herring Prospectus.

Pre-Issue and Price Band Advertisement

Subject to Section 30 of the Companies Act, 2013 our Company shall, after filing the Red Herring Prospectus/ Prospectus with the ROC publish a pre-Issue and price band advertisement, in the form prescribed by the SEBI (ICDR) Regulations, in one widely circulated English language national daily newspaper; one widely circulated Hindi language national daily newspaper and one regional newspaper with wide circulation where the Registered Office of our Company is situated at least two Working Days prior to the Issue Opening Date and shall be available to the Stock Exchange for the purpose of uploading on the website.

Withdrawal of the Issue

Our Company in consultation with the Book Running Lead Manager, reserve the right not to proceed with the Issue after the Bid/ Issue Opening date but before the Allotment. In such an event, our Company would issue a public notice in the newspaper in which the pre-Issue and price band advertisements were published, within two working days of the Bid/ Issue Closing date or such other time as may be prescribed by SEBI, providing reasons for not proceeding with the Issue. The Book Running Lead Manager through, the Registrar of the Issue, shall notify the SCSBs to unblock the bank accounts of the ASBA Bidders within one working day from the date of receipt of such notification. Our Company shall also inform the same to the stock exchange on which equity shares are proposed to be listed.

The above information is given for the benefit of the Applicants. The Applicants are advised to make their own enquiries about the limits applicable to them. Our Company and the Book Running Lead Manager do not accept any responsibility for the completeness and accuracy of the information stated hereinabove. Our Company and the Book Running Lead Manager are not liable to inform the investors of any amendments or modifications or changes in applicable laws and regulations, which may occur after the date of this Draft Red Herring Prospectus. Applicants are advised to make their independent investigations and ensure that the number of Equity Shares applied for do not exceed the applicable limits under laws and regulations.

ISSUE STRUCTURE

This Issue is being made in terms of Regulation 229(2) of Chapter IX of SEBI (ICDR) Regulations, 2018, as amended from time to time, whereby, an issuer whose post issue paid up capital is more than or equal to ten crore rupees but less than twenty-five crore rupees, shall issue shares to the public and propose to list the same on the Small and Medium Enterprise Exchange (“SME Exchange”, in this case being the BSE SME i.e. SME platform of BSE). For further details regarding the salient features and terms of such an issue please refer chapter titled “*Terms of the Issue*” and “*Issue Procedure*” on page 260 and 273 of this Draft Red Herring Prospectus

Issue Structure:

Initial Public Issue of upto 27,36,000 Equity Shares of ₹10 each (*the “Equity Shares”*) for cash at a price of ₹ [●] per Equity Share (including a Share Premium of ₹ [●] per Equity Share), aggregating up to ₹ [●] Lakhs (*“the Issue”*) by the issuer Company (the “Company”).

The Issue comprises a reservation of upto [●] Equity Shares of ₹10 each for subscription by the designated Market Maker (*“the Market Maker Reservation Portion”*) and Net Issue to Public of upto [●] Equity Shares of ₹10 each (*“the Net Issue”*). The Issue and the Net Issue will constitute 26.34% and [●] %, respectively of the post Issue paid up equity share capital of the Company. The Issue is being made through the Book Building Process.

Particulars of the Issue ⁽²⁾	Market Maker Reservation Portion	QIBs ⁽¹⁾	Non-Institutional Investors	Individual Investors
Number of Equity Shares available for allocation	Upto [●] Equity Shares of face value of ₹10/- each	Not more than [●] Equity Shares of face value of ₹10/- each	Not less than [●] Equity Shares of face value of ₹10/- each	Not less than [●] Equity Shares of face value of ₹10/- each
Percentage of Issue Size available for allocation	[●] of the Issue Size	Not more than 50% of the Net Issue being available for allocation to QIB Bidders. However, up to 5% of the Net QIB Portion will be available for allocation proportionately to Mutual Funds only. Mutual Funds participating in the Mutual Fund Portion will also be eligible for allocation in the remaining QIB Portion. The unsubscribed portion in the Mutual Fund Portion will be added to the Net QIB Portion.	Not less than 15.00% of the Net Issue subject to the following: (i) one-third of the portion available to Non-Institutional Bidders shall be reserved for applicants with an application size of more than two lots and up to such lots equivalent to not more than ₹10 lakhs; and (ii) two-third of the portion available to Non-Institutional Bidders shall be reserved for applicants with application size of more than ₹ 10,00,000	Not less than 35.00% of the Issue or the Issue less allocation to QIB Bidders and Non-Institutional Bidders shall be available for allocation.
Basis of Allotment⁽³⁾	Firm Allotment	Proportionate as follows (excluding the Anchor Investor Portion): (a) Up to [●] Equity Shares of face value of ₹10/- each shall be available for allocation on a	Allotment to each Non-Institutional Bidder shall not be less than the Minimum NIB Application Size, subject to the availability of Equity Shares of face	Allotment to each Individual Bidder shall not be less than the maximum Bid lot, subject to availability of Equity Shares of face value of ₹10/- each in the

Particulars of the Issue ⁽²⁾	Market Maker Reservation Portion	QIBs ⁽¹⁾	Non-Institutional Investors	Individual Investors
		proportionate basis to Mutual Funds only; and (b) Up to [●] Equity Shares of face value of ₹10/- each shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds receiving allocation as per (a) above. Up to 60% of the QIB Portion (of up to [●] Equity Shares of face value of ₹10/- each may be allocated on a discretionary basis to Anchor Investors of which one-third shall be available for allocation to Mutual Funds only, subject to valid Bid received from Mutual Funds at or above the Anchor Investor Allocation Price	value of ₹10/- each in the Non-Institutional Portion, and the remaining Equity Shares, if any, shall be allotted on a proportionate basis as follows – One-third of the Non Institutional Category will be made available for allocation to Bidders with an application size of more than two lots and up to such lots equivalent to not more than ₹10 lakhs. Two-third of the Non Institutional Category will be made available for allocation to Bidders with an application size of more than ₹ 1,000,000. For details, see “Issue Procedure” beginning on page 273 of this Draft Red Herring Prospectus. Provided that the unsubscribed portion in either of the aforementioned subcategories may be allocated to Non-Institutional Bidders in the other subcategory of Non-Institutional Bidders.	Individual Investor Portion and the remaining available Equity Shares if any, shall be allotted on proportionate basis. For details, see “Issue Procedure” beginning on page 273 of this Draft Red Herring Prospectus.
Mode of Allotment	Compulsorily in dematerialized form.			
Minimum Bid Size	[●] Equity Shares of face value of ₹10/- each	Such number of Equity Shares and in multiples of [●] Equity Shares of face value of ₹10/- each that the Bid exceeds two lots	Such number of Equity Shares and in multiples of [●] Equity Shares of face value of ₹10/- each that the Bid exceeds two lots	Two lots with minimum application size of above Rs 2 lakhs
Maximum Bid Size	[●] Equity Shares of face value of ₹10/- each	Such number of Equity Shares in multiples of [●] Equity Shares of face value of ₹10/- each not exceeding the size of the Net Issue, subject to applicable limits	Such number of Equity Shares in multiples of [●] Equity Shares of face value of ₹10/- each not exceeding the size of the Net Issue (excluding the QIB portion), subject to applicable limits	Two lots with minimum application size of above Rs 2 lakhs

Particulars of the Issue ⁽²⁾	Market Maker Reservation Portion	QIBs ⁽¹⁾	Non-Institutional Investors	Individual Investors
Trading Lot	[●] Equity Shares of face value of ₹10/- each, However the Market Maker may accept odd lots if any in the market as required under the SEBI (ICDR) Regulations, 2018.	[●] Equity Shares of face value of ₹10/- each and in multiples thereof	[●] Equity Shares of face value of ₹10/- each and in multiples thereof	[●] Equity Shares of face value of ₹10/- each and in multiples thereof
Terms of Payment	Full Bid Amount shall be blocked by the SCSBs in the bank account of the ASBA Bidder (other than Anchor Investors) or by the Sponsor Bank through the UPI Mechanism, that is specified in the ASBA Form at the time of submission of the ASBA Form. In case of Anchor Investors: Full Bid Amount shall be payable by the Anchor Investors at the time of submission of their Bids ⁽⁴⁾			
Mode of Bid	Only through the ASBA process.	Only through the ASBA process. (Except for Anchor investors)	Only through the ASBA process	Through ASBA Process via Banks or by using UPI ID for payment

This Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, as amended from time to time.

- ⁽¹⁾ Our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI (ICDR) Regulations. One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the price Anchor Investor Allocation Price.
- ⁽²⁾ In terms of Rule 19(2) of the SCRR read with Regulation 252 of the SEBI (ICDR) Regulations, 2018 this is an Issue for at least 25% of the post Issue paid-up Equity share capital of the Company. This Issue is being made through Book Building Process, wherein allocation to the public shall be as per Regulation 252 of the SEBI (ICDR) Regulations.
- ⁽³⁾ Subject to valid Bids being received at or above the Issue Price, undersubscription, if any, in any category, except in the QIB Portion, would be allowed to be met with spill-over from any other category or combination of categories of Bidders at the discretion of our Company in consultation with the Book Running Lead Managers and the Designated Stock Exchange, subject to applicable laws.
- ⁽⁴⁾ Full Bid Amount shall be payable by the Anchor Investors at the time of submission of the Anchor Investor Bid-cum-Application Forms provided that any difference between the Anchor Investor Allocation Price and the Anchor Investor Issue Price shall be payable by the Anchor Investor Pay-In Date as indicated in the CAN.

The Bids by FPIs with certain structures as described under “**Issue Procedure - Bids by FPIs**” on pages 283 and having same PAN may be collated and identified as a single Bid in the Bidding process. The Equity Shares Allocated and Allotted to such successful Bidders (with same PAN) may be proportionately distributed.

If the Bid is submitted in joint names, the Bid cum Application Form should contain only the name of the first Bidder whose name should also appear as the first holder of the depository account held in joint names. The signature of only the first Bidder would be required in the Bid cum Application Form and such first Bidder would be deemed to have signed on behalf of the joint holders. Bidders will be required to confirm and will be deemed to have represented to our Company, the Underwriters, their respective directors, officers, agents, affiliates and representatives that they are eligible under applicable law, rules, regulations, guidelines and approvals to acquire the Equity Shares.

Withdrawal of the Issue

In accordance with SEBI (ICDR) Regulations, the Company, in consultation with the Book Running Lead Manager, reserves the right not to proceed with the Issue at any time before the Bid/Issue Opening Date, without assigning any reason thereof.

In case, the Company wishes to withdraw the Issue after Bid/Issue Opening but before allotment, the Company will give public notice giving reasons for withdrawal of Issue. The public notice will appear in two widely circulated national newspapers (*one each in English and Hindi*) and one in regional newspaper.

The Book Running Lead Manager, through the Registrar to the Issue, will instruct the SCSBs, to unblock the ASBA Accounts within one Working Day from the day of receipt of such instruction. The notice of withdrawal will be issued in the same newspapers where the pre-Issue and price band advertisements have appeared and the Stock Exchange will also be informed promptly.

If our Company withdraws the Issue after the Bid/Issue Closing Date and subsequently decides to undertake a public Issue of Equity Shares, our Company will file a fresh Draft Red Herring Prospectus with the stock exchange where the Equity Shares may be proposed to be listed.

Notwithstanding the foregoing, the Issue is subject to obtaining (i) the final listing and trading approvals of the Stock Exchange, which our Company will apply for only after Allotment; and (ii) filing of the Red Herring Prospectus/ Prospectus with ROC.

Issue Program

Event	Indicative Date
Bid/ Issue Opening Date	[●] ¹
Bid/ Issue Closing Date	[●] ²
Finalization of Basis of Allotment with the Designated Stock Exchange (T+1)	On or about [●]
Initiation of Allotment/ Refunds/ Unblocking of Funds from ASBA Account or UPI Id Linked Bank Account* (T+2)	On or about [●]
Credit of Equity Shares to Demat Accounts of Allottees (T+2)	On or about [●]
Commencement of Trading of The Equity Shares on the Stock Exchange (T+3)	On or about [●]

Note ¹Our Company, in consultation with the Book Running Lead Manager, may consider participation by Anchor Investors in accordance with the SEBI (ICDR) Regulations. The Anchor Investor Bid/Issue Period shall be one Working Day prior to the Bid/Issue Opening Date in accordance with the SEBI (ICDR) Regulations.

²Our Company, in consultation with the Book Running Lead Manager, consider closing the Bid/Issue Period for QIBs one Working Day prior to the Bid/Issue Closing Date in accordance with the SEBI (ICDR) Regulations.

Applications and any revisions to the same will be accepted only between 10.00 A.M. to 5.00 P.M. (Indian Standard Time) during the Issue Period at the Application Centres mentioned in the Bid-Cum Application Form.

Standardization of cut-off time for uploading of applications on the Bid/ Issue Closing Date:

- A standard cut-off time of 3.00 P.M. for acceptance of applications.
- A standard cut-off time of 4.00 P.M. for uploading of applications received from all bidders.

It is clarified that Applications not uploaded would be rejected. In case of discrepancy in the data entered in the electronic form vis-à-vis the data contained in the physical Bid-Cum Application form, for a particular applicant, the details as per physical Bid-Cum application form of that Applicant may be taken as the final data for the purpose of allotment.

Bids will be accepted only on Working Days, i.e., Monday to Friday (excluding bank holidays)

ISSUE PROCEDURE

All Bidders should read the General Information Document for Investing in Public Issue prepared and issued in accordance with the circular no. SEBI/HO/CFD/DIL1/CIR/P/2020/37 dated March 17, 2020, and the UPI Circulars (the “General Information Document”) which highlights the key rules, processes, and procedures applicable to public issues in general in accordance with the provisions of the Companies Act, the SCRA, the SCRR and the SEBI ICDR Regulations which is part of the Abridged Prospectus accompanying the Bid cum Application Form. The General Information Document is available on the websites of the Stock Exchanges and the BRLMs. Please refer to the relevant provisions of the General Information Document which are applicable to the Issue.

Additionally, all Applicants may refer to the General Information Document for information in relation to (i) Category of investor eligible to participate in the Issue; (ii) maximum and minimum Issue size; (iii) price discovery and allocation; (iv) Payment Instructions for ASBA Applicants; (v) Issuance of CAN and Allotment in the Issue; (vi) General instructions (limited to instructions for completing the Application Form); (vii) designated date; (viii) disposal of applications; (ix) submission of Application Form; (x) other instructions (limited to joint applications in cases of individual, multiple applications and instances when an application would be rejected on technical grounds); (xi) applicable provisions of Companies Act, 2013 relating to punishment for fictitious applications; (xii) mode of making refunds; and (xiii) interest in case of delay in Allotment or refund.

SEBI through its UPI Circular no. SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 1, 2018 read with its circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/50 dated April 3, 2019 and circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/76 dated June 28, 2019, has introduced an alternate payment mechanism using Unified Payments Interface (UPI) and consequent reduction in timelines for listing in a phased manner. From January 1, 2019, the UPI Mechanism for Individual Investors applying through Designated Intermediaries was made effective along with the existing process and existing timeline of T+3 days (“UPI Phase I”). The UPI Phase I was effective till June 30, 2019.

Subsequently, for applications by Retail Individual Investors through Designated Intermediaries, the process of physical movement of forms from Designated Intermediaries to SCSBs for blocking of funds has been discontinued and only the UPI Mechanism with existing timeline of T+3 days is applicable for a period of three months or launch of five main board public Issues, whichever is later (“UPI Phase II”), with effect from July 1, 2019, by SEBI circular (SEBI/HO/CFD/DIL2/CIR/P/2019/76) dated June 28, 2019, read with circular (SEBI/HO/CFD/DIL2/CIR/P/2019/85) dated July 26, 2019. Further, as per the SEBI circular (SEBI/HO/CFD/DCR2/CIR/P/2019/133) dated November 8, 2019, the UPI Phase II had been extended until March 31, 2020. However, due to the outbreak of COVID-19 pandemic, UPI Phase II has been further extended by SEBI until further notice, by its circular (SEBI/HO/CFD/DIL2/CIR/P/2020/50) dated March 30, 2020. Thereafter, the final reduced timeline of T+3 days may be made effective using the UPI Mechanism for applications by Retail Individual Investors (“UPI Phase III”), as may be prescribed by SEBI. Further, SEBI, vide its circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021, and circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021, has introduced certain additional measures for streamlining the process of initial public Issues and redressing investor grievances. This circular is effective for initial public Issues opening on or after May 1, 2021, except as amended pursuant to SEBI circular SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021, and SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022, and the provisions of this circular are deemed to form part of this Prospectus. Furthermore, pursuant to SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/P/2022/45 dated April 5, 2022, all individual Investors in initial public Issue (opening on or after May 1, 2022) whose application sizes are up to ₹ 500,000 shall use the UPI Mechanism.

Further, SEBI has vide its circular no. SEBI/HO/CFD/TPD1/CIR/P/2023/140 dated August 9, 2023 reduced the time taken for listing of specified securities after the closure of a public Issue to three Working Days. Accordingly, the Issue will be made under UPI Phase III on a mandatory basis, subject to any circulars, clarification or notification issued by the SEBI from time to time.

The list of Banks that have been notified by SEBI as Issuer Banks for UPI are provided on <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=40>. The list of Stockbrokers, Depository Participants (DP), Registrar to an Issue and Share Transfer Agent (RTA) that have been notified by SME Platform of BSE Limited (“BSE SME”) to act as intermediaries for submitting Application Forms are provided on www.bseindia.com. For details on their designated branches for submitting Application Forms, please see the above-mentioned website of Platform of BSE Limited (“BSE SME”). Please note that the information stated/covered in this section may not be complete and/or accurate and as such would be subject to modification/change. Our Company and Book Running Lead Manager do not accept

any responsibility for the completeness and accuracy of the information stated in this section and the General Information Document. Our Company and Book Running Lead Manager would not be able to include any amendment, modification or change in applicable law, which may occur after the date of Prospectus. Applicants are advised to make their independent investigations and ensure that their application do not exceed the investment limits or maximum number of Equity Shares that can be held by them under applicable law or as specified in the Draft Red Herring Prospectus and Red Herring Prospectus.

Further, the Company and the LM are not liable for any adverse occurrence's consequent to the implementation of the UPI Mechanism for application in this Issue.

Phased implementation of Unified Payments Interface

SEBI has issued the UPI Circulars in relation to streamlining the process of public Issue of inter alia, equity shares. Pursuant to the SEBI circular bearing number SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 1, 2018, SEBI circular bearing number SEBI/HO/CFD/DIL2/CIR/P/2019/50 dated April 3, 2019, SEBI circular bearing number SEBI/HO/CFD/DIL2/CIR/P/2019/76 dated June 28, 2019, SEBI circular bearing number SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019, SEBI circular bearing number SEBI/HO/CFD/DIL2/CIR/P/2020/50 dated March 30, 2020 ("Previous UPI Circulars") and the UPI Circulars, the UPI Mechanism has been introduced in a phased manner as a payment mechanism (in addition to mechanism of blocking funds in the account maintained with SCSBs under ASBA) for applications by UPI Bidders through Designated Intermediaries with the objective to reduce the time duration from public Issue closure to listing from six Working Days to up to three Working Days. Considering the time required for making necessary changes to the systems and to ensure complete and smooth transition to the UPI payment mechanism, the UPI Circulars and the Previous UPI Circulars have introduced the UPI Mechanism in three phases in the following manner:

Phase I: This phase has become applicable from January 1, 2019 until March 31, 2019 or floating of five main board public Issues, whichever is later. Subsequently, the timeline for implementation of Phase I was extended till June 30, 2019. Under this phase, an Individual Applicant had the option to submit the Application Form with any of the intermediary and use his / her UPI ID for the purpose of blocking of funds. The time duration from public Issue closure to listing continued to be three Working Days.

Phase II: This phase has become applicable from July 1, 2019 and was to initially continue for a period of three months or floating of five main board public Issues, whichever is later. Subsequently, it was decided to extend the timeline for implementation of Phase II until March 31, 2020. Further, as per SEBI circular SEBI/HO/CFD/DIL2/CIR/P/2020/50 dated March 30, 2020, the current Phase II of Unified Payments Interface with Application Supported by Blocked Amount is continued till further notice. Under this phase, submission of the ASBA Form by RIIs through Designated Intermediaries (other than SCSBs) to SCSBs for blocking of funds will be discontinued and will be replaced by the UPI payment mechanism. However, the time duration from public Issue closure to listing continues to be three Working Days during this phase.

Phase III: This phase has become applicable on a voluntary basis for all Issues opening on or after September 1, 2023 and on a mandatory basis for all Issues opening on or after December 1, 2023, vide SEBI circular bearing number SEBI/HO/CFD/TPD1/CIR/P/2023/140 dated August 9, 2023 ("T+3 Notification"). In this phase, the time duration from public Issue closure to listing has been reduced to three Working Days. The Issue shall be undertaken pursuant to the processes and procedures as notified in the T+3 Notification as applicable, subject to any circulars, clarification or notification issued by the SEBI from time to time, including any circular, clarification or notification which may be issued by SEBI.

The Issue is being made under Phase III of the UPI (on a mandatory basis).

All SCSBs Offering facility of making application in public Issues shall also provide facility to make application using the UPI Mechanism. The Issuers will be required to appoint one of the SCSBs as a sponsor bank to act as a conduit between the Stock Exchanges and NPCI in order to facilitate collection of requests and / or payment instructions of the Individual Applicants into the UPI mechanism.

For further details, refer to the General Information Document available on the websites of the Stock Exchanges and the Book Running Lead Manager.

PART A

Book Building Procedure

In terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (the “SCRR”) read with Regulation 252 of SEBI (ICDR) Regulations, 2018, the Issue is being made for at least 25% of the post-Issue Paid-up Equity Share capital of our Company. The Issue is being made under Regulation 229(2) of Chapter IX of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 via book building process wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to QIBs, provided that our Company and may, in consultation with the Book Running Lead Manager, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI (ICDR) Regulations, of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion. Further, 5% of the QIB Portion (excluding the Anchor Investor Portion) shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIBs (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Issue Price. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Investors, out of which (a) one-third of such portion shall be reserved for applicants with application size of more than 2 lots and up to ₹ 10.00 lakhs; and (b) two-third of such portion shall be reserved for applicants with application size of more than ₹ 10.00 lakhs, provided that the unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders and not less than 35% of the Net Issue shall be available for allocation to Individual Investors who applies for minimum application size in accordance with the SEBI (ICDR) Regulations, subject to valid Bids being received at or above the Issue Price.

Subject to valid Bids being received at or above the Issue Price, undersubscription, if any, in any category, except the QIB Portion, would be allowed to be met with spill-over from any other category or a combination of categories at the discretion of our Company in consultation with the Book Running Lead Manager, and the Designated Stock Exchange. However, under-subscription, if any, in the QIB Portion will not be allowed to be met with spillover from other categories or a combination of categories.

The Equity Shares, on Allotment, shall be traded only in the dematerialised segment of the Stock Exchanges.

Investors should note that the Equity Shares will be Allotted to all successful Bidders only in dematerialized form. The Bid cum Application Forms which do not have the details of the Bidders' depository account, including DP ID, Client ID, PAN and UPI ID, as applicable, shall be treated as incomplete and will be rejected. Bidders will not have the option of being Allotted Equity Shares in physical form. However, they may get the Equity Shares rematerialized subsequent to Allotment of the Equity Shares in the Issue, subject to applicable laws.

Bid cum Application Form

Copies of the Bid cum Application Form (other than for Anchor Investors) and the abridged prospectus will be available at the offices of the Book Running Lead Manager, the Designated Intermediaries at Bidding Centres, and Registered Office of our Company. An electronic copy of the Bid cum Application Form will also be available for download on the websites of the BSE, at least one day prior to the Bid/Issue Opening Date.

Copies of the Anchor Investor Application Form will be available at the offices of the Book Running Lead Manager.

ASBA Bidders (other than UPI Bidders using UPI Mechanism) must provide bank account details and authorization to block funds in their respective ASBA Accounts in the relevant space provided in the ASBA Form and the ASBA Forms that do not contain such details are liable to be rejected. The ASBA Bidders shall ensure that they have sufficient balance in their bank accounts to be blocked through ASBA for their respective Bid as the application made by a Bidder shall only be processed after the Bid amount is blocked in the ASBA account of the Bidder.

ASBA Bidders shall ensure that the Bids are made on ASBA Forms bearing the stamp of the Designated Intermediary, submitted at the Bidding Centres only (except in case of electronic ASBA Forms) and the ASBA Forms not bearing such specified stamp are liable to be rejected. UPI Bidders using UPI Mechanism, may submit their ASBA Forms, including details of their UPI IDs, with the Syndicate, Sub-Syndicate Members, Registered Brokers, RTAs or CDPs. RIBs authorizing an SCSB to block the Bid Amount in the ASBA Account may submit their ASBA Forms with the SCSBs. ASBA Bidders must ensure that the ASBA

Account has sufficient credit balance such that an amount equivalent to the full Bid Amount can be blocked by the SCSB or the Sponsor Banks, as applicable at the time of submitting the Bid. In order to ensure timely information to investors, SCSBs are required to send SMS alerts to investors intimating them about Bid Amounts blocked/ unblocked.

Anchor Investors are not permitted to participate in the Issue through the ASBA process. For Anchor Investors, the Anchor Investor Application Form will be available at the office of the Book Running Lead Manager. ASBA Bidders are also required to ensure that the ASBA Account has sufficient credit balance as an amount equivalent to the full Bid Amount which can be blocked by the SCSB.

The prescribed colour of the Bid cum Application Form for various categories is as follows:

Category	Colour*
Anchor Investor**	[•]
Indian Public / eligible NRI's applying on a non-repatriation basis (ASBA)	[•]
Non-Residents including eligible NRI's, FPI's, FIIs, FVCIs, etc. applying on a repatriation basis (ASBA)	[•]

*Excluding Electronic Bid cum Application Form

** Bid cum application for Anchor Investor shall be made available at the Office of the Book Running Lead Manager.

Designated Intermediaries (other than SCSBs) after accepting Bid Cum Application Form submitted by Individual Investors (without using UPI for payment), NIIs and QIBs shall capture and upload the relevant details in the electronic bidding system of stock exchange(s) and shall submit/deliver the Bid Cum Application Forms to respective SCSBs where the Bidders has a bank account and shall not submit it to any non-SCSB Bank .

Further, for applications submitted to designated intermediaries (other than SCSBs), with use of UPI for payment, after accepting the Bid Cum Application Form, respective intermediary shall capture and upload the relevant application details, including UPI ID, in the electronic bidding system of stock exchange(s)..

Bidders shall only use the specified Bid Cum Application Form for making an Application in terms of the Draft Red Herring Prospectus.

The Bid Cum Application Form shall contain information about the Bidder and the price and the number of Equity Shares that the Bidders wish to apply for. Bid Cum Application Forms downloaded and printed from the websites of the Stock Exchange shall bear a system generated unique application number. Bidders are required to ensure that the ASBA Account has sufficient credit balance as an amount equivalent to the full Application Amount can be blocked by the SCSB or Sponsor Bank at the time of submitting the Application.

An Investor, intending to subscribe to this Issue, shall submit a completed Bid Cum Application Form to any of the following intermediaries (Collectively called – Designated Intermediaries”)

Sr. No.	Designated Intermediaries
1.	An SCSB, with whom the bank account to be blocked, is maintained
2.	A syndicate member (or sub-syndicate member)
3.	A stock broker registered with a recognized stock exchange (and whose name is mentioned on the website of the stock exchange as eligible for this activity) ('broker')
4.	A depository participant ('DP') (whose name is mentioned on the website of the stock exchange as eligible for this activity)
5.	A registrar to an Issue and share transfer agent ('RTA') (whose name is mentioned on the website of the stock exchange as eligible for this activity)

Individual investors submitting application with any of the entities at (ii) to (v) above (hereinafter referred as “Intermediaries”), and intending to use UPI, shall also enter their UPI ID in the Bid Cum Application Form.

The aforesaid intermediary shall, at the time of receipt of application, give an acknowledgement to investor, by giving the counter foil or specifying the application number to the investor, as a proof of having accepted the Bid Cum Application Form, in physical or electronic mode, respectively.

The upload of the details in the electronic bidding system of stock exchange will be done by:

For Applications submitted by Investors to SCSB	After accepting the form, SCSB shall capture and upload the relevant details in the electronic bidding system as specified by the stock exchange and may begin blocking funds available in the bank account specified in the form, to the extent of the application money specified.
For applications submitted by investors to intermediaries other than SCSBs	After accepting the Bid Cum Application Form, respective Intermediary shall capture and upload the relevant details in the electronic bidding system of the stock exchange. Post uploading, they shall forward a schedule as per prescribed format along with the Bid Cum Application Forms to designated branches of the respective SCSBs for blocking of funds within one day of closure of Issue.
For applications submitted by investors to intermediaries other than SCSBs with use of UPI for payment	After accepting the Bid Cum Application Form, respective intermediary shall capture and upload the relevant application details, including UPI ID, in the electronic bidding system of stock exchange. Stock exchange shall share application details including the UPI ID with sponsor bank on a continuous basis, to enable sponsor bank to initiate mandate request on investors for blocking of funds. Sponsor bank shall initiate request for blocking of funds through NPCI to investor. Investor to accept mandate request for blocking of funds, on his/her mobile application, associated with UPI ID linked bank account.

Stock exchange shall validate the electronic bid details with depository's records for DP ID/Client ID and PAN, on a real-time basis and bring the inconsistencies to the notice of intermediaries concerned, for rectification and re-submission within the time specified by stock exchange.

Stock exchange shall allow modification of selected fields viz. DP ID/Client ID or Pan ID (Either DP ID/Client ID or Pan ID can be modified but not both), Bank code and Location code, in the bid details already uploaded.

Upon completion and submission of the Bid Cum Application Form to Application Collecting intermediaries, the Bidders are deemed to have authorized our Company to make the necessary changes in the Red Herring Prospectus, without prior or subsequent notice of such changes to the Bidders.

Availability of Draft Red Herring Prospectus and Bid Cum Application Forms

Copies of the Bid cum Application Form and the abridged prospectus will be available at the offices of the Book Running Lead Manager, the Designated Intermediaries at Bidding Centres, and Registered Office of our Company. An electronic copy of the Bid cum Application Form will also be available for download on the websites of SCSBs (via Internet Banking) and BSE (www.bseindia.com) at least one day prior to the Bid/Issue Opening Date.

Bid cum application for Anchor Investor shall be made available at the Office of the Book Running Lead Manager.

Who can Bid?

Each Bidder should check whether it is eligible to apply under applicable law, rules, regulations, guidelines and policies. Furthermore, certain categories of Bidders, such as NRIs, FPIs and FVCIs may not be allowed to apply in the Issue or to hold Equity Shares, in excess of certain limits specified under applicable law. Bidders are requested to refer to the Draft Red Herring Prospectus for more details.

Subject to the above, an illustrative list of Bidders is as follows:

- Indian nationals' resident in India who are not incompetent to contract under the Indian Contract Act, 1872, as amended, in single or as a joint application and minors having valid Demat account as per Demographic Details provided by the Depositories. Furthermore, based on the information provided by the Depositories, our Company shall have the right to accept the Applications belonging to an account for the benefit of minor (under guardianship);
- Hindu Undivided Families or HUFs, in the individual name of the Karta. The Bidder should specify that the application is being made in the name of the HUF in the Bid Cum Application Form as follows: -Name of Sole or First Bidder: XYZ Hindu Undivided Family applying through XYZ, where XYZ is the name of the Kartal. Applications by HUFs would be considered at par with those from individuals;

- c) Companies, corporate bodies and societies registered under the applicable laws in India and authorized to invest in the Equity Shares under their respective constitutional and charter documents;
- d) Mutual Funds registered with SEBI;
- e) Eligible NRIs on a repatriation basis or on a non-repatriation basis, subject to applicable laws. NRIs other than Eligible NRIs are not eligible to participate in this Issue;
- f) Indian Financial Institutions, scheduled commercial banks, regional rural banks, co-operative banks (subject to RBI permission, and the SEBI Regulations and other laws, as applicable);
- g) FPIs other than Category III FPI; VCFs and FVCIs registered with SEBI;
- h) Limited Liability Partnerships (LLPs) registered in India and authorized to invest in equity shares;
- i) Sub-accounts of FIIs registered with SEBI, which are foreign corporate or foreign individuals only under the Non-Institutional Bidder 's category;
- j) Venture Capital Funds and Alternative Investment Fund (I) registered with SEBI; State Industrial Development Corporations;
- k) Foreign Venture Capital Investors registered with the SEBI;
- l) Trusts/societies registered under the Societies Registration Act, 1860, as amended, or under any other law relating to Trusts and who are authorized under their constitution to hold and invest in equity shares;
- m) Scientific and/or Industrial Research Organizations authorized to invest in equity shares;
- n) Insurance Companies registered with Insurance Regulatory and Development Authority, India;
- o) Provident Funds with minimum corpus of ₹25 Crores and who are authorized under their constitution to hold and invest in equity shares;
- p) Pension Funds and Pension Funds with minimum corpus of ₹25 Crores and who are authorized under their constitution to hold and invest in equity shares;
- q) National Investment Fund set up by Resolution no. F. No. 2/3/2005-DDII dated November 23, 2005 of Government of India published in the Gazette of India;
- r) Multilateral and bilateral development financial institution;
- s) Eligible QFIs;
- t) Insurance funds set up and managed by army, navy or air force of the Union of India;
- u) Insurance funds set up and managed by the Department of Posts, India;
- v) Any other person eligible to apply in this Issue, under the laws, rules, regulations, guidelines and policies applicable to them.

Applications not to be made by:

1. Minors (except through their Guardians)
2. Partnership firms or their nominations
3. Foreign Nationals (except NRIs)
4. Overseas Corporate Bodies

As per the existing regulations, OCBs are not eligible to participate in this Issue. The RBI has however clarified in its circular, A.P. (DIR Series) Circular No. 44, dated December 8, 2003 that OCBs which are incorporated and are not under the adverse notice of the RBI are permitted to undertake fresh investments as 138 incorporated non-resident entities in terms of Regulation 5(1) of RBI Notification No.20/2000-RB dated May 3, 2000 under FDI Scheme with the prior approval of Government if the investment is through Government Route and with the prior approval of RBI if the investment is through Automatic Route on case by case basis. OCBs may invest in this Issue provided it obtains a prior approval from the RBI. On submission of such approval along with the Bid Cum Application Form, the OCB shall be eligible to be considered for share allocation.

MAXIMUM AND MINIMUM APPLICATION SIZE

1. For Individual Bidders

The Application must be for a minimum of two lots, provided that the minimum application size shall be above ₹2 lakhs. In case of revision of Applications, the Individual Bidders have to ensure that the Application lots are two lots and amount exceeds Rs 2,00,000 as applicable.

2. For Other than Individual Bidders (Non-Institutional Applicants and QIBs):

The Application must be for more than two lots and in multiples of [●] Equity Shares thereafter. An application cannot be submitted for more than the Net Issue Size. However, the maximum Application by a QIB investor should not exceed the investment limits prescribed for them by applicable laws. Under existing SEBI Regulations, none of the Bidders can withdraw its Application.

In case of revision in Applications, the Non-Institutional Bidders, who are individuals, have to ensure that the Application is for more than two lots for being considered for allocation in the Non-Institutional Portion.

Bidders are advised to ensure that any single Application from them does not exceed the investment limits or maximum number of Equity Shares that can be held by them under applicable law or regulation or as specified in this Draft Red Herring Prospectus.

The above information is given for the benefit of the Bidders. The Company and the Book Running Lead Manager are not liable for any amendments or modification or changes in applicable laws or regulations, which may occur after the date of this Draft Red Herring Prospectus. Bidders are advised to make their independent investigations and ensure that the number of Equity Shares applied for do not exceed the applicable limits under laws or regulations.

METHOD OF BIDDING PROCESS

Our Company in consultation with the Book Running Lead Manager will decide the Price Band and the minimum Bid lot size for the Issue and the same shall be advertised in all editions of the English national newspaper [●] and all editions of Hindi national newspaper [●] and Gujarati Edition of Regional newspaper [●] where the registered office of the company is situated, each with wide circulation at least two Working Days prior to the Bid/ Issue Opening Date. The Book Running Lead Manager and the SCSBs shall accept Bids from the Bidders during the Bid/ Issue Period.

- a) The Bid / Issue Period shall be for a minimum of three Working Days and shall not exceed 10 Working Days. The Bid/ Issue Period maybe extended, if required, by an additional one Working Days, subject to the total Bid/ Issue Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/ Issue Period, if applicable, will be published in all editions of the English national newspaper [●] and all editions of Hindi national newspaper [●], each with wide circulation and also by indicating the change on the websites of the Book Running Lead Manager.
- b) During the Bid/ Issue Period, Individual Bidders, should approach the Book Running Lead Manager or their authorized agents to register their Bids. The Book Running Lead Manager shall accept Bids from Anchor Investors and ASBA Bidders in Specified Cities and it shall have the right to vet the Bids during the Bid/ Issue Period in accordance with the terms of the Red Herring Prospectus. ASBA Bidders should approach the Designated Branches or the Book Running Lead Manager (for the Bids to be submitted in the Specified Cities) to register their Bids.
- c) Each Bid cum Application Form will give the Bidder the choice to Bid for up to three optional prices (for details refer to the paragraph titled “Bids at Different Price Levels and Revision of Bids” below) within the Price Band and specify the demand (i.e., the number of Equity Shares Bid for) in each option. The price and demand options submitted by the Bidder in the Bid cum Application Form will be treated as optional demands from the Bidder and will not be cumulated. After determination of the Issue Price, the maximum number of Equity Shares Bid for by a Bidder/Applicant at or above the Issue Price will be considered for allocation/Allotment and the rest of the Bid(s), irrespective of the Bid Amount, will become automatically invalid.
- d) The Bidder/ Applicant cannot Bid through another Bid cum Application Form after Bids through one Bid cum Application Form have been submitted to a Book Running Lead Manager or the SCSBs. Submission of a second Bid cum Application Form to either the same or to another Book Running Lead Manager or SCSB will be treated as multiple Bid and is liable to be rejected either before entering the Bid into the electronic bidding system, or at any point of time prior to the allocation or Allotment of Equity Shares in this Issue. However, the Bidder can revise the Bid through the Revision Form, the procedure for which is detailed under the paragraph “Buildup of the Book and Revision of Bids”.
- e) Except in relation to the Bids received from the Anchor Investors, the Book Running Lead Manager /the SCSBs will enter each Bid option into the electronic bidding system as a separate Bid and generate a Transaction Registration Slip, (“TRS”),

for each price and demand option and give the same to the Bidder. Therefore, a Bidder can receive up to three TRSs for each Bid cum Application Form

- f) The Book Running Lead Manager shall accept the Bids from the Anchor Investors during the Anchor Investor Bid/ Issue Period i.e. one working day prior to the Bid/ Issue Opening Date. Bids by QIBs under the Anchor Investor Portion and the QIB Portion shall not be considered as multiple Bids.
- g) Along with the Bid cum Application Form, Anchor Investors will make payment in the manner described in “*Escrow Mechanism - Terms of payment and payment into the Escrow Accounts*” in the section “**Issue Procedure**” beginning on page 273 of this Draft Red Herring Prospectus
- h) Upon receipt of the Bid cum Application Form, submitted whether in physical or electronic mode, the Designated Branch of the SCSB shall verify if sufficient funds equal to the Bid Amount are available in the ASBA Account, as mentioned in the Bid cum Application Form prior to uploading such Bids with the Stock Exchange.
- i) If sufficient funds are not available in the ASBA Account, the Designated Branch of the SCSB shall reject such Bids and shall not upload such Bids with the Stock Exchange.
- j) If sufficient funds are available in the ASBA Account, the SCSB shall block an amount equivalent to the Bid Amount mentioned in the Bid cum Application Form and will enter each Bid option into the electronic bidding system as a separate Bid and generate a TRS for each price and demand option. The TRS shall be furnished to the ASBA Bidder on request.
- k) The Bid Amount shall remain blocked in the aforesaid ASBA Account until finalisation of the Basis of Allotment and consequent transfer of the Bid Amount against the Allotted Equity Shares to the Public Issue Account, or until withdrawal/failure of the Issue or until withdrawal/rejection of the Bid cum Application Form, as the case may be. Once the Basis of Allotment is finalized, the Registrar to the Issue shall send an appropriate request to the SCSB for unblocking the relevant ASBA Accounts and for transferring the amount allocable to the successful Bidders to the Public Issue Account. In case of withdrawal/failure of the Issue, the blocked amount shall be unblocked on receipt of such information from the Registrar to the Issue.

BIDS AT DIFFERENT PRICE LEVELS AND REVISION OF BIDS

- a. Our Company in consultation with the Book Running Lead Manager, and without the prior approval of, or intimation, to the Bidders, reserves the right to revise the Price Band during the Bid/ Issue Period, provided that the Cap Price shall be less than or equal to 120% of the Floor Price and the Floor Price shall not be less than the face value of the Equity Shares. The revision in Price Band shall not exceed 20% on the either side i.e. the floor price can move up or down to the extent of 20% of the floor price disclosed. If the revised price band decided, falls within two different price bands than the minimum application lot size shall be decided based on the price band in which the higher price falls into.
- b. Our Company in consultation with the Book Running Lead Manager, will finalize the Issue Price within the Price Band, without the prior approval of, or intimation, to the Bidders.
- c. The Bidders can Bid at any price within the Price Band. The Bidder has to Bid for the desired number of Equity Shares at a specific price.
- d. The price of the specified securities Issued to an anchor investor shall not be lower than the price Issued to other applicants.

Participation by Associates /Affiliates of Book Running Lead Manager and the Syndicate Members

The Book Running Lead Manager and the Syndicate Members, if any, shall not be allowed to purchase in this Issue in any manner, except towards fulfilling their underwriting obligations. However, the associates and affiliates of the Book Running Lead Manager and the Syndicate Members, if any, may subscribe the Equity Shares in the Issue, either in the QIB Category or in the Non-Institutional Category as may be applicable to such Bidders, where the allocation is on a proportionate basis and such subscription may be on their own account or on behalf of their clients. All categories of investors, including associates or affiliates of the BRLMs and Syndicate Members, shall be treated equally for the purpose of allocation.

Neither the Book Running Lead Manager nor any persons related to the Book Running Lead Manager (other than Mutual Funds sponsored by entities related to the Book Running Lead Manager), Promoters and Promoter Group can apply in the Issue under the Anchor Investor Portion. Further, the member of the Promoter Group shall not participate by applying for Equity Shares. Further, persons related to the Promoter and Promoter Group shall not apply in the Issue under the Anchor Investor Portion.

Further, an Anchor Investor shall be deemed to be an associate of the BRLMs, if: (a) either of them controls, directly or indirectly through its subsidiary or holding company, not less than 15% of the voting rights in the other; or (b) either of them, directly or indirectly, by itself or in combination with other persons, exercises control over the other; or (c) there is a common director, excluding a nominee director, among the Anchor Investor and the BRLMs.

Option to Subscribe in the Issue

- a. As per Section 29(1) of the Companies Act 2013, allotment of Equity Shares shall be made in dematerialized form only. Investors will not have the option of getting allotment of specified securities in physical form.
- b. The Equity Shares, on allotment, shall be traded on the Stock Exchange in demat segment only.
- c. A single application from any investor shall not exceed the investment limit/minimum number of Equity Shares that can be held by him/her/it under the relevant regulations/statutory guidelines and applicable law.

Information for the Bidders

1. Our Company and the Book Running Lead Manager shall declare the Bid/ Issue Opening Date and Bid/ Issue Closing Date in the Red Herring Prospectus to be file with the ROC and also publish the same in two national newspapers (one each in English and Hindi) and Gujarati Edition of Regional newspaper [●] where the registered office of the company is situated, with wide circulation. This advertisement shall be in prescribed format.
2. Our Company will file the Red Herring Prospectus with the RoC at least 3 (three) days before the Bid/ Issue Opening Date.
3. Copies of the Bid Cum Application Form along with Abridge Prospectus and copies of the Red Herring Prospectus will be available with the, the Book Running Lead Manager, the Registrar to the Issue, and at the Registered Office of our Company. Electronic Bid Cum Application Forms will also be available on the websites of the Stock Exchange.
4. Any Bidder who would like to obtain the Draft Red Herring Prospectus and/ or the Bid Cum Application Form can obtain the same from our Registered Office.
5. Bidders who are interested in subscribing for the Equity Shares should approach Designated Intermediaries to register their applications.
6. Bid Cum Application Forms submitted directly to the SCSBs should bear the stamp of the SCSBs and/or the Designated Branch, or the respective Designated Intermediaries. Bid Cum Application Form submitted by Applicants whose beneficiary account is inactive shall be rejected.
7. The Bid Cum Application Form can be submitted either in physical or electronic mode, to the SCSBs with whom the ASBA Account is maintained, or other Designated Intermediaries (Other than SCSBs). SCSBs may provide the electronic mode of collecting either through an internet enabled collecting and banking facility or such other secured, electronically enabled mechanism for applying and blocking funds in the ASBA Account. The Individual Applicants may apply through UPI Channel, they have to provide the UPI ID and validate the blocking of the funds and such Bid Cum Application Forms that do not contain such details are liable to be rejected.
8. Bidders applying directly through the SCSBs should ensure that the Bid Cum Application Form is submitted to a Designated Branch of SCSB, where the ASBA Account is maintained. Applications submitted directly to the SCSB's or other Designated Intermediaries (Other than SCSBs), the relevant SCSB, shall block an amount in the ASBA Account equal to the Application Amount specified in the Bid Cum Application Form, before entering the ASBA application into the electronic system.

9. Except for applications by or on behalf of the Central or State Government and the Officials appointed by the courts and by investors residing in the State of Sikkim, the Bidders, or in the case of application in joint names, the first Bidder (the first name under which the beneficiary account is held), should mention his/her PAN allotted under the Income Tax Act. In accordance with the SEBI Regulations, the PAN would be the sole identification number for participating transacting in the securities market, irrespective of the amount of transaction. Any Bid Cum Application Form without PAN is liable to be rejected. The demat accounts of Bidders for whom PAN details have not been verified, excluding person resident in the State of Sikkim or persons who may be exempted from specifying their PAN for transacting in the securities market, shall be “suspended for credit” and no credit of Equity Shares pursuant to the Issue will be made into the accounts of such Bidders.
10. The Bidders may note that in case the PAN, the DP ID and Client ID mentioned in the Bid Cum Application Form and entered into the electronic collecting system of the Stock Exchange Designated Intermediaries do not match with PAN, the DP ID and Client ID available in the Depository database, the Bid Cum Application Form is liable to be rejected.

BIDS BY ANCHOR INVESTORS:

Our Company in consultation with the Book Running Lead Manager, may consider participation by Anchor Investors in the Issue for up to 60% of the QIB Portion in accordance with the SEBI Regulations. Only QIBs as defined in Regulation 2(1) (ss) of the SEBI Regulations and not otherwise excluded pursuant to Schedule XIII of the SEBI Regulations are eligible to invest. The QIB Portion will be reduced in proportion to allocation under the Anchor Investor Portion. In the event of undersubscription in the Anchor Investor Portion, the balance Equity Shares will be added to the QIB Portion. In accordance with the SEBI Regulations, the key terms for participation in the Anchor Investor Portion are provided below.

- 1) Anchor Investor Bid cum Application Forms will be made available for the Anchor Investors at the offices of the Book Running Lead Manager.
- 2) The Bid must be for a minimum of such number of Equity Shares so that the Bid Amount is at least ₹200.00 lakhs. A Bid cannot be submitted for over 60% of the QIB Portion. In case of a Mutual Fund, separate Bids by individual schemes of a Mutual Fund will be aggregated to determine the minimum application size of ₹200.00 lakhs
- 3) One-third of the Anchor Investor Portion will be reserved for allocation to domestic Mutual Funds.
- 4) Bidding for Anchor Investors will open one Working Day before the Bid/ Issue Opening Date and be completed on the same day.
- 5) Our Company in consultation with the Book Running Lead Manager, will finalize allocation to the Anchor Investors on a discretionary basis, provided that the minimum and maximum number of Allottees in the Anchor Investor Portion will be, as mentioned below:
 - where allocation in the Anchor Investor Portion is up to ₹ 200.00 Lakhs, maximum of 2 (two) Anchor Investors.
 - where the allocation under the Anchor Investor Portion is more than ₹ 200.00 Lakhs but upto ₹ 2500.00 Lakhs, minimum of 2 (two) and maximum of 15 (fifteen) Anchor Investors, subject to a minimum Allotment of ₹ 100.00 Lakhs per Anchor Investor; and
 - where the allocation under the Anchor Investor portion is more than ₹ 2500.00 Lakhs:(i) minimum of 5 (five) and maximum of 15 (fifteen) Anchor Investors for allocation upto ₹ 2500.00 Lakhs; and (ii) an additional 10 Anchor Investors for every additional allocation of ₹ 2500.00 Lakhs or part thereof in the Anchor Investor Portion; subject to a minimum Allotment of ₹ 100.00 Lakhs per Anchor Investor.
- 6) Allocation to Anchor Investors will be completed on the Anchor Investor Bid/ Issue Period. The number of Equity Shares allocated to Anchor Investors and the price at which the allocation is made will be made available in the public domain by the Book Running Lead Manager before the Bid/Issue Opening Date, through intimation to the Stock Exchange.
- 7) Anchor Investors cannot withdraw or lower the size of their Bids at any stage after submission of the Bid.
- 8) If the Issue Price is greater than the Anchor Investor Allocation Price, the additional amount being the difference between the Issue Price and the Anchor Investor Allocation Price will be payable by the Anchor Investors within 2 (two) Working

Days from the Bid/ Issue Closing Date. If the Issue Price is lower than the Anchor Investor Allocation Price, Allotment to successful Anchor Investors will be at the higher price, i.e., the Anchor Investor Issue Price.

- 9) At the end of each day of the bidding period, the demand including allocation made to anchor investors, shall be shown graphically on the bidding terminals of syndicate members and website of stock exchange offering electronically linked transparent bidding facility, for information of public.
- 10) 50% of the Equity Shares Allotted to Anchor Investors in the Anchor Investor Portion shall be locked in for a period of 90 days from the date of Allotment, while the remaining 50% of the Equity Shares Allotted to Anchor Investors in the Anchor Investor Portion shall be locked in for a period of 30 days from the date of Allotment.
- 11) The Book Running Lead Manager, our Promoters, Promoter Group or any person related to them (except for Mutual Funds sponsored by entities related to the Book Running Lead Manager) will not participate in the Anchor Investor Portion. The parameters for selection of Anchor Investors will be clearly identified by the Book Running Lead Manager and made available as part of the records of the Book Running Lead Manager for inspection by SEBI.
- 12) Bids made by QIBs under both the Anchor Investor Portion and the QIB Portion will not be considered multiple Bids.
- 13) Anchor Investors are not permitted to Bid in the Issue through the ASBA process.

BIDS BY ELIGIBLE NRI'S:

Eligible NRIs may obtain copies of Bid cum Application Form from the offices of the Book Running Lead Manager and the Designated Intermediaries. Eligible NRI Bidders bidding on a repatriation basis by using the Non- Resident Forms should authorize their SCSB to block their Non-Resident External ("NRE") accounts, or Foreign Currency Non-Resident ("FCNR") ASBA Accounts, and eligible NRI Bidders bidding on a non-repatriation basis by using Resident Forms should authorize their SCSB to block their Non- Resident Ordinary ("NRO") accounts for the full Bid Amount, at the time of the submission of the Bid cum Application Form.

- Eligible NRIs bidding on non-repatriation basis are advised to use the Bid cum Application Form for residents ([●] in colour).
- Eligible NRIs bidding on a repatriation basis are advised to use the Bid cum Application Form meant for Non-Residents ([●] in colour).

BIDS BY FPI INCLUDING FIH'S:

In terms of the SEBI FPI Regulations, the issue of Equity Shares to a single FPI including its investor group (which means multiple entities registered as FPIs and directly or indirectly having common ownership of more than 50% or common control) must be below 10% of the post-Offer paid-up capital.

In case of Bids made by FPIs, a certified copy of the certificate of registration issued under the SEBI FPI Regulations is required to be attached to the Bid cum Application Form, failing which our Company reserves the right to reject any Bid without assigning any reason. FPIs who wish to participate in the Offer are advised to use the Bid cum Application Form for Non-Residents ([●] in colour).

If the total holding of an FPI increases beyond 10% of the total paid-up Equity Share capital, on a fully diluted basis or 10% or more of the paid-up value of any series of debentures or preference shares or share warrants issued that may be issued by our Company, the total investment made by the FPI will be re-classified as FDI subject to the conditions as specified by SEBI and the RBI in this regard and our Company and the investor will be required to comply with applicable reporting requirements. Further, the total holdings of all FPIs put together, with effect from April 1, 2020, can be up to the sectoral cap applicable to the sector in which our Company operates.

In terms of the FEMA Regulations, for calculating the aggregate holding of FPIs in a company, holding of all registered FPIs shall be included.

The FEMA Non-Debt Instruments Rules was enacted on October 17, 2019 in supersession of the Foreign Exchange Management (Transfer or Issue of Security by a Person Resident Outside India) Regulations, 2017, except as respects things done or omitted to be done before such supersession. FPIs are permitted to participate in the Offer subject to compliance with conditions and restrictions which may be specified by the Government from time to time.

To ensure compliance with the above requirement, SEBI, pursuant to its circular dated July 13, 2018, has directed that at the time of finalisation of the Basis of Allotment, the Registrar shall (i) use the PAN issued by the Income Tax Department of India for checking compliance for a single FPI; and (ii) obtain validation from Depositories for the FPIs who have invested in the Offer to ensure there is no breach of the investment limit, within the timelines for issue procedure, as prescribed by SEBI from time to time.

Subject to compliance with all applicable Indian laws, rules, regulations, guidelines and approvals in terms of Regulation 21 of the SEBI FPI Regulations, an FPI, may issue, subscribe to or otherwise deal in offshore derivative instruments (as defined under the SEBI FPI Regulations as any instrument, by whatever name called, which is issued overseas by a FPI against securities held by it in India, as its underlying) directly or indirectly, only in the event (i) such offshore derivative instruments are issued only by persons registered as Category I FPIs; (ii) such offshore derivative instruments are issued only to persons eligible for registration as Category I FPIs; (iii) such offshore derivative instruments are issued after compliance with 'know your client' norms as specified by SEBI; and (iv) such other conditions as may be specified by SEBI from time to time.

An FPI is required to ensure that the transfer of an offshore derivative instruments issued by or on behalf of it, is subject to (a) the transfer being made to persons which fulfil the criteria provided under the SEBI FPI Regulations (as mentioned above from points (a) to (d)); and (b) prior consent of the FPI is obtained for such transfer, except in cases, where the persons to whom the offshore derivative instruments are to be transferred, are pre-approved by the FPI.

Bids by following FPIs, submitted with the same PAN but with different beneficiary account numbers, Client IDs and DP IDs shall not be treated as multiple Bids:

- FPIs which utilise the multi investment manager ("MIM") structure
- Offshore derivative instruments which have obtained separate FPI registration for ODI and proprietary derivative investments
- Sub funds or separate class of investors with segregated portfolio who obtain separate FPI registration
- FPI registrations granted at investment strategy level/sub fund level where a collective investment scheme or fund has multiple investment strategies/sub-funds with identifiable differences and managed by a single investment manager
- Multiple branches in different jurisdictions of foreign bank registered as FPIs
- Government and Government related investors registered as Category 1 FPIs; and
- Entities registered as collective investment scheme having multiple share classes.

The Bids belonging to any of the above mentioned seven structures and having same PAN may be collated and identified as a single Bid in the Bidding process. The Equity Shares allotted in the Bid may be proportionately distributed to the applicant FPIs (with same PAN).

In order to ensure valid Bids, FPIs making multiple Bids using the same PAN, and with different beneficiary account numbers, Client IDs and DP IDs, are required to provide a confirmation along with each of their Bid cum Application Forms that the relevant FPIs making multiple Bids utilize any of the above-mentioned structures and indicate the name of their respective investment managers in such confirmation. In the absence of such confirmation from the relevant FPIs, such multiple Bids shall be rejected.

The FPIs who wish to participate in the Offer are advised to use the Bid cum Application Form for non-residents.

BIDS BY SEBI REGISTERED VCF'S, AIF'S AND FVCI'S:

The SEBI FVCI Regulations and the SEBI AIF Regulations inter-alia prescribe the investment restrictions on the VCFs, FVCIs and AIFs registered with SEBI. Further, the SEBI AIF Regulations prescribe, among others, the investment restrictions on AIF's.

The holding by any individual VCF registered with SEBI in one venture capital undertaking should not exceed 25% of the

corpus of the VCF. Further, VCFs and FVCIs can invest only up to 33.33% of the investible funds by way of subscription to an initial public offering.

The category I and II AIFs cannot invest more than 25% of the corpus in one Investee Company. A category III AIF cannot invest more than 10% of the corpus in one Investee Company. A venture capital fund registered as a category I AIF, as defined in the SEBI AIF Regulations, cannot invest more than 1/3rd of its corpus by way of subscription to an initial public offering of a venture capital undertaking. Additionally, the VCFs which have not re-registered as an AIF under the SEBI AIF Regulations shall continue to be regulated by the VCF Regulation until the existing fund or scheme managed by the fund is wound up and such funds shall not launch any new scheme after the notification of the SEBI AIF Regulations.

All FIIs and FVCIs should note that refunds, dividends and other distributions, if any, will be payable in Indian Rupees only and net of Bank charges and commission.

Our Company or the Book Running Lead Manager will not be responsible for loss, if any, incurred by the Bidder on account of conversion of foreign currency.

There is no reservation for Eligible NRIs, FPIs and FVCIs and all Bidders will be treated on the same basis with other categories for the purpose of allocation.

BIDS BY HUFs:

Hindu Undivided Families or HUFs, in the individual name of the Karta. The Bidder should specify that the Application is being made in the name of the HUF in the Bid cum Application Form as follows: "Name of sole or first Applicant: XYZ Hindu Undivided Family applying through XYZ, where XYZ is the name of the Karta". Bid cum Applications by HUFs may be considered at par with Bid cum Applications from individuals.

BIDS BY MUTUAL FUNDS:

No Mutual Fund scheme shall invest more than 10% of its net asset value in equity shares or equity related instruments of any single company provided that the limit of 10% shall not be applicable for investments in index funds or sector or industry specific funds. No Mutual Fund under all its schemes should own more than 10% of any company's paid-up share capital carrying voting rights.

With respect to Bids by Mutual Funds, a certified copy of their SEBI registration certificate must be lodged with the Bid cum Application Form. Failing this, our Company reserves the right to accept or reject any Bid cum Application in whole or in part, in either case, without assigning any reason thereof.

In case of a mutual fund, a separate Bid cum Application can be made in respect of each scheme of the mutual fund registered with SEBI and such Applications in respect of more than one scheme of the mutual fund will not be treated as multiple applications provided that the Bids clearly indicate the scheme concerned for which the Bids has been made.

The Bids made by the asset management companies or custodians of Mutual Funds shall specifically state the names of the concerned schemes for which the Applications are made.

BIDS BY SYSTEMATICALLY IMPORTANT NON-BANKING FINANCIAL COMPANIES:

In case of applications made by Systemically Important Non-Banking Financial Companies, a certified copy of the certificate of registration issued by the RBI, a certified copy of its last audited financial statements on a standalone basis and a net worth certificate from its statutory auditor(s), must be attached to the Bid cum Application Form. Failing this, our Company reserve the right to reject any Application, without assigning any reason thereof. Systemically Important Non-Banking Financial Companies participating in the Issue shall comply with all applicable legislations, regulations, directions, guidelines and circulars issued by RBI from time to time.

BIDS BY LIMITED LIABILITY PARTNERSHIPS:

In case of Bids made by limited liability partnerships registered under the Limited Liability Partnership Act, 2008, a certified copy of certificate of registration issued under the Limited Liability Partnership Act, 2008, must be attached to the Bid cum

Application Form. Failing this, our Company reserves the right to reject any bid without assigning any reason thereof. Limited liability partnerships can participate in the Issue only through the ASBA process.

BIDS BY INSURANCE COMPANIES:

In case of Bids made by insurance companies registered with the IRDA, a certified copy of certificate of registration issued by IRDA must be attached to the Bid cum Application Form. Failing this, our Company reserves the right to reject any Bid by Insurance Companies without assigning any reason thereof.

The exposure norms for insurers are prescribed under the IRDAI Investment Regulations, based on investments in equity shares of the investee company, the entire group of the investee company and the industry sector in which the investee company operates. Insurance companies participating in the Issue are advised to refer to the IRDAI Investment Regulations for specific investment limits applicable to them and comply with all applicable regulations, guidelines and circulars issued by the IRDAI from time to time.

BIDS UNDER POWER OF ATTORNEY:

In case of Bids made pursuant to a power of attorney or by limited companies, corporate bodies, registered societies, FIIs, Mutual Funds, insurance companies and provident funds with a minimum corpus of ₹ 2500 Lakhs (subject to applicable law) and pension funds with a minimum corpus of ₹2500 Lakhs, a certified copy of the power of attorney or the relevant resolution or authority, as the case may be, along with a certified copy of the memorandum of association and articles of association and/or bye laws must be lodged along with the Bid cum Application Form. Failing this, our Company, in consultation with the BRLMs, reserves the right to accept or reject any Bid in whole or in part, in either case without assigning any reason therefor. In addition to the above, certain additional documents are required to be submitted by the following entities:

- a) With respect to Bids by FIIs and Mutual Funds, a certified copy of their SEBI registration certificate must be lodged along with the Bid cum Application Form.
- b) With respect to Bids by insurance companies registered with the Insurance Regulatory and Development Authority, in addition to the above, a certified copy of the certificate of registration issued by the Insurance Regulatory and Development Authority must be lodged along with the Bid cum Application Form.
- c) With respect to Bids made by provident funds with a minimum corpus of ₹ 2500 Lakhs (subject to applicable law) and pension funds with a minimum corpus of ₹ 2500 Lakhs, a certified copy of a certificate from a chartered accountant certifying the corpus of the provident fund/pension fund must be lodged along with the Bid cum Application Form.
- d) With respect to Bids made by limited liability partnerships registered under the Limited Liability Partnership Act, 2008, a certified copy of certificate of registration issued under the Limited Liability Partnership Act, 2008, must be attached to the Bid cum Application Form
- e) Our Company in consultation with the Book Running Lead Manager in their absolute discretion, reserves the right to relax the above condition of simultaneous lodging of the power of attorney along with the Bid cum Application form, subject to such terms and conditions that our Company and the Book Running Lead Manager may deem fit.

BIDS BY PROVIDENT FUNDS / PENSION FUNDS:

In case of Bids made by provident funds with minimum corpus of ₹25 Crore (subject to applicable law) and pension funds with minimum corpus of ₹ 25 Crore, a certified copy of certificate from a chartered accountant certifying the corpus of the provident fund/ pension fund must be lodged along with the Bid cum Application Form. Failing this, the Company reserves the right to accept or reject any bid in whole or in part, in either case, without assigning any reason thereof.

BIDS BY BANKING COMPANY:

In case of Bids made by banking companies registered with RBI, certified copies of: (i) the certificate of registration issued by RBI, and (ii) the approval of such banking company's investment committee are required to be attached to the Bid cum Application Form, failing which our Company reserves the right to reject any Bid by a banking company without assigning

any reason.

The investment limit for banking companies in non-financial services companies as per the Banking Regulation Act, 1949, as amended (the “Banking Regulation Act”), and the Reserve Bank of India (Financial Services provided by Banks) Directions, 2016, is 10% of the paid-up share capital of the investee company not being its subsidiary engaged in non-financial services or 10% of the banks’ own paid-up share capital and reserves, whichever is lower. However, a banking company would be permitted to invest in excess of 10% but not exceeding 30% of the paid-up share capital of such investee company if (i) the investee company is engaged in non-financial activities permitted for banks in terms of Section 6(1) of the Banking Regulation Act, or (ii) the additional acquisition is through restructuring of debt / corporate debt restructuring / strategic debt restructuring, or to protect the banks’ interest on loans / investments made to a company. The bank is required to submit a time bound action plan for disposal of such shares within a specified period to RBI.. A banking company must obtain prior RBI approval to make: (i) investment in a subsidiary or in a financial services company that is not a subsidiary (subject to exemptions, including profitability, minimum capital, and prescribed holding limits under 10% individually and 20% cumulatively); and (ii) investment in a non-financial services company exceeding 10% of such investee’s paid-up share capital, as specified under Clause 5(a)(v)(c)(i) of the Reserve Bank of India (Financial Services provided by Banks) Directions, 2016

BIDS BY SCSB’S:

SCSBs participating in the Issue are required to comply with the terms of the SEBI circulars dated September 13, 2012 and January 2, 2013. Such SCSBs are required to ensure that for making Bid cum Applications on their own account using ASBA, they should have a separate account in their own name with any other SEBI registered SCSBs. Further, such account shall be used solely for the purpose of making Bid cum application in public Issues and clear demarcated funds should be available in such account for such Bid cum applications.

In accordance with existing regulations issued by the RBI, OCBs cannot participate in the Issue.

The Equity Shares offered in the Issue have not been and will not be registered under the U.S. Securities Act of 1933, as amended, or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, such Equity Shares are being offered and sold outside of the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur.

The above information is given for the benefit of the Bidders. Our Company, the Promoter and the BRLMs are not liable for any amendments or modification or changes in applicable laws or regulations, which may occur after the date of this Draft Red Herring Prospectus. Bidders are advised to make their independent investigations and ensure that any single Bid from them does not exceed the applicable investment limits or maximum number of the Equity Shares that can be held by them under applicable law or regulation or as specified in this Draft Red Herring Prospectus, or as will be specified in the Red Herring Prospectus/Prospectus

ISSUANCE OF A CONFIRMATION NOTE (“CAN”) AND ALLOTMENT IN THE ISSUE:

1. Upon approval of the basis of allotment by the Designated Stock Exchange, the Book Running Lead Manager or Registrar to the Issue shall send to the SCSBs a list of their Bidders who have been allocated Equity Shares in the Issue.
2. The Registrar will then dispatch a CAN to their Bidders who have been allocated Equity Shares in the Issue. The dispatch of a CAN shall be deemed a valid, binding and irrevocable contract for the Bidder

Issue Procedure for Application Supported by Blocked Account (ASBA) Bidders

In accordance with the SEBI Circular No. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 all the Bidders have to compulsorily apply through the ASBA Process. Our Company and the Book Running Lead Manager are not liable for any amendments, modifications, or changes in applicable laws or regulations, which may occur after the date of this Draft Red Herring Prospectus. ASBA Bidders are advised to make their independent investigations and to ensure that the ASBA Bid Cum Application Form is correctly filled up, as described in this section.

The lists of banks that have been notified by SEBI to act as SCSB (Self Certified Syndicate Banks) for the ASBA Process are

provided on <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes>. For details on designated branches of SCSB collecting the Bid Cum Application Form, please refer the above-mentioned SEBI link.

Terms of payment

The entire Issue price of ₹ [●] per share is payable on application. In case of allotment of lesser number of Equity Shares than the number applied, the Registrar shall instruct the SCSBs to unblock the excess amount paid on Application to the Bidders.

SCSBs will transfer the amount as per the instruction of the Registrar to the Public Issue Account, the balance amount after transfer will be unblocked by the SCSBs.

The Bidders should note that the arrangement with Bankers to the Issue or the Registrar is not prescribed by SEBI and has been established as an arrangement between our Company, Banker to the Issue and the Registrar to the Issue to facilitate collections from the Bidders.

Payment mechanism

The Bidders shall specify the bank account number in their Bid Cum Application Form and the SCSBs shall block an amount equivalent to the Application Amount in the bank account specified in the Bid Cum Application Form. The SCSB shall keep the Application Amount in the relevant bank account blocked until rejection of the Application or receipt of instructions from the Registrar to unblock the Application Amount. However, Bidders shall not be allowed to either withdraw or lower the size of their applications at any stage. In the event of rejection of the Bid Cum Application Form or for unsuccessful Bid Cum Application Forms, the Registrar to the Issue shall give instructions to the SCSBs to unblock the application money in the relevant bank account within one day of receipt of such instruction. The Application Amount shall remain blocked in the ASBA Account until finalization of the Basis of Allotment in the Issue and consequent transfer of the Application Amount to the Public Issue Account, or until withdrawal/failure of the Issue or until rejection of the Application by the ASBA Bidder, as the case may be.

Please note that, in terms of SEBI Circular No. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, all the investors applying in a public Issue shall use only Application Supported by Blocked Amount (ASBA) process for application providing details of the bank account which will be blocked by the Self-Certified Syndicate Banks (SCSBs) for the same. Further, pursuant to SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 01, 2018, Individual Investors applying in public Issue have to use UPI as a payment mechanism with Application Supported by Blocked Amount for making application.

Payment into Escrow Account for Anchor Investors

All the investors other than Anchor Investors are required to bid through ASBA Mode. Anchor Investors are requested to note the following:

Our Company in consultation with the Book Running Lead Manager, in its absolute discretion, will decide the list of Anchor Investors to whom the CAN will be sent, pursuant to which the details of the Equity Shares allocated to them in their respective names will be notified to such Anchor Investors. For Anchor Investors, the payment instruments for payment into the Escrow Account should be drawn in favour of:

- In case of resident Anchor Investors: “[●]”
- In case of Non-Resident Anchor Investors: “[●]”

Bidders should note that the escrow mechanism is not prescribed by SEBI and has been established as an arrangement between our Company, the Syndicate, the Escrow Collection Bank and the Registrar to the Issue to facilitate collections from the Anchor Investors.

Electronic Registration of Applications

1. The Designated Intermediaries will register the applications using the on-line facilities of the Stock Exchange.

2. The Designated Intermediaries will undertake modification of selected fields in the application details already uploaded before 5.00 p.m. of the Issue Closing Date.
3. The Designated Intermediaries shall be responsible for any acts, mistakes or errors or omissions and commissions in relation to,
 - a) the applications accepted by them,
 - b) the applications uploaded by them
 - c) the applications accepted but not uploaded by them or
 - d) With respect to applications by Bidders, applications accepted and uploaded by any Designated Intermediary other than SCSBs, the Bid Cum Application Form along with relevant schedules shall be sent to the SCSBs or the Designated Branch of the relevant SCSBs for blocking of funds and they will be responsible for blocking the necessary amounts in the ASBA Accounts. In case of Application accepted and Uploaded by SCSBs, the SCSBs or the Designated Branch of the relevant SCSBs will be responsible for blocking the necessary amounts in the ASBA Accounts.
4. Neither the Book Running Lead Manager nor our Company nor the Registrar to the Issue, shall be responsible for any acts, mistakes or errors or omission and commissions in relation to,
 - (i) The applications accepted by any Designated Intermediaries
 - (ii) The applications uploaded by any Designated Intermediaries or
 - (iii) The applications accepted but not uploaded by any Designated Intermediaries
5. The Stock Exchange will Issue an electronic facility for registering applications for the Issue. This facility will be available at the terminals of Designated Intermediaries and their authorized agents during the Issue Period. The Designated Branches or agents of Designated Intermediaries can also set up facilities for off-line electronic registration of applications subject to the condition that they will subsequently upload the off-line data file into the online facilities on a regular basis. On the Issue Closing Date, the Designated Intermediaries shall upload the applications till such time as may be permitted by the Stock Exchange. This information will be available with the Book Running Lead Manager on a regular basis.
6. With respect to applications by Bidders, at the time of registering such applications, the Syndicate members, DPs and RTAs shall forward a Schedule as per format given below along with the Bid Cum Application Forms to Designated Branches of the SCSBs for blocking of funds:

S. No.	Details*
1.	Symbol
2.	Intermediary Code
3.	Location Code
4.	Application No.
5.	Category
6.	PAN
7.	DP ID
8.	Client ID
9.	Quantity
10.	Amount

**Stock Exchanges shall uniformly prescribe character length for each of the above-mentioned fields*

7. With respect to applications by Bidders, at the time of registering such applications, the Designated Intermediaries shall enter the following information pertaining to the Bidders into the on-line system:
 - Name of the Bidder;
 - IPO Name;
 - Bid Cum Application Form Number;
 - Investor Category;
 - PAN (of First Bidder, if more than one Bidder);
 - DP ID of the demat account of the Bidder;
 - Client Identification Number of the demat account of the Bidder;

- Number of Equity Shares Applied for;
 - Bank Account details;
 - Locations of the Banker to the Issue or Designated Branch, as applicable, and bank code of the SCSB branch where the ASBA Account is maintained; and
 - Bank account number.
8. In case of submission of the Application by a Bidder through the Electronic Mode, the Bidder shall complete the above-mentioned details and mention the bank account number, except the Electronic ASBA Bid Cum Application Form number which shall be system generated.
 9. The aforesaid Designated Intermediaries shall, at the time of receipt of application, give an acknowledgment to the investor, by giving the counter foil or specifying the application number to the investor, as a proof of having accepted the Bid Cum Application Form in physical as well as electronic mode. The registration of the Application by the Designated Intermediaries does not guarantee that the Equity Shares shall be allocated / allotted either by our Company.
 10. Such acknowledgment will be non-negotiable and by itself will not create any obligation of any kind.
 11. In case of Non- Institutional Bidders and Individual Bidders, applications would not be rejected except on the technical grounds as mentioned in the Draft Red Herring Prospectus. The Designated Intermediaries shall have no right to reject applications, except on technical grounds.
 12. The permission given by the Stock Exchanges to use their network and software of the Online IPO system should not in any way be deemed or construed to mean that the compliance with various statutory and other requirements by our Company and/or the Book Running Lead Manager are cleared or approved by the Stock Exchanges; nor does it in any manner warrant, certify or endorse the correctness or completeness of any of the compliance with the statutory and other requirements nor does it take any responsibility for the financial or other soundness of our company; our Promoter, our management or any scheme or project of our Company; nor does it in any manner warrant, certify or endorse the correctness or completeness of any of the contents of this Draft Red Herring Prospectus, nor does it warrant that the Equity Shares will be listed or will continue to be listed on the Stock Exchanges.
 13. The Designated Intermediaries will be given time till 5.00 p.m. on the Bid/Issue Closing Date to verify the DP ID and Client ID uploaded in the online IPO system during the Issue Period, after which the Registrar to the Issue will receive this data from the Stock Exchange and will validate the electronic application details with Depository's records. In case no corresponding record is available with Depositories, which matches the three parameters, namely DP ID, Client ID and PAN, then such applications are liable to be rejected.
 14. The SCSBs shall after the Bid/Issue Closing Date send confirmation of Funds blocked (Final certificate) to the Registrar to the Issue.
 15. The details uploaded in the online IPO system shall be considered as final and Allotment will be based on such details for applications.

Build of the Book

- a) Bids received from various Bidders through the Designated Intermediaries may be electronically uploaded on the Bidding Platform of the Stock Exchange on a regular basis. The book gets built up at various price levels. This information may be available with the Book Running Lead Manager at the end of the Bid/ Issue Period.
- b) Based on the aggregate demand and price for Bids registered on the Stock Exchange Platform, a graphical representation of consolidated demand and price as available on the websites of the Stock Exchange may be made available at the Bidding centres during the Bid/ Issue Period.

Withdrawal of Bids

None of the bidders can withdraw their Bids or lower the size of their Bids at any stage

Price Discovery and Allocation

- a) Based on the demand generated at various price levels, our Company in consultation with the Book Running Lead Manager, shall finalise the Issue Price and the Anchor Investor Issue Price.
- b) The SEBI (ICDR) Regulations, 2018 specify the allocation or Allotment that may be made to various categories of Bidders in an Issue depending on compliance with the eligibility conditions. Certain details pertaining to the percentage of Issue size available for allocation to each category is disclosed overleaf of the Bid cum Application Form and in the Red Herring Prospectus. For details in relation to allocation, the Bidder may refer to the Red Herring Prospectus.
- c) Under-subscription in any category (except QIB Category) is allowed to be met with spillover from any other category or combination of categories at the discretion of the Issuer and the in consultation with the Book Running Lead Manager and the Designated Stock Exchange and in accordance with the SEBI (ICDR) Regulations. Unsubscribed portion in QIB Category is not available for subscription to other categories.
- d) In case of under subscription in the Issue, spill-over to the extent of such under-subscription may be permitted from the Reserved Portion to the Issue. For allocation in the event of an undersubscription applicable to the Issuer, Bidders may refer to the Red Herring Prospectus.
- e) In case if the Individual Investor category is entitled to more than the allocated portion on proportionate basis, the category shall be allotted that higher percentage.
- f) Allocation to Anchor Investors shall be at the discretion of our Company and in consultation with the Book Running Lead Manager, subject to compliance with the SEBI Regulations.

Illustration of the Book Building and Price Discovery Process: Bidders should note that this example is solely for illustrative purposes and is not specific to the Issue; it also excludes Bidding by Anchor Investors. Bidders can bid at any price within the Price Band. For instance, assume a Price Band of ₹20 to ₹24 per share, Issue size of 3,000 Equity Shares and receipt of five Bids from Bidders, details of which are shown in the table below. The illustrative book given below shows the demand for the Equity Shares of the Issuer at various prices and is collated from Bids received from various investors.

Bid Quantity	Bid Amount (₹)	Cumulative Quantity	Subscription
500	24	500	16.67%
1,000	23	1,500	50.00%
1,500	22	3,000	100.00%
2,000	21	5,000	166.67%
2,500	20	7,500	250.00%

The price discovery is a function of demand at various prices. The highest price at which the Issuer is able to Issue the desired number of Equity Shares is the price at which the book cuts off, i.e., ₹22.00 in the above example. The Issuer, in consultation with the Book Running Lead Manager, may finalise the Issue Price at or below such Cut-Off Price, i.e., at or below ₹22.00. All Bids at or above this Issue Price are valid Bids and are considered for allocation in the respective categories.

Signing of Underwriting Agreement and Filing of Red Herring Prospectus/ Prospectus with RoC

- a) Our company has entered into an Underwriting Agreement dated [●]
- b) A copy of Red Herring Prospectus will be filed with the ROC and copy of Prospectus will be filed with ROC in terms of Section 32 of Companies Act, 2013 and Section 26 of Companies Act, 2013.

Pre-Issue and Price Band Advertisement

Subject to Section 30 of the Companies Act 2013, our Company shall, after filing the Red Herring Prospectus with the ROC, publish a pre-Issue and Price Band advertisement, in the form prescribed by the SEBI (ICDR) Regulations, in (i) English National Newspaper, (ii) Hindi National Newspaper and (iii) One Gujarati regional newspaper where the registered office of the Company is situated, each with wide circulation. In the pre-Issue and Price Band advertisement, we shall state the Bid Opening Date and the Bid/Issue Closing Date and the floor price or price band along with necessary details subject to regulation

250 of SEBI (ICDR) Regulations. This advertisement, subject to the provisions of section 30 of the Companies Act, 2013, shall be in the format prescribed in Part A of Schedule X of the SEBI Regulations.

ADVERTISEMENT REGARDING ISSUE PRICE AND PROSPECTUS:

Our Company will issue a statutory advertisement after the filing of the Red Herring Prospectus/ Prospectus with the RoC. This advertisement, in addition to the information that has to be set out in the statutory advertisement, shall indicate the final derived Issue Price. Any material updates between the date of the Red Herring Prospectus and the date of Prospectus will be included in such statutory advertisement.

GENERAL INSTRUCTIONS:

Please note that the Bidders are not permitted to withdraw their bids or lower the size of Bids in terms of quantity of Equity Shares or Bid Amount) at any stage. Further, anchor investors are not allowed to withdraw their Bids after Anchor Investors bidding date.

Do's:

1. Check if you are eligible to apply as per the terms of the Draft Red Herring Prospectus and under applicable law, rules, regulations, guidelines and approvals;
2. Ensure that you have Bid within the Price Band;
3. Read all the instructions carefully and complete the Bid cum Application Form in the prescribed form;
4. Ensure that the details about the PAN, DP ID, Client ID, UPI ID are correct and the Bidders depository account is active, as Allotment of the Equity Shares will be in the dematerialized form only;
5. Ensure that your Bid cum Application Form bearing the stamp of a Designated Intermediary is submitted to the Designated Intermediary at the Bidding Centre;
6. If the first applicant is not the account holder, ensure that the Bid cum Application Form is signed by the account holder. Ensure that you have mentioned the correct bank account number in the Bid cum Application Form;
7. In case of Joint bids, ensure the first bidder is the ASBA Account holder (or the UPI linked bank account holder, as the case may be) and the signature of the first bidder is included in the Bid cum Application Form;
8. QIBs, Non-Institutional Bidders and the Individual Bidders should submit their Bids through the ASBA process only. However, pursuant to SEBI circular dated November 01, 2018, Bidders may submit their bid by using UPI mechanism for payment.
9. Ensure that the name(s) given in the Bid cum Application Form is/are exactly the same as the name(s) in which the beneficiary account is held with the Depository Participant. In case of joint Bids, the Bid cum Application Form should contain only the name of the First Bidder whose name should also appear as the first holder of the beneficiary account held in joint names;
10. Ensure that you request for and receive a stamped acknowledgement of the Bid cum Application Form for all your Bid options;
11. Ensure that you have funds equal to the Bid Amount in the Bank Account maintained with the SCSB before submitting the Bid cum Application Form under the ASBA process or application forms submitted by Individual Investors using UPI mechanism for payment, to the respective member of the Syndicate (in the Specified Locations), the SCSBs, the Registered Broker (at the Broker Centres), the RTA (at the Designated RTA Locations) or CDP (at the Designated CDP Locations);
12. Submit revised Bids to the same Designated Intermediary, through whom the original Bid was placed and obtain a revised acknowledgment;
13. Except for Bids (i) on behalf of the Central or State Governments and the officials appointed by the courts, who, in terms of a SEBI circular dated June 30, 2008, may be exempt from specifying their PAN for transacting in the securities market, and (ii) Bids by persons resident in the state of Sikkim, who, in terms of a SEBI circular dated July 20, 2006, may be exempted from specifying their PAN for transacting in the securities market, all Bidders should mention their PAN allotted under the IT Act. The exemption for the Central or the State Government and officials appointed by the courts and for investors residing in the State of Sikkim is subject to (a) the Demographic Details received from the respective depositories confirming the exemption granted to the beneficiary owner by a suitable description in the PAN field and the beneficiary account remaining in "active status"; and (b) in the case of residents of Sikkim, the address as per the Demographic Details evidencing the same. All other applications in which PAN is not mentioned will be rejected;

14. Ensure that the Demographic Details are updated, true and correct in all respects;
15. Ensure that the signature of the First Bidder in case of joint Bids, is included in the Bid cum Application Forms;
16. Ensure that thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India are attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal;
17. Ensure that the category and the investor status is indicated;
18. Ensure that in case of Bids under power of attorney or by limited companies, corporate, trust etc., relevant documents are submitted;
19. Ensure that Bids submitted by any person outside India should be in compliance with applicable foreign and Indian laws;
20. Bidders should note that in case the DP ID, Client ID and the PAN mentioned in their Bid cum Application Form and entered into the online IPO system of the Stock Exchange by the relevant Designated Intermediary, as the case may be, do not match with the DP ID, Client ID and PAN available in the Depository database, then such Bids are liable to be rejected. Where the Bid cum Application Form is submitted in joint names, ensure that the beneficiary account is also held in the same joint names and such names are in the same sequence in which they appear in the Bid cum Application Form;
21. Ensure that the Bid cum Application Forms is delivered by the Bidders within the time prescribed as per the Bid cum Application Form and the Red Herring Prospectus;
22. Ensure that you have mentioned the correct ASBA Account number or UPI ID in the Bid cum Application Form;
23. Ensure that you have mentioned the details of your own bank account for blocking of fund or your own bank account linked UPI ID to make application in the Public Issue;
24. Ensure that on receipt of the mandate request from sponsor bank, you have taken necessary step in timely manner for blocking of fund on your account through UPI ID using UPI application;
25. Ensure that you have correctly signed the authorization / undertaking box in the Bid cum Application Form, or have otherwise provided an authorization to the SCSB via the electronic mode, for blocking funds in the ASBA Account equivalent to the Bid Amount mentioned in the Bid cum Application Form at the time of submission of the Bid;
26. Ensure that you receive an acknowledgement from the concerned Designated Intermediary, for the submission of your Bid cum Application Form; and

The Bid cum Application Form is liable to be rejected if the above instructions, as applicable, are not complied with.

Don'ts:

1. Do not Bid for lower than the minimum Bid size;
2. Do not Bid / revise Bid Amount to less than the Floor Price or higher than the Cap Price;
3. Do not pay the Bid Amount in cash, by money order, cheques or demand drafts or by postal order or by stock invest;
4. Do not send Bid cum Application Forms by post; instead submit the same to the Designated Intermediary only;
5. Do not submit the Bid cum Application Forms to any non-SCSB bank or our Company;
6. Do not Bid on a Bid cum Application Form that does not have the stamp of the relevant Designated Intermediary;
7. Do not Bid at Cut-off Price;
8. Do not instruct your respective Banks to release the funds blocked in the ASBA Account under the ASBA process;
9. Do not Bid for a Bid Amount for less than ₹ 2,00,000/-;
10. Do not Bid for a Bid Amount exceeding ₹ 500,000 (for Bids by UPI Bidders);
11. Do not fill up the Bid cum Application Form such that the Equity Shares Application exceeds the Issue size and / or investment limit or maximum number of the Equity Shares that can be held under the applicable laws or regulations or maximum amount permissible under the applicable regulations or under the terms of the Red Herring Prospectus;
12. Do not submit the General Index Register number instead of the PAN;
13. Do not submit the Bid without ensuring that funds equivalent to the entire Bid Amount are blocked in the relevant ASBA Account;
14. Do not submit Bids on plain paper or on incomplete or illegible Bid cum Application Forms or on Bid cum Application Forms in a colour prescribed for another category of Applicant;
15. Do not submit a Bid in case you are not eligible to acquire Equity Shares under applicable law or your relevant constitutional documents or otherwise;
16. Do not Bid if you are not competent to contract under the Indian Contract Act, 1872 (other than minors having valid depository accounts as per Demographic Details provided by the depository);
17. Do not submit a Bid by using details of the third party's bank account or UPI ID which is linked with bank account of

the third party. Kindly note that Bids made using third party bank account or using third party linked bank account UPI ID are liable for rejection.

The Bid cum Application Form is liable to be rejected if the above instructions, as applicable, are not complied with.

Other instructions for the Bidders

Joint Bids

In the case of Joint Bids, the Bids should be made in the name of the Bidders whose name appears first in the Depository account. The name so entered should be the same as it appears in the Depository records. The signature of only such first Bidders would be required in the Bid cum Application Form/Application Form and such first Bidder would be deemed to have signed on behalf of the joint holders. All payments may be made out in favour of the Bidder whose name appears in the Bid cum Application Form or the Revision Form and all communications may be addressed to such Bidder and may be dispatched to his or her address as per the Demographic Details received from the Depositories.

Multiple Bids

Bidder should submit only one Bid cum Application Form. Bidder shall have the option to make a maximum of Bids at three different price levels in the Bid cum Application Form and such options are not considered as multiple Bids. Submission of a second Bid cum Application Form to either the same or to another member of the Syndicate, SCSB or Registered Broker and duplicate copies of Bid\ cum Application Forms bearing the same application number shall be treated as multiple Bids and are liable to be rejected.

Investor Grievance

In case of any pre-Issue or post Issue related problems regarding demat credit/ refund orders/ unblocking etc. the Investors can contact the Compliance Officer of our Company.

Nomination Facility to Bidders

Nomination facility is available in accordance with the provisions of Section 72 of the Companies Act, 2013. In case of allotment of the Equity Shares in dematerialized form, there is no need to make a separate nomination as the nomination registered with the Depository may prevail. For changing nominations, the Bidders should inform their respective DP.

Submission of Bids

- a) During the Bid/Issue Period, Bidders may approach any of the Designated Intermediaries to register their Bids.
- b) The Bidders may instruct the SCSBs to block Bid Amount based on the highest bid price less discount (if applicable).
- c) For details of the timing on acceptance and upload of Bids in the Stock Exchange platform Bidders are requested to refer to the Draft Red Herring Prospectus.

GROUND OF TECHNICAL REJECTIONS

Bidders are advised to note that Bids are liable to be rejected inter alia on the following technical grounds:

- Amount blocked does not tally with the amount payable for the Equity Shares applied for;
- In case of partnership firms, Equity Shares may be registered in the names of the individual partners and no firm as such shall be entitled to apply;
- Bid by persons not competent to contract under the Indian Contract Act, 1872 including minors, insane persons;
- PAN not mentioned in the Bid cum Application Form;
- Bids at a price less than the Floor Price and Bids at a price more than the Cap Price;
- GIR number furnished instead of PAN;

- Bid for lower number of Equity Shares than specified for that category of investors;
- Bids at Cut-off Price;
- Bids for number of Equity Shares which are not in multiples as specified in the Red Herring Prospectus;
- The amounts mentioned in the Bid cum Application Form/Application Form does not tally with the amount payable for the value of the Equity Shares Bid/Applied for;
- Bids for lower number of Equity Shares than the minimum specified for that category of investors;
- Category not ticked;
- Multiple Bids as defined in the Draft Red Herring Prospectus;
- In case of Bids under power of attorney or by limited companies, corporate, trust etc., where relevant documents are not submitted;
- Bid accompanied by Stock invest/ money order/ postal order/ cash/ cheque/ demand draft/ pay order;
- Signature of sole Bidder is missing;
- Bid cum Application Forms not delivered by the Bidder within the time prescribed as per the Bid cum Application Forms, Bid/Issue Opening Date advertisement and the Draft Red Herring Prospectus and as per the instructions in the Draft Red Herring Prospectus and the Bid cum Application Forms;
- In case no corresponding record is available with the Depositories that matches three parameters namely, names of the Bidders (including the order of names of joint holders), the Depository Participant's identity (DP ID) and the beneficiary's account number;
- Bids for amounts greater than the maximum permissible amounts prescribed by the regulations;
- Bid by OCBs;
- Bids by US persons other than reliance on Regulation S or "qualified institutional buyers" as defined in Rule 144A under the Securities Act;
- Inadequate funds in the bank account to block the Bid Amount specified in the Bid cum Application Form/Application Form at the time of blocking such Bid Amount in the bank account;
- Bids not uploaded on the terminals of the Stock Exchanges;
- Where no confirmation is received from SCSB for blocking of funds;
- Bids by SCSBs wherein a separate account in its own name held with any other SCSB is not mentioned as the ASBA Account in the Bid cum Application Form/Application Form. Bids not duly signed by the sole/First Bidder;
- Bids by any persons outside India if not in compliance with applicable foreign and Indian laws;
- Bids that do not comply with the securities laws of their respective jurisdictions are liable to be rejected;
- Bids by persons prohibited from buying, selling or dealing in the shares directly or indirectly by SEBI or any other regulatory authority;
- Bids by persons who are not eligible to acquire Equity Shares of the Company in terms of all applicable laws, rules, regulations, guidelines, and approvals; and
- Details of ASBA Account not provided in the Bid cum Application form.

For details of instructions in relation to the Bid cum Application Form, Bidders may refer to the relevant section the GID.

BIDDERS SHOULD NOTE THAT IN CASE THE PAN, THE DP ID AND CLIENT ID MENTIONED IN THE BID CUM APPLICATION FORM AND ENTERED INTO THE ELECTRONIC APPLICATION SYSTEM OF THE STOCK EXCHANGES BY THE BIDS COLLECTING INTERMEDIARIES DO NOT MATCH WITH PAN, THE DP ID AND CLIENT ID AVAILABLE IN THE DEPOSITORY DATABASE, THE BID CUM APPLICATION FORM IS LIABLE TO BE REJECTED.

BASIS OF ALLOCATION

- a) The SEBI (ICDR) Regulations specify the allocation or Allotment that may be made to various categories of Bidders in an Issue depending on compliance with the eligibility conditions. Certain details pertaining to the percentage of Issue size available for allocation to each category is disclosed overleaf of the Bid cum Application Form and in the Draft Red Herring Prospectus. For details in relation to allocation, the Bidder may refer to the Red Herring Prospectus.
- b) Under-subscription in any category (except QIB Category) is allowed to be met with spill over from any other category or combination of categories at the discretion of the Issuer and in consultation with the Book Running Lead Manager and the Designated Stock Exchange and in accordance with the SEBI (ICDR) Regulations, Unsubscribed portion in QIB

Category is not available for subscription to other categories.

- c) In case of under subscription in the Issue, spill-over to the extent of such under- subscription may be permitted from the Reserved Portion to the Issue. For allocation in the event of an under-subscription applicable to the Issuer, Bidders may refer to the Red Herring Prospectus.

ALLOTMENT PROCEDURE AND BASIS OF ALLOTMENT

The allotment of Equity Shares to Bidders other than Individual Investors may be on proportionate basis. No Individual Investors will be allotted less than the minimum Bid Lot subject to availability of shares in Individual Investors Category.

BASIS OF ALLOTMENT

a. For Individual Bidders

Bids received from the Individual Bidders at or above the Issue Price shall be grouped together to determine the total demand under this category. The Allotment to all the successful Individual Bidders will be made at the Issue Price.

The Issue size less Allotment to Non-Institutional and QIB Bidders shall be available for Allotment to Individual Bidders who have Bid in the Issue at a price that is equal to or greater than the Issue Price. If the aggregate demand in this category is less than or equal to [●] Equity Shares at or above the Issue Price, full Allotment shall be made to the Individual Bidders to the extent of their valid Bids.

If the aggregate demand in this category is greater than [●] Equity Shares of face value of ₹10/- each at or above the Issue Price, the Allotment shall be made by draw of lots in such a manner that the total number of Shares allotted in that category is equal to the number of Shares allocated.

In the event of the Issue being over-subscribed, the Issuer may finalise the Basis of Allotment in consultation with the BSE SME (The Designated Stock Exchange). The allocation may be made in marketable lots on proportionate basis as set forth hereunder:

- a) The number of Shares to be allocated to the successful Bidders will be arrived in that category multiplied by the inverse of the oversubscription ratio (number of Bidders in the category multiplied by number of Shares applied for).
- b) The successful Bidder out of the total bidders for that category shall be determined by draw of lots in such a manner that the total number of Shares allotted in that category is equal to the number of Shares allocated.
- c) Each successful Bidder shall be allotted [●] equity shares

b. For Non-Institutional Bidders

Bids received from Non-Institutional Bidders at or above the Issue Price shall be grouped together to determine the total demand under this category. The Allotment to all successful Non- Institutional Bidders will be made at the Issue Price. The allotment of specified securities to each non-institutional investor shall not be less than the minimum application size in the non-institutional investor category, and the remaining shares, if any, shall be allotted on proportionate basis.

The Issue size less Allotment to QIBs and Individual Investors shall be available for Allotment to Non- Institutional Bidders who have Bid in the Issue at a price that is equal to or greater than the Issue Price. If the aggregate demand in this category is less than or equal to [●] Equity Shares of face value of ₹10/- each at or above the Issue Price, full Allotment shall be made to Non-Institutional Bidders to the extent of their demand.

In case the aggregate demand in this category is greater than [●] Equity Shares of face value of ₹10/- each at or above the Issue Price, Allotment shall be made on a proportionate basis up to a minimum of [●] Equity Shares of face value of ₹10/- each and in multiples of [●] Equity Shares of face value of ₹10/- each thereafter. The allocation may be made in marketable lots on proportionate basis as set forth hereunder:

- a. The number of Equity Shares to be allocated to the successful Bidders in a particular category shall be determined.

- b. The successful Bidders, from amongst all valid Bidders in that category, shall be determined by a draw of lots, such that the total number of Equity Shares allotted in that category equals the number of Equity Shares allocated.
- c. If the proportionate allotment to any Bidder results in a number that is not a multiple of [●] Equity Shares of face value ₹10/- each, the number of Equity Shares allotted shall be rounded off to the nearest multiple of [●] Equity Shares of face value ₹10/- each, subject to a minimum allotment of [●] Equity Shares of face value ₹10/- each.

If as a result of the process of rounding off to the nearest multiple of [●] Equity Shares of face value of ₹10/- each, results in the actual allotment being higher than the shares Issued, the final allotment may be higher at the sole discretion of the Board of Directors, up to 110% of the size of the Issue specified under the Capital Structure mentioned in this Draft Red Herring Prospectus.

c. For QIBs

For the Basis of Allotment to Anchor Investors, Bidders/Applicants may refer to the SEBI (ICDR) Regulations or Red Herring Prospectus / Prospectus. Bids received from QIBs Bidding in the QIB Category (net of Anchor Portion) at or above the Issue Price may be grouped together to determine the total demand under this category. The QIB Category may be available for Allotment to QIBs who have Bid at a price that is equal to or greater than the Issue Price. Allotment may be undertaken in the following manner:

- a) In the first instance allocation to Mutual Funds for [●] % of the QIB Portion shall be determined as follows:
 - In the event that Bids by Mutual Fund exceeds [●] % of the QIB Portion, allocation to Mutual Funds shall be done on a proportionate basis for [●] % of the QIB Portion.
 - In the event that the aggregate demand from Mutual Funds is less than [●] % of the QIB Portion then all Mutual Funds shall get full Allotment to the extent of valid Bids received above the Issue Price.
 - Equity Shares remaining unsubscribed, if any, not allocated to Mutual Funds shall be available for Allotment to all QIB Bidders as set out in (b) below;
- b) In the second instance Allotment to all QIBs shall be determined as follows:
 - In the event that the oversubscription in the QIB Portion, all QIB Bidders who have submitted Bids above the Issue Price shall be allotted Equity Shares on a proportionate basis, upto a minimum of [●] Equity Shares of face value of ₹10/- each and in multiples of [●] Equity Shares of face value of ₹10/- each thereafter for [●] % of the QIB Portion.
 - Mutual Funds, who have received allocation as per (a) above, for less than the number of Equity Shares of face value of ₹10/- each Bid for by them, are eligible to receive Equity Shares on a proportionate basis, upto a minimum of [●] Equity Shares of face value of ₹10/- each and in multiples of [●] Equity Shares of face value of ₹10/- each thereafter, along with other QIB Bidders.
 - Under-subscription below [●] % of the QIB Portion, if any, from Mutual Funds, would be included for allocation to the remaining QIB Bidders on a proportionate basis. The aggregate Allotment to QIB Bidders shall not be more than [●] Equity Shares of face value of ₹10/- each.

d. ALLOTMENT TO ANCHOR INVESTOR (IF APPLICABLE)

- a) Allocation of Equity Shares to Anchor Investors at the Anchor Investor Allocation Price will be at the discretion of the Issuer, in consultation with the Book Running Lead Manager, subject to compliance with the following requirements:
 - i) not more than 60% of the QIB Portion will be allocated to Anchor Investors;
 - ii) one-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the price at which allocation is being done to other Anchor Investors; and

iii) allocation to Anchor Investors shall be on a discretionary basis and subject to:

- a maximum number of two Anchor Investors for allocation up to ₹ 2 crores; a minimum number of two Anchor Investors and maximum number of 15 Anchor Investors for allocation of more than ₹ 2 crores and up to ₹ 25 crores subject to minimum allotment of ₹ 1 crores per such Anchor Investor; and
- in case of allocation above twenty-five crore rupees; a minimum of 5 such investors and a maximum of 15 such investors for allocation up to twenty-five crore rupees and an additional 10 such investors for every additional twenty-five crore rupees or part thereof, shall be permitted, subject to a minimum allotment of one crore rupees per such investor.

b) A physical book is prepared by the Registrar on the basis of the Anchor Investor Application Forms received from Anchor Investors. Based on the physical book and at the discretion of the Issuer, in consultation with the Book Running Lead Manager, selected Anchor Investors will be sent a CAN and if required, a revised CAN.

c) In the event that the Issue Price is higher than the Anchor Investor Allocation Price:

Anchor Investors will be sent a revised CAN within one day of the Pricing Date indicating the number of Equity Shares allocated to such Anchor Investor and the pay-in date for payment of the balance amount. Anchor Investors are then required to pay any additional amounts, being the difference between the Issue Price and the Anchor Investor Allocation Price, as indicated in the revised CAN within the pay-in date referred to in the revised CAN. Thereafter, the Allotment Advice will be issued to such Anchor Investors

d) In the event the Issue Price is lower than the Anchor Investor Allocation Price:

Anchor Investors who have been Allotted Equity Shares will directly receive Allotment Advice.

Individual Investor' means an investor who applies for minimum two lots -Investors may note that in case of over subscription allotment shall be on proportionate basis and will be finalized in consultation with BSE.

The Executive Director/ Managing Director of BSE - the Designated Stock Exchange in addition to Book Running Lead Manager and Registrar to the Public Issue shall be responsible to ensure that the basis of allotment is finalized in a fair and proper manner in accordance with the SEBI (ICDR) Regulations.

Flow of Events from the closure of Bidding period (T DAY) Till Allotment:

- On T Day, RTA To validate the electronic bid details with the depository records and also reconcile the final certificates received from the Sponsor Bank for UPI process and the SCSBs for ASBA and Syndicate ASBA process with the electronic bid details.
- RTA identifies cases with mismatch of account number as per bid file / FC and as per applicant's bank account linked to depository demat account and seek clarification from SCSB to identify the applications with third party account for rejection.
- Third party confirmation of applications to be completed by SCSBs on T+1 day.
- RTA prepares the list of final rejections and circulates the rejections list with BRLM(s)/ Company for their review/ comments.
- Post rejection, the RTA submits the basis of allotment with the Designated Stock Exchange (DSE).
- The DSE, post verification approves the basis and generates drawl of lots wherever applicable, through a random number generation software.
- The RTA uploads the drawl numbers in their system and generates the final list of allottees as per process mentioned below:

Process for generating list of allottees: -

- Instruction is given by RTA in their Software System to reverse category wise all the application numbers in the ascending order and generate the bucket /batch as per the allotment ratio. For example, if the application number is 78654321 then system reverses it to 12345687 and if the ratio of allottees to applicants in a category is 2:7 then the system will create lots of 7. If the drawl of lots provided by DSE is 3 and 5 then the system will pick every 3rd and 5th application in each of the lot of the category and these application s will be allotted the shares in that category.
- In categories where there is proportionate allotment, the Registrar will prepare the proportionate working based on the oversubscription times.
- In categories where there is undersubscription, the Registrar will do full allotment for all valid applications.
- On the basis of the above, the RTA will work out the allottees, partial allottees and non- allottees, prepare the fund transfer letters and advice the SCSBs to debit or unblock the respective accounts.

Issuance of Allotment Advice

- 1) Upon approval of the Basis of Allotment by the Designated Stock Exchange.
- 2) On the basis of approved Basis of Allotment, the Issuer shall pass necessary corporate action to facilitate the allotment and credit of equity shares. Bidders are advised to instruct their Depository Participants to accept the Equity Shares that may be allotted to them pursuant to the Issue.

The Book Running Lead Manager or the Registrar to the Issue will dispatch an Allotment Advice to their Bidders who have been allocated Equity Shares in the Issue. The dispatch of Allotment Advice shall be deemed a valid, binding and irrevocable contract for the Allotment to such Bidder.

- 3) Issuer will make the allotment of the Equity Shares and initiate corporate action for credit of shares to the successful Bidders Depository Account within 2 working days of the Issue Closing date. The Issuer also ensures the credit of shares to the successful Bidders Depository Account is completed within one working Day from the date of allotment, after the funds are transferred from ASBA Public Issue Account to Public Issue account of the issuer.

Designated Date:

On the Designated date, the SCSBs shall transfers the funds represented by allocations of the Equity Shares into Public Issue Account with the Bankers to the Issue.

The Company will issue and dispatch letters of allotment/ or letters of regret along with refund order or credit the allotted securities to the respective beneficiary accounts, if any within a period of 2 working days of the Bid/Issue Closing Date. The Company will intimate the details of allotment of securities to Depository immediately on allotment of securities under relevant provisions of the Companies Act, 2013 or other applicable provisions, if any

Instructions for Completing the Bid Cum Application Form

The Applications should be submitted on the prescribed Bid Cum Application Form and in BLOCK LETTERS in ENGLISH only in accordance with the instructions contained herein and in the Bid Cum Application Form. Applications not so made are liable to be rejected. Applications made using a third-party bank account or using third party UPI ID linked bank account are liable to be rejected. Bid Cum Application Forms should bear the stamp of the Designated Intermediaries. ASBA Bid Cum Application Forms, which do not bear the stamp of the Designated Intermediaries, will be rejected.

SEBI, vide Circular No. CIR/CFD/14/2012 dated October 04, 2012 has introduced an additional mechanism for investors to submit Bid Cum Application Forms in public Issues using the stock broker (broker) network of Stock Exchanges, who may not be syndicate members in an Issue with effect from January 01, 2013. The list of Broker Centre is available on the websites of BSE i.e. www.bseindia.com and NSE i.e. www.nseindia.com. With a view to broad base the reach of Investors by substantial, enhancing the points for submission of applications, SEBI vide Circular No. CIR/CFD/POLICY CELL/11/2015 dated

November 10, 2015 has permitted Registrar to the Issue and Share Transfer Agent and Depository Participants registered with SEBI to accept the Bid Cum Application Forms in Public Issue with effect from January 01, 2016. The List of ETA and DPs centres for collecting the application shall be disclosed is available on the websites of BSE i.e. www.bseindia.com and NSE i.e. www.nseindia.com.

Bidder's Depository Account and Bank Details

Please note that, providing bank account details, PAN No's, Client ID and DP ID in the space provided in the Bid Cum Application Form is mandatory and applications that do not contain such details are liable to be rejected.

Bidders should note that on the basis of name of the Bidders, Depository Participant's name, Depository Participant Identification number and Beneficiary Account Number provided by them in the Bid Cum Application Form as entered into the Stock Exchange online system, the Registrar to the Issue will obtain from the Depository the demographic details including address, Bidders bank account details, MICR code and occupation (hereinafter referred to as 'Demographic Details'). These Demographic Details would be used for all correspondence with the Bidders including mailing of the Allotment Advice. The Demographic Details given by Bidders in the Bid Cum Application Form would not be used for any other purpose by the Registrar to the Issue.

By signing the Bid Cum Application Form, the Bidder would be deemed to have authorized the depositories to provide, upon request, to the Registrar to the Issue, the required Demographic Details as available on its records.

Submission of Bid Cum Application Form

All Bid Cum Application Forms duly completed shall be submitted to the Designated Intermediaries. The aforesaid intermediaries shall, at the time of receipt of application, give an acknowledgement to investor, by giving the counter foil or specifying the application number to the investor, as a proof of having accepted the Bid Cum Application Form, in physical or electronic mode, respectively.

Communications

All future communications in connection with Applications made in this Issue should be addressed to the Registrar to the Issue quoting the full name of the sole or First Bidder, Bid Cum Application Form number, Bidders Depository Account Details, number of Equity Shares applied for, date of Bid Cum Application Form, name and address of the Designated Intermediary where the Application was submitted thereof and a copy of the acknowledgement slip.

Investors can contact the Compliance Officer or the Registrar to the Issue in case of any pre-Issue or post Issue related problems such as non-receipt of letters of allotment, credit of allotted shares in the respective beneficiary accounts, etc.

Disposal of Application and Application Moneys and Interest in Case of Delay

The Company shall ensure the dispatch of Allotment advice, and give benefit to the beneficiary account with Depository Participants and submit the documents pertaining to the Allotment to the Stock Exchange within 2 (two) working days of date of Allotment of Equity Shares.

The Company shall use best efforts to ensure that all steps for completion of the necessary formalities for listing and commencement of trading at BSE SME where the Equity Shares are proposed to be listed are taken within 3 (Three) working days from Issue Closing Date.

In accordance with the Companies Act, the requirements of the Stock Exchange and the SEBI Regulations, the Company further undertakes that:

1. Allotment and Listing of Equity Shares shall be made within 3 (Three) days of the Issue Closing Date;
2. Giving of Instructions for refund by unblocking of amount via ASBA not later than 2(two) working days of the Issue Closing Date, would be ensured; and
3. If such money is not repaid within prescribed time from the date our Company becomes liable to repay it, then our Company and every officer in default shall, on and from expiry of prescribed time, be liable to repay such application

money, with interest as prescribed under SEBI (ICDR) Regulations, the Companies Act, 2013 and applicable law. Further, in accordance with Section 40 of the Companies Act, 2013, the Company and each officer in default may be punishable with fine and/or imprisonment in such a case.

Right to Reject Applications

In case of QIB Bidders, the Company in consultation with the Book Running Lead Manager may reject Applications provided that the reasons for rejecting the same shall be provided to such Bidder in writing. In case of Non-Institutional Bidders, Individual Bidders who applied, the Company has a right to reject Applications based on technical grounds.

Impersonation

Attention of the Bidders is specifically drawn to the provisions of sub-section (1) of Section 38 of the Companies Act, 2013 which is reproduced below:

“Any person who-

- (a) Makes or abets making of an application in a fictitious name to a company for acquiring, or subscribing for, its securities; or
- (b) Makes or abets making of multiple applications to a company in different names or in different combinations of his name or surname for acquiring or subscribing for its securities; or
- (c) Otherwise induces directly or indirectly a company to allot, or register any transfer of, securities to him, or to any other person in a fictitious name, shall be liable for action under Section 447.”

Undertakings by Our Company

We undertake as follows:

1. That the complaints received in respect of the Issue shall be attended expeditiously and satisfactorily;
2. That all steps will be taken for the completion of the necessary formalities for listing and commencement of trading on Stock Exchange where the Equity Shares are proposed to be listed within three working days from Issue Closure date.
3. That the funds required for making refunds as per the modes disclosed or dispatch of allotment advice by registered post or speed post shall be made available to the Registrar and Share Transfer Agent to the Issue by our Company;
4. Where refunds (to the extent applicable) are made through electronic transfer of funds, a suitable communication shall be sent to the applicant within two Working Days from the Issue Closing Date, giving details of the bank where refunds shall be credited along with amount and expected date of electronic credit of refund;
5. That our Promoter 's contribution in full has already been brought in;
6. That no further Issue of Equity Shares shall be made till the Equity Shares Issued through the Prospectus are listed or until the Application monies are refunded on account of non-listing, undersubscription etc.;
7. That adequate arrangement shall be made to collect all Applications Supported by Blocked Amount while finalizing the Basis of Allotment;
8. If our Company does not proceed with the Issue after the Bid/Issue Opening Date but before allotment, then the reason thereof shall be given as a public notice to be issued by our Company within two days of the Bid/Issue Closing Date. The public notice shall be issued in the same newspapers where the Pre-Issue and price band advertisements were published. The stock exchange on which the Equity Shares are proposed to be listed shall also be informed promptly;
9. If our Company withdraws the Issue after the Bid/Issue Closing Date, our Company shall be required to file a fresh Draft Red Herring Prospectus with the Stock exchange/RoC/SEBI, in the event our Company subsequently decides to proceed with the Issue;

10. If allotment is not made within the prescribed time period under applicable law, the entire subscription amount received will be refunded/ unblocked within the time prescribed under applicable law. If there is delay beyond the prescribed time, our Company shall pay interest prescribed under the Companies Act, 2013, the SEBI Regulations and applicable law for the delayed period.

Utilization of Issue Proceeds

The Board of Directors of our Company certifies that:

- 1) All monies received out of the Issue shall be credited/ transferred to a separate bank account other than the bank account referred to in sub section (3) of Section 40 of the Companies Act 2013;
- 2) Details of all monies utilized out of the Issue referred above shall be disclosed and continue to be disclosed till the time any part of the Issue proceeds remains unutilized, under an appropriate head in our balance sheet of our company indicating the purpose for which such monies have been utilized;
- 3) Details of all unutilized monies out of the Issue, if any shall be disclosed under the appropriate separate head in the balance sheet of our company indicating the form in which such unutilized monies have been invested and
- 4) Our Company shall comply with the requirements of SEBI Listing Regulations, 2015 in relation to the disclosure and monitoring of the utilization of the proceeds of the Issue.
- 5) Our Company shall not have recourse to the Issue Proceeds until the approval for listing and trading of the Equity Shares from the Stock Exchange where listing is sought has been received.
- 6) The Book Running Lead Manager undertakes that the complaints or comments received in respect of the Issue shall be attended by our Company expeditiously and satisfactorily.

Equity Shares in Dematerialized Form with NSDL or CDSL

To enable all shareholders of our Company to have their shareholding in electronic form, the Company has signed the following tripartite agreements with the Depositories and the Registrar and Share Transfer Agent:

- Tripartite Agreement dated September 24, 2025 between NSDL, the Company and the Registrar to the Issue;
- Tripartite Agreement dated September 24, 2025 between CDSL, the Company and the Registrar to the Issue;

The Company's equity shares bear an ISIN: INE16E601016

RESTRICTIONS ON FOREIGN OWNERSHIP OF INDIAN SECURITIES

The Department for Promotion of Industry and Internal Trade, Ministry of Commerce and Industry, Government of India (“**DPIIT**”) makes policy announcements on FDI through press notes and press releases which are notified by the RBI as amendments to the FEMA. The DPIIT also issues the Consolidated Foreign Direct Investment Policy (“**FDI Policy**”) from time to time. The regulatory framework pertaining to foreign investment, over a period of time, thus, consists of acts, regulations, master circulars, press notes, press releases, and clarifications among other amendments.

India’s current FDI Policy issued by the DPIIT with effect from October 15, 2020, consolidates and supersedes all previous press notes, press releases and clarifications on FDI issued by the DPIIT till October 15, 2020. All the press notes, press releases, clarifications on FDI issued by DPIIT till October 15, 2020 stand rescinded as on October 15, 2020. In terms of the FDI Policy, Foreign investment is permitted (except in the prohibited sectors) in Indian companies either through the automatic route or the Government route, depending upon the sector in which foreign investment is sought to be made. In terms of the FDI Policy, the work of granting government approval for foreign investment under the FDI Policy and FEMA Regulations has now been entrusted to the concerned Administrative Ministries/Departments.

In accordance with Press Note No. 3 (2020 Series), dated April 17, 2020 issued by the DPIIT and the Foreign Exchange Management (Non-debt Instruments) Amendment Rules, 2020 which came into effect from April 22, 2020, any investment, subscription, purchase or sale of equity instruments by entities of a country which shares land border with India or where the beneficial owner of an investment into India is situated in or is a citizen of any such country, will require prior approval of the Government, as prescribed in the FDI Policy and the Foreign Exchange Management (Non-debt Instruments) Rules, 2019. Further, in the event of transfer of ownership of any existing or future foreign direct investment in an entity in India, directly or indirectly, resulting in the beneficial ownership falling within the aforesaid restriction/ purview, such subsequent change in the beneficial ownership will also require approval of the Government. Pursuant to the Foreign Exchange Management (Non-debt Instruments) (Fourth Amendment) Rules, 2020 issued on December 8, 2020, a multilateral bank or fund, of which India is a member, shall not be treated as an entity of a particular country nor shall any country be treated as the beneficial owner of the investments of such bank or fund in India.

Further, the existing individual and aggregate investment limits for an FPI in our Company are not exceeding 10% of the total paid-up Equity Share capital of our Company for each FPI and the total holdings of all FPIs in the Company shall not exceed 24% of the total paid-up Equity Share capital of our Company. The RBI, in exercise of its power under the FEMA, has also notified Foreign Exchange Management (Non-debt Instruments) Rules, 2019 (“**Rules**”) and Foreign Exchange Management (Mode of Payment and Reporting of Non-Debt Instruments) Regulations, 2019 to prohibit, restrict or regulate, transfer by or issue security to a person resident outside India. SEBI registered FPIs have been permitted to purchase shares of an Indian company through the Issue, subject to total FPI investment being within the individual FPI/sub account investment limit of less than 10% of the total paid-up equity capital on a fully diluted basis of the Company subject to the total holdings of all FPIs/sub accounts including any other direct and indirect foreign investments in the Company shall not exceed 24% of the paid-up equity capital of the Company on a fully diluted basis. The aggregate limit of 24% in case of FPIs may be increased up to the sectoral cap/statutory ceiling, as applicable, by the Company concerned by passing of resolution by the Board of the Company to that effect and by passing of a special resolution to that effect by its Shareholders. With effect from April 1, 2020, the aggregate limit of 24% has increased to the sectoral cap applicable to the Indian Company which in case of the Company is 100% provided that the Company complies with conditions provided under the FDI Policy. As per the Rules, the aggregate limit as provided above was permitted to be decreased by the Company to a lower threshold limit of 24% or 49% or 74% as deemed fit, with the approval of its Board of Directors through a resolution and also of its shareholders by means of a special resolution, before March 31, 2020. The Company has passed no such Board Resolution and hence, has not revised its sectoral caps. Further, eligible NRIs and OCIs investing on repatriation basis are subject to individual investment limit of 5% of the total paid-up equity capital on a fully diluted basis subject to the aggregate paid-value of the shares purchased by all NRIs and OCIs put together on repatriation basis not exceeding 10% of the total paid-up equity capital on a fully diluted basis of the Company. The aggregate limit of 10% in case of NRIs and OCIs together may be raised to 24 % if a special resolution to that effect is passed by the shareholders of the Company. The Company has not passed such resolutions as yet.

The transfer of shares between an Indian resident and a Non-resident does not require prior approval of RBI, subject to fulfillment of certain conditions as specified by DPIIT / RBI, from time to time. Such conditions include (i) the activities of the investee company are under the automatic route under the FDI Policy and transfer does not attract the provisions of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011; (ii) the non-resident shareholding is within the sectoral limits under the FDI Policy; and (iii) the pricing is in accordance with the guidelines prescribed by the SEBI/RBI. Investors are

advised to refer to the exact text of the relevant statutory provisions of law before investing and / or subsequent purchase or sale transaction in the Equity Shares of our Company.

As per the existing policy of the Government of India, OCBs cannot participate in this Issue.

As per the FDI Policy, FDI in companies engaged in manufacturing sector is permitted up to 100% of the paid-up share capital of such company under the automatic route.

For further details, see “*Issue Procedure*” on page 273. Each Bidder should seek independent legal advice about its ability to participate in the Issue. In the event such prior approval of the Government of India is required, and such approval has been obtained, the Bidder shall intimate our Company and the Registrar in writing about such approval along with a copy thereof within the Bid/Issue Period.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or the securities laws of any state of the United States and may not be offered or sold within the United States, except pursuant to exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold only outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sale occur. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Applications may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

The above information is given for the benefit of the Bidders. Our Company and the BRLM are not liable for any amendments or modification or changes in applicable laws or regulations, which may occur after the date of this Draft Red Herring Prospectus. Bidders are advised to make their independent investigations and ensure that the Bids are not in violation of laws or regulations applicable to them.

SECTION IX - MAIN PROVISIONS OF THE ARTICLES OF ASSOCIATION OF OUR COMPANY

THE COMPANIES ACT, 2013

THE COMPANY LIMITED BY SHARES

ARTICLES OF ASSOCIATION

OF

REDNEX PHARMACEUTICALS LIMITED

The regulations contained in Table “F” in Schedule I to the Companies Act, 2013 (hereinafter referred to as Table ‘F’) shall apply to the Company so far and so far, only as they are not inconsistent with any of the provisions contained in these regulations or modifications thereof and only to the extent that there is no specific provision in these regulations.

INTERPRETATION

1. In these regulations-
 - a. “the Act” means the Companies Act, 2013,
 - b. “the seal” means the common seal of the company.
2. Unless the context otherwise requires, words or expressions contained in these regulations shall bear the same meaning as in the Act or any statutory modification thereof in force at the date at which these regulations become binding on the company.

“Public Company” The Company is a Public company within the meaning of Sections 2(71) of the Companies Act, 2013.

SHARE CAPITAL AND VARIATION OF RIGHTS

1. Subject to the provisions of the Act and these Articles, the shares in the capital of the company shall be under the control of the Directors who may issue, allot or otherwise dispose of the same or any of them to such persons, in such proportion and on such terms and conditions and either at a premium or at par and at such time as they may from time to time think fit.
2. Every person whose name is entered as a member in the register of members shall be entitled to receive within two months after incorporation, in case of subscribers to the memorandum or after allotment or within one month after the application for the registration of transfer or transmission or within such other period as the conditions of issue shall be provided-
 - a. one certificate for all his shares without payment of any charges; or
 - b. several certificates, each for one or more of his shares, upon payment of twenty rupees for each certificate after the first.

Every certificate shall be under the seal and shall specify the shares to which it relates and the amount paid - up thereon.

In respect of any share or shares held jointly by several persons, the company shall not be bound to issue more than one certificate, and delivery of a certificate for a share to one of several joint holders shall be sufficient delivery to all such holders.

3. If any share certificate be worn out, defaced, mutilated or torn or if there be no further space on the back for endorsement of transfer, then upon production and surrender thereof to the company, a new certificate may be issued in lieu thereof, and if any certificate is lost or destroyed then upon proof thereof to the satisfaction of the company and on execution of such indemnity as the company deem adequate, a new certificate in lieu thereof shall be given. Every certificate under this Article shall be issued on payment of twenty rupees for each certificate.

The provisions of Articles (2) and (3) shall mutatis mutandis apply to debentures of the company.

4. Except as required by law, no person shall be recognized by the company as holding any share upon any trust, and the company shall not be bound by, or be compelled in any way to recognize (even when having notice thereof) any equitable, contingent, future or partial interest in any share, or any interest in any fractional part of a share, or (except only as by these regulations or by law otherwise provided) any other rights in respect of any share except an absolute right to the entirety thereof in the registered holder.
5. The company may exercise the powers of paying commissions conferred by sub-section (6) of section 40, provided that the rate per cent or the amount of the commission paid or agreed to be paid shall be disclosed in the manner required by that section and rules made thereunder.

The rate or amount of the commission shall not exceed the rate or amount prescribed in rules made under sub-section (6) of section 40.

The commission may be satisfied by the payment of cash or the allotment of fully or partly paid shares or partly in the one way and partly in the other.

6. If at any time the share capital is divided into different classes of shares, the rights attached to any class (unless otherwise provided by the terms of issue of the shares of that class) may, subject to the provisions of section 48, and whether or not the company is being wound up, be varied with the consent in writing of the holders of three-fourths of the issued shares of that class, or with the sanction of a special resolution passed at a separate meeting of the holders of the shares of that class.

To every such separate meeting, the provisions of these regulations relating to general meetings shall mutatis mutandis apply, but so that the necessary quorum shall be at least two persons holding at least one-third of the issued shares of the class in question.

7. The rights conferred upon the holders of the shares of any class issued with preferred or other rights shall not, unless otherwise expressly provided by the terms of issue of the shares of that class, be deemed to be varied by the creation or issue of further shares ranking pari-passu therewith.
8. Subject to the provisions of section 55, any preference shares may, with the sanction of an ordinary resolution, be issued on the terms that they are to be redeemed on such terms and in such manner as the company before the issue of the shares may, by special resolution, determine.

LIEN

9. The company shall have a first and paramount lien
 - a. on every share (not being a fully paid share), for all monies (whether presently payable or not) called, or payable at a fixed time, in respect of that share; and
 - b. on all shares (not being fully paid shares) standing registered in the name of a single person, for all monies presently payable by him or his estate to the company:Provided that the Board of directors may at any time declare any share to be wholly or in part exempt from the provisions of this clause.

The company's lien, if any, on a share shall extend to all dividends payable and bonuses declared from time to time in respect of such shares.

That fully paid shares shall be free from all lien and that in the case of partly paid shares the Issuer's lien shall be restricted to moneys called or payable at a fixed time in respect of such shares.

10. The company may sell, in such manner as the Board thinks fit, any shares on which the company has a lien: Provided that no sale shall be made-
 - a. unless a sum in respect of which the lien exists is presently payable; or

b. until the expiration of fourteen days after a notice in writing stating and demanding payment of such part of the amount in respect of which the lien exists as is presently payable, has been given to the registered holder for the time being of the share or the person entitled thereto by reason of his death or insolvency.

11. To give effect to any such sale, the Board may authorize some person to transfer the shares sold to the purchaser thereof

The purchaser shall be registered as the holder of the shares comprised in any such transfer.

The purchaser shall not be bound to see to the application of the purchase money, nor shall his title to the shares be affected by any irregularity or invalidity in the proceedings in reference to the sale.

12. The proceeds of the sale shall be received by the company and applied in payment of such part of the amount in respect of which the lien exists as is presently payable.
The residue, if any, shall, subject to a like lien for sums not presently payable as existed upon the shares before the sale, be paid to the person entitled to the shares at the date of the sale.

CALLS ON SHARES

13. The Board may, from time to time, make calls upon the members in respect of any monies unpaid on their shares (whether on account of the nominal value of the shares or by way of premium) and not by the conditions of allotment thereof made payable at fixed times:

Provided that no call shall exceed one-fourth of the nominal value of the share or be payable at less than one month from the date fixed for the payment of the last preceding call.

Each member shall, subject to receiving at least fourteen days' notice specifying the time or times and place of payment, pay to the company, at the time or times and place so specified, the amount called on his shares.

A call may be revoked or postponed at the discretion of the Board.

That any amount paid up in advance of calls on any share may carry interest but shall not in respect thereof confer a right to dividend or to participate in profits

14. A call shall be deemed to have been made at the time when the resolution of the Board authorizing the call was passed and may be required to be paid by installments.
15. The joint holders of a share shall be jointly and severally liable to pay all calls in respect thereof.
16. If a sum called in respect of a share is not paid before or on the day appointed for payment thereof, the person from whom the sum is due shall pay interest thereon from the day appointed for payment thereof to the time of actual payment at ten per cent per annum or at such lower rate, if any, as the Board may determine.

The Board shall be at liberty to waive payment of any such interest wholly or in part.

17. Any sum which by the terms of issue of a share becomes payable on allotment or at any fixed date, whether on account of the nominal value of the share or by way of premium, shall, for the purposes of these regulations, be deemed to be a call duly made and payable on the date on which by the terms of issue such sum becomes payable.

In case of non-payment of such sum, all the relevant provisions of these regulations as to payment of interest and expenses, forfeiture or otherwise shall apply as if such sum had become payable by virtue of a call duly made and notified.

18. The Board -
a. may, if it thinks fit, receive from any member willing to advance the same, all or any part of the monies uncalled and unpaid upon any shares held by him and

b. upon all or any of the monies so advanced, may (until the same would, but for such advance, become presently payable) pay interest at such rate not exceeding, unless the company in general meeting shall otherwise direct, twelve per cent per annum, as may be agreed upon between the Board and the member paying the sum in advance.

TRANSFER OF SHARES

19. The instrument of transfer of any share in the company shall be executed by or on behalf of both the transferor and transferee.

The transferor shall be deemed to remain a holder of the share until the name of the transferee is entered in the register of members in respect thereof.

That a common form of transfer shall be used

20. The Board may, subject to the right of appeal conferred by section 58 decline to register—

the transfer of a share, not being a fully paid share, to a person of whom they do not approve; or

any transfer of shares on which the company has a lien.

21. The Board may decline to recognize any instrument of transfer unless—
- the instrument of transfer is in the form as prescribed in rules made under sub-section (1) of section 56;
 - the instrument of transfer is accompanied by the certificate of the shares to which it relates, and such other evidence as the Board may reasonably require to show the right of the transferor to make the transfer; and
 - the instrument of transfer is in respect of only one class of shares.

That registration of transfer shall not be refused on the ground of the transferor being either alone or jointly with any other person or persons indebted to the Issuer on any account whatsoever

22. On giving not less than seven days' previous notice in accordance with section 91 and rules made thereunder, the registration of transfers may be suspended at such times and for such periods as the Board may from time to time determine:

Provided that such registration shall not be suspended for more than thirty days at any one time or for more than forty-five days in the aggregate in any year.

TRANSMISSION OF SHARES

23. On the death of a member, the survivor or survivors where the member was a joint holder, and his nominee or nominees or legal representatives where he was a sole holder, shall be the only persons recognized by the company as having any title to his interest in the shares

Nothing in clause (i) shall release the estate of a deceased joint holder from any liability in respect of any share which had been jointly held by him with other persons.

That a common form of transmission shall be used

24. Any person becoming entitled to a share in consequence of the death or insolvency of a member may, upon such evidence being produced as may from time to time properly be required by the Board and subject as hereinafter provided, elect, either—
- to be registered himself as holder of the share; or
 - to make such transfer of the share as the deceased or insolvent member could have made.

The Board shall, in either case, have the same right to decline or suspend registration as it would have had, if the deceased or insolvent member had transferred the share before his death or insolvency.

25. If the person so becoming entitled shall elect to be registered as holder of the share himself, he shall deliver or send to the company a notice in writing signed by him stating that he so elects.

If the person aforesaid shall elect to transfer the share, he shall testify his election by executing a transfer of the share.

All the limitations, restrictions and provisions of these regulations relating to the right to transfer and the registration of transfers of shares shall be applicable to any such notice or transfer as aforesaid as if the death or insolvency of the member had not occurred and the notice or transfer were a transfer signed by that member.

26. A person becoming entitled to a share by reason of the death or insolvency of the holder shall be entitled to the same dividends and other advantages to which he would be entitled if he were the registered holder of the share, except that he shall not, before being registered as a member in respect of the share, be entitled in respect of it to exercise any right conferred by membership in relation to meetings of the company:

Provided that the Board may, at any time, give notice requiring any such person to elect either to be registered himself or to transfer the share, and if the notice is not complied with within ninety days, the Board may thereafter withhold payment of all dividends, bonuses or other monies payable in respect of the share, until the requirements of the notice have been complied with.

FORFEITURE OF SHARES

27. If a member fails to pay any call, or installment of a call, on the day appointed for payment thereof, the Board may, at any time thereafter during such time as any part of the call or installment remains unpaid, serve a notice on him requiring payment of so much of the call or installment as is unpaid, together with any interest which may have accrued.
28. The notice aforesaid shall-
- a. name a further day (not being earlier than the expiry of fourteen days from the date of service of the notice) on or before which the payment required by the notice is to be made; and
 - b. state that, in the event of non-payment on or before the day so named, the shares in respect of which the call was made shall be liable to be forfeited.
29. If the requirements of any such notice as aforesaid are not complied with, any share in respect of which the notice has been given may, at any time thereafter, before the payment required by the notice has been made, be forfeited by a resolution of the Board to that effect.
30. A forfeited share may be sold or otherwise disposed of on such terms and in such manner as the Board thinks fit.

At any time before a sale or disposal as aforesaid, the Board may cancel the forfeiture on such terms as it thinks fit.

31. A person whose shares have been forfeited shall cease to be a member in respect of the forfeited shares, but shall, notwithstanding the forfeiture, remain liable to pay to the company all monies which, at the date of forfeiture, were presently payable by him to the company in respect of the shares.

The liability of such person shall cease if and when the company shall have received payment in full of all such monies in respect of the shares.

32. A duly verified declaration in writing that the declarant is a director, the manager or the secretary, of the company, and that a share in the company has been duly forfeited on a date stated in the declaration, shall be conclusive evidence of the facts therein stated as against all persons claiming to be entitled to the share;

The company may receive the consideration, if any, given for the share on any sale or disposal thereof and may execute a transfer of the share in favour of the person to whom the share is sold or disposed of;

The transferee shall thereupon be registered as the holder of the share; and

The transferee shall not be bound to see to the application of the purchase money, if any, nor shall his title to the share be affected by any irregularity or invalidity in the proceedings in reference to the forfeiture, sale or disposal of the share.

33. The provisions of these regulations as to forfeiture shall apply in the case of non-payment of any sum which, by the terms of issue of a share, becomes payable at a fixed time, whether on account of the nominal value of the share or by way of premium, as if the same had been payable by virtue of a call duly made and notified.

ALTERATION OF CAPITAL

34. The company may, from time to time, by ordinary resolution increase the share capital by such sum, to be divided into shares of such amount, as may be specified in the resolution.

35. Subject to the provisions of section 61, the company may, by ordinary resolution-
consolidate and divide all or any of its share capital into shares of larger amount than its existing shares;

convert all or any of its fully paid-up shares into stock, and reconvert that stock into fully paid-up shares of any denomination;

sub-divide its existing shares or any of them into shares of smaller amount than is fixed by the memorandum; and

cancel any shares which, at the date of the passing of the resolution, have not been taken or agreed to be taken by any person.

Permission for sub-division/ consolidation of share certificates

36. Where shares are converted into stock,—
- the holders of stock may transfer the same or any part thereof in the same manner as, and subject to the same regulations under which, the shares from which the stock arose might before the conversion have been transferred, or as near thereto as circumstances admit:
 - Provided that the Board may, from time to time, fix the minimum amount of stock transferable, so, however, that such minimum shall not exceed the nominal amount of the shares from which the stock arose.
 - the holders of stock shall, according to the amount of stock held by them, have the same rights, privileges and advantages as regards dividends, voting at meetings of the company, and other matters, as if they held the shares from which the stock arose; but no such privilege or advantage (except participation in the dividends and profits of the company and in the assets on winding up) shall be conferred by an amount of stock which would not, if existing in shares, have conferred that privilege or advantage.
 - such of the regulations of the company as are applicable to paid-up shares shall apply to stock and the words “share” and “shareholder” in those regulations shall include “stock” and “stock-holder” respectively.
37. The company may, by special resolution, reduce in any manner and with, and subject to, any incident authorized and consent required by law-
- it share capital;
 - any capital redemption reserve account; or
 - any share premium account.

CAPITALISATION OF PROFITS

38. The company in general meeting may, upon the recommendation of the Board, resolve-
that it is desirable to capitalize any part of the amount for the time being standing to the credit of any of the company’s reserve accounts, or to the credit of the, profit and loss account, or otherwise available for distribution; and

that such sum be accordingly set free for distribution in the manner specified in clause (ii) amongst the members who would have been entitled thereto, if distributed by way of dividend and in the same proportions.

The sum aforesaid shall not be paid in cash but shall be applied, subject to the provision contained in clause (iii), either in or towards-

- a. paying up any amounts for the time being unpaid on any shares held by such members respectively;
- b. paying up in full, unissued shares of the company to be allotted and distributed, credited as fully paid-up, to and amongst such members in the proportions aforesaid;
- c. partly in the way specified in sub-clause (A) and partly in that specified in sub-clause (B);

A securities premium account and a capital redemption reserve account may, for the purposes of this regulation, be applied in the paying up of unissued shares to be issued to members of the company as fully paid bonus shares;

The Board shall give effect to the resolution passed by the company in pursuance of this regulation.

39. Whenever such a resolution as aforesaid shall have been passed, the Board shall-

- a. make all appropriations and applications of the undivided profits resolved to be capitalized thereby, and all
- b. allotments and issues of fully paid shares if any; and
- c. generally, do all acts and things required to give effect thereto.

The Board shall have power-

- a. to make such provisions, by the issue of fractional certificates or by payment in cash or otherwise as it thinks fit, for the case of shares becoming distributable in fractions; and
- b. to authorise any person to enter, on behalf of all the members entitled thereto, into an agreement with the company providing for the allotment to them respectively, credited as fully paid-up, of any further shares to which they may be entitled upon such capitalization, or as the case may require, for the payment by the company on their behalf, by the application thereto of their respective proportions of profits resolved to be capitalized, of the amount or any part of the amounts remaining unpaid on their existing shares;

Any agreement made under such authority shall be effective and binding on such members;

BUY-BACK OF SHARES

40. Notwithstanding anything contained in these articles but subject to the provisions of sections 68 to 70 and any other applicable provision of the Act or any other law for the time being in force, the company may purchase its own shares or other specified securities.

GENERAL MEETINGS

41. All general meetings other than annual general meeting shall be called extraordinary general meeting.

42. The Board may, whenever it thinks fit, call an extraordinary general meeting.

If at any time directors capable of acting who are sufficient in number to form a quorum are not within India, any director or any two members of the company may call an extraordinary general meeting in the same manner, as nearly as possible, as that in which such a meeting may be called by the Board.

PROCEEDINGS AT GENERAL MEETINGS

43. No business shall be transacted at any general meeting unless a quorum of members is present at the time when the meeting proceeds to business.

Save as otherwise provided herein, the quorum for the general meetings shall be as provided in section 103.

44. The chairperson, if any, of the Board shall preside as Chairperson at every general meeting of the company.

45. If there is no such Chairperson, or if he is not present within fifteen minutes after the time appointed for holding the meeting or is unwilling to act as chairperson of the meeting, the directors present shall elect one of their members to be Chairperson of the meeting.
46. If at any meeting no director is willing to act as Chairperson or if no director is present within fifteen minutes after the time appointed for holding the meeting, the members present shall choose one of their members to be Chairperson of the meeting.

ADJOURNMENT OF MEETING

47. The Chairperson may, with the consent of any meeting at which a quorum is present, and shall, if so directed by the meeting, adjourn the meeting from time to time and from place to place.

No business shall be transacted at any adjourned meeting other than the business left unfinished at the meeting from which the adjournment took place.

When a meeting is adjourned for thirty days or more, notice of the adjourned meeting shall be given as in the case of an original meeting.

Save as aforesaid, and as provided in section 103 of the Act, it shall not be necessary to give any notice of an adjournment or of the business to be transacted at an adjourned meeting.

VOTING RIGHTS

48. Subject to any rights or restrictions for the time being attached to any class or classes of shares, on a show of hands, every member present in person shall have one vote;

and on a poll, the voting rights of members shall be in proportion to his share in the paid-up equity share capital of the company.

That option or right to call of shares shall not be given to any person except with the sanction of the Issuer in general meetings

49. A member may exercise his vote at a meeting by electronic means in accordance with section 108 and shall vote only once.
50. In the case of joint holders, the vote of the senior who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders.

For this purpose, seniority shall be determined by the order in which the names stand in the register of members.

51. A member of unsound mind, or in respect of whom an order has been made by any court having jurisdiction in lunacy, may vote, whether on a show of hands or on a poll, by his committee or other legal guardian, and any such committee or guardian may, on a poll, vote by proxy.
52. Any business other than that upon which a poll has been demanded maybe proceeded with, pending the taking of the poll.
53. No member shall be entitled to vote at any general meeting unless all calls or other sums presently payable by him in respect of shares in the company have been paid
54. No objection shall be raised to the qualification of any voter except at the meeting or adjourned meeting at which the vote objected to is given or tendered, and every vote not disallowed at such meeting shall be valid for all purposes.

Any such objection made in due time shall be referred to the Chairperson of the meeting, whose decision shall be final and conclusive.

PROXY

55. The instrument appointing a proxy and the power-of-attorney or other authority, if any, under which it is signed or a notarized copy of that power or authority, shall be deposited at the registered office of the company not less than 48 hours before the time for holding the meeting or adjourned meeting at which the person named in the instrument proposes to vote, or, in the case of a poll, not less than 24 hours before the time appointed for the taking of the poll; and in default the instrument of proxy shall not be treated as valid.
56. An instrument appointing a proxy shall be in the form as prescribed in the rules made under section 105
57. A vote given in accordance with the terms of an instrument of proxy shall be valid, notwithstanding the previous death or insanity of the principal or the revocation of the proxy or of the authority under which the proxy was executed, or the transfer of the shares in respect of which the proxy is given:

Provided that no intimation in writing of such death, insanity, revocation or transfer shall have been received by the company at its office before the commencement of the meeting or adjourned meeting at which the proxy is used.

BOARD OF DIRECTORS

58. Unless otherwise determined by a General Meeting the number of Directors shall not be less than 3 and not more than 15. The First Directors of the Company are:
1. Akashbhai Mansukhbhai Gangadiya
 2. Chetan Rugnathbhai Matholiya
 3. Jayeshkumar Amarshibhai Sabava
59. The remuneration of the directors shall, in so far as it consists of a monthly payment, be deemed to accrue from day-to-day.

In addition to the remuneration payable to them in pursuance of the Act, the directors may be paid all travelling, hotel and other expenses properly incurred by them-

- in attending and returning from meetings of the Board of Directors or any committee thereof or general meetings of the company; or
- in connection with the business of the company.

60. The Board may pay all expenses incurred in getting up and registering the company.
61. The company may exercise the powers conferred on it by section 88 with regard to the keeping of a foreign register; and the Board may (subject to the provisions of that section) make and vary such regulations as it may think fit respecting the keeping of any such register.
62. All cheques, promissory notes, drafts, hundis, bills of exchange and other negotiable instruments, and all receipts for monies paid to the company, shall be signed, drawn, accepted, endorsed, or otherwise executed, as the case may be, by such person and in such manner as the Board shall from time to time by resolution determine.
63. Every director present at any meeting of the Board or of a committee thereof shall sign his name in a book to be kept for that purpose.
64. Subject to the provisions of section 149, the Board shall have power at any time, and from time to time, to appoint a person as an additional director, provided the number of the directors and additional directors together shall not at any time exceed the maximum strength fixed for the Board by the articles.

Such person shall hold office only up to the date of the next annual general meeting of the company but shall be eligible for appointment by the company as a director at that meeting subject to the provisions of the Act.

PROCEEDINGS OF THE BOARD

65. The Board of Directors may meet for the conduct of business, adjourn and otherwise regulate its meetings, as it thinks fit.

A director may, and the manager or secretary on the requisition of a director shall, at any time, summon a meeting of the Board.

66. Save as otherwise expressly provided in the Act, questions arising at any meeting of the Board shall be decided by a majority of votes.

In case of an equality of votes, the Chairperson of the Board, if any, shall have a second or casting vote.

67. The continuing directors may act notwithstanding any vacancy in the Board; but, if and so long as their number is reduced below the quorum fixed by the Act for a meeting of the Board, the continuing directors or director may act for the purpose of increasing the number of directors to that fixed for the quorum, or of summoning a general meeting of the company, but for no other purpose.

68. The Board may elect a Chairperson of its meetings and determine the period for which he is to hold office.

If no such Chairperson is elected, or if at any meeting the Chairperson is not present within five minutes after the time appointed for holding the meeting, the directors present may choose one of their number to be Chairperson of the meeting.

69. The Board may, subject to the provisions of the Act, delegate any of its powers to committees consisting of such member or members of its body as it thinks fit.

Any committee so formed shall, in the exercise of the powers so delegated, conform to any regulations that may be imposed on it by the Board.

70. A committee may elect a Chairperson of its meetings.

If no such Chairperson is elected, or if at any meeting the 72 Chairperson is not present within five minutes after the time appointed for holding the meeting, the members present may choose one of their members to be Chairperson of the meeting.

71. A committee may meet and adjourn as it thinks fit.

Questions arising at any meeting of a committee shall be determined by a majority of votes of the members present, and in case of an equality of votes, the Chairperson shall have a second or casting vote.

72. All acts done in any meeting of the Board or of a committee thereof or by any person acting as a director, shall, notwithstanding that it may be afterwards discovered that there was some defect in the appointment of any one or more of such directors or of any person acting as aforesaid, or that they or any of them were disqualified, be as valid as if every such director or such person had been duly appointed and was qualified to be a director.

73. Save as otherwise expressly provided in the Act, a resolution in writing, signed by all the members of the Board or of a committee thereof, for the time being entitled to receive notice of a meeting of the Board or committee, shall be valid and effective as if it had been passed at a meeting of the Board or committee, duly convened and held.

CHIEF EXECUTIVE OFFICER, MANAGER, COMPANY SECRETARY OR CHIEF FINANCIAL OFFICER

74. Subject to the provisions of the Act,
A chief executive officer, manager, company secretary or chief financial officer may be appointed by the Board for such term, at such remuneration and upon such conditions as it may think fit; and any chief executive officer, manager, company secretary or chief financial officer so appointed may be removed by means of a resolution of the Board;

A director may be appointed as chief executive officer, manager, company secretary or chief financial officer

75. A provision of the Act or these regulations requiring or authorizing a thing to be done by or to a director and chief executive officer, manager, company secretary or chief financial officer shall not be satisfied by its being done by or to the same person acting both as director and as, or in place of, chief executive officer, manager, company secretary or chief financial officer.

THE SEAL

76. The Board shall provide for the safe custody of the seal.

The seal of the company shall not be affixed to any instrument except by the authority of a resolution of the Board or of a committee of the Board authorized by it in that behalf, and except in the presence of at least two directors and of the secretary or such other person as the Board may appoint for the purpose; and those two directors and the secretary or other person aforesaid shall sign every instrument to which the seal of the company is so affixed in their presence.

DIVIDENDS AND RESERVE

77. The company in general meeting may declare dividends, but no dividend shall exceed the amount recommended by the Board.

78. Subject to the provisions of section 123, the Board may from time to time pay to the members such interim dividends as appear to it to be justified by the profits of the company.

79. The Board may, before recommending any dividend, set aside out of the profits of the company such sums as it thinks fit as a reserve or reserves which shall, at the discretion of the Board, be applicable for any purpose to which the profits of the company may be properly applied, including provision for meeting contingencies or for equalizing dividends; and pending such application, may, at the like discretion, either be employed in the business of the company or be invested in such investments (other than shares of the company) as the Board may, from time to time, think fit.

The Board may also carry forward any profits which it may consider necessary not to divide, without setting them aside as a reserve.

80. Subject to the rights of persons, if any, entitled to shares with special rights as to dividends, all dividends shall be declared and paid according to the amounts paid or credited as paid on the shares in respect whereof the dividend is paid, but if and so long as nothing is paid upon any of the shares in the company, dividends may be declared and paid according to the amounts of the shares.

No amount paid or credited as paid on a share in advance of calls shall be treated for the purposes of this regulation as paid on the share.

All dividends shall be apportioned and paid proportionately to the amounts paid or credited as paid on the shares during any portion or portions of the period in respect of which the dividend is paid; but if any share is issued on terms providing that it shall rank for dividend as from a particular date such share shall rank for dividend accordingly. That there shall be no forfeiture of unclaimed dividends before the claim becomes barred by law.

81. The Board may deduct from any dividend payable to any member all sums of money, if any, presently payable by him to the company on account of calls or otherwise in relation to the shares of the company.

82. Any dividend, interest or other monies payable in cash in respect of shares may be paid by cheque or warrant sent through the post directed to the registered address of the holder or, in the case of joint holders, to the registered address of that one of the joint holders who is first named on the register of members, or to such person and to such address as the holder or joint holders may in writing direct.

Every such cheque or warrant shall be made payable to the order of the person to whom it is sent.

83. Any one of two or more joint holders of a share may give effective receipts for any dividends, bonuses or other monies payable in respect of such share.
84. Notice of any dividend that may have been declared shall be given to the persons entitled to share therein in the manner mentioned in the Act.
85. No dividend shall bear interest against the company.

ACCOUNTS

86. The Board shall from time to time determine whether and to what extent and at what times and places and under what conditions or regulations, the accounts and books of the company, or any of them, shall be open to the inspection of members not being directors.

No member (not being a director) shall have any right of inspecting any account or book or document of the company except as conferred by law or authorized by the Board or by the company in general meeting.

WINDING UP

87. Subject to the provisions of Chapter XX of the Act and rules made thereunder-
If the company shall be wound up, the liquidator may, with the sanction of a special resolution of the company and any other sanction required by the Act, divide amongst the members, in specie or kind, the whole or any part of the assets of the company, whether they shall consist of property of the same kind or not.

For the purpose aforesaid, the liquidator may set such value as he deems fair upon any property to be divided as aforesaid and may determine how such division shall be carried out as between the members or different classes of members.

The liquidator may, with the like sanction, vest the whole or any part of such assets in trustees upon such trusts for the benefit of the contributories if he considers necessary, but so that no member shall be compelled to accept any shares or other securities whereon there is any liability.

INDEMNITY

88. Every officer of the company shall be indemnified out of the assets of the company against any liability incurred by him in defending any proceedings, whether civil or criminal, in which judgment is given in his favour or in which he is acquitted or in which relief is granted to him by the court or the Tribunal.

MATERIAL CONTRACTS AND DOCUMENTS FOR INSPECTION

The following contracts (not being contracts entered into in the ordinary course of business carried on by the Company or entered into more than two years before the date of the Draft Red Herring Prospectus) which are or may be deemed material have been entered or to be entered into by the Company which are or may be deemed material will be attached to the copy of the Prospectus, will be filed with the Registrar of Companies. Copies of the abovementioned contracts and also the documents for inspection referred to hereunder, may be inspected at the Registered Office between 10 a.m. and 5 p.m. on all Working Days from the date of this Draft Red Herring Prospectus until the Issue Closing Date.

Material Contracts

1. Issue Agreement dated September 29, 2025 between our Company and the Book Running Lead Manager to the Issue.
2. Registrar Agreement dated September 26, 2025 executed between our Company and the Registrar to the Issue.
3. Banker to the Issue and Sponsor Bank Agreement dated [●] among our Company, Book Running Lead Manager, Banker to the Issue and the Registrar to the Issue.
4. Underwriting Agreement dated [●] between our Company, Book Running Lead Manager and Underwriter.
5. Market Making Agreement dated [●] between our Company, Book Running Lead Manager and Market Maker.
6. Tripartite Agreement dated September 24, 2025 among CDSL, the Company and the Registrar to the Issue.
7. Tripartite Agreement dated September 24, 2025 among NSDL, the Company and the Registrar to the Issue.
8. Syndicate Agreement dated [●] between the Company, BRLM, Registrar to the Issue and Syndicate Members.

Material Documents

1. Certified copies of the Memorandum and Articles of Association of the Company as amended.
2. Certificate of Incorporation of Company dated December 29, 2020 issued by Registrar of Companies, Central Registration Centre.
3. Certificate of Incorporation pursuant to the Conversion of Private Limited Company into the Public Limited Company dated January 21, 2025 issued by the Registrar of Companies, Central Registration Centre.
4. Copy of the Board Resolution dated September 26, 2025 authorizing the Issue and other related matters.
5. Copy of Shareholder's Resolution dated September 26, 2025 authorizing the Issue and other related matters.
6. Copies of Audited Financial Statements of our Company for the financial year ended March 31, 2025, 2024 and 2023.
7. Copies of the Restated Financial Statement of our Company for the financial year ended March 31, 2025, 2024 and 2023.
8. Copy of the Statement of Possible Special Tax Benefits dated September 26, 2025 from the Statutory Auditor.
9. Certificate on KPI's issued by Statutory Auditor dated September 26, 2025.
10. Consents of the Book Running Lead Manager, Legal Advisor to the Issue, Registrar to the Issue, Statutory Auditor of the Company, Market Maker, Underwriter, Bankers to our Company, Banker to the Issue/ Sponsor Bank, Syndicate Member, Promoters of our Company, Directors of our Company, Company Secretary and Compliance Officer and Chief Financial Officer, as referred to, in their respective capacities.
11. Board Resolution dated September 30, 2025 for approval of Draft Red Herring Prospectus and dated [●] for approval of Red Herring Prospectus and dated [●] for approval of Prospectus.
12. Due Diligence Certificate from Book Running Lead Manager dated September 30, 2025 Site visit report prepared by the Book Running Lead Manager dated September 18, 2025.
13. Approval from BSE vide letter dated [●] to use the name of BSE in the offer Documents for listing of Equity Shares on the SME Platform of BSE Limited (BSE SME).

DECLARATION

I certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, regulations and guidelines issued by the Government of India, or the regulations or guidelines issued by SEBI, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Draft Red Herring Prospectus is contrary to the provisions of the Companies Act, the Securities Contracts (Regulation) Act, 1956, as amended, the Securities and Exchange Board of India Act, 1992, as amended or the rules, regulations or guidelines issued thereunder, as the case may be. I further certify that all the statements in this Draft Red Herring Prospectus are true and correct.

SIGNED BY THE BOARD OF DIRECTORS OF OUR COMPANY:

Name and Designation	Signature
Chetan Rugnathbhai Matholiya Chairman & Whole-Time Director DIN: 09013701	Sd/-

Date: September 30, 2025

Place: Ahmedabad

DECLARATION

I certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, regulations and guidelines issued by the Government of India, or the regulations or guidelines issued by SEBI, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Draft Red Herring Prospectus is contrary to the provisions of the Companies Act, the Securities Contracts (Regulation) Act, 1956, as amended, the Securities and Exchange Board of India Act, 1992, as amended or the rules, regulations or guidelines issued thereunder, as the case may be. I further certify that all the statements in this Draft Red Herring Prospectus are true and correct.

SIGNED BY THE BOARD OF DIRECTORS OF OUR COMPANY:

Name and Designation	Signature
Jayeshkumar Amarshibhai Sabava Managing Director DIN: 09013702	Sd/-

Date: September 30, 2025

Place: Ahmedabad

DECLARATION

I certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, regulations and guidelines issued by the Government of India, or the regulations or guidelines issued by SEBI, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Draft Red Herring Prospectus is contrary to the provisions of the Companies Act, the Securities Contracts (Regulation) Act, 1956, as amended, the Securities and Exchange Board of India Act, 1992, as amended or the rules, regulations or guidelines issued thereunder, as the case may be. I further certify that all the statements in this Draft Red Herring Prospectus are true and correct.

SIGNED BY THE BOARD OF DIRECTORS OF OUR COMPANY:

Name and Designation	Signature
Akashbhai Mansukhbhai Gangadiya Whole Time Director DIN: 09013700	Sd/-

Date: September 30, 2025

Place: Ahmedabad

DECLARATION

I certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, regulations and guidelines issued by the Government of India, or the regulations or guidelines issued by SEBI, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Draft Red Herring Prospectus is contrary to the provisions of the Companies Act, the Securities Contracts (Regulation) Act, 1956, as amended, the Securities and Exchange Board of India Act, 1992, as amended or the rules, regulations or guidelines issued thereunder, as the case may be. I further certify that all the statements in this Draft Red Herring Prospectus are true and correct.

SIGNED BY THE BOARD OF DIRECTORS OF OUR COMPANY:

Name and Designation	Signature
Narendrabhai Dineshbhai Khambhaliya Non-executive Director DIN: 11259501	Sd/-

Date: September 30, 2025

Place: Ahmedabad

DECLARATION

I certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, regulations and guidelines issued by the Government of India, or the regulations or guidelines issued by SEBI, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Draft Red Herring Prospectus is contrary to the provisions of the Companies Act, the Securities Contracts (Regulation) Act, 1956, as amended, the Securities and Exchange Board of India Act, 1992, as amended or the rules, regulations or guidelines issued thereunder, as the case may be. I further certify that all the statements in this Draft Red Herring Prospectus are true and correct.

SIGNED BY THE BOARD OF DIRECTORS OF OUR COMPANY:

Name and Designation	Signature
Rashmi Krunal Lakhani Independent Director DIN: 08206547	Sd/-

Date: September 30, 2025

Place: Ahmedabad

DECLARATION

I certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, regulations and guidelines issued by the Government of India, or the regulations or guidelines issued by SEBI, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Draft Red Herring Prospectus is contrary to the provisions of the Companies Act, the Securities Contracts (Regulation) Act, 1956, as amended, the Securities and Exchange Board of India Act, 1992, as amended or the rules, regulations or guidelines issued thereunder, as the case may be. I further certify that all the statements in this Draft Red Herring Prospectus are true and correct.

SIGNED BY THE BOARD OF DIRECTORS OF OUR COMPANY:

Name and Designation	Signature
Kashyap Naranbhai Thummar Independent Director DIN: 11297561	Sd/-

Date: September 30, 2025

Place: Ahmedabad

DECLARATION

I certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, regulations and guidelines issued by the Government of India, or the regulations or guidelines issued by SEBI, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Draft Red Herring Prospectus is contrary to the provisions of the Companies Act, the Securities Contracts (Regulation) Act, 1956, as amended, the Securities and Exchange Board of India Act, 1992, as amended or the rules, regulations or guidelines issued thereunder, as the case may be. I further certify that all the statements in this Draft Red Herring Prospectus are true and correct.

SIGNED BY THE COMPANY SECRETARY & COMPLIANCE OFFICER OF OUR COMPANY:

Name and Designation	Signature
Rima Amitbhai Dalal Company Secretary & Compliance Officer M No. – A39280	Sd/-

Date: September 30, 2025

Place: Ahmedabad

DECLARATION

I certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, regulations and guidelines issued by the Government of India, or the regulations or guidelines issued by SEBI, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Draft Red Herring Prospectus is contrary to the provisions of the Companies Act, the Securities Contracts (Regulation) Act, 1956, as amended, the Securities and Exchange Board of India Act, 1992, as amended or the rules, regulations or guidelines issued thereunder, as the case may be. I further certify that all the statements in this Draft Red Herring Prospectus are true and correct.

SIGNED BY THE CHIEF FINANCIAL OFFICER OF OUR COMPANY:

Name and Designation	Signature
Akashbhai Mansukhbhai Gangadiya Chief Financial Officer	Sd/-

Date: September 30, 2025

Place: Ahmedabad